7977601
2425813
D011239_D009133 CID prednisolone/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) following/VBG (r_prep) occurred/VBD (l_nsubj) enlargement/NN (l_conj) wastage/NN
D011239_D006529 CID prednisolone/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) following/VBG (r_prep) occurred/VBD (l_nsubj) enlargement/NN
1147734
D011441_D008107 NONE propylthiouracil/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) disease/NN
D011441_D006521 CID propylthiouracil/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) hepatitis/NN
1835291
D013806_D029424 NONE theophylline/NN (r_conj) bromide/NN (r_pobj) of/IN (r_prep) effects/NNS (l_prep) in/IN (l_pobj) disease/NN -PUNC- theophylline/NN (r_amod) tablets/NNS (r_conj) aerosol/NN (r_pobj) of/IN (r_prep) dose/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubjpass) compared/VBN (l_prep) in/IN (l_pobj) study/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disease/NN -PUNC- theophylline/NN (r_pobj) than/IN (r_prep) bronchodilator/NN (r_attr) is/VBZ (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) obstruction/NN
D013806_D002318 CID theophylline/JJ (r_amod) use/NN (r_pobj) after/IN (r_prep) experienced/VBN (r_acl) those/DT (r_nsubj) involve/VB (l_dobj) systems/NNS
D009241_D029424 NONE bromide/NN (r_pobj) of/IN (r_prep) effects/NNS (l_prep) in/IN (l_pobj) disease/NN -PUNC- bromide/NN (r_compound) aerosol/NN (r_pobj) of/IN (r_prep) dose/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubjpass) compared/VBN (l_prep) in/IN (l_pobj) study/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disease/NN -PUNC- ipratropium/NN (r_nsubj) is/VBZ (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) obstruction/NN
D013806_D005767 CID theophylline/JJ (r_amod) use/NN (r_pobj) after/IN (r_prep) experienced/VBN (r_acl) those/DT (r_nsubj) involve/VB (l_dobj) systems/NNS
10579464
D008694_D006948 CID methamphetamine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) hyperactivity/NN -PUNC- MAP/NNP (r_appos) methamphetamine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) hyperactivity/NN
D003024_D006948 NONE clozapine/NN (r_conj) NRA0160/NNP (r_nsubj) antagonized/VBN (l_dobj) hyperactivity/NN
C121249_D006948 NONE NRA0160/NNP (r_nsubj) antagonized/VBN (l_dobj) hyperactivity/NN
D003024_D002375 CID clozapine/NN (r_conj) NRA0160/NNP (r_nsubj) induced/VBN (l_dobj) catalepsy/NN
C121249_D002375 CID NRA0160/NNP (r_nsubj) induced/VBN (l_dobj) catalepsy/NN
11391224
D003042_D057049 NONE cocaine/NN (r_npadvmod) related/VBN (r_amod) failure/NN (r_conj) glomerulonephritis/NN (r_conj) nephritis/NN (r_conj) nephritis/NN (r_dobj) lupus/NN (l_nsubj) microangiopathy/NN
D003042_D058186 CID cocaine/NN (r_npadvmod) related/VBN (r_amod) failure/NN
D003042_D008181 NONE cocaine/NN (r_npadvmod) related/VBN (r_amod) failure/NN (r_conj) glomerulonephritis/NN (r_conj) nephritis/NN (r_conj) nephritis/NN
D003042_D006974 NONE cocaine/NN (r_npadvmod) related/VBN (r_amod) failure/NN (r_conj) glomerulonephritis/NN (r_conj) nephritis/NN (r_conj) nephritis/NN (r_dobj) lupus/NN (r_conj) included/VBD (l_dobj) cases/NNS (l_prep) of/IN (l_pobj) hypertension/NN
D003042_D011695 NONE cocaine/NN (r_npadvmod) related/VBN (r_amod) failure/NN (r_conj) glomerulonephritis/NN (r_conj) nephritis/NN
D003042_D005921 NONE cocaine/NN (r_npadvmod) related/VBN (r_amod) failure/NN (r_conj) glomerulonephritis/NN
16755009
D012601_D000647 CID scopolamine-/NN (r_nmod) amnesia/NN -PUNC- scopolamine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) amnesia/NN
D010936_D000647 NONE DCE/NNP (r_nsubj) reversed/VBD (l_dobj) amnesia/NN
D002784_D003072 NONE cholesterol/NN (r_nsubj) lowering/VBG (r_conj) property/NN (r_dobj) improving/VBG (r_acl) remedy/NN (l_prep) for/IN (l_pobj) management/NN (l_prep) of/IN (l_pobj) dysfunctions/NNS
D003975_D000647 CID Diazepam-/NN (l_appos) amnesia/NN -PUNC- diazepam/NN (r_conj) scopolamine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) amnesia/NN
D010936_D003072 NONE DCE/NNP (r_nsubj) prove/VB (l_xcomp) be/VB (l_attr) remedy/NN (l_prep) for/IN (l_pobj) management/NN (l_prep) of/IN (l_pobj) dysfunctions/NNS
11250767
D011441_D010493 CID Propylthiouracil/NNP (r_npadvmod) induced/VBN (r_amod) vasculitis/NN (l_prep) in/IN (l_pobj) conjunction/NN (l_prep) with/IN (l_pobj) pericarditis/NN -PUNC- propylthiouracil/NN (r_npadvmod) induced/VBN (r_amod) vasculitis/NN (l_acl) manifesting/VBG (l_prep) with/IN (l_pobj) pericarditis/NN -PUNC- propylthiouracil/NN (l_relcl) developed/VBD (l_nsubj) syndrome/NN (l_prep) of/IN (l_pobj) pericarditis/NN -PUNC- uracil/NN (r_compound) therapy/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) vasculitis/NN (r_pobj) in/IN (r_prep) reports/NNS (l_prep) of/IN (l_pobj) pericarditis/NN -PUNC- uracil/NN (r_compound) therapy/NN (r_appos) propylthio-/VB (r_pobj) to/IN (r_prep) attributable/JJ (r_amod) manifestation/NN (r_attr) be/VB (l_nsubj) Pericarditis/NNP
D011441_D005334 CID propylthiouracil/NN (l_relcl) developed/VBD (l_nsubj) syndrome/NN (l_prep) of/IN (l_pobj) pericarditis/NN (l_conj) fever/NN
D011441_D014657 NONE Propylthiouracil/NNP (r_npadvmod) induced/VBN (r_amod) vasculitis/NN -PUNC- propylthiouracil/NN (r_npadvmod) induced/VBN (r_amod) vasculitis/NN -PUNC- uracil/NN (r_compound) therapy/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) vasculitis/NN -PUNC- uracil/NN (r_compound) therapy/NN (r_appos) propylthio-/VB (r_pobj) to/IN (r_prep) attributable/JJ (r_amod) manifestation/NN (l_prep) of/IN (l_pobj) vasculitis/NN
D011441_D005921 CID propylthiouracil/NN (l_relcl) developed/VBD (l_nsubj) syndrome/NN (l_prep) of/IN (l_pobj) pericarditis/NN (l_conj) fever/NN (l_conj) glomerulonephritis/NN
D011441_D006980 NONE propylthiouracil/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) report/NN (l_prep) of/IN (l_pobj) woman/NN (l_prep) with/IN (l_pobj) hyperthyroidism/NN
9245658
D009538_D002318 CID nicotine/NN (r_pobj) of/IN (r_prep) role/NN (l_prep) in/IN (l_pobj) disease/NN -PUNC- Nicotine/NNP (r_nsubj) activates/VBZ (l_conj) contribute/VB (l_prep) to/IN (l_pobj) disease/NN
D009538_D013927 NONE Nicotine/NN (r_nsubj) appear/VB (l_xcomp) enhance/VB (l_dobj) thrombosis/NN
D009538_D050197 CID nicotine/NN (r_nsubj) play/VB (l_dobj) role/NN (l_prep) in/IN (l_pcomp) accelerating/VBG (l_dobj) atherosclerosis/NN
12464714
D004878_D006261 NONE ergotamine/NN (r_nmod) caffeine/NN (r_dobj) preferred/VBD (r_relcl) patients/NNS (r_pobj) of/IN (r_prep) %/NN (r_conj) rizatriptan/JJ (r_dobj) preferring/VBG (r_acl) patients/NNS (r_pobj) of/IN (r_prep) %/NN (r_pobj) by/IN (r_agent) cited/VBN (r_acl) reason/NN (r_attr) was/VBD (l_nsubj) relief/NN (l_prep) of/IN (l_pobj) headache/NN
C093622_D009325 CID Rizatriptan/NNP (r_nsubj) was/VBD (l_acomp) superior/JJ (l_prep) to/IN (l_pobj) caffeine/NN (l_prep) in/IN (l_pobj) proportions/NNS (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) nausea/NN -PUNC- rizatriptan/NN (r_pobj) after/IN (r_prep) >/XX (r_appos) events/NNS (l_appos) nausea/NN
D004878_D014839 NONE ergotamine/NN (r_nmod) caffeine/NN (l_prep) in/IN (l_pobj) proportions/NNS (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) nausea/NN (l_conj) vomiting/VBG
C093622_D004244 CID rizatriptan/NN (r_pobj) after/IN (r_prep) >/XX (r_appos) events/NNS (r_nsubj) were/VBD (l_attr) dizziness/NN
D004878_D012001 NONE ergotamine/NN (r_nmod) caffeine/NN (l_prep) in/IN (l_pobj) proportions/NNS (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) nausea/NN (l_conj) vomiting/VBG (l_conj) phonophobia/NNS
D002110_D010146 NONE caffeine/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) %/NN (r_pobj) with/IN (r_prep) compared/VBN (r_prep) were/VBD (l_acomp) free/JJ (l_npadvmod) pain/NN -PUNC- caffeine/NN (r_pobj) on/IN (r_prep) patients/NNS (r_pobj) of/IN (r_prep) %/NN (r_pobj) to/IN (r_prep) compared/VBN (r_prep) were/VBD (l_acomp) free/JJ (l_npadvmod) pain/NN
D004878_D006970 NONE ergotamine/NNP (r_nmod) caffeine/NN (r_conj) rizatriptan/NN (r_pobj) after/IN (r_prep) >/XX (r_appos) events/NNS (l_appos) nausea/NN (l_conj) somnolence/NN
C093622_D008881 NONE rizatriptan/JJ (r_pobj) for/IN (r_prep) preference/NN (r_conj) efficacy/NN (r_pobj) of/IN (r_prep) comparison/NN (l_conj) caffeine/NN (l_prep) in/IN (l_pobj) migraine/NN -PUNC- Rizatriptan/NNP (r_nsubj) is/VBZ (l_attr) agonist/NN (l_prep) with/IN (l_pobj) absorption/NN (l_conj) onset/NN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) migraine/NN -PUNC- rizatriptan/JJ (r_pobj) for/IN (r_prep) preference/NN (r_dobj) assessed/VBD (l_prep) in/IN (l_pobj) patients/NNS (l_acl) treating/VBG (l_dobj) attack/NN (l_compound) migraine/JJ
C093622_D014839 NONE Rizatriptan/NNP (r_nsubj) was/VBD (l_acomp) superior/JJ (l_prep) to/IN (l_pobj) caffeine/NN (l_prep) in/IN (l_pobj) proportions/NNS (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) nausea/NN (l_conj) vomiting/VBG
C093622_D012001 NONE Rizatriptan/NNP (r_nsubj) was/VBD (l_acomp) superior/JJ (l_prep) to/IN (l_pobj) caffeine/NN (l_prep) in/IN (l_pobj) proportions/NNS (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) nausea/NN (l_conj) vomiting/VBG (l_conj) phonophobia/NNS
C093622_D006261 NONE rizatriptan/JJ (r_dobj) preferring/VBG (r_acl) patients/NNS (r_pobj) of/IN (r_prep) %/NN (r_pobj) by/IN (r_agent) cited/VBN (r_acl) reason/NN (r_attr) was/VBD (l_nsubj) relief/NN (l_prep) of/IN (l_pobj) headache/NN
D012701_D008881 NONE 5-HT(1B/1D/CD (r_nummod) receptor/NN (r_compound) agonist/NN (l_prep) with/IN (l_pobj) absorption/NN (l_conj) onset/NN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) migraine/NN
C093622_D010146 NONE rizatriptan/NN (r_pobj) after/IN (r_prep) h/NN (r_npadvmod) were/VBD (l_acomp) free/JJ (l_npadvmod) pain/NN -PUNC- rizatriptan/JJ (r_nsubj) being/VBG (r_advcl) were/VBD (l_acomp) free/JJ (l_npadvmod) pain/NN -PUNC- rizatriptan/NN (r_dobj) taking/VBG (r_acl) patients/NNS (r_pobj) of/IN (r_prep) %/NN (r_nsubj) were/VBD (l_acomp) free/JJ (l_npadvmod) pain/NN
D004878_D004244 NONE ergotamine/NNP (r_nmod) caffeine/NN (r_conj) rizatriptan/NN (r_pobj) after/IN (r_prep) >/XX (r_appos) events/NNS (r_nsubj) were/VBD (l_attr) dizziness/NN
D004878_D020795 NONE ergotamine/NN (r_nmod) caffeine/NN (l_prep) in/IN (l_pobj) proportions/NNS (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) nausea/NN (l_conj) vomiting/VBG (l_conj) phonophobia/NNS (l_conj) photophobia/NNS
C093622_D006970 NONE rizatriptan/NN (r_pobj) after/IN (r_prep) >/XX (r_appos) events/NNS (l_appos) nausea/NN (l_conj) somnolence/NN
C093622_D020795 NONE Rizatriptan/NNP (r_nsubj) was/VBD (l_acomp) superior/JJ (l_prep) to/IN (l_pobj) caffeine/NN (l_prep) in/IN (l_pobj) proportions/NNS (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) nausea/NN (l_conj) vomiting/VBG (l_conj) phonophobia/NNS (l_conj) photophobia/NNS
D004878_D008881 NONE ergotamine/NN (r_nmod) caffeine/NN (l_prep) in/IN (l_pobj) migraine/NN -PUNC- ergotamine/NN (r_pobj) to/IN (r_prep) tablet/NN (r_amod) rizatriptan/JJ (r_pobj) for/IN (r_prep) preference/NN (r_dobj) assessed/VBD (l_prep) in/IN (l_pobj) patients/NNS (l_acl) treating/VBG (l_dobj) attack/NN (l_compound) migraine/JJ
D002110_D006261 NONE caffeine/NN (r_dobj) preferred/VBD (r_relcl) patients/NNS (r_pobj) of/IN (r_prep) %/NN (r_conj) rizatriptan/JJ (r_dobj) preferring/VBG (r_acl) patients/NNS (r_pobj) of/IN (r_prep) %/NN (r_pobj) by/IN (r_agent) cited/VBN (r_acl) reason/NN (r_attr) was/VBD (l_nsubj) relief/NN (l_prep) of/IN (l_pobj) headache/NN
D002110_D008881 NONE caffeine/NN (l_prep) in/IN (l_pobj) migraine/NN -PUNC- caffeine/NN (r_appos) ergotamine/NN (r_pobj) to/IN (r_prep) tablet/NN (r_amod) rizatriptan/JJ (r_pobj) for/IN (r_prep) preference/NN (r_dobj) assessed/VBD (l_prep) in/IN (l_pobj) patients/NNS (l_acl) treating/VBG (l_dobj) attack/NN (l_compound) migraine/JJ
D004878_D010146 NONE ergotamine/NN (r_nmod) caffeine/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) %/NN (r_pobj) with/IN (r_prep) compared/VBN (r_prep) were/VBD (l_acomp) free/JJ (l_npadvmod) pain/NN -PUNC- ergotamine/NNP (r_nmod) caffeine/NN (r_pobj) on/IN (r_prep) patients/NNS (r_pobj) of/IN (r_prep) %/NN (r_pobj) to/IN (r_prep) compared/VBN (r_prep) were/VBD (l_acomp) free/JJ (l_npadvmod) pain/NN
D004878_D009325 NONE ergotamine/NN (r_nmod) caffeine/NN (l_prep) in/IN (l_pobj) proportions/NNS (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) nausea/NN -PUNC- ergotamine/NNP (r_nmod) caffeine/NN (r_conj) rizatriptan/NN (r_pobj) after/IN (r_prep) >/XX (r_appos) events/NNS (l_appos) nausea/NN
D002110_D020795 NONE caffeine/NN (l_prep) in/IN (l_pobj) proportions/NNS (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) nausea/NN (l_conj) vomiting/VBG (l_conj) phonophobia/NNS (l_conj) photophobia/NNS
D002110_D004244 NONE caffeine/NN (r_conj) rizatriptan/NN (r_pobj) after/IN (r_prep) >/XX (r_appos) events/NNS (r_nsubj) were/VBD (l_attr) dizziness/NN
D002110_D009325 NONE caffeine/NN (l_prep) in/IN (l_pobj) proportions/NNS (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) nausea/NN -PUNC- caffeine/NN (r_conj) rizatriptan/NN (r_pobj) after/IN (r_prep) >/XX (r_appos) events/NNS (l_appos) nausea/NN
D002110_D012001 NONE caffeine/NN (l_prep) in/IN (l_pobj) proportions/NNS (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) nausea/NN (l_conj) vomiting/VBG (l_conj) phonophobia/NNS
D002110_D006970 NONE caffeine/NN (r_conj) rizatriptan/NN (r_pobj) after/IN (r_prep) >/XX (r_appos) events/NNS (l_appos) nausea/NN (l_conj) somnolence/NN
D002110_D014839 NONE caffeine/NN (l_prep) in/IN (l_pobj) proportions/NNS (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) nausea/NN (l_conj) vomiting/VBG
8996652
D005665_D006311 NONE furosemide/NN (r_conj) aminoglycosides/NNS (r_appos) administration/NN (r_pobj) to/IN (r_prep) related/JJ (r_oprd) appeared/VBD (l_nsubj) Ototoxicity/NN -PUNC- furosemide/NN (r_conj) aminoglycosides/NNS (r_appos) administration/NN (l_conj) dose/NN (l_prep) of/IN (l_pobj) drugs/NNS (l_compound) ototoxic/JJ
D000617_D006311 NONE aminoglycosides/NNS (r_appos) administration/NN (r_pobj) to/IN (r_prep) related/JJ (r_oprd) appeared/VBD (l_nsubj) Ototoxicity/NN -PUNC- aminoglycosides/NNS (r_appos) administration/NN (l_conj) dose/NN (l_prep) of/IN (l_pobj) drugs/NNS (l_compound) ototoxic/JJ
19308880
D014635_D003221 CID acid/NN (r_pobj) with/IN (r_prep) reaction/NN (r_appos) Confusion/NN -PUNC- acid/NN (r_pobj) with/IN (r_prep) observed/VBD (r_acl) reaction/NN (r_attr) is/VBZ (l_nsubj) Confusion/NN -PUNC- acid/NN (r_pobj) with/IN (r_prep) reported/VBN (r_acl) confusion/NN -PUNC- acid/NN (r_pobj) with/IN (r_prep) reported/VBN (l_nsubjpass) cases/NNS (l_prep) of/IN (l_pobj) confusion/NN -PUNC- acid/NN (r_compound) exposure/NN (r_pobj) following/VBG (r_prep) weeks/NNS (r_pobj) during/IN (r_prep) occurred/VBD (l_nsubj) Confusion/NN -PUNC- acid/NN (r_pobj) with/IN (r_prep) confusion/NN
16298782
D009569_D006316 NONE oxide/NN (r_nsubj) act/VB (l_prep) as/IN (l_pobj) otoprotectant/NN (l_prep) against/IN (l_pobj) loss/NN -PUNC- NO/NNP (r_intj) ester/NN (r_appos) oxide/NN (r_nsubj) act/VB (l_prep) as/IN (l_pobj) otoprotectant/NN (l_prep) against/IN (l_pobj) loss/NN
D000617_D006319 NONE aminoglycoside/NN (r_npadvmod) induced/VBN (r_amod) loss/NN
D005839_D006311 NONE gentamicin/NN (r_compound) ototoxicity/NN
D019331_D034381 NONE NAME/NN (r_nsubj) reduced/VBN (l_dobj) loss/NN
D009569_D006311 NONE NO/DT (r_pobj) of/IN (r_prep) production/NN (r_dobj) involves/VBZ (r_conj) is/VBZ (l_nsubj) ototoxicity/NN -PUNC- NO/DT (r_pobj) of/IN (r_prep) production/NN (r_dobj) involves/VBZ (l_nsubj) mechanism/NN (l_compound) ototoxic/JJ -PUNC- NO/DT (r_det) inhibitors/NNS (r_pobj) of/IN (r_prep) use/NN (r_dobj) assess/VB (r_xcomp) need/VBP (l_ccomp) is/VBZ (l_nsubj) ototoxicity/NN -PUNC- NO/DT (r_det) inhibitors/NNS (r_pobj) of/IN (r_prep) use/NN (r_dobj) assess/VB (r_xcomp) need/VBP (l_ccomp) is/VBZ (l_conj) involves/VBZ (l_nsubj) mechanism/NN (l_compound) ototoxic/JJ
D000617_D006311 NONE aminoglycoside/NN (r_npadvmod) induced/VBN (r_amod) loss/NN (r_pobj) of/IN (r_prep) prevention/NN (r_pobj) for/IN (r_prep) use/NN (r_dobj) assess/VB (r_xcomp) need/VBP (l_ccomp) is/VBZ (l_nsubj) ototoxicity/NN -PUNC- aminoglycoside/NN (r_npadvmod) induced/VBN (r_amod) loss/NN (r_pobj) of/IN (r_prep) prevention/NN (r_pobj) for/IN (r_prep) use/NN (r_dobj) assess/VB (r_xcomp) need/VBP (l_ccomp) is/VBZ (l_conj) involves/VBZ (l_nsubj) mechanism/NN (l_compound) ototoxic/JJ
D019331_D006316 NONE ester/NN (r_appos) oxide/NN (r_nsubj) act/VB (l_prep) as/IN (l_pobj) otoprotectant/NN (l_prep) against/IN (l_pobj) loss/NN -PUNC- NAME/NN (r_appos) ester/NN (r_appos) oxide/NN (r_nsubj) act/VB (l_prep) as/IN (l_pobj) otoprotectant/NN (l_prep) against/IN (l_pobj) loss/NN
D019331_D006311 NONE ester/NN (l_appos) protector/NN (l_prep) against/IN (l_pobj) ototoxicity/NN
D009569_D006319 NONE NO/DT (r_pobj) of/IN (r_prep) production/NN (r_dobj) involves/VBZ (r_conj) is/VBZ (r_ccomp) need/VBP (l_xcomp) assess/VB (l_dobj) use/NN (l_prep) for/IN (l_pobj) prevention/NN (l_prep) of/IN (l_pobj) loss/NN -PUNC- NO/DT (r_det) inhibitors/NNS (r_pobj) of/IN (r_prep) use/NN (l_prep) for/IN (l_pobj) prevention/NN (l_prep) of/IN (l_pobj) loss/NN
D005839_D034381 CID gentamicin/NN (r_npadvmod) induced/VBN (r_amod) loss/NN
D005839_D006316 NONE gentamicin/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) loss/NN
3714122
C005238_D013118 CID Mipafox/NNP (r_pobj) of/IN (r_prep) dosages/NNS (r_nsubj) produced/VBN (l_dobj) degree/NN (l_prep) of/IN (l_pobj) damage/NN
C005238_D020258 NONE mipafox/NN (r_npadvmod) induced/VBN (r_amod) damage/NN (r_conj) inhibition/NN (l_amod) neurotoxic/JJ -PUNC- Mipafox/NNP (r_pobj) to/IN (r_prep) exposed/VBN (r_acl) rats/NNS (r_pobj) in/IN (r_prep) examined/VBN (l_nsubjpass) correlation/NN (l_prep) between/IN (l_pobj) damage/NN (l_prep) of/IN (l_pobj) esterase/NN (l_amod) neurotoxic/JJ -PUNC- Mipafox/NNP (l_appos) organophosphate/NN (l_amod) neurotoxic/JJ -PUNC- N'-diisopropylphosphorodiamidofluoridate/NNP (r_appos) Mipafox/NNP (r_pobj) to/IN (r_prep) exposed/VBN (r_acl) rats/NNS (r_pobj) in/IN (r_prep) examined/VBN (l_nsubjpass) correlation/NN (l_prep) between/IN (l_pobj) damage/NN (l_prep) of/IN (l_pobj) esterase/NN (l_amod) neurotoxic/JJ -PUNC- N'-diisopropylphosphorodiamidofluoridate/NNP (r_appos) Mipafox/NNP (l_appos) organophosphate/NN (l_amod) neurotoxic/JJ
D010755_D009422 NONE organophosphate/NN (r_appos) Mipafox/NNP (r_pobj) to/IN (r_prep) exposed/VBN (r_acl) rats/NNS (r_pobj) in/IN (r_prep) examined/VBN (l_nsubjpass) correlation/NN (l_prep) between/IN (l_pobj) damage/NN -PUNC- organophosphate/NN (r_appos) Mipafox/NNP (r_pobj) to/IN (r_prep) exposed/VBN (r_acl) rats/NNS (r_pobj) in/IN (r_prep) examined/VBN (l_nsubjpass) correlation/NN (l_prep) between/IN (l_pobj) damage/NN (l_prep) of/IN (l_pobj) esterase/NN (l_conj) enzyme/NN (l_compound) target/NN (l_compound) neuropathy/NN
C005238_D009422 NONE mipafox/NN (r_npadvmod) induced/VBN (r_amod) damage/NN -PUNC- Mipafox/NNP (r_pobj) to/IN (r_prep) exposed/VBN (r_acl) rats/NNS (r_pobj) in/IN (r_prep) examined/VBN (l_nsubjpass) correlation/NN (l_prep) between/IN (l_pobj) damage/NN -PUNC- Mipafox/NNP (r_pobj) to/IN (r_prep) exposed/VBN (r_acl) rats/NNS (r_pobj) in/IN (r_prep) examined/VBN (l_nsubjpass) correlation/NN (l_prep) between/IN (l_pobj) damage/NN (l_prep) of/IN (l_pobj) esterase/NN (l_conj) enzyme/NN (l_compound) target/NN (l_compound) neuropathy/NN -PUNC- N'-diisopropylphosphorodiamidofluoridate/NNP (r_appos) Mipafox/NNP (r_pobj) to/IN (r_prep) exposed/VBN (r_acl) rats/NNS (r_pobj) in/IN (r_prep) examined/VBN (l_nsubjpass) correlation/NN (l_prep) between/IN (l_pobj) damage/NN -PUNC- N'-diisopropylphosphorodiamidofluoridate/NNP (r_appos) Mipafox/NNP (r_pobj) to/IN (r_prep) exposed/VBN (r_acl) rats/NNS (r_pobj) in/IN (r_prep) examined/VBN (l_nsubjpass) correlation/NN (l_prep) between/IN (l_pobj) damage/NN (l_prep) of/IN (l_pobj) esterase/NN (l_conj) enzyme/NN (l_compound) target/NN (l_compound) neuropathy/NN -PUNC- Mipafox/NNP (r_compound) exposure/NN (r_nsubj) predict/VB (l_dobj) damage/NN
D010755_D020258 NONE organophosphate/NN (r_appos) Mipafox/NNP (r_pobj) to/IN (r_prep) exposed/VBN (r_acl) rats/NNS (r_pobj) in/IN (r_prep) examined/VBN (l_nsubjpass) correlation/NN (l_prep) between/IN (l_pobj) damage/NN (l_prep) of/IN (l_pobj) esterase/NN (l_amod) neurotoxic/JJ -PUNC- organophosphate/NN (l_amod) neurotoxic/JJ
10901305
D007649_D050723 NONE Ketamine/NN (l_dobj) sedation/NN (l_prep) for/IN (l_pobj) reduction/NN (l_prep) of/IN (l_pobj) fractures/NNS -PUNC- ketamine/NN (l_prep) for/IN (l_pobj) sedation/NN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) fractures/NNS -PUNC- ketamine/NN (l_prep) to/IN (l_pobj) manipulation/NN (l_prep) of/IN (l_pobj) fracture/NN -PUNC- Ketamine/NNP (r_nsubj) provided/VBD (l_dobj) sedation/NN (l_acl) facilitate/VB (l_dobj) reduction/NN (l_prep) of/IN (l_pobj) fractures/NNS
D007649_D004204 NONE ketamine/NN (l_prep) to/IN (l_pobj) manipulation/NN (l_prep) of/IN (l_pobj) fracture/NN (l_conj) dislocation/NN
15957009
D014236_D008569 NONE metrifonate/NN (r_conj) Ro4368554/NNP (r_nsubj) reversed/VBD (l_dobj) deficits/NNS
D014364_D008569 NONE TRP/NNP (r_compound) depletion/NN (r_conj) scopolamine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) deficits/NNS
D012701_D008569 NONE 5-HT(6/CD (r_compound) antagonists/NNS (r_conj) involved/VBN (r_ccomp) suggesting/VBG (r_advcl) reversed/VBD (l_dobj) cholinergic/JJ (l_conj) deficit/NN
D012601_D008569 CID scopolamine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) deficits/NNS
C507242_D008569 NONE Ro4368554/NN (r_nsubj) restores/VBZ (l_prep) in/IN (l_pobj) models/NNS (l_prep) of/IN (l_pobj) deficiency/NN -PUNC- Ro4368554/NNP (r_nsubj) reversed/VBD (l_dobj) deficits/NNS -PUNC- Ro4368554/NN (r_nsubj) improve/VB (r_advcl) reversed/VBD (l_dobj) cholinergic/JJ (l_conj) deficit/NN -PUNC- Ro4368554/NN (r_pobj) by/IN (r_prep) facilitation/NN (r_pobj) in/IN (r_prep) involved/VBN (r_ccomp) suggesting/VBG (r_advcl) reversed/VBD (l_dobj) cholinergic/JJ (l_conj) deficit/NN
8092427
-1_D007645 NONE BPO/NNP (r_pobj) to/IN (r_prep) negative/JJ (r_amod) test/NN (r_attr) were/VBD (r_ccomp) were/VBD (l_acomp) negative/JJ (l_prep) to/IN (l_pobj) MDM/NNP
D010400_D004342 NONE PG/NNP (r_pobj) of/IN (r_prep) tolerance/NN (r_pobj) with/IN (r_prep) allergy/NN -PUNC- PG/NNP (r_dobj) tolerated/VBN (r_relcl) patients/NNS (l_amod) allergic/JJ
D000658_D004342 CID amoxicillin/NNP (r_pobj) to/IN (r_prep) reactions/NNS -PUNC- amoxicillin/NNP (r_pobj) to/IN (r_prep) responses/NNS (r_dobj) had/VBD (r_conj) used/VBN (l_xcomp) establish/VB (l_ccomp) allergic/JJ -PUNC- amoxicillin/NNP (r_pobj) to/IN (r_prep) responses/NNS (l_amod) allergic/JJ -PUNC- AX/NN (r_appos) amoxicillin/NNP (r_pobj) to/IN (r_prep) responses/NNS (r_dobj) had/VBD (r_conj) used/VBN (l_xcomp) establish/VB (l_ccomp) allergic/JJ -PUNC- AX/NN (r_appos) amoxicillin/NNP (r_pobj) to/IN (r_prep) responses/NNS (l_amod) allergic/JJ -PUNC- AX/NNP (r_compound) allergy/NN -PUNC- AX/NN (r_pobj) with/IN (r_prep) tests/NNS (r_nsubjpass) performed/VBN (l_advcl) establish/VB (l_dobj) diagnosis/NN (l_prep) of/IN (l_pobj) reaction/NN -PUNC- AX/NN (r_pobj) to/IN (r_prep) reaction/NN -PUNC- AX/NN (r_pobj) for/IN (r_prep) RAST/NNP (r_conj) test/NN (r_appos) %/NN (r_nsubj) were/VBD (r_conj) performed/VBN (l_advcl) establish/VB (l_dobj) diagnosis/NN (l_prep) of/IN (l_pobj) reaction/NN -PUNC- AX/NN (r_npadvmod) allergic/JJ
D010400_D007645 NONE PG/NNP (r_pobj) to/IN (r_prep) 44/CD (r_conj) were/VBD (l_acomp) negative/JJ (l_prep) to/IN (l_pobj) MDM/NNP
D047090_D004342 NONE lactam/NN (r_amod) antibiotics/NNS (r_pobj) to/IN (r_prep) reactions/NNS -PUNC- lactam/NN (r_amod) antibiotics/NNS (r_pobj) to/IN (r_prep) allergic/JJ -PUNC- lactam/NN (r_amod) antibiotics/NNS (r_pobj) to/IN (r_prep) allergic/JJ (r_ccomp) establish/VB (r_xcomp) used/VBN (l_conj) had/VBD (l_dobj) responses/NNS (l_amod) allergic/JJ -PUNC- lactam/NN (r_amod) antibiotics/NNS (r_pobj) to/IN (r_prep) allergic/JJ
D010406_D004342 NONE penicillin/NN (r_compound) derivatives/NNS (r_pobj) with/IN (r_prep) reacting/VBG (r_acomp) were/VBD (r_conj) had/VBD (r_conj) used/VBN (l_xcomp) establish/VB (l_ccomp) allergic/JJ -PUNC- penicillin/NN (r_compound) derivatives/NNS (r_pobj) with/IN (r_prep) reacting/VBG (r_acomp) were/VBD (r_conj) had/VBD (l_dobj) responses/NNS (l_amod) allergic/JJ
19387625
D002211_D006930 CID capsaicin/NN (r_npadvmod) induced/VBN (r_amod) hyperalgesia/NN -PUNC- capsaicin/NN (r_npadvmod) induced/VBN (r_amod) hyperalgesia/NN -PUNC- capsaicin/NN (r_npadvmod) untreated/VBN (r_amod) condition/NN (r_pobj) of/IN (r_prep) that/DT (r_pobj) to/IN (r_prep) similar/JJ (r_acomp) is/VBZ (l_nsubj) magnitude/NN (l_prep) of/IN (l_pobj) modulation/NN (l_prep) in/IN (l_pobj) hyperalgesia/NN -PUNC- capsaicin/NN (r_compound) treatment/NN (r_pobj) between/IN (r_prep) interaction/NN (r_dobj) showing/VBG (r_csubj) suggest/VBP (l_ccomp) affect/VB (l_nsubj) hyperalgesia/NN -PUNC- capsaicin/NN (r_npadvmod) induced/VBN (r_amod) hyperalgesia/NN
D002211_D010146 NONE capsaicin/NN (r_npadvmod) induced/VBN (r_amod) hyperalgesia/NN (r_pobj) in/IN (r_prep) intensity/NN (l_compound) pain/NN -PUNC- capsaicin/NN (r_npadvmod) induced/VBN (r_amod) hyperalgesia/NN (r_pobj) in/IN (r_prep) attention/NN (r_pobj) by/IN (r_agent) affected/VBN (l_nsubjpass) ratings/NNS (l_compound) intensity/NN (l_compound) pain/NN -PUNC- capsaicin/NN (r_compound) treatment/NN (r_pobj) between/IN (r_prep) interaction/NN (r_dobj) showing/VBG (r_csubj) suggest/VBP (l_ccomp) affect/VB (l_dobj) pain/NN -PUNC- capsaicin/NN (r_npadvmod) induced/VBN (r_amod) hyperalgesia/NN (r_nsubj) affect/VB (l_dobj) pain/NN
14765563
D011803_D003128 CID quinine/NN (r_dobj) containing/VBG (r_acl) products/NNS (r_nsubj) produce/VB (l_dobj) status/NN (l_conj) seizures/NNS (l_conj) coma/NN
D011803_D020922 NONE quinine/NN (r_nsubj) is/VBZ (l_advcl) banned/VBD (l_dobj) use/NN (l_prep) for/IN (l_pobj) cramps/NNS
D011803_D002493 NONE quinine/NN (r_dobj) containing/VBG (r_acl) products/NNS (r_nsubj) produce/VB (l_dobj) complications/NNS
D011803_D012640 CID quinine/NN (r_dobj) containing/VBG (r_acl) products/NNS (r_nsubj) produce/VB (l_dobj) status/NN (l_conj) seizures/NNS
D011803_D003221 CID quinine/NN (r_dobj) containing/VBG (r_acl) products/NNS (r_nsubj) produce/VB (l_dobj) complications/NNS (l_prep) including/VBG (l_pobj) confusion/NN
9088814
D000527_D007022 CID E1-induced/JJ (r_amod) hypotension/NN -PUNC- E1/NN (l_appos) hypotension/NN -PUNC- PGE1)-induced/JJ (r_amod) hypotension/NN -PUNC- PGE1/NNP (r_pobj) with/IN (r_prep) induced/VBN (l_nsubjpass) hypotension/NN -PUNC- PGE1-induced/JJ (r_amod) hypotension/NN
D001663_D007022 NONE bilirubin/NN (r_conj) LDH/NNP (r_conj) SGPT/NNP (r_appos) SGOT/NNP (r_nsubj) showed/VBD (r_conj) showed/VBD (l_prep) after/IN (l_pobj) start/NN (l_prep) of/IN (l_pobj) hypotension/NN
D003911_D020141 NONE dextran/NN (r_amod) solution/NN (r_pobj) of/IN (r_prep) amount/NN (r_pobj) with/IN (r_prep) replacing/VBG (r_conj) withdrawing/VBG (r_pcomp) by/IN (r_prep) produced/VBN (l_nsubjpass) Haemodilution/NN
D000527_D020141 NONE E1-induced/JJ (r_amod) hypotension/NN (l_conj) haemodilution/NN -PUNC- E1/NN (l_appos) hypotension/NN (l_conj) haemodilution/NN -PUNC- PGE1)-induced/JJ (r_amod) hypotension/NN (l_conj) haemodilution/NN -PUNC- PGE1-induced/JJ (r_amod) hypotension/NN (l_conj) haemodilution/NN
D000527_D008107 CID PGE1-induced/JJ (r_amod) hypotension/NN (r_pobj) of/IN (r_prep) min/NN (r_pobj) of/IN (r_prep) combination/NN (r_nsubj) cause/VB (l_dobj) impairment/NN (l_prep) of/IN (l_pobj) function/NN
3780846
D006220_D009127 CID haloperidol/NN (r_nsubjpass) used/VBN (l_prep) in/IN (l_pobj) order/NN (l_acl) block/VB (l_conj) estimate/VB (l_dobj) degree/NN (l_prep) of/IN (l_pobj) tolerance/NN (l_prep) to/IN (l_pobj) rigidity/NN -PUNC- Haloperidol/NNP (r_nsubj) enhanced/VBD (l_dobj) rigidity/NN
D009020_D018476 CID morphine/NN (r_pobj) with/IN (r_prep) treated/VBD (l_conj) showed/VBD (l_prep) after/IN (l_pobj) dose/NN (l_relcl) was/VBD (l_conj) were/VBD (l_acomp) akinetic/JJ -PUNC- morphine/NN (r_pobj) of/IN (r_prep) dose/NN (l_relcl) was/VBD (l_conj) were/VBD (l_acomp) akinetic/JJ
D009020_D009127 CID morphine/NN (r_pobj) by/IN (r_agent) produced/VBN (r_acl) rigidity/NN -PUNC- morphine/NN (r_pobj) by/IN (r_agent) produced/VBN (r_acl) rigidity/NN -PUNC- morphine/NN (r_pobj) of/IN (r_prep) dose/NN (r_dobj) given/VBN (r_csubj) showed/VBD (l_dobj) rigidity/NN -PUNC- morphine/NN (r_pobj) with/IN (r_prep) treated/VBD (l_conj) showed/VBD (l_dobj) rigidity/NN -PUNC- morphine/NN (r_pobj) of/IN (r_prep) dose/NN (r_pobj) after/IN (r_prep) showed/VBD (l_dobj) rigidity/NN -PUNC- morphine/NN (r_pobj) of/IN (r_prep) action/NN (r_pobj) to/IN (r_prep) due/JJ (r_acomp) be/VB (r_xcomp) assumed/VBN (r_relcl) rigidity/NN
12584269
D016559_D007674 CID FK506/NNP (r_nsubjpass) tolerated/VBN (r_advcl) demonstrated/VBD (l_dobj) effect/NN (l_amod) nephrotoxic/JJ
D016559_D005355 NONE FK506/NNP (r_nmod) combination/NN (r_nsubj) showed/VBD (l_dobj) degree/NN (l_prep) of/IN (l_pobj) fibrosis/NN
D020123_D007674 CID SRL/NN (r_nsubj) seems/VBZ (r_conj) are/VBP (l_acomp) nephrotoxic/JJ -PUNC- SRL/NN (r_nsubj) seems/VBZ (l_xcomp) act/VB (l_advcl) displaying/VBG (l_dobj) effects/NNS (l_amod) nephrotoxic/JJ -PUNC- SRL/NN (r_nsubjpass) combined/VBN (l_prep) with/IN (l_pobj) indications/NNS (l_prep) of/IN (l_pobj) effect/NN (l_amod) nephrotoxic/JJ -PUNC- SRL/NNP (r_conj) CsA/NNP (r_pobj) of/IN (r_prep) effect/NN (l_amod) nephrotoxic/JJ -PUNC- SRL/NNP (r_conj) FK506/NNP (r_nsubjpass) tolerated/VBN (r_advcl) demonstrated/VBD (l_dobj) effect/NN (l_amod) nephrotoxic/JJ
D020123_D005355 NONE SRL/NNP (r_compound) combination/NN (r_nsubj) showed/VBD (l_dobj) degree/NN (l_prep) of/IN (l_pobj) fibrosis/NN
D016572_D007674 CID CsA/NNP (r_pobj) of/IN (r_prep) effect/NN (l_amod) nephrotoxic/JJ
9625142
D047090_-1 NONE lactam/NN (r_compound) antibiotic/NN (r_dobj) withholding/VBG (r_pcomp) after/IN (r_prep) returned/VBD (r_advcl) was/VBD (l_attr) increase/NN (l_conj) decrease/NN (l_prep) in/IN (l_pobj) concentration/NN (l_acl) caused/VBN (l_agent) by/IN (l_pobj) anemia/NN (l_conj) erythroblastocytopenia/NN
D001663_-1 NONE bilirubin/NN (r_pobj) in/IN (r_prep) increase/NN (l_conj) decrease/NN (l_prep) in/IN (l_pobj) concentration/NN (l_acl) caused/VBN (l_agent) by/IN (l_pobj) anemia/NN (l_conj) erythroblastocytopenia/NN
D002443_D000744 CID ceftriaxone/NN (r_pobj) by/IN (r_prep) induced/VBN (l_nsubj) hepatitis/NNP (l_appos) anemia/NN
D002443_D056486 CID ceftriaxone/NN (r_pobj) by/IN (r_prep) induced/VBN (l_nsubj) hepatitis/NNP -PUNC- ceftriaxone/NN (r_dobj) ingesting/VBG (r_pcomp) after/IN (r_prep) developed/VBD (l_dobj) hepatitis/NN
D002443_-1 NONE ceftriaxone/NN (r_pobj) by/IN (r_prep) induced/VBN (l_nsubj) hepatitis/NNP (l_appos) anemia/NN (l_conj) erythroblastocytopenia/NN
D001663_D000744 NONE bilirubin/NN (r_pobj) in/IN (r_prep) increase/NN (l_conj) decrease/NN (l_prep) in/IN (l_pobj) concentration/NN (l_acl) caused/VBN (l_agent) by/IN (l_pobj) anemia/NN
D047090_D000744 NONE lactam/NN (r_compound) antibiotic/NN (r_dobj) withholding/VBG (r_pcomp) after/IN (r_prep) returned/VBD (r_advcl) was/VBD (l_attr) increase/NN (l_conj) decrease/NN (l_prep) in/IN (l_pobj) concentration/NN (l_acl) caused/VBN (l_agent) by/IN (l_pobj) anemia/NN
1728522
D019980_D056486 CID acid/NN (r_pobj) of/IN (r_prep) combination/NN (r_pobj) due/JJ (r_prep) hepatitis/NN -PUNC- acid/NN (r_npadvmod) induced/VBN (r_amod) hepatitis/NN
D019980_D006099 CID acid/NN (r_pobj) of/IN (r_prep) combination/NN (r_pobj) due/JJ (r_prep) hepatitis/NN -PUNC- acid/NN (r_npadvmod) induced/VBN (r_amod) hepatitis/NN (r_pobj) with/IN (r_prep) patient/NN (r_pobj) of/IN (r_prep) case/NN (l_prep) with/IN (l_pobj) granulomas/NNS
15036754
D003975_D064420 NONE diazepam/NN (r_conj) CPA/NN (r_nsubj) prevented/VBD (l_conj) reduced/VBD (l_dobj) toxicity/NN
D000109_D064420 NONE acetylcholine/NN (r_nmod) levels/NNS (r_dobj) elevates/VBZ (r_relcl) system/NN (r_pobj) in/IN (r_prep) AChEs/NNP (r_pobj) with/IN (r_prep) binding/NN (r_pobj) of/IN (r_prep) result/NN (r_attr) is/VBZ (l_nsubj) toxicity/NN -PUNC- ACh/NNS (r_nmod) levels/NNS (r_dobj) elevates/VBZ (r_relcl) system/NN (r_pobj) in/IN (r_prep) AChEs/NNP (r_pobj) with/IN (r_prep) binding/NN (r_pobj) of/IN (r_prep) result/NN (r_attr) is/VBZ (l_nsubj) toxicity/NN
D011220_D064420 NONE 2PAM/CD (r_conj) diazepam/NN (r_conj) CPA/NN (r_nsubj) prevented/VBD (l_conj) reduced/VBD (l_dobj) toxicity/NN
D003975_D011041 NONE diazepam/NN (r_nsubjpass) given/VBN (r_advcl) prevented/VBD (l_conj) delayed/VBN (l_conj) shortened/VBN (l_dobj) occurrence/NN (l_prep) of/IN (l_pobj) signs/NNS (l_prep) of/IN (l_pobj) poisoning/NN -PUNC- diazepam/NN (r_conj) CPA/NN (r_nsubj) prevented/VBD (l_dobj) occurrence/NN (l_prep) of/IN (l_pobj) signs/NNS (l_prep) of/IN (l_pobj) poisoning/NN
C048599_D064420 NONE CPA/NN (r_nsubj) prevented/VBD (l_conj) reduced/VBD (l_dobj) toxicity/NN
D001285_D064420 NONE atropine/NN (r_pobj) with/IN (r_prep) treated/VBD (l_conj) showed/VBD (l_dobj) signs/NNS (l_compound) toxicity/NN -PUNC- Atropine/NNP (r_compound) MK801/NNP (r_nsubj) offer/VB (l_dobj) protection/NN (l_prep) against/IN (l_pobj) toxicity/NN -PUNC- atropine/NN (r_pobj) with/IN (r_prep) combination/NN (r_pobj) in/IN (r_prep) diazepam/NN (r_conj) CPA/NN (r_nsubj) prevented/VBD (l_conj) reduced/VBD (l_dobj) toxicity/NN
D016291_D064420 NONE MK801/NNP (r_nsubj) offer/VB (l_dobj) protection/NN (l_prep) against/IN (l_pobj) toxicity/NN
D001285_D011041 NONE atropine/NN (r_pobj) after/IN (r_prep) given/VBN (r_advcl) prevented/VBD (l_conj) delayed/VBN (l_conj) shortened/VBN (l_dobj) occurrence/NN (l_prep) of/IN (l_pobj) signs/NNS (l_prep) of/IN (l_pobj) poisoning/NN -PUNC- atropine/NN (r_pobj) with/IN (r_prep) combination/NN (r_pobj) in/IN (r_prep) diazepam/NN (r_conj) CPA/NN (r_nsubj) prevented/VBD (l_dobj) occurrence/NN (l_prep) of/IN (l_pobj) signs/NNS (l_prep) of/IN (l_pobj) poisoning/NN
D011220_D011041 NONE 2PAM/CD (r_conj) diazepam/NN (r_nsubjpass) given/VBN (r_advcl) prevented/VBD (l_conj) delayed/VBN (l_conj) shortened/VBN (l_dobj) occurrence/NN (l_prep) of/IN (l_pobj) signs/NNS (l_prep) of/IN (l_pobj) poisoning/NN -PUNC- 2PAM/CD (r_conj) diazepam/NN (r_conj) CPA/NN (r_nsubj) prevented/VBD (l_dobj) occurrence/NN (l_prep) of/IN (l_pobj) signs/NNS (l_prep) of/IN (l_pobj) poisoning/NN
D007531_D064420 NONE DFP/NNP (r_compound) atropine/NN (r_pobj) with/IN (r_prep) treated/VBD (l_conj) showed/VBD (l_dobj) signs/NNS (l_compound) toxicity/NN -PUNC- DFP/NNP (r_compound) toxicity/NN -PUNC- DFP/NNP (r_pobj) of/IN (r_prep) toxicity/NN
D010755_D012640 NONE Organophosphate/NNP (r_npadvmod) induced/VBN (r_amod) convulsions/NNS
D010755_D004194 NONE Organophosphate/NNP (r_npadvmod) induced/VBN (r_amod) convulsions/NNS (l_prep) of/IN (l_pobj) damages/NNS
D010755_D064420 NONE OPs/NNS (r_pobj) of/IN (r_prep) toxicity/NN -PUNC- OP/NN (r_npadvmod) induced/VBN (r_amod) signs/NNS (l_compound) toxicity/NN
C048599_D011041 NONE CPA/NN (r_nsubjpass) given/VBN (r_advcl) prevented/VBD (l_conj) delayed/VBN (l_conj) shortened/VBN (l_dobj) occurrence/NN (l_prep) of/IN (l_pobj) signs/NNS (l_prep) of/IN (l_pobj) poisoning/NN -PUNC- CPA/NN (r_nsubj) prevented/VBD (l_dobj) occurrence/NN (l_prep) of/IN (l_pobj) signs/NNS (l_prep) of/IN (l_pobj) poisoning/NN
D007531_D011041 NONE DFP/NNP (r_compound) atropine/NN (r_pobj) after/IN (r_prep) given/VBN (r_advcl) prevented/VBD (l_conj) delayed/VBN (l_conj) shortened/VBN (l_dobj) occurrence/NN (l_prep) of/IN (l_pobj) signs/NNS (l_prep) of/IN (l_pobj) poisoning/NN -PUNC- DFP/NNP (r_pobj) of/IN (r_prep) toxicity/NN (r_dobj) reduced/VBD (r_conj) prevented/VBD (l_dobj) occurrence/NN (l_prep) of/IN (l_pobj) signs/NNS (l_prep) of/IN (l_pobj) poisoning/NN
14568327
D015632_D004409 NONE MPTP/NNP (r_npadvmod) induced/VBN (r_amod) parkinsonism/NN (r_pobj) of/IN (r_prep) types/NNS (r_pobj) with/IN (r_prep) Using/VBG (r_advcl) evaluated/VBD (l_dobj) degree/NN (l_relcl) involved/VBN (l_prep) in/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) LIDs/NNS -PUNC- MPTP/NNP (r_compound) exposure/NN (r_pobj) with/IN (r_prep) Monkeys/NNS (r_nsubj) developed/VBD (l_dobj) dyskinesia/RB -PUNC- MPTP/NNP (r_compound) exposure/NN (r_pobj) with/IN (r_prep) monkeys/NNS (r_nsubj) progression/NN (r_nsubj) were/VBD (l_acomp) resistant/JJ (l_prep) to/IN (l_pcomp) developing/VBG (l_dobj) LIDs/NNS -PUNC- MPTP/NNP (r_compound) exposure/NN (r_pobj) with/IN (r_prep) monkeys/NNS (r_nsubj) progression/NN (r_nsubj) were/VBD (l_parataxis) developed/VBD (l_nsubj) dyskinesia/NN
D007980_D004409 CID levodopa/NN (r_npadvmod) induced/VBN (r_amod) dyskinesias/NNS -PUNC- Levodopa/NNP (r_npadvmod) induced/VBN (r_amod) dyskinesias/NNS -PUNC- Levodopa/NNP (r_npadvmod) induced/VBN (r_amod) dyskinesias/NNS (l_appos) LIDs/NNPS -PUNC- levodopa/NN (r_compound) therapy/NN (r_pobj) of/IN (r_prep) duration/NN (r_conj) response/NN (r_conj) severity/NN (r_nsubjpass) involved/VBN (l_prep) in/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) LIDs/NNS -PUNC- levodopa/NN (r_compound) therapy/NN (r_pobj) of/IN (r_prep) initiation/NN (r_pobj) to/IN (r_prep) prior/RB (r_advmod) developed/VBD (l_dobj) dyskinesia/RB -PUNC- levodopa/JJ (r_compound) administration/NN (r_pobj) of/IN (r_prep) days/NNS (r_npadvmod) developed/VBD (l_dobj) dyskinesia/RB -PUNC- levodopa/NN (r_compound) therapy/NN (r_pobj) of/IN (r_prep) initiation/NN (r_pobj) to/IN (r_prep) prior/RB (r_advmod) progression/NN (r_nsubj) were/VBD (l_acomp) resistant/JJ (l_prep) to/IN (l_pcomp) developing/VBG (l_dobj) LIDs/NNS -PUNC- levodopa/NN (r_compound) therapy/NN (r_pobj) of/IN (r_prep) initiation/NN (r_pobj) to/IN (r_prep) prior/RB (r_advmod) progression/NN (r_nsubj) were/VBD (l_parataxis) developed/VBD (l_nsubj) dyskinesia/NN -PUNC- levodopa/JJ (r_compound) administration/NN (r_pobj) of/IN (r_prep) days/NNS (r_pobj) than/IN (r_prep) sooner/RBR (r_advmod) developed/VBD (r_parataxis) were/VBD (l_acomp) resistant/JJ (l_prep) to/IN (l_pcomp) developing/VBG (l_dobj) LIDs/NNS -PUNC- levodopa/JJ (r_compound) administration/NN (r_pobj) of/IN (r_prep) days/NNS (r_pobj) than/IN (r_prep) sooner/RBR (r_advmod) developed/VBD (l_nsubj) dyskinesia/NN -PUNC- levodopa/VB (r_pobj) to/IN (r_prep) prior/RB (r_advmod) develop/VB (l_dobj) LIDs/NNS -PUNC- levodopa/VB (r_pobj) to/IN (r_prep) prior/RB (r_advmod) develop/VB (r_acl) propensity/NN (r_pobj) in/IN (r_prep) differences/NNS (r_dobj) suggest/VBP (l_conj) demonstrate/VB (l_dobj) value/NN (l_prep) for/IN (l_pcomp) studying/VBG (l_dobj) pathophysiology/NN (l_prep) of/IN (l_pobj) LIDs/NNS
D015632_D010302 CID MPTP/NNP (r_npadvmod) induced/VBN (r_amod) parkinsonism/NN
D007980_D010302 NONE levodopa/NN (r_compound) therapy/NN (r_pobj) of/IN (r_prep) duration/NN (r_conj) response/NN (r_conj) severity/NN (r_nsubjpass) involved/VBN (r_relcl) degree/NN (r_dobj) evaluated/VBD (l_advcl) Using/VBG (l_prep) with/IN (l_pobj) types/NNS (l_prep) of/IN (l_pobj) parkinsonism/NN
D007980_D010300 NONE levodopa/NN (r_npadvmod) induced/VBN (r_amod) dyskinesias/NNS (l_prep) in/IN (l_pobj) monkeys/NNS (l_amod) parkinsonian/JJ -PUNC- Levodopa/NNP (r_npadvmod) induced/VBN (r_amod) dyskinesias/NNS (r_nsubj) present/VBP (l_dobj) problem/NN (l_prep) for/IN (l_pobj) management/NN (l_prep) of/IN (l_pobj) patients/NNS (l_nmod) disease/NN -PUNC- Levodopa/NNP (r_npadvmod) induced/VBN (r_amod) dyskinesias/NNS (r_nsubj) present/VBP (l_dobj) problem/NN (l_prep) for/IN (l_pobj) management/NN (l_prep) of/IN (l_pobj) patients/NNS (l_nmod) PD/NNP
3676049
D010100_D007022 NONE oxygen/NN (r_pobj) for/IN (r_prep) rate/NN (r_conj) flow/NN (r_nsubjpass) measured/VBN (l_prep) during/IN (l_pobj) hypotension/NN
D010100_D002532 NONE oxygen/NN (r_pobj) for/IN (r_prep) rate/NN (r_conj) flow/NN (r_nsubjpass) measured/VBN (l_prep) during/IN (l_pobj) hypotension/NN (l_prep) in/IN (l_pobj) patients/NNS (l_acl) subjected/VBN (l_prep) to/IN (l_pobj) craniotomy/NN (l_prep) for/IN (l_pobj) clipping/NN (l_prep) of/IN (l_pobj) aneurysm/NN
D008628_D007022 NONE Hg/NNP (r_pobj) of/IN (r_prep) MAP/NNP (r_pobj) to/IN (r_prep) hypotension/NN
D007530_D000783 NONE isoflurane/JJ (r_amod) concentration/NN (r_nsubjpass) reduced/VBN (l_prep) After/IN (l_pobj) clipping/NN (l_prep) of/IN (l_pobj) aneurysm/NN
D014978_D013345 NONE xenon-133/. (r_punct) measured/VBN (l_prep) after/IN (l_pobj) haemorrhage/NN
D007530_D007022 CID isoflurane/RB (r_npadvmod) induced/VBN (r_amod) hypotension/NN -PUNC- isoflurane/RB (r_npadvmod) induced/VBN (r_amod) hypotension/NN -PUNC- isoflurane/NN (r_pobj) of/IN (r_prep) dose/NN (r_dobj) increasing/VBG (r_pcomp) by/IN (r_prep) induced/VBN (l_nsubjpass) hypotension/NN
D007530_D002532 NONE isoflurane/RB (r_npadvmod) induced/VBN (r_amod) hypotension/NN (l_prep) in/IN (l_pobj) patients/NNS (l_acl) subjected/VBN (l_prep) for/IN (l_pobj) aneurysms/NNS -PUNC- isoflurane/RB (r_npadvmod) induced/VBN (r_amod) hypotension/NN (l_prep) in/IN (l_pobj) patients/NNS (l_acl) subjected/VBN (l_prep) to/IN (l_pobj) craniotomy/NN (l_prep) for/IN (l_pobj) clipping/NN (l_prep) of/IN (l_pobj) aneurysm/NN
16787750
D014635_D056486 CID VPA/NNP (r_npadvmod) induced/VBN (r_amod) hepatotoxicity/NN -PUNC- VPA/NNP (r_npadvmod) induced/VBN (r_compound) encephalopathy/NN (r_conj) hepatotoxicity/NN
D014635_D022124 NONE VPA/NNP (r_npadvmod) induced/VBN (r_amod) encephalopathy/NN (r_pobj) of/IN (r_prep) signs/NNS (r_nsubj) are/VBP (l_advcl) marked/VBD (l_ccomp) slowing/VBG (l_dobj) frequency/NN (l_prep) with/IN (l_conj) without/IN (l_pobj) hyperammonemia/NN
D014635_D001855 CID VPA/NNP (r_npadvmod) induced/VBN (r_amod) hepatotoxicity/NN (r_npadvmod) occur/VB (l_prep) in/IN (l_pobj) patients/NNS (l_prep) including/VBG (l_pobj) pancreatitis/NN (l_conj) suppression/NN -PUNC- VPA/NNP (r_npadvmod) induced/VBN (r_compound) encephalopathy/NN (r_conj) hepatotoxicity/NN (r_npadvmod) occur/VB (l_prep) in/IN (l_pobj) patients/NNS (l_prep) including/VBG (l_pobj) pancreatitis/NN (l_conj) suppression/NN
D014635_D012640 NONE VPA/NNP (r_npadvmod) induced/VBN (r_amod) encephalopathy/NN (r_pobj) of/IN (r_prep) signs/NNS (r_nsubj) are/VBP (l_advcl) marked/VBD (l_ccomp) slowing/VBG (l_dobj) frequency/NN (l_compound) seizure/NN
D014635_D001927 CID acid/NN (r_nsubj) induced/VBD (l_advmod) encephalopathy--19/NNP -PUNC- VPA/NNP (r_compound) therapy/NN (r_pobj) to/IN (r_prep) associated/VBN (r_acl) effect/NN (r_pobj) to/IN (r_prep) induced/VBD (l_advmod) encephalopathy--19/NNP -PUNC- VPA/NNP (r_npadvmod) induced/VBN (r_amod) hepatotoxicity/NN (l_conj) encephalopathy/NN -PUNC- VPA/NNP (r_npadvmod) induced/VBN (r_compound) encephalopathy/NN -PUNC- VPA/NNP (r_npadvmod) induced/VBN (r_amod) encephalopathy/NN -PUNC- VPA/NNP (r_pobj) of/IN (r_prep) effect/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) encephalopathy/JJ -PUNC- VPA/NNP (r_npadvmod) associated/VBN (r_amod) encephalopathy/NN
D014635_D010195 CID VPA/NNP (r_npadvmod) induced/VBN (r_amod) hepatotoxicity/NN (r_npadvmod) occur/VB (l_prep) in/IN (l_pobj) patients/NNS (l_prep) including/VBG (l_pobj) pancreatitis/NN -PUNC- VPA/NNP (r_npadvmod) induced/VBN (r_compound) encephalopathy/NN (r_conj) hepatotoxicity/NN (r_npadvmod) occur/VB (l_prep) in/IN (l_pobj) patients/NNS (l_prep) including/VBG (l_pobj) pancreatitis/NN
D014635_D003244 CID VPA/NNP (r_npadvmod) induced/VBN (r_amod) encephalopathy/NN (r_pobj) of/IN (r_prep) signs/NNS (r_nsubj) are/VBP (l_attr) consciousness/NN
18020536
D001569_D007319 CID BZDs/NNP (r_nmod) RDs/NNS (r_pobj) of/IN (r_prep) use/NN (r_nsubjpass) associated/VBN (l_npadvmod) inability/NN (l_acl) sleep/VB
D001569_D004244 CID BZDs/NNP (r_nmod) RDs/NNS (r_pobj) of/IN (r_prep) use/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) dizziness/NN
D001569_D005221 CID BZDs/NNP (r_nmod) RDs/NNS (r_pobj) of/IN (r_prep) use/NN (r_nsubjpass) associated/VBN (l_npadvmod) inability/NN (l_acl) sleep/VB (l_prep) after/IN (l_pcomp) awaking/VBG (l_prep) at/IN (l_pobj) night/NN (l_conj) tiredness/NN
D001569_D003866 CID BZDs/NNP (r_nmod) RDs/NNS (r_pobj) of/IN (r_prep) use/NN (r_nsubjpass) associated/VBN (l_npadvmod) inability/NN (l_acl) sleep/VB (l_prep) after/IN (l_conj) with/IN (l_pobj) symptoms/NNS
2549018
D000928_D017109 NONE antidepressant/NN (r_npadvmod) induced/VBN (r_amod) jitteriness/NN (r_conj) akathisia/NN (r_pobj) of/IN (r_prep) pathophysiology/NN (r_nsubj) be/VB (r_conj) caused/VBN (l_nsubjpass) akathisia/NN -PUNC- antidepressant/NN (r_npadvmod) induced/VBN (r_amod) jitteriness/NN (r_conj) akathisia/NN
D011433_D017109 NONE propranolol/NN (r_acl) antagonist/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) to/IN (r_prep) responded/VBD (r_conj) appeared/VBD (l_nsubj) Akathisia/NNP
D005473_D009771 NONE fluoxetine/NN (r_dobj) receiving/VBG (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) disorder/NN
D005473_D001008 NONE fluoxetine/NN (r_npadvmod) induced/VBN (r_amod) symptoms/NNS (l_prep) of/IN (l_pobj) restlessness/NN (l_conj) pacing/NN (l_conj) movements/NNS (l_conj) anxiety/NN
D005473_D017109 CID Fluoxetine/NNP (r_npadvmod) induced/VBN (r_amod) akathisia/NN -PUNC- fluoxetine/NN (r_dobj) receiving/VBG (r_acl) patients/NNS (r_nsubj) developed/VBD (l_dobj) akathisia/NN -PUNC- fluoxetine/NN (r_npadvmod) induced/VBN (r_amod) symptoms/NNS (r_nsubj) were/VBD (l_acomp) indistinguishable/JJ (l_prep) from/IN (l_pobj) those/DT (l_prep) of/IN (l_pobj) akathisia/NN -PUNC- fluoxetine/NN (r_advmod) induced/VBN (r_amod) akathisia/NN (r_pobj) of/IN (r_prep) symptoms/NNS (r_nsubj) were/VBD (r_ccomp) reported/VBD (l_nsubj) patients/NNS (l_relcl) experienced/VBN (l_dobj) akathisia/NN -PUNC- fluoxetine/NN (r_advmod) induced/VBN (r_amod) akathisia/NN -PUNC- fluoxetine/NN (r_pobj) of/IN (r_prep) effect/NN (r_attr) be/VB (r_xcomp) appeared/VBD (l_nsubj) Akathisia/NNP -PUNC- fluoxetine/NN (r_advmod) induced/VBN (r_amod) akathisia/NN -PUNC- fluoxetine/NN (r_advmod) induced/VBN (r_amod) akathisia/NN (r_nsubjpass) caused/VBN (l_conj) be/VB (l_nsubj) pathophysiology/NN (l_prep) of/IN (l_pobj) akathisia/NN -PUNC- fluoxetine/NN (r_advmod) induced/VBN (r_amod) akathisia/NN (r_pobj) of/IN (r_prep) pathophysiology/NN (r_nsubj) be/VB (r_conj) caused/VBN (l_nsubjpass) akathisia/NN -PUNC- fluoxetine/NN (r_advmod) induced/VBN (r_amod) akathisia/NN
D005473_D003865 NONE fluoxetine/NN (r_dobj) receiving/VBG (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) disorder/NN (l_conj) depression/NN
9401499
D013988_D000380 CID ticlopidine/NN (r_pobj) of/IN (r_prep) initiation/NN (r_pobj) after/IN (r_prep) occurred/VBD (l_nsubj) Agranulocytosis/NN
D013988_D000741 CID Ticlopidine/NNP (r_npadvmod) induced/VBN (r_amod) anemia/NN -PUNC- ticlopidine/NN (r_npadvmod) induced/VBN (r_amod) anemia/NN -PUNC- ticlopidine/NN (r_npadvmod) induced/VBN (r_amod) anemia/NN
9862868
D004997_D002780 CID estradiol/NNP (r_nmod) treatment/NN (r_nmod) cholestasis/NN (r_dobj) used/VBD (l_dobj) models/NNS (l_prep) of/IN (l_pobj) cholestasis/NN -PUNC- EE/NNP (r_nmod) treatment/NN (r_nmod) cholestasis/NN (r_dobj) used/VBD (l_dobj) models/NNS (l_prep) of/IN (l_pobj) cholestasis/NN
D004997_D001651 NONE estradiol/NNP (r_nmod) treatment/NN (r_nmod) cholestasis/NN -PUNC- EE/NNP (r_nmod) treatment/NN (r_nmod) cholestasis/NN
17344566
D013974_D007037 NONE thyroxine/NN (l_compound) taking/VBG (l_nsubj) male/NN (l_amod) hypothyroid/JJ
D013974_D003161 NONE thyroxine/NN (r_nsubj) presented/VBD (l_prep) with/IN (l_pobj) syndrome/NN
D019821_D009135 NONE Simvastatin/NNP (r_npadvmod) induced/VBN (r_amod) syndrome/NN (l_conj) myonecrosis/NN -PUNC- simvastatin/NN (r_conj) thyroxine/NN (r_nsubj) presented/VBD (l_prep) with/IN (l_pobj) syndrome/NN (l_conj) myonecrosis/NN
D013974_D009135 NONE thyroxine/NN (r_nsubj) presented/VBD (l_prep) with/IN (l_pobj) syndrome/NN (l_conj) myonecrosis/NN
D019821_D003161 CID Simvastatin/NNP (r_npadvmod) induced/VBN (r_amod) syndrome/NN -PUNC- simvastatin/NN (r_conj) thyroxine/NN (r_nsubj) presented/VBD (l_prep) with/IN (l_pobj) syndrome/NN
D019821_D007037 NONE Simvastatin/NNP (r_npadvmod) induced/VBN (r_amod) syndrome/NN (l_acl) associated/VBN (l_prep) with/IN (l_pobj) hypothyroidism/NN -PUNC- simvastatin/NN (r_conj) thyroxine/NN (l_compound) taking/VBG (l_nsubj) male/NN (l_amod) hypothyroid/JJ
2312209
D007548_D009203 CID dinitrate/NN (r_pobj) of/IN (r_prep) administration/NN (r_dobj) following/VBG (r_prep) infarction/NN -PUNC- dinitrate/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) following/VBG (r_prep) suffered/VBD (l_dobj) infarction/NN
D007548_D009336 NONE dinitrate/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) following/VBG (r_prep) suffered/VBD (l_nsubj) necrosis/NN
19581773
C417083_D019698 NONE interferon/NN (r_nmod) treatment/NN (l_prep) for/IN (l_pobj) C./NNP -PUNC- alpha-2b/CD (r_conj) IFN/NNP (r_appos) interferon/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) of/IN (r_prep) weeks/NNS (r_pobj) after/IN (r_prep) diplopia/NN (l_prep) for/IN (l_pobj) C/NNP -PUNC- alpha-2b/CD (r_conj) IFN/NNP (r_appos) interferon/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) of/IN (r_prep) weeks/NNS (r_pobj) after/IN (r_prep) diplopia/NN (l_prep) for/IN (l_pobj) C/NNP (l_appos) CHC/NNP -PUNC- alpha-2b/CD (l_prep) for/IN (l_pobj) CHC/NNP -PUNC- IFN/NNP (r_compound) therapy/NN (r_pobj) of/IN (r_prep) complications/NNS (r_pobj) of/IN (r_prep) review/NN (r_pobj) with/IN (r_prep) present/VBP (l_ccomp) reported/VBN (l_nsubjpass) myasthenia/NN (l_acl) associated/VBN (l_prep) with/IN (l_pobj) therapy/NN (l_prep) of/IN (l_pobj) alpha-2b/CD (l_prep) for/IN (l_pobj) CHC/NNP
D012254_D004172 NONE ribavirin/RB (r_conj) alpha-2b/CD (r_conj) IFN/NNP (r_appos) interferon/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) of/IN (r_prep) weeks/NNS (r_pobj) after/IN (r_prep) diplopia/NN
D012254_D019698 NONE ribavirin/JJ (r_conj) interferon/NN (r_nmod) treatment/NN (l_prep) for/IN (l_pobj) C./NNP -PUNC- ribavirin/RB (r_conj) alpha-2b/CD (r_conj) IFN/NNP (r_appos) interferon/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) of/IN (r_prep) weeks/NNS (r_pobj) after/IN (r_prep) diplopia/NN (l_prep) for/IN (l_pobj) C/NNP -PUNC- ribavirin/RB (r_conj) alpha-2b/CD (r_conj) IFN/NNP (r_appos) interferon/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) of/IN (r_prep) weeks/NNS (r_pobj) after/IN (r_prep) diplopia/NN (l_prep) for/IN (l_pobj) C/NNP (l_appos) CHC/NNP -PUNC- ribavirin/RB (r_conj) alpha-2b/CD (l_prep) for/IN (l_pobj) CHC/NNP
D012254_D009157 CID ribavirin/JJ (r_conj) interferon/NN (r_nmod) treatment/NN (r_pobj) during/IN (r_prep) Development/NN (l_prep) of/IN (l_pobj) myasthenia/NN -PUNC- ribavirin/RB (r_conj) alpha-2b/CD (r_pobj) of/IN (r_prep) therapy/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) myasthenia/NN
C417083_D009157 CID interferon/NN (r_nmod) treatment/NN (r_pobj) during/IN (r_prep) Development/NN (l_prep) of/IN (l_pobj) myasthenia/NN -PUNC- alpha-2b/CD (r_pobj) of/IN (r_prep) therapy/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) myasthenia/NN -PUNC- IFN/NNP (r_compound) therapy/NN (r_pobj) of/IN (r_prep) complications/NNS (r_pobj) of/IN (r_prep) review/NN (r_pobj) with/IN (r_prep) present/VBP (l_ccomp) reported/VBN (l_nsubjpass) myasthenia/NN
C417083_D004172 NONE alpha-2b/CD (r_conj) IFN/NNP (r_appos) interferon/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) of/IN (r_prep) weeks/NNS (r_pobj) after/IN (r_prep) diplopia/NN
6727060
D008787_D004409 CID metoclopramide/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) dyskinesia/JJ -PUNC- metoclopramide/RB (r_dobj) took/VBD (r_advcl) appeared/VBD (l_nsubj) movements/NNS -PUNC- metoclopramide/JJ (r_compound) administration/NN (r_nsubjpass) discontinued/VBN (r_advcl) improved/VBD (l_nsubj) movements/NNS
D008787_D005767 NONE metoclopramide/RB (r_dobj) took/VBD (l_prep) for/IN (l_pobj) disorder/NN
3865016
D005047_D017254 NONE etoposide/NN (r_nmod) A/NNP (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) resulted/VBD (l_prep) in/IN (l_pobj) eradication/NN (l_prep) of/IN (l_pobj) infiltration/NN
D016572_D017254 NONE A/NNP (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) resulted/VBD (l_prep) in/IN (l_pobj) eradication/NN (l_prep) of/IN (l_pobj) infiltration/NN
D016572_D054218 NONE A/NNP (r_pobj) of/IN (r_prep) effect/NN (r_nsubjpass) observed/VBN (l_prep) in/IN (l_pobj) patient/NN (l_prep) with/IN (l_pobj) leukemia/NN
D005047_D054218 NONE etoposide/NN (r_nmod) A/NNP (r_pobj) of/IN (r_prep) effect/NN (r_nsubjpass) observed/VBN (l_prep) in/IN (l_pobj) patient/NN (l_prep) with/IN (l_pobj) leukemia/NN
16160878
D014579_D001919 NONE II/NNP (r_pobj) of/IN (r_prep) injection/NN (r_nsubj) causes/NNS (l_dobj) hypertension/NN (l_conj) bradycardia/NN
D001058_D010409 CID apomorphine/NN (r_npadvmod) induced/VBN (r_amod) erection/NN
D014579_D001523 NONE II/NNP (r_nsubjpass) involved/VBN (l_prep) in/IN (l_pobj) aspects/NNS (l_prep) of/IN (l_pobj) disorders/NNS
D014579_D010409 NONE II/NNP (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) had/VBD (l_dobj) erection/NN
D003345_D010409 NONE corticosterone/NN (r_compound) level/NN (r_conj) had/VBD (l_dobj) erection/NN
D014579_D006973 NONE II/NNP (r_pobj) of/IN (r_prep) injection/NN (r_nsubj) causes/NNS (l_dobj) hypertension/NN
19759529
D004298_D012559 NONE dopamine/NN (r_compound) neurotransmission/NN (r_pobj) in/IN (r_prep) dysfunction/NN (r_pobj) with/IN (r_prep) associated/VBN (l_nsubjpass) Schizophrenia/NNP
D016202_D012559 NONE aspartate/NNP (r_appos) methyl/NN (r_nmod) receptor/NN (r_pobj) of/IN (r_prep) antagonists/NNS (r_nsubj) produce/VBP (l_dobj) symptoms/NNS (l_amod) like/JJ (l_npadvmod) schizophrenic/JJ -PUNC- NMDA/NNP (r_nmod) receptor/NN (r_pobj) of/IN (r_prep) antagonists/NNS (r_nsubj) produce/VBP (l_dobj) symptoms/NNS (l_amod) like/JJ (l_npadvmod) schizophrenic/JJ -PUNC- NMDA/NNP (r_compound) receptor/NN (r_pobj) via/IN (r_prep) dysfunctioning/NN (r_pobj) of/IN (r_prep) idea/NN (r_pobj) to/IN (r_prep) led/VBN (l_nsubj) observation/NN (l_relcl) produce/VBP (l_dobj) symptoms/NNS (l_amod) like/JJ (l_npadvmod) schizophrenic/JJ
D000661_D006948 CID amphetamine/NN (r_appos) challenge/NN (r_dobj) involving/VBG (r_prep) properties/NNS (r_dobj) investigating/VBG (l_prep) with/IN (l_pobj) focus/NN (l_prep) on/IN (l_pobj) models/NNS (l_prep) of/IN (l_pobj) hyperactivity/NN -PUNC- amphetamine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) hyperactivity/NN
D003024_D006948 NONE clozapine/NN (r_nmod) antipsychotics/NNS (r_nsubj) were/VBD (l_acomp) effective/JJ (l_prep) in/IN (l_pobj) models/NNS (l_prep) of/IN (l_pobj) hyperactivity/NN
D004298_D006948 NONE dopamine/NN (r_compound) transporter/NN (r_pobj) in/IN (r_prep) observed/VBN (r_conj) failed/VBD (l_xcomp) affect/VB (l_dobj) hyperactivity/NN
D018698_D012559 NONE glutamate/NN (r_nmod) receptor/NN (r_pobj) of/IN (r_prep) antagonists/NNS (r_nsubj) produce/VBP (l_dobj) symptoms/NNS (l_amod) like/JJ (l_npadvmod) schizophrenic/JJ
D006220_D006948 NONE haloperidol/NN (r_nmod) antipsychotics/NNS (r_nsubj) were/VBD (l_acomp) effective/JJ (l_prep) in/IN (l_pobj) models/NNS (l_prep) of/IN (l_pobj) hyperactivity/NN
C076029_D006948 NONE olanzapine/NN (r_nmod) clozapine/NN (r_nmod) antipsychotics/NNS (r_nsubj) were/VBD (l_acomp) effective/JJ (l_prep) in/IN (l_pobj) models/NNS (l_prep) of/IN (l_pobj) hyperactivity/NN
-1_D002375 NONE SSR103800/NNP (r_nsubj) produce/VB (l_dobj) catalepsy/NN
C094645_D006948 NONE aripiprazole/NN (r_conj) clozapine/NN (r_nmod) antipsychotics/NNS (r_nsubj) were/VBD (l_acomp) effective/JJ (l_prep) in/IN (l_pobj) models/NNS (l_prep) of/IN (l_pobj) hyperactivity/NN
D016291_D006948 CID MK-801/NNP (r_punct) )/-RRB- (r_punct) amphetamine/NN (r_appos) challenge/NN (r_dobj) involving/VBG (r_prep) properties/NNS (r_dobj) investigating/VBG (l_prep) with/IN (l_pobj) focus/NN (l_prep) on/IN (l_pobj) models/NNS (l_prep) of/IN (l_pobj) hyperactivity/NN -PUNC- MK-801/NNP (r_punct) and/CC (r_cc) showed/VBD (l_dobj) that/IN (l_punct) hyperactivity/NN -PUNC- MK-801/NNP (r_punct) and/CC (r_cc) showed/VBD (l_conj) reversed/VBD (l_dobj) hyperactivity/NN
-1_D006948 NONE SSR103800/NNP (r_pobj) of/IN (r_prep) properties/NNS (r_dobj) investigating/VBG (l_prep) with/IN (l_pobj) focus/NN (l_prep) on/IN (l_pobj) models/NNS (l_prep) of/IN (l_pobj) hyperactivity/NN -PUNC- SSR103800/NNP (r_nmod) hyperactivity/NN -PUNC- SSR103800/NNP (r_nmod) hyperactivity/NN (r_punct) that/IN (r_dobj) showed/VBD (l_conj) reversed/VBD (l_dobj) hyperactivity/NN -PUNC- SSR103800/NNP (r_nsubj) failed/VBD (l_xcomp) affect/VB (l_dobj) hyperactivity/NN
D016202_D006948 NONE NMDA/NNP (r_compound) Nr1(neo-/-/NNP (r_appos) mice/NNS (r_conj) challenge/NN (r_dobj) involving/VBG (r_prep) properties/NNS (r_dobj) investigating/VBG (l_prep) with/IN (l_pobj) focus/NN (l_prep) on/IN (l_pobj) models/NNS (l_prep) of/IN (l_pobj) hyperactivity/NN -PUNC- NMDA/NNP (r_compound) antagonist/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) hyperactivity/NN -PUNC- NMDA/NNP (r_compound) antagonist/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) hyperactivity/NN (r_punct) that/IN (r_dobj) showed/VBD (l_conj) reversed/VBD (l_dobj) hyperactivity/NN -PUNC- NMDA/NNP (r_nmod) mice/NNS (r_pobj) of/IN (r_prep) hyperactivity/NN (r_dobj) reversed/VBD (r_conj) showed/VBD (l_dobj) that/IN (l_punct) hyperactivity/NN -PUNC- NMDA/NNP (r_nmod) mice/NNS (r_pobj) of/IN (r_prep) hyperactivity/NN
6861444
D009638_D006973 CID noradrenaline/NN (r_pobj) of/IN (r_prep) infusion/NN (r_nsubj) caused/VBD (l_dobj) hypertension/NN -PUNC- noradrenaline/NN (r_amod) infusion/NN (r_pobj) after/IN (r_prep) hypertension/NN -PUNC- noradrenaline/NN (r_dobj) circulating/VBG (r_pcomp) of/IN (r_prep) levels/NNS (r_pobj) by/IN (r_agent) produced/VBN (l_nsubjpass) hypertension/NN
3560095
D005480_D001168 NONE flurbiprofen/JJ (r_pobj) with/IN (r_prep) treated/VBN (r_relcl) arthritis/NN (r_pobj) with/IN (r_prep) patients/NNS (r_nsubj) had/VBD (l_dobj) decreases/NNS (l_prep) in/IN (l_pobj) indices/NNS (l_compound) arthritis/NN
D005480_D001171 NONE Flurbiprofen/NNP (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) arthritis/NN -PUNC- flurbiprofen/JJ (r_pobj) with/IN (r_prep) treated/VBN (r_relcl) arthritis/NN
11581460
D005283_D001745 CID fentanyl/NN (r_pobj) of/IN (r_prep) infusion/NN (r_pobj) of/IN (r_prep) result/NN (r_pobj) as/IN (r_prep) mimicking/VBG (r_acl) dilatation/NN (r_pobj) to/IN (r_prep) leading/VBG (r_acl) cases/NNS (l_prep) of/IN (l_pobj) retention/NN
D005283_D001919 CID fentanyl/NN (r_compound) administration/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubj) include/VBP (l_dobj) rigidity/NN (l_conj) hypotension/NN (l_conj) depression/NN (l_conj) bradycardia/NN
D005283_D012131 CID fentanyl/NN (r_compound) administration/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubj) include/VBP (l_dobj) rigidity/NN (l_conj) hypotension/NN (l_conj) depression/NN
D005283_D016055 CID fentanyl/NN (r_pobj) of/IN (r_prep) infusion/NN (r_pobj) of/IN (r_prep) result/NN (r_pobj) as/IN (r_prep) retention/NN (l_prep) of/IN (l_pobj) urine/NN
D005283_D009127 NONE fentanyl/NN (r_compound) administration/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubj) include/VBP (l_dobj) rigidity/NN
D005283_D007022 CID fentanyl/NN (r_compound) administration/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubj) include/VBP (l_dobj) rigidity/NN (l_conj) hypotension/NN
D005283_D006869 NONE fentanyl/NN (r_pobj) of/IN (r_prep) infusion/NN (r_pobj) of/IN (r_prep) result/NN (r_pobj) as/IN (r_prep) mimicking/VBG (l_dobj) hydronephrosis/NN
9199746
D000583_D013290 NONE amikacin/JJ (r_prep) presumed/VBN (l_prep) following/VBG (l_pobj) treatment/NN (l_prep) with/IN (l_pobj) amikacin/JJ (l_conj) vancomycin/NNP (l_prep) for/IN (l_pobj) endophthalmitis/NN -PUNC- amikacin/JJ (l_conj) vancomycin/NNP (l_prep) for/IN (l_pobj) endophthalmitis/NN
D014640_D012164 NONE vancomycin/NNP (r_conj) amikacin/JJ (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) following/VBG (r_prep) presumed/VBN (l_prep) amikacin/JJ (l_pobj) toxicity/NN
D000617_D007238 NONE aminoglycosides/NNS (r_nsubj) improved/VBN (r_advcl) impair/VB (l_nsubj) infarction/NN
D000617_D009877 NONE aminoglycosides/NNS (r_nsubj) improved/VBN (l_dobj) prognosis/NN (l_prep) in/IN (l_pobj) endophthalmitis/NN
D000583_D012164 CID amikacin/JJ (l_pobj) toxicity/NN -PUNC- amikacin/JJ (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) following/VBG (r_prep) presumed/VBN (l_prep) amikacin/JJ (l_pobj) toxicity/NN
D014640_D013290 NONE vancomycin/NNP (l_prep) for/IN (l_pobj) endophthalmitis/NN
D019793_D013684 NONE fluorescein/NN (r_amod) angiography/NN (r_nsubj) confirmed/VBD (l_dobj) closure/NN (l_conj) telangiectasis/NN
D000583_D064420 NONE amikacin/RB (l_nsubj) toxicity/NN
3782049
D008972_D012206 CID molindone/NN (r_compound) administration/NN (r_pobj) following/VBG (r_prep) rhabdomyolysis/NN -PUNC- molindone/NN (r_compound) administration/NN (r_pobj) following/VBG (r_prep) rhabdomyolysis/NN
D008972_D058186 CID molindone/NN (r_compound) administration/NN (r_pobj) following/VBG (r_prep) rhabdomyolysis/NN (l_conj) failure/NN
D008972_D012559 NONE molindone/NN (r_compound) administration/NN (r_pobj) following/VBG (r_prep) rhabdomyolysis/NN (r_dobj) illustrate/VB (r_xcomp) reported/VBN (l_nsubjpass) case/NN (l_prep) of/IN (l_pobj) patient/NN (l_amod) schizophrenic/JJ
7199841
C004616_D013118 CID CE/NNP (r_dobj) received/VBD (r_relcl) animals/NNS (r_pobj) of/IN (r_prep) cords/NNS (r_pobj) Of/IN (r_prep) 13/CD (r_nsubj) showed/VBD (l_dobj) necrosis/NN
C004616_D010243 CID CE/NN (r_nmod) %/NN (r_pobj) of/IN (r_prep) injection/NN (r_dobj) received/VBD (r_relcl) animals/NNS (r_pobj) Of/IN (r_prep) paralysis/NN
D002045_D010243 NONE bupivacaine/NN (r_dobj) received/VBD (r_relcl) animals/NNS (r_pobj) of/IN (r_prep) None/NN (r_nsubj) titrated/VBN (l_prep) to/IN (l_pobj) paralysis/NN
1592014
C005618_D003643 NONE BE/NNP (r_pobj) by/IN (r_agent) induced/VBN (r_acl) those/DT (r_nsubj) were/VBD (l_advcl) characterized/VBN (l_conj) resulted/VBD (l_prep) in/IN (l_pobj) death/NN -PUNC- BE/NNP (r_pobj) by/IN (r_agent) induced/VBN (r_acl) those/DT (r_nsubj) were/VBD (l_conj) resulted/VBD (l_prep) in/IN (l_pobj) death/NN
D003042_D003643 NONE cocaine/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS (r_nsubjpass) characterized/VBN (l_conj) resulted/VBD (l_prep) in/IN (l_pobj) death/NN -PUNC- cocaine/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS (r_nsubjpass) characterized/VBN (r_advcl) were/VBD (l_conj) resulted/VBD (l_prep) in/IN (l_pobj) death/NN
C005618_D012640 CID benzoylecgonine/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubj) Seizures/NNS -PUNC- benzoylecgonine/NN (r_appos) metabolite/NN (r_pobj) of/IN (r_prep) potential/NN (r_dobj) evaluated/VBD (l_advcl) cause/VB (l_dobj) seizures/NNS -PUNC- BE/VB (r_appos) metabolite/NN (r_pobj) of/IN (r_prep) potential/NN (r_dobj) evaluated/VBD (l_advcl) cause/VB (l_dobj) seizures/NNS -PUNC- BE/VB (r_advmod) Induced/VBN (r_amod) seizures/NNS -PUNC- BE/NNP (r_pobj) by/IN (r_agent) induced/VBN (r_acl) those/DT (r_nsubj) were/VBD (l_advcl) characterized/VBN (l_nsubjpass) seizures/NNS -PUNC- BE/VB (r_advmod) Injected/VBN (r_amod) rats/NNS (l_relcl) have/VB (l_dobj) seizures/NNS -PUNC- BE/VB (r_advmod) Injected/VBN (r_amod) rats/NNS (r_nsubj) had/VBD (l_prep) without/IN (l_pobj) seizures/NNS -PUNC- BE/VB (r_advmod) induced/VBN (r_conj) cocaine-/NN (r_nmod) seizures/NNS -PUNC- BE/VB (r_advmod) induced/VBN (r_conj) cocaine-/NN (r_nmod) seizures/NNS (r_nsubj) differ/VBP (r_relcl) finding/NN (r_nsubj) suggests/VBZ (l_dobj) mechanism/NN (l_prep) for/IN (l_pobj) seizures/NNS -PUNC- BE/VB (r_conj) emphasizes/VBZ (r_conj) suggests/VBZ (l_nsubj) finding/NN (l_relcl) differ/VBP (l_nsubj) seizures/NNS -PUNC- BE/VB (r_conj) emphasizes/VBZ (r_conj) suggests/VBZ (l_dobj) mechanism/NN (l_prep) for/IN (l_pobj) seizures/NNS
D003042_D012640 CID cocaine/NN (r_compound) metabolite/NN (r_amod) benzoylecgonine/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubj) Seizures/NNS -PUNC- cocaine/NN (r_pobj) of/IN (r_prep) t1/2/NN (r_appos) life/NN (r_nsubj) is/VBZ (l_conj) occur/VB (l_nsubj) some/DT (l_prep) of/IN (l_pobj) consequences/NNS (l_prep) of/IN (l_pobj) use/NN (l_prep) as/IN (l_pobj) seizures/NNS -PUNC- cocaine/NN (r_pobj) of/IN (r_prep) metabolite/NN (r_pobj) of/IN (r_prep) potential/NN (r_dobj) evaluated/VBD (l_advcl) cause/VB (l_dobj) seizures/NNS -PUNC- cocaine/NN (r_pobj) of/IN (r_prep) amounts/NNS (r_pobj) by/IN (r_agent) induced/VBN (r_acl) those/DT (r_pobj) than/IN (r_prep) latencies/NNS (r_dobj) had/VBD (r_conj) occurred/VBD (l_nsubj) seizures/NNS -PUNC- cocaine/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS -PUNC- cocaine/NN (r_npadvmod) injected/VBN (r_amod) animals/NNS (r_pobj) than/IN (r_prep) activity/NN (r_dobj) had/VBD (l_nsubj) rats/NNS (l_relcl) have/VB (l_dobj) seizures/NNS -PUNC- cocaine/NN (r_npadvmod) injected/VBN (r_amod) animals/NNS (r_pobj) than/IN (r_prep) activity/NN (r_dobj) had/VBD (l_prep) without/IN (l_pobj) seizures/NNS -PUNC- cocaine-/NN (r_nmod) seizures/NNS -PUNC- cocaine-/NN (r_nmod) seizures/NNS (r_nsubj) differ/VBP (r_relcl) finding/NN (r_nsubj) suggests/VBZ (l_dobj) mechanism/NN (l_prep) for/IN (l_pobj) seizures/NNS -PUNC- cocaine/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS (r_pobj) for/IN (r_prep) mechanism/NN (r_dobj) suggests/VBZ (l_nsubj) finding/NN (l_relcl) differ/VBP (l_nsubj) seizures/NNS -PUNC- cocaine/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS -PUNC- cocaine/NN (r_compound) metabolite/NN (r_pobj) of/IN (r_prep) importance/NN (r_dobj) emphasizes/VBZ (r_conj) suggests/VBZ (l_nsubj) finding/NN (l_relcl) differ/VBP (l_nsubj) seizures/NNS -PUNC- cocaine/NN (r_compound) metabolite/NN (r_pobj) of/IN (r_prep) importance/NN (r_dobj) emphasizes/VBZ (r_conj) suggests/VBZ (l_dobj) mechanism/NN (l_prep) for/IN (l_pobj) seizures/NNS
D003042_D020521 NONE cocaine/NN (r_pobj) of/IN (r_prep) t1/2/NN (r_appos) life/NN (r_nsubj) is/VBZ (l_conj) occur/VB (l_nsubj) some/DT (l_prep) of/IN (l_pobj) consequences/NNS (l_prep) of/IN (l_pobj) use/NN (l_prep) as/IN (l_pobj) seizures/NNS (l_conj) strokes/NNS
15737522
D002443_D001660 CID Ceftriaxone/NN (r_npadvmod) associated/VBN (r_amod) pseudolithiasis/NN -PUNC- ceftriaxone/NN (r_nsubj) leads/VBZ (l_xcomp) pseudolithiasis/NN -PUNC- ceftriaxone/CD (r_compound) treatment/NN (r_dobj) receiving/VBG (r_acl) patients/NNS (r_pobj) in/IN (r_prep) pseudolithiasis/NN
18809400
D008063_D020258 NONE acid/NN (r_nsubj) prevents/VBZ (l_dobj) damage/NN (l_conj) neurotoxicity/NN -PUNC- acid/NN (r_nsubj) is/VBZ (l_advcl) induced/VBN (l_dobj) neurotoxicity/NN -PUNC- acid/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubj) depend/VBP (r_conj) plays/VBZ (r_advcl) is/VBZ (l_advcl) induced/VBN (l_dobj) neurotoxicity/NN -PUNC- acid/NN (r_nsubj) exerts/VBZ (l_conj) induced/VBN (l_dobj) neurotoxicity/NN
D002945_D010523 CID cisplatin/NN (r_conj) paclitaxel/NN (r_pobj) to/IN (r_prep) neurons/NNS (r_appos) ganglion/NN (r_pobj) of/IN (r_prep) cultures/NNS (r_dobj) exposing/VBG (r_pcomp) by/IN (r_prep) mimic/VBP (r_relcl) model/NN (r_dobj) used/VBD (l_xcomp) induced/VBD (l_dobj) neuropathy/NN
D002945_D020258 NONE cisplatin/NN (r_conj) in/IN (r_prep) event/NN (r_attr) is/VBZ (l_advcl) induced/VBN (l_dobj) neurotoxicity/NN
D017239_D028361 NONE paclitaxel/NN (r_conj) cisplatin/NN (r_nsubj) cause/VBP (l_dobj) impairment/NN -PUNC- paclitaxel/NN (r_pobj) in/IN (r_prep) event/NN (r_attr) is/VBZ (l_nsubj) toxicity/NN
D002945_D028361 NONE cisplatin/NN (r_nsubj) cause/VBP (l_dobj) impairment/NN -PUNC- cisplatin/NN (r_conj) in/IN (r_prep) event/NN (r_attr) is/VBZ (l_nsubj) toxicity/NN
D008063_D009410 NONE acid/NN (r_nsubj) is/VBZ (l_advcl) plays/VBZ (l_dobj) role/NN (l_prep) in/IN (l_pobj) cascade/NN -PUNC- acid/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubj) depend/VBP (r_conj) plays/VBZ (l_dobj) role/NN (l_prep) in/IN (l_pobj) cascade/NN
D017239_D010523 CID paclitaxel/NN (r_pobj) to/IN (r_prep) neurons/NNS (r_appos) ganglion/NN (r_pobj) of/IN (r_prep) cultures/NNS (r_dobj) exposing/VBG (r_pcomp) by/IN (r_prep) mimic/VBP (r_relcl) model/NN (r_dobj) used/VBD (l_xcomp) induced/VBD (l_dobj) neuropathy/NN
D008063_D010523 NONE acid/NN (r_nsubj) reduce/VB (l_dobj) risk/NN (l_prep) of/IN (l_pcomp) developing/VBG (l_dobj) toxicity/NN
D008063_D028361 NONE acid/NN (r_nsubj) prevents/VBZ (l_dobj) damage/NN -PUNC- acid/NN (r_nsubj) is/VBZ (l_advcl) plays/VBZ (l_nsubj) damage/NN -PUNC- acid/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubj) depend/VBP (r_conj) plays/VBZ (l_nsubj) damage/NN -PUNC- acid/NN (r_nsubj) exerts/VBZ (r_ccomp) rescues/VBZ (l_dobj) toxicity/NN
D008063_D001480 NONE acid/NN (r_pobj) of/IN (r_prep) efficacy/NN (l_prep) in/IN (l_pcomp) preventing/VBG (l_dobj) damage/NN -PUNC- acid/NN (r_conj) agents/NNS (r_pobj) to/IN (r_prep) exposure/NN (r_pobj) after/IN (r_prep) function/NN (r_conj) apoptosis/NN (r_conj) investigating/VBG (l_dobj) efficacy/NN (l_prep) in/IN (l_pcomp) preventing/VBG (l_dobj) damage/NN
D017239_D020258 NONE paclitaxel/NN (r_pobj) in/IN (r_prep) event/NN (r_attr) is/VBZ (l_advcl) induced/VBN (l_dobj) neurotoxicity/NN
D008063_D009422 NONE acid/NN (r_nsubj) prevents/VBZ (l_dobj) damage/NN (l_prep) in/IN (l_pobj) neuropathy/NN
18951540
D007980_D004409 CID levodopa/NN (r_npadvmod) induced/VBN (r_amod) dyskinesias/NNS
D007980_D010300 NONE levodopa/NN (r_npadvmod) induced/VBN (r_amod) dyskinesias/NNS (l_prep) in/IN (l_pobj) disease/NN
11431197
D011899_D009395 CID Ranitidine/NNP (r_npadvmod) induced/VBN (r_amod) nephritis/NN -PUNC- ranitidine/NN (r_npadvmod) induced/VBN (r_amod) nephritis/NN
15859940
D016572_D064420 NONE cyclosporine/NN (r_nmod) toxicity/NN
D016559_D064420 NONE tacrolimus/NN (r_conj) cyclosporine/NN (r_nmod) toxicity/NN
D016572_D057049 CID cyclosporine/NN (r_pobj) to/IN (r_prep) secondary/JJ (r_amod) related/VBN (r_acomp) was/VBD (l_nsubj) cause/NN (l_prep) of/IN (l_pobj) microangiopathy/NN
3828020
D010665_D002544 CID phenylpropanolamine/NN (r_pobj) of/IN (r_prep) dose/NN (r_pobj) with/IN (r_prep) infarction/NN -PUNC- PPA/NNP (r_pobj) of/IN (r_prep) dose/NN (r_dobj) taking/VBG (r_pcomp) after/IN (r_prep) suffered/VBD (l_dobj) infarction/NN
10406016
C007789_D002543 NONE fucoidan/JJ (r_compound) treatment/NN (l_prep) on/IN (l_pobj) hemorrhage/NN -PUNC- fucoidan/RB (r_dobj) tested/VBD (l_prep) in/IN (l_pobj) model/NN (l_prep) of/IN (l_pobj) hemorrhage/NN
C007789_D001925 NONE fucoidan/RB (l_relcl) reported/VBN (l_xcomp) reduce/VB (l_dobj) damage/NN
C007789_D007249 NONE Fucoidan/NNP (r_npadvmod) treated/VBN (r_amod) rats/NNS (r_nsubj) exhibited/VBD (l_conj) had/VBD (l_conj) tended/VBD (l_xcomp) have/VB (l_dobj) inflammation/NN
C007789_D020141 CID Fucoidan/NNP (r_npadvmod) treated/VBN (r_amod) rats/NNS (r_nsubj) exhibited/VBD (l_dobj) evidence/NN (l_prep) of/IN (l_pobj) clotting/NN -PUNC- Fucoidan/NNP (r_npadvmod) treated/VBN (r_amod) rats/NNS (r_nsubj) exhibited/VBD (l_dobj) evidence/NN (l_prep) of/IN (l_pobj) clotting/NN (l_conj) hemodilution/NN
C007789_D006406 NONE Fucoidan/NNP (r_npadvmod) treated/VBN (r_amod) rats/NNS (r_nsubj) exhibited/VBD (l_conj) had/VBD (l_dobj) hematomas/NNS -PUNC- Fucoidan/NNP (r_npadvmod) treated/VBN (r_amod) rats/NNS (r_nsubj) exhibited/VBD (l_conj) had/VBD (l_conj) tended/VBD (l_xcomp) have/VB (l_dobj) inflammation/NN (l_prep) in/IN (l_pobj) vicinity/NN (l_prep) of/IN (l_pobj) hematoma/NN
16938416
D004967_D050197 NONE estrogen/NN (r_compound) testosterone/NN (r_compound) therapy/NN (l_conj) atherosclerosis/NN
D002784_D003920 NONE cholesterol/NN (r_compound) level/NN (r_conj) diabetes/NNS
D013739_D050197 CID testosterone/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) atherosclerosis/NN -PUNC- testosterone/NN (r_compound) therapy/NN (l_conj) atherosclerosis/NN -PUNC- testosterone/NN (r_compound) therapy/NN (r_nsubj) affect/VB (l_dobj) atherosclerosis/NN
C032109_D050197 NONE esters/NNS (r_appos) therapy/NN (l_conj) atherosclerosis/NN
D000431_D003920 NONE alcohol/NN (r_compound) use/NN (r_conj) pressure/NN (r_conj) level/NN (r_conj) diabetes/NNS
2505783
C004656_D001745 NONE CAA/NNP (r_nsubj) contribute/VB (l_prep) to/IN (l_pobj) damage/NN
C004656_D006470 CID chloroacetaldehyde/NN (r_nsubj) is/VBZ (l_attr) metabolite/NN (l_relcl) carried/VBN (l_prep) in/IN (l_pobj) order/NN (l_acl) elucidate/VB (l_prep) in/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) cystitis/NN -PUNC- CAA/NNP (r_appos) chloroacetaldehyde/NN (r_nsubj) is/VBZ (l_attr) metabolite/NN (l_relcl) carried/VBN (l_prep) in/IN (l_pobj) order/NN (l_acl) elucidate/VB (l_prep) in/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) cystitis/NN -PUNC- CAA/NNP (r_pobj) of/IN (r_prep) role/NN (r_dobj) elucidate/VB (l_prep) in/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) cystitis/NN
C004656_D003556 CID chloroacetaldehyde/NN (r_nsubj) is/VBZ (l_attr) metabolite/NN (l_relcl) carried/VBN (l_prep) in/IN (l_pobj) order/NN (l_acl) elucidate/VB (l_prep) in/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) cystitis/NN -PUNC- CAA/NNP (r_appos) chloroacetaldehyde/NN (r_nsubj) is/VBZ (l_attr) metabolite/NN (l_relcl) carried/VBN (l_prep) in/IN (l_pobj) order/NN (l_acl) elucidate/VB (l_prep) in/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) cystitis/NN -PUNC- CAA/NNP (r_pobj) of/IN (r_prep) role/NN (r_dobj) elucidate/VB (l_prep) in/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) cystitis/NN
6103707
D005445_D010146 CID flunitrazepam/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) on/IN (r_prep) pain/NN
2440413
D010433_D012640 CID PTZ/NNP (r_pobj) to/TO (r_prep) decrease/VB (l_dobj) threshold/NN (l_compound) seizure/NN -PUNC- PTZ/NNP (r_npadvmod) induced/VBN (r_amod) seizures/NNS -PUNC- PTZ/NNP (r_pobj) due/IN (r_amod) activity/NN (l_compound) Seizure/NN -PUNC- PTZ/NNP (r_pobj) due/IN (r_amod) activity/NN (r_nsubjpass) decreased/VBN (r_ccomp) was/VBD (l_nsubj) activity/NN (l_compound) seizure/NN -PUNC- PTZ/NNP (r_pobj) by/IN (r_agent) induced/VBN (r_acl) activity/NN (l_compound) seizure/NN -PUNC- PTZ/NNP (r_pobj) by/IN (r_agent) induced/VBN (r_acl) activity/NN (r_pobj) to/IN (r_prep) occur/VB (l_advcl) decreased/VBN (l_nsubjpass) response/NN (l_prep) to/IN (l_pobj) agents/NNS (l_amod) inducing/VBG (l_npadvmod) seizure/NN
C034818_D012640 CID carboline-3-carboxylate/NNP (r_conj) acid/NN (r_pobj) to/IN (r_pcomp) due/IN (r_prep) activity/NN (r_nsubj) was/VBD (l_ccomp) decreased/VBN (l_nsubjpass) activity/NN (l_compound) Seizure/NN -PUNC- carboline-3-carboxylate/NNP (r_conj) acid/NN (r_pobj) to/IN (r_pcomp) due/IN (r_prep) activity/NN (l_compound) seizure/NN -PUNC- DMCM/NNP (r_appos) carboline-3-carboxylate/NNP (r_conj) acid/NN (r_pobj) to/IN (r_pcomp) due/IN (r_prep) activity/NN (r_nsubj) was/VBD (l_ccomp) decreased/VBN (l_nsubjpass) activity/NN (l_compound) Seizure/NN -PUNC- DMCM/NNP (r_appos) carboline-3-carboxylate/NNP (r_conj) acid/NN (r_pobj) to/IN (r_pcomp) due/IN (r_prep) activity/NN (l_compound) seizure/NN
D010852_D012640 CID picrotoxin/NN (r_conj) PTZ/NNP (r_pobj) due/IN (r_amod) activity/NN (l_compound) Seizure/NN -PUNC- picrotoxin/NN (r_conj) PTZ/NNP (r_pobj) due/IN (r_amod) activity/NN (r_nsubjpass) decreased/VBN (r_ccomp) was/VBD (l_nsubj) activity/NN (l_compound) seizure/NN -PUNC- PTX/NNP (r_appos) PTZ/NNP (r_pobj) due/IN (r_amod) activity/NN (l_compound) Seizure/NN -PUNC- PTX/NNP (r_appos) PTZ/NNP (r_pobj) due/IN (r_amod) activity/NN (r_nsubjpass) decreased/VBN (r_ccomp) was/VBD (l_nsubj) activity/NN (l_compound) seizure/NN -PUNC- PTX/NNP (r_conj) PTZ/NNP (r_pobj) by/IN (r_agent) induced/VBN (r_acl) activity/NN (l_compound) seizure/NN -PUNC- PTX/NNP (r_conj) PTZ/NNP (r_pobj) by/IN (r_agent) induced/VBN (r_acl) activity/NN (r_pobj) to/IN (r_prep) occur/VB (l_advcl) decreased/VBN (l_nsubjpass) response/NN (l_prep) to/IN (l_pobj) agents/NNS (l_amod) inducing/VBG (l_npadvmod) seizure/NN
D001640_D012640 CID bicuculline/NN (r_conj) acid/NN (r_pobj) to/IN (r_pcomp) due/IN (r_prep) activity/NN (r_nsubj) was/VBD (l_ccomp) decreased/VBN (l_nsubjpass) activity/NN (l_compound) Seizure/NN -PUNC- bicuculline/NN (r_conj) acid/NN (r_pobj) to/IN (r_pcomp) due/IN (r_prep) activity/NN (l_compound) seizure/NN -PUNC- BCC/NNP (r_appos) acid/NN (r_pobj) to/IN (r_pcomp) due/IN (r_prep) activity/NN (r_nsubj) was/VBD (l_ccomp) decreased/VBN (l_nsubjpass) activity/NN (l_compound) Seizure/NN -PUNC- BCC/NNP (r_appos) acid/NN (r_pobj) to/IN (r_pcomp) due/IN (r_prep) activity/NN (l_compound) seizure/NN
D005680_D012640 NONE GABA/NNP (r_compound) A/NNP (r_nmod) channel/NN (r_attr) be/VB (l_nsubj) site/NN (l_amod) responsible/JJ (l_prep) for/IN (l_pobj) decrease/NN (l_prep) in/IN (l_pobj) activity/NN (l_compound) seizure/NN
D013331_D012640 CID strychnine/NN (r_conj) carboline-3-carboxylate/NNP (r_conj) acid/NN (r_pobj) to/IN (r_pcomp) due/IN (r_prep) activity/NN (r_nsubj) was/VBD (l_ccomp) decreased/VBN (l_nsubjpass) activity/NN (l_compound) Seizure/NN -PUNC- strychnine/NN (r_conj) carboline-3-carboxylate/NNP (r_conj) acid/NN (r_pobj) to/IN (r_pcomp) due/IN (r_prep) activity/NN (l_compound) seizure/NN -PUNC- STR/NNP (r_appos) acid/NN (r_pobj) to/IN (r_pcomp) due/IN (r_prep) activity/NN (r_nsubj) was/VBD (l_ccomp) decreased/VBN (l_nsubjpass) activity/NN (l_compound) Seizure/NN -PUNC- STR/NNP (r_appos) acid/NN (r_pobj) to/IN (r_pcomp) due/IN (r_prep) activity/NN (l_compound) seizure/NN
D015097_D012640 CID acid/NN (r_pobj) to/IN (r_pcomp) due/IN (r_prep) activity/NN (r_nsubj) was/VBD (l_ccomp) decreased/VBN (l_nsubjpass) activity/NN (l_compound) Seizure/NN -PUNC- acid/NN (r_pobj) to/IN (r_pcomp) due/IN (r_prep) activity/NN (l_compound) seizure/NN -PUNC- MPA/NNP (r_appos) acid/NN (r_pobj) to/IN (r_pcomp) due/IN (r_prep) activity/NN (r_nsubj) was/VBD (l_ccomp) decreased/VBN (l_nsubjpass) activity/NN (l_compound) Seizure/NN -PUNC- MPA/NNP (r_appos) acid/NN (r_pobj) to/IN (r_pcomp) due/IN (r_prep) activity/NN (l_compound) seizure/NN
D001556_D012640 NONE hexachlorocyclohexane/NN (r_pobj) of/IN (r_prep) effects/NNS (l_prep) on/IN (l_pobj) seizures/NNS -PUNC- lindane/NN (r_appos) hexachlorocyclohexane/NN (r_pobj) of/IN (r_prep) effects/NNS (l_prep) on/IN (l_pobj) seizures/NNS -PUNC- hexachlorocyclohexane/NN (r_nsubjpass) shown/VBN (l_xcomp) decrease/VB (l_dobj) threshold/NN (l_compound) seizure/NN -PUNC- HCH/NNP (r_appos) hexachlorocyclohexane/NN (r_nsubjpass) shown/VBN (l_xcomp) decrease/VB (l_dobj) threshold/NN (l_compound) seizure/NN -PUNC- lindane/NN (r_pobj) of/IN (r_prep) ingredient/NN (r_appos) hexachlorocyclohexane/NN (r_nsubjpass) shown/VBN (l_xcomp) decrease/VB (l_dobj) threshold/NN (l_compound) seizure/NN -PUNC- HCH/NNP (r_pobj) to/IN (r_prep) exposure/NN (r_pobj) after/IN (r_prep) h/NN (l_conj) increase/VB (l_prep) to/IN (l_pobj) seizures/NNS -PUNC- HCH/NNP (r_pobj) to/IN (r_prep) exposure/NN (r_pobj) after/IN (r_prep) h/NN (l_dep) h/NN (l_conj) increase/VB (l_prep) to/IN (l_pobj) seizures/NNS -PUNC- HCH/NNP (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) tested/VBN (l_nsubjpass) severity/NN (l_prep) of/IN (l_pobj) response/NN (l_prep) to/IN (l_pobj) agents/NNS (l_amod) inducing/VBG (l_npadvmod) seizure/NN -PUNC- HCH/NNP (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) increased/VBN (l_nsubjpass) activity/NN (l_prep) of/IN (l_pobj) agents/NNS (l_amod) inducing/VBG (l_npadvmod) seizure/NN -PUNC- HCH/NNP (r_appos) h/NN (r_dep) observed/VBN (l_advcl) increased/VBN (l_nsubjpass) activity/NN (l_prep) of/IN (l_pobj) agents/NNS (l_amod) inducing/VBG (l_npadvmod) seizure/NN -PUNC- HCH/NNP (r_pobj) after/IN (r_prep) h/NN (r_npadvmod) occur/VB (l_prep) to/IN (l_pobj) activity/NN (l_compound) seizure/NN -PUNC- HCH/NNP (r_pobj) after/IN (r_prep) h/NN (r_npadvmod) occur/VB (l_advcl) decreased/VBN (l_nsubjpass) response/NN (l_prep) to/IN (l_pobj) agents/NNS (l_amod) inducing/VBG (l_npadvmod) seizure/NN -PUNC- HCH/NNP (r_nsubj) be/VB (l_nsubj) site/NN (l_amod) responsible/JJ (l_prep) for/IN (l_pobj) decrease/NN (l_prep) in/IN (l_pobj) activity/NN (l_compound) seizure/NN
9284778
-1_D008107 NONE hydrochlorofluorocarbons/NNS (r_pobj) by/IN (r_agent) caused/VBN (r_acl) Epidemic/NN (l_prep) of/IN (l_pobj) disease/NN
D010126_D008107 NONE ozone/NN (r_npadvmod) sparing/VBG (r_amod) substitutes/NNS (r_pobj) as/IN (r_prep) used/VBN (r_acl) hydrochlorofluorocarbons/NNS (r_pobj) by/IN (r_agent) caused/VBN (r_acl) Epidemic/NN (l_prep) of/IN (l_pobj) disease/NN
C072959_D056486 NONE 124/CD (r_conj) HCFCs/NNS (r_pobj) to/IN (r_prep) exposure/NN (r_nsubj) result/VB (l_prep) in/IN (l_pobj) injury/NN
D006221_D056486 NONE 1-bromo-1-chloro-2,2,2-trifluoroethane/CD (r_pobj) as/IN (r_prep) way/NN (r_pobj) in/IN (r_prep) metabolised/VBN (l_advcl) form/VB (l_dobj) intermediates/NNS (l_relcl) implicated/VBN (l_prep) in/IN (l_pobj) hepatotoxicity/NN -PUNC- halothane/NN (r_appos) 1-bromo-1-chloro-2,2,2-trifluoroethane/CD (r_pobj) as/IN (r_prep) way/NN (r_pobj) in/IN (r_prep) metabolised/VBN (l_advcl) form/VB (l_dobj) intermediates/NNS (l_relcl) implicated/VBN (l_prep) in/IN (l_pobj) hepatotoxicity/NN -PUNC- halothane/NN (r_pobj) of/IN (r_prep) hepatotoxicity/NN
D014269_D056486 NONE trifluoroacetyl/NNS (r_compound) halide/NN (r_compound) intermediates/NNS (l_relcl) implicated/VBN (l_prep) in/IN (l_pobj) hepatotoxicity/NN -PUNC- trifluoroacetyl/NN (r_npadvmod) altered/VBN (r_amod) proteins/NNS (r_nsubjpass) involved/VBN (r_ccomp) suggest/VBP (l_advcl) known/VBN (l_nsubjpass) mechanism/NN (l_prep) of/IN (l_pobj) hepatotoxicity/NN
D017402_D008107 NONE chlorofluorocarbons/NNS (r_pobj) of/IN (r_prep) substitutes/NNS (r_pobj) as/IN (r_prep) used/VBN (r_acl) hydrochlorofluorocarbons/NNS (r_pobj) by/IN (r_agent) caused/VBN (r_acl) Epidemic/NN (l_prep) of/IN (l_pobj) disease/NN
C067411_D008107 CID 1,1-dichloro-2,2,2-trifluoroethane/CD (r_pobj) of/IN (r_prep) mixture/NN (r_pobj) to/IN (r_prep) exposure/NN (r_dobj) repeated/VBN (r_relcl) workers/NNS (r_pobj) in/IN (r_prep) epidemic/NN (l_prep) of/IN (l_pobj) disease/NN -PUNC- 123/CD (r_nummod) HCFC/NNP (r_appos) 1,1-dichloro-2,2,2-trifluoroethane/CD (r_pobj) of/IN (r_prep) mixture/NN (r_pobj) to/IN (r_prep) exposure/NN (r_dobj) repeated/VBN (r_relcl) workers/NNS (r_pobj) in/IN (r_prep) epidemic/NN (l_prep) of/IN (l_pobj) disease/NN -PUNC- 124/CD (r_conj) HCFCs/NNS (r_nsubj) result/VB (l_prep) in/IN (l_pobj) disease/NN
C067411_D056486 NONE 124/CD (r_conj) HCFCs/NNS (r_pobj) to/IN (r_prep) exposure/NN (r_nsubj) result/VB (l_prep) in/IN (l_pobj) injury/NN
C072959_D008107 CID 1-chloro-1,2,2,2-tetrafluoroethane/NN (r_conj) HCFC/NNP (r_appos) 1,1-dichloro-2,2,2-trifluoroethane/CD (r_pobj) of/IN (r_prep) mixture/NN (r_pobj) to/IN (r_prep) exposure/NN (r_dobj) repeated/VBN (r_relcl) workers/NNS (r_pobj) in/IN (r_prep) epidemic/NN (l_prep) of/IN (l_pobj) disease/NN -PUNC- 124/CD (r_nummod) HCFC/NNP (r_appos) HCFC/NNP (r_appos) 1,1-dichloro-2,2,2-trifluoroethane/CD (r_pobj) of/IN (r_prep) mixture/NN (r_pobj) to/IN (r_prep) exposure/NN (r_dobj) repeated/VBN (r_relcl) workers/NNS (r_pobj) in/IN (r_prep) epidemic/NN (l_prep) of/IN (l_pobj) disease/NN -PUNC- 124/CD (r_conj) HCFCs/NNS (r_nsubj) result/VB (l_prep) in/IN (l_pobj) disease/NN
11679859
D011346_D014839 NONE prochlorperazine/NN (l_prep) for/IN (l_pobj) headache/NN (l_conj) nausea/NN (l_conj) vomiting/NN
D011346_D009325 NONE prochlorperazine/NN (l_prep) for/IN (l_pobj) headache/NN (l_conj) nausea/NN -PUNC- prochlorperazine/NN (r_pobj) of/IN (r_prep) efficacy/NN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) headache/NN (l_conj) nausea/NN
D011346_D017109 CID prochlorperazine/NN (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) affect/VB (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) akathisia/NN -PUNC- prochlorperazine/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) akathisia/NN -PUNC- prochlorperazine/NN (r_nsubjpass) administered/VBN (r_advcl) reduction/NN (l_prep) in/IN (l_pobj) incidence/NN (l_prep) of/IN (l_pobj) akathisia/NN
D011346_D006261 NONE prochlorperazine/NN (l_prep) for/IN (l_pobj) headache/NN -PUNC- prochlorperazine/NN (r_pobj) of/IN (r_prep) efficacy/NN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) headache/NN
7053303
D002927_D007674 NONE cimetidine/NN (l_prep) in/IN (l_pobj) group/NN (l_prep) of/IN (l_pobj) patients/NNS (l_prep) without/IN (l_pobj) disease/NN -PUNC- cimetidine/JJ (r_compound) levels/NNS (r_dobj) had/VBD (r_relcl) disease/NN
D002927_D008107 NONE cimetidine/NN (l_prep) in/IN (l_pobj) group/NN (l_prep) of/IN (l_pobj) patients/NNS (l_prep) without/IN (l_pobj) disease/NN -PUNC- cimetidine/JJ (r_compound) levels/NNS (r_dobj) had/VBD (r_relcl) disease/NN
D002927_D003704 CID cimetidine/NN (r_pobj) due/IN (r_amod) case/NN (l_prep) of/IN (l_pobj) dementia/NN -PUNC- cimetidine/JJ (r_compound) levels/NNS (r_dobj) had/VBD (r_relcl) disease/NN (r_pobj) without/IN (r_prep) patients/NNS (r_pobj) of/IN (r_prep) group/NN (r_pobj) in/IN (r_prep) cimetidine/NN (r_pobj) due/IN (r_amod) case/NN (l_prep) of/IN (l_pobj) dementia/NN -PUNC- cimetidine/NN (r_compound) levels/NNS (r_nsubj) induce/VB (l_dobj) dementia/NN
8741744
D009538_D006948 CID nicotine/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) hypoactivity/NN (r_dobj) blunted/VBD (l_advcl) enhanced/VBD (l_dobj) hyperactivity/NN -PUNC- nicotine/NN (r_npadvmod) induced/VBN (r_amod) hyperactivity/NN
D009538_D009069 NONE nicotine/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) hypoactivity/NN -PUNC- nicotine/NN (r_npadvmod) induced/VBN (r_amod) hyperactivity/NN (r_dobj) enhanced/VBD (r_advcl) blunted/VBD (l_dobj) hypoactivity/NN
3564823
D013874_D002545 NONE pentothal/NNS (r_nsubjpass) infused/VBN (l_advcl) minimize/VB (l_dobj) ischaemia/NN
D008012_D013035 NONE lidocaine/NN (r_pobj) by/IN (r_prep) relieved/VBN (l_nsubj) spasm/NN
D008012_D020301 NONE lidocaine/NN (r_nsubjpass) given/VBN (l_advcl) counteract/VB (l_dobj) vasospasm/NN
16005948
-1_D062787 NONE GNC92H2/NNP (r_pobj) of/IN (r_prep) Evaluation/NN (l_prep) as/IN (l_pobj) immunotherapy/NN (l_prep) for/IN (l_pobj) overdose/NN -PUNC- GNC92H2/NNP (r_pobj) of/IN (r_prep) potential/NN (r_nsubjpass) examined/VBN (l_advcl) using/VBG (l_dobj) model/NN (l_prep) of/IN (l_pobj) overdose/NN -PUNC- GNC92H2/NNP (r_pobj) of/IN (r_prep) potential/NN (l_prep) as/IN (l_pobj) tool/NN (l_prep) against/IN (l_pobj) overdose/NN
D003042_D064420 NONE cocaine/NN (r_compound) toxicity/NN
-1_D003643 NONE GNC92H2/NNP (r_pobj) of/IN (r_prep) dose/NN (l_appos) seizures/NNS (l_prt) up/IN (l_prep) to/TO (l_pobj) %/NN (l_conj) death/NN -PUNC- GNC92H2/NNP (r_nsubj) prevented/VBD (l_dobj) death/NN
D003042_D062787 NONE cocaine/NN (r_pobj) of/IN (r_prep) use/NN (r_nsubj) continues/VBZ (l_prep) in/IN (l_pobj) proportions/NNS (l_conj) treatment/NN (l_prep) for/IN (l_pobj) overdose/NN
-1_D064420 NONE GNC92H2/NNP (r_pobj) of/IN (r_prep) dose/NN (r_pobj) with/IN (r_prep) observed/VBN (l_nsubjpass) blockade/NN (l_prep) of/IN (l_pobj) toxicity/NN
D003042_D003643 NONE cocaine/NN (r_compound) toxicity/NN (r_pobj) of/IN (r_prep) blockade/NN (r_nsubjpass) observed/VBN (l_prep) with/IN (l_pobj) dose/NN (l_appos) seizures/NNS (l_prt) up/IN (l_prep) to/TO (l_pobj) %/NN (l_conj) death/NN -PUNC- cocaine/NN (r_compound) injection/NN (r_dobj) prevented/VBD (l_dobj) death/NN
D003042_D012640 CID cocaine/NN (r_compound) toxicity/NN (r_pobj) of/IN (r_prep) blockade/NN (r_nsubjpass) observed/VBN (l_prep) with/IN (l_pobj) dose/NN (l_appos) seizures/NNS
-1_D012640 NONE GNC92H2/NNP (r_pobj) of/IN (r_prep) dose/NN (l_appos) seizures/NNS
6773726
D005996_D007022 CID nitroglycerin/NN (r_pobj) by/IN (r_prep) hypotension/NN
D005996_D003929 NONE nitroglycerin/NN (l_prep) in/IN (l_pobj) neuropathy/NN
D005996_D009422 NONE nitroglycerin/NN (r_pobj) of/IN (r_prep) effect/NN (r_nsubjpass) compared/VBN (l_prep) in/IN (l_pobj) subjects/NNS (l_appos) subjects/NNS (l_prep) without/IN (l_pobj) neuropathy/NN -PUNC- nitroglycerin/NN (r_pobj) of/IN (r_prep) effect/NN (r_nsubjpass) compared/VBN (l_prep) in/IN (l_pobj) subjects/NNS (l_appos) subjects/NNS (l_conj) subjects/NNS (l_prep) with/IN (l_pobj) neuropathy/NN -PUNC- nitroglycerin/NN (r_pobj) after/IN (r_prep) decrease/NN (r_conj) increase/NN (r_pobj) of/IN (r_prep) course/NN (r_nsubj) were/VBD (l_acomp) similar/JJ (l_prep) in/IN (l_pobj) subjects/NNS (l_prep) without/IN (l_pobj) neuropathy/NN -PUNC- nitroglycerin/NN (r_pobj) after/IN (r_prep) decrease/NN (r_conj) increase/NN (r_pobj) of/IN (r_prep) course/NN (r_nsubj) were/VBD (l_advcl) occurred/VBD (l_prep) in/IN (l_pobj) subjects/NNS (l_prep) with/IN (l_pobj) neuropathy/NN
D005996_D003920 NONE nitroglycerin/NN (r_pobj) of/IN (r_prep) effect/NN (r_nsubjpass) compared/VBN (l_prep) in/IN (l_pobj) subjects/NNS (l_appos) subjects/NNS (l_amod) diabetic/JJ -PUNC- nitroglycerin/NN (r_pobj) of/IN (r_prep) effect/NN (r_nsubjpass) compared/VBN (l_prep) in/IN (l_pobj) subjects/NNS (l_appos) subjects/NNS (l_conj) subjects/NNS (l_amod) diabetic/JJ -PUNC- nitroglycerin/NN (r_pobj) after/IN (r_prep) decrease/NN (r_conj) increase/NN (r_pobj) of/IN (r_prep) course/NN (r_nsubj) were/VBD (l_acomp) similar/JJ (l_prep) in/IN (l_pobj) subjects/NNS (l_amod) normal/JJ (l_conj) diabetic/JJ -PUNC- nitroglycerin/NN (r_pobj) after/IN (r_prep) decrease/NN (r_conj) increase/NN (r_pobj) of/IN (r_prep) course/NN (r_nsubj) were/VBD (l_advcl) occurred/VBD (l_prep) in/IN (l_pobj) subjects/NNS (l_amod) diabetic/JJ
9100294
D020748_D018376 CID 5967/CD (r_prep) 40/CD (r_nummod) Ro/NNP (r_appos) blocker/NN (r_nsubj) induced/VBD (l_dobj) alterations/NNS
D002118_D018376 NONE calcium/NN (r_compound) channel/NN (r_compound) blockers/NNS (r_pobj) to/IN (r_prep) exposed/VBN (r_acl) alterations/NNS -PUNC- calcium/NN (r_compound) channel/NN (r_compound) blocker/NN (r_nsubj) induced/VBD (l_dobj) alterations/NNS -PUNC- calcium/NN (r_compound) channel/NN (r_compound) blockers/NNS (r_nsubj) induce/VBP (l_dobj) malformations/NNS -PUNC- calcium/NN (r_compound) channel/NN (r_compound) blockers/NNS (r_pobj) of/IN (r_prep) one/CD (r_dobj) administered/VBN (l_prep) during/IN (l_pobj) period/NN (l_prep) of/IN (l_pobj) morphogenesis/NN (l_conj) offspring/NN (l_acl) examined/VBD (l_prep) on/IN (l_pobj) day/NN (l_prep) of/IN (l_pobj) gestation/NN (l_prep) for/IN (l_pobj) malformations/NNS -PUNC- calcium/NN (r_compound) channel/NN (r_compound) blockers/NNS (r_pobj) of/IN (r_prep) each/DT (r_pobj) to/IN (r_prep) exposure/NN (r_pobj) after/IN (r_prep) observed/VBN (l_nsubjpass) incidence/NN (l_prep) of/IN (l_pobj) malformations/NNS
D014700_D018376 CID verapamil/NN (r_pobj) for/IN (r_prep) significant/JJ (r_acomp) was/VBD (r_conj) observed/VBN (l_nsubjpass) incidence/NN (l_prep) of/IN (l_pobj) malformations/NNS
D009543_D018376 CID nifedipine/NN (r_conj) verapamil/NN (r_pobj) for/IN (r_prep) significant/JJ (r_acomp) was/VBD (r_conj) observed/VBN (l_nsubjpass) incidence/NN (l_prep) of/IN (l_pobj) malformations/NNS
20080419
D010862_D004827 CID pilocarpine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) model/NN (l_prep) of/IN (l_pobj) epilepsy/NN
3719553
D011241_D004342 NONE prednisone/NNP (r_conj) diphenhydramine/NN (r_nsubj) were/VBD (l_prep) in/IN (l_pcomp) preventing/VBG (l_dobj) recurrence/NN (l_prep) of/IN (l_pobj) reaction/NN
D005472_D009062 NONE 5-fluorouracil/CD (r_punct) reaction/NN (r_nsubj) occurred/VBD (l_prep) in/IN (l_pobj) patient/NN (l_prep) with/IN (l_pobj) carcinoma/NN (l_prep) of/IN (l_pobj) cavity/NN
D004155_D004342 NONE diphenhydramine/NN (r_nsubj) were/VBD (l_prep) in/IN (l_pcomp) preventing/VBG (l_dobj) recurrence/NN (l_prep) of/IN (l_pobj) reaction/NN
D005472_D000799 CID 5-fluorouracil/CD (r_punct) reaction/NN (l_acl) consisting/VBG (l_prep) of/IN (l_pobj) edema/NN
D002945_D007674 NONE cisplatin/NN (r_advmod) induced/VBN (r_amod) function/NN
D005472_D004342 NONE 5-fluorouracil/CD (r_punct) infusion/NN (r_pobj) to/IN (r_prep) reaction/NN -PUNC- 5-fluorouracil/CD (r_punct) reaction/NN
D002945_D004342 NONE cisplatin/NN (r_advmod) induced/VBN (r_amod) function/NN (r_conj) cirrhosis/NN (r_conj) cavity/NN (r_pobj) of/IN (r_prep) carcinoma/NN (r_pobj) with/IN (r_prep) patient/NN (r_pobj) in/IN (r_prep) occurred/VBD (l_nsubj) reaction/NN
D005472_D005355 NONE 5-fluorouracil/CD (r_punct) reaction/NN (r_nsubj) occurred/VBD (l_prep) in/IN (l_pobj) patient/NN (l_prep) with/IN (l_pobj) carcinoma/NN (l_prep) of/IN (l_pobj) cavity/NN (l_conj) cirrhosis/NN
D005472_D007674 NONE 5-fluorouracil/CD (r_punct) reaction/NN (r_nsubj) occurred/VBD (l_prep) in/IN (l_pobj) patient/NN (l_prep) with/IN (l_pobj) carcinoma/NN (l_prep) of/IN (l_pobj) cavity/NN (l_conj) cirrhosis/NN (l_conj) function/NN
D002945_D005355 NONE cisplatin/NN (r_advmod) induced/VBN (r_amod) function/NN (r_conj) cirrhosis/NN
D002945_D009062 NONE cisplatin/NN (r_advmod) induced/VBN (r_amod) function/NN (r_conj) cirrhosis/NN (r_conj) cavity/NN
D002945_D000799 NONE cisplatin/NN (r_advmod) induced/VBN (r_amod) function/NN (r_conj) cirrhosis/NN (r_conj) cavity/NN (r_pobj) of/IN (r_prep) carcinoma/NN (r_pobj) with/IN (r_prep) patient/NN (r_pobj) in/IN (r_prep) occurred/VBD (l_nsubj) reaction/NN (l_acl) consisting/VBG (l_prep) of/IN (l_pobj) edema/NN
8955532
D003911_D006973 NONE dextran/NN (r_pobj) of/IN (r_prep) clearance/NN (l_prep) before/IN (l_conj) during/IN (l_pobj) hypertension/NN
D001920_D006973 NONE bradykinin/NN (l_prep) in/IN (l_pobj) disruption/NN (l_prep) during/IN (l_pobj) hypertension/NN -PUNC- bradykinin/NN (r_pobj) of/IN (r_prep) release/NN (r_pobj) of/IN (r_prep) role/NN (r_dobj) determine/VB (l_xcomp) activate/VB (l_prep) in/IN (l_pobj) disruption/NN (l_prep) during/IN (l_pobj) hypertension/NN -PUNC- bradykinin/NN (r_pobj) of/IN (r_prep) release/NN (r_pobj) to/IN (r_prep) related/VBN (l_auxpass) is/VBZ (l_nsubj) disruption/NN (l_prep) during/IN (l_pobj) hypertension/NN
D010656_D006973 CID phenylephrine/NN (r_npadvmod) induced/VBN (r_amod) hypertension/NN
C065679_D006973 NONE Hoe-140/NNP (r_conj) vehicle/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) rats/NNS (r_pobj) in/IN (r_prep) hypertension/NN
18768591
D012964_D005355 NONE sodium/NN (r_compound) channel/NN (l_appos) retention/NN (l_conj) fibrosis/NN
D004317_D009404 CID doxorubicin/NN (r_npadvmod) induced/VBN (r_amod) syndrome/NN -PUNC- Doxorubicin/NNP (r_compound) treatment/NN (r_nsubj) resulted/VBD (l_conj) 15/44/CD (l_prep) of/IN (l_pobj) mice/NNS (l_acl) leading/VBG (l_prep) to/IN (l_pobj) syndrome/NN
D014508_D009404 NONE urea/NN (r_compound) concentrations/NNS (r_nsubj) increased/VBD (l_prep) During/IN (l_pobj) course/NN (l_prep) of/IN (l_pobj) syndrome/NN
D012964_D016055 NONE sodium/NN (r_compound) channel/NN (l_appos) retention/NN
D004317_D034141 CID Doxorubicin/NNP (r_compound) treatment/NN (r_nsubj) resulted/VBD (l_conj) 15/44/CD (l_prep) of/IN (l_pobj) mice/NNS (l_acl) leading/VBG (l_prep) to/IN (l_pobj) syndrome/NN (l_prep) with/IN (l_pobj) ascites/NNS (l_conj) lipidemia/NN (l_conj) hypoalbuminemia/VB
D000450_D005355 NONE aldosterone/NN (r_npadvmod) sensitive/JJ (r_amod) SGK1/NNP (r_nsubjpass) shown/VBN (l_xcomp) participate/VB (l_conj) mediate/VB (l_dobj) fibrosis/NN
D000450_D009404 NONE aldosterone/NN (r_compound) levels/NNS (r_nsubj) increased/VBD (l_prep) in/IN (l_pobj) mice/NNS (l_amod) nephrotic/JJ
D004317_D011507 CID Doxorubicin/NNP (r_compound) treatment/NN (r_nsubj) resulted/VBD (l_prep) in/IN (l_pobj) proteinuria/NN
D012964_D007674 NONE sodium/NN (r_compound) channel/NN (r_pobj) to/IN (r_prep) leads/VBZ (l_nsubj) nephropathy/NN
D004317_D007674 NONE Doxorubicin/NNP (r_npadvmod) induced/VBN (r_amod) nephropathy/NN
D004317_D016055 NONE Doxorubicin/NNP (r_npadvmod) induced/VBN (r_amod) nephropathy/NN (r_nsubj) leads/VBZ (l_prep) to/IN (l_pobj) channel/NN (l_appos) retention/NN
D004317_D005355 NONE Doxorubicin/NNP (r_npadvmod) induced/VBN (r_amod) nephropathy/NN (r_nsubj) leads/VBZ (l_prep) to/IN (l_pobj) channel/NN (l_appos) retention/NN (l_conj) fibrosis/NN
D004317_D001201 CID Doxorubicin/NNP (r_compound) treatment/NN (r_nsubj) resulted/VBD (l_conj) 15/44/CD (l_prep) of/IN (l_pobj) mice/NNS (l_acl) leading/VBG (l_prep) to/IN (l_pobj) syndrome/NN (l_prep) with/IN (l_pobj) ascites/NNS
D004317_D006949 CID Doxorubicin/NNP (r_compound) treatment/NN (r_nsubj) resulted/VBD (l_conj) 15/44/CD (l_prep) of/IN (l_pobj) mice/NNS (l_acl) leading/VBG (l_prep) to/IN (l_pobj) syndrome/NN (l_prep) with/IN (l_pobj) ascites/NNS (l_conj) lipidemia/NN
1919871
D001241_D007681 CID aspirin/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) during/IN (r_prep) developed/VBN (r_acl) ability/NN (r_conj) necrosis/NN -PUNC- aspirin/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) during/IN (r_prep) developed/VBN (r_acl) ability/NN (r_conj) necrosis/NN (l_appos) RPN/NNP
D000082_D007681 CID paracetamol/JJ (r_conj) aspirin/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) during/IN (r_prep) developed/VBN (r_acl) ability/NN (r_conj) necrosis/NN -PUNC- paracetamol/JJ (r_conj) aspirin/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) during/IN (r_prep) developed/VBN (r_acl) ability/NN (r_conj) necrosis/NN (l_appos) RPN/NNP
9495837
D012601_D000647 CID scopolamine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) amnesia/NN
C087567_D000647 NONE /-)-PG-9/. (r_nsubj) was/VBD (l_acomp) able/JJ (l_xcomp) prevent/VB (l_dobj) amnesia/NN -PUNC- /-)-PG-9/NFP (r_conj) of/IN (r_prep) profiles/NNS (r_nsubj) shown/VBN (l_dobj) ratio/NN (l_relcl) be/VB (l_acomp) responsible/JJ (l_prep) for/IN (l_pobj) antinociception/NN (l_conj) effect/NN (l_amod) amnesic/JJ -PUNC- /-)-PG-9/NFP (r_punct) shown/VBN (l_dobj) ratio/NN (l_relcl) be/VB (l_acomp) responsible/JJ (l_prep) for/IN (l_pobj) antinociception/NN (l_conj) effect/NN (l_amod) amnesic/JJ
D004025_D000647 CID dicyclomine/NN (r_conj) kg-1/NNP (r_appos) scopolamine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) amnesia/NN
D000109_D000647 NONE acetylcholine/NN (r_amod) levels/NNS (r_pobj) in/IN (r_prep) increase/NN (r_pobj) through/IN (r_prep) /-)-PG-9/NFP (r_punct) shown/VBN (l_dobj) ratio/NN (l_relcl) be/VB (l_acomp) responsible/JJ (l_prep) for/IN (l_pobj) antinociception/NN (l_conj) effect/NN (l_amod) amnesic/JJ
11426838
D009838_D012640 NONE oligodeoxynucleotide/NN (r_appos) receptors/NNS (r_pobj) of/IN (r_prep) antagonism/NN (r_dobj) involved/VBD (r_acl) ligands/NNS (r_pobj) of/IN (r_prep) effects/NNS (r_nsubjpass) shown/VBN (l_xcomp) attenuate/VB (l_dobj) effects/NNS (l_amod) convulsive/JJ
D003042_D064420 NONE cocaine/NN (r_pobj) of/IN (r_prep) toxicity/NN
C093337_D012640 NONE BD1063/NNP (r_conj) BD1018/NN (r_pobj) with/IN (r_punct) attenuated/VBD (r_amod) convulsions/NNS
C050232_D064420 NONE tolylguanidine/NN (r_nmod) DTG/NNP (r_appos) antagonists/NNS (r_pobj) by/IN (r_agent) provided/VBN (r_acl) protection/NN (r_pobj) to/IN (r_prep) contrast/NN (r_pobj) In/IN (r_prep) worsened/VBD (l_dobj) toxicity/NN -PUNC- DTG/NNP (r_appos) antagonists/NNS (r_pobj) by/IN (r_agent) provided/VBN (r_acl) protection/NN (r_pobj) to/IN (r_prep) contrast/NN (r_pobj) In/IN (r_prep) worsened/VBD (l_dobj) toxicity/NN
-1_D064420 NONE BD1031/NN (r_conj) DTG/NNP (r_appos) antagonists/NNS (r_pobj) by/IN (r_agent) provided/VBN (r_acl) protection/NN (r_pobj) to/IN (r_prep) contrast/NN (r_pobj) In/IN (r_prep) worsened/VBD (l_dobj) toxicity/NN -PUNC- 3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane/NN (r_appos) BD1031/NN (r_conj) DTG/NNP (r_appos) antagonists/NNS (r_pobj) by/IN (r_agent) provided/VBN (r_acl) protection/NN (r_pobj) to/IN (r_prep) contrast/NN (r_pobj) In/IN (r_prep) worsened/VBD (l_dobj) toxicity/NN
D003042_D012640 CID cocaine/NN (r_npadvmod) induced/VBN (r_amod) convulsions/NNS -PUNC- cocaine/NN (r_compound) effects/NNS (r_nsubjpass) shown/VBN (l_xcomp) attenuate/VB (l_dobj) effects/NNS (l_amod) convulsive/JJ -PUNC- cocaine/NN (r_pobj) of/IN (r_prep) effects/NNS (l_amod) convulsive/JJ
-1_D012640 NONE BD1018/NN (r_pobj) with/IN (r_punct) attenuated/VBD (r_amod) convulsions/NNS -PUNC- LR132/NNS (r_conj) BD1063/NNP (r_conj) BD1018/NN (r_pobj) with/IN (r_punct) attenuated/VBD (r_amod) convulsions/NNS
9931093
C079574_D006973 NONE 139317/CD (r_nummod) FR/NNP (l_prep) on/IN (l_pobj) hypertension/NN
D016559_D006973 CID 506-induced/JJ (r_nummod) hypertension/NN -PUNC- 506/CD (r_nummod) FK/NNP (r_pobj) of/IN (r_prep) utility/NN (r_nsubjpass) complicated/VBN (l_agent) by/IN (l_pobj) hypertension/NN -PUNC- 506-induced/JJ (r_compound) hypertension/NN -PUNC- 506/CD (r_nummod) FK/NNP (r_pobj) of/IN (r_prep) effects/NNS (r_dobj) studied/VBD (l_advcl) clarify/VB (l_dobj) mechanisms/NNS (l_prep) of/IN (l_pobj) hypertension/NN -PUNC- 506-induced/JJ (r_nummod) FK/NNP (r_poss) hypertension/NN -PUNC- 506-induced/JJ (r_nummod) hypertension/NN
D009569_D006973 NONE oxide/NN (r_compound) synthase/NN (r_conj) expression/NN (r_dobj) studied/VBD (l_advcl) clarify/VB (l_dobj) mechanisms/NNS (l_prep) of/IN (l_pobj) hypertension/NN
D016559_D007674 NONE 506/CD (r_nummod) FK/NNP (r_pobj) of/IN (r_prep) utility/NN (r_nsubjpass) complicated/VBN (l_agent) by/IN (l_pobj) hypertension/NN (l_conj) nephrotoxicity/NN
20882060
D009496_D010302 NONE neurotensin/NN (l_prep) on/IN (l_pobj) symptoms/NNS
D006220_D010302 NONE haloperidol/NN (r_npadvmod) induced/VBN (r_amod) symptoms/NNS
D009496_D002375 NONE neurotensin/NN (l_prep) on/IN (l_pobj) catalepsy/NN -PUNC- neurotensin/NN (r_pobj) of/IN (r_prep) infusions/NNS (r_nsubj) reversed/VBD (l_dobj) catalepsy/NN
D006220_D002375 CID haloperidol/NN (r_npadvmod) induced/VBN (r_amod) catalepsy/NN -PUNC- haloperidol/NN (r_npadvmod) induced/VBN (r_amod) catalepsy/NN
8170551
D000086_D009468 NONE Acetazolamide/RB (r_npadvmod) induced/VBN (r_amod) nephrolithiasis/NN (l_appos) implications/NNS (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) disorders/NNS
D000086_D007669 CID acetazolamide/NN (r_pobj) on/IN (r_prep) patients/NNS (r_nsubj) developed/VBN (l_dobj) calculi/NNS
D000086_D053040 NONE Acetazolamide/RB (r_npadvmod) induced/VBN (r_amod) nephrolithiasis/NN -PUNC- acetazolamide/NN (r_pobj) of/IN (r_prep) complication/NN (r_attr) is/VBZ (l_nsubj) Nephrolithiasis/NNP
15130900
D003520_D014890 NONE cyclophosphamide/NN (r_pobj) to/IN (r_prep) risks/NNS (r_appos) granulomatosis/NN -PUNC- cyclophosphamide/NN (r_pobj) to/IN (r_prep) relation/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) granulomatosis/NN -PUNC- cyclophosphamide/NN (r_pobj) between/IN (r_prep) relationship/NN (l_conj) risk/NN (l_conj) risks/NNS (l_conj) possibility/NN (l_prep) of/IN (l_pobj) factors/NNS (l_acl) operating/VBG (l_prep) before/IN (l_pobj) granulomatosis/NN
D003520_D001749 CID cyclophosphamide/NN (r_pobj) to/IN (r_prep) risks/NNS (r_appos) granulomatosis/NN (r_pobj) in/IN (r_prep) cancer/NN -PUNC- cyclophosphamide/NN (r_pobj) to/IN (r_prep) relation/NN (r_conj) assess/VB (l_conj) characterise/VB (l_dobj) risk/NN (l_prep) of/IN (l_pobj) cancer/NN -PUNC- cyclophosphamide/NN (l_conj) cancer/NN -PUNC- cyclophosphamide/NN (r_pobj) in/IN (r_prep) increment/NN (r_pobj) for/IN (r_prep) doubled/VBD (l_nsubj) risk/NN (l_prep) of/IN (l_pobj) cancer/NN -PUNC- cyclophosphamide/NN (r_pobj) between/IN (r_prep) relationship/NN (l_conj) risk/NN (l_prep) of/IN (l_pobj) cancer/NN
7234705
D011342_D008133 NONE procainamide/NN (r_nsubj) produce/VB (l_dobj) syndrome/NN
D011342_D001282 NONE procainamide/NN (r_nsubjpass) administered/VBN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) contractions/NNS (l_conj) flutter/NN
D011342_D018879 NONE procainamide/NN (r_nsubjpass) administered/VBN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) contractions/NNS
D011342_D017180 CID Procainamide/NNP (r_npadvmod) induced/VBN (l_dobj) tachycardia/NN -PUNC- procainamide/RB (r_advmod) induced/VBN (r_amod) tachycardia/NNS -PUNC- procainamide/NN (r_pobj) of/IN (r_prep) mg/IN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) appeared/VBD (l_nsubj) tachycardia/NN -PUNC- procainamide/NN (r_pobj) of/IN (r_prep) mg/IN (r_pobj) of/IN (r_prep) administration/NN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) tachycardia/NN -PUNC- procainamide/NN (r_amod) therapy/NN (r_pobj) of/IN (r_prep) continuation/NN (r_pobj) despite/IN (r_prep) reoccur/VB (l_nsubj) tachycardia/NN -PUNC- procainamide/NN (r_nsubj) produce/VB (l_prep) with/IN (l_pobj) tachycardia/NN
6466532
D006024_D001919 NONE glycopyrrolate/NN (l_prep) in/IN (l_pobj) prevention/NN (l_prep) of/IN (l_pobj) bradycardia/NN -PUNC- glycopyrrolate/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) of/IN (r_prep) effectiveness/NN (l_acl) prevent/VB (l_dobj) arrhythmia/NN (l_conj) bradycardia/NNP
D013390_D001145 NONE suxamethonium/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) following/VBG (r_prep) bradycardia/NN (l_conj) arrhythmias/NNS -PUNC- suxamethonium/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) following/VBG (r_prep) prevent/VB (l_dobj) arrhythmia/NN
D001285_D001919 NONE atropine/NN (r_conj) glycopyrrolate/NN (l_prep) in/IN (l_pobj) prevention/NN (l_prep) of/IN (l_pobj) bradycardia/NN -PUNC- atropine/NN (r_conj) kg-1/NNS (r_dobj) glycopyrrolate/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) of/IN (r_prep) effectiveness/NN (l_acl) prevent/VB (l_dobj) arrhythmia/NN (l_conj) bradycardia/NNP
D001285_D001145 NONE atropine/NN (r_conj) glycopyrrolate/NN (l_prep) in/IN (l_pobj) prevention/NN (l_prep) of/IN (l_pobj) bradycardia/NN (l_conj) arrhythmias/NNS -PUNC- atropine/NN (r_conj) kg-1/NNS (r_dobj) glycopyrrolate/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) of/IN (r_prep) effectiveness/NN (l_acl) prevent/VB (l_dobj) arrhythmia/NN
D006024_D001145 NONE glycopyrrolate/NN (l_prep) in/IN (l_pobj) prevention/NN (l_prep) of/IN (l_pobj) bradycardia/NN (l_conj) arrhythmias/NNS -PUNC- glycopyrrolate/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) of/IN (r_prep) effectiveness/NN (l_acl) prevent/VB (l_dobj) arrhythmia/NN
D013390_D001919 CID suxamethonium/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) following/VBG (r_prep) bradycardia/NN -PUNC- suxamethonium/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) following/VBG (r_prep) prevent/VB (l_dobj) arrhythmia/NN (l_conj) bradycardia/NNP
2476560
D001556_D012532 NONE lindane/NN (r_dobj) consider/VBP (l_ccomp) initiated/VBN (l_nsubjpass) Treatment/NN (l_prep) for/IN (l_pobj) scabies/NNS -PUNC- hexachloride/NN (r_appos) lindane/NN (r_dobj) consider/VBP (l_ccomp) initiated/VBN (l_nsubjpass) Treatment/NN (l_prep) for/IN (l_pobj) scabies/NNS
D001556_D002493 CID lindane/NN (r_dobj) accumulating/VBG (r_csubj) be/VB (l_acomp) toxic/JJ (l_prep) to/IN (l_pobj) system/NN
D001556_D000741 CID lindane/NN (r_dobj) accumulating/VBG (r_csubj) be/VB (l_conj) associated/VBN (l_prep) with/IN (l_pobj) anaemia/NN
20196116
D001663_D001927 NONE bilirubin/NN (l_appos) time/NN (l_conj) encephalopathy/NN
D000995_D017114 CID Antituberculosis/NNP (r_nsubj) induced/VBN (l_dobj) failure/NN -PUNC- Antituberculosis/NN (r_compound) therapy/NN (l_appos) failure/NN -PUNC- Antituberculosis/NN (r_compound) therapy/NN (l_appos) failure/NN (l_appos) ALF/NNP -PUNC- Antituberculosis/NN (r_compound) therapy/NN (r_nsubj) is/VBZ (l_attr) ALF/NNP
12707296
D001120_D006973 NONE arginine/NN (r_compound) transport/NN (l_prep) with/IN (l_pobj) hypertension/NN -PUNC- arginine/NN (r_compound) nitric/NN (r_compound) system/NN (r_nsubjpass) implicated/VBN (l_prep) in/IN (l_pobj) hypertension/NN -PUNC- arginine/NN (r_compound) system/NN (r_pobj) in/IN (r_prep) abnormalities/NNS (r_pobj) with/IN (r_prep) associated/VBN (l_nsubjpass) increases/NNS (l_prep) in/IN (l_pobj) pressure/NN
D006854_D006973 NONE cortisol/NN (r_npadvmod) induced/VBN (r_amod) hypertension/NN -PUNC- cortisol/NN (r_npadvmod) induced/VBN (r_amod) hypertension/NN -PUNC- cortisol/NN (r_npadvmod) induced/VBN (r_amod) increases/NNS (l_prep) in/IN (l_pobj) pressure/NN
D009569_D006973 NONE oxide/NN (r_compound) system/NN (r_nsubjpass) implicated/VBN (l_prep) in/IN (l_pobj) hypertension/NN
16337777
D010862_D004827 NONE pilocarpine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) model/NN (l_prep) of/IN (l_pobj) epilepsy/NN
D010862_D013226 NONE pilocarpine/NN (r_amod) model/NN (r_pobj) of/IN (r_prep) phase/NN (r_pobj) in/IN (r_prep) provoke/VB (r_xcomp) sufficient/JJ (r_acomp) be/VB (l_nsubj) generation/NN (l_prep) during/IN (l_pobj) epilepticus/NN
D010862_D004833 CID pilocarpine/NN (r_amod) model/NN (l_prep) of/IN (l_pobj) epilepsy/NN
220563
C023470_D010523 CID maleate/NN (l_conj) neuropathy/NN -PUNC- maleate/NN (r_pobj) with/IN (r_prep) complication/NN (r_pobj) as/IN (r_prep) noted/VBN (l_nsubjpass) neuropathy/NN
C023470_D000787 NONE maleate/NN (r_pobj) with/IN (r_prep) complication/NN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) pectoris/NN
19356053
D003404_D011507 NONE creatinine/NN (r_compound) ratios/NNS (r_conj) measurement/NN (r_pobj) by/IN (r_agent) assessed/VBN (l_nsubjpass) magnitude/NN (l_prep) of/IN (l_pobj) proteinuria/NN -PUNC- creatinine/NN (r_compound) ratios/NNS (l_appos) estimate/NN (l_prep) of/IN (l_pobj) grams/NNS (l_prep) of/IN (l_pobj) proteinuria/NN
D020123_D009404 NONE sirolimus/NN (r_pobj) of/IN (r_prep) initiation/NN (l_conj) development/NN (l_prep) of/IN (l_pobj) proteinuria/NN (l_compound) range/NN (l_amod) nephrotic/JJ
D020123_D007674 NONE Sirolimus/NNP (r_nsubj) is/VBZ (l_conj) have/VB (l_dobj) nephrotoxicity/NN
D020123_D011507 CID sirolimus/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) following/VBG (r_prep) proteinuria/NN -PUNC- sirolimus/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) with/IN (r_prep) linked/VBN (r_acl) proteinuria/NN -PUNC- sirolimus/NN (r_compound) use/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) proteinuria/NN -PUNC- sirolimus/NN (r_compound) therapy/NN (l_conj) proteinuria/NN -PUNC- sirolimus/NN (r_compound) therapy/NN (r_pobj) of/IN (r_prep) commencement/NN (r_pobj) between/IN (r_prep) association/NN (r_nsubj) implicated/VBN (l_prep) as/IN (l_pobj) etiology/NN (l_prep) of/IN (l_pobj) proteinuria/NN -PUNC- sirolimus/NN (r_dobj) implicated/VBN (l_nsubj) association/NN (l_prep) between/IN (l_pobj) commencement/NN (l_prep) of/IN (l_pobj) therapy/NN (l_conj) proteinuria/NN -PUNC- sirolimus/NN (r_dobj) implicated/VBN (l_prep) as/IN (l_pobj) etiology/NN (l_prep) of/IN (l_pobj) proteinuria/NN -PUNC- sirolimus/NN (r_pobj) of/IN (r_prep) initiation/NN (l_conj) development/NN (l_prep) of/IN (l_pobj) proteinuria/NN -PUNC- sirolimus/NN (r_compound) therapy/NN (r_pobj) with/IN (r_prep) correlated/VBD (l_nsubj) Proteinuria/NNP -PUNC- sirolimus/NN (r_pobj) of/IN (r_prep) discontinuation/NN (r_nsubj) resulted/VBD (l_conj) resolution/NN (l_prep) of/IN (l_pobj) proteinuria/NN -PUNC- Sirolimus/NNP (r_nsubj) induces/VBZ (l_conj) aggravates/VBZ (l_dobj) proteinuria/NN -PUNC- sirolimus/NN (r_nsubjpass) withdrawn/VBN (r_advcl) resolve/VB (r_conj) improve/VB (l_nsubj) Proteinuria/NNP
7919560
D000667_D004892 CID ampicillin/NN (r_pobj) by/IN (r_agent) caused/VBN (l_nsubj) multiforme/NN -PUNC- ampicillin/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) case/NN (l_prep) of/IN (l_pobj) multiforme/NNS
D000667_D018805 NONE ampicillin/NN (r_pobj) with/IN (r_prep) treated/VBN (l_conj) gentamicin/NN (l_prep) because/IN (l_pobj) septicemia/NN
D000667_D009205 CID ampicillin/NN (r_pobj) by/IN (r_agent) caused/VBN (l_nsubj) multiforme/NN (l_conj) myocarditis/NN -PUNC- ampicillin/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) case/NN (l_prep) of/IN (l_pobj) multiforme/NNS (l_conj) myocarditis/NN
D010406_D009205 NONE penicillins/NNS (r_pobj) to/IN (r_prep) is/VBZ (l_nsubj) myocarditis/NN
D010406_D004342 NONE penicillins/NNS (r_pobj) to/IN (r_prep) is/VBZ (l_attr) manifestation/NN (l_prep) of/IN (l_pobj) allergy/NN
D005839_D018805 NONE gentamicin/NN (l_prep) because/IN (l_pobj) septicemia/NN
2515254
D005996_D010146 NONE nitroglycerin/NN (r_pobj) of/IN (r_prep) effect/NN (r_nsubj) seems/VBZ (l_xcomp) depend/VB (l_prep) on/IN (l_pobj) stimulation/NN (l_prep) of/IN (l_pobj) site/NN (l_prep) of/IN (l_pobj) pain/NN
D005996_D008881 CID nitroglycerin/NN (r_pobj) of/IN (r_prep) application/NN (r_dobj) received/VBD (l_nsubj) patients/NNS (l_compound) migraine/NN -PUNC- nitroglycerin/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubjpass) attacks/NNS (l_compound) migraine/NN -PUNC- nitroglycerin/NN (r_pobj) with/IN (r_prep) attack/NN (r_dobj) developed/VBD (r_relcl) patients/NNS (l_compound) migraine/NN -PUNC- nitroglycerin/NN (r_pobj) of/IN (r_prep) effect/NN (l_amod) inducing/VBG (l_npadvmod) migraine/NN -PUNC- nitroglycerin/NN (r_pobj) of/IN (r_prep) effect/NN (r_nsubj) seems/VBZ (l_advcl) suggesting/VBG (l_ccomp) is/VBZ (l_prep) of/IN (l_pobj) importance/NN (l_prep) in/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) crisis/NN (l_compound) migraine/JJ
9869257
D012601_D000647 CID scopolamine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) amnesia/NN
C087567_D000647 NONE PG-9/NNP (r_nsubj) administered/VBN (l_conj) prevented/VBN (l_dobj) amnesia/NN -PUNC- PG-9/NNP (r_nmod) microg/NN (r_nsubj) was/VBD (l_acomp) able/JJ (l_xcomp) prevent/VB (l_dobj) amnesia/NN
C098725_D000647 CID S-(-)-ET-126/NNP (r_appos) antagonist/NN (r_conj) scopolamine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) amnesia/NN
19300402
D013311_D003929 CID streptozotocin/NNS (r_conj) antagonists/NNS (r_nsubj) induced/VBD (l_dobj) hyperalgesia/NN (l_prep) in/IN (l_pobj) chemotherapy/NN (l_conj) model/NN (l_compound) rat/NN (l_compound) neuropathy/NN
D013311_D006930 CID streptozotocin/NNS (r_conj) antagonists/NNS (r_nsubj) induced/VBD (l_dobj) hyperalgesia/NN -PUNC- streptozotocin/JJ (r_npadvmod) induced/VBN (r_amod) hyperalgesia/NN -PUNC- streptozotocin/JJ (r_npadvmod) induced/VBN (r_amod) hyperalgesia/NN (r_pobj) In/IN (r_prep) participates/VBZ (l_advcl) induced/VBN (l_dobj) hyperalgesia/NN
D009569_D006930 NONE oxide/NN (r_compound) synthase/NN (r_compound) inhibitors/NNS (r_conj) antagonists/NNS (r_nsubj) induced/VBD (l_dobj) hyperalgesia/NN -PUNC- NO/DT (r_det) synthase/NN (r_conj) inhibition/NN (r_nsubj) reduces/VBZ (l_dobj) hyperalgesia/NN -PUNC- NO/DT (r_det) activity/NN (r_nsubj) reduces/VBZ (l_dobj) hyperalgesia/NN -PUNC- NO/DT (r_compound) synthase/NN (r_pobj) of/IN (r_prep) products/NNS (r_nsubjpass) involved/VBN (l_prep) in/IN (l_pobj) hyperalgesia/NN -PUNC- NO/DT (r_det) activation/NN (r_conj) synthase/NN (r_pobj) of/IN (r_prep) products/NNS (r_nsubjpass) involved/VBN (l_prep) in/IN (l_pobj) hyperalgesia/NN -PUNC- NO/DT (r_compound) synthase/NN (r_nsubj) participates/VBZ (l_prep) In/IN (l_pobj) hyperalgesia/NN -PUNC- NO/DT (r_compound) synthase/NN (r_nsubj) participates/VBZ (l_advcl) induced/VBN (l_dobj) hyperalgesia/NN -PUNC- NO/DT (r_det) pathway/NN (r_dobj) activate/VB (r_xcomp) seemed/VBD (r_conj) participates/VBZ (l_prep) In/IN (l_pobj) hyperalgesia/NN -PUNC- NO/DT (r_det) pathway/NN (r_dobj) activate/VB (r_xcomp) seemed/VBD (r_conj) participates/VBZ (l_advcl) induced/VBN (l_dobj) hyperalgesia/NN
D014750_D006930 CID vincristine/NN (r_pobj) in/IN (r_prep) antagonists/NNS (r_nsubj) induced/VBD (l_dobj) hyperalgesia/NN -PUNC- vincristine/NN (r_pobj) by/IN (r_agent) produced/VBN (r_acl) hyperalgesia/NN -PUNC- vincristine/NN (r_pobj) in/IN (r_prep) induced/VBN (r_advcl) participates/VBZ (l_prep) In/IN (l_pobj) hyperalgesia/NN -PUNC- vincristine/NN (r_pobj) in/IN (r_prep) induced/VBN (l_dobj) hyperalgesia/NN
D009569_D003929 NONE oxide/NN (r_compound) synthase/NN (r_compound) inhibitors/NNS (r_conj) antagonists/NNS (r_nsubj) induced/VBD (l_dobj) hyperalgesia/NN (l_prep) in/IN (l_pobj) chemotherapy/NN (l_conj) model/NN (l_compound) rat/NN (l_compound) neuropathy/NN
D001920_D006930 NONE Bradykinin/NN (r_compound) antagonists/NNS (r_nsubj) induced/VBD (l_dobj) hyperalgesia/NN -PUNC- bradykinin/NN (r_compound) receptors/NNS (r_pobj) of/IN (r_prep) inhibition/NN (r_nsubj) reduces/VBZ (l_dobj) hyperalgesia/NN -PUNC- bradykinin/NN (r_conj) activation/NN (r_conj) synthase/NN (r_pobj) of/IN (r_prep) products/NNS (r_nsubjpass) involved/VBN (l_prep) in/IN (l_pobj) hyperalgesia/NN -PUNC- bradykinin/NN (r_pobj) of/IN (r_prep) activity/NN (r_pobj) in/IN (r_prep) participates/VBZ (l_prep) In/IN (l_pobj) hyperalgesia/NN -PUNC- bradykinin/NN (r_pobj) of/IN (r_prep) activity/NN (r_pobj) in/IN (r_prep) participates/VBZ (l_advcl) induced/VBN (l_dobj) hyperalgesia/NN -PUNC- bradykinin/NN (r_nsubj) seemed/VBD (r_conj) participates/VBZ (l_prep) In/IN (l_pobj) hyperalgesia/NN -PUNC- bradykinin/NN (r_nsubj) seemed/VBD (r_conj) participates/VBZ (l_advcl) induced/VBN (l_dobj) hyperalgesia/NN
D001920_D009437 NONE bradykinin/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) be/VB (l_acomp) effective/JJ (l_prep) in/IN (l_pobj) alleviation/NN (l_prep) of/IN (l_pobj) pain/NN
D009569_D009437 NONE NO/DT (r_det) inhibitors/NNS (r_conj) antagonists/NNS (r_dobj) bradykinin/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) be/VB (l_acomp) effective/JJ (l_prep) in/IN (l_pobj) alleviation/NN (l_prep) of/IN (l_pobj) pain/NN
D001920_D003929 NONE Bradykinin/NN (r_compound) antagonists/NNS (r_nsubj) induced/VBD (l_dobj) hyperalgesia/NN (l_prep) in/IN (l_pobj) chemotherapy/NN (l_conj) model/NN (l_compound) rat/NN (l_compound) neuropathy/NN
D014750_D003929 NONE vincristine/NN (r_pobj) in/IN (r_prep) antagonists/NNS (r_nsubj) induced/VBD (l_dobj) hyperalgesia/NN (l_prep) in/IN (l_pobj) chemotherapy/NN (l_conj) model/NN (l_compound) rat/NN (l_compound) neuropathy/NN
12615818
D004997_D054556 CID estradiol/NN (r_appos) risk/NN (l_prep) of/IN (l_pobj) thromboembolism/NN -PUNC- EE/NNP (r_pobj) with/IN (r_prep) associated/VBN (r_acl) thromboembolism/NN -PUNC- EE/NNP (r_pobj) with/IN (r_prep) associated/VBN (r_acl) thromboembolism/NN (l_appos) VTE/NNP -PUNC- EE/NNP (r_pobj) with/IN (r_prep) associated/VBN (r_acl) VTE/NNP -PUNC- EE/NNP (r_pobj) of/IN (r_prep) use/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) risk/NN (l_prep) of/IN (l_pobj) VTE/NNP
D003276_D054556 NONE contraceptives/NNS (r_pobj) with/IN (r_prep) compared/VBN (r_prep) demonstrated/VBN (l_dobj) risk/NN (l_prep) of/IN (l_pobj) thromboembolism/NN -PUNC- contraceptives/NNS (r_pobj) with/IN (r_prep) compared/VBN (r_prep) demonstrated/VBN (l_dobj) risk/NN (l_prep) of/IN (l_pobj) thromboembolism/NN (l_appos) VTE/NNP
D017373_D000152 NONE acetate/NN (r_nsubjpass) licensed/VBN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) women/NNS (l_prep) with/IN (l_pobj) acne/NN -PUNC- CPA/NNP (r_nmod) EE/NNP (r_appos) estradiol/NN (r_nsubjpass) licensed/VBN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) women/NNS (l_prep) with/IN (l_pobj) acne/NN -PUNC- CPA/NNP (r_nmod) EE/NNP (r_pobj) with/IN (r_prep) associated/VBN (r_acl) VTE/NNP (r_pobj) of/IN (r_prep) risk/NN (r_dobj) estimate/VB (r_advcl) conducted/VBD (l_npadvmod) years/NNS (l_prep) with/IN (l_pobj) acne/NN -PUNC- CPA/NNP (r_nmod) EE/NNP (r_pobj) of/IN (r_prep) use/NN (l_prep) in/IN (l_pobj) women/NNS (l_prep) with/IN (l_pobj) acne/NN
D004997_D011085 NONE estradiol/NN (r_nsubjpass) licensed/VBN (l_conj) is/VBZ (l_attr) option/NN (l_prep) for/IN (l_pobj) syndrome/NN -PUNC- estradiol/NN (r_nsubjpass) licensed/VBN (l_conj) is/VBZ (l_attr) option/NN (l_prep) for/IN (l_pobj) syndrome/NN (l_appos) PCOS/NNP -PUNC- EE/NNP (r_appos) estradiol/NN (r_nsubjpass) licensed/VBN (l_conj) is/VBZ (l_attr) option/NN (l_prep) for/IN (l_pobj) syndrome/NN -PUNC- EE/NNP (r_appos) estradiol/NN (r_nsubjpass) licensed/VBN (l_conj) is/VBZ (l_attr) option/NN (l_prep) for/IN (l_pobj) syndrome/NN (l_appos) PCOS/NNP -PUNC- EE/NNP (r_pobj) with/IN (r_prep) associated/VBN (r_acl) VTE/NNP (r_pobj) of/IN (r_prep) risk/NN (r_dobj) estimate/VB (r_advcl) conducted/VBD (l_npadvmod) years/NNS (l_prep) with/IN (l_pobj) acne/NN (l_conj) hirsutism/NN (l_conj) PCOS/NNP -PUNC- EE/NNP (r_pobj) of/IN (r_prep) use/NN (l_prep) in/IN (l_pobj) women/NNS (l_prep) with/IN (l_pobj) acne/NN (l_conj) hirsutism/NN (l_conj) PCOS/NNP
D017373_D006628 NONE acetate/NN (r_nsubjpass) licensed/VBN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) women/NNS (l_prep) with/IN (l_pobj) acne/NN (l_conj) hirsutism/NN -PUNC- CPA/NNP (r_nmod) EE/NNP (r_appos) estradiol/NN (r_nsubjpass) licensed/VBN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) women/NNS (l_prep) with/IN (l_pobj) acne/NN (l_conj) hirsutism/NN -PUNC- CPA/NNP (r_nmod) EE/NNP (r_pobj) with/IN (r_prep) associated/VBN (r_acl) VTE/NNP (r_pobj) of/IN (r_prep) risk/NN (r_dobj) estimate/VB (r_advcl) conducted/VBD (l_npadvmod) years/NNS (l_prep) with/IN (l_pobj) acne/NN (l_conj) hirsutism/NN -PUNC- CPA/NNP (r_nmod) EE/NNP (r_pobj) of/IN (r_prep) use/NN (l_prep) in/IN (l_pobj) women/NNS (l_prep) with/IN (l_pobj) acne/NN (l_conj) hirsutism/NN
D017373_D011085 NONE acetate/NN (r_nsubjpass) licensed/VBN (l_conj) is/VBZ (l_attr) option/NN (l_prep) for/IN (l_pobj) syndrome/NN -PUNC- acetate/NN (r_nsubjpass) licensed/VBN (l_conj) is/VBZ (l_attr) option/NN (l_prep) for/IN (l_pobj) syndrome/NN (l_appos) PCOS/NNP -PUNC- CPA/NNP (r_nmod) EE/NNP (r_appos) estradiol/NN (r_nsubjpass) licensed/VBN (l_conj) is/VBZ (l_attr) option/NN (l_prep) for/IN (l_pobj) syndrome/NN -PUNC- CPA/NNP (r_nmod) EE/NNP (r_appos) estradiol/NN (r_nsubjpass) licensed/VBN (l_conj) is/VBZ (l_attr) option/NN (l_prep) for/IN (l_pobj) syndrome/NN (l_appos) PCOS/NNP -PUNC- CPA/NNP (r_nmod) EE/NNP (r_pobj) with/IN (r_prep) associated/VBN (r_acl) VTE/NNP (r_pobj) of/IN (r_prep) risk/NN (r_dobj) estimate/VB (r_advcl) conducted/VBD (l_npadvmod) years/NNS (l_prep) with/IN (l_pobj) acne/NN (l_conj) hirsutism/NN (l_conj) PCOS/NNP -PUNC- CPA/NNP (r_nmod) EE/NNP (r_pobj) of/IN (r_prep) use/NN (l_prep) in/IN (l_pobj) women/NNS (l_prep) with/IN (l_pobj) acne/NN (l_conj) hirsutism/NN (l_conj) PCOS/NNP
D004997_D000152 NONE estradiol/NN (r_nsubjpass) licensed/VBN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) women/NNS (l_prep) with/IN (l_pobj) acne/NN -PUNC- EE/NNP (r_appos) estradiol/NN (r_nsubjpass) licensed/VBN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) women/NNS (l_prep) with/IN (l_pobj) acne/NN -PUNC- EE/NNP (r_pobj) with/IN (r_prep) associated/VBN (r_acl) VTE/NNP (r_pobj) of/IN (r_prep) risk/NN (r_dobj) estimate/VB (r_advcl) conducted/VBD (l_npadvmod) years/NNS (l_prep) with/IN (l_pobj) acne/NN -PUNC- EE/NNP (r_pobj) of/IN (r_prep) use/NN (l_prep) in/IN (l_pobj) women/NNS (l_prep) with/IN (l_pobj) acne/NN
D017373_D054556 CID acetate/NN (r_oprd) prescribed/VBD (r_acl) women/NNS (r_pobj) in/IN (r_prep) thromboembolism/NN -PUNC- CPA/NNP (r_nmod) EE/NNP (r_pobj) with/IN (r_prep) associated/VBN (r_acl) thromboembolism/NN -PUNC- CPA/NNP (r_nmod) EE/NNP (r_pobj) with/IN (r_prep) associated/VBN (r_acl) thromboembolism/NN (l_appos) VTE/NNP -PUNC- CPA/NNP (r_nmod) EE/NNP (r_pobj) with/IN (r_prep) associated/VBN (r_acl) VTE/NNP -PUNC- CPA/NNP (r_nmod) EE/NNP (r_pobj) of/IN (r_prep) use/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) risk/NN (l_prep) of/IN (l_pobj) VTE/NNP
D004997_D006628 NONE estradiol/NN (r_nsubjpass) licensed/VBN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) women/NNS (l_prep) with/IN (l_pobj) acne/NN (l_conj) hirsutism/NN -PUNC- EE/NNP (r_appos) estradiol/NN (r_nsubjpass) licensed/VBN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) women/NNS (l_prep) with/IN (l_pobj) acne/NN (l_conj) hirsutism/NN -PUNC- EE/NNP (r_pobj) with/IN (r_prep) associated/VBN (r_acl) VTE/NNP (r_pobj) of/IN (r_prep) risk/NN (r_dobj) estimate/VB (r_advcl) conducted/VBD (l_npadvmod) years/NNS (l_prep) with/IN (l_pobj) acne/NN (l_conj) hirsutism/NN -PUNC- EE/NNP (r_pobj) of/IN (r_prep) use/NN (l_prep) in/IN (l_pobj) women/NNS (l_prep) with/IN (l_pobj) acne/NN (l_conj) hirsutism/NN
2673163
D003042_D002544 CID cocaine/NN (r_compound) use/NN (r_pobj) to/IN (r_prep) related/VBN (r_acl) stroke/NN (r_pobj) of/IN (r_prep) incidence/NN (r_nsubj) increasing/VBG (r_ccomp) indicate/VBP (r_ccomp) occurs/VBZ (r_ccomp) follow/VB (r_ccomp) exceeds/VBZ (l_dobj) that/DT (l_prep) of/IN (l_pobj) infarction/NN -PUNC- cocaine/NN (r_npadvmod) associated/VBN (r_amod) stroke/NN (r_nsubj) occurs/VBZ (r_ccomp) follow/VB (r_ccomp) exceeds/VBZ (l_dobj) that/DT (l_prep) of/IN (l_pobj) infarction/NN -PUNC- cocaine/NN (r_compound) administration/NN (r_pobj) of/IN (r_prep) route/NN (r_dobj) follow/VB (r_ccomp) exceeds/VBZ (l_dobj) that/DT (l_prep) of/IN (l_pobj) infarction/NN -PUNC- cocaine/NN (r_compound) use/NN (r_nsubjpass) associated/VBN (r_advcl) stroke/NN (r_nmod) frequency/NN (r_nsubj) exceeds/VBZ (l_dobj) that/DT (l_prep) of/IN (l_pobj) infarction/NN -PUNC- cocaine/NN (r_npadvmod) associated/VBN (r_amod) stroke/NN (r_pobj) in/IN (r_prep) 5/CD (r_conj) stroke/NN (r_nmod) frequency/NN (r_nsubj) exceeds/VBZ (l_dobj) that/DT (l_prep) of/IN (l_pobj) infarction/NN
D003042_D001165 NONE cocaine/NN (r_compound) use/NN (r_pobj) to/IN (r_prep) related/VBN (r_acl) stroke/NN (r_pobj) of/IN (r_prep) incidence/NN (r_nsubj) increasing/VBG (r_ccomp) indicate/VBP (r_ccomp) occurs/VBZ (r_ccomp) follow/VB (r_ccomp) exceeds/VBZ (l_nsubj) frequency/NN (l_nmod) stroke/NN (l_advcl) associated/VBN (l_prep) with/IN (l_pobj) aneurysms/NNS (l_conj) malformations/NNS -PUNC- cocaine/NN (r_npadvmod) associated/VBN (r_amod) stroke/NN (r_nsubj) occurs/VBZ (r_ccomp) follow/VB (r_ccomp) exceeds/VBZ (l_nsubj) frequency/NN (l_nmod) stroke/NN (l_advcl) associated/VBN (l_prep) with/IN (l_pobj) aneurysms/NNS (l_conj) malformations/NNS -PUNC- cocaine/NN (r_compound) administration/NN (r_pobj) of/IN (r_prep) route/NN (r_dobj) follow/VB (r_ccomp) exceeds/VBZ (l_nsubj) frequency/NN (l_nmod) stroke/NN (l_advcl) associated/VBN (l_prep) with/IN (l_pobj) aneurysms/NNS (l_conj) malformations/NNS -PUNC- cocaine/NN (r_compound) use/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) aneurysms/NNS (l_conj) malformations/NNS -PUNC- cocaine/NN (r_npadvmod) associated/VBN (r_amod) stroke/NN (r_pobj) in/IN (r_prep) 5/CD (r_conj) stroke/NN (l_advcl) associated/VBN (l_prep) with/IN (l_pobj) aneurysms/NNS (l_conj) malformations/NNS
D003042_D020300 NONE cocaine/NN (r_compound) use/NN (r_pobj) to/IN (r_prep) related/VBN (r_acl) stroke/NN (r_pobj) of/IN (r_prep) incidence/NN (r_nsubj) increasing/VBG (r_ccomp) indicate/VBP (r_ccomp) occurs/VBZ (r_ccomp) follow/VB (r_ccomp) exceeds/VBZ (l_nsubj) frequency/NN (l_prep) of/IN (l_pobj) hemorrhage/NN -PUNC- cocaine/NN (r_npadvmod) associated/VBN (r_amod) stroke/NN (r_nsubj) occurs/VBZ (r_ccomp) follow/VB (r_ccomp) exceeds/VBZ (l_nsubj) frequency/NN (l_prep) of/IN (l_pobj) hemorrhage/NN -PUNC- cocaine/NN (r_compound) administration/NN (r_pobj) of/IN (r_prep) route/NN (r_dobj) follow/VB (r_ccomp) exceeds/VBZ (l_nsubj) frequency/NN (l_prep) of/IN (l_pobj) hemorrhage/NN -PUNC- cocaine/NN (r_compound) use/NN (r_nsubjpass) associated/VBN (r_advcl) stroke/NN (r_nmod) frequency/NN (l_prep) of/IN (l_pobj) hemorrhage/NN -PUNC- cocaine/NN (r_npadvmod) associated/VBN (r_amod) stroke/NN (r_pobj) in/IN (r_prep) 5/CD (r_conj) stroke/NN (r_nmod) frequency/NN (l_prep) of/IN (l_pobj) hemorrhage/NN
D003042_D020521 NONE cocaine/NN (r_compound) use/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) Stroke/NN -PUNC- cocaine/NN (r_compound) use/NN (r_nsubjpass) related/VBN (l_prep) to/IN (l_pobj) stroke/NN -PUNC- cocaine/NN (r_compound) use/NN (r_dobj) followed/VBD (l_nsubj) Stroke/NN -PUNC- cocaine/NN (r_compound) use/NN (r_pobj) to/IN (r_prep) related/VBN (r_acl) stroke/NN -PUNC- cocaine/NN (r_compound) use/NN (r_pobj) to/IN (r_prep) related/VBN (r_acl) stroke/NN (r_pobj) of/IN (r_prep) incidence/NN (r_nsubj) increasing/VBG (r_ccomp) indicate/VBP (r_ccomp) occurs/VBZ (l_nsubj) stroke/NN -PUNC- cocaine/NN (r_compound) use/NN (r_pobj) to/IN (r_prep) related/VBN (r_acl) stroke/NN (r_pobj) of/IN (r_prep) incidence/NN (r_nsubj) increasing/VBG (r_ccomp) indicate/VBP (r_ccomp) occurs/VBZ (r_ccomp) follow/VB (l_nsubj) stroke/NN -PUNC- cocaine/NN (r_compound) use/NN (r_pobj) to/IN (r_prep) related/VBN (r_acl) stroke/NN (r_pobj) of/IN (r_prep) incidence/NN (r_nsubj) increasing/VBG (r_ccomp) indicate/VBP (r_ccomp) occurs/VBZ (r_ccomp) follow/VB (r_ccomp) exceeds/VBZ (l_nsubj) frequency/NN (l_nmod) stroke/NN -PUNC- cocaine/NN (r_compound) use/NN (r_pobj) to/IN (r_prep) related/VBN (r_acl) stroke/NN (r_pobj) of/IN (r_prep) incidence/NN (r_nsubj) increasing/VBG (r_ccomp) indicate/VBP (r_ccomp) occurs/VBZ (r_ccomp) follow/VB (r_ccomp) exceeds/VBZ (l_nsubj) frequency/NN (l_nmod) stroke/NN (l_conj) 5/CD (l_prep) in/IN (l_pobj) stroke/NN -PUNC- cocaine/NN (r_npadvmod) associated/VBN (r_amod) stroke/NN (r_nsubj) occurs/VBZ (l_ccomp) indicate/VBP (l_ccomp) increasing/VBG (l_nsubj) incidence/NN (l_prep) of/IN (l_pobj) stroke/NN -PUNC- cocaine/NN (r_npadvmod) associated/VBN (r_amod) stroke/NN -PUNC- cocaine/NN (r_npadvmod) associated/VBN (r_amod) stroke/NN (r_nsubj) occurs/VBZ (r_ccomp) follow/VB (l_nsubj) stroke/NN -PUNC- cocaine/NN (r_npadvmod) associated/VBN (r_amod) stroke/NN (r_nsubj) occurs/VBZ (r_ccomp) follow/VB (r_ccomp) exceeds/VBZ (l_nsubj) frequency/NN (l_nmod) stroke/NN -PUNC- cocaine/NN (r_npadvmod) associated/VBN (r_amod) stroke/NN (r_nsubj) occurs/VBZ (r_ccomp) follow/VB (r_ccomp) exceeds/VBZ (l_nsubj) frequency/NN (l_nmod) stroke/NN (l_conj) 5/CD (l_prep) in/IN (l_pobj) stroke/NN -PUNC- cocaine/NN (r_compound) administration/NN (r_pobj) of/IN (r_prep) route/NN (r_dobj) follow/VB (l_ccomp) occurs/VBZ (l_ccomp) indicate/VBP (l_ccomp) increasing/VBG (l_nsubj) incidence/NN (l_prep) of/IN (l_pobj) stroke/NN -PUNC- cocaine/NN (r_compound) administration/NN (r_pobj) of/IN (r_prep) route/NN (r_dobj) follow/VB (l_ccomp) occurs/VBZ (l_nsubj) stroke/NN -PUNC- cocaine/NN (r_compound) administration/NN (r_pobj) of/IN (r_prep) route/NN (r_dobj) follow/VB (l_nsubj) stroke/NN -PUNC- cocaine/NN (r_compound) administration/NN (r_pobj) of/IN (r_prep) route/NN (r_dobj) follow/VB (r_ccomp) exceeds/VBZ (l_nsubj) frequency/NN (l_nmod) stroke/NN -PUNC- cocaine/NN (r_compound) administration/NN (r_pobj) of/IN (r_prep) route/NN (r_dobj) follow/VB (r_ccomp) exceeds/VBZ (l_nsubj) frequency/NN (l_nmod) stroke/NN (l_conj) 5/CD (l_prep) in/IN (l_pobj) stroke/NN -PUNC- cocaine/NN (r_compound) use/NN (r_nsubjpass) associated/VBN (r_advcl) stroke/NN (r_nmod) frequency/NN (r_nsubj) exceeds/VBZ (l_ccomp) follow/VB (l_ccomp) occurs/VBZ (l_ccomp) indicate/VBP (l_ccomp) increasing/VBG (l_nsubj) incidence/NN (l_prep) of/IN (l_pobj) stroke/NN -PUNC- cocaine/NN (r_compound) use/NN (r_nsubjpass) associated/VBN (r_advcl) stroke/NN (r_nmod) frequency/NN (r_nsubj) exceeds/VBZ (l_ccomp) follow/VB (l_ccomp) occurs/VBZ (l_nsubj) stroke/NN -PUNC- cocaine/NN (r_compound) use/NN (r_nsubjpass) associated/VBN (r_advcl) stroke/NN (r_nmod) frequency/NN (r_nsubj) exceeds/VBZ (l_ccomp) follow/VB (l_nsubj) stroke/NN -PUNC- cocaine/NN (r_compound) use/NN (r_nsubjpass) associated/VBN (r_advcl) stroke/NN -PUNC- cocaine/NN (r_compound) use/NN (r_nsubjpass) associated/VBN (r_advcl) stroke/NN (l_conj) 5/CD (l_prep) in/IN (l_pobj) stroke/NN -PUNC- cocaine/NN (r_npadvmod) associated/VBN (r_amod) stroke/NN (r_pobj) in/IN (r_prep) 5/CD (r_conj) stroke/NN (r_nmod) frequency/NN (r_nsubj) exceeds/VBZ (l_ccomp) follow/VB (l_ccomp) occurs/VBZ (l_ccomp) indicate/VBP (l_ccomp) increasing/VBG (l_nsubj) incidence/NN (l_prep) of/IN (l_pobj) stroke/NN -PUNC- cocaine/NN (r_npadvmod) associated/VBN (r_amod) stroke/NN (r_pobj) in/IN (r_prep) 5/CD (r_conj) stroke/NN (r_nmod) frequency/NN (r_nsubj) exceeds/VBZ (l_ccomp) follow/VB (l_ccomp) occurs/VBZ (l_nsubj) stroke/NN -PUNC- cocaine/NN (r_npadvmod) associated/VBN (r_amod) stroke/NN (r_pobj) in/IN (r_prep) 5/CD (r_conj) stroke/NN (r_nmod) frequency/NN (r_nsubj) exceeds/VBZ (l_ccomp) follow/VB (l_nsubj) stroke/NN -PUNC- cocaine/NN (r_npadvmod) associated/VBN (r_amod) stroke/NN (r_pobj) in/IN (r_prep) 5/CD (r_conj) stroke/NN -PUNC- cocaine/NN (r_npadvmod) associated/VBN (r_amod) stroke/NN
D003042_D002532 NONE cocaine/NN (r_compound) use/NN (r_pobj) to/IN (r_prep) related/VBN (r_acl) stroke/NN (r_pobj) of/IN (r_prep) incidence/NN (r_nsubj) increasing/VBG (r_ccomp) indicate/VBP (r_ccomp) occurs/VBZ (r_ccomp) follow/VB (r_ccomp) exceeds/VBZ (l_nsubj) frequency/NN (l_nmod) stroke/NN (l_advcl) associated/VBN (l_prep) with/IN (l_pobj) aneurysms/NNS -PUNC- cocaine/NN (r_npadvmod) associated/VBN (r_amod) stroke/NN (r_nsubj) occurs/VBZ (r_ccomp) follow/VB (r_ccomp) exceeds/VBZ (l_nsubj) frequency/NN (l_nmod) stroke/NN (l_advcl) associated/VBN (l_prep) with/IN (l_pobj) aneurysms/NNS -PUNC- cocaine/NN (r_compound) administration/NN (r_pobj) of/IN (r_prep) route/NN (r_dobj) follow/VB (r_ccomp) exceeds/VBZ (l_nsubj) frequency/NN (l_nmod) stroke/NN (l_advcl) associated/VBN (l_prep) with/IN (l_pobj) aneurysms/NNS -PUNC- cocaine/NN (r_compound) use/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) aneurysms/NNS -PUNC- cocaine/NN (r_npadvmod) associated/VBN (r_amod) stroke/NN (r_pobj) in/IN (r_prep) 5/CD (r_conj) stroke/NN (l_advcl) associated/VBN (l_prep) with/IN (l_pobj) aneurysms/NNS
7582165
D010248_D004342 NONE paramethasone/NN (r_pobj) from/IN (r_prep) different/JJ (r_amod) Corticosteroids/NNS (r_nsubj) produced/VBD (l_dobj) reactions/NNS (l_compound) hypersensitivity/NN -PUNC- paramethasone/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) allergy/NN
D000305_D004342 NONE corticosteroids/NNS (r_pobj) to/IN (r_prep) reactions/NNS
14698717
D010672_D014277 NONE phenytoin/JJ (r_compound) treatment/NN (l_prep) for/IN (l_pobj) neuralgia/NN
D010672_D011605 NONE phenytoin/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) due/IN (r_amod) psychosis/NN -PUNC- phenytoin/JJ (r_compound) treatment/NN (r_dobj) following/VBG (r_acl) psychosis/NN -PUNC- phenytoin/JJ (r_compound) treatment/NN (r_pobj) following/VBG (r_prep) occur/VBP (r_relcl) symptoms/NNS
D010672_D012640 NONE phenytoin/JJ (r_compound) treatment/NN (r_pobj) following/VBG (r_prep) occur/VBP (r_relcl) symptoms/NNS (r_nsubj) be/VB (l_attr) result/NN (l_amod) unrelated/JJ (l_prep) to/IN (l_pobj) seizures/NNS
D010672_D004827 NONE phenytoin/JJ (r_compound) treatment/NN (l_prep) in/IN (l_pobj) patients/NNS (l_amod) epileptic/JJ
3101906
D007654_D056486 CID ketoconazole/JJ (r_compound) treatment/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) deaths/NNS (r_pobj) of/IN (r_prep) two/CD (r_pobj) In/IN (r_prep) continued/VBN (l_prep) after/IN (l_pobj) onset/NN (l_prep) of/IN (l_pobj) jaundice/NN (l_conj) symptoms/NNS (l_prep) of/IN (l_pobj) hepatitis/NN -PUNC- ketoconazole/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) during/IN (r_prep) advised/VBN (l_nsubjpass) monitoring/NN (l_prep) for/IN (l_pobj) evidence/NN (l_prep) of/IN (l_pobj) hepatitis/NN -PUNC- ketoconazole/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) during/IN (r_prep) advised/VBN (l_advcl) prevent/VB (l_dobj) injury/NN
D007654_D007565 CID ketoconazole/JJ (r_compound) treatment/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) deaths/NNS (r_pobj) of/IN (r_prep) two/CD (r_pobj) In/IN (r_prep) continued/VBN (l_prep) after/IN (l_pobj) onset/NN (l_prep) of/IN (l_pobj) jaundice/NN
D007654_D003643 NONE ketoconazole/JJ (r_compound) treatment/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) deaths/NNS
3425586
D003622_D006461 NONE dapsone/NN (r_pobj) of/IN (r_prep) dose/NN (l_acl) associated/VBN (l_prep) with/IN (l_pobj) hemolysis/NN
D003622_D000743 CID Dapsone/NN (r_npadvmod) associated/VBN (r_amod) anemia/NN -PUNC- dapsone/NN (r_pobj) of/IN (r_prep) dose/NN (r_dobj) taking/VBG (r_advcl) developed/VBD (l_dobj) anemia/NN -PUNC- dapsone/NN (r_nsubj) cause/VB (l_dobj) anemia/NN
D003622_D007918 NONE dapsone/NN (r_pobj) of/IN (r_prep) dose/NN (r_dobj) taking/VBG (r_advcl) developed/VBD (l_nsubj) woman/NN (l_conj) leprosy/NN
3192036
11166519
D003042_D012640 CID cocaine/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS -PUNC- cocaine/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) seizures/NNS -PUNC- cocaine/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS
6287825
D012256_D010523 CID riboflavin/NN (r_conj) thiamine/NN (r_pobj) of/IN (r_prep) deficiency/NN (r_pobj) due/IN (r_prep) neuropathy/NNS -PUNC- riboflavin/NN (r_conj) thiamine/NN (r_pobj) of/IN (r_prep) deficiency/NN (r_pobj) due/IN (r_prep) neuropathy/NNS (r_nsubj) was/VBD (l_conj) presented/VBN (l_prep) as/IN (l_pobj) neuropathy/NN
D013831_D044342 NONE thiamine/NN (r_pobj) of/IN (r_prep) deficiency/NN
D007538_D009422 NONE Isoniazid/NNP (r_nsubj) was/VBD (l_attr) agent/NN (l_prep) in/IN (l_pobj) neuropathy/NN
D012256_D044342 NONE riboflavin/NN (r_conj) thiamine/NN (r_pobj) of/IN (r_prep) deficiency/NN
D013831_D010523 CID thiamine/NN (r_pobj) of/IN (r_prep) deficiency/NN (r_pobj) due/IN (r_prep) neuropathy/NNS -PUNC- thiamine/NN (r_pobj) of/IN (r_prep) deficiency/NN (r_pobj) due/IN (r_prep) neuropathy/NNS (r_nsubj) was/VBD (l_conj) presented/VBN (l_prep) as/IN (l_pobj) neuropathy/NN
8739323
D008727_D007674 NONE methotrexate/NNP (r_conj) nitrogranulogen/NN (r_pobj) as/IN (r_prep) drugs/NNS (r_pobj) of/IN (r_prep) action/NN (l_amod) nephrotoxic/JJ -PUNC- MTX/NNP (r_appos) methotrexate/NNP (r_conj) nitrogranulogen/NN (r_pobj) as/IN (r_prep) drugs/NNS (r_pobj) of/IN (r_prep) action/NN (l_amod) nephrotoxic/JJ -PUNC- MTX/NNP (r_appos) action/NN (l_amod) nephrotoxic/JJ -PUNC- MTX/NNP (r_pobj) of/IN (r_prep) nephrotoxicity/NN
D003520_D007674 NONE cyclophosphamide/NN (r_conj) 5-FU/CD (r_appos) action/NN (l_amod) nephrotoxic/JJ -PUNC- CY/NNP (r_appos) cyclophosphamide/NN (r_conj) 5-FU/CD (r_appos) action/NN (l_amod) nephrotoxic/JJ -PUNC- CY/NNP (r_conj) 5-FU/CD (r_conj) MTX/NNP (r_appos) action/NN (l_amod) nephrotoxic/JJ -PUNC- CY/NNP (r_conj) 5-FU/CD (r_nsubj) is/VBZ (r_ccomp) indicate/VBP (l_dobj) nephrotoxicity/NN
D005472_D007674 NONE 5-fluorouracil/CD (r_punct) 5-FU/CD (r_appos) action/NN (l_amod) nephrotoxic/JJ -PUNC- 5-FU/CD (r_appos) action/NN (l_amod) nephrotoxic/JJ -PUNC- 5-FU/CD (r_conj) MTX/NNP (r_appos) action/NN (l_amod) nephrotoxic/JJ -PUNC- 5-FU/CD (r_nsubj) is/VBZ (r_ccomp) indicate/VBP (l_dobj) nephrotoxicity/NN
D008466_D007674 NONE nitrogranulogen/NN (r_pobj) as/IN (r_prep) drugs/NNS (r_pobj) of/IN (r_prep) action/NN (l_amod) nephrotoxic/JJ -PUNC- NG/NNP (r_appos) nitrogranulogen/NN (r_pobj) as/IN (r_prep) drugs/NNS (r_pobj) of/IN (r_prep) action/NN (l_amod) nephrotoxic/JJ
D008727_D003556 NONE MTX/NNP (r_conj) 5-FU/CD (r_pobj) with/IN (r_prep) combined/VBN (r_advcl) cause/VB (r_conj) caused/VBD (l_dobj) cystitis/NN
D005472_D003556 NONE 5-FU/CD (r_pobj) with/IN (r_prep) combined/VBN (r_advcl) cause/VB (r_conj) caused/VBD (l_dobj) cystitis/NN
D008727_D006470 NONE MTX/NNP (r_conj) 5-FU/CD (r_pobj) with/IN (r_prep) combined/VBN (r_advcl) cause/VB (r_conj) caused/VBD (l_dobj) cystitis/NN
D003520_D006470 CID CY/NNP (r_nsubj) caused/VBD (l_dobj) cystitis/NN
D005472_D006470 NONE 5-FU/CD (r_pobj) with/IN (r_prep) combined/VBN (r_advcl) cause/VB (r_conj) caused/VBD (l_dobj) cystitis/NN
D003520_D003556 CID CY/NNP (r_nsubj) caused/VBD (l_dobj) cystitis/NN
230316
D007464_D009422 NONE clioquinol/NN (r_pobj) of/IN (r_prep) dose/NN (r_pobj) of/IN (r_prep) ingestion/NN (r_pobj) to/IN (r_prep) related/VBN (r_acl) encephalopathy/NN (r_pobj) of/IN (r_prep) consisted/VBD (l_nsubj) disturbance/NN
D006912_D020258 NONE hydroxyquinolines/NNS (r_pobj) of/IN (r_prep) Neurotoxicity/NN -PUNC- hydroxyquinolines/NNS (r_pobj) to/IN (r_prep) reactions/NNS (l_amod) neurotoxic/JJ
D007464_C538178 NONE clioquinol/NN (l_prep) as/IN (l_pobj) treatment/NN (l_prep) for/IN (l_pobj) enteropathica/NN
D007464_D001927 CID clioquinol/NN (r_pobj) of/IN (r_prep) dose/NN (r_pobj) of/IN (r_prep) ingestion/NN (r_pobj) to/IN (r_prep) related/VBN (r_acl) encephalopathy/NN
7834920
D012293_D014397 NONE rifampin/NN (r_amod) therapy/NN (l_prep) for/IN (l_pobj) tuberculosis/NN -PUNC- rifampin/NN (r_pobj) of/IN (r_prep) regimen/NN (r_dobj) underwent/VBD (l_conj) isoniazid/NN (l_prep) for/IN (l_pobj) tuberculosis/NN
D012293_D051437 CID rifampin/NN (r_pobj) of/IN (r_prep) regimen/NN (r_dobj) underwent/VBD (l_conj) discovered/VBN (l_xcomp) developed/VBN (l_dobj) signs/NNS (l_prep) of/IN (l_pobj) failure/NN
D007538_D051437 NONE isoniazid/NN (r_conj) underwent/VBD (l_conj) discovered/VBN (l_xcomp) developed/VBN (l_dobj) signs/NNS (l_prep) of/IN (l_pobj) failure/NN
D007538_D014397 NONE isoniazid/NN (l_prep) for/IN (l_pobj) tuberculosis/NN
D012293_D005921 CID rifampin/NN (r_amod) therapy/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) glomerulonephritis/NN -PUNC- rifampin/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patient/NN (r_pobj) in/IN (r_prep) finding/NN (l_prep) of/IN (l_pobj) glomerulonephritis/NN -PUNC- rifampin/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patient/NN (r_pobj) in/IN (r_prep) occurrence/NN (l_prep) of/IN (l_pobj) glomerulonephritis/NN -PUNC- rifampin/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patient/NN (r_pobj) in/IN (r_prep) occurrence/NN (l_prep) of/IN (l_pobj) glomerulonephritis/NN (l_prep) with/IN (l_pobj) crescents/NNS (l_conj) glomerulonephritis/NN
17439425
D003907_D015431 CID Dex/NNP (r_nsubj) increased/VBD (l_dep) P/NN (l_conj) decreased/VBN (l_dobj) thymus/NN (l_conj) bodyweights/NNS
D003907_D006973 CID dexamethasone/NN (r_npadvmod) induced/VBN (r_amod) hypertension/NN -PUNC- dexamethasone/NN (r_npadvmod) induced/VBN (r_amod) hypertension/NN -PUNC- dexamethasone/NN (r_npadvmod) induced/VBN (r_amod) hypertension/NN (l_appos) HT/NNP -PUNC- dex/NN (r_compound) HT/NNP (r_appos) hypertension/NN -PUNC- dex/NN (r_compound) HT/NNP -PUNC- Dex/NNP (r_nsubj) increased/VBD (l_dobj) SBP/NNP -PUNC- dex/NN (r_compound) HT/NNP
D000493_D006973 NONE Allopurinol/NNP (r_nsubj) prevent/VB (l_dobj) HT/NNP -PUNC- allopurinol/NN (r_nsubj) failed/VBD (r_acl) findings/NNS (r_pobj) with/IN (r_prep) induced/VBN (l_dobj) hypertension/NN -PUNC- allopurinol/NN (r_nsubj) failed/VBD (r_acl) findings/NNS (r_pobj) with/IN (r_prep) induced/VBN (r_ccomp) suggests/VBZ (l_ccomp) is/VBZ (l_attr) determinant/NN (l_prep) of/IN (l_pobj) HT/NNP
D009569_D006973 NONE oxide/NN (r_compound) redox/NN (r_compound) imbalance/NN (r_pobj) with/IN (r_prep) associated/VBN (l_nsubjpass) hypertension/NN -PUNC- oxide/NN (r_compound) redox/NN (r_compound) imbalance/NN (r_pobj) with/IN (r_prep) associated/VBN (l_nsubjpass) hypertension/NN (l_appos) HT/NNP
D019820_D006973 NONE xanthine/NN (r_compound) oxidase/NN (r_pobj) of/IN (r_prep) Role/NN (l_prep) in/IN (l_pobj) hypertension/NN -PUNC- xanthine/NN (r_compound) oxidase/NN (r_pobj) of/IN (r_prep) role/NN (l_prep) in/IN (l_pobj) hypertension/NN -PUNC- xanthine/NN (r_compound) oxidase/NN (r_pobj) of/IN (r_prep) role/NN (l_prep) in/IN (l_pobj) hypertension/NN (l_appos) HT/NNP
19889778
1786266
D000928_D001480 NONE antidepressant/NN (r_compound) use/NN (r_conj) syndrome/NN
9672936
D008614_D010149 NONE Pethidine/NNP (r_npadvmod) associated/VBN (r_amod) seizure/NN (l_prep) in/IN (l_pobj) adolescent/JJ (l_acl) receiving/VBG (l_prep) for/IN (l_pobj) control/NN (l_compound) pain/NN -PUNC- pethidine/NN (r_dobj) receiving/VBG (l_prep) for/IN (l_pobj) control/NN (l_compound) pain/NN -PUNC- pethidine/NN (r_pobj) of/IN (r_prep) doses/NNS (r_nsubj) pump/NN (l_prep) for/IN (l_pobj) management/NN (l_prep) of/IN (l_pobj) control/NN (l_compound) pain/NN
D008614_D012640 CID Pethidine/NNP (r_npadvmod) associated/VBN (r_amod) seizure/NN -PUNC- pethidine/NN (r_dobj) receiving/VBG (r_acl) adolescent/JJ (r_pobj) in/IN (r_prep) seizure/NN
2348231
C008514_D007383 NONE methylxanthine/NN (r_compound) derivative/NN (l_relcl) improve/VB (l_dobj) claudication/NN
D004176_D006940 CID dipyridamole/NN (r_npadvmod) induced/VBN (r_amod) hyperemia/NN -PUNC- dipyridamole/JJ (r_npadvmod) thallium-201/NN (r_nmod) imaging/NN (r_pobj) for/IN (r_prep) implications/NNS (r_appos) hyperemia/NN -PUNC- dipyridamole/NN (r_dep) induced/VBN (r_amod) hyperemia/NN -PUNC- dipyridamole/NN (r_compound) thallium-201/NN (r_compound) imaging/NN (r_pobj) to/IN (r_prep) prior/RB (r_advmod) stopped/VBN (r_conj) inhibits/VBZ (l_dobj) hyperemia/NN -PUNC- dipyridamole/NN (r_npadvmod) induced/VBN (r_amod) hyperemia/NN -PUNC- dipyridamole/NN (r_npadvmod) induced/VBN (r_amod) hyperemia/NN
D013793_D006940 NONE thallium-201/NN (r_nmod) imaging/NN (r_pobj) for/IN (r_prep) implications/NNS (r_appos) hyperemia/NN -PUNC- thallium-201/NN (r_compound) imaging/NN (r_pobj) to/IN (r_prep) prior/RB (r_advmod) stopped/VBN (r_conj) inhibits/VBZ (l_dobj) hyperemia/NN
C008514_D006940 NONE methylxanthines/NNS (r_pobj) like/IN (r_prep) hyperemia/NN
D010431_D007383 CID pentoxifylline/NN (r_dobj) taking/VBG (l_conj) derivative/NN (l_relcl) improve/VB (l_dobj) claudication/NN -PUNC- Trental/NNP (r_npadvmod) taking/VBG (l_conj) derivative/NN (l_relcl) improve/VB (l_dobj) claudication/NN
D013806_D006940 NONE theophylline/NN (r_pobj) as/IN (r_prep) methylxanthines/NNS (r_pobj) like/IN (r_prep) hyperemia/NN -PUNC- theophylline/NN (r_pobj) after/IN (r_prep) was/VBD (r_ccomp) peak/JJ (r_advcl) decreased/VBD (l_dobj) hyperemia/NN
D010431_D006940 NONE Pentoxifylline/NNP (r_nsubj) inhibit/VB (l_dobj) hyperemia/NN -PUNC- Trental/NNP (r_appos) Pentoxifylline/NNP (r_nsubj) inhibit/VB (l_dobj) hyperemia/NN -PUNC- pentoxifylline/NN (r_nsubj) inhibits/VBZ (l_dobj) hyperemia/NN -PUNC- pentoxifylline/NN (r_pobj) of/IN (r_prep) dose/NN (r_nsubj) decreased/VBD (l_dobj) hyperemia/NN -PUNC- pentoxyifylline/NN (r_nsubj) inhibit/VB (l_dobj) hyperemia/NN
3437726
D013034_D064420 NONE sparteine/NN (r_nmod) debrisoquine/JJ (r_compound) polymorphism/NN (r_pobj) of/IN (r_prep) phenotype/NN (r_pobj) to/IN (r_prep) belonging/VBG (r_acl) patients/NNS (r_nsubj) experience/VB (l_dobj) reactions/NNS
D003647_D064420 NONE debrisoquine/JJ (r_compound) polymorphism/NN (r_pobj) of/IN (r_prep) phenotype/NN (r_pobj) to/IN (r_prep) belonging/VBG (r_acl) patients/NNS (r_nsubj) experience/VB (l_dobj) reactions/NNS
7083920
D000638_D013617 NONE amiodarone/NN (r_compound) treatment/NN (l_prep) for/IN (l_pobj) tachycardia/NNS
D000638_D006345 NONE amiodarone/NN (r_compound) treatment/NN (r_pobj) under/IN (r_prep) occurring/VBG (l_prep) without/IN (l_pobj) abnormalities/NNS
D000638_D006327 CID amiodarone/NN (r_compound) treatment/NN (r_pobj) under/IN (r_prep) occurring/VBG (r_acl) block/NN
D000638_D001282 NONE amiodarone/NN (r_compound) discontinuation/NN (r_pobj) after/IN (r_prep) showed/VBD (l_dobj) flutter/NN
17608141
D008070_D020258 NONE lipopolysaccharide/NN (r_compound) pretreatment/NN (r_pobj) by/IN (r_prep) neurotoxicity/NN -PUNC- lipopolysaccharide/NN (r_pobj) of/IN (r_prep) roles/NNS (l_appos) factor/NN (l_conj) treatment/NN (l_prep) in/IN (l_pcomp) modulating/VBG (l_dobj) neurotoxicity/NN -PUNC- lipopolysaccharide/NN (r_compound) pretreatment/NN (l_prep) in/IN (l_pcomp) exerting/VBG (l_dobj) protection/NN (l_prep) against/IN (l_pobj) neurotoxicity/NN
D008694_D009422 NONE methamphetamine/NN (r_npadvmod) induced/VBN (r_amod) damage/NN
D008694_D020258 NONE methamphetamine/NN (r_npadvmod) induced/VBN (l_dobj) neurotoxicity/NN -PUNC- methamphetamine/NN (r_npadvmod) induced/VBN (r_amod) neurotoxicity/NN -PUNC- methamphetamine/NN (r_npadvmod) induced/VBN (r_amod) neurotoxicity/NN
D008694_D005334 CID methamphetamine/NN (r_npadvmod) elicited/VBN (r_amod) hyperthermia/NN
D004298_D020258 NONE dopamine/NN (r_compound) neurotoxicity/NN -PUNC- dopamine/NN (r_compound) neurotoxicity/NN
D008070_D005334 NONE Lipopolysaccharide/JJ (r_compound) pretreatment/NN (r_nsubj) affect/VB (l_dobj) temperature/NN (l_conj) hyperthermia/NN
8682684
D000082_D002318 NONE acetaminophen/NN (r_pobj) for/IN (r_prep) potential/NN (l_acl) produce/VB (l_dobj) toxicities/NNS
D000082_D000707 NONE acetaminophen/RB (r_nsubjpass) demonstrated/VBN (l_xcomp) produce/VB (l_dobj) symptoms/NNS (l_prep) of/IN (l_pobj) anaphylaxis/NN
D000082_D016638 NONE acetaminophen/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) developed/VBN (r_relcl) patients/NNS (l_amod) ill/JJ
D000082_D007022 CID Acetaminophen/NNP (r_npadvmod) induced/VBN (r_amod) hypotension/NN -PUNC- acetaminophen/RB (r_nsubjpass) demonstrated/VBN (l_xcomp) produce/VB (l_dobj) symptoms/NNS (l_prep) including/VBG (l_pobj) hypotension/NN -PUNC- acetaminophen/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) developed/VBN (l_nsubj) episodes/NNS (l_prep) of/IN (l_pobj) hypotension/NN -PUNC- acetaminophen/NN (r_dobj) consider/VB (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) hypotension/NN
18821488
C068820_D008708 NONE WR242511/NNP (l_relcl) produced/VBD (l_dobj) methemoglobinemia/NN
C068820_D006456 CID WR242511/NNP (r_pobj) of/IN (r_prep) postinjection/NN (r_dobj) noted/VBN (l_nsubjpass) hemoglobinuria/NN
C068820_D064420 NONE hexyloxy)-6-methoxy-4-methylquinoline/NNP (r_nmod) WR242511/NNP (r_pobj) of/IN (r_prep) administration/NN (r_pobj) following/VBG (r_prep) Toxicity/NN -PUNC- WR242511/NNP (r_pobj) of/IN (r_prep) administration/NN (r_pobj) following/VBG (r_prep) Toxicity/NN -PUNC- WR242511/NNP (r_nsubjpass) pursued/VBN (l_advcl) dissociated/VBN (l_prep) from/IN (l_pobj) those/DT (l_acl) producing/VBG (l_dobj) toxicity/NN
C080436_D064420 NONE 8-aminoquinoline/JJ (r_compound) 8-[(4-amino/CD (r_compound) l/NN (r_compound) methylbutyl)amino]-/NN (r_punct) WR242511/NNP (r_pobj) of/IN (r_prep) administration/NN (r_pobj) following/VBG (r_prep) Toxicity/NN
C068820_D011041 NONE WR242511/NNP (r_nsubjpass) pursued/VBN (l_prep) as/IN (l_pobj) pretreatment/NN (l_prep) for/IN (l_pobj) poisoning/NN
1601297
D003042_D009202 NONE cocaine/NN (r_compound) abusers/NNS (r_pobj) in/IN (r_prep) injury/NN -PUNC- cocaine/NN (r_compound) abusers/NNS (r_pobj) of/IN (r_prep) Eleven/CD (r_nsubj) had/VBD (l_dobj) evidence/NN (l_prep) of/IN (l_pobj) injury/NN
D003042_D012559 NONE cocaine/NN (r_npadvmod) abusing/VBG (r_amod) patients/NNS (r_pobj) of/IN (r_prep) ECG/NNP (r_appos) electrocardiograms/NNS (r_nsubjpass) compared/VBN (l_prep) with/IN (l_pobj) ECGs/NNS (l_prep) of/IN (l_pobj) controls/NNS (l_amod) schizophrenic/JJ
D003042_D002037 CID cocaine/NN (r_compound) abusers/NNS (r_pobj) of/IN (r_prep) Eleven/CD (r_nsubj) had/VBD (l_dobj) evidence/NN (l_prep) of/IN (l_pobj) injury/NN (l_acl) defined/VBN (l_prep) as/IN (l_pobj) infarction/NN (l_conj) ischemia/NN (l_conj) block/NN
D003042_D009203 CID cocaine/NN (r_compound) abusers/NNS (r_pobj) of/IN (r_prep) Eleven/CD (r_nsubj) had/VBD (l_dobj) evidence/NN (l_prep) of/IN (l_pobj) injury/NN (l_acl) defined/VBN (l_prep) as/IN (l_pobj) infarction/NN
D003042_D007511 NONE cocaine/NN (r_compound) abusers/NNS (r_pobj) of/IN (r_prep) Eleven/CD (r_nsubj) had/VBD (l_dobj) evidence/NN (l_prep) of/IN (l_pobj) injury/NN (l_acl) defined/VBN (l_prep) as/IN (l_pobj) infarction/NN (l_conj) ischemia/NN
26094
D008750_D003866 CID dopa/NN (r_pobj) in/IN (r_prep) occurring/VBG (r_acl) depressions/NNS
D008750_D001523 NONE dopa/NN (r_pobj) in/IN (r_prep) occurring/VBG (r_acl) depressions/NNS (r_pobj) of/IN (r_prep) number/NN (l_acl) treated/VBD (l_dobj) patients/NNS (l_prep) with/IN (l_pobj) histories/NNS (l_amod) psychiatric/JJ
2696505
D007741_D007022 CID labetalol/NN (l_conj) nitroprusside/RB (l_prep) for/IN (l_pobj) hypotension/NN -PUNC- labetalol/RB (r_npadvmod) induced/VBN (r_amod) hypotension/NN -PUNC- labetalol/RB (r_npadvmod) induced/VBN (r_amod) hypotension/NN (l_conj) hypotension/NN
D009599_D016534 CID nitroprusside/NN (r_pobj) of/IN (r_prep) discontinuation/NN (r_pobj) after/IN (r_prep) observed/VBN (l_ccomp) associated/VBN (l_advcl) increase/NN (l_prep) in/IN (l_pobj) rate/NN (l_conj) output/NN
D009599_D007022 CID nitroprusside/RB (l_prep) for/IN (l_pobj) hypotension/NN -PUNC- nitroprusside/RB (r_advmod) induced/VBN (r_amod) hypotension/NN (r_conj) hypotension/NN -PUNC- nitroprusside/RB (r_advmod) induced/VBN (r_amod) hypotension/NN
D009599_D006973 NONE nitroprusside/NN (r_pobj) of/IN (r_prep) discontinuation/NN (r_pobj) after/IN (r_prep) observed/VBN (l_nsubjpass) hypertension/NN
6229975
D013999_D001919 NONE timolol/NN (r_npadvmod) induced/VBN (r_amod) bradycardia/NN
D013999_D009203 NONE timolol/NN (r_compound) treatment/NN (l_prep) after/IN (l_pobj) infarction/NN -PUNC- timolol/NN (r_compound) treatment/NN (r_pobj) of/IN (r_prep) effect/NN (l_prep) after/IN (l_pobj) infarction/NN -PUNC- timolol/NN (r_conj) evaluated/VBN (l_nsubjpass) effect/NN (l_prep) after/IN (l_pobj) infarction/NN
D013999_D007238 NONE timolol/NN (r_compound) group/NN (r_pobj) in/IN (r_prep) remained/VBD (r_conj) increased/VBD (l_punct) ,/, (l_punct) infarction/NN
15188772
D004837_D062787 NONE epinephrine/NN (r_amod) overdose/NN
D004837_D009202 NONE epinephrine/NN (r_pobj) of/IN (r_prep) mg/NN (r_nsubj) developed/VBN (l_dobj) markers/NNS (l_prep) of/IN (l_pobj) necrosis/NN
D004837_D017682 CID epinephrine/NN (r_pobj) of/IN (r_prep) mg/NN (r_nsubj) developed/VBN (l_dobj) markers/NNS (l_amod) stunning/JJ
D004837_D018487 NONE epinephrine/NN (r_amod) overdose/NN (r_pobj) due/IN (r_prep) dysfunction/NN -PUNC- epinephrine/NN (r_pobj) of/IN (r_prep) mg/NN (r_nsubj) developed/VBN (l_dobj) markers/NNS (l_amod) stunning/JJ (l_relcl) characterized/VBN (l_conj) left/VBD (l_dobj) dysfunction/NN
D002395_D009202 NONE Catecholamine/NN (r_npadvmod) induced/VBN (r_amod) cardiomyopathy/NN -PUNC- catecholamines/NNS (r_pobj) of/IN (r_prep) excess/NN (r_pobj) due/IN (r_prep) cardiomyopathy/NN
8590259
C016986_D015814 CID apraclonidine/NN (r_npadvmod) treated/VBN (r_amod) eyes/NNS (r_pobj) for/IN (r_prep) significant/JJ (r_acomp) were/VBD (l_nsubj) effects/NNS (l_amod) hypotensive/JJ -PUNC- apraclonidine/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) hours/NNS (r_pobj) from/IN (r_prep) significant/JJ (r_conj) significant/JJ (r_acomp) were/VBD (l_nsubj) effects/NNS (l_amod) hypotensive/JJ
16274958
D017255_D055154 CID acitretin/NN (r_conj) dysphonia/NN -PUNC- acitretin/NN (r_pobj) by/IN (r_agent) treated/VBN (r_advcl) report/VBP (l_dobj) case/NN (l_prep) of/IN (l_pobj) woman/NN (l_acl) complaining/VBG (l_prep) of/IN (l_pobj) dysphonia/NN -PUNC- acitretin/NN (r_advmod) induced/VBN (r_amod) dysphonia/NN
9746003
D002220_D009207 CID carbamazepine/NN (l_conj) two/CD (l_prep) of/IN (l_pobj) jerks/NNS -PUNC- carbamazepine/NN (r_pobj) of/IN (r_prep) withdrawal/NN (r_pobj) on/IN (r_prep) resolved/VBD (r_relcl) jerks/NNS
D002220_D004832 CID carbamazepine/NN (l_conj) vigabatrin/VBP (l_prep) in/IN (l_pobj) seizures/NNS -PUNC- Carbamazepine/NNP (r_nsubjpass) contraindicated/VBN (l_prep) in/IN (l_pobj) seizures/NNS
D020888_D004832 CID vigabatrin/VBP (l_prep) in/IN (l_pobj) seizures/NNS -PUNC- vigabatrin/NN (r_conj) Carbamazepine/NNP (r_nsubjpass) contraindicated/VBN (l_prep) in/IN (l_pobj) seizures/NNS
10835440
D009553_D020521 NONE nimodipine/NN (r_pobj) of/IN (r_prep) Effect/NN (l_prep) after/IN (l_pobj) stroke/NN -PUNC- Nimodipine/NNP (r_compound) Trial/NN (l_compound) Stroke/NNP -PUNC- Nimodipine/NNP (r_compound) Trial/NN (r_nsubj) found/VBD (l_dobj) correlation/NN (l_prep) between/IN (l_pobj) reduction/NN (l_conj) outcome/NN (l_prep) in/IN (l_pobj) stroke/NN -PUNC- nimodipine/NN (r_npadvmod) induced/VBN (r_amod) reduction/NN (r_pobj) between/IN (r_prep) correlation/NN (r_dobj) found/VBD (l_nsubj) Trial/NN (l_compound) Stroke/NNP -PUNC- nimodipine/NN (r_npadvmod) induced/VBN (r_amod) reduction/NN (l_conj) outcome/NN (l_prep) in/IN (l_pobj) stroke/NN -PUNC- nimodipine/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) worsening/VBG (l_prep) after/IN (l_pobj) stroke/NN
D009553_D007022 CID Nimodipine/NNP (r_compound) Trial/NN (r_nsubj) found/VBD (l_dobj) correlation/NN (l_prep) between/IN (l_pobj) reduction/NN (l_prep) in/IN (l_pobj) pressure/NN -PUNC- nimodipine/NN (r_npadvmod) induced/VBN (r_amod) reduction/NN (l_prep) in/IN (l_pobj) pressure/NN -PUNC- Nimodipine/NNP (r_compound) treatment/NN (r_nsubj) resulted/VBD (l_prep) in/IN (l_pobj) reduction/NN (l_prep) in/IN (l_pobj) BP/NNP
D009553_D002544 NONE nimodipine/NN (r_parataxis) h/NN (r_appos) receive/VB (r_advcl) allocated/VBN (l_nsubjpass) METHODS/NNS (l_appos) Patients/NNS (l_prep) with/IN (l_pobj) diagnosis/NN (l_prep) of/IN (l_pobj) stroke/NN -PUNC- nimodipine/NN (r_conj) nimodipine/NN (r_parataxis) h/NN (r_appos) receive/VB (r_advcl) allocated/VBN (l_nsubjpass) METHODS/NNS (l_appos) Patients/NNS (l_prep) with/IN (l_pobj) diagnosis/NN (l_prep) of/IN (l_pobj) stroke/NN
6692345
D005200_D013274 CID N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide/NNP (r_pobj) with/IN (r_prep) aspirin/NN (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) resulted/VBD (l_prep) in/IN (l_pobj) incidence/NN (l_conj) induction/NN (l_prep) of/IN (l_pobj) tumors/NNS -PUNC- FANFT/NNP (r_appos) N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide/NNP (r_pobj) with/IN (r_prep) aspirin/NN (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) resulted/VBD (l_prep) in/IN (l_pobj) incidence/NN (l_conj) induction/NN (l_prep) of/IN (l_pobj) tumors/NNS -PUNC- FANFT/NNP (r_npadvmod) induced/VBN (r_amod) carcinomas/NNS (r_pobj) of/IN (r_prep) incidence/NN (l_conj) induction/NN (l_prep) of/IN (l_pobj) tumors/NNS
D005200_D001749 CID N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide/NNP (r_pobj) with/IN (r_prep) aspirin/NN (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) resulted/VBD (l_prep) in/IN (l_pobj) incidence/NN (l_prep) of/IN (l_pobj) carcinomas/NNS -PUNC- FANFT/NNP (r_appos) N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide/NNP (r_pobj) with/IN (r_prep) aspirin/NN (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) resulted/VBD (l_prep) in/IN (l_pobj) incidence/NN (l_prep) of/IN (l_pobj) carcinomas/NNS -PUNC- FANFT/NNP (r_npadvmod) induced/VBN (r_amod) carcinomas/NNS
D001241_D013274 NONE aspirin/NN (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) resulted/VBD (l_prep) in/IN (l_pobj) incidence/NN (l_conj) induction/NN (l_prep) of/IN (l_pobj) tumors/NNS
D001241_D063646 NONE aspirin/NN (r_poss) effect/NN (r_nsubj) is/VBZ (r_conj) involved/VBN (l_prep) in/IN (l_pobj) carcinogenesis/NN
D001241_D001749 NONE aspirin/NN (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) resulted/VBD (l_prep) in/IN (l_pobj) incidence/NN (l_prep) of/IN (l_pobj) carcinomas/NNS
D005200_D063646 NONE FANFT/NNP (r_compound) carcinogenesis/NN -PUNC- FANFT/NNP (r_pobj) on/IN (r_prep) effect/NN (r_nsubj) is/VBZ (r_conj) involved/VBN (l_prep) in/IN (l_pobj) carcinogenesis/NN
15602202
D017963_D009395 CID azithromycin/PRP (r_pobj) by/IN (r_prep) induced/VBN (l_nsubj) nephritis/NN -PUNC- azithromycin/RB (r_advmod) induced/VBN (r_amod) nephritis/NN
8386779
D010208_D007172 NONE papaverine/NN (r_appos) drugs/NNS (r_pobj) of/IN (r_prep) combination/NN (r_pobj) of/IN (r_prep) ml./NN (r_dobj) received/VBD (l_nsubj) total/NN (l_prep) of/IN (l_pobj) patients/NNS (l_relcl) presented/VBD (l_prep) with/IN (l_pobj) impotence/NN
D017693_D004414 NONE bicarbonate/NN (r_nsubj) alleviates/VBZ (l_dobj) pain/NN -PUNC- bicarbonate/NN (r_pobj) of/IN (r_prep) addition/NN (r_pobj) without/IN (r_conj) with/IN (r_prep) injections/NNS (r_pobj) following/VBG (r_prep) comparing/VBG (r_acl) study/NN (r_dobj) performed/VBD (l_prep) In/IN (l_pobj) attempt/NN (l_acl) determine/VB (l_ccomp) be/VB (l_nsubj) pain/NN -PUNC- bicarbonate/NN (r_pobj) of/IN (r_prep) addition/NN (r_pobj) without/IN (r_conj) with/IN (r_prep) injections/NNS (r_pobj) following/VBG (r_prep) comparing/VBG (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) pain/NN -PUNC- bicarbonate/NN (r_pobj) without/IN (r_prep) patients/NNS (r_pobj) Of/IN (r_prep) complained/VBD (l_prep) of/IN (l_pobj) pain/NN -PUNC- bicarbonate/NN (r_pobj) without/IN (r_prep) patients/NNS (r_pobj) Of/IN (r_prep) complained/VBD (l_advcl) complained/VBD (l_prep) of/IN (l_pobj) pain/NN -PUNC- bicarbonate/NN (r_dobj) received/VBD (r_relcl) men/NNS (r_pobj) of/IN (r_prep) 1/CD (r_nsubj) complained/VBD (r_advcl) complained/VBD (l_prep) of/IN (l_pobj) pain/NN -PUNC- bicarbonate/NN (r_dobj) received/VBD (r_relcl) men/NNS (r_pobj) of/IN (r_prep) 1/CD (r_nsubj) complained/VBD (l_prep) of/IN (l_pobj) pain/NN
D017693_D007172 NONE bicarbonate/NN (r_nsubj) alleviates/VBZ (l_advcl) induced/VBN (l_agent) by/IN (l_pobj) injections/NNS (l_prep) for/IN (l_pobj) dysfunction/NN
8669433
D010615_D007676 CID phenacetin/NN (r_pobj) with/IN (r_prep) comparison/NN (r_appos) use/NN (l_prep) as/IN (l_pobj) factor/NN (l_prep) for/IN (l_pobj) failure/NN -PUNC- phenacetin/NN (r_pobj) of/IN (r_prep) use/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) failure/NN -PUNC- phenacetin/NN (r_pobj) of/IN (r_prep) use/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) failure/NN (l_conj) disease/NN -PUNC- phenacetin/NN (r_pobj) of/IN (r_prep) use/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) failure/NN (l_conj) disease/NN (l_appos) ESRD/NNP -PUNC- phenacetin/NN (r_nsubj) contribute/VB (l_prep) to/IN (l_pobj) burden/NN (l_prep) of/IN (l_pobj) ESRD/NNP
D000082_D007676 NONE acetaminophen/NN (r_pobj) of/IN (r_prep) use/NN (l_prep) as/IN (l_pobj) factor/NN (l_prep) for/IN (l_pobj) failure/NN -PUNC- acetaminophen/NN (r_pobj) of/IN (r_prep) use/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) failure/NN -PUNC- acetaminophen/NN (r_pobj) of/IN (r_prep) use/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) failure/NN (l_conj) ESRD/NNP -PUNC- acetaminophen/RB (r_conj) phenacetin/NN (r_nsubj) contribute/VB (l_prep) to/IN (l_pobj) burden/NN (l_prep) of/IN (l_pobj) ESRD/NNP -PUNC- acetaminophen/NN (r_pobj) of/IN (r_prep) use/NN (r_nsubj) increases/VBZ (l_dobj) risk/NN (l_prep) of/IN (l_pobj) ESRD/NNP
8423889
D005473_D009069 CID fluoxetine/NN (r_amod) medication/NN (r_pobj) after/IN (r_prep) Increase/NNP (l_prep) of/IN (l_pobj) disability/NN -PUNC- fluoxetine/NN (r_pobj) to/IN (r_prep) exposure/NN (r_pobj) after/IN (r_prep) amount/NN (l_prep) of/IN (l_pobj) disability/NN
D005473_D010300 NONE fluoxetine/NN (r_pobj) to/IN (r_prep) exposure/NN (r_pobj) after/IN (r_prep) amount/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disease/NN -PUNC- fluoxetine/NN (r_pobj) of/IN (r_prep) capacity/NN (l_prep) in/IN (l_pobj) patients/NNS (l_compound) disease/NN
D000928_D009069 NONE antidepressant/JJ (r_amod) fluoxetine/NN (r_pobj) to/IN (r_prep) exposure/NN (r_pobj) after/IN (r_prep) amount/NN (l_prep) of/IN (l_pobj) disability/NN
D000928_D010300 NONE antidepressant/JJ (r_amod) fluoxetine/NN (r_pobj) to/IN (r_prep) exposure/NN (r_pobj) after/IN (r_prep) amount/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disease/NN
D004298_D010300 NONE dopamine/NN (r_npadvmod) antagonistic/JJ (r_amod) capacity/NN (l_prep) in/IN (l_pobj) patients/NNS (l_compound) disease/NN
4071154
D007213_D005355 CID indomethacin/NN (r_advcl) reported/VBN (l_dobj) case/NN (l_prep) in/IN (l_pobj) patient/NN (l_prep) with/IN (l_pobj) cirrhosis/NN
D007213_D011660 CID indomethacin/NN (r_advcl) reported/VBN (l_dobj) case/NN (l_prep) in/IN (l_pobj) patient/NN (l_prep) with/IN (l_pobj) cirrhosis/NN (l_conj) ascites/NNS (l_conj) pulmonale/NN
D007213_D051437 NONE Indomethacin/NNP (r_npadvmod) induced/VBN (r_amod) insufficiency/NN -PUNC- indomethacin/NN (r_advcl) reported/VBN (l_dobj) case/NN (l_prep) of/IN (l_pobj) failure/NN
D007213_D001201 CID indomethacin/NN (r_advcl) reported/VBN (l_dobj) case/NN (l_prep) in/IN (l_pobj) patient/NN (l_prep) with/IN (l_pobj) cirrhosis/NN (l_conj) ascites/NNS
D007213_D009846 CID indomethacin/NN (r_pobj) of/IN (r_prep) dose/NN (r_pobj) to/IN (r_punct) caused/VBD (l_dobj) recurrence/NN (l_prep) of/IN (l_pobj) oliguria/NN
D007213_D006947 CID indomethacin/NN (r_advcl) reported/VBN (l_dobj) case/NN (l_prep) of/IN (l_pobj) failure/NN (l_prep) with/IN (l_pobj) hyperkalemia/NN
19820426
C558899_D066126 NONE ritonavir/NNS (r_compound) therapy/NN (r_appos) lopinavir/NNS (r_pobj) to/IN (r_prep) related/VBN (r_acl) toxicity/NN
C558899_D001919 CID ritonavir/NNS (r_compound) therapy/NN (r_appos) lopinavir/NNS (r_pobj) to/IN (r_prep) related/VBN (r_acl) cardiomyopathy/NN (r_conj) block/NN (r_dobj) developed/VBD (l_advcl) developed/VBD (l_dobj) bradycardia/NNS
C558899_D002311 CID ritonavir/NNS (r_compound) therapy/NN (r_appos) lopinavir/NNS (r_pobj) to/IN (r_prep) related/VBN (r_acl) cardiomyopathy/NN
C558899_D006327 CID ritonavir/NNS (r_compound) therapy/NN (r_appos) lopinavir/NNS (r_pobj) to/IN (r_prep) related/VBN (r_acl) cardiomyopathy/NN (r_conj) block/NN
15572383
D004317_D009404 NONE adriamycin/NNS (l_pobj) proteinuria/NN (l_amod) nephrotic/JJ
D004317_D005923 NONE adriamycin/NNS (l_pobj) proteinuria/NN (l_conj) damage/NN (l_conj) glomerulosclerosis/NN
D004317_D011507 CID adriamycin/NNS (r_pobj) by/IN (r_agent) induced/VBN (l_nsubjpass) proteinuria/NN -PUNC- adriamycin/NNS (l_pobj) proteinuria/NN -PUNC- adriamycin/NNS (r_advcl) correlated/VBD (l_prep) with/IN (l_pobj) rise/NN (l_prep) in/IN (l_pobj) proteinuria/NN
D004317_D007674 NONE adriamycin/NNS (r_advmod) induced/VBN (r_amod) damage/NN -PUNC- adriamycin/NNS (r_pobj) of/IN (r_prep) injection/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) severity/NN (l_prep) of/IN (l_pobj) damage/NN -PUNC- adriamycin/NNS (l_pobj) proteinuria/NN (l_conj) damage/NN -PUNC- adriamycin/NNS (r_advmod) induced/VBN (r_amod) damage/NN
18343374
D002996_D014786 CID CC/NN (r_pobj) of/IN (r_prep) complications/NNS (r_pobj) on/IN (r_prep) search/NN (r_nsubj) include/VB (l_advcl) is/VBZ (l_nsubj) disturbance/NN -PUNC- CC/NN (r_compound) intake/NN (r_pobj) after/IN (r_prep) disturbance/NN
D002996_D007247 NONE CC/NN (r_pobj) with/IN (r_prep) treating/VBG (l_dobj) patients/NNS (l_compound) infertility/NN
D002996_D013923 NONE CC/NN (r_pobj) of/IN (r_prep) complications/NNS (l_compound) thromboembolic/JJ -PUNC- CC/NN (r_compound) intake/NN (r_pobj) after/IN (r_prep) disturbance/NN (r_nsubj) is/VBZ (r_advcl) include/VB (l_nsubj) search/NN (l_prep) on/IN (l_pobj) complications/NNS (l_compound) thromboembolic/JJ
D002996_D012170 CID clomiphene/NN (r_npadvmod) induced/VBN (r_amod) ovulation/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) occlusion/NN -PUNC- citrate/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) occlusion/NN -PUNC- CC/NN (r_appos) citrate/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) occlusion/NN -PUNC- CC/NN (r_pobj) with/IN (r_prep) induction/NN (r_pobj) after/IN (r_prep) occlusion/NN -PUNC- CC/NN (r_pobj) of/IN (r_prep) courses/NNS (r_pobj) after/IN (r_prep) developed/VBD (l_dobj) occlusion/NN -PUNC- CC/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) after/IN (r_prep) occlusion/NN
11706060
D019259_D000163 NONE lamivudine/NN (r_pobj) of/IN (r_prep) combination/NN (r_pobj) with/IN (r_prep) treated/VBN (l_nsubjpass) mice/NNS (l_compound) AIDS/NNP
D019469_D000163 NONE indinavir/NNS (r_conj) lamivudine/NN (r_pobj) of/IN (r_prep) combination/NN (r_pobj) with/IN (r_prep) treated/VBN (l_nsubjpass) mice/NNS (l_compound) AIDS/NNP
D019344_D009202 NONE lactate/NN (r_dobj) elevates/VBZ (r_conj) causes/VBZ (l_advmod) cardiomyopathy/NN -PUNC- lactate/NN (r_pobj) in/IN (r_conj) in/IN (l_pobj) CM/NNP (l_amod) cardiomyopathy/NN -PUNC- lactate/NN (r_pobj) in/IN (r_conj) in/IN (l_pobj) CM/NNP -PUNC- LA/NNP (r_appos) lactate/NN (r_pobj) in/IN (r_conj) in/IN (l_pobj) CM/NNP (l_amod) cardiomyopathy/NN -PUNC- LA/NNP (r_appos) lactate/NN (r_pobj) in/IN (r_conj) in/IN (l_pobj) CM/NNP -PUNC- LA/NNP (r_pobj) of/IN (r_prep) determination/NN (r_conj) underwent/VBD (l_dobj) echocardiography/RB (l_appos) quantitation/NN (l_prep) of/IN (l_pobj) abundance/NN (l_prep) of/IN (l_pobj) markers/NNS (l_prep) of/IN (l_pobj) CM/NNP -PUNC- LA/NNP (r_pobj) with/IN (r_prep) CM/NNP
D019344_D028361 NONE lactate/NN (r_pobj) in/IN (r_conj) in/IN (r_prep) implicated/VBN (l_prep) through/IN (l_pobj) mechanisms/NNS (l_prep) of/IN (l_pobj) dysfunction/NN -PUNC- LA/NNP (r_appos) lactate/NN (r_pobj) in/IN (r_conj) in/IN (r_prep) implicated/VBN (l_prep) through/IN (l_pobj) mechanisms/NNS (l_prep) of/IN (l_pobj) dysfunction/NN
D002118_D009202 NONE calcium/NN (r_compound) ATPase/NNP (r_conj) encoding/VBG (r_parataxis) quantitation/NN (l_prep) of/IN (l_pobj) abundance/NN (l_prep) of/IN (l_pobj) markers/NNS (l_prep) of/IN (l_pobj) CM/NNP
D019344_D000163 NONE lactate/NN (r_dobj) elevates/VBZ (l_prep) in/IN (l_pobj) mice/NNS (l_compound) AIDS/NNP -PUNC- lactate/NN (l_prep) in/IN (l_pobj) AIDS/NNP -PUNC- LA/NNP (r_appos) lactate/NN (l_prep) in/IN (l_pobj) AIDS/NNP -PUNC- LA/NNP (l_prep) in/IN (l_pobj) mice/NNS (l_compound) transgenic/JJ (l_compound) AIDS/NNP
D015215_D000163 NONE zidovudine/NN (r_nmod) lamivudine/NN (r_pobj) of/IN (r_prep) combination/NN (r_pobj) with/IN (r_prep) treated/VBN (l_nsubjpass) mice/NNS (l_compound) AIDS/NNP
1833784
D004298_D006948 NONE dopamine/NN (r_conj) D1/NN (r_nmod) receptors/NNS (r_pobj) of/IN (r_prep) involvement/NN (l_prep) in/IN (l_pcomp) mediating/VBG (l_dobj) hyperactivity/NN
C534628_D006948 NONE 23390/CD (r_nummod) SCH/NNP (r_appos) antagonist/NN (r_pobj) by/IN (r_agent) blocked/VBN (l_nsubjpass) hyperactivity/NN
D005476_D006948 NONE fluphenazine/NN (r_conj) raclopride/NN (l_ccomp) blocked/VBN (l_nsubjpass) hyperactivity/NN
D009538_D006948 CID nicotine/NN (r_npadvmod) induced/VBN (r_amod) hyperactivity/NN -PUNC- Nicotine/NNP (r_nsubj) caused/VBD (l_dobj) increase/NN (l_prep) in/IN (l_pobj) activity/NN -PUNC- Nicotine/NN (r_npadvmod) induced/VBN (r_amod) hyperactivity/NN -PUNC- nicotine/NN (r_npadvmod) induced/VBN (r_amod) hyperactivity/NN -PUNC- nicotine/NN (r_compound) injection/NN (r_nsubj) induces/VBZ (l_dobj) hyperactivity/NN
D020891_D006948 NONE raclopride/NN (l_ccomp) blocked/VBN (l_nsubjpass) hyperactivity/NN
D015647_D006948 NONE 38393/CD (r_nummod) SKF/NNP (r_appos) agonist/NN (r_nsubj) had/VBD (r_advcl) Pretreatment/NN (l_prep) with/IN (l_pobj) agonist/NN (l_appos) hyperactivity/NN
-1_D006948 NONE PHNO/NNP (r_npadvmod) enhanced/VBN (r_amod) hyperactivity/NN
7453952
D008094_D011141 NONE lithium/NN (r_npadvmod) induced/VBN (r_amod) polydipsia/NN (l_conj) polyuria/NN -PUNC- lithium/NN (r_compound) concentration/NN (r_pobj) on/IN (r_conj) on/IN (l_pobj) polydipsia/NN (l_conj) polyuria/NN -PUNC- lithium/NN (r_npadvmod) treated/VBN (r_amod) patients/NNS (l_acl) suffering/VBG (l_prep) from/IN (l_pobj) polydipsia/NN (l_conj) polyuria/NN -PUNC- lithium/NN (r_compound) levels/NNS (r_pobj) in/IN (r_prep) result/VB (r_conj) relieve/VB (l_nsubj) administration/NN (l_prep) to/IN (l_pobj) patients/NNS (l_acl) suffering/VBG (l_prep) from/IN (l_pobj) polydipsia/NN (l_conj) polyuria/NN
D008094_D059606 NONE lithium/NN (r_npadvmod) induced/VBN (r_amod) polydipsia/NN -PUNC- lithium/NN (r_compound) concentration/NN (r_pobj) on/IN (r_conj) on/IN (l_pobj) polydipsia/NN -PUNC- lithium/NN (r_npadvmod) treated/VBN (r_amod) patients/NNS (l_acl) suffering/VBG (l_prep) from/IN (l_pobj) polydipsia/NN -PUNC- lithium/NN (r_compound) levels/NNS (r_pobj) in/IN (r_prep) result/VB (r_conj) relieve/VB (l_nsubj) administration/NN (l_prep) to/IN (l_pobj) patients/NNS (l_acl) suffering/VBG (l_prep) from/IN (l_pobj) polydipsia/NN
D008094_D003919 CID lithium/NN (r_npadvmod) induced/VBN (r_amod) syndrome/NN -PUNC- lithium/NN (r_npadvmod) induced/VBN (r_amod) syndrome/NN -PUNC- lithium/NN (r_compound) concentration/NN (r_pobj) between/IN (r_prep) ratio/NN (r_pobj) of/IN (r_prep) reduction/NN (r_pobj) by/IN (r_agent) accompanied/VBN (l_nsubjpass) attenuation/NN (l_prep) of/IN (l_pobj) syndrome/NN
D011188_D003919 NONE potassium/NN (r_compound) level/NN (r_pobj) in/IN (r_prep) elevation/NN (r_conj) concentration/NN (r_pobj) between/IN (r_prep) ratio/NN (r_pobj) of/IN (r_prep) reduction/NN (r_pobj) by/IN (r_agent) accompanied/VBN (l_nsubjpass) attenuation/NN (l_prep) of/IN (l_pobj) syndrome/NN
D018021_D059606 NONE LiCl/NNP (r_pobj) with/IN (r_prep) treated/VBN (r_conj) investigated/VBN (l_nsubjpass) effect/NN (l_prep) on/IN (l_pobj) polydipsia/NN
D000584_D003919 NONE amiloride/NN (r_pobj) by/IN (r_prep) syndrome/NN -PUNC- amiloride/NN (r_pobj) by/IN (r_prep) syndrome/NN
D000584_D059606 NONE amiloride/NN (r_pobj) of/IN (r_prep) effect/NN (l_prep) on/IN (l_pobj) polydipsia/NN -PUNC- amiloride/NN (r_compound) administration/NN (l_prep) to/IN (l_pobj) patients/NNS (l_acl) suffering/VBG (l_prep) from/IN (l_pobj) polydipsia/NN -PUNC- amiloride/JJ (r_compound) supplementation/NN (r_nsubj) result/VB (r_conj) relieve/VB (l_nsubj) administration/NN (l_prep) to/IN (l_pobj) patients/NNS (l_acl) suffering/VBG (l_prep) from/IN (l_pobj) polydipsia/NN
D018021_D011141 NONE LiCl/NNP (r_pobj) with/IN (r_prep) treated/VBN (r_conj) investigated/VBN (l_nsubjpass) effect/NN (l_prep) on/IN (l_pobj) polydipsia/NN (l_conj) polyuria/NN
D000584_D011141 NONE amiloride/NN (r_pobj) of/IN (r_prep) effect/NN (l_prep) on/IN (l_pobj) polydipsia/NN (l_conj) polyuria/NN -PUNC- amiloride/NN (r_compound) administration/NN (l_prep) to/IN (l_pobj) patients/NNS (l_acl) suffering/VBG (l_prep) from/IN (l_pobj) polydipsia/NN (l_conj) polyuria/NN -PUNC- amiloride/JJ (r_compound) supplementation/NN (r_nsubj) result/VB (r_conj) relieve/VB (l_nsubj) administration/NN (l_prep) to/IN (l_pobj) patients/NNS (l_acl) suffering/VBG (l_prep) from/IN (l_pobj) polydipsia/NN (l_conj) polyuria/NN
3985451
D014859_D020428 CID Warfarin/NNP (r_npadvmod) induced/VBN (r_amod) hemorrhage/NN (l_prep) with/IN (l_pobj) palsy/JJ -PUNC- warfarin/RB (r_npadvmod) induced/VBN (r_amod) neuropathy/NN (r_pobj) of/IN (r_prep) form/NN (r_dobj) represents/VBZ (l_nsubj) palsy/JJ
D014859_D003286 NONE warfarin/NN (r_compound) therapy/NN (r_pobj) on/IN (r_prep) man/NN (l_relcl) sustained/VBD (l_conj) developed/VBD (l_dobj) pain/NN (l_conj) contracture/NN -PUNC- warfarin/RB (r_npadvmod) induced/VBN (r_amod) neuropathy/NN (r_pobj) of/IN (r_prep) form/NN (r_dobj) represents/VBZ (r_ccomp) characterized/VBN (l_agent) by/IN (l_pobj) pain/NN (l_conj) degrees/NNS (l_conj) contracture/NN
D014859_D009135 CID warfarin/NN (r_compound) therapy/NN (r_pobj) on/IN (r_prep) man/NN (l_relcl) sustained/VBD (l_dobj) tear/NN
D014859_D015417 NONE warfarin/RB (r_npadvmod) induced/VBN (r_amod) neuropathy/NN (r_pobj) of/IN (r_prep) form/NN (r_dobj) represents/VBZ (r_ccomp) characterized/VBN (l_agent) by/IN (l_pobj) pain/NN (l_conj) degrees/NNS (l_prep) of/IN (l_pobj) impairment/NN
D014859_D010146 NONE warfarin/NN (r_compound) therapy/NN (r_pobj) on/IN (r_prep) man/NN (l_relcl) sustained/VBD (l_conj) developed/VBD (l_dobj) pain/NN -PUNC- warfarin/RB (r_npadvmod) induced/VBN (r_amod) neuropathy/NN (r_pobj) of/IN (r_prep) form/NN (r_dobj) represents/VBZ (r_ccomp) characterized/VBN (l_agent) by/IN (l_pobj) pain/NN
D014859_D006470 NONE Warfarin/NNP (r_npadvmod) induced/VBN (r_amod) hemorrhage/NN
D014859_D010523 NONE warfarin/RB (r_npadvmod) induced/VBN (r_amod) neuropathy/NN
1468485
D003520_D014890 NONE cyclophosphamide/NN (r_compound) therapy/NN (l_prep) for/IN (l_pobj) granulomatosis/NN
D015237_D006470 NONE alpha/NN (r_pobj) of/IN (r_prep) saline/NN (r_pobj) with/IN (r_prep) irrigation/NN (r_pobj) including/VBG (r_prep) treatment/NN (r_nsubj) failed/VBD (l_xcomp) control/VB (l_dobj) hemorrhage/NN
D010100_D003556 NONE oxygen/NN (r_compound) therapy/NN (l_prep) for/IN (l_pobj) control/NN (l_prep) of/IN (l_pobj) cystitis/NN
D010100_D006470 NONE oxygen/NN (r_compound) therapy/NN (l_prep) for/IN (l_pobj) control/NN (l_prep) of/IN (l_pobj) cystitis/NN
D003520_D006470 CID cyclophosphamide/NN (r_npadvmod) induced/VBN (r_amod) cystitis/NN -PUNC- cyclophosphamide/NN (r_compound) therapy/NN (r_pobj) due/IN (r_prep) report/VBP (l_dobj) case/NN (l_prep) of/IN (l_pobj) cystitis/NN -PUNC- cyclophosphamide/NN (r_pobj) of/IN (r_prep) treatment/NN (r_pobj) in/IN (r_prep) alternative/NN (r_dobj) offer/VB (l_dobj) cystitis/NN
D003520_D003556 CID cyclophosphamide/NN (r_npadvmod) induced/VBN (r_amod) cystitis/NN -PUNC- cyclophosphamide/NN (r_compound) therapy/NN (r_pobj) due/IN (r_prep) report/VBP (l_dobj) case/NN (l_prep) of/IN (l_pobj) cystitis/NN -PUNC- cyclophosphamide/NN (r_pobj) of/IN (r_prep) treatment/NN (r_pobj) in/IN (r_prep) alternative/NN (r_dobj) offer/VB (l_dobj) cystitis/NN
17244258
D003520_D003556 CID cyclophosphamide/NN (r_npadvmod) induced/VBN (r_amod) cystitis/NN -PUNC- cyclophosphamide/NN (r_npadvmod) induced/VBN (r_amod) cystitis/NN
869641
D006916_D001919 NONE 5-HTP/NNP (r_nsubj) decreased/VBD (l_conj) decreased/VBD (l_dobj) bradycardia/NN
D005406_D007022 NONE FLA-63/NN (r_mark) have/VB (l_dobj) effect/NN (l_prep) on/IN (l_pobj) hypotension/NN
D005406_D001919 NONE FLA-63/NN (r_mark) have/VB (l_dobj) effect/NN (l_prep) on/IN (l_pobj) hypotension/NN (l_appos) effect/NN (l_amod) bradycardia/NN
D004298_D007022 NONE dopamine/NN (r_compound) oxidase/NN (r_compound) inhibitor/NN (r_nsubj) have/VB (l_dobj) effect/NN (l_prep) on/IN (l_pobj) hypotension/NN
D015103_D001919 NONE dihydroxyphenylserine/NN (r_conj) dopa/NNP (r_pobj) by/IN (r_agent) enhanced/VBN (l_nsubjpass) bradycardia/NN
D007980_D007022 NONE dopa/NNP (r_pobj) of/IN (r_prep) effect/NN (r_appos) hypotension/NN
D004298_D001919 NONE dopamine/NN (r_compound) formation/NN (r_pobj) via/IN (r_prep) Mediation/NN (l_prep) of/IN (l_pobj) bradycardia/NNP -PUNC- dopamine/NN (r_compound) oxidase/NN (r_compound) inhibitor/NN (r_nsubj) have/VB (l_dobj) effect/NN (l_prep) on/IN (l_pobj) hypotension/NN (l_appos) effect/NN (l_amod) bradycardia/NN
D009638_D001919 CID norepinephrine/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) bradycardia/NN -PUNC- norepinephrine/NN (r_pobj) to/IN (r_prep) responses/NNS (r_conj) rate/NN (r_conj) pressure/NN (r_pobj) on/IN (r_prep) effect/NN (r_dobj) had/VBD (r_conj) enhanced/VBN (l_nsubjpass) bradycardia/NN -PUNC- norepinephrine/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) bradycardia/NN -PUNC- norepinephrine/NN (r_pobj) to/IN (r_prep) bradycardia/NN
D007980_D001919 NONE dopa/NN (r_pobj) by/IN (r_prep) Mediation/NN (l_prep) of/IN (l_pobj) bradycardia/NNP -PUNC- dopa/NNP (r_pobj) by/IN (r_agent) enhanced/VBN (l_nsubjpass) bradycardia/NN -PUNC- dopa/NNP (r_pobj) of/IN (r_prep) effect/NN (l_amod) bradycardia/NN -PUNC- dopa/NNP (r_nsubj) restored/VBD (l_dobj) bradycardia/NN -PUNC- dopa/NNP (r_nsubj) enhances/VBZ (l_dobj) bradycardia/NN
11807648
D014148_D012640 CID tAMCA/NN (r_nsubj) retains/VBZ (l_dobj) action/NN (l_amod) convulsive/JJ -PUNC- tAMCA/NN (r_appos) FINDINGS/NNS (r_nsubj) caused/VBD (l_dobj) activity/NN (l_relcl) associated/VBN (l_prep) with/IN (l_pobj) behaviours/NNS (l_amod) convulsive/JJ -PUNC- tAMCA/CD (r_pobj) of/IN (r_prep) concentration/NN (r_pobj) with/IN (r_prep) increased/VBD (l_nsubj) degree/NN (l_prep) of/IN (l_pobj) seizures/NNS -PUNC- tAMCA/NN (r_advmod) evoked/VBD (l_dobj) seizures/NNS -PUNC- tAMCA/NN (r_advmod) evoked/VBD (l_advcl) evoked/VBD (l_dobj) episodes/NNS (l_prep) of/IN (l_pobj) potentials/NNS (l_amod) convulsive/JJ -PUNC- tAMCA/NN (r_nmod) ml/NNS (r_pobj) of/IN (r_prep) concentration/NN (r_nsubj) evoked/VBD (r_advcl) evoked/VBD (l_dobj) seizures/NNS -PUNC- tAMCA/NN (r_nmod) ml/NNS (r_pobj) of/IN (r_prep) concentration/NN (r_nsubj) evoked/VBD (l_dobj) episodes/NNS (l_prep) of/IN (l_pobj) potentials/NNS (l_amod) convulsive/JJ -PUNC- acid/NN (r_nsubj) retains/VBZ (l_dobj) action/NN (l_amod) convulsive/JJ
D014148_D004827 NONE acid/NN (r_dobj) containing/VBG (r_acl) sealants/NNS (r_pobj) of/IN (r_prep) application/NN (r_dobj) following/VBG (r_prep) seizures/NNS -PUNC- tAMCA/NN (r_nsubjpass) shown/VBN (l_xcomp) cause/VB (l_dobj) seizures/NNS
18083142
D003042_D001008 CID cocaine/NN (r_npadvmod) induced/VBN (r_amod) anxiety/NN -PUNC- cocaine/NN (r_poss) effects/NNS (r_nsubjpass) studied/VBN (r_advcl) paid/VBN (l_dative) to/IN (l_pobj) states/NNS (l_acl) induced/VBN (l_agent) by/IN (l_pobj) cocaine/NN (l_prep) as/IN (l_pobj) anxiety/NN -PUNC- cocaine/NN (l_prep) as/IN (l_pobj) anxiety/NN -PUNC- cocaine/NN (r_npadvmod) induced/VBN (r_amod) anxiety/NN -PUNC- cocaine/NN (r_nsubj) increased/VBN (l_dobj) behavior/NN (l_amod) like/JJ (l_npadvmod) anxiety/NN -PUNC- Cocaine/NN (r_npadvmod) induced/VBN (r_amod) anxiety/NN -PUNC- cocaine/NN (r_npadvmod) induced/VBN (r_amod) behavior/NN (l_amod) like/JJ (l_npadvmod) anxiety/NN -PUNC- cocaine/NN (r_npadvmod) induced/VBN (r_amod) anxiety/NN
D009638_D001008 NONE Norepinephrine/NN (r_compound) signaling/VBG (r_nsubj) is/VBZ (l_acomp) critical/JJ (l_prep) for/IN (l_pobj) expression/NN (l_prep) of/IN (l_pobj) anxiety/NN -PUNC- norepinephrine/NN (r_dobj) lack/VBP (r_relcl) mice/NNS (r_appos) knockout/NN (r_pobj) of/IN (r_prep) performance/NN (r_dobj) evaluated/VBD (l_advcl) examine/VB (l_dobj) contribution/NN (l_prep) of/IN (l_pobj) signaling/NN (l_prep) to/IN (l_pobj) anxiety/NN -PUNC- NE/NNP (r_appos) norepinephrine/NN (r_dobj) lack/VBP (r_relcl) mice/NNS (r_appos) knockout/NN (r_pobj) of/IN (r_prep) performance/NN (r_dobj) evaluated/VBD (l_advcl) examine/VB (l_dobj) contribution/NN (l_prep) of/IN (l_pobj) signaling/NN (l_prep) to/IN (l_pobj) anxiety/NN
D011224_D001008 NONE prazosin/NN (r_nsubj) had/VBD (r_advcl) pretreatment/NN (l_prep) with/IN (l_pobj) antagonist/NN (l_acl) propranolol/NN (l_dobj) behavior/NN (l_amod) like/JJ (l_npadvmod) anxiety/NN
D015016_D001008 NONE yohimbine/NN (r_appos) antagonist/NN (r_conj) prazosin/NN (r_nsubj) had/VBD (r_advcl) pretreatment/NN (l_prep) with/IN (l_pobj) antagonist/NN (l_acl) propranolol/NN (l_dobj) behavior/NN (l_amod) like/JJ (l_npadvmod) anxiety/NN
D011433_D001008 NONE propranolol/NN (l_dobj) behavior/NN (l_amod) like/JJ (l_npadvmod) anxiety/NN
D004298_D001008 NONE dopamine/NN (r_compound) knockout/NN (r_pobj) of/IN (r_prep) performance/NN (r_dobj) evaluated/VBD (l_advcl) examine/VB (l_dobj) contribution/NN (l_prep) of/IN (l_pobj) signaling/NN (l_prep) to/IN (l_pobj) anxiety/NN -PUNC- dopamine/NN (r_nmod) hydroxylase/NN (r_nmod) inhibitor/NN (r_appos) administration/NN (r_pobj) following/VBG (r_prep) attenuated/VBN (l_nsubjpass) anxiety/NN
D004221_D001008 NONE disulfiram/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) following/VBG (r_prep) attenuated/VBN (l_nsubjpass) anxiety/NN
11752354
D017135_D009203 NONE desogestrel/NN (r_appos) generation/NN (r_nmod) contraceptives/NNS (r_pobj) in/IN (r_prep) included/VBN (r_acl) type/NN (r_pobj) to/IN (r_prep) according/VBG (r_prep) investigated/VBD (l_conj) identified/VBD (l_conj) enrolled/VBD (l_dobj) women/NNS (l_relcl) had/VBN (l_dobj) infarction/NN -PUNC- desogestrel/NN (r_appos) generation/NN (r_nmod) contraceptives/NNS (r_pobj) in/IN (r_prep) included/VBN (r_acl) type/NN (r_pobj) to/IN (r_prep) according/VBG (r_prep) investigated/VBD (l_conj) identified/VBD (l_conj) enrolled/VBD (l_dobj) women/NNS (l_relcl) had/VBN (l_dobj) infarction/NN (l_prep) between/IN (l_pobj) 1990/CD (l_conj) women/NNS (l_relcl) had/VBN (l_dobj) infarction/NN
D003276_D009203 CID contraceptives/NNS (l_conj) risk/NN (l_prep) of/IN (l_pobj) infarction/NN -PUNC- contraceptives/NNS (r_pobj) of/IN (r_prep) use/NN (l_conj) risk/NN (l_prep) of/IN (l_pobj) infarction/NN -PUNC- contraceptives/NNS (r_pobj) in/IN (r_prep) included/VBN (r_acl) type/NN (r_pobj) to/IN (r_prep) according/VBG (r_prep) investigated/VBD (l_conj) identified/VBD (l_conj) enrolled/VBD (l_dobj) women/NNS (l_relcl) had/VBN (l_dobj) infarction/NN -PUNC- contraceptives/NNS (r_pobj) in/IN (r_prep) included/VBN (r_acl) type/NN (r_pobj) to/IN (r_prep) according/VBG (r_prep) investigated/VBD (l_conj) identified/VBD (l_conj) enrolled/VBD (l_dobj) women/NNS (l_relcl) had/VBN (l_dobj) infarction/NN (l_prep) between/IN (l_pobj) 1990/CD (l_conj) women/NNS (l_relcl) had/VBN (l_dobj) infarction/NN -PUNC- contraceptive/NN (r_pobj) of/IN (r_prep) type/NN (r_dobj) used/VBD (r_relcl) women/NNS (r_pobj) among/IN (r_prep) infarction/NN -PUNC- contraceptives/NNS (r_dobj) used/VBD (r_relcl) women/NNS (r_pobj) Among/IN (r_prep) was/VBD (r_ccomp) increased/VBN (l_nsubjpass) risk/NN (l_prep) of/IN (l_pobj) infarction/NN -PUNC- contraceptives/NNS (r_dobj) used/VBD (r_relcl) women/NNS (r_pobj) among/IN (r_prep) increased/VBN (l_nsubjpass) risk/NN (l_prep) of/IN (l_pobj) infarction/NN -PUNC- contraceptives/NNS (r_dobj) used/VBD (r_relcl) women/NNS (r_pobj) among/IN (r_prep) similar/JJ (r_acomp) was/VBD (l_nsubj) risk/NN (l_prep) of/IN (l_pobj) infarction/NN
D016912_D009203 NONE levonorgestrel/JJ (r_conj) desogestrel/NN (r_appos) generation/NN (r_nmod) contraceptives/NNS (r_pobj) in/IN (r_prep) included/VBN (r_acl) type/NN (r_pobj) to/IN (r_prep) according/VBG (r_prep) investigated/VBD (l_conj) identified/VBD (l_conj) enrolled/VBD (l_dobj) women/NNS (l_relcl) had/VBN (l_dobj) infarction/NN -PUNC- levonorgestrel/JJ (r_conj) desogestrel/NN (r_appos) generation/NN (r_nmod) contraceptives/NNS (r_pobj) in/IN (r_prep) included/VBN (r_acl) type/NN (r_pobj) to/IN (r_prep) according/VBG (r_prep) investigated/VBD (l_conj) identified/VBD (l_conj) enrolled/VBD (l_dobj) women/NNS (l_relcl) had/VBN (l_dobj) infarction/NN (l_prep) between/IN (l_pobj) 1990/CD (l_conj) women/NNS (l_relcl) had/VBN (l_dobj) infarction/NN
D011372_D009203 NONE progestagen/NN (r_pobj) of/IN (r_prep) type/NN (r_pobj) to/IN (r_prep) according/VBG (r_prep) investigated/VBD (l_conj) identified/VBD (l_conj) enrolled/VBD (l_dobj) women/NNS (l_relcl) had/VBN (l_dobj) infarction/NN -PUNC- progestagen/NN (r_pobj) of/IN (r_prep) type/NN (r_pobj) to/IN (r_prep) according/VBG (r_prep) investigated/VBD (l_conj) identified/VBD (l_conj) enrolled/VBD (l_dobj) women/NNS (l_relcl) had/VBN (l_dobj) infarction/NN (l_prep) between/IN (l_pobj) 1990/CD (l_conj) women/NNS (l_relcl) had/VBN (l_dobj) infarction/NN
C033273_D009203 NONE gestodene/NN (r_conj) desogestrel/NN (r_appos) generation/NN (r_nmod) contraceptives/NNS (r_pobj) in/IN (r_prep) included/VBN (r_acl) type/NN (r_pobj) to/IN (r_prep) according/VBG (r_prep) investigated/VBD (l_conj) identified/VBD (l_conj) enrolled/VBD (l_dobj) women/NNS (l_relcl) had/VBN (l_dobj) infarction/NN -PUNC- gestodene/NN (r_conj) desogestrel/NN (r_appos) generation/NN (r_nmod) contraceptives/NNS (r_pobj) in/IN (r_prep) included/VBN (r_acl) type/NN (r_pobj) to/IN (r_prep) according/VBG (r_prep) investigated/VBD (l_conj) identified/VBD (l_conj) enrolled/VBD (l_dobj) women/NNS (l_relcl) had/VBN (l_dobj) infarction/NN (l_prep) between/IN (l_pobj) 1990/CD (l_conj) women/NNS (l_relcl) had/VBN (l_dobj) infarction/NN
D004967_D009203 NONE estrogen/NN (r_pobj) of/IN (r_prep) dose/NN (r_dep) identified/VBD (l_conj) enrolled/VBD (l_dobj) women/NNS (l_relcl) had/VBN (l_dobj) infarction/NN -PUNC- estrogen/NN (r_pobj) of/IN (r_prep) dose/NN (r_dep) identified/VBD (l_conj) enrolled/VBD (l_dobj) women/NNS (l_relcl) had/VBN (l_dobj) infarction/NN (l_prep) between/IN (l_pobj) 1990/CD (l_conj) women/NNS (l_relcl) had/VBN (l_dobj) infarction/NN
3070035
D002216_D006978 NONE captopril/NN (r_npadvmod) induced/VBN (r_amod) insufficiency/NN (r_pobj) of/IN (r_prep) Reversibility/NN (l_prep) after/IN (l_pobj) use/NN (l_prep) in/IN (l_pobj) case/NN (l_prep) of/IN (l_pobj) hypertension/NN
D002216_D058186 CID captopril/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) following/VBG (r_prep) deterioration/NN (l_prep) of/IN (l_pobj) function/NN
D002216_D051437 NONE captopril/NN (r_npadvmod) induced/VBN (r_amod) insufficiency/NN -PUNC- captopril/NN (r_npadvmod) induced/VBN (r_amod) failure/NN
D002216_D006973 NONE captopril/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) following/VBG (r_prep) deterioration/NN (r_dobj) developed/VBD (r_relcl) kidney/NN (r_pobj) to/IN (r_prep) artery/NN (r_pobj) with/IN (r_prep) hypertension/NN
1428568
D015784_D003866 NONE betaxolol/NN (r_nsubj) be/VB (l_attr) less/JJR (l_prep) of/IN (l_pobj) inducer/NN (l_compound) depression/NN
D013999_D003866 CID timolol/NN (r_compound) 0.5%/12h/CD (r_pobj) with/IN (r_prep) treated/VBN (l_advcl) suffering/VBG (l_prep) from/IN (l_pobj) depression/NN -PUNC- timolol/NN (r_compound) treatment/NN (r_pobj) under/IN (r_prep) patients/NNS (r_nsubj) presented/VBD (l_dobj) values/NNS (l_compound) depression/NN -PUNC- timolol/NN (r_pobj) than/IN (r_prep) less/JJR (l_prep) of/IN (l_pobj) inducer/NN (l_compound) depression/NN
D013999_D005901 NONE timolol/NN (r_compound) 0.5%/12h/CD (r_pobj) with/IN (r_prep) treated/VBN (l_nsubj) patients/NNS (l_amod) glaucomatous/JJ
12716030
D006493_D006470 NONE heparin/VBN (r_nsubj) enhanced/VBD (l_dobj) volume/NN (l_prep) over/IN (l_pobj) that/DT (l_acl) seen/VBN (l_prep) in/IN (l_pobj) control/NN (l_dobj) animals/NNS (l_conj) bleeding/NN
D006493_D002543 NONE heparin/VBN (r_nsubj) enhanced/VBD (l_prep) In/IN (l_pobj) induction/NN (l_compound) ICH/NNP -PUNC- heparin/VBN (r_nsubj) enhanced/VBD (l_dobj) volume/NN (l_prep) over/IN (l_pobj) that/DT (l_acl) seen/VBN (l_prep) in/IN (l_pobj) control/NN (l_dobj) animals/NNS (l_compound) ICH/NNP
D006493_D006406 CID heparin/VBN (r_nsubj) enhanced/VBD (l_dobj) volume/NN (l_compound) hematoma/NN
17600377
D012601_D003072 CID scopolamine/NN (r_npadvmod) injected/VBN (r_amod) rats/NNS (r_pobj) in/IN (r_prep) decline/NN
C524754_D003704 NONE coumarate/NN (r_appos) compound/NN (r_nsubj) attenuates/VBZ (l_conj) shows/VBZ (l_dobj) effects/NNS (l_prep) in/IN (l_amod) vitro/FW (l_conj) in/IN (l_pobj) models/NNS (l_compound) dementia/NN
C524754_D000544 NONE coumarate/NN (r_nsubj) is/VBZ (l_attr) candidate/NN (l_prep) against/IN (l_pobj) disease/NN
C524754_D003072 NONE coumarate/NN (r_appos) compound/NN (r_nsubj) attenuates/VBZ (l_dobj) deficits/NNS -PUNC- coumarate/NN (r_nsubj) improve/VB (l_dobj) decline/NN -PUNC- coumarate/NN (r_nsubjpass) found/VBN (l_xcomp) attenuate/VB (l_dobj) deficits/NNS -PUNC- coumarate/NN (r_nsubj) is/VBZ (l_attr) candidate/NN (l_relcl) characterized/VBN (l_agent) by/IN (l_pobj) death/NN (l_conj) decline/NN (l_prep) of/IN (l_pobj) function/NN
C524754_D009410 NONE coumarate/NN (r_nsubj) is/VBZ (l_attr) candidate/NN (l_relcl) characterized/VBN (l_agent) by/IN (l_pobj) death/NN
C544092_D003072 NONE beta/NN (r_pobj) in/IN (r_conj) in/IN (r_prep) decline/NN -PUNC- 42)-infused/VBN (r_amod) rats/NNS (r_dobj) beta/NN (r_advcl) found/VBN (l_xcomp) attenuate/VB (l_dobj) deficits/NNS
2578334
D001374_D011230 CID 5-azacytidine/RB (r_nsubj) potentiates/VBZ (l_dobj) initiation/NN (l_acl) induced/VBN (l_agent) by/IN (l_pobj) carcinogens/NNS -PUNC- 5-azacytidine/JJ (r_punct) 5-AzC/CD (l_advcl) test/VB (l_dobj) validity/NN (l_prep) of/IN (l_pobj) hypothesis/NN (l_acl) plays/VBZ (l_prep) in/IN (l_pobj) initiation/NN (l_prep) of/IN (l_pobj) process/NN -PUNC- 5-AzC/CD (l_advcl) test/VB (l_dobj) validity/NN (l_prep) of/IN (l_pobj) hypothesis/NN (l_acl) plays/VBZ (l_prep) in/IN (l_pobj) initiation/NN (l_prep) of/IN (l_pobj) process/NN
D019813_D011230 CID 1,2-dimethylhydrazine/CD (r_conj) 60/CD (r_appos) nitrosourea/NN (r_appos) carcinogens/NNS (r_pobj) by/IN (r_agent) induced/VBN (r_acl) phase/NN (r_pobj) during/IN (r_prep) given/VBN (l_nsubjpass) 5-AzC/CD (l_advcl) test/VB (l_dobj) validity/NN (l_prep) of/IN (l_pobj) hypothesis/NN (l_acl) plays/VBZ (l_prep) in/IN (l_pobj) initiation/NN (l_prep) of/IN (l_pobj) process/NN -PUNC- 1,2-DMH/NNP (r_appos) nitrosourea/NN (r_appos) carcinogens/NNS (r_pobj) by/IN (r_agent) induced/VBN (r_acl) phase/NN (r_pobj) during/IN (r_prep) given/VBN (l_nsubjpass) 5-AzC/CD (l_advcl) test/VB (l_dobj) validity/NN (l_prep) of/IN (l_pobj) hypothesis/NN (l_acl) plays/VBZ (l_prep) in/IN (l_pobj) initiation/NN (l_prep) of/IN (l_pobj) process/NN
D008770_D011230 CID nitrosourea/NN (r_appos) carcinogens/NNS (r_pobj) by/IN (r_agent) induced/VBN (r_acl) phase/NN (r_pobj) during/IN (r_prep) given/VBN (l_nsubjpass) 5-AzC/CD (l_advcl) test/VB (l_dobj) validity/NN (l_prep) of/IN (l_pobj) hypothesis/NN (l_acl) plays/VBZ (l_prep) in/IN (l_pobj) initiation/NN (l_prep) of/IN (l_pobj) process/NN
D001564_D011230 CID benzo[a]-pyrene/NN (r_appos) carcinogens/NNS (r_pobj) by/IN (r_agent) induced/VBN (r_acl) phase/NN (r_pobj) during/IN (r_prep) given/VBN (l_nsubjpass) 5-AzC/CD (l_advcl) test/VB (l_dobj) validity/NN (l_prep) of/IN (l_pobj) hypothesis/NN (l_acl) plays/VBZ (l_prep) in/IN (l_pobj) initiation/NN (l_prep) of/IN (l_pobj) process/NN
150790
D007538_D001523 NONE isoniazid/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) sleeping/VBG (r_conj) irritability/NN
D007538_D002653 CID isoniazid/NN (r_pobj) by/IN (r_agent) unmasked/VBD (r_acl) disorder/NN -PUNC- isoniazid/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) sleeping/VBG (r_conj) irritability/NN (r_conj) hyperkinesis/NN (r_pobj) with/IN (r_prep) had/VBD (l_dobj) deterioration/NN
D007538_D006948 CID isoniazid/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) sleeping/VBG (r_conj) irritability/NN (r_conj) hyperkinesis/NN
D007538_D012893 NONE isoniazid/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) sleeping/VBG (l_dobj) difficulties/NNS
D011736_D006948 NONE pyridoxine/NN (r_pobj) of/IN (r_prep) withdrawal/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) return/NN (l_prep) of/IN (l_pobj) hyperkinesis/NN
D011736_D002653 NONE pyridoxine/JJ (r_advmod) dependent/JJ (r_amod) disorder/NN
15458908
D020849_D016889 NONE Raloxifene/NNP (r_nsubj) increase/VB (l_dep) disease/NN (l_appos) CI/NNP (l_appos) hyperplasia/NN (l_appos) %/NN (l_conj) cancer/NN -PUNC- Raloxifene/NNP (r_nsubjpass) associated/VBN (l_conj) was/VBD (l_attr) risk/NN (l_prep) for/IN (l_pobj) cataracts/NNS (l_conj) disease/NN (l_conj) hyperplasia/NN (l_conj) cancer/NN
D020849_D010024 NONE Raloxifene/NNP (r_compound) Evaluation/NNP (r_pobj) of/IN (r_prep) Outcomes/NNPS (r_nsubj) enrolled/VBD (l_prep) with/IN (l_pobj) osteoporosis/NN
D020849_D004714 NONE Raloxifene/NNP (r_nsubj) increase/VB (l_dep) disease/NN (l_appos) CI/NNP (l_appos) hyperplasia/NN -PUNC- Raloxifene/NNP (r_nsubjpass) associated/VBN (l_conj) was/VBD (l_attr) risk/NN (l_prep) for/IN (l_pobj) cataracts/NNS (l_conj) disease/NN (l_conj) hyperplasia/NN
D020849_D002386 NONE Raloxifene/NNP (r_nsubj) increase/VB (l_dobj) risk/NN (l_prep) for/IN (l_pobj) cataracts/NNS -PUNC- Raloxifene/NNP (r_nsubjpass) associated/VBN (l_conj) was/VBD (l_attr) risk/NN (l_prep) for/IN (l_pobj) cataracts/NNS
D020849_D005705 NONE Raloxifene/NNP (r_nsubj) increase/VB (l_dep) disease/NN -PUNC- Raloxifene/NNP (r_nsubjpass) associated/VBN (l_conj) was/VBD (l_attr) risk/NN (l_prep) for/IN (l_pobj) cataracts/NNS (l_conj) disease/NN
D020849_D054556 CID raloxifene/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) risk/NN (l_prep) for/IN (l_pobj) thromboembolism/NN -PUNC- Raloxifene/NNP (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) risk/NN (l_prep) for/IN (l_pobj) thromboembolism/NN
17042910
D003907_D006973 CID dexamethasone/NN (r_npadvmod) induced/VBN (r_amod) hypertension/NN -PUNC- Dexamethasone/NNP (l_parataxis) characterized/VBN (l_nsubjpass) hypertension/NN -PUNC- Dex)-induced/JJ (r_amod) hypertension/NN
D013481_D006973 NONE superoxide/NN (r_advmod) increased/VBN (r_conj) characterized/VBN (l_nsubjpass) hypertension/NN -PUNC- O2-/NNPS (r_nmod) production/NN (r_appos) Dexamethasone/NNP (l_parataxis) characterized/VBN (l_nsubjpass) hypertension/NN -PUNC- O2-/JJ (r_compound) production/NN (l_prep) in/IN (l_pobj) forms/NNS (l_prep) of/IN (l_pobj) hypertension/NN
D009569_D006973 NONE oxide/NN (r_nmod) deficiency/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) dysfunction/NN (r_pobj) by/IN (r_agent) characterized/VBN (l_nsubjpass) hypertension/NN -PUNC- NO/NNP (r_intj) deficiency/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) dysfunction/NN (r_pobj) by/IN (r_agent) characterized/VBN (l_nsubjpass) hypertension/NN -PUNC- NO/DT (r_amod) production/NN (l_prep) in/IN (l_pobj) forms/NNS (l_prep) of/IN (l_pobj) hypertension/NN
C065179_D006973 NONE atorvastatin/NN (r_pobj) of/IN (r_prep) effects/NNS (l_prep) in/IN (l_pobj) hypertension/NN -PUNC- Atorvastatin/NNP (r_nsubj) possesses/VBZ (l_dobj) properties/NNS (l_relcl) reported/VBN (l_xcomp) improve/VB (l_prep) through/IN (l_pobj) availability/NN (l_prep) of/IN (l_pobj) production/NN (l_prep) in/IN (l_pobj) forms/NNS (l_prep) of/IN (l_pobj) hypertension/NN -PUNC- Ato/NNP (r_appos) Atorvastatin/NNP (r_nsubj) possesses/VBZ (l_dobj) properties/NNS (l_relcl) reported/VBN (l_xcomp) improve/VB (l_prep) through/IN (l_pobj) availability/NN (l_prep) of/IN (l_pobj) production/NN (l_prep) in/IN (l_pobj) forms/NNS (l_prep) of/IN (l_pobj) hypertension/NN
11198499
D017706_D009128 NONE lisinopril/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) boy/NN (r_dobj) present/VBP (l_advcl) control/VB (l_dobj) hypertension/NN (l_relcl) developed/VBD (l_prep) following/VBG (l_pobj) addition/NN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) spasticity/NN
D017706_D006973 NONE lisinopril/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) boy/NN (r_dobj) present/VBP (l_advcl) control/VB (l_dobj) hypertension/NN
C023754_D009128 NONE tizanidine/NN (r_pobj) of/IN (r_prep) addition/NN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) spasticity/NN -PUNC- tizanidine/NN (r_pobj) of/IN (r_prep) interaction/NN (r_nsubjpass) kept/VBN (l_advcl) prescribing/VBG (l_xcomp) treat/VB (l_dobj) hypertension/NN (l_conj) spasticity/NN
C023754_D006973 NONE tizanidine/NN (r_pobj) of/IN (r_prep) initiation/NN (l_prep) in/IN (l_pobj) patient/NN (l_acl) treated/VBN (l_prep) with/IN (l_pobj) angiotensin/NN (l_acl) converting/VBG (l_prep) for/IN (l_pobj) hypertension/NN -PUNC- tizanidine/NN (r_pobj) of/IN (r_prep) addition/NN (r_pobj) following/VBG (r_prep) developed/VBD (r_relcl) hypertension/NN -PUNC- tizanidine/NN (r_pobj) of/IN (r_prep) interaction/NN (r_nsubjpass) kept/VBN (l_advcl) prescribing/VBG (l_xcomp) treat/VB (l_dobj) hypertension/NN
D000809_D009128 NONE angiotensin/NN (r_appos) lisinopril/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) boy/NN (r_dobj) present/VBP (l_advcl) control/VB (l_dobj) hypertension/NN (l_relcl) developed/VBD (l_prep) following/VBG (l_pobj) addition/NN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) spasticity/NN
C023754_D007022 CID tizanidine/NN (r_pobj) of/IN (r_prep) initiation/NN (r_dobj) following/VBG (r_acl) Hypotension/NN -PUNC- tizanidine/NN (r_pobj) of/IN (r_prep) addition/NN (r_pobj) following/VBG (r_prep) developed/VBD (l_dobj) hypotension/NN
D000809_D007022 NONE angiotensin/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patient/NN (r_pobj) in/IN (r_prep) initiation/NN (r_dobj) following/VBG (r_acl) Hypotension/NN -PUNC- angiotensin/NN (r_pobj) with/IN (r_prep) treated/VBN (r_csubj) have/VB (l_dobj) ability/NN (l_acl) respond/VB (l_prep) to/IN (l_pobj) hypotension/NN -PUNC- angiotensin/NN (r_appos) lisinopril/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) boy/NN (r_dobj) present/VBP (l_advcl) control/VB (l_dobj) hypertension/NN (l_relcl) developed/VBD (l_dobj) hypotension/NN
D017706_D007022 CID lisinopril/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) boy/NN (r_dobj) present/VBP (l_advcl) control/VB (l_dobj) hypertension/NN (l_relcl) developed/VBD (l_dobj) hypotension/NN
D000809_D006973 NONE angiotensin/NN (l_acl) converting/VBG (l_prep) for/IN (l_pobj) hypertension/NN -PUNC- angiotensin/NN (r_appos) lisinopril/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) boy/NN (r_dobj) present/VBP (l_advcl) control/VB (l_dobj) hypertension/NN
17437408
D010862_D012640 CID pilocarpine/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS
12905102
D003024_D003693 CID clozapine/NN (r_amod) treatment/NN (r_pobj) during/IN (r_prep) Delirium/NN -PUNC- clozapine/NN (r_compound) treatment/NN (r_pobj) during/IN (r_prep) factors/NNS (l_prep) for/IN (l_pobj) delirium/NN -PUNC- clozapine/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) inpatients/NNS (r_dobj) identify/VB (r_xcomp) used/VBD (l_conj) reviewed/VBD (l_advcl) score/VB (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) delirium/NN -PUNC- clozapine/NN (r_npadvmod) treated/VBN (r_amod) inpatients/NNS (r_pobj) of/IN (r_prep) %/NN (r_pobj) in/IN (r_prep) found/VBN (l_nsubjpass) Delirium/NNP
D003024_D001523 NONE clozapine/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) inpatients/NNS (l_amod) psychiatric/JJ
3827439
D000666_D005355 NONE B/NNP (r_pobj) of/IN (r_prep) administration/NN (r_dobj) following/VBG (r_acl) failure/NN (r_dobj) developed/VBD (l_nsubj) patient/NN (l_prep) with/IN (l_pobj) cirrhosis/NN
D000666_D058186 CID amphotericin/JJ (r_pobj) from/IN (r_prep) failure/NN -PUNC- B/NNP (r_pobj) of/IN (r_prep) administration/NN (r_dobj) following/VBG (r_acl) failure/NN -PUNC- amphotericin/JJ (r_advmod) propose/VBP (l_conj) activate/VB (l_advcl) contributing/VBG (l_prep) to/IN (l_pobj) failure/NN
D000666_D013174 NONE B/NNP (r_pobj) of/IN (r_prep) administration/NN (r_dobj) following/VBG (r_acl) failure/NN (r_dobj) developed/VBD (l_nsubj) patient/NN (l_conj) disseminated/VBN (l_dobj) sporotrichosis/NN
6503301
D003606_D008545 NONE dacarbazine/NN (r_compound) therapy/NN (l_prep) for/IN (l_pobj) melanoma/NN -PUNC- DTIC/NNP (r_appos) therapy/NN (l_prep) for/IN (l_pobj) melanoma/NN -PUNC- dacarbazine/NN (r_nmod) therapy/NN (l_prep) for/IN (l_pobj) melanoma/NN -PUNC- DTIC/NNP (r_nmod) therapy/NN (l_prep) for/IN (l_pobj) melanoma/NN
D003606_D006504 CID dacarbazine/NN (r_compound) therapy/NN (r_pobj) after/IN (r_prep) disease/NN -PUNC- DTIC/NNP (r_appos) therapy/NN (r_pobj) after/IN (r_prep) disease/NN -PUNC- dacarbazine/NN (r_nmod) therapy/NN (r_nsubjpass) reported/VBN (l_nsubjpass) case/NN (l_prep) of/IN (l_pobj) disease/NN (l_prep) of/IN (l_pobj) liver/NN -PUNC- DTIC/NNP (r_nmod) therapy/NN (r_nsubjpass) reported/VBN (l_nsubjpass) case/NN (l_prep) of/IN (l_pobj) disease/NN (l_prep) of/IN (l_pobj) liver/NN
11256525
D000804_D014652 NONE II/NNP (r_compound) antagonist/NN (r_compound) losartan/NN (r_nsubj) cause/VB (l_dobj) complications/NNS (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disease/NN
D000809_D006333 NONE angiotensin/NN (r_compound) system/NN (r_pobj) of/IN (r_prep) activation/NN (r_pobj) in/IN (r_prep) resulted/VBD (l_nsubj) stenosis/NN (l_acl) combined/VBN (l_prep) with/IN (l_pobj) failure/NN
D000809_D012078 NONE angiotensin/NN (r_compound) system/NN (r_pobj) of/IN (r_prep) activation/NN (r_pobj) in/IN (r_prep) resulted/VBD (l_nsubj) stenosis/NN
D019808_D001002 CID losartan/NN (r_amod) administration/NN (r_dobj) following/VBG (r_prep) anuria/NN -PUNC- losartan/NN (r_amod) administration/NN (r_pobj) after/IN (r_prep) developed/VBD (l_dobj) episodes/NNS (l_prep) of/IN (l_pobj) anuria/NN -PUNC- losartan/NN (r_pobj) of/IN (r_prep) mg/NN (r_pobj) of/IN (r_prep) dose/NN (r_nsubj) resulted/VBD (l_prep) in/IN (l_pobj) anuria/NN -PUNC- losartan/NN (r_nsubjpass) prescribed/VBN (l_conj) developed/VBD (l_dobj) episode/NN (l_prep) of/IN (l_pobj) anuria/NN
D000588_D001002 NONE amine/NN (r_conj) furosemide/NN (r_nmod) infusion/NN (r_pobj) despite/IN (r_prep) lasted/VBD (r_relcl) anuria/NN
D019808_D006973 NONE losartan/NN (r_amod) administration/NN (r_pobj) after/IN (r_prep) developed/VBD (r_relcl) kidney/NN (r_pobj) with/IN (r_prep) man/NN (l_amod) hypertensive/JJ
D019808_D014652 NONE losartan/NN (r_nsubj) cause/VB (l_dobj) complications/NNS (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disease/NN
D005665_D001002 NONE furosemide/NN (r_nmod) infusion/NN (r_pobj) despite/IN (r_prep) lasted/VBD (r_relcl) anuria/NN
D019808_D006331 NONE losartan/NN (l_compound) dysfunction/NN
D019808_D051436 NONE losartan/NN (r_amod) administration/NN (r_pobj) after/IN (r_prep) developed/VBD (r_relcl) kidney/NN (l_conj) insufficiency/NN
9034419
C047426_D062787 CID venlafaxine/NNP (r_amod) overdose/NN -PUNC- venlafaxine/NNP (r_amod) overdose/NN -PUNC- venlafaxine/NN (r_pobj) of/IN (r_prep) overdose/NN -PUNC- venlafaxine/NNP (r_amod) overdose/NN -PUNC- venlafaxine/NNP (r_amod) overdose/NN
C047426_D003865 NONE venlafaxine/NN (r_pobj) of/IN (r_prep) overdose/NN (r_dobj) took/VBD (l_nsubj) woman/NN (l_prep) with/IN (l_pobj) depression/NN
C047426_D012640 CID venlafaxine/NNP (r_amod) overdose/NN (r_pobj) from/IN (r_prep) resulting/VBG (r_acl) Seizure/NN -PUNC- venlafaxine/NNP (r_pobj) of/IN (r_prep) ingestion/NN (r_pobj) After/IN (r_prep) experienced/VBD (l_dobj) seizure/NN -PUNC- venlafaxine/NNP (r_amod) overdose/NN (r_pobj) of/IN (r_prep) case/NN (l_relcl) resulted/VBD (l_prep) in/IN (l_pobj) seizure/NN -PUNC- venlafaxine/NNP (r_amod) overdose/NN (r_nsubj) resulted/VBD (l_prep) in/IN (l_pobj) episode/NN (l_prep) of/IN (l_pobj) seizure/NN
8319760
D019808_D011507 NONE 753/CD (r_nummod) Dup/NN (r_nmod) losartan/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) by/IN (r_agent) inhibited/VBN (l_ccomp) induced/VBN (l_nsubj) appearance/NN (l_prep) of/IN (l_pobj) syndromes/NNS (l_prep) as/IN (l_pobj) proteinuria/NN -PUNC- losartan/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) by/IN (r_agent) inhibited/VBN (l_ccomp) induced/VBN (l_nsubj) appearance/NN (l_prep) of/IN (l_pobj) syndromes/NNS (l_prep) as/IN (l_pobj) proteinuria/NN
D000804_D006937 NONE II/NNP (r_compound) antagonist/NN (r_appos) inhibited/VBN (l_ccomp) induced/VBN (l_nsubj) appearance/NN (l_prep) of/IN (l_pobj) syndromes/NNS (l_prep) as/IN (l_pobj) proteinuria/NN (l_conj) hypoalbuminemia/NN (l_conj) hypercholesterolemia/NN
D000804_D011507 NONE II/NNP (r_compound) antagonist/NN (r_appos) inhibited/VBN (l_ccomp) induced/VBN (l_nsubj) appearance/NN (l_prep) of/IN (l_pobj) syndromes/NNS (l_prep) as/IN (l_pobj) proteinuria/NN
D011692_D009404 CID aminonucleoside/NN (r_advmod) induced/VBN (l_nsubj) appearance/NN (l_prep) of/IN (l_pobj) syndromes/NNS
D011692_D006937 CID aminonucleoside/NN (r_advmod) induced/VBN (l_nsubj) appearance/NN (l_prep) of/IN (l_pobj) syndromes/NNS (l_prep) as/IN (l_pobj) proteinuria/NN (l_conj) hypoalbuminemia/NN (l_conj) hypercholesterolemia/NN
D019808_D009401 NONE 753/CD (r_nummod) Dup/NN (r_nsubj) prevents/VBZ (l_dobj) development/NN (l_prep) of/IN (l_pobj) nephrosis/NN
D001806_D009404 NONE urea/NN (r_pobj) in/IN (r_prep) increase/NN (r_conj) hypercholesterolemia/NN (r_conj) hypoalbuminemia/NN (r_conj) proteinuria/NN (r_pobj) as/IN (r_prep) syndromes/NNS
D001806_D034141 NONE urea/NN (r_pobj) in/IN (r_prep) increase/NN (r_conj) hypercholesterolemia/NN (r_conj) hypoalbuminemia/NN
D019808_D006937 NONE 753/CD (r_nummod) Dup/NN (r_nmod) losartan/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) by/IN (r_agent) inhibited/VBN (l_ccomp) induced/VBN (l_nsubj) appearance/NN (l_prep) of/IN (l_pobj) syndromes/NNS (l_prep) as/IN (l_pobj) proteinuria/NN (l_conj) hypoalbuminemia/NN (l_conj) hypercholesterolemia/NN -PUNC- losartan/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) by/IN (r_agent) inhibited/VBN (l_ccomp) induced/VBN (l_nsubj) appearance/NN (l_prep) of/IN (l_pobj) syndromes/NNS (l_prep) as/IN (l_pobj) proteinuria/NN (l_conj) hypoalbuminemia/NN (l_conj) hypercholesterolemia/NN
D000804_D009404 NONE II/NNP (r_compound) antagonist/NN (r_appos) inhibited/VBN (l_ccomp) induced/VBN (l_nsubj) appearance/NN (l_prep) of/IN (l_pobj) syndromes/NNS
D019808_D009404 NONE 753/CD (r_nummod) Dup/NN (r_nmod) losartan/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) by/IN (r_agent) inhibited/VBN (l_ccomp) induced/VBN (l_nsubj) appearance/NN (l_prep) of/IN (l_pobj) syndromes/NNS -PUNC- losartan/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) by/IN (r_agent) inhibited/VBN (l_ccomp) induced/VBN (l_nsubj) appearance/NN (l_prep) of/IN (l_pobj) syndromes/NNS
D019808_D034141 NONE 753/CD (r_nummod) Dup/NN (r_nmod) losartan/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) by/IN (r_agent) inhibited/VBN (l_ccomp) induced/VBN (l_nsubj) appearance/NN (l_prep) of/IN (l_pobj) syndromes/NNS (l_prep) as/IN (l_pobj) proteinuria/NN (l_conj) hypoalbuminemia/NN -PUNC- losartan/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) by/IN (r_agent) inhibited/VBN (l_ccomp) induced/VBN (l_nsubj) appearance/NN (l_prep) of/IN (l_pobj) syndromes/NNS (l_prep) as/IN (l_pobj) proteinuria/NN (l_conj) hypoalbuminemia/NN
D001806_D011507 NONE urea/NN (r_pobj) in/IN (r_prep) increase/NN (r_conj) hypercholesterolemia/NN (r_conj) hypoalbuminemia/NN (r_conj) proteinuria/NN
D011692_D011507 CID aminonucleoside/NN (r_advmod) induced/VBN (l_nsubj) appearance/NN (l_prep) of/IN (l_pobj) syndromes/NNS (l_prep) as/IN (l_pobj) proteinuria/NN
D011692_D034141 CID aminonucleoside/NN (r_advmod) induced/VBN (l_nsubj) appearance/NN (l_prep) of/IN (l_pobj) syndromes/NNS (l_prep) as/IN (l_pobj) proteinuria/NN (l_conj) hypoalbuminemia/NN
D011692_D009401 NONE aminonucleoside/NN (r_advmod) induced/VBN (r_amod) nephrosis/NN -PUNC- aminonucleoside/NN (r_advmod) induced/VBN (r_amod) nephrosis/NN
D000809_D009401 NONE angiotensin/NN (r_compound) system/NN (l_prep) in/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) nephrosis/NN
D001806_D006937 NONE urea/NN (r_pobj) in/IN (r_prep) increase/NN (r_conj) hypercholesterolemia/NN
D000804_D034141 NONE II/NNP (r_compound) antagonist/NN (r_appos) inhibited/VBN (l_ccomp) induced/VBN (l_nsubj) appearance/NN (l_prep) of/IN (l_pobj) syndromes/NNS (l_prep) as/IN (l_pobj) proteinuria/NN (l_conj) hypoalbuminemia/NN
2070391
D008012_D010146 CID lidocaine/NN (r_dobj) using/VBG (r_acl) Reduction/NN (l_prep) in/IN (l_pobj) pain/NN -PUNC- lidocaine/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) pain/NN -PUNC- lidocaine/NN (r_pobj) of/IN (r_prep) pH/NN (r_dobj) adjust/VB (r_relcl) solution/NN (r_pobj) of/IN (r_prep) addition/NN (r_nsubj) reduce/VB (l_dobj) pain/NN -PUNC- lidocaine/NN (r_dobj) receiving/VBG (r_pcomp) after/IN (r_prep) quantify/VB (l_dobj) severity/NN (l_prep) of/IN (l_pobj) pain/NN -PUNC- lidocaine/NN (r_conj) receiving/VBG (r_pcomp) after/IN (r_prep) quantify/VB (l_dobj) severity/NN (l_prep) of/IN (l_pobj) pain/NN -PUNC- lidocaine/NN (r_pobj) for/IN (r_prep) score/NN (l_compound) pain/NN -PUNC- lidocaine/NN (r_pobj) for/IN (r_prep) score/NN (r_pobj) than/IN (r_prep) lower/JJR (r_acomp) was/VBD (l_nsubj) score/NN (l_compound) pain/NN -PUNC- lidocaine/NN (r_pobj) of/IN (r_prep) adjustment/NN (r_nsubjpass) accomplished/VBN (l_prep) in/IN (l_pobj) laboratory/NN (l_prep) before/IN (l_pobj) injection/NN (l_prep) in/IN (l_pobj) reduction/NN (l_prep) of/IN (l_pobj) pain/NN
10193204
C009438_D013927 NONE tetrandrine/NN (r_pobj) of/IN (r_prep) Effects/NNS (l_prep) on/IN (l_pobj) thrombosis/NN -PUNC- TET/NNP (r_pobj) of/IN (r_prep) effects/NNS (l_prep) on/IN (l_pobj) thrombosis/NN -PUNC- TET/NNP (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) showed/VBD (l_dobj) inhibition/NN (l_prep) of/IN (l_pobj) thrombosis/NN
C060802_D013927 NONE fangchinoline/NN (r_conj) tetrandrine/NN (r_pobj) of/IN (r_prep) Effects/NNS (l_prep) on/IN (l_pobj) thrombosis/NN -PUNC- FAN/NNP (r_conj) TET/NNP (r_pobj) of/IN (r_prep) effects/NNS (l_prep) on/IN (l_pobj) thrombosis/NN -PUNC- FAN/NNP (r_conj) TET/NNP (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) showed/VBD (l_dobj) inhibition/NN (l_prep) of/IN (l_pobj) thrombosis/NN
C009438_D001778 NONE TET/NNP (r_pobj) of/IN (r_prep) effects/NNS (r_dobj) investigate/VB (r_advcl) undertaken/VBN (l_conj) in/IN (l_nsubj) aggregation/NN (l_conj) coagulation/NN
D001241_D013927 NONE acid/NN (r_dobj) acetylsalicylic/JJ (r_advcl) showed/VBD (l_dobj) inhibition/NN (l_prep) of/IN (l_pobj) thrombosis/NN -PUNC- ASA/NNP (r_appos) acid/NN (r_dobj) acetylsalicylic/JJ (r_advcl) showed/VBD (l_dobj) inhibition/NN (l_prep) of/IN (l_pobj) thrombosis/NN
C060802_D001791 NONE fangchinoline/NN (r_conj) tetrandrine/NN (r_pobj) of/IN (r_prep) Effects/NNS (l_prep) on/IN (l_pobj) thrombosis/NN (l_prep) in/IN (l_pobj) mice/NNS (l_conj) aggregation/NN -PUNC- FAN/NNP (r_conj) TET/NNP (r_pobj) of/IN (r_prep) effects/NNS (r_dobj) investigate/VB (r_advcl) undertaken/VBN (l_conj) in/IN (l_nsubj) aggregation/NN -PUNC- FAN/NNP (r_conj) TET/NNP (r_nsubj) showed/VBD (l_prep) In/IN (l_pobj) aggregations/NNS
D004837_D001791 NONE epinephrine/NN (r_conj) collagen/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) thrombosis/NN (r_pobj) on/IN (r_prep) effects/NNS (r_dobj) investigate/VB (r_advcl) undertaken/VBN (l_conj) in/IN (l_nsubj) aggregation/NN -PUNC- EP/NN (r_appos) epinephrine/NN (r_conj) collagen/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) thrombosis/NN (r_pobj) on/IN (r_prep) effects/NNS (r_dobj) investigate/VB (r_advcl) undertaken/VBN (l_conj) in/IN (l_nsubj) aggregation/NN
C060802_D001778 NONE FAN/NNP (r_conj) TET/NNP (r_pobj) of/IN (r_prep) effects/NNS (r_dobj) investigate/VB (r_advcl) undertaken/VBN (l_conj) in/IN (l_nsubj) aggregation/NN (l_conj) coagulation/NN
C009438_D001791 NONE tetrandrine/NN (r_pobj) of/IN (r_prep) Effects/NNS (l_prep) on/IN (l_pobj) thrombosis/NN (l_prep) in/IN (l_pobj) mice/NNS (l_conj) aggregation/NN -PUNC- TET/NNP (r_pobj) of/IN (r_prep) effects/NNS (r_dobj) investigate/VB (r_advcl) undertaken/VBN (l_conj) in/IN (l_nsubj) aggregation/NN -PUNC- TET/NNP (r_nsubj) showed/VBD (l_prep) In/IN (l_pobj) aggregations/NNS
D004837_D001778 NONE epinephrine/NN (r_conj) collagen/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) thrombosis/NN (r_pobj) on/IN (r_prep) effects/NNS (r_dobj) investigate/VB (r_advcl) undertaken/VBN (l_conj) in/IN (l_nsubj) aggregation/NN (l_conj) coagulation/NN -PUNC- EP/NN (r_appos) epinephrine/NN (r_conj) collagen/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) thrombosis/NN (r_pobj) on/IN (r_prep) effects/NNS (r_dobj) investigate/VB (r_advcl) undertaken/VBN (l_conj) in/IN (l_nsubj) aggregation/NN (l_conj) coagulation/NN
D004837_D013927 CID epinephrine/NN (r_conj) collagen/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) thrombosis/NN -PUNC- EP/NN (r_appos) epinephrine/NN (r_conj) collagen/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) thrombosis/NN
6286738
D002762_D064420 NONE D3/NN (r_compound) toxicity/NN -PUNC- D3/NNP (r_compound) toxicity/NN -PUNC- D3/NNP (r_compound) toxicity/NN (r_pobj) of/IN (r_prep) Signs/NNS (r_nsubjpass) observed/VBN (r_ccomp) developed/VBN (l_dobj) signs/NNS (l_prep) of/IN (l_pobj) toxicity/NN -PUNC- D3/NNP (r_compound) toxicity/NN (r_pobj) of/IN (r_prep) signs/NNS (r_dobj) developed/VBN (l_ccomp) observed/VBN (l_nsubjpass) Signs/NNS (l_prep) of/IN (l_pobj) toxicity/NN -PUNC- D3/NNP (r_compound) toxicity/NN -PUNC- D3/NN (r_pobj) of/IN (r_prep) toxicity/NN -PUNC- D3/NNP (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) between/IN (r_prep) safety/NN (r_pobj) of/IN (r_prep) margin/NN (r_conj) toxicity/NN -PUNC- D3/NNP (r_nsubjpass) used/VBN (r_ccomp) concluded/VBD (l_prep) Because/IN (l_pobj) toxicity/NN
D002762_D054559 CID D3/NNP (r_pobj) of/IN (r_prep) doses/NNS (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) hypercalcemia/NN (l_conj) hyperphosphatemia/NN -PUNC- D3/NNP (r_appos) doses/NNS (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) hypercalcemia/NN (l_conj) hyperphosphatemia/NN -PUNC- D3/NNP (r_pobj) of/IN (r_prep) increases/NNS (r_conj) hyperphosphatemia/NN
D002762_D010319 NONE D3/NNP (r_pobj) with/IN (r_prep) treated/VBN (r_acl) cows/NNS (r_pobj) of/IN (r_prep) None/NN (r_nsubj) showed/VBD (l_dobj) signs/NNS (l_prep) of/IN (l_pobj) fever/NN -PUNC- D3/NNP (r_pobj) with/IN (r_prep) treated/VBN (r_acl) cows/NNS (r_pobj) of/IN (r_prep) None/NN (r_nsubj) showed/VBD (r_ccomp) developed/VBD (l_dobj) signs/NNS (l_prep) of/IN (l_pobj) fever/NN -PUNC- D3/NN (r_pobj) of/IN (r_prep) toxicity/NN (l_conj) margin/NN (l_prep) of/IN (l_pobj) safety/NN (l_prep) between/IN (l_pobj) doses/NNS (l_prep) of/IN (l_pobj) D3/NNP (l_relcl) prevent/VBP (l_dobj) fever/NN -PUNC- D3/NN (r_pobj) of/IN (r_prep) toxicity/NN (l_conj) margin/NN (l_prep) of/IN (l_pobj) safety/NN (l_prep) between/IN (l_pobj) doses/NNS (l_prep) of/IN (l_pobj) D3/NNP (l_relcl) prevent/VBP (l_dobj) fever/NN (l_relcl) induce/VBP (l_dobj) fever/NN -PUNC- D3/NN (r_pobj) of/IN (r_prep) toxicity/NN (r_pobj) Because/IN (r_prep) concluded/VBD (l_ccomp) used/VBN (l_xcomp) prevent/VB (l_dobj) fever/NN -PUNC- D3/NNP (l_relcl) prevent/VBP (l_dobj) fever/NN -PUNC- D3/NNP (l_relcl) prevent/VBP (l_dobj) fever/NN (l_relcl) induce/VBP (l_dobj) fever/NN -PUNC- D3/NNP (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) between/IN (r_prep) safety/NN (r_pobj) of/IN (r_prep) margin/NN (r_conj) toxicity/NN (r_pobj) Because/IN (r_prep) concluded/VBD (l_ccomp) used/VBN (l_xcomp) prevent/VB (l_dobj) fever/NN -PUNC- D3/NNP (r_nsubjpass) used/VBN (r_ccomp) concluded/VBD (l_prep) Because/IN (l_pobj) toxicity/NN (l_conj) margin/NN (l_prep) of/IN (l_pobj) safety/NN (l_prep) between/IN (l_pobj) doses/NNS (l_prep) of/IN (l_pobj) D3/NNP (l_relcl) prevent/VBP (l_dobj) fever/NN -PUNC- D3/NNP (r_nsubjpass) used/VBN (r_ccomp) concluded/VBD (l_prep) Because/IN (l_pobj) toxicity/NN (l_conj) margin/NN (l_prep) of/IN (l_pobj) safety/NN (l_prep) between/IN (l_pobj) doses/NNS (l_prep) of/IN (l_pobj) D3/NNP (l_relcl) prevent/VBP (l_dobj) fever/NN (l_relcl) induce/VBP (l_dobj) fever/NN -PUNC- D3/NNP (r_nsubjpass) used/VBN (l_xcomp) prevent/VB (l_dobj) fever/NN
D002762_D006934 CID D3/NNP (r_pobj) of/IN (r_prep) doses/NNS (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) hypercalcemia/NN -PUNC- D3/NNP (r_appos) doses/NNS (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) hypercalcemia/NN -PUNC- D3/NNP (r_pobj) of/IN (r_prep) increases/NNS (r_conj) hyperphosphatemia/NN (r_conj) hypercalcemia/NN
10457883
1616457
D010424_D000647 CID pentobarbital/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) amnesia/NN -PUNC- pentobarbital/NN (r_nmod) ip/NNP (r_pobj) by/IN (r_agent) produced/VBN (r_acl) amnesia/NN
20080983
D003042_D012893 CID cocaine/NN (r_compound) users/NNS (r_pobj) in/IN (r_prep) sleepiness/NN -PUNC- cocaine/NN (r_compound) users/NNS (r_pobj) in/IN (r_prep) sleepiness/NN
C048833_D012893 NONE modafinil/NN (l_conj) sleepiness/NN -PUNC- Modafinil/NNP (r_nsubjpass) associated/VBN (l_advcl) measured/VBN (l_conj) decrease/NN (l_prep) in/IN (l_pobj) sleepiness/NN -PUNC- modafinil/NN (r_nsubj) promotes/VBZ (l_conj) normalizes/VBZ (l_conj) decreases/VBZ (l_dobj) sleepiness/NN
435349
D013390_D013746 NONE Sch/NNP (r_nsubjpass) exceeded/VBN (r_advcl) was/VBD (l_attr) response/NN (l_prep) to/IN (l_pobj) stimulation/NN (l_compound) tetanic/JJ
D013390_D005207 CID Suxamethonium/JJ (r_compound) rate/NN (l_conj) observed/JJ (l_dobj) fasciculations/NNS
12202650
D002211_D063806 NONE Capsaicin/NN (r_npadvmod) induced/VBN (r_amod) pain/NN
D002211_D010146 CID Capsaicin/NNS (r_nsubjpass) injected/VBN (l_advcl) induce/VB (l_dobj) pain/NN
19957053
D010656_D007022 NONE Phenylephrine/NNP (r_nsubj) reduces/VBZ (l_dobj) oxygenation/NN (l_prep) following/VBG (l_dobj) hypotension/NN -PUNC- phenylephrine/NN (r_pobj) of/IN (r_prep) effect/NN (r_dobj) describe/VBP (l_prep) following/VBG (l_dobj) hypotension/NN -PUNC- phenylephrine/NN (r_pobj) of/IN (r_prep) utilization/NN (l_acl) correct/VB (l_dobj) hypotension/NN
D010656_D002534 CID Phenylephrine/NNP (r_nsubj) reduces/VBZ (l_dobj) oxygenation/NN
D004809_D007022 NONE ephedrine/JJ (r_conj) Phenylephrine/NNP (r_nsubj) reduces/VBZ (l_dobj) oxygenation/NN (l_prep) following/VBG (l_dobj) hypotension/NN -PUNC- ephedrine/JJ (r_conj) phenylephrine/NN (r_pobj) of/IN (r_prep) effect/NN (r_dobj) describe/VBP (l_prep) following/VBG (l_dobj) hypotension/NN -PUNC- ephedrine/JJ (r_nsubj) maintains/VBZ (r_advcl) has/VBZ (l_nsubj) utilization/NN (l_acl) correct/VB (l_dobj) hypotension/NN
D004809_D002534 NONE ephedrine/JJ (r_conj) Phenylephrine/NNP (r_nsubj) reduces/VBZ (l_dobj) oxygenation/NN
19037603
D019259_D012216 NONE lamivudine/NN (r_pobj) of/IN (r_prep) use/NN (l_prep) with/IN (l_pobj) therapy/NN (l_prep) for/IN (l_pobj) disorders/NNS -PUNC- lamivudine/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) of/IN (r_prep) effectiveness/NN (r_pobj) concerning/VBG (r_prep) report/VB (r_xcomp) was/VBD (l_attr) patients/NNS (l_prep) with/IN (l_pobj) disease/NN -PUNC- lamivudine/JJ (r_compound) therapies/NNS (r_pobj) on/IN (r_prep) were/VBD (r_relcl) diseases/NNS
D006514_D012216 NONE antigen/NN (r_pobj) in/IN (r_prep) administration/NN (r_pobj) of/IN (r_prep) effectiveness/NN (r_pobj) concerning/VBG (r_prep) report/VB (r_xcomp) was/VBD (l_attr) patients/NNS (l_prep) with/IN (l_pobj) disease/NN -PUNC- Ag/NNP (r_appos) antigen/NN (r_pobj) in/IN (r_prep) administration/NN (r_pobj) of/IN (r_prep) effectiveness/NN (r_pobj) concerning/VBG (r_prep) report/VB (r_xcomp) was/VBD (l_attr) patients/NNS (l_prep) with/IN (l_pobj) disease/NN -PUNC- Ag/NNP (r_nmod) patients/NNS (l_prep) with/IN (l_pobj) diseases/NNS
18004067
D000431_D017093 NONE alcohol/NN (r_pobj) of/IN (r_prep) consumers/NNS (r_attr) were/VBD (l_conj) developed/VBD (l_dobj) failure/NN -PUNC- alcohol/NN (r_compound) consumption/NN (r_dobj) stopping/VBG (r_conj) developed/VBD (l_dobj) failure/NN -PUNC- alcohol/NN (r_pobj) of/IN (r_prep) consumption/NN (r_appos) factors/NNS (r_pobj) with/IN (r_prep) patients/NNS (r_pobj) In/IN (r_prep) is/VBZ (l_nsubj) failure/NN
D000431_D056486 NONE alcohol/NN (r_pobj) of/IN (r_prep) role/NN (l_prep) in/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) hepatotoxicity/NN
D000082_D017114 NONE paracetamol/NN (r_dobj) ingesting/VBG (r_acl) consumption/NN (r_pobj) with/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) failure/NN
D000082_D017093 CID paracetamol/JJ (r_advmod) 4/CD (r_nummod) day/NN (r_pobj) with/IN (r_prep) treated/VBN (r_advcl) stopping/VBG (r_conj) developed/VBD (l_dobj) failure/NN
D000431_D017114 NONE alcohol/NN (r_compound) consumption/NN (r_pobj) with/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) failure/NN
D000082_D056486 CID paracetamol/JJ (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) with/IN (r_prep) associated/VBN (r_acl) hepatotoxicity/NN -PUNC- acetaminophen/NN (r_appos) paracetamol/JJ (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) with/IN (r_prep) associated/VBN (r_acl) hepatotoxicity/NN -PUNC- paracetamol/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (r_pobj) in/IN (r_prep) development/NN (l_prep) of/IN (l_pobj) hepatotoxicity/NN
6209318
D008801_D014202 CID mexiletine/NN (r_amod) group/NN (r_pobj) in/IN (r_prep) frequent/JJ (r_acomp) were/VBD (l_nsubj) effects/NNS (l_appos) tremor/JJ
D008801_D009203 NONE mexiletine/NN (r_pobj) of/IN (r_prep) form/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubjpass) evaluated/VBN (l_prep) in/IN (l_pobj) trial/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) infarction/NN -PUNC- Perlongets/NNP (r_pobj) of/IN (r_prep) form/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubjpass) evaluated/VBN (l_prep) in/IN (l_pobj) trial/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) infarction/NN
D008801_D012817 CID mexiletine/NN (r_amod) group/NN (r_pobj) in/IN (r_prep) frequent/JJ (r_acomp) were/VBD (l_nsubj) effects/NNS (l_appos) tremor/JJ (l_conj) problems/NNS
D008801_D003643 NONE mexiletine/NN (r_amod) group/NN (r_pobj) in/IN (r_prep) deaths/NNS
D008801_D001145 NONE mexiletine/NN (r_nmod) trial/NN (l_appos) Report/NNP (l_prep) on/IN (l_pobj) arrhythmia/NN
19657887
D000431_D004417 CID alcohol/NN (r_pobj) of/IN (r_prep) ingestion/NN (r_pobj) after/IN (r_prep) hour/NN (r_pobj) In/IN (r_prep) developed/VBD (l_dobj) malaise/NN (l_prep) with/IN (l_pobj) flushing/NN (l_prep) of/IN (l_pobj) face/NN (l_conj) tachycardia/NN (l_conj) dyspnea/NN
D004221_D005483 NONE disulfiram/NN (r_npadvmod) like/JJ (r_amod) syndrome/NN (l_prep) with/IN (l_pcomp) flushing/NN
D004221_D013610 NONE disulfiram/NN (r_npadvmod) like/JJ (r_amod) syndrome/NN (l_prep) with/IN (l_pcomp) flushing/NN (l_conj) tachycardia/NN
D000431_D005483 CID alcohol/NN (r_pobj) of/IN (r_prep) ingestion/NN (r_pobj) after/IN (r_prep) hour/NN (r_pobj) In/IN (r_prep) developed/VBD (l_dobj) malaise/NN (l_prep) with/IN (l_pobj) flushing/NN (l_prep) of/IN (l_pobj) face/NN
D004221_D007022 NONE disulfiram/NN (r_npadvmod) like/JJ (r_amod) syndrome/NN (l_prep) with/IN (l_pcomp) flushing/NN (l_conj) tachycardia/NN (l_conj) hypotension/NN
D000431_D013610 CID alcohol/NN (r_pobj) of/IN (r_prep) ingestion/NN (r_pobj) after/IN (r_prep) hour/NN (r_pobj) In/IN (r_prep) developed/VBD (l_dobj) malaise/NN (l_prep) with/IN (l_pobj) flushing/NN (l_prep) of/IN (l_pobj) face/NN (l_conj) tachycardia/NN
17400887
D013726_D001321 CID terbutaline/JJ (r_compound) treatment/NN (r_pobj) after/IN (r_prep) abnormalities/NNS (l_appos) implications/NNS (l_prep) for/IN (l_pobj) autism/NN -PUNC- Terbutaline/NNP (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) concordance/NN (l_prep) for/IN (l_pobj) autism/NN
D013726_D001523 NONE terbutaline/JJ (r_compound) treatment/NN (r_pobj) after/IN (r_prep) abnormalities/NNS
D013726_D007752 NONE Terbutaline/NNP (l_appos) agonist/NN (l_acl) used/VBN (l_xcomp) arrest/VB (l_dobj) labor/NN
D013726_D020078 NONE terbutaline/JJ (r_compound) treatment/NN (r_pobj) after/IN (r_prep) abnormalities/NNS (l_nmod) Neuroinflammation/NN
11379838
D008094_D001714 NONE lithium/NN (r_appos) stabilizers/NNS (r_pobj) of/IN (r_prep) type/NN (r_conj) use/NN (r_conj) inhibitors/NNS (r_appos) episodes/NNS (r_pobj) of/IN (r_prep) number/NN (r_appos) those/DT (r_pobj) with/IN (r_prep) compared/VBN (l_nsubjpass) Patients/NNS (l_relcl) experienced/VBD (l_dobj) switch/NN (l_amod) manic/JJ -PUNC- lithium/NN (r_appos) stabilizers/NNS (r_pobj) of/IN (r_prep) type/NN (r_conj) use/NN (r_conj) inhibitors/NNS (r_appos) episodes/NNS (r_pobj) of/IN (r_prep) number/NN (r_appos) those/DT (r_pobj) with/IN (r_prep) compared/VBN (l_nsubjpass) Patients/NNS (l_relcl) experienced/VBD (l_dobj) switch/NN (l_amod) manic/JJ (l_conj) hypomanic/JJ -PUNC- lithium/NN (r_appos) stabilizers/NNS (r_pobj) of/IN (r_prep) type/NN (r_conj) use/NN (r_conj) inhibitors/NNS (r_appos) episodes/NNS (r_pobj) of/IN (r_prep) number/NN (r_appos) those/DT (l_relcl) did/VBD (l_prep) on/IN (l_pobj) variables/NNS (l_prep) including/VBG (l_pobj) age/NN (l_conj) sex/NN (l_conj) diagnosis/NN (l_appos) IV/NNP (l_appos) I/PRP -PUNC- lithium/NN (r_appos) stabilizers/NNS (r_pobj) of/IN (r_prep) type/NN (r_conj) use/NN (r_conj) inhibitors/NNS (r_appos) episodes/NNS (r_pobj) of/IN (r_prep) number/NN (r_appos) those/DT (l_relcl) did/VBD (l_prep) on/IN (l_pobj) variables/NNS (l_prep) including/VBG (l_pobj) age/NN (l_conj) sex/NN (l_conj) diagnosis/NN (l_appos) IV/NNP (l_appos) I/PRP (l_prep) vs./IN (l_pobj) II/NNP -PUNC- lithium/NN (r_appos) stabilizers/NNS (r_pobj) of/IN (r_prep) type/NN (r_conj) use/NN (r_conj) inhibitors/NNS (r_appos) episodes/NNS (l_amod) manic/JJ
D017367_D001714 CID inhibitors/NNS (r_appos) episodes/NNS (r_pobj) of/IN (r_prep) number/NN (r_appos) those/DT (r_pobj) with/IN (r_prep) compared/VBN (l_nsubjpass) Patients/NNS (l_relcl) experienced/VBD (l_dobj) switch/NN (l_amod) manic/JJ -PUNC- inhibitors/NNS (r_appos) episodes/NNS (r_pobj) of/IN (r_prep) number/NN (r_appos) those/DT (r_pobj) with/IN (r_prep) compared/VBN (l_nsubjpass) Patients/NNS (l_relcl) experienced/VBD (l_dobj) switch/NN (l_amod) manic/JJ (l_conj) hypomanic/JJ -PUNC- inhibitors/NNS (r_appos) episodes/NNS (r_pobj) of/IN (r_prep) number/NN (r_appos) those/DT (l_relcl) did/VBD (l_prep) on/IN (l_pobj) variables/NNS (l_prep) including/VBG (l_pobj) age/NN (l_conj) sex/NN (l_conj) diagnosis/NN (l_appos) IV/NNP (l_appos) I/PRP -PUNC- inhibitors/NNS (r_appos) episodes/NNS (r_pobj) of/IN (r_prep) number/NN (r_appos) those/DT (l_relcl) did/VBD (l_prep) on/IN (l_pobj) variables/NNS (l_prep) including/VBG (l_pobj) age/NN (l_conj) sex/NN (l_conj) diagnosis/NN (l_appos) IV/NNP (l_appos) I/PRP (l_prep) vs./IN (l_pobj) II/NNP -PUNC- inhibitors/NNS (r_appos) episodes/NNS (l_amod) manic/JJ -PUNC- SSRIs/NNPS (r_appos) inhibitors/NNS (r_appos) episodes/NNS (r_pobj) of/IN (r_prep) number/NN (r_appos) those/DT (r_pobj) with/IN (r_prep) compared/VBN (l_nsubjpass) Patients/NNS (l_relcl) experienced/VBD (l_dobj) switch/NN (l_amod) manic/JJ -PUNC- SSRIs/NNPS (r_appos) inhibitors/NNS (r_appos) episodes/NNS (r_pobj) of/IN (r_prep) number/NN (r_appos) those/DT (r_pobj) with/IN (r_prep) compared/VBN (l_nsubjpass) Patients/NNS (l_relcl) experienced/VBD (l_dobj) switch/NN (l_amod) manic/JJ (l_conj) hypomanic/JJ -PUNC- SSRIs/NNPS (r_appos) inhibitors/NNS (r_appos) episodes/NNS (r_pobj) of/IN (r_prep) number/NN (r_appos) those/DT (l_relcl) did/VBD (l_prep) on/IN (l_pobj) variables/NNS (l_prep) including/VBG (l_pobj) age/NN (l_conj) sex/NN (l_conj) diagnosis/NN (l_appos) IV/NNP (l_appos) I/PRP -PUNC- SSRIs/NNPS (r_appos) inhibitors/NNS (r_appos) episodes/NNS (r_pobj) of/IN (r_prep) number/NN (r_appos) those/DT (l_relcl) did/VBD (l_prep) on/IN (l_pobj) variables/NNS (l_prep) including/VBG (l_pobj) age/NN (l_conj) sex/NN (l_conj) diagnosis/NN (l_appos) IV/NNP (l_appos) I/PRP (l_prep) vs./IN (l_pobj) II/NNP -PUNC- SSRIs/NNPS (r_appos) inhibitors/NNS (r_appos) episodes/NNS (l_amod) manic/JJ -PUNC- SSRIs/NNS (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (r_pobj) of/IN (r_prep) subgroup/NN (r_pobj) of/IN (r_prep) %/NN (r_pobj) in/IN (r_prep) experienced/JJ (r_parataxis) patients/NNS (r_pobj) of/IN (r_prep) %/NN (r_pobj) in/IN (r_prep) occurred/VBD (l_nsubj) Switches/NNS (l_prep) to/IN (l_pobj) hypomania/NN -PUNC- SSRIs/NNS (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (r_pobj) of/IN (r_prep) subgroup/NN (r_pobj) of/IN (r_prep) %/NN (r_pobj) in/IN (r_prep) experienced/JJ (r_parataxis) patients/NNS (r_pobj) of/IN (r_prep) %/NN (r_pobj) in/IN (r_prep) occurred/VBD (l_nsubj) Switches/NNS (l_prep) to/IN (l_pobj) hypomania/NN (l_conj) mania/NN -PUNC- SSRIs/NNS (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (r_pobj) of/IN (r_prep) subgroup/NN (r_pobj) of/IN (r_prep) %/NN (r_pobj) in/IN (r_prep) experienced/JJ (l_dobj) episodes/NNS (l_amod) manic/JJ -PUNC- SSRIs/NNS (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (r_pobj) of/IN (r_prep) subgroup/NN (r_pobj) of/IN (r_prep) %/NN (r_pobj) in/IN (r_prep) experienced/JJ (r_parataxis) patients/NNS (r_pobj) of/IN (r_prep) %/NN (r_pobj) in/IN (r_prep) occurred/VBD (l_npadvmod) episodes/NNS (l_amod) hypomanic/JJ
D000928_D001714 CID Antidepressant/NNP (r_npadvmod) induced/VBN (r_amod) mania/NN -PUNC- Antidepressant/NNP (r_npadvmod) induced/VBN (r_amod) mania/NN (l_prep) in/IN (l_pobj) patients/NNS (l_amod) bipolar/JJ -PUNC- antidepressants/NNS (r_pobj) with/IN (r_prep) associated/VBN (r_acl) mania/NN -PUNC- antidepressants/NNS (r_pobj) with/IN (r_prep) associated/VBN (r_acl) mania/NN (r_pobj) to/IN (r_prep) switching/VBG (r_pcomp) of/IN (r_prep) risks/NNS (r_pobj) about/IN (r_prep) Concerns/NNS (r_nsubj) continue/VBP (l_xcomp) interfere/VB (l_prep) with/IN (l_pobj) establishment/NN (l_prep) of/IN (l_pobj) paradigm/NN (l_prep) for/IN (l_pobj) depression/NN -PUNC- antidepressant/NN (r_amod) therapy/NN (r_pobj) of/IN (r_prep) type/NN (r_appos) episodes/NNS (r_pobj) of/IN (r_prep) number/NN (r_appos) those/DT (r_pobj) with/IN (r_prep) compared/VBN (l_nsubjpass) Patients/NNS (l_relcl) experienced/VBD (l_dobj) switch/NN (l_amod) manic/JJ -PUNC- antidepressant/NN (r_amod) therapy/NN (r_pobj) of/IN (r_prep) type/NN (r_appos) episodes/NNS (r_pobj) of/IN (r_prep) number/NN (r_appos) those/DT (r_pobj) with/IN (r_prep) compared/VBN (l_nsubjpass) Patients/NNS (l_relcl) experienced/VBD (l_dobj) switch/NN (l_amod) manic/JJ (l_conj) hypomanic/JJ -PUNC- antidepressant/NN (r_amod) therapy/NN (r_pobj) of/IN (r_prep) type/NN (r_appos) episodes/NNS (r_pobj) of/IN (r_prep) number/NN (r_appos) those/DT (l_relcl) did/VBD (l_prep) on/IN (l_pobj) variables/NNS (l_prep) including/VBG (l_pobj) age/NN (l_conj) sex/NN (l_conj) diagnosis/NN (l_appos) IV/NNP (l_appos) I/PRP -PUNC- antidepressant/NN (r_amod) therapy/NN (r_pobj) of/IN (r_prep) type/NN (r_appos) episodes/NNS (r_pobj) of/IN (r_prep) number/NN (r_appos) those/DT (l_relcl) did/VBD (l_prep) on/IN (l_pobj) variables/NNS (l_prep) including/VBG (l_pobj) age/NN (l_conj) sex/NN (l_conj) diagnosis/NN (l_appos) IV/NNP (l_appos) I/PRP (l_prep) vs./IN (l_pobj) II/NNP -PUNC- antidepressant/NN (r_amod) therapy/NN (r_pobj) of/IN (r_prep) type/NN (r_appos) episodes/NNS (l_amod) manic/JJ -PUNC- antidepressant/NN (r_amod) drugs/NNS (r_pobj) vs./IN (r_prep) therapy/NN (r_dobj) used/VBN (r_acl) episodes/NNS (r_pobj) of/IN (r_prep) number/NN (r_appos) those/DT (r_pobj) with/IN (r_prep) compared/VBN (l_nsubjpass) Patients/NNS (l_relcl) experienced/VBD (l_dobj) switch/NN (l_amod) manic/JJ -PUNC- antidepressant/NN (r_amod) drugs/NNS (r_pobj) vs./IN (r_prep) therapy/NN (r_dobj) used/VBN (r_acl) episodes/NNS (r_pobj) of/IN (r_prep) number/NN (r_appos) those/DT (r_pobj) with/IN (r_prep) compared/VBN (l_nsubjpass) Patients/NNS (l_relcl) experienced/VBD (l_dobj) switch/NN (l_amod) manic/JJ (l_conj) hypomanic/JJ -PUNC- antidepressant/NN (r_amod) drugs/NNS (r_pobj) vs./IN (r_prep) therapy/NN (r_dobj) used/VBN (r_acl) episodes/NNS (r_pobj) of/IN (r_prep) number/NN (r_appos) those/DT (l_relcl) did/VBD (l_prep) on/IN (l_pobj) variables/NNS (l_prep) including/VBG (l_pobj) age/NN (l_conj) sex/NN (l_conj) diagnosis/NN (l_appos) IV/NNP (l_appos) I/PRP -PUNC- antidepressant/NN (r_amod) drugs/NNS (r_pobj) vs./IN (r_prep) therapy/NN (r_dobj) used/VBN (r_acl) episodes/NNS (r_pobj) of/IN (r_prep) number/NN (r_appos) those/DT (l_relcl) did/VBD (l_prep) on/IN (l_pobj) variables/NNS (l_prep) including/VBG (l_pobj) age/NN (l_conj) sex/NN (l_conj) diagnosis/NN (l_appos) IV/NNP (l_appos) I/PRP (l_prep) vs./IN (l_pobj) II/NNP -PUNC- antidepressant/NN (r_amod) drugs/NNS (r_pobj) vs./IN (r_prep) therapy/NN (r_dobj) used/VBN (r_acl) episodes/NNS (l_amod) manic/JJ
2008831
D008755_D013035 NONE methylergonovine/NN (r_pobj) of/IN (r_prep) dose/NN (r_pobj) of/IN (r_prep) injection/NN (r_dobj) use/VBP (r_relcl) tests/NNS (l_compound) spasm/NN
D008755_D000787 NONE methylergonovine/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubjpass) studied/VBN (l_prep) without/IN (l_pobj) angina/NN (l_appos) pectoris/NN
D008755_D000788 NONE methylergonovine/NN (r_pobj) of/IN (r_prep) administration/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_conj) without/IN (l_pobj) angina/NN -PUNC- methylergonovine/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubjpass) studied/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) angina/NN -PUNC- methylergonovine/NN (r_pobj) of/IN (r_prep) dose/NN (r_pobj) of/IN (r_prep) injection/NN (r_dobj) use/VBP (r_relcl) tests/NNS (r_nsubj) have/VBP (l_dobj) sensitivity/NN (l_prep) in/IN (l_pobj) angina/NN
D008755_D002637 NONE methylergonovine/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubjpass) studied/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) angina/NN (l_conj) patients/NNS (l_prep) with/IN (l_pobj) pain/NN
2670794
D000809_D004211 NONE angiotensin/NN (r_pobj) of/IN (r_prep) inhibitor/NN (r_pobj) of/IN (r_prep) Effects/NNS (l_amod) due/IN (l_pobj) coagulation/NN
D002216_D007674 NONE Captopril/NNP (r_pobj) by/IN (r_agent) prevented/VBN (l_nsubjpass) damage/NN -PUNC- Captopril/NNP (r_nsubj) reduce/VB (l_advcl) diminishing/VBG (l_prep) with/IN (l_pobj) result/NN (l_acl) deposited/VBN (l_conj) produced/VBN (l_nsubjpass) damage/NN
D000809_D051437 NONE angiotensin/NN (l_acl) converting/VBG (l_prep) on/IN (l_pobj) insufficiency/NN -PUNC- angiotensin/NN (r_pobj) of/IN (r_prep) inhibitor/NN (r_appos) Injection/NN (r_nsubj) reduced/VBD (l_dobj) insufficiency/NN
D014148_D004211 CID acid/NN (r_conj) thrombin/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) by/IN (r_prep) Induction/NN (l_prep) of/IN (l_pobj) coagulation/NN -PUNC- AMCA/NNP (r_appos) acid/NN (r_conj) thrombin/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) by/IN (r_prep) Induction/NN (l_prep) of/IN (l_pobj) coagulation/NN
D002216_D051437 NONE Captopril/NNP (r_appos) enzyme/NN (r_dobj) converting/VBG (l_prep) on/IN (l_pobj) insufficiency/NN -PUNC- Captopril/NNP (r_pobj) of/IN (r_prep) Injection/NN (r_nsubj) reduced/VBD (l_dobj) insufficiency/NN
D014148_D051437 NONE acid/NN (r_conj) thrombin/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) by/IN (r_prep) Induction/NN (r_nsubj) gives/VBZ (l_dobj) rise/NN (l_prep) to/IN (l_pobj) insufficiency/NN -PUNC- AMCA/NNP (r_appos) acid/NN (r_conj) thrombin/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) by/IN (r_prep) Induction/NN (r_nsubj) gives/VBZ (l_dobj) rise/NN (l_prep) to/IN (l_pobj) insufficiency/NN
D014148_D014947 NONE acid/NN (r_conj) thrombin/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) by/IN (r_prep) Induction/NN (r_nsubj) gives/VBZ (l_advcl) resembling/VBG (l_ccomp) occurring/VBG (l_prep) after/IN (l_pobj) trauma/NN -PUNC- AMCA/NNP (r_appos) acid/NN (r_conj) thrombin/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) by/IN (r_prep) Induction/NN (r_nsubj) gives/VBZ (l_advcl) resembling/VBG (l_ccomp) occurring/VBG (l_prep) after/IN (l_pobj) trauma/NN
D002216_D011665 NONE Captopril/NNP (r_appos) enzyme/NN (r_dobj) converting/VBG (l_prep) on/IN (l_pobj) insufficiency/NN -PUNC- Captopril/NNP (r_pobj) of/IN (r_prep) Injection/NN (r_nsubj) reduced/VBD (l_dobj) insufficiency/NN
D000809_D011665 NONE angiotensin/NN (l_acl) converting/VBG (l_prep) on/IN (l_pobj) insufficiency/NN -PUNC- angiotensin/NN (r_pobj) of/IN (r_prep) inhibitor/NN (r_appos) Injection/NN (r_nsubj) reduced/VBD (l_dobj) insufficiency/NN
D002216_D004211 NONE Captopril/NNP (r_appos) enzyme/NN (r_dobj) converting/VBG (r_acl) angiotensin/NN (r_pobj) of/IN (r_prep) inhibitor/NN (r_pobj) of/IN (r_prep) Effects/NNS (l_amod) due/IN (l_pobj) coagulation/NN
D014148_D011665 NONE acid/NN (r_conj) thrombin/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) by/IN (r_prep) Induction/NN (r_nsubj) gives/VBZ (l_dobj) rise/NN (l_prep) to/IN (l_pobj) insufficiency/NN -PUNC- AMCA/NNP (r_appos) acid/NN (r_conj) thrombin/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) by/IN (r_prep) Induction/NN (r_nsubj) gives/VBZ (l_dobj) rise/NN (l_prep) to/IN (l_pobj) insufficiency/NN
D014508_D007674 NONE urea/NN (r_pobj) in/IN (r_prep) increase/NN (r_pobj) by/IN (r_agent) reflected/VBN (r_advcl) damage/NN
D014148_D018805 NONE acid/NN (r_conj) thrombin/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) by/IN (r_prep) Induction/NN (r_nsubj) gives/VBZ (l_advcl) resembling/VBG (l_ccomp) occurring/VBG (l_prep) after/IN (l_pobj) trauma/NN (l_conj) sepsis/NN -PUNC- AMCA/NNP (r_appos) acid/NN (r_conj) thrombin/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) by/IN (r_prep) Induction/NN (r_nsubj) gives/VBZ (l_advcl) resembling/VBG (l_ccomp) occurring/VBG (l_prep) after/IN (l_pobj) trauma/NN (l_conj) sepsis/NN
12198388
D000109_D012640 NONE acetylcholine/NN (r_compound) release/NN (l_conj) sensitivity/NN (l_prep) in/IN (l_pobj) lines/NNS (l_amod) prone/JJ (l_npadvmod) seizure/NN -PUNC- acetylcholine/NN (r_compound) release/NN (l_conj) sensitivity/NN (l_prep) in/IN (l_pobj) lines/NNS (l_amod) resistant/JJ (l_npadvmod) seizure/NN -PUNC- ACh/NNS (r_nsubjpass) measured/VBN (l_prep) during/IN (l_pobj) testing/VBG (l_prep) for/IN (l_pobj) convulsions/NNS -PUNC- ACh/NNS (r_nsubjpass) measured/VBN (l_prep) during/IN (l_pobj) testing/VBG (l_prep) for/IN (l_pobj) convulsions/NNS -PUNC- ACh/NNS (r_nsubjpass) elevated/JJ (l_advcl) measured/VBN (l_prep) during/IN (l_pobj) testing/VBG (l_prep) for/IN (l_pobj) convulsions/NNS
D002217_D014202 NONE carbachol/NN (r_conj) nicotine/NN (r_dobj) administered/VBN (l_conj) recorded/VBN (l_nsubjpass) latencies/NNS (l_relcl) onset/VB (l_prep) of/IN (l_pobj) tremor/NN
D009388_D014202 NONE neostigmine/JJ (r_conj) carbachol/NN (r_conj) nicotine/NN (r_dobj) administered/VBN (l_conj) recorded/VBN (l_nsubjpass) latencies/NNS (l_relcl) onset/VB (l_prep) of/IN (l_pobj) tremor/NN
D009388_D012640 CID neostigmine/NN (r_conj) Sensitivity/NN (l_prep) to/IN (l_pobj) endpoints/NNS (l_compound) convulsion/NN
D000431_D012640 NONE alcohol/NN (r_compound) na/TO (r_aux) ve/VB (l_dobj) mice/NNS (l_nmod) Prone/NNP (l_compound) Seizure/NN -PUNC- ethanol/NN (r_compound) withdrawal/NN (r_compound) severity/NN (r_pobj) with/IN (r_prep) associated/VBN (l_nsubjpass) differences/NNS (l_prep) in/IN (l_pobj) activity/NN (l_conj) sensitivity/NN (l_prep) to/IN (l_pobj) convulsants/NNS -PUNC- alcohol/NN (r_compound) withdrawal/NN (r_pobj) in/IN (r_prep) mechanisms/NNS (r_dobj) implicate/VB (r_conj) associated/VBN (l_nsubjpass) differences/NNS (l_prep) in/IN (l_pobj) activity/NN (l_conj) sensitivity/NN (l_prep) to/IN (l_pobj) convulsants/NNS
D002217_D012640 CID carbachol/NN (r_conj) nicotine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) endpoints/NNS (l_compound) convulsion/NN
D009538_D012640 CID nicotine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) endpoints/NNS (l_compound) convulsion/NN
D009538_D014202 NONE nicotine/NN (r_dobj) administered/VBN (l_conj) recorded/VBN (l_nsubjpass) latencies/NNS (l_relcl) onset/VB (l_prep) of/IN (l_pobj) tremor/NN
12443032
D003042_D002637 CID Cocaine/NN (r_nsubj) related/VBN (l_dobj) pain/NN -PUNC- cocaine/NN (r_pobj) of/IN (r_prep) tendency/NN (l_acl) produce/VB (l_dobj) pain/NN -PUNC- cocaine/NN (r_pobj) of/IN (r_prep) tendency/NN (r_nsubj) ought/MD (l_xcomp) be/VB (l_advcl) faced/VBN (l_prep) with/IN (l_pobj) victim/NN (l_prep) of/IN (l_pobj) pain/NN -PUNC- cocaine/NN (r_compound) use/NN (r_pobj) to/IN (r_prep) related/VBN (r_acl) mechanism/NN (l_prep) of/IN (l_pobj) pain/NN
2071257
D012601_D000647 NONE scopolamine/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) amnesia/NN
D005997_D000647 NONE phosphorylcholine/NN (r_pobj) of/IN (r_prep) Effect/NN (l_prep) on/IN (l_pobj) amnesia/NN
D012601_D008569 CID scopolamine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) impairment/NN -PUNC- scopolamine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) impairment/NN (l_prep) of/IN (l_pobj) attention/NN (l_conj) memory/NN
D005997_D008569 NONE glycerylphosphorylcholine/NN (r_pobj) of/IN (r_prep) effects/NNS (l_prep) on/IN (l_pobj) impairment/NN -PUNC- GFC/NNP (r_appos) glycerylphosphorylcholine/NN (r_pobj) of/IN (r_prep) effects/NNS (l_prep) on/IN (l_pobj) impairment/NN
7504976
D002231_D056486 CID carbimazole/NN (r_pobj) between/IN (r_prep) reactivity/NN (r_pobj) with/IN (r_prep) one/CD (r_pobj) including/VBG (r_prep) cases/NNS (r_appos) induced/VBN (l_nsubj) hepatitis/NN -PUNC- carbimazole/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubj) hepatitis/NN -PUNC- omercazole/NN (r_appos) carbimazole/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubj) hepatitis/NN -PUNC- carbimazole/NN (l_amod) following/VBG (l_compound) hepatitis/NN -PUNC- carbimazole/NN (r_dobj) replaced/VBN (l_nsubj) experienced/VBD (l_dobj) hepatitis/NN
C019269_D056486 NONE benzylthiouracil/NN (r_conj) carbimazole/NN (r_pobj) between/IN (r_prep) reactivity/NN (r_pobj) with/IN (r_prep) one/CD (r_pobj) including/VBG (r_prep) cases/NNS (r_appos) induced/VBN (l_nsubj) hepatitis/NN -PUNC- Benzylthiouracil/NNP (r_pobj) after/IN (r_prep) appeared/VBD (r_relcl) hepatitis/NN -PUNC- ne/NNP (r_appos) Benzylthiouracil/NNP (r_pobj) after/IN (r_prep) appeared/VBD (r_relcl) hepatitis/NN
D002231_D002779 CID carbimazole/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubj) hepatitis/NN -PUNC- omercazole/NN (r_appos) carbimazole/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubj) hepatitis/NN -PUNC- carbimazole/NN (l_amod) mixed/JJ (l_conj) cholestatic/JJ
10704919
D024502_D006461 NONE tocopherol/NN (r_pobj) of/IN (r_prep) concentrations/NNS (r_pobj) by/IN (r_agent) prevented/VBN (l_nsubjpass) effect/NN (l_amod) hemolytic/JJ -PUNC- tocopherol/NN (r_pobj) of/IN (r_prep) concentrations/NNS (r_pobj) by/IN (r_agent) prevented/VBN (l_advcl) indicating/VBG (l_ccomp) related/VBN (l_nsubjpass) hemolysis/NN -PUNC- T/NNP (r_appos) tocopherol/NN (r_pobj) of/IN (r_prep) concentrations/NNS (r_pobj) by/IN (r_agent) prevented/VBN (l_nsubjpass) effect/NN (l_amod) hemolytic/JJ -PUNC- T/NNP (r_appos) tocopherol/NN (r_pobj) of/IN (r_prep) concentrations/NNS (r_pobj) by/IN (r_agent) prevented/VBN (l_advcl) indicating/VBG (l_ccomp) related/VBN (l_nsubjpass) hemolysis/NN -PUNC- acetate/NN (r_conj) concentrations/NNS (r_pobj) by/IN (r_agent) prevented/VBN (l_nsubjpass) effect/NN (l_amod) hemolytic/JJ -PUNC- acetate/NN (r_conj) concentrations/NNS (r_pobj) by/IN (r_agent) prevented/VBN (l_advcl) indicating/VBG (l_ccomp) related/VBN (l_nsubjpass) hemolysis/NN -PUNC- TAc/NNS (r_appos) acetate/NN (r_conj) concentrations/NNS (r_pobj) by/IN (r_agent) prevented/VBN (l_nsubjpass) effect/NN (l_amod) hemolytic/JJ -PUNC- TAc/NNS (r_appos) acetate/NN (r_conj) concentrations/NNS (r_pobj) by/IN (r_agent) prevented/VBN (l_advcl) indicating/VBG (l_ccomp) related/VBN (l_nsubjpass) hemolysis/NN
D017665_D006461 NONE hydroxyl/NN (r_dobj) inactivated/VBN (r_parataxis) prevented/VBN (l_nsubjpass) effect/NN (l_amod) hemolytic/JJ -PUNC- hydroxyl/NN (r_dobj) inactivated/VBN (r_parataxis) prevented/VBN (l_advcl) indicating/VBG (l_ccomp) related/VBN (l_nsubjpass) hemolysis/NN
D013629_D006461 CID tamoxifen/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubj) Hemolysis/NNP -PUNC- TAM/NNP (r_nsubj) induces/VBZ (l_dobj) hemolysis/NN -PUNC- TAM/NNP (r_nsubj) induces/VBZ (r_conj) is/VBZ (l_nsubj) extension/NN (l_prep) of/IN (l_pobj) hemolysis/NN -PUNC- TAM/NNP (r_nsubj) induces/VBZ (l_dobj) hemolysis/NN -PUNC- TAM/NNP (r_pobj) of/IN (r_prep) effect/NN (l_amod) hemolytic/JJ -PUNC- TAM/NNP (r_pobj) of/IN (r_prep) effect/NN (r_nsubjpass) prevented/VBN (l_advcl) indicating/VBG (l_ccomp) related/VBN (l_nsubjpass) hemolysis/NN -PUNC- TAM/NNP (r_npadvmod) induced/VBN (r_amod) hemolysis/NN (r_nsubjpass) related/VBN (r_ccomp) indicating/VBG (r_advcl) prevented/VBN (l_nsubjpass) effect/NN (l_amod) hemolytic/JJ -PUNC- TAM/NNP (r_npadvmod) induced/VBN (r_amod) hemolysis/NN -PUNC- TAM/NNP (r_npadvmod) induced/VBN (r_amod) hemolysis/NN -PUNC- TAM/NNP (r_pobj) by/IN (r_agent) caused/VBN (r_acl) Hemolysis/NNP -PUNC- TAM/NNP (r_pobj) by/IN (r_agent) caused/VBN (r_acl) Hemolysis/NNP (r_nsubjpass) preceded/VBN (l_prep) excluding/VBG (l_pobj) mechanism/NN (l_prep) of/IN (l_pobj) hemolysis/NN -PUNC- TAM/NNP (r_compound) incorporation/NN (r_pobj) to/IN (r_prep) related/VBN (l_nsubjpass) protection/NN (l_prep) from/IN (l_pobj) hemolysis/NN -PUNC- TAM/NNP (r_npadvmod) induced/VBN (r_amod) results/NNS (l_compound) hemolysis/NN
D024505_D006461 NONE tocopherols/NNS (r_pobj) by/IN (r_prep) protection/NN (l_prep) from/IN (l_pobj) hemolysis/NN
D011188_D006461 NONE K(+/NNP (r_pobj) of/IN (r_prep) leakage/NN (r_pobj) by/IN (r_agent) preceded/VBN (l_nsubjpass) Hemolysis/NNP -PUNC- K(+/NNP (r_pobj) of/IN (r_prep) leakage/NN (r_pobj) by/IN (r_agent) preceded/VBN (l_prep) excluding/VBG (l_pobj) mechanism/NN (l_prep) of/IN (l_pobj) hemolysis/NN
D013629_D000743 CID Tamoxifen/NNP (r_nsubj) induces/VBZ (l_dobj) changes/NNS (l_prep) in/IN (l_pobj) shape/NN (l_prep) of/IN (l_pobj) erythrocytes/NNS (l_conj) anemia/NN -PUNC- TAM/NNP (r_appos) Tamoxifen/NNP (r_nsubj) induces/VBZ (l_dobj) changes/NNS (l_prep) in/IN (l_pobj) shape/NN (l_prep) of/IN (l_pobj) erythrocytes/NNS (l_conj) anemia/NN -PUNC- TAM/NNP (r_pobj) of/IN (r_prep) effects/NNS (r_dobj) evaluates/VBZ (l_advcl) attempting/VBG (l_xcomp) identify/VB (l_dobj) mechanisms/NNS (l_prep) on/IN (l_pobj) anemia/NN -PUNC- TAM/NNP (r_npadvmod) induced/VBN (r_amod) anemia/NN -PUNC- TAM/NNP (r_pobj) by/IN (r_agent) promoted/VBN (r_acl) stability/NN (r_dobj) decreased/VBD (l_conj) resulting/VBG (l_prep) in/IN (l_pobj) anemia/NN
D010100_D006461 NONE oxygen/NN (r_compound) consumption/NN (r_pobj) of/IN (r_prep) absence/NN (r_pobj) by/IN (r_agent) evidenced/VBN (l_conj) determined/VBN (l_prep) in/IN (l_pobj) parallel/NN (l_prep) with/IN (l_pobj) hemolysis/NN
D013629_D001943 NONE Tamoxifen/NNP (r_nsubj) induces/VBZ (l_nsubj) drug/NN (l_acl) prescribed/VBN (l_prep) in/IN (l_pobj) chemotherapy/NN (l_prep) of/IN (l_pobj) cancer/NN -PUNC- TAM/NNP (r_appos) Tamoxifen/NNP (r_nsubj) induces/VBZ (l_nsubj) drug/NN (l_acl) prescribed/VBN (l_prep) in/IN (l_pobj) chemotherapy/NN (l_prep) of/IN (l_pobj) cancer/NN
2273650
D012601_D000647 CID scopolamine/NN (r_pobj) by/IN (r_agent) produced/VBN (r_acl) Amnesia/NNP -PUNC- scopolamine/NN (r_nsubj) reversed/VBD (l_dobj) amnesia/NN -PUNC- scopolamine/NN (r_nsubj) reversed/VBD (l_conj) failed/VBD (l_xcomp) reverse/VB (l_dobj) amnesia/NN -PUNC- scopolamine/NN (r_npadvmod) induced/VBN (r_amod) amnesia/NN -PUNC- scopolamine/NN (r_npadvmod) induced/VBN (r_amod) amnesia/NN (r_dobj) reversed/VBD (l_conj) failed/VBD (l_xcomp) reverse/VB (l_dobj) amnesia/NN
D003513_D000647 CID cycloheximide/NN (r_conj) scopolamine/NN (r_pobj) by/IN (r_agent) produced/VBN (r_acl) Amnesia/NNP -PUNC- cycloheximide/NN (r_nsubj) failed/VBD (r_conj) reversed/VBD (l_dobj) amnesia/NN -PUNC- cycloheximide/NN (r_nsubj) failed/VBD (l_xcomp) reverse/VB (l_dobj) amnesia/NN -PUNC- cycloheximide/RB (r_advmod) induced/VBN (r_amod) amnesia/NN (r_dobj) reverse/VB (r_xcomp) failed/VBD (r_conj) reversed/VBD (l_dobj) amnesia/NN -PUNC- cycloheximide/RB (r_advmod) induced/VBN (r_amod) amnesia/NN
D009270_D000647 NONE naloxone/NN (r_dobj) administered/VBN (r_acl) retrieval/NN (r_dobj) facilitated/VBD (r_conj) reversed/VBN (l_nsubjpass) Amnesia/NNP
D009020_D000647 NONE morphine/NN (r_pobj) by/IN (r_agent) reversed/VBN (l_nsubjpass) Amnesia/NNP -PUNC- morphine/NN (r_nsubj) facilitated/VBD (r_conj) reversed/VBN (l_nsubjpass) Amnesia/NNP
7292072
D003891_D064420 NONE desipramine/JJ (r_amod) toxicity/NN -PUNC- desipramine/NN (r_amod) toxicity/NN
D003891_D017180 CID desipramine/JJ (r_amod) toxicity/NN (r_pobj) in/IN (r_prep) tachycardia/NN -PUNC- desipramine/NN (r_amod) toxicity/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) tachycardia/NN
19884587
D009582_D008850 CID Nitrofurantoins/NNS (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) anophthalmia/NN (l_conj) microphthalmos/NNS
D009582_D002972 CID Nitrofurantoins/NNS (r_nsubjpass) associated/VBN (l_appos) AOR/NNP (l_appos) AOR/NNP (l_conj) lip/NN (l_prep) with/IN (l_pobj) palate/NN
D009582_D000014 CID nitrofurantoins/NNS (r_conj) Sulfonamides/NNS (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) defects/NNS
D009582_D006344 CID Nitrofurantoins/NNS (r_nsubjpass) associated/VBN (l_appos) AOR/NNP (l_appos) AOR/NNP (l_appos) defects/NNS
D010406_D000014 NONE penicillins/NNS (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) defects/NNS
D013449_D000014 CID Sulfonamides/NNS (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) defects/NNS
D013449_D018636 CID Sulfonamides/NNS (r_nsubjpass) associated/VBN (r_ccomp) interval/NN (l_appos) syndrome/NN
D002511_D000014 NONE cephalosporins/NNS (r_conj) erythromycins/NNS (r_conj) penicillins/NNS (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) defects/NNS
D013449_D000757 CID Sulfonamides/NNS (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) AOR/NNP (l_amod) anencephaly/NNS
D009582_D002971 CID Nitrofurantoins/NNS (r_nsubjpass) associated/VBN (l_appos) AOR/NNP (l_appos) AOR/NNP (l_conj) lip/NN
D009582_D018636 CID Nitrofurantoins/NNS (r_nsubjpass) associated/VBN (l_appos) AOR/NNP (l_appos) syndrome/NN
D009582_D000853 CID Nitrofurantoins/NNS (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) anophthalmia/NN
D004917_D000014 NONE erythromycins/NNS (r_conj) penicillins/NNS (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) defects/NNS
18503483
C107135_D020968 NONE everolimus/NN (r_pobj) to/TO (r_prep) conversion/NN (r_pobj) after/IN (r_prep) Recovery/NN (l_prep) of/IN (l_pobj) neuritis/NN
D016559_D020968 CID tacrolimus/NN (r_npadvmod) associated/VBN (r_amod) neuritis/NN
9721172
D007052_D013262 CID ibuprofen/JJ (r_compound) use/NN (r_pobj) with/IN (r_prep) associated/VBN (l_nsubjpass) child/NN (l_relcl) described/VBN (l_nsubjpass) syndrome/NN
D014580_D002779 NONE acid/NN (l_conj) prednisone/NN (l_conj) tacrolimus/VB (l_conj) disease/NN
D016559_D002779 NONE tacrolimus/VB (l_conj) disease/NN
D014580_D005355 NONE acid/NN (r_pobj) with/IN (r_prep) therapy/NN (r_pobj) Despite/IN (r_prep) was/VBD (l_prep) with/IN (l_pobj) cirrhosis/NN
D011241_D002779 NONE prednisone/NN (l_conj) tacrolimus/VB (l_conj) disease/NN
D007052_D001649 NONE ibuprofen/JJ (r_compound) use/NN (r_pobj) with/IN (r_prep) associated/VBN (l_nsubjpass) child/NN (l_relcl) developed/VBD (l_dobj) syndrome/NN
D011241_D005355 NONE prednisone/NN (r_conj) acid/NN (r_pobj) with/IN (r_prep) therapy/NN (r_pobj) Despite/IN (r_prep) was/VBD (l_prep) with/IN (l_pobj) cirrhosis/NN
D016559_D005355 NONE tacrolimus/VB (r_conj) prednisone/NN (r_conj) acid/NN (r_pobj) with/IN (r_prep) therapy/NN (r_pobj) Despite/IN (r_prep) was/VBD (l_prep) with/IN (l_pobj) cirrhosis/NN
10365197
D003042_D001523 NONE Cocaine/NN (r_npadvmod) induced/VBN (r_amod) disorder/NN (l_appos) rates/NNS (l_conj) symptoms/NNS (l_amod) psychiatric/JJ -PUNC- cocaine/NN (r_npadvmod) dependent/JJ (r_amod) sample/NN (r_pobj) in/IN (r_prep) rates/NNS (l_conj) symptoms/NNS (l_amod) psychiatric/JJ -PUNC- cocaine/NN (r_npadvmod) dependent/JJ (r_amod) outpatients/NNS (r_nsubjpass) compared/VBN (l_prep) on/IN (l_pobj) measures/NNS (l_prep) of/IN (l_pobj) symptoms/NNS (l_amod) psychiatric/JJ -PUNC- cocaine/NN (r_npadvmod) induced/VBN (r_amod) disorder/NN (r_pobj) with/IN (r_prep) outpatients/NNS (r_nsubjpass) compared/VBN (l_prep) on/IN (l_pobj) measures/NNS (l_prep) of/IN (l_pobj) symptoms/NNS (l_amod) psychiatric/JJ
D003042_D019964 CID Cocaine/NN (r_npadvmod) induced/VBN (r_amod) disorder/NN -PUNC- cocaine/NN (r_npadvmod) dependent/JJ (r_amod) sample/NN (r_pobj) in/IN (r_prep) rates/NNS (r_appos) disorder/NN -PUNC- cocaine/NN (r_npadvmod) dependent/JJ (r_amod) outpatients/NNS (l_prep) with/IN (l_pobj) disorder/NN -PUNC- cocaine/NN (r_npadvmod) dependent/JJ (r_amod) outpatients/NNS (l_conj) disorders/NNS -PUNC- cocaine/NN (r_npadvmod) dependent/JJ (r_amod) outpatients/NNS (l_conj) disorders/NNS (l_conj) disorder/NN -PUNC- cocaine/NN (r_npadvmod) induced/VBN (r_amod) disorder/NN -PUNC- cocaine/NN (r_npadvmod) induced/VBN (r_amod) disorder/NN (r_pobj) with/IN (r_prep) outpatients/NNS (l_conj) disorders/NNS -PUNC- cocaine/NN (r_npadvmod) induced/VBN (r_amod) disorder/NN (r_pobj) with/IN (r_prep) outpatients/NNS (l_conj) disorders/NNS (l_conj) disorder/NN
D003042_D019970 NONE cocaine/NN (r_npadvmod) dependent/JJ (r_amod) outpatients/NNS (l_prep) with/IN (l_pobj) disorder/NN (l_appos) CIMD/NNP -PUNC- cocaine/NN (r_npadvmod) induced/VBN (r_amod) disorder/NN (l_appos) CIMD/NNP
14657095
D000666_D003047 NONE B/NNP (r_pobj) with/IN (r_prep) developed/VBD (l_prep) for/IN (l_pobj) coccidioidomycosis/NN -PUNC- AmB/NNP (r_appos) B/NNP (r_pobj) with/IN (r_prep) developed/VBD (l_prep) for/IN (l_pobj) coccidioidomycosis/NN
D000666_D002311 CID B/NNP (r_compound) therapy/NN (r_pobj) to/IN (r_prep) related/VBN (r_acl) cardiomyopathy/NN -PUNC- B/NNP (r_pobj) with/IN (r_prep) developed/VBD (l_dobj) failure/NN (l_amod) cardiomyopathy/NN -PUNC- AmB/NNP (r_appos) B/NNP (r_pobj) with/IN (r_prep) developed/VBD (l_dobj) failure/NN (l_amod) cardiomyopathy/NN
D000666_D006333 CID B/NNP (r_pobj) with/IN (r_prep) developed/VBD (l_dobj) failure/NN -PUNC- AmB/NNP (r_appos) B/NNP (r_pobj) with/IN (r_prep) developed/VBD (l_dobj) failure/NN -PUNC- AmB./NN (r_pobj) for/IN (r_prep) substituted/VBN (r_advcl) resolved/VBD (r_acl) abnormalities/NNS (l_conj) failure/NN
D000666_D064420 NONE AmB./NN (r_pobj) of/IN (r_prep) toxicity/NN
C101425_D006333 NONE posaconazole/NN (r_nsubjpass) substituted/VBN (r_advcl) resolved/VBD (r_acl) abnormalities/NNS (l_conj) failure/NN
12639165
D013988_D056486 CID Ticlopidine/NNP (r_npadvmod) induced/VBN (r_amod) hepatitis/NN -PUNC- ticlopidine/NN (r_npadvmod) induced/VBN (r_amod) hepatitis/NN -PUNC- ticlopidine/NN (r_advmod) receiving/VBG (r_pcomp) after/IN (r_prep) developed/VBD (l_dobj) hepatitis/NN -PUNC- ticlopidine/NN (r_advmod) complication/NN (r_attr) is/VBZ (l_nsubj) hepatitis/NN -PUNC- ticlopidine/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) following/VBG (r_prep) developed/VBD (l_conj) showed/VBD (l_dobj) characteristics/NNS (l_prep) of/IN (l_pobj) hepatitis/NN -PUNC- ticlopidine/NN (r_pobj) of/IN (r_prep) effect/NN (r_attr) is/VBZ (l_nsubj) hepatitis/NN
D013988_D002779 CID Ticlopidine/NNP (r_npadvmod) induced/VBN (r_amod) hepatitis/NN -PUNC- ticlopidine/NN (r_npadvmod) induced/VBN (r_amod) hepatitis/NN -PUNC- ticlopidine/NN (r_advmod) receiving/VBG (r_pcomp) after/IN (r_prep) developed/VBD (l_dobj) hepatitis/NN -PUNC- ticlopidine/NN (r_advmod) complication/NN (r_attr) is/VBZ (l_nsubj) hepatitis/NN -PUNC- ticlopidine/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) following/VBG (r_prep) developed/VBD (l_conj) showed/VBD (l_dobj) characteristics/NNS (l_prep) of/IN (l_pobj) hepatitis/NN -PUNC- ticlopidine/NN (r_npadvmod) induced/VBN (r_amod) cholestasis/NN -PUNC- ticlopidine/NN (r_pobj) of/IN (r_prep) effect/NN (r_attr) is/VBZ (l_nsubj) hepatitis/NN
D013988_D007565 CID ticlopidine/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) following/VBG (r_prep) developed/VBD (l_dobj) jaundice/NN
19299179
D015662_D011020 NONE trimoxazole/NN (r_amod) treatment/NN (l_prep) for/IN (l_pobj) pneumonia/NN -PUNC- trimoxazole/NN (r_punct) ./. (r_punct) treated/VBN (l_nsubjpass) pneumonia/NN -PUNC- trimoxazole/NN (r_punct) ./. (r_punct) treated/VBN (l_nsubjpass) pneumonia/NN (l_appos) PCP/NNP -PUNC- trimoxazole/NN (r_amod) treatment/NN (l_prep) for/IN (l_pobj) PCP/NNP
D015662_D002780 CID trimoxazole/NN (r_amod) treatment/NN (r_dobj) report/VBP (l_dobj) cases/NNS (l_prep) of/IN (l_pobj) patients/NNS (l_relcl) developed/VBD (l_dobj) cholestasis/NN
D015662_D015658 NONE trimoxazole/NN (r_amod) treatment/NN (l_prep) for/IN (l_pobj) pneumonia/NN (l_prep) in/IN (l_pobj) patients/NNS (l_amod) infected/VBN -PUNC- trimoxazole/NN (r_punct) ./. (r_punct) treated/VBN (l_nsubjpass) pneumonia/NN (l_appos) infection/NN (l_prep) in/IN (l_pobj) individuals/NNS (l_amod) infected/VBN -PUNC- trimoxazole/NN (r_amod) treatment/NN (r_dobj) report/VBP (l_dobj) cases/NNS (l_prep) of/IN (l_pobj) patients/NNS (l_amod) infected/VBN
D015662_D008100 NONE trimoxazole/NN (r_amod) treatment/NN (r_dobj) report/VBP (l_dobj) cases/NNS (l_conj) in/IN (l_pobj) lesions/NNS (l_acl) mimicking/VBG (l_dobj) formation/NN (l_compound) abscess/NN
D015662_D002779 NONE trimoxazole/NN (r_amod) treatment/NN (r_pobj) after/IN (r_prep) cholestasis/NN
D015662_D009894 NONE trimoxazole/NN (r_punct) ./. (r_punct) treated/VBN (l_nsubjpass) pneumonia/NN (l_appos) infection/NN
11419773
D002110_D014693 CID caffeine/NN (r_pobj) of/IN (r_prep) concentration/NN (r_dobj) containing/VBG (r_acl) drink/NN (r_dobj) consuming/VBG (r_pcomp) after/IN (r_prep) developed/VBD (l_dobj) fibrillation/NN
D002110_D008945 NONE caffeine/NN (r_pobj) of/IN (r_prep) concentration/NN (r_dobj) containing/VBG (r_acl) drink/NN (r_dobj) consuming/VBG (r_pcomp) after/IN (r_prep) developed/VBD (r_relcl) woman/NN (l_prep) with/IN (l_pobj) prolapse/NN
D002110_D001145 NONE Caffeine/NN (r_nsubj) induced/VBN (r_amod) arrhythmia/NN
17261653
D003000_D001919 CID Clonidine/NNP (r_npadvmod) induced/VBN (l_dobj) bradycardia/NN
20470218
D008727_D020521 NONE methotrexate/NN (r_compound) toxicity/NN (r_conj) syndrome/NN (l_conj) stroke/NN
D008727_D004833 NONE methotrexate/NN (r_compound) toxicity/NN (r_conj) syndrome/NN (l_conj) stroke/NN (l_conj) epilepsy/NN
D008727_D056784 NONE methotrexate/NN (r_compound) toxicity/NN (r_conj) syndrome/NN (l_compound) leukoencephalopathy/JJ
D008727_D007177 NONE methotrexate/NN (r_compound) toxicity/NN (l_conj) syndrome/NN (l_prep) of/IN (l_pobj) secretion/NN
D008727_D064420 NONE methotrexate/NN (r_compound) toxicity/NN
7265370
D014223_D006973 NONE triamterene/JJ (r_compound) nephrolithiasis/NN (r_pobj) of/IN (r_prep) case/NN (r_nsubjpass) reported/VBN (l_prep) after/IN (l_pobj) years/NNS (l_prep) for/IN (l_pobj) hypertension/NN
C020743_D053040 NONE dyazide/RB (r_compound) therapy/NN (r_dobj) complicating/VBG (l_nsubj) nephrolithiasis/JJ -PUNC- triamterene/JJ (r_compound) therapy/NN (r_pobj) of/IN (r_prep) years/NNS (r_pobj) after/IN (r_prep) reported/VBN (l_nsubjpass) case/NN (l_prep) of/IN (l_pobj) nephrolithiasis/NN
C020743_D006973 NONE triamterene/JJ (r_compound) therapy/NN (r_pobj) of/IN (r_prep) years/NNS (l_prep) for/IN (l_pobj) hypertension/NN
D014223_D053040 CID Triamterene/JJ (r_compound) nephrolithiasis/JJ -PUNC- triamterene/JJ (r_compound) nephrolithiasis/NN -PUNC- triamterene/JJ (r_compound) nephrolithiasis/NN
7444978
D013307_D020258 NONE streptomycin/NNS (r_pobj) of/IN (r_prep) effects/NNS (l_amod) neurotoxic/JJ
D013307_D004409 CID streptomycin/NNS (r_pobj) to/IN (r_prep) sensitive/JJ (r_acomp) is/VBZ (r_ccomp) indicating/VBG (r_advcl) occurred/VBD (l_ccomp) occurred/VBD (l_nsubj) movements/NNS -PUNC- streptomycin/NNS (l_prep) than/IN (l_pobj) site/NN (l_amod) responsible/JJ (l_prep) for/IN (l_pobj) dyskinesias/NNS
D013307_D003638 CID streptomycin/NNS (r_pobj) to/IN (r_prep) sensitive/JJ (r_acomp) is/VBZ (r_ccomp) indicating/VBG (r_advcl) occurred/VBD (l_ccomp) occurred/VBD (l_nsubj) movements/NNS (l_conj) deafness/NN
12627929
D013792_D054556 CID thalidomide/NN (r_conj) docetaxel/NNS (r_pobj) of/IN (r_prep) combination/NN (r_pobj) with/IN (r_prep) thromboembolism/NN -PUNC- thalidomide/NN (r_pobj) with/IN (r_prep) combination/NN (r_pobj) in/IN (r_conj) alone/RB (r_advmod) treated/VBN (r_relcl) cancer/NN (r_pobj) with/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) frequency/NN (l_prep) of/IN (l_pobj) thromboembolism/NN -PUNC- thalidomide/NN (r_pobj) with/IN (r_prep) combination/NN (r_pobj) in/IN (r_conj) alone/RB (r_advmod) treated/VBN (r_relcl) cancer/NN (r_pobj) with/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) frequency/NN (l_prep) of/IN (l_pobj) thromboembolism/NN (l_appos) VTE/NNP -PUNC- thalidomide/NN (r_conj) 9/CD (r_nsubj) developed/VBD (r_advcl) developed/VBN (l_dobj) VTE/NNP -PUNC- thalidomide/NN (r_conj) 9/CD (r_nsubj) developed/VBD (l_dobj) VTE/NNP -PUNC- thalidomide/NN (r_pobj) of/IN (r_prep) addition/NN (r_nsubj) increases/VBZ (l_dobj) frequency/NN (l_prep) of/IN (l_pobj) VTE/NNP
C067311_D011471 NONE docetaxel/NNS (r_pobj) of/IN (r_prep) combination/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) cancer/NN -PUNC- docetaxel/NNS (r_pobj) with/IN (r_prep) treated/VBN (r_relcl) cancer/NN -PUNC- docetaxel/NNS (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) cancer/NN
C067311_D054556 CID docetaxel/NNS (r_pobj) of/IN (r_prep) combination/NN (r_pobj) with/IN (r_prep) thromboembolism/NN -PUNC- docetaxel/NNS (r_pobj) with/IN (r_prep) treated/VBN (r_relcl) cancer/NN (r_pobj) with/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) frequency/NN (l_prep) of/IN (l_pobj) thromboembolism/NN -PUNC- docetaxel/NNS (r_pobj) with/IN (r_prep) treated/VBN (r_relcl) cancer/NN (r_pobj) with/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) frequency/NN (l_prep) of/IN (l_pobj) thromboembolism/NN (l_appos) VTE/NNP -PUNC- docetaxel/NNS (r_dobj) received/VBD (r_relcl) patients/NNS (r_pobj) of/IN (r_prep) None/NN (r_nsubj) developed/VBN (l_dobj) VTE/NNP -PUNC- docetaxel/NNS (r_dobj) received/VBD (r_relcl) patients/NNS (r_pobj) of/IN (r_prep) None/NN (r_nsubj) developed/VBN (l_advcl) developed/VBD (l_dobj) VTE/NNP -PUNC- docetaxel/NNS (r_dobj) received/VBD (r_relcl) patients/NNS (r_pobj) of/IN (r_prep) 9/CD (r_nsubj) developed/VBD (r_advcl) developed/VBN (l_dobj) VTE/NNP -PUNC- docetaxel/NNS (r_dobj) received/VBD (r_relcl) patients/NNS (r_pobj) of/IN (r_prep) 9/CD (r_nsubj) developed/VBD (l_dobj) VTE/NNP -PUNC- docetaxel/NNS (r_relcl) addition/NN (r_nsubj) increases/VBZ (l_dobj) frequency/NN (l_prep) of/IN (l_pobj) VTE/NNP
D013792_D011471 NONE thalidomide/NN (r_conj) docetaxel/NNS (r_pobj) of/IN (r_prep) combination/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) cancer/NN -PUNC- thalidomide/NN (r_pobj) with/IN (r_prep) combination/NN (r_pobj) in/IN (r_conj) alone/RB (r_advmod) treated/VBN (r_relcl) cancer/NN -PUNC- thalidomide/NN (r_pobj) of/IN (r_prep) addition/NN (l_relcl) docetaxel/NNS (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) cancer/NN
18221780
D016202_D010146 NONE NMDA/NNP (r_compound) enhancement/NN (r_pobj) in/IN (r_prep) differences/NNS (l_prep) in/IN (l_pobj) model/NN (l_prep) of/IN (l_pobj) pain/NN -PUNC- NMDA/NNP (r_compound) antagonists/NNS (r_pobj) between/IN (r_prep) interaction/NN (l_prep) in/IN (l_pobj) model/NN (l_compound) pain/NN
D009020_D010146 NONE morphine/NN (r_compound) antihyperalgesia/NN (r_pobj) of/IN (r_prep) enhancement/NN (r_pobj) in/IN (r_prep) differences/NNS (l_prep) in/IN (l_pobj) model/NN (l_prep) of/IN (l_pobj) pain/NN -PUNC- morphine/NN (r_conj) antagonists/NNS (r_pobj) between/IN (r_prep) interaction/NN (l_prep) in/IN (l_pobj) model/NN (l_compound) pain/NN
D002211_D059787 NONE capsaicin/NN (r_compound) model/NN (r_pobj) in/IN (r_prep) differences/NNS (l_appos) comparisons/NNS (l_prep) to/IN (l_pobj) models/NNS (l_prep) of/IN (l_pobj) pain/NN
D002211_D010146 NONE capsaicin/NN (r_compound) model/NN (l_prep) of/IN (l_pobj) pain/NN
D003915_D059787 NONE dextromethorphan/NNP (r_pobj) by/IN (r_prep) Enhancement/NN (r_nsubjpass) seen/VBN (l_prep) in/IN (l_pobj) males/NNS (l_prep) in/IN (l_pobj) models/NNS (l_compound) pain/NN
D016202_D059787 NONE NMDA/NNP (r_compound) enhancement/NN (r_pobj) in/IN (r_prep) differences/NNS (l_appos) comparisons/NNS (l_prep) to/IN (l_pobj) models/NNS (l_prep) of/IN (l_pobj) pain/NN -PUNC- aspartate/NNP (r_nmod) antagonists/NNS (r_nsubj) enhance/VBP (l_prep) In/IN (l_pobj) models/NNS (l_compound) pain/NN -PUNC- NMDA/NNP (r_nmod) antagonists/NNS (r_nsubj) enhance/VBP (l_prep) In/IN (l_pobj) models/NNS (l_compound) pain/NN -PUNC- NMDA/NNP (r_compound) antagonists/NNS (r_pobj) between/IN (r_prep) interaction/NN (l_prep) in/IN (l_pobj) model/NN (l_relcl) distinguished/VBN (l_prep) from/IN (l_pobj) those/DT (l_acl) observed/VBN (l_prep) in/IN (l_pobj) models/NNS (l_compound) pain/NN
D002211_D006930 CID capsaicin/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubjpass) hyperalgesia/NN
D009020_D059787 NONE morphine/NN (r_compound) antihyperalgesia/NN (r_pobj) of/IN (r_prep) enhancement/NN (r_pobj) in/IN (r_prep) differences/NNS (l_appos) comparisons/NNS (l_prep) to/IN (l_pobj) models/NNS (l_prep) of/IN (l_pobj) pain/NN -PUNC- morphine/NN (r_pobj) of/IN (r_prep) effects/NNS (r_dobj) enhance/VBP (l_prep) In/IN (l_pobj) models/NNS (l_compound) pain/NN -PUNC- morphine/NN (r_compound) antinociception/NN (r_pobj) of/IN (r_prep) Enhancement/NN (r_nsubjpass) seen/VBN (l_prep) in/IN (l_pobj) males/NNS (l_prep) in/IN (l_pobj) models/NNS (l_compound) pain/NN -PUNC- morphine/NN (r_conj) antagonists/NNS (r_pobj) between/IN (r_prep) interaction/NN (l_prep) in/IN (l_pobj) model/NN (l_relcl) distinguished/VBN (l_prep) from/IN (l_pobj) those/DT (l_acl) observed/VBN (l_prep) in/IN (l_pobj) models/NNS (l_compound) pain/NN
20067456
D016642_D012735 NONE bupropion/NN (l_prep) on/IN (l_pobj) dysfunction/NN -PUNC- bupropion/NN (l_prep) on/IN (l_pobj) dysfunction/NN -PUNC- bupropion/NN (l_prep) on/IN (l_pobj) dysfunction/NN (l_appos) SD/NN -PUNC- bupropion/NN (r_pobj) of/IN (r_prep) safety/NN (r_dobj) determine/VB (r_csubj) induced/VBN (l_advcl) is/VBZ (l_nsubj) SD/NN -PUNC- Bupropion/NN (r_nsubj) is/VBZ (l_attr) treatment/NN (l_prep) for/IN (l_pobj) SD/NN
D017367_D012735 NONE inhibitor/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) dysfunction/NN -PUNC- inhibitor/NN (r_pobj) by/IN (r_agent) induced/VBN (l_csubj) determine/VB (l_dobj) safety/NN (l_prep) of/IN (l_pobj) bupropion/NN (l_prep) on/IN (l_pobj) dysfunction/NN -PUNC- inhibitor/NN (r_pobj) by/IN (r_agent) induced/VBN (l_csubj) determine/VB (l_dobj) safety/NN (l_prep) of/IN (l_pobj) bupropion/NN (l_prep) on/IN (l_pobj) dysfunction/NN (l_appos) SD/NN -PUNC- inhibitor/NN (r_pobj) by/IN (r_agent) induced/VBN (l_advcl) is/VBZ (l_nsubj) SD/NN -PUNC- SSRI/NNP (r_appos) inhibitor/NN (r_pobj) by/IN (r_agent) induced/VBN (l_csubj) determine/VB (l_dobj) safety/NN (l_prep) of/IN (l_pobj) bupropion/NN (l_prep) on/IN (l_pobj) dysfunction/NN -PUNC- SSRI/NNP (r_appos) inhibitor/NN (r_pobj) by/IN (r_agent) induced/VBN (l_csubj) determine/VB (l_dobj) safety/NN (l_prep) of/IN (l_pobj) bupropion/NN (l_prep) on/IN (l_pobj) dysfunction/NN (l_appos) SD/NN -PUNC- SSRI/NNP (r_appos) inhibitor/NN (r_pobj) by/IN (r_agent) induced/VBN (l_advcl) is/VBZ (l_nsubj) SD/NN -PUNC- SSRIs/NNS (r_pobj) of/IN (r_prep) effect/NN (r_attr) is/VBZ (r_advcl) induced/VBN (l_csubj) determine/VB (l_dobj) safety/NN (l_prep) of/IN (l_pobj) bupropion/NN (l_prep) on/IN (l_pobj) dysfunction/NN -PUNC- SSRIs/NNS (r_pobj) of/IN (r_prep) effect/NN (r_attr) is/VBZ (r_advcl) induced/VBN (l_csubj) determine/VB (l_dobj) safety/NN (l_prep) of/IN (l_pobj) bupropion/NN (l_prep) on/IN (l_pobj) dysfunction/NN (l_appos) SD/NN -PUNC- SSRIs/NNS (r_pobj) of/IN (r_prep) effect/NN (r_attr) is/VBZ (l_nsubj) SD/NN -PUNC- SSRI/NNP (r_pobj) of/IN (r_prep) type/NN (r_appos) SD/NN -PUNC- SSRIs/NNS (r_pobj) by/IN (r_agent) induced/VBN (r_acl) treatment/NN (l_prep) for/IN (l_pobj) SD/NN
17242861
D010862_D004833 CID pilocarpine/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS (l_appos) model/NN (l_prep) of/IN (l_pobj) epilepsy/NN
D010862_D012640 NONE pilocarpine/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS -PUNC- pilocarpine/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS (r_pobj) to/IN (r_prep) susceptibility/NN (r_pobj) for/IN (r_prep) QTLs/NNS (r_nsubjpass) reported/VBN (l_conj) used/VBN (l_xcomp) localize/VB (l_dobj) genes/NNS (l_compound) susceptibility/NN (l_compound) seizure/NN -PUNC- pilocarpine/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS -PUNC- pilocarpine/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS
17241784
D019821_-1 NONE Statins/NNS (r_nsubj) cause/VB (l_ccomp) myopathy/NN (l_conj) hyperCKaemia/NN
D019821_D009135 CID statin/NN (r_compound) therapy/NN (r_pobj) with/IN (r_prep) associated/VBD (r_acl) myopathy/NNS -PUNC- Statins/NNS (r_nsubj) cause/VB (l_ccomp) myopathy/NN -PUNC- statins/NNS (r_nsubj) induce/VB (l_dobj) myopathy/NN -PUNC- statins/NNS (r_nsubj) initiate/VB (l_dobj) myopathy/NN -PUNC- statins/NNS (r_pobj) by/IN (r_prep) induction/NN (r_dobj) involve/VB (r_conj) is/VBZ (l_nsubj) mechanism/NN (l_prep) of/IN (l_pobj) myopathy/NN
18182964
D008774_D001289 NONE methylphenidate/NN (l_prep) with/IN (l_pobj) disorder/NN -PUNC- methylphenidate/NN (l_prep) with/IN (l_pobj) disorder/NN (l_appos) ADHD/NNP -PUNC- methylphenidate/NN (r_conj) clonidine/NN (r_xcomp) assigned/VBN (l_nsubjpass) children/NNS (l_prep) with/IN (l_pobj) ADHD/NNP -PUNC- methylphenidate/NN (r_conj) clonidine/NN (r_conj) methylphenidate/NN (r_conj) clonidine/NN (r_xcomp) assigned/VBN (l_nsubjpass) children/NNS (l_prep) with/IN (l_pobj) ADHD/NNP -PUNC- methylphenidate/NN (r_pobj) with/IN (r_conj) used/VBN (r_acl) Clonidine/NNP (r_nsubj) appears/VBZ (l_conj) tolerated/VBN (l_prep) in/IN (l_pobj) ADHD/NNP
D003000_D001919 CID clonidine/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) subjects/NNS (r_pobj) in/IN (r_prep) incidents/NNS (l_prep) of/IN (l_pobj) bradycardia/NN -PUNC- clonidine/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) those/DT (r_pobj) with/IN (r_prep) compared/VBN (r_prep) treated/VBN (r_acl) subjects/NNS (r_pobj) in/IN (r_prep) incidents/NNS (l_prep) of/IN (l_pobj) bradycardia/NN -PUNC- clonidine/NN (r_dobj) prescribing/VBG (r_acl) Physicians/NNS (r_nsubj) monitor/VB (l_prep) for/IN (l_pobj) bradycardia/NN
D003000_D001289 NONE Clonidine/NNP (l_prep) for/IN (l_pobj) disorder/NN -PUNC- clonidine/NN (r_pobj) of/IN (r_prep) safety/NN (r_dobj) examine/VB (r_csubj) used/VBN (l_conj) with/IN (l_pobj) methylphenidate/NN (l_prep) with/IN (l_pobj) disorder/NN -PUNC- clonidine/NN (r_pobj) of/IN (r_prep) safety/NN (r_dobj) examine/VB (r_csubj) used/VBN (l_conj) with/IN (l_pobj) methylphenidate/NN (l_prep) with/IN (l_pobj) disorder/NN (l_appos) ADHD/NNP -PUNC- clonidine/NN (r_xcomp) assigned/VBN (l_nsubjpass) children/NNS (l_prep) with/IN (l_pobj) ADHD/NNP -PUNC- clonidine/NN (r_conj) methylphenidate/NN (r_conj) clonidine/NN (r_xcomp) assigned/VBN (l_nsubjpass) children/NNS (l_prep) with/IN (l_pobj) ADHD/NNP -PUNC- Clonidine/NNP (r_nsubj) appears/VBZ (l_conj) tolerated/VBN (l_prep) in/IN (l_pobj) ADHD/NNP
D003000_D006970 NONE clonidine/NN (r_pobj) on/IN (r_prep) was/VBD (l_nsubj) Drowsiness/NN -PUNC- clonidine/NN (r_dobj) prescribing/VBG (r_acl) Physicians/NNS (r_nsubj) monitor/VB (l_conj) advise/VB (l_dobj) patients/NNS (l_prep) about/IN (l_pobj) likelihood/NN (l_prep) of/IN (l_pobj) drowsiness/NN
2054792
D004317_D005334 NONE adriamycin/NNS (r_pobj) of/IN (r_prep) Effect/NN (l_acl) combined/VBN (l_prep) with/IN (l_pobj) hyperthermia/NN -PUNC- Adriamycin/NNP (r_npadvmod) mediated/VBN (r_amod) activity/NN (l_conj) toxicities/NNS (l_prep) by/IN (l_pobj) hyperthermia/NN -PUNC- Adriamycin/NNP (r_npadvmod) mediated/VBN (r_amod) activity/NN (r_dobj) enhanced/VBD (l_nsubj) hyperthermia/NN -PUNC- Adriamycin/NNP (r_npadvmod) mediated/VBN (r_amod) effect/NN (r_dobj) enhances/VBZ (l_nsubj) hyperthermia/NN
D004317_D009369 NONE adriamycin/NNS (r_pobj) of/IN (r_prep) Effect/NN (l_acl) combined/VBN (l_prep) on/IN (l_pobj) tumor/NN
D004317_D064420 NONE Adriamycin/NNP (r_npadvmod) mediated/VBN (r_amod) activity/NN (l_conj) toxicities/NNS -PUNC- Adriamycin/NNP (r_npadvmod) mediated/VBN (r_amod) effect/NN (r_dobj) enhances/VBZ (r_advcl) increased/VBN (l_nsubjpass) toxicity/NN
17919553
C106791_D064420 NONE telithromycin/NNS (r_nsubj) was/VBD (l_prep) Based/VBN (l_prep) on/IN (l_pobj) score/NN (l_prep) on/IN (l_pobj) scale/NN (l_compound) probability/NN (l_compound) reaction/NN
C106791_D056486 CID telithromycin/NNS (r_relcl) exposure/NN (r_pobj) after/IN (r_prep) attack/NN (l_compound) hepatitis/NNP -PUNC- telithromycin/NNS (r_compound) usage/NN (r_pobj) after/IN (r_prep) occurred/VBD (l_ccomp) suffered/VBN (l_dobj) episode/NN (l_prep) of/IN (l_pobj) hepatitis/NN -PUNC- telithromycin/NNS (r_nsubj) was/VBD (l_attr) cause/NN (l_prep) of/IN (l_pobj) hepatitis/NN -PUNC- telithromycin/NNS (r_nsubj) was/VBD (l_conj) suggested/VBD (l_dobj) hepatitis/NN -PUNC- telithromycin/NNS (r_dobj) prescribed/VBD (r_relcl) physician/NN (r_pobj) to/IN (r_prep) communicated/VBN (r_advcl) avoided/VBN (l_nsubjpass) Recurrence/NN (l_prep) of/IN (l_pobj) attack/NN (l_compound) hepatitis/NN -PUNC- telithromycin/NNS (r_pobj) of/IN (r_prep) administration/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) case/NN (l_prep) of/IN (l_pobj) hepatitis/NN
20520283
C522667_D001714 NONE Asenapine/NNP (r_nsubjpass) approved/VBN (l_prep) in/IN (l_pobj) adults/NNS (l_prep) for/IN (l_conj) of/IN (l_pobj) episodes/NNS (l_amod) manic/JJ -PUNC- Asenapine/NNP (r_nsubjpass) approved/VBN (l_prep) in/IN (l_pobj) adults/NNS (l_prep) for/IN (l_conj) of/IN (l_pobj) episodes/NNS (l_acl) associated/VBN (l_prep) with/IN (l_pobj) disorder/NN
C522667_D012559 NONE asenapine/NN (r_pobj) of/IN (r_prep) Efficacy/NN (l_prep) in/IN (l_pobj) trial/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) exacerbation/NN (l_prep) of/IN (l_pobj) schizophrenia/NN -PUNC- Asenapine/NNP (r_nsubjpass) approved/VBN (l_prep) in/IN (l_pobj) adults/NNS (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) schizophrenia/NN -PUNC- asenapine/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) to/IN (r_prep) assigned/VBN (l_nsubjpass) patients/NNS (l_prep) with/IN (l_pobj) schizophrenia/NN -PUNC- asenapine/NN (r_dep) assigned/VBN (l_nsubjpass) patients/NNS (l_prep) with/IN (l_pobj) schizophrenia/NN
D006220_D001480 CID haloperidol/NN (r_conj) BID/NN (r_pobj) at/IN (r_prep) %/NN (r_conj) %/NN (r_appos) %/NN (r_pobj) in/IN (r_prep) occurred/VBD (r_advcl) reported/VBD (l_nsubj) symptoms/NNS -PUNC- haloperidol/NN (r_conj) asenapine/NN (r_pobj) with/IN (r_prep) similar/JJ (r_acomp) was/VBD (r_ccomp) indicated/VBD (r_ccomp) seen/VBN (l_prep) in/IN (l_pobj) AEs/NNS (l_appos) symptoms/NNS
D006220_D012559 NONE haloperidol/NN (r_npadvmod) controlled/VBN (r_amod) trial/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) exacerbation/NN (l_prep) of/IN (l_pobj) schizophrenia/NN -PUNC- haloperidol/NN (r_conj) placebo/NN (r_conj) BID/NN (r_pobj) at/IN (r_prep) asenapine/NN (r_dep) assigned/VBN (l_nsubjpass) patients/NNS (l_prep) with/IN (l_pobj) schizophrenia/NN
C522667_D001480 CID asenapine/NN (r_pobj) of/IN (r_prep) %/NN (r_conj) %/NN (r_appos) %/NN (r_pobj) in/IN (r_prep) occurred/VBD (r_advcl) reported/VBD (l_nsubj) symptoms/NNS -PUNC- asenapine/NN (r_pobj) with/IN (r_prep) similar/JJ (r_acomp) was/VBD (r_ccomp) indicated/VBD (r_ccomp) seen/VBN (l_prep) in/IN (l_pobj) AEs/NNS (l_appos) symptoms/NNS
C522667_D011618 NONE Asenapine/NNP (r_nsubjpass) approved/VBN (l_prep) in/IN (l_pobj) adults/NNS (l_prep) for/IN (l_conj) of/IN (l_pobj) episodes/NNS (l_acl) associated/VBN (l_prep) with/IN (l_pobj) disorder/NN (l_prep) with/IN (l_conj) without/IN (l_pobj) features/NNS (l_amod) psychotic/JJ
16167916
D020849_D054556 CID raloxifene/NN (r_compound) treatment/NN (r_pobj) to/IN (r_pcomp) due/IN (r_amod) thromboembolism/NN
1436384
D000596_D020258 NONE acid/NN (r_compound) antagonist/NN (r_appos) LY274614/NNP (r_pobj) by/IN (r_prep) rodents/NNS (r_pobj) in/IN (r_prep) neurons/NNS (r_pobj) toward/IN (r_prep) neurotoxicity/NN
C070935_D020258 NONE LY274614/NNP (r_pobj) by/IN (r_prep) rodents/NNS (r_pobj) in/IN (r_prep) neurons/NNS (r_pobj) toward/IN (r_prep) neurotoxicity/NN -PUNC- LY274614/NNP (r_nsubj) is/VBZ (r_conj) involves/VBZ (l_nsubj) effect/NN (l_amod) neurotoxic/JJ
D004298_D020258 NONE dopamine/NN (r_compound) neurons/NNS (r_pobj) toward/IN (r_prep) neurotoxicity/NN -PUNC- dopamine/NN (r_compound) neurons/NNS (r_pobj) toward/IN (r_prep) compounds/NNS (r_pobj) of/IN (r_prep) effect/NN (l_amod) neurotoxic/JJ
D000661_D020258 CID amphetamine/NN (r_npadvmod) induced/VBN (r_amod) neurotoxicity/NN -PUNC- amphetamine/NN (r_nmod) compounds/NNS (r_pobj) of/IN (r_prep) effect/NN (l_amod) neurotoxic/JJ
D016202_D020258 NONE NMDA/NNP (r_compound) receptors/NNS (r_dobj) involves/VBZ (l_nsubj) effect/NN (l_amod) neurotoxic/JJ -PUNC- NMDA/NNP (r_compound) antagonist/NN (r_attr) is/VBZ (r_conj) involves/VBZ (l_nsubj) effect/NN (l_amod) neurotoxic/JJ
8302922
D000527_D007022 CID E1/NNP (r_pobj) during/IN (r_prep) flow/NN (r_nsubj) induced/VBD (l_dobj) hypotension/NN -PUNC- E1/NNP (r_nmod) PGE1/NNP (r_pobj) of/IN (r_prep) effect/NN (r_dobj) evaluate/VB (r_csubj) induced/VBN (l_dobj) hypotension/NN -PUNC- PGE1/NNP (r_pobj) of/IN (r_prep) effect/NN (r_dobj) evaluate/VB (r_csubj) induced/VBN (l_dobj) hypotension/NN -PUNC- PGE1/NNP (r_dobj) starting/VBG (r_pcomp) After/IN (r_prep) decreased/VBD (l_conj) remained/VBD (l_nsubj) degree/NN (l_prep) of/IN (l_pobj) hypotension/NN -PUNC- PGE1/NNP (r_pobj) to/IN (r_pcomp) due/IN (r_prep) degree/NN (l_prep) of/IN (l_pobj) hypotension/NN -PUNC- PGE1/NNP (r_nsubj) be/VB (l_acomp) preferable/JJ (l_xcomp) TMP/VB (l_prep) for/IN (l_pobj) anaesthesia/NN (l_amod) hypotensive/JJ
D007530_D007022 NONE isoflurane/JJ (r_amod) anaesthesia/NN (r_pobj) under/IN (r_prep) fusion/NN (r_dobj) underwent/VBD (r_relcl) patients/NNS (r_pobj) in/IN (r_prep) using/VBG (r_advcl) measured/VBN (l_advcl) induced/VBN (l_dobj) hypotension/NN
D014294_D007022 CID trimethaphan/RB (r_conj) E1/NNP (r_pobj) during/IN (r_prep) flow/NN (r_nsubj) induced/VBD (l_dobj) hypotension/NN -PUNC- trimethaphan/NN (r_conj) PGE1/NNP (r_pobj) of/IN (r_prep) effect/NN (r_dobj) evaluate/VB (r_csubj) induced/VBN (l_dobj) hypotension/NN -PUNC- TMP/NNP (r_appos) trimethaphan/NN (r_conj) PGE1/NNP (r_pobj) of/IN (r_prep) effect/NN (r_dobj) evaluate/VB (r_csubj) induced/VBN (l_dobj) hypotension/NN -PUNC- TMP/NNP (r_conj) PGE1/NNP (r_dobj) starting/VBG (r_pcomp) After/IN (r_prep) decreased/VBD (l_conj) remained/VBD (l_nsubj) degree/NN (l_prep) of/IN (l_pobj) hypotension/NN -PUNC- TMP/VB (l_prep) for/IN (l_pobj) anaesthesia/NN (l_amod) hypotensive/JJ -PUNC- TMP/NNP (r_nsubj) decreased/VBD (r_advcl) be/VB (l_acomp) preferable/JJ (l_xcomp) TMP/VB (l_prep) for/IN (l_pobj) anaesthesia/NN (l_amod) hypotensive/JJ
16574712
D018817_D008569 NONE MDMA/NNP (r_pobj) of/IN (r_prep) users/NNS (r_pobj) in/IN (r_prep) reported/VBN (l_nsubjpass) deficits/NNS -PUNC- 3,4-methylenedioxymethamphetamine/CD (r_intj) MDMA/NNP (r_pobj) of/IN (r_prep) users/NNS (r_pobj) in/IN (r_prep) reported/VBN (l_nsubjpass) deficits/NNS -PUNC- ecstasy/NN (r_appos) MDMA/NNP (r_pobj) of/IN (r_prep) users/NNS (r_pobj) in/IN (r_prep) reported/VBN (l_nsubjpass) deficits/NNS
D018817_D003072 CID MDMA/NN (r_compound) users/NNS (r_nsubj) show/VBP (l_dobj) impairments/NNS (l_acl) coupled/VBN (l_prep) with/IN (l_pobj) processes/NNS
17147461
D000809_D011507 NONE angiotensin/NN (r_npadvmod) converting/VBG (r_amod) inhibitors/NNS (r_pobj) of/IN (r_prep) use/NN (r_conj) monitoring/NN (l_prep) of/IN (l_pobj) proteinuria/NN -PUNC- angiotensin/NN (r_npadvmod) converting/VBG (r_amod) inhibitors/NNS (r_pobj) of/IN (r_prep) use/NN (r_conj) monitoring/NN (l_advcl) occurs/VBZ (l_nsubj) proteinuria/NN
D020123_D007674 CID Sirolimus/NNP (r_npadvmod) associated/VBN (r_amod) proteinuria/NN (l_conj) dysfunction/NN -PUNC- Sirolimus/NNP (r_nsubj) represents/VBZ (l_dobj) advance/NN (l_prep) in/IN (l_pobj) prevention/NN (l_prep) of/IN (l_pobj) rejection/NN (l_conj) nephropathy/NN -PUNC- sirolimus/NN (r_nsubj) share/VB (r_advcl) designated/VBN (l_oprd) drug/NN (l_amod) nephrotoxic/JJ
D020123_D058186 NONE sirolimus/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) proteinuria/NN (l_conj) dysfunction/NN -PUNC- sirolimus/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) dysfunction/NN
D000804_D011507 NONE II/CD (r_compound) blockers/NNS (r_conj) inhibitors/NNS (r_pobj) of/IN (r_prep) use/NN (r_conj) monitoring/NN (l_prep) of/IN (l_pobj) proteinuria/NN -PUNC- II/CD (r_compound) blockers/NNS (r_conj) inhibitors/NNS (r_pobj) of/IN (r_prep) use/NN (r_conj) monitoring/NN (l_advcl) occurs/VBZ (l_nsubj) proteinuria/NN
D020123_D011507 CID Sirolimus/NNP (r_npadvmod) associated/VBN (r_amod) proteinuria/NN -PUNC- sirolimus/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) proteinuria/NN -PUNC- sirolimus/NN (r_npadvmod) associated/VBN (r_amod) proteinuria/NN -PUNC- sirolimus/NN (r_pobj) of/IN (r_prep) effects/NNS (r_pobj) of/IN (r_prep) knowledge/NN (r_pobj) by/IN (r_agent) minimised/VBN (l_dep) use/NN (l_appos) monitoring/NN (l_prep) of/IN (l_pobj) proteinuria/NN -PUNC- sirolimus/NN (r_pobj) of/IN (r_prep) effects/NNS (r_pobj) of/IN (r_prep) knowledge/NN (r_pobj) by/IN (r_agent) minimised/VBN (l_dep) use/NN (l_appos) monitoring/NN (l_advcl) occurs/VBZ (l_nsubj) proteinuria/NN -PUNC- sirolimus/NN (r_pobj) of/IN (r_prep) use/NN (l_appos) monitoring/NN (l_prep) of/IN (l_pobj) proteinuria/NN -PUNC- sirolimus/NN (r_pobj) of/IN (r_prep) use/NN (l_appos) monitoring/NN (l_advcl) occurs/VBZ (l_nsubj) proteinuria/NN
9406968
D008094_D011141 NONE lithium/NN (r_pobj) with/IN (r_prep) rats/NNS (r_pobj) in/IN (r_prep) investigated/VBN (l_parataxis) polyuria/NN -PUNC- Li)-induced/JJ (r_amod) polyuria/NN
D001127_D003681 NONE AVP/NNP (r_pobj) of/IN (r_prep) elevation/NN (r_pobj) to/IN (r_prep) contribute/VB (l_nsubj) dehydration/NN -PUNC- AVP/NNP (r_compound) expression/NN (r_pobj) of/IN (r_prep) upregulation/NN (r_conj) elevation/NN (r_pobj) to/IN (r_prep) contribute/VB (l_nsubj) dehydration/NN
D014667_D003919 NONE vasopressin/NN (r_compound) gene/NN (l_prep) in/IN (l_pobj) nuclei/NNS (l_prep) of/IN (l_pobj) rat/NN (l_compound) insipidus/NN
D008094_D003681 NONE Li/NNP (r_npadvmod) induced/VBN (r_amod) diabetes/NN (r_compound) rat/NN (r_pobj) of/IN (r_prep) SON/NN (r_conj) PVN/NN (r_pobj) in/IN (r_prep) expression/NN (r_pobj) of/IN (r_prep) upregulation/NN (r_conj) elevation/NN (r_pobj) to/IN (r_prep) contribute/VB (l_nsubj) dehydration/NN
D018021_D011141 CID LiCl/NNP (r_dobj) contained/VBD (r_relcl) diet/NN (r_dobj) consuming/VBG (r_acl) rats/NNS (r_nsubj) developed/VBN (l_dobj) polyuria/NN
D008094_D003919 NONE lithium/NN (r_npadvmod) induced/VBN (r_amod) diabetes/NN (r_compound) rat/NN (l_compound) insipidus/NN -PUNC- Li/NNP (r_npadvmod) induced/VBN (r_amod) diabetes/NN (r_compound) rat/NN (l_compound) insipidus/NN
D001127_D003919 NONE AVP/NNP (r_pobj) of/IN (r_prep) elevation/NN (l_conj) upregulation/NN (l_prep) of/IN (l_pobj) expression/NN (l_prep) in/IN (l_pobj) PVN/NN (l_conj) SON/NN (l_prep) of/IN (l_pobj) rat/NN (l_compound) insipidus/NN -PUNC- AVP/NNP (r_compound) expression/NN (l_prep) in/IN (l_pobj) PVN/NN (l_conj) SON/NN (l_prep) of/IN (l_pobj) rat/NN (l_compound) insipidus/NN
D001127_D011141 NONE vasopressin/NN (r_pobj) of/IN (r_prep) expression/NN (r_nsubjpass) investigated/VBN (l_parataxis) polyuria/NN -PUNC- AVP/NNP (r_nmod) gene/NN (r_nsubjpass) investigated/VBN (l_parataxis) polyuria/NN
11334364
D000082_D007674 CID acetaminophen/RB (r_advmod) induced/VBN (r_amod) nephrotoxicity/NN -PUNC- acetaminophen/RB (r_advmod) prevent/VB (l_dobj) toxicity/NN (l_nmod) nephrotoxicity/NN -PUNC- AAP)-induced/VBN (r_compound) nephrotoxicity/NN
D004317_D008171 NONE doxorubicin/NN (r_npadvmod) induced/VBN (r_amod) cardiotoxicity/NN (r_conj) toxicity/NN -PUNC- doxorubicin/NN (r_conj) toxicity/NN -PUNC- DOX)-induced/JJ (r_amod) cardiotoxicity/NN (r_dobj) doxorubicin/NN (r_conj) toxicity/NN
D000638_D008171 CID amiodarone/NN (r_npadvmod) induced/VBN (r_amod) toxicity/NN -PUNC- amiodarone/NN (r_appos) nephrotoxicity/NN (r_nmod) toxicity/NN -PUNC- AMI)-induced/JJ (r_amod) toxicity/NN
D004317_D009336 CID doxorubicin/NN (r_npadvmod) induced/VBN (r_amod) cardiotoxicity/NN (r_conj) toxicity/NN (r_conj) nephrotoxicity/NN (r_pobj) during/IN (r_prep) deaths/NNS (l_amod) apoptotic/JJ (l_conj) necrotic/JJ -PUNC- DOX/NNP (r_conj) AMI/NNP (r_conj) AAP/NNP (r_appos) drugs/NNS (r_nsubj) induced/VBD (l_prep) in/IN (l_pobj) addition/NN (l_prep) to/IN (l_pobj) necrosis/NN
D000638_D007674 NONE amiodarone/NN (r_npadvmod) induced/VBN (r_amod) toxicity/NN (r_conj) nephrotoxicity/NN -PUNC- amiodarone/NN (r_appos) nephrotoxicity/NN -PUNC- AMI)-induced/JJ (r_amod) toxicity/NN (l_nmod) nephrotoxicity/NN
D004317_D066126 CID doxorubicin/NN (r_npadvmod) induced/VBN (r_amod) cardiotoxicity/NN -PUNC- doxorubicin/NN (l_dobj) cardiotoxicity/NN -PUNC- DOX)-induced/JJ (r_amod) cardiotoxicity/NN
D000082_D009336 CID acetaminophen/RB (r_advmod) induced/VBN (r_amod) nephrotoxicity/NN (r_pobj) during/IN (r_prep) deaths/NNS (l_amod) apoptotic/JJ (l_conj) necrotic/JJ -PUNC- AAP/NNP (r_appos) drugs/NNS (r_nsubj) induced/VBD (l_prep) in/IN (l_pobj) addition/NN (l_prep) to/IN (l_pobj) necrosis/NN
D000638_D066126 NONE amiodarone/NN (r_npadvmod) induced/VBN (r_amod) toxicity/NN (l_conj) cardiotoxicity/NN -PUNC- amiodarone/NN (r_appos) nephrotoxicity/NN (r_nmod) toxicity/NN (l_conj) doxorubicin/NN (l_dobj) cardiotoxicity/NN -PUNC- AMI)-induced/JJ (r_amod) toxicity/NN (l_conj) doxorubicin/NN (l_dobj) cardiotoxicity/NN
C511402_D017695 NONE GSPE/NNP (r_compound) preexposure/NN (r_pobj) of/IN (r_prep) absence/NN (r_pobj) in/IN (r_prep) variety/NN (r_pobj) with/IN (r_prep) damage/NN
D000082_D008171 NONE acetaminophen/RB (r_advmod) induced/VBN (r_amod) nephrotoxicity/NN (l_conj) toxicity/NN -PUNC- acetaminophen/RB (r_advmod) prevent/VB (l_dobj) toxicity/NN -PUNC- AAP)-induced/VBN (r_compound) nephrotoxicity/NN (r_nmod) toxicity/NN
D004317_D007674 NONE doxorubicin/NN (r_npadvmod) induced/VBN (r_amod) cardiotoxicity/NN (r_conj) toxicity/NN (r_conj) nephrotoxicity/NN -PUNC- doxorubicin/NN (r_conj) toxicity/NN (l_nmod) nephrotoxicity/NN -PUNC- DOX)-induced/JJ (r_amod) cardiotoxicity/NN (r_dobj) doxorubicin/NN (r_conj) toxicity/NN (l_nmod) nephrotoxicity/NN
D000638_D009336 CID amiodarone/NN (r_npadvmod) induced/VBN (r_amod) toxicity/NN (r_conj) nephrotoxicity/NN (r_pobj) during/IN (r_prep) deaths/NNS (l_amod) apoptotic/JJ (l_conj) necrotic/JJ -PUNC- AMI/NNP (r_conj) AAP/NNP (r_appos) drugs/NNS (r_nsubj) induced/VBD (l_prep) in/IN (l_pobj) addition/NN (l_prep) to/IN (l_pobj) necrosis/NN
C511402_D066126 NONE extract/NN (r_pobj) by/IN (r_prep) cardiotoxicity/NN -PUNC- extract/NN (r_pobj) of/IN (r_prep) ability/NN (l_acl) prevent/VB (l_dobj) toxicity/NN (l_conj) doxorubicin/NN (l_dobj) cardiotoxicity/NN -PUNC- GSPE/NNP (r_appos) extract/NN (r_pobj) of/IN (r_prep) ability/NN (l_acl) prevent/VB (l_dobj) toxicity/NN (l_conj) doxorubicin/NN (l_dobj) cardiotoxicity/NN
C511402_D008171 NONE extract/NN (r_pobj) by/IN (r_prep) cardiotoxicity/NN (r_conj) toxicity/NN -PUNC- extract/NN (r_pobj) of/IN (r_prep) ability/NN (l_acl) prevent/VB (l_dobj) toxicity/NN -PUNC- GSPE/NNP (r_appos) extract/NN (r_pobj) of/IN (r_prep) ability/NN (l_acl) prevent/VB (l_dobj) toxicity/NN
D000082_D066126 NONE acetaminophen/RB (r_advmod) induced/VBN (r_amod) nephrotoxicity/NN (l_conj) toxicity/NN (l_conj) cardiotoxicity/NN -PUNC- acetaminophen/RB (r_advmod) prevent/VB (l_dobj) toxicity/NN (l_conj) doxorubicin/NN (l_dobj) cardiotoxicity/NN -PUNC- AAP)-induced/VBN (r_compound) nephrotoxicity/NN (r_nmod) toxicity/NN (l_conj) doxorubicin/NN (l_dobj) cardiotoxicity/NN
C511402_D009336 NONE extract/NN (r_pobj) by/IN (r_prep) cardiotoxicity/NN (r_conj) toxicity/NN (r_conj) nephrotoxicity/NN (r_pobj) during/IN (r_prep) deaths/NNS (l_amod) apoptotic/JJ (l_conj) necrotic/JJ -PUNC- GSPE/NNP (r_pobj) by/IN (r_agent) blocked/VBN (r_relcl) necrosis/NN
C511402_D007674 NONE extract/NN (r_pobj) by/IN (r_prep) cardiotoxicity/NN (r_conj) toxicity/NN (r_conj) nephrotoxicity/NN -PUNC- extract/NN (r_pobj) of/IN (r_prep) ability/NN (l_acl) prevent/VB (l_dobj) toxicity/NN (l_nmod) nephrotoxicity/NN -PUNC- GSPE/NNP (r_appos) extract/NN (r_pobj) of/IN (r_prep) ability/NN (l_acl) prevent/VB (l_dobj) toxicity/NN (l_nmod) nephrotoxicity/NN
9766615
D003024_D012735 NONE clozapine/NN (r_appos) threshold/NN (r_dobj) lowered/VBD (l_nsubj) effects/NNS (l_conj) effects/NNS (l_conj) gain/NN (l_conj) dysfunction/NN -PUNC- clozapine/NN (r_appos) agranulocytosis/NN (r_conj) lowered/VBD (l_nsubj) effects/NNS (l_conj) effects/NNS (l_conj) gain/NN (l_conj) dysfunction/NN
D003024_D015430 NONE clozapine/NN (r_appos) threshold/NN (r_dobj) lowered/VBD (l_nsubj) effects/NNS (l_conj) effects/NNS (l_conj) gain/NN -PUNC- clozapine/NN (r_appos) agranulocytosis/NN (r_conj) lowered/VBD (l_nsubj) effects/NNS (l_conj) effects/NNS (l_conj) gain/NN
D003024_D001480 NONE clozapine/NN (r_appos) threshold/NN (r_dobj) lowered/VBD (r_conj) associated/VBN (r_conj) have/VBP (l_dobj) risk/NN (l_prep) of/IN (l_pobj) EPS/NNP -PUNC- clozapine/NN (r_appos) agranulocytosis/NN (r_conj) lowered/VBD (r_conj) associated/VBN (r_conj) have/VBP (l_dobj) risk/NN (l_prep) of/IN (l_pobj) EPS/NNP
D003024_D000380 CID clozapine/NN (r_appos) threshold/NN (r_dobj) lowered/VBD (l_conj) agranulocytosis/NN -PUNC- clozapine/NN (r_appos) agranulocytosis/NN
D003024_D012640 NONE clozapine/NN (r_appos) threshold/NN (l_compound) seizure/NN -PUNC- clozapine/NN (r_appos) agranulocytosis/NN (r_conj) lowered/VBD (l_dobj) threshold/NN (l_compound) seizure/NN
20084309
D008874_D000402 NONE MZ/NNP (r_compound) use/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) hypoxia/NN (r_pobj) due/JJ (r_prep) presented/VBD (l_prep) due/IN (l_pobj) obstruction/NN
D008874_D008944 NONE MZ/NNP (r_compound) dose/NN (r_conj) MR/NNP (r_appos) regurgitation/NN -PUNC- MZ/NNP (r_compound) dose/NN (r_conj) MR/NNP -PUNC- MZ/NNP (r_pobj) of/IN (r_prep) doses/NNS (r_appos) MP/NNP (l_nmod) MR/NNP
D008874_D020521 NONE MZ/NNP (r_compound) dose/NN (r_conj) MR/NNP (r_appos) regurgitation/NN (r_conj) duration/NN (r_dobj) test/VB (l_dobj) influence/NN (l_prep) of/IN (l_pobj) variables/NNS (l_appos) age/NN (l_conj) sex/NN (l_conj) stroke/UH
D008874_D000860 CID MZ/NNP (r_compound) use/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) hypoxia/NN (r_pobj) due/JJ (r_prep) presented/VBD (l_dobj) hypoxia/NN -PUNC- MZ/NNP (r_compound) use/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) hypoxia/NN
D008874_D009202 NONE MZ/NNP (r_compound) dose/NN (r_conj) MR/NNP (r_appos) regurgitation/NN (r_conj) duration/NN (r_dobj) test/VB (l_dobj) influence/NN (l_prep) of/IN (l_pobj) variables/NNS (l_appos) age/NN (l_conj) sex/NN (l_conj) stroke/UH (l_conj) MP/NNP (l_amod) myocardiopathy/NN -PUNC- MZ/NNP (r_compound) dose/NN (r_conj) MR/NNP (r_appos) regurgitation/NN (r_conj) duration/NN (r_dobj) test/VB (l_dobj) influence/NN (l_prep) of/IN (l_pobj) variables/NNS (l_appos) age/NN (l_conj) sex/NN (l_conj) stroke/UH (l_conj) MP/NNP -PUNC- MZ/NNP (r_pobj) of/IN (r_prep) doses/NNS (r_appos) MP/NNP
19445921
D007545_D006331 NONE isoproterenol/NN (r_npadvmod) induced/VBN (r_amod) dysfunction/NN
D000244_D012131 NONE ADP/NNP (r_nmod) O/NNP (r_conj) ratio/NN (r_pobj) by/IN (r_agent) characterized/VBN (r_acl) dysfunction/NN
D007545_D012131 NONE isoproterenol/NN (r_npadvmod) treated/VBN (r_amod) rats/NNS (r_pobj) in/IN (r_prep) observed/VBN (l_nsubjpass) dysfunction/NN
C066201_D006331 NONE A/NN (r_appos) Administration/NN (l_conj) dysfunction/NN
C066201_D009202 NONE A/NN (r_appos) Administration/NN (l_conj) dysfunction/NN (l_conj) injury/NN -PUNC- A/NN (r_pobj) of/IN (r_prep) role/NN (l_prep) against/IN (l_pobj) damage/NN
C066201_D009203 NONE A/NN (l_prep) on/IN (l_pobj) infarction/NN -PUNC- A/NN (r_pobj) of/IN (r_prep) potential/NN (l_prep) on/IN (l_pobj) infarction/NN -PUNC- A/DT (r_appos) salvianolic/JJ (r_nsubj) has/VBZ (l_dobj) effect/NN (l_prep) against/IN (l_pobj) infarction/NN
D007545_D009202 NONE isoproterenol/NN (r_npadvmod) induced/VBN (r_amod) dysfunction/NN (l_conj) injury/NN -PUNC- isoproterenol/NN (r_npadvmod) induced/VBN (r_amod) damage/NN
D007545_D009203 CID isoproterenol/NN (r_npadvmod) induced/VBN (r_amod) infarction/NN -PUNC- isoproterenol/NN (r_npadvmod) induced/VBN (r_amod) infarction/NN -PUNC- isoproterenol/NN (r_npadvmod) induced/VBN (r_amod) infarction/NN
17615423
D019821_D058186 CID simvastatin/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) to/IN (r_prep) secondary/JJ (r_amod) failure/NN -PUNC- simvastatin/NN (l_conj) amiodarone/NN (l_conj) atazanavir/NNS (l_acl) resulting/VBG (l_prep) in/IN (l_pobj) rhabdomyolysis/NN (l_conj) failure/NN
D000638_D012206 CID amiodarone/NN (r_conj) simvastatin/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) to/IN (r_prep) secondary/JJ (r_amod) failure/NN (r_conj) rhabdomyolysis/NN -PUNC- amiodarone/NN (l_conj) atazanavir/NNS (l_acl) resulting/VBG (l_prep) in/IN (l_pobj) rhabdomyolysis/NN
C413408_D058186 CID atazanavir/NNS (r_conj) amiodarone/NN (r_conj) simvastatin/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) to/IN (r_prep) secondary/JJ (r_amod) failure/NN -PUNC- atazanavir/NNS (l_acl) resulting/VBG (l_prep) in/IN (l_pobj) rhabdomyolysis/NN (l_conj) failure/NN
D019821_D015658 NONE Simvastatin/NNP (r_nmod) medications/NNS (l_compound) virus/NN
C413408_D012206 CID atazanavir/NNS (r_conj) amiodarone/NN (r_conj) simvastatin/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) to/IN (r_prep) secondary/JJ (r_amod) failure/NN (r_conj) rhabdomyolysis/NN -PUNC- atazanavir/NNS (l_acl) resulting/VBG (l_prep) in/IN (l_pobj) rhabdomyolysis/NN
D000638_D058186 CID amiodarone/NN (r_conj) simvastatin/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) to/IN (r_prep) secondary/JJ (r_amod) failure/NN -PUNC- amiodarone/NN (l_conj) atazanavir/NNS (l_acl) resulting/VBG (l_prep) in/IN (l_pobj) rhabdomyolysis/NN (l_conj) failure/NN
D000638_D015658 NONE amiodarone/NN (r_conj) Simvastatin/NNP (r_nmod) medications/NNS (l_compound) virus/NN
D019821_D012206 CID simvastatin/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) to/IN (r_prep) secondary/JJ (r_amod) failure/NN (r_conj) rhabdomyolysis/NN -PUNC- simvastatin/NN (l_conj) amiodarone/NN (l_conj) atazanavir/NNS (l_acl) resulting/VBG (l_prep) in/IN (l_pobj) rhabdomyolysis/NN -PUNC- simvastatin/NN (r_amod) metabolism/NN (r_dobj) inhibit/VBP (r_relcl) drugs/NNS (r_pobj) of/IN (r_prep) presence/NN (r_pobj) in/IN (r_prep) increased/VBN (l_nsubjpass) risk/NN (l_prep) of/IN (l_pobj) rhabdomyolysis/NN
8953972
D004837_D013345 CID epinephrine/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) bleeding/NN
D004837_D005076 NONE epinephrine/NN (r_dobj) administer/VB (r_xcomp) led/VBD (l_nsubj) onset/NN (l_prep) of/IN (l_pobj) distress/NN (l_conj) rash/JJ
D004837_D012128 NONE epinephrine/NN (r_dobj) administer/VB (r_xcomp) led/VBD (l_nsubj) onset/NN (l_prep) of/IN (l_pobj) distress/NN
D004837_D006323 CID Epinephrine/NN (r_nsubj) has/VBZ (l_dobj) role/NN (l_prep) in/IN (l_pobj) arrest/NN
D004837_D004342 NONE Epinephrine/NN (r_nsubj) has/VBZ (r_ccomp) use/NN (l_prep) by/IN (l_pobj) paramedics/NNS (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) reaction/NN
D004837_D006973 NONE Epinephrine/NN (r_nsubj) has/VBZ (r_ccomp) use/NN (l_prep) by/IN (l_pobj) paramedics/NNS (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) reaction/NN (l_conj) hypertension/NN
14976857
D011405_D062787 NONE propafenone/NN (r_compound) overdose/NN -PUNC- propafenone/NN (r_compound) overdose/NN
D011405_D004437 NONE propafenone/NN (r_compound) overdose/NN (l_prep) in/IN (l_pobj) woman/NN (l_prep) with/IN (l_pobj) anomaly/NN
D011405_D054092 NONE propafenone/NN (r_compound) overdose/NN (r_pobj) by/IN (r_agent) precipitated/VBN (r_conj) occurred/VBD (l_nsubj) shunt/NN (l_prep) via/IN (l_pobj) ovale/NN
D011405_-1 NONE propafenone/NN (r_compound) overdose/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) syndrome/NN
7516729
D014700_D001919 CID verapamil/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) bradycardia/NNS
3412544
D000082_D014516 NONE paracetamol/NNP (r_conj) phenacetin/JJ (r_pobj) of/IN (r_prep) consumption/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) pelvis/NN (l_conj) ureter/NN (l_conj) bladder/NN -PUNC- paracetamol/JJ (r_compound) consumption/NN (r_pobj) from/IN (r_prep) risk/NN (r_dobj) substantiate/VB (r_xcomp) unable/JJ (r_acomp) were/VBD (l_advcl) was/VBD (l_attr) suggestion/NN (l_prep) of/IN (l_pobj) association/NN (l_prep) with/IN (l_pobj) cancer/NN (l_prep) of/IN (l_pobj) ureter/NN
D000082_D001749 NONE paracetamol/NNP (r_conj) phenacetin/JJ (r_pobj) of/IN (r_prep) consumption/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) pelvis/NN (l_conj) ureter/NN (l_conj) bladder/NN
D010615_D014516 NONE phenacetin/JJ (r_pobj) of/IN (r_prep) consumption/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) pelvis/NN (l_conj) ureter/NN (l_conj) bladder/NN -PUNC- phenacetin/NN (r_pobj) of/IN (r_prep) consumption/NN (l_relcl) increased/VBD (l_conj) for/IN (l_pobj) cancer/NN
D000082_D007680 NONE paracetamol/NNP (r_conj) phenacetin/JJ (r_pobj) of/IN (r_prep) consumption/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) pelvis/NN (l_conj) ureter/NN (l_conj) bladder/NN
D000082_D009369 NONE paracetamol/JJ (r_compound) consumption/NN (r_pobj) from/IN (r_prep) risk/NN (l_conj) any/DT (l_prep) of/IN (l_pobj) cancers/NNS
D010615_D007681 CID phenacetin/JJ (r_pobj) of/IN (r_prep) consumption/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) pelvis/NN (r_pobj) of/IN (r_prep) necrosis/NN -PUNC- phenacetin/NN (r_pobj) of/IN (r_prep) consumption/NN (r_pobj) by/IN (r_agent) increased/VBN (l_nsubjpass) risk/NN (l_prep) of/IN (l_pobj) necrosis/NN
D000082_D014523 NONE paracetamol/JJ (r_nsubj) cause/VB (l_dobj) cancer/NN
D010615_D007680 CID phenacetin/NN (r_pobj) of/IN (r_prep) consumption/NN (l_relcl) increased/VBD (l_dobj) risk/NN (l_prep) for/IN (l_pobj) cancer/NN (l_prep) of/IN (l_pobj) pelvis/NN (l_conj) bladder/NN
D010615_D007680 NONE phenacetin/JJ (r_pobj) of/IN (r_prep) consumption/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) pelvis/NN (l_conj) ureter/NN (l_conj) bladder/NN
D010615_D001749 CID phenacetin/NN (r_pobj) of/IN (r_prep) consumption/NN (l_relcl) increased/VBD (l_dobj) risk/NN (l_prep) for/IN (l_pobj) cancer/NN (l_prep) of/IN (l_pobj) pelvis/NN (l_conj) bladder/NN
D010615_D001749 NONE phenacetin/JJ (r_pobj) of/IN (r_prep) consumption/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) pelvis/NN (l_conj) ureter/NN (l_conj) bladder/NN
D000082_D007681 NONE paracetamol/JJ (r_nsubj) cause/VB (l_dobj) cancer/NN (l_conj) necrosis/NN -PUNC- paracetamol/NNP (r_conj) phenacetin/JJ (r_pobj) of/IN (r_prep) consumption/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) pelvis/NN (r_pobj) of/IN (r_prep) necrosis/NN -PUNC- paracetamol/JJ (r_compound) consumption/NN (r_pobj) from/IN (r_prep) risk/NN (l_prep) for/IN (l_pobj) necrosis/NN
11961407
D011692_D005921 NONE PAN/NNP (r_compound) injection/NN (r_pobj) after/IN (r_prep) days/NNS (r_npadvmod) analyzed/VBN (l_advcl) include/VB (l_dobj) phase/NN (l_appos) days/NNS (l_conj) phase/NN (l_acl) associated/VBN (l_prep) with/IN (l_pobj) glomerulosclerosis/NN
D011692_D009401 CID PAN/NNP (r_compound) nephrosis/NN -PUNC- aminonucleoside/JJ (r_amod) nephrosis/NN -PUNC- aminonucleoside/NN (r_advmod) induced/VBN (l_nsubjpass) nephrosis/NN -PUNC- PAN/NNP (r_appos) aminonucleoside/NN (r_advmod) induced/VBN (l_nsubjpass) nephrosis/NN
D011692_D011507 CID PAN/NNP (r_compound) injection/NN (r_pobj) after/IN (r_prep) days/NNS (r_npadvmod) analyzed/VBN (l_advcl) include/VB (l_dobj) phase/NN (l_prep) of/IN (l_pobj) proteinuria/NN -PUNC- PAN/NNP (r_compound) injection/NN (r_pobj) after/IN (r_prep) days/NNS (r_npadvmod) analyzed/VBN (l_advcl) include/VB (l_dobj) phase/NN (l_appos) days/NNS (l_conj) phase/NN (l_prep) of/IN (l_pobj) proteinuria/NN
D014443_D009401 NONE tyrosine/NN (r_compound) phosphatase/NN (l_prep) in/IN (l_pobj) nephrosis/NN
9522143
D011318_D034381 CID prilocaine/NN (r_dobj) given/VBN (r_acl) Patients/NNS (r_nsubj) were/VBD (l_acomp) likely/JJ (l_xcomp) develop/VB (l_xcomp) hearing/VBG (l_dobj) loss/NN -PUNC- prilocaine/NN (r_pobj) after/IN (r_prep) was/VBD (l_nsubj) loss/NN
D002045_D034381 CID bupivacaine/NN (r_pobj) than/IN (r_prep) loss/NN -PUNC- bupivacaine/NN (r_pobj) after/IN (r_prep) dB/NN (r_conj) prilocaine/NN (r_pobj) after/IN (r_prep) was/VBD (l_nsubj) loss/NN
17491223
D017256_D007511 NONE Sestamibi/NNP (r_nmod) emission/NN (r_dobj) using/VBG (r_conj) detecting/VBG (r_pcomp) for/IN (r_prep) assess/VB (l_conj) computed/VBD (l_advcl) assess/VB (l_dobj) presence/NN (l_prep) of/IN (l_pobj) ischemia/NN
D017256_D017202 NONE Sestamibi/NNP (r_nmod) emission/NN (r_dobj) using/VBG (r_conj) detecting/VBG (l_dobj) ischemia/NN
D004280_D007511 NONE dobutamine/NN (r_npadvmod) induced/VBN (r_amod) ischemia/NN (r_dobj) detecting/VBG (r_pcomp) for/IN (r_prep) assess/VB (l_conj) computed/VBD (l_advcl) assess/VB (l_dobj) presence/NN (l_prep) of/IN (l_pobj) ischemia/NN
D004280_D017202 CID dobutamine/NN (r_npadvmod) induced/VBN (r_amod) ischemia/NN -PUNC- dobutamine/NN (r_npadvmod) induced/VBN (r_amod) ischemia/NN -PUNC- dobutamine/NN (r_npadvmod) induced/VBN (r_amod) ischemia/NN
347884
D006220_D019967 NONE haloperidol/NN (r_pobj) with/IN (r_prep) study/NN (r_pobj) In/IN (r_prep) found/VBN (l_xcomp) be/VB (l_acomp) effective/JJ (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) syndromes/NNS (l_acl) belonging/VBG (l_prep) to/IN (l_pobj) group/NN
2951327
D006830_D013610 NONE hydralazine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) hypotension/NN (r_pobj) to/IN (r_prep) contrast/NN (r_pobj) in/IN (r_prep) is/VBZ (r_advcl) observed/VBN (r_conj) was/VBD (l_appos) +/-/NN (l_conj) tachycardia/NN
D005996_D013610 NONE nitroglycerin/NN (r_conj) hydralazine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) hypotension/NN (r_pobj) to/IN (r_prep) contrast/NN (r_pobj) in/IN (r_prep) is/VBZ (r_advcl) observed/VBN (r_conj) was/VBD (l_appos) +/-/NN (l_conj) tachycardia/NN
D009638_D007022 NONE norepinephrine/NN (r_amod) rate/NN (r_pobj) of/IN (r_prep) augmentation/NN (r_conj) tachycardia/NN (r_conj) +/-/NN (r_appos) was/VBD (l_conj) observed/VBN (l_advcl) is/VBZ (l_prep) in/IN (l_pobj) contrast/NN (l_prep) to/IN (l_pobj) hypotension/NN
D005996_D007022 CID nitroglycerin/NN (r_conj) hydralazine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) hypotension/NN
D006830_D007022 CID hydralazine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) hypotension/NN
D009638_D013610 NONE norepinephrine/NN (r_amod) rate/NN (r_pobj) of/IN (r_prep) augmentation/NN (r_conj) tachycardia/NN
8638206
-1_D010243 NONE benzylisoquinolinium/NN (r_amod) NMBA/NNP (r_appos) besylate/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) paralysis/NN
D014673_D010243 CID bromide/NN (r_pobj) as/IN (r_prep) NMBAs/NNS (r_dobj) involved/VBN (l_nsubj) Reports/NNS (l_prep) of/IN (l_pobj) paralysis/NN
D001279_D010243 CID atracurium/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) after/IN (r_prep) paralysis/NN -PUNC- besylate/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) paralysis/NN -PUNC- atracurium/NN (r_npadvmod) related/VBN (r_amod) paralysis/NN
15338796
D000420_D008173 NONE salbutamol/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) disease/NN
D000420_D014202 CID salbutamol/NN (r_pobj) of/IN (r_prep) effects/NNS (l_compound) Tremor/NNP -PUNC- salbutamol/NN (r_pobj) of/IN (r_prep) effects/NNS (l_compound) tremor/JJ -PUNC- salbutamol/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) disease/NN (r_pobj) with/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) assessed/VBD (l_dobj) tremor/NN -PUNC- Salbutamol/NNP (r_nsubj) increased/VBD (l_dobj) severity/NN (l_compound) tremor/NN
2802551
D012964_D007674 NONE Sodium/NN (r_compound) status/NN (r_nsubj) influences/VBZ (l_dobj) nephrotoxicity/NN
D000666_D007674 CID B/NN (r_compound) nephrotoxicity/NN -PUNC- B/NNP (r_pobj) of/IN (r_prep) potential/NN (l_amod) nephrotoxic/JJ
20619828
D002997_D008569 CID Clomipramine/NNP (r_compound) exposure/NN (r_nsubj) produced/VBD (l_npadvmod) inflexibility/NN (l_appos) impairment/NN
D002997_D060845 CID Clomipramine/NNP (r_compound) exposure/NN (r_nsubj) produced/VBD (l_npadvmod) inflexibility/NN (l_appos) impairment/NN (l_conj) hoarding/NN
D002997_D001008 CID Clomipramine/NNP (r_compound) exposure/NN (r_nsubj) produced/VBD (l_dobj) changes/NNS (l_relcl) include/VBP (l_dobj) anxiety/NN
D002997_-1 NONE Clomipramine/NNP (r_compound) exposure/NN (r_nsubj) produced/VBD (l_npadvmod) inflexibility/NN -PUNC- Clomipramine/NNP (r_compound) exposure/NN (r_nsubj) produced/VBD (l_npadvmod) inflexibility/NN (l_appos) impairment/NN (l_conj) hoarding/NN (l_conj) dysfunction/NN
16680561
C476217_D006261 CID cinacalcet/NN (r_pobj) with/IN (r_prep) receiving/VBG (r_pcomp) than/IN (r_prep) alone/RB (r_amod) events/NNS (r_dobj) reported/VBD (r_ccomp) reported/VBN (l_nsubjpass) nausea/NN (l_conj) headache/NN -PUNC- cinacalcet/NN (r_conj) desipramine/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (r_pobj) for/IN (r_prep) reported/VBN (l_nsubjpass) nausea/NN (l_conj) headache/NN
D003891_D006261 CID desipramine/NN (r_pobj) with/IN (r_prep) treatment/NN (r_dobj) following/VBG (r_acl) events/NNS (r_dobj) reported/VBD (r_ccomp) reported/VBN (l_nsubjpass) nausea/NN (l_conj) headache/NN -PUNC- desipramine/NN (r_dobj) receiving/VBG (r_pcomp) than/IN (r_prep) alone/RB (r_amod) events/NNS (r_dobj) reported/VBD (r_ccomp) reported/VBN (l_nsubjpass) nausea/NN (l_conj) headache/NN -PUNC- desipramine/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (r_pobj) for/IN (r_prep) reported/VBN (l_nsubjpass) nausea/NN (l_conj) headache/NN
D003891_D009325 CID desipramine/NN (r_pobj) with/IN (r_prep) treatment/NN (r_dobj) following/VBG (r_acl) events/NNS (r_dobj) reported/VBD (r_ccomp) reported/VBN (l_nsubjpass) nausea/NN -PUNC- desipramine/NN (r_dobj) receiving/VBG (r_pcomp) than/IN (r_prep) alone/RB (r_amod) events/NNS (r_dobj) reported/VBD (r_ccomp) reported/VBN (l_nsubjpass) nausea/NN -PUNC- desipramine/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (r_pobj) for/IN (r_prep) reported/VBN (l_nsubjpass) nausea/NN
C476217_D009325 CID cinacalcet/NN (r_pobj) with/IN (r_prep) receiving/VBG (r_pcomp) than/IN (r_prep) alone/RB (r_amod) events/NNS (r_dobj) reported/VBD (r_ccomp) reported/VBN (l_nsubjpass) nausea/NN -PUNC- cinacalcet/NN (r_conj) desipramine/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (r_pobj) for/IN (r_prep) reported/VBN (l_nsubjpass) nausea/NN
2870085
D007545_D013610 CID isoproterenol/NN (r_npadvmod) induced/VBN (r_amod) tachycardia/NN
C047847_D002637 NONE flestolol/NN (r_compound) infusion/NN (r_nsubjpass) found/VBN (l_xcomp) be/VB (l_acomp) safe/JJ (l_conj) effective/JJ (l_prep) in/IN (l_pcomp) controlling/VBG (l_dobj) pain/NN
C047847_D013610 NONE Flestolol/NNP (r_nsubj) produced/VBD (l_dobj) attenuation/NN (l_prep) of/IN (l_pobj) tachycardia/NN
C047847_D013617 NONE Flestolol/NNP (r_nsubj) reduced/VBD (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) tachyarrhythmia/NN
C047847_D000789 NONE flestolol/NN (r_compound) infusion/NN (r_nsubjpass) found/VBN (l_prep) In/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) angina/NN
11027905
D016202_D009437 NONE aspartate/NNP (r_nmod) antagonists/NNS (r_nsubj) be/VB (l_acomp) effective/JJ (l_prep) in/IN (l_pcomp) improving/VBG (l_dobj) analgesia/NN (l_prep) in/IN (l_pobj) syndromes/NNS (l_prep) as/IN (l_pobj) pain/NN -PUNC- NMDA/NNP (r_nmod) antagonists/NNS (r_nsubj) be/VB (l_acomp) effective/JJ (l_prep) in/IN (l_pcomp) improving/VBG (l_dobj) analgesia/NN (l_prep) in/IN (l_pobj) syndromes/NNS (l_prep) as/IN (l_pobj) pain/NN
D016202_D010146 NONE aspartate/NNP (r_nmod) antagonists/NNS (r_nsubj) be/VB (l_acomp) effective/JJ (l_prep) in/IN (l_pcomp) improving/VBG (l_dobj) analgesia/NN (l_prep) in/IN (l_pobj) syndromes/NNS (l_compound) pain/NN -PUNC- NMDA/NNP (r_nmod) antagonists/NNS (r_nsubj) be/VB (l_acomp) effective/JJ (l_prep) in/IN (l_pcomp) improving/VBG (l_dobj) analgesia/NN (l_prep) in/IN (l_pobj) syndromes/NNS (l_compound) pain/NN
D009020_D010146 NONE morphine/NN (r_pobj) to/IN (r_prep) responsive/JJ (r_amod) Pain/NN -PUNC- morphine/NN (r_pobj) by/IN (r_prep) unrelieved/JJ (r_acomp) was/VBD (l_nsubj) pain/NN -PUNC- morphine/NN (r_compound) analgesia/NN (l_prep) in/IN (l_pobj) syndromes/NNS (l_compound) pain/NN
D007649_D009437 NONE ketamine/NN (r_pobj) as/IN (r_prep) antagonists/NNS (r_nsubj) be/VB (l_acomp) effective/JJ (l_prep) in/IN (l_pcomp) improving/VBG (l_dobj) analgesia/NN (l_prep) in/IN (l_pobj) syndromes/NNS (l_prep) as/IN (l_pobj) pain/NN -PUNC- Ketamine/NNP (r_nsubj) improve/VB (l_dobj) analgesia/NN (l_prep) in/IN (l_pobj) syndromes/NNS (l_prep) as/IN (l_pobj) pain/NN
D007649_D010146 NONE ketamine/NN (r_pobj) as/IN (r_prep) antagonists/NNS (r_nsubj) be/VB (l_acomp) effective/JJ (l_prep) in/IN (l_pcomp) improving/VBG (l_dobj) analgesia/NN (l_prep) in/IN (l_pobj) syndromes/NNS (l_compound) pain/NN -PUNC- ketamine/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) of/IN (r_prep) bolus/NN (r_nsubjpass) given/VBN (l_dative) to/IN (l_pobj) patients/NNS (l_relcl) was/VBD (l_nsubj) pain/NN -PUNC- Ketamine/NN (r_nsubj) reduced/VBD (l_dobj) intensity/NN (l_compound) pain/NN -PUNC- Ketamine/NNP (r_nsubj) improve/VB (l_dobj) analgesia/NN (l_prep) in/IN (l_pobj) syndromes/NNS (l_compound) pain/NN
D007649_D009369 NONE ketamine/NN (l_prep) in/IN (l_pobj) patients/NNS (l_compound) cancer/NN -PUNC- ketamine/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) of/IN (r_prep) bolus/NN (r_nsubjpass) given/VBN (l_dative) to/IN (l_pobj) patients/NNS (l_compound) cancer/NN
D009020_D009369 NONE morphine/NN (r_compound) therapy/NN (r_pobj) on/IN (r_prep) patients/NNS (l_compound) cancer/NN -PUNC- morphine/NN (r_pobj) by/IN (r_prep) unrelieved/JJ (r_acomp) was/VBD (r_relcl) patients/NNS (l_compound) cancer/NN
D009020_D009437 NONE morphine/NN (r_compound) analgesia/NN (l_prep) in/IN (l_pobj) syndromes/NNS (l_prep) as/IN (l_pobj) pain/NN
20003049
C031942_D008107 NONE argatroban/NN (r_pobj) of/IN (r_prep) concentrations/NNS (r_nsubjpass) measured/VBN (l_conj) is/VBZ (l_attr) minutes/NNS (l_appos) minutes/NNS (l_prep) with/IN (l_pobj) impairment/NN -PUNC- argatroban/JJ (r_amod) life/NN (r_npadvmod) plasma/NN (r_nsubjpass) observed/VBN (r_conj) measured/VBN (l_conj) is/VBZ (l_attr) minutes/NNS (l_appos) minutes/NNS (l_prep) with/IN (l_pobj) impairment/NN
C031942_D001778 NONE argatroban/JJ (r_amod) concentration/NN (r_nsubj) suggest/VBP (l_ccomp) contributed/VBN (l_prep) to/IN (l_pobj) coagulopathy/NN -PUNC- argatroban/NN (r_amod) levels/NNS (r_nsubj) contributed/VBN (l_prep) to/IN (l_pobj) coagulopathy/NN -PUNC- argatroban/JJ (r_amod) concentration/NN (r_dobj) measure/VB (l_conj) extended/VBN (l_dobj) coagulopathy/NN
C031942_D013921 NONE argatroban/NN (l_prep) in/IN (l_pobj) patient/NN (l_prep) with/IN (l_pobj) history/NN (l_prep) of/IN (l_pobj) thrombocytopenia/NN -PUNC- argatroban/NN (r_oprd) administered/VBN (l_nsubjpass) patient/JJ (l_prep) with/IN (l_pobj) history/NN (l_prep) of/IN (l_pobj) HITT/NNP
D006493_D013921 NONE heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN -PUNC- heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN -PUNC- heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN (l_appos) HIT/NNP -PUNC- heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN (r_pobj) of/IN (r_prep) history/NN (r_pobj) with/IN (r_prep) patients/NNS (r_pobj) for/IN (r_prep) anticoagulation/NN (r_pobj) of/IN (r_prep) method/NN (r_dobj) provide/VBP (l_conj) HIT/VB -PUNC- heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN (r_pobj) of/IN (r_prep) history/NN (r_pobj) with/IN (r_prep) patients/NNS (r_pobj) for/IN (r_prep) anticoagulation/NN (r_pobj) of/IN (r_prep) method/NN (r_dobj) provide/VBP (l_conj) HIT/VB (l_prep) with/IN (l_pobj) thrombosis/NN (l_appos) HITT/NNP
D006493_D013927 NONE heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN (l_prep) with/IN (l_pobj) thrombosis/NN -PUNC- heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN (r_pobj) of/IN (r_prep) history/NN (r_pobj) with/IN (r_prep) patients/NNS (r_pobj) for/IN (r_prep) anticoagulation/NN (r_pobj) of/IN (r_prep) method/NN (r_dobj) provide/VBP (l_conj) HIT/VB (l_prep) with/IN (l_pobj) thrombosis/NN -PUNC- heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN (r_pobj) of/IN (r_prep) history/NN (r_pobj) with/IN (r_prep) patients/NNS (r_pobj) for/IN (r_prep) anticoagulation/NN (r_pobj) of/IN (r_prep) method/NN (r_dobj) provide/VBP (l_conj) HIT/VB (l_prep) with/IN (l_pobj) thrombosis/NN (l_appos) HITT/NNP
C031942_D013927 NONE argatroban/NN (l_prep) in/IN (l_pobj) patient/NN (l_prep) with/IN (l_pobj) history/NN (l_prep) of/IN (l_pobj) thrombocytopenia/NN (l_prep) with/IN (l_pobj) thrombosis/NN -PUNC- argatroban/NN (r_oprd) administered/VBN (l_nsubjpass) patient/JJ (l_prep) with/IN (l_pobj) history/NN (l_prep) of/IN (l_pobj) HITT/NNP
C031942_D016638 NONE argatroban/NN (r_oprd) administered/VBN (l_nsubjpass) patient/JJ (l_amod) ill/JJ
6640832
D004317_D002277 NONE adriamycin/NNS (l_prep) in/IN (l_pobj) carcinoma/NN
D004317_D001749 NONE adriamycin/NNS (l_prep) in/IN (l_pobj) carcinoma/NN -PUNC- Adriamycin/NNP (r_nsubjpass) administered/VBN (l_prep) after/IN (l_pobj) resection/NN (l_prep) of/IN (l_pobj) tumors/NNS
9754849
D003042_D002819 CID cocaine/NN (r_pobj) with/IN (r_prep) intoxications/NNS (r_pobj) during/IN (r_prep) be/VB (r_xcomp) known/VBN (l_nsubjpass) hyperkinesias/NNS -PUNC- cocaine/NN (r_conj) heroine/NN (r_dobj) abusing/VBG (r_acl) inpatient/NN (r_pobj) in/IN (r_prep) adjustment/NN (r_pobj) by/IN (r_agent) induced/VBN (r_xcomp) choreoathetoid/JJ (l_dobj) movements/NNS
D003042_D006948 CID cocaine/NN (r_pobj) with/IN (r_prep) intoxications/NNS (r_pobj) during/IN (r_prep) be/VB (r_xcomp) known/VBN (l_nsubjpass) hyperkinesias/NNS
D003042_D020820 NONE cocaine/NN (r_pobj) with/IN (r_prep) intoxications/NNS (r_pobj) during/IN (r_prep) be/VB (l_attr) abnormalities/NNS
D003932_D002819 NONE heroine/NN (r_dobj) abusing/VBG (r_acl) inpatient/NN (r_pobj) in/IN (r_prep) adjustment/NN (r_pobj) by/IN (r_agent) induced/VBN (r_xcomp) choreoathetoid/JJ (l_dobj) movements/NNS
D008691_D002819 CID methadone/NN (r_pobj) to/IN (r_prep) adjustment/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) movements/NNS -PUNC- methadone/NN (r_pobj) to/IN (r_prep) adjustment/NN (r_pobj) by/IN (r_agent) induced/VBN (r_xcomp) choreoathetoid/JJ (l_dobj) movements/NNS
19346865
D008795_D001927 CID metronidazole/NN (r_npadvmod) induced/VBN (r_amod) encephalopathy/NN (r_pobj) in/IN (r_prep) lesion/NN -PUNC- metronidazole/NN (r_npadvmod) induced/VBN (r_amod) encephalopathy/NN -PUNC- metronidazole/NN (r_npadvmod) induced/VBN (r_amod) encephalopathy/NN (r_pobj) in/IN (r_prep) lesions/NNS -PUNC- metronidazole/NN (r_npadvmod) induced/VBN (r_amod) encephalopathy/NN -PUNC- metronidazole/NN (r_npadvmod) induced/VBN (r_amod) encephalopathy/NN -PUNC- metronidazole/NN (r_npadvmod) induced/VBN (r_amod) encephalopathy/NN (r_pobj) for/IN (r_prep) characteristic/NN (r_pobj) as/IN (r_prep) considered/VBN (l_nsubjpass) lesions/NNS -PUNC- metronidazole/NN (r_npadvmod) induced/VBN (r_amod) encephalopathy/NN
D008795_D007239 NONE metronidazole/NN (r_dobj) taking/VBG (l_advcl) treat/VB (l_dobj) infection/NN
7088431
D004054_D014625 CID diethylstilbestrol/NN (r_pobj) to/IN (r_prep) exposed/VBN (r_acl) women/NNS (r_pobj) in/IN (r_prep) up/NN (r_pobj) at/IN (r_prep) detected/VBD (l_nsubj) cases/NNS (l_prep) of/IN (l_pobj) adenocarcinoma/NN (l_prep) of/IN (l_pobj) vagina/NN
D004054_D018262 CID DES/NNP (r_npadvmod) exposed/VBN (r_amod) offspring/NN (r_pobj) in/IN (r_prep) Development/NN (l_prep) of/IN (l_pobj) adenocarcinoma/NN -PUNC- diethylstilbestrol/NN (r_pobj) to/IN (r_prep) exposed/VBN (r_acl) women/NNS (r_pobj) in/IN (r_prep) up/NN (r_pobj) at/IN (r_prep) detected/VBD (l_nsubj) cases/NNS (l_prep) of/IN (l_pobj) adenocarcinoma/NN (l_prep) of/IN (l_pobj) vagina/NN
3693336
D014229_D003866 NONE Triazolam/NNP (r_npadvmod) induced/VBN (l_dobj) episodes/NNS (l_prep) in/IN (l_pobj) patient/NN (l_amod) depressed/JJ -PUNC- triazolam/NN (r_pobj) of/IN (r_prep) doses/NNS (r_nsubj) induced/VBD (l_dobj) episodes/NNS (l_prep) in/IN (l_pobj) woman/NN (l_amod) depressed/JJ
D014229_D001714 CID Triazolam/NNP (r_npadvmod) induced/VBN (l_dobj) episodes/NNS (l_prep) of/IN (l_pobj) mania/NN -PUNC- triazolam/NN (r_pobj) of/IN (r_prep) doses/NNS (r_nsubj) induced/VBD (l_dobj) episodes/NNS (l_prep) of/IN (l_pobj) mania/NN -PUNC- triazolam/NN (r_pobj) of/IN (r_prep) action/NN (r_pobj) of/IN (r_prep) duration/NN (r_pobj) with/IN (r_prep) coincident/JJ (r_acomp) was/VBD (l_nsubj) excitement/NN (l_amod) Manic/JJ
2304736
D011224_D014550 CID Prazosin/NN (r_npadvmod) induced/VBN (r_amod) incontinence/NN -PUNC- prazosin/NN (r_pobj) due/IN (r_amod) case/NN (l_prep) of/IN (l_pobj) incontinence/NN -PUNC- prazosin/NN (r_dobj) taking/VBG (r_advcl) present/VBP (l_prep) with/IN (l_pobj) incontinence/NN
D011224_D014549 NONE prazosin/NN (r_dobj) taking/VBG (r_advcl) present/VBP (r_relcl) Patients/NNS (r_nsubj) change/VB (l_advcl) resolve/VB (l_nsubj) incontinence/NN
17562951
D000111_D003920 NONE acetylcysteine/NN (r_pobj) of/IN (r_prep) use/NN (r_appos) volume/NN (l_appos) presence/NN (l_prep) of/IN (l_pobj) mellitus/NN
D007479_D007674 CID iopamidol/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) is/VBZ (l_nsubj) rate/NN (l_prep) of/IN (l_pobj) nephropathy/NN
D007479_D003920 NONE iopamidol/NN (r_pobj) with/IN (r_prep) were/VBD (r_conj) increases/VBZ (l_prep) In/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) diabetes/NNS -PUNC- iopamidol/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) is/VBZ (l_prep) with/IN (l_conj) without/IN (l_pobj) mellitus/NN
C044834_D051436 NONE iodixanol/NN (r_conj) iopamidol/NN (r_pobj) of/IN (r_prep) comparison/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disease/NN
C044834_D003920 NONE iodixanol/NN (r_pobj) with/IN (r_prep) with/IN (r_prep) were/VBD (r_conj) increases/VBZ (l_prep) In/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) diabetes/NNS -PUNC- iodixanol/NN (r_conj) iopamidol/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) is/VBZ (l_prep) with/IN (l_conj) without/IN (l_pobj) mellitus/NN
D007479_D051436 NONE iopamidol/NN (r_pobj) of/IN (r_prep) comparison/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disease/NN
C044834_D007674 CID iodixanol/NN (r_conj) iopamidol/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) is/VBZ (l_nsubj) rate/NN (l_prep) of/IN (l_pobj) nephropathy/NN
18619688
C025946_D006333 NONE 3-methyladenine/LS (r_appos) METHODS/NNS (r_nsubjpass) used/VBN (l_prep) in/IN (l_pobj) model/NN (l_compound) failure/NN -PUNC- 3MA/VBN (r_appos) 3-methyladenine/LS (r_appos) METHODS/NNS (r_nsubjpass) used/VBN (l_prep) in/IN (l_pobj) model/NN (l_compound) failure/NN
D004317_D003643 NONE Adriamycin/NNP (r_advmod) induced/VBN (r_amod) death/NN -PUNC- adriamycin/NNS (r_pobj) by/IN (r_agent) induced/VBN (r_advcl) plays/VBZ (l_nsubj) death/NN
D004317_D006333 CID Adriamycin/NNP (r_advmod) induced/VBN (r_amod) death/NN (r_nsubj) plays/VBZ (l_prep) in/IN (l_pobj) model/NN (l_prep) of/IN (l_pobj) failure/NN -PUNC- adriamycin/NNS (r_pobj) by/IN (r_agent) induced/VBN (r_acl) failure/NN -PUNC- adriamycin/NNS (r_pobj) by/IN (r_agent) induced/VBN (r_acl) progression/NN (l_prep) of/IN (l_pobj) failure/NN -PUNC- adriamycin/NNS (r_pobj) by/IN (r_agent) induced/VBN (r_acl) progression/NN (r_pobj) in/IN (r_prep) involved/VBN (r_ccomp) investigate/VB (l_advcl) develop/VB (l_dobj) strategy/NN (l_prep) for/IN (l_pobj) failure/NN -PUNC- adriamycin/NNS (r_pobj) by/IN (r_agent) induced/VBN (r_acl) model/NN (l_compound) failure/NN -PUNC- adriamycin/NNS (r_pobj) by/IN (r_agent) induced/VBN (r_advcl) plays/VBZ (l_prep) in/IN (l_pobj) pathogenesis/NN (l_prep) of/IN (l_pobj) failure/NN -PUNC- adriamycin/NNS (r_pobj) by/IN (r_agent) caused/VBN (r_acl) failure/NN
16330293
19058010
D010936_D009203 NONE tea/NN (r_nmod) combination/NN (r_pobj) of/IN (r_prep) Effect/NN (r_nsubj) induced/VBN (l_dobj) infarction/NN -PUNC- tea/NN (r_pobj) of/IN (r_prep) effects/NNS (r_dobj) investigate/VB (r_xcomp) aimed/VBN (l_parataxis) ISO)-induced/VBN (l_dobj) infarction/NN -PUNC- tea/NN (r_pobj) of/IN (r_prep) effect/NN (r_dobj) indicate/VBP (l_ccomp) induced/VBN (l_dobj) infarction/NN
D014810_D009203 NONE E/NN (r_conj) tea/NN (r_nmod) combination/NN (r_pobj) of/IN (r_prep) Effect/NN (r_nsubj) induced/VBN (l_dobj) infarction/NN -PUNC- E/NN (r_conj) tea/NN (r_pobj) of/IN (r_prep) effects/NNS (r_dobj) investigate/VB (r_xcomp) aimed/VBN (l_parataxis) ISO)-induced/VBN (l_dobj) infarction/NN -PUNC- E/NN (r_conj) tea/NN (r_pobj) of/IN (r_prep) effect/NN (r_dobj) indicate/VBP (l_ccomp) induced/VBN (l_dobj) infarction/NN
D007545_D009203 CID isoproterenol/JJ (r_pobj) in/IN (r_prep) combination/NN (r_pobj) of/IN (r_prep) Effect/NN (r_nsubj) induced/VBN (l_dobj) infarction/NN -PUNC- isoproterenol/NN (r_pobj) in/IN (r_prep) bound/VBN (r_acl) effects/NNS (r_dobj) investigate/VB (r_xcomp) aimed/VBN (l_parataxis) ISO)-induced/VBN (l_dobj) infarction/NN -PUNC- ISO)-induced/VBN (l_dobj) infarction/NN -PUNC- ISO/NN (r_pobj) during/IN (r_prep) effect/NN (r_dobj) indicate/VBP (l_ccomp) induced/VBN (l_dobj) infarction/NN
17466854
D008775_D002386 NONE methylprednisolone/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) incidence/NN (r_dobj) assess/VB (l_conj) gentamicin/NN (l_prep) at/IN (l_pobj) end/NN (l_prep) of/IN (l_pobj) surgery/NN (l_compound) cataract/NN
D005839_D006261 CID gentamicin/NN (r_conj) administration/NN (r_nsubjpass) related/VBN (l_prep) to/IN (l_pobj) incidence/NN (l_prep) of/IN (l_pobj) effects/NNS (l_prep) including/VBG (l_pobj) nausea/NN (l_conj) vomiting/NN (l_conj) headache/NN
D005839_D002386 NONE gentamicin/NN (l_prep) at/IN (l_pobj) end/NN (l_prep) of/IN (l_pobj) surgery/NN (l_compound) cataract/NN
D008775_D006261 CID methylprednisolone/NN (r_pobj) of/IN (r_prep) administration/NN (r_nsubjpass) related/VBN (l_prep) to/IN (l_pobj) incidence/NN (l_prep) of/IN (l_pobj) effects/NNS (l_prep) including/VBG (l_pobj) nausea/NN (l_conj) vomiting/NN (l_conj) headache/NN
D008775_D020250 CID methylprednisolone/NN (r_pobj) of/IN (r_prep) administration/NN (r_nsubjpass) related/VBN (l_prep) to/IN (l_pobj) incidence/NN (l_prep) of/IN (l_pobj) effects/NNS (l_prep) including/VBG (l_pobj) nausea/NN (l_conj) vomiting/NN
D005839_D020250 CID gentamicin/NN (r_conj) administration/NN (r_nsubjpass) related/VBN (l_prep) to/IN (l_pobj) incidence/NN (l_prep) of/IN (l_pobj) effects/NNS (l_prep) including/VBG (l_pobj) nausea/NN (l_conj) vomiting/NN
15233872
C007145_D009203 NONE Crataegus/NNP (r_pobj) of/IN (r_prep) tincture/NN (r_pobj) of/IN (r_prep) effect/NN (l_prep) on/IN (l_pobj) infarction/NN -PUNC- TCR/NNP (r_pobj) of/IN (r_prep) effect/NN (l_prep) on/IN (l_pobj) infarction/NN
D007545_D009203 CID isoproterenol/NN (r_npadvmod) induced/VBN (r_amod) infarction/NN
17854040
D019259_D015658 NONE lamivudine/NN (r_compound) resistance/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) Mutations/NNS (r_nsubj) ve/VB (l_dobj) virus/NN (l_appos) patients/NNS (l_prep) with/IN (l_conj) without/IN (l_pobj) implications/NNS (l_punct) :/: (l_punct) infection/NN -PUNC- lamivudine/NN (r_compound) resistance/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) Mutations/NNS (r_nsubj) ve/VB (l_dobj) virus/NN (l_appos) patients/NNS (l_prep) with/IN (l_conj) without/IN (l_pobj) implications/NNS (l_conj) patients/NNS (l_amod) infected/VBN -PUNC- lamivudine/JJ (r_npadvmod) resistant/JJ (r_amod) virus/NN (r_dobj) investigate/VB (r_acl) study/NN (r_attr) was/VBD (l_punct) ./. (l_punct) in/IN (l_punct) infection/NN -PUNC- lamivudine/NN (r_compound) na/NN (r_aux) ve/VB (r_acl) study/NN (r_attr) was/VBD (l_punct) ./. (l_punct) in/IN (l_punct) infection/NN -PUNC- lamivudine/NN (r_npadvmod) resistant/JJ (r_amod) strains/NNS (r_nsubjpass) detected/VBN (l_conj) patients/NNS (l_amod) infected/VBN -PUNC- lamivudine/NN (r_npadvmod) resistant/JJ (r_amod) strains/NNS (l_prep) in/IN (l_pcomp) ve/VB (l_dobj) patients/NNS (l_amod) infected/VBN -PUNC- lamivudine/NN (r_npadvmod) containing/VBG (r_advcl) emergence/NN (r_pobj) in/IN (r_prep) result/VB (l_conj) applied/VBN (l_advcl) is/VBZ (l_acomp) likely/JJ (l_xcomp) have/VB (l_dobj) implications/NNS (l_prep) in/IN (l_pobj) management/NN (l_prep) of/IN (l_pobj) patients/NNS (l_amod) infected/VBN
D012964_D015658 NONE na/TO (r_aux) ve/VB (l_dobj) virus/NN (l_appos) patients/NNS (l_prep) with/IN (l_conj) without/IN (l_pobj) implications/NNS (l_punct) :/: (l_punct) infection/NN -PUNC- na/TO (r_aux) ve/VB (l_dobj) virus/NN (l_appos) patients/NNS (l_prep) with/IN (l_conj) without/IN (l_pobj) implications/NNS (l_conj) patients/NNS (l_amod) infected/VBN -PUNC- na/NN (r_aux) ve/VB (r_acl) study/NN (r_attr) was/VBD (l_punct) ./. (l_punct) in/IN (l_punct) infection/NN -PUNC- na/TO (r_aux) ve/VB (l_dobj) patients/NNS (l_amod) infected/VBN
D019259_D006509 NONE lamivudine/NN (r_compound) resistance/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) Mutations/NNS (r_nsubj) ve/VB (l_dobj) virus/NN (l_appos) patients/NNS (l_amod) infected/JJ -PUNC- lamivudine/NN (r_compound) resistance/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) Mutations/NNS (r_nsubj) ve/VB (l_dobj) virus/NN (l_appos) patients/NNS (l_prep) with/IN (l_conj) without/IN (l_pobj) implications/NNS (l_conj) patients/NNS (l_amod) infected/VBN -PUNC- lamivudine/JJ (r_npadvmod) resistant/JJ (r_amod) virus/NN (l_compound) B/NN -PUNC- lamivudine/NN (r_compound) na/NN (r_aux) ve/VB (r_acl) study/NN (l_acl) investigate/VB (l_dobj) virus/NN (l_compound) B/NN -PUNC- lamivudine/NN (r_npadvmod) resistant/JJ (r_amod) strains/NNS (r_nsubjpass) detected/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_compound) B/NNP -PUNC- lamivudine/NN (r_npadvmod) resistant/JJ (r_amod) strains/NNS (r_nsubjpass) detected/VBN (l_conj) patients/NNS (l_amod) infected/VBN -PUNC- lamivudine/NN (r_npadvmod) resistant/JJ (r_amod) strains/NNS (l_prep) in/IN (l_pcomp) ve/VB (l_dobj) patients/NNS (l_amod) infected/VBN -PUNC- lamivudine/NN (r_npadvmod) containing/VBG (r_advcl) emergence/NN (r_pobj) in/IN (r_prep) result/VB (l_conj) applied/VBN (l_advcl) is/VBZ (l_acomp) likely/JJ (l_xcomp) have/VB (l_dobj) implications/NNS (l_prep) in/IN (l_pobj) management/NN (l_prep) of/IN (l_pobj) patients/NNS (l_amod) infected/VBN
D012964_D006509 NONE na/TO (r_aux) ve/VB (l_dobj) virus/NN (l_appos) patients/NNS (l_amod) infected/JJ -PUNC- na/TO (r_aux) ve/VB (l_dobj) virus/NN (l_appos) patients/NNS (l_prep) with/IN (l_conj) without/IN (l_pobj) implications/NNS (l_conj) patients/NNS (l_amod) infected/VBN -PUNC- na/NN (r_aux) ve/VB (r_acl) study/NN (l_acl) investigate/VB (l_dobj) virus/NN (l_compound) B/NN -PUNC- na/TO (r_aux) ve/VB (l_dobj) patients/NNS (l_amod) infected/VBN
6203452
D014748_D002277 NONE alkaloid/NN (r_amod) vinca/JJ (r_conj) bleomycin/NNS (r_conj) treatment/NN (r_pobj) after/IN (r_prep) developed/VBD (l_nsubj) patients/NNS (l_prep) with/IN (l_pobj) carcinoma/NN
D001761_D002277 NONE bleomycin/NNS (r_conj) treatment/NN (r_pobj) after/IN (r_prep) developed/VBD (l_nsubj) patients/NNS (l_prep) with/IN (l_pobj) carcinoma/NN
D002945_D057049 NONE cisplatin/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) after/IN (r_prep) developed/VBD (l_dobj) microangiopathy/NN
D002945_D013921 NONE cisplatin/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) after/IN (r_prep) developed/VBD (l_dobj) microangiopathy/NN (l_acl) characterized/VBN (l_conj) anemia/NN (l_conj) thrombocytopenia/JJ -PUNC- cisplatin/VB (r_amod) nephrotoxicity/NN (l_conj) thrombocytopenia/NN
D002945_D002277 NONE cisplatin/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) after/IN (r_prep) developed/VBD (l_nsubj) patients/NNS (l_prep) with/IN (l_pobj) carcinoma/NN
D002945_D000740 NONE cisplatin/VB (r_amod) nephrotoxicity/NN (l_conj) anemia/NN
D002945_D007674 CID cisplatin/VB (r_amod) nephrotoxicity/NN
D001761_D013921 NONE bleomycin/NNS (r_conj) treatment/NN (r_pobj) after/IN (r_prep) developed/VBD (l_dobj) microangiopathy/NN (l_acl) characterized/VBN (l_conj) anemia/NN (l_conj) thrombocytopenia/JJ
D002945_D000743 NONE cisplatin/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) after/IN (r_prep) developed/VBD (l_dobj) microangiopathy/NN (l_acl) characterized/VBN (l_conj) anemia/NN
D014748_D000743 NONE alkaloid/NN (r_amod) vinca/JJ (r_conj) bleomycin/NNS (r_conj) treatment/NN (r_pobj) after/IN (r_prep) developed/VBD (l_dobj) microangiopathy/NN (l_acl) characterized/VBN (l_conj) anemia/NN
D001761_D000743 NONE bleomycin/NNS (r_conj) treatment/NN (r_pobj) after/IN (r_prep) developed/VBD (l_dobj) microangiopathy/NN (l_acl) characterized/VBN (l_conj) anemia/NN
D014748_D057049 NONE alkaloid/NN (r_amod) vinca/JJ (r_conj) bleomycin/NNS (r_conj) treatment/NN (r_pobj) after/IN (r_prep) developed/VBD (l_dobj) microangiopathy/NN
D001761_D057049 NONE bleomycin/NNS (r_conj) treatment/NN (r_pobj) after/IN (r_prep) developed/VBD (l_dobj) microangiopathy/NN
D002945_D051437 NONE cisplatin/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) after/IN (r_prep) developed/VBD (l_dobj) microangiopathy/NN (l_acl) characterized/VBN (l_agent) by/IN (l_pobj) insufficiency/NN -PUNC- cisplatin/VB (r_amod) nephrotoxicity/NN (r_pobj) to/IN (r_prep) ascribed/VBN (l_nsubjpass) failure/NN
D002945_D001855 NONE cisplatin/VB (r_amod) nephrotoxicity/NN (l_conj) thrombocytopenia/NN (l_prep) to/IN (l_pobj) suppression/NN
D001761_D051437 NONE bleomycin/NNS (r_conj) treatment/NN (r_pobj) after/IN (r_prep) developed/VBD (l_dobj) microangiopathy/NN (l_acl) characterized/VBN (l_agent) by/IN (l_pobj) insufficiency/NN
D014748_D013921 NONE alkaloid/NN (r_amod) vinca/JJ (r_conj) bleomycin/NNS (r_conj) treatment/NN (r_pobj) after/IN (r_prep) developed/VBD (l_dobj) microangiopathy/NN (l_acl) characterized/VBN (l_conj) anemia/NN (l_conj) thrombocytopenia/JJ
D014748_D051437 NONE alkaloid/NN (r_amod) vinca/JJ (r_conj) bleomycin/NNS (r_conj) treatment/NN (r_pobj) after/IN (r_prep) developed/VBD (l_dobj) microangiopathy/NN (l_acl) characterized/VBN (l_agent) by/IN (l_pobj) insufficiency/NN
12907309
C121465_D020258 NONE MPEP/NNP (r_pobj) of/IN (r_prep) action/NN (l_prep) in/IN (l_pobj) neurotoxicity/NN
D004298_D005334 NONE dopamine/NN (r_compound) outflow/NN (l_conj) inhibition/NN (l_prep) of/IN (l_pobj) hyperthermia/NN -PUNC- dopamine/NN (r_compound) efflux/NN (r_pobj) of/IN (r_prep) reduction/NN (r_pobj) with/IN (r_prep) associated/VBN (l_conj) with/IN (l_pobj) decrease/NN (l_prep) in/IN (l_pobj) hyperthermia/NN
C121465_D064420 NONE MPEP/NNP (r_pobj) by/IN (r_prep) blockade/NN (r_nsubj) protect/VB (l_dobj) neurones/NNS (l_prep) against/IN (l_pobj) toxicity/NN
C121465_D005334 NONE MPEP/NNP (r_pobj) of/IN (r_prep) action/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) decrease/NN (l_prep) in/IN (l_pobj) outflow/NN (l_conj) inhibition/NN (l_prep) of/IN (l_pobj) hyperthermia/NN -PUNC- MPEP/NNP (r_pobj) by/IN (r_agent) rendered/VBN (r_acl) Neuroprotection/NNP (r_nsubjpass) associated/VBN (l_conj) with/IN (l_pobj) decrease/NN (l_prep) in/IN (l_pobj) hyperthermia/NN
D008694_D005334 CID methamphetamine/NN (r_npadvmod) induced/VBN (r_amod) neurotoxicity/NN (r_pobj) in/IN (r_prep) action/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) decrease/NN (l_prep) in/IN (l_pobj) outflow/NN (l_conj) inhibition/NN (l_prep) of/IN (l_pobj) hyperthermia/NN -PUNC- methamphetamine/NN (r_npadvmod) induced/VBN (r_amod) efflux/NN (r_pobj) of/IN (r_prep) reduction/NN (r_pobj) with/IN (r_prep) associated/VBN (l_conj) with/IN (l_pobj) decrease/NN (l_prep) in/IN (l_pobj) hyperthermia/NN
D008694_D064420 NONE methamphetamine/NN (r_npadvmod) induced/VBN (r_amod) toxicity/NN
D004298_D020258 NONE dopamine/NN (r_compound) outflow/NN (r_pobj) in/IN (r_prep) decrease/NN (r_pobj) with/IN (r_prep) associated/VBN (l_nsubjpass) action/NN (l_prep) in/IN (l_pobj) neurotoxicity/NN
D008694_D020258 NONE methamphetamine/NN (r_npadvmod) induced/VBN (r_amod) neurotoxicity/NN
15009014
D001285_D006940 NONE atropine/NN (r_pobj) by/IN (r_agent) abolished/VBN (l_nsubjpass) increases/NNS (l_prep) in/IN (l_pobj) flow/NN
D002211_D006940 CID Capsaicin/NNS (r_nsubj) applied/VBN (l_conj) induced/VBN (l_dobj) increases/NNS (l_prep) in/IN (l_pobj) flow/NN
12617329
D005839_D058186 CID gentamicin/NN (r_nmod) nephrotoxicity/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) failure/NN -PUNC- GM/NNP (r_nmod) nephrotoxicity/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) failure/NN
D006170_D007674 NONE Arabic/JJ (r_pobj) with/IN (r_prep) treatment/NN (l_prep) on/IN (l_pobj) nephrotoxicity/NN -PUNC- Arabic/JJ (r_pobj) with/IN (r_prep) rats/NNS (r_pobj) of/IN (r_prep) treatment/NN (l_prep) on/IN (l_pobj) failure/NN (l_acl) induced/VBN (l_agent) by/IN (l_pobj) nephrotoxicity/NN -PUNC- Arabic/JJ (r_amod) treatment/NN (r_nsubj) induced/VBN (l_dobj) amelioration/NN (l_prep) of/IN (l_pobj) some/DT (l_prep) of/IN (l_pobj) indices/NNS (l_prep) of/IN (l_pobj) nephrotoxicity/NN
D005839_D007674 NONE gentamicin/NN (r_amod) nephrotoxicity/NN -PUNC- gentamicin/NN (r_nmod) nephrotoxicity/NN -PUNC- GM/NNP (r_nmod) nephrotoxicity/NN -PUNC- GM/NNP (r_compound) nephrotoxicity/NN
D006170_D007683 NONE Arabic/JJ (r_pobj) with/IN (r_prep) given/VBN (r_acl) rats/NNS (r_pobj) in/IN (r_prep) severe/JJ (r_acomp) be/VB (r_xcomp) appeared/VBD (l_nsubj) necrosis/NN
D005978_D007674 NONE glutathione/NN (r_conj) measuring/VBG (r_pcomp) by/IN (r_prep) assessed/VBN (l_nsubjpass) Nephrotoxicity/NN -PUNC- GSH/NNP (r_appos) glutathione/NN (r_conj) measuring/VBG (r_pcomp) by/IN (r_prep) assessed/VBN (l_nsubjpass) Nephrotoxicity/NN
D005839_D007683 NONE GM/NNP (r_npadvmod) induced/VBN (r_amod) necrosis/NN -PUNC- GM/NNP (r_dobj) given/VBN (r_acl) rats/NNS (r_pobj) in/IN (r_prep) severe/JJ (r_acomp) be/VB (r_xcomp) appeared/VBD (l_nsubj) necrosis/NN -PUNC- GM/NNP (r_pobj) given/VBN (r_acl) those/DT (r_pobj) in/IN (r_prep) than/IN (r_prep) given/VBN (r_acl) rats/NNS (r_pobj) in/IN (r_prep) severe/JJ (r_acomp) be/VB (r_xcomp) appeared/VBD (l_nsubj) necrosis/NN
D003404_D007674 NONE creatinine/NN (r_pobj) of/IN (r_prep) concentrations/NNS (r_dobj) measuring/VBG (r_pcomp) by/IN (r_prep) assessed/VBN (l_nsubjpass) Nephrotoxicity/NN
D006170_D058186 CID Arabic/JJ (r_pobj) with/IN (r_prep) rats/NNS (r_pobj) of/IN (r_prep) treatment/NN (l_prep) on/IN (l_pobj) failure/NN
D014508_D007674 NONE urea/NN (r_conj) creatinine/NN (r_pobj) of/IN (r_prep) concentrations/NNS (r_dobj) measuring/VBG (r_pcomp) by/IN (r_prep) assessed/VBN (l_nsubjpass) Nephrotoxicity/NN
10737864
D003000_D001919 CID clonidine/NN (r_pobj) given/VBN (r_prep) induces/VBZ (l_dobj) withdrawal/NN (l_conj) bradycardia/NNP -PUNC- clonidine/NN (r_poss) effects/NNS (r_nsubj) mirror/VB (r_ccomp) hypothesized/VBD (l_ccomp) exhibits/VBZ (l_conj) induces/VBZ (l_dobj) withdrawal/NN (l_conj) bradycardia/NNP -PUNC- clonidine/NN (r_npadvmod) induced/VBN (r_amod) bradycardia/NN
18754075
D013256_D009404 NONE steroid/NN (r_compound) therapy/NN (r_pobj) to/IN (r_prep) responding/VBG (l_nsubj) man/NN (l_prep) with/IN (l_pobj) syndrome/NN
D013256_D005923 NONE steroid/NN (r_compound) therapy/NN (r_pobj) to/IN (r_prep) responding/VBG (l_nsubj) man/NN (l_amod) due/IN (l_pobj) glomerulosclerosis/NN
D019386_D058186 CID alendronate/JJ (r_nmod) administration/NN (r_pobj) after/IN (r_prep) proteinuria/NN (l_conj) failure/NN -PUNC- sodium/NN (r_nmod) administration/NN (r_nsubj) increased/VBD (l_prep) with/IN (l_pobj) failure/NN
D004164_D005923 NONE bisphosphonate/NN (r_nmod) administration/NN (l_prep) in/IN (l_pobj) patient/NN (l_prep) with/IN (l_pobj) glomerulosclerosis/NN
D019386_D005923 NONE alendronate/JJ (r_nmod) administration/NN (l_prep) in/IN (l_pobj) patient/NN (l_prep) with/IN (l_pobj) glomerulosclerosis/NN
D019386_D011507 CID alendronate/JJ (r_nmod) administration/NN (r_pobj) after/IN (r_prep) proteinuria/NN
D004164_D058186 NONE bisphosphonate/NN (r_nmod) administration/NN (r_pobj) after/IN (r_prep) proteinuria/NN (l_conj) failure/NN -PUNC- bisphosphonate/NN (r_pobj) of/IN (r_prep) days/NNS (r_pobj) Within/IN (r_prep) increased/VBD (l_prep) with/IN (l_pobj) failure/NN -PUNC- bisphosphonates/NNS (r_nsubj) aggravate/VB (l_dobj) proteinuria/NN (l_conj) failure/NN
D004164_D011507 NONE bisphosphonate/NN (r_nmod) administration/NN (r_pobj) after/IN (r_prep) proteinuria/NN -PUNC- bisphosphonates/NNS (r_nsubj) aggravate/VB (l_dobj) proteinuria/NN
11263551
D016572_D010146 CID cyclosporine-/NN (r_nmod) levels/NNS (r_pobj) of/IN (r_prep) reduction/NN (r_nsubj) led/VBD (l_prep) to/IN (l_pobj) relief/NN (l_prep) of/IN (l_pobj) pain/NN -PUNC- cyclosporine/NN (r_pobj) of/IN (r_prep) effect/NN (r_attr) is/VBZ (l_nsubj) Syndrome/NNP (l_compound) Pain/NNP
D016559_-1 NONE tacrolimus/NN (r_conj) cyclosporine/NN (r_pobj) of/IN (r_prep) effect/NN (r_attr) is/VBZ (l_nsubj) Syndrome/NNP (l_appos) CIPS/NNP
D002118_D010146 NONE calcium/NN (r_compound) channel/NN (r_compound) blockers/NNS (r_pobj) of/IN (r_prep) administration/NN (r_conj) reduction/NN (r_nsubj) led/VBD (l_prep) to/IN (l_pobj) relief/NN (l_prep) of/IN (l_pobj) pain/NN
D016559_D010146 CID tacrolimus/VB (r_compound) trough/NN (r_compound) levels/NNS (r_pobj) of/IN (r_prep) reduction/NN (r_nsubj) led/VBD (l_prep) to/IN (l_pobj) relief/NN (l_prep) of/IN (l_pobj) pain/NN -PUNC- tacrolimus/NN (r_conj) cyclosporine/NN (r_pobj) of/IN (r_prep) effect/NN (r_attr) is/VBZ (l_nsubj) Syndrome/NNP (l_compound) Pain/NNP
D016572_-1 NONE cyclosporine/NN (r_pobj) of/IN (r_prep) effect/NN (r_attr) is/VBZ (l_nsubj) Syndrome/NNP (l_appos) CIPS/NNP
2484011
D009638_D011596 NONE norepinephrine/NN (r_pobj) of/IN (r_prep) methylation/NN (r_pobj) in/IN (r_prep) increase/NN (l_relcl) account/VB (l_prep) for/IN (l_pobj) depression/NN
D000588_D011596 NONE amines/NNS (r_pobj) of/IN (r_prep) results/NNS (r_nsubj) suggest/VBP (l_dobj) decrease/NN (l_conj) increase/NN (l_relcl) account/VB (l_prep) for/IN (l_pobj) depression/NN
D002395_D011596 NONE catecholamine/NN (r_compound) rate/NN (r_pobj) of/IN (r_prep) decrease/NN (l_conj) increase/NN (l_relcl) account/VB (l_prep) for/IN (l_pobj) depression/NN
D000547_D011596 CID amantadine/NN (r_pobj) of/IN (r_prep) Readministration/NN (r_nsubj) increased/VBN (l_prep) with/IN (l_pobj) exception/NN (l_prep) of/IN (l_pobj) mice/NNS (l_relcl) occurred/VBD (l_nsubj) suppression/NN (l_prep) of/IN (l_pobj) motility/NN -PUNC- amantadine/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) depression/NN
D000547_D003866 NONE amantadine/JJ (r_nmod) activity/NN (l_amod) depressed/JJ
3031535
D013759_D002375 CID 9-tetrahydrocannabinol/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubj) involvement/NN (l_prep) in/IN (l_pobj) catalepsy/NN -PUNC- THC/NNP (r_pobj) by/IN (r_agent) induced/VBN (r_acl) manifestation/NN (l_prep) of/IN (l_pobj) catalepsy/NN -PUNC- THC/NNP (r_pobj) by/IN (r_agent) induced/VBN (r_acl) manifestation/NN (r_pobj) in/IN (r_prep) role/NN (r_dobj) have/VBP (l_advcl) are/VBP (l_prep) in/IN (l_pobj) catalepsy/NN
D006220_D002375 CID haloperidol/NN (r_pobj) by/IN (r_agent) induced/VBN (r_advcl) are/VBP (r_advcl) have/VBP (l_dobj) role/NN (l_prep) in/IN (l_pobj) manifestation/NN (l_prep) of/IN (l_pobj) catalepsy/NN -PUNC- haloperidol/NN (r_pobj) by/IN (r_agent) induced/VBN (r_advcl) are/VBP (l_prep) in/IN (l_pobj) catalepsy/NN
11135224
C056507_D064420 NONE gemcitabine/NN (r_compound) combination/NN (r_conj) paclitaxel/NN (r_pobj) of/IN (r_prep) toxicity/NN
D002945_D002289 NONE cisplatin/NN (l_conj) chemotherapy/NN (l_prep) within/IN (l_pobj) approach/NN (l_prep) in/IN (l_pobj) carcinoma/NN -PUNC- Cisplatin/NN (r_npadvmod) based/VBN (r_amod) combinations/NNS (r_nsubj) improve/VBP (l_dobj) quality/NN (l_prep) in/IN (l_pobj) carcinoma/NN -PUNC- Cisplatin/NN (r_npadvmod) based/VBN (r_amod) combinations/NNS (r_nsubj) improve/VBP (l_dobj) quality/NN (l_prep) in/IN (l_pobj) carcinoma/NN (l_appos) NSCLC/NNP -PUNC- cisplatin/NN (r_conj) paclitaxel/NN (r_pobj) of/IN (r_prep) toxicity/NN (r_conj) rate/NN (r_conj) feasibility/NN (r_dobj) determine/VB (l_xcomp) treat/VB (l_dobj) NSCLC/NN -PUNC- cisplatin/NN (r_conj) treated/VBN (l_nsubjpass) patients/NNS (l_prep) with/IN (l_pobj) NSCLC/NNP -PUNC- cisplatin/NN (r_conj) paclitaxel/NN (r_pobj) of/IN (r_prep) combination/NN (r_nsubjpass) tolerated/VBN (l_conj) shows/VBZ (l_prep) in/IN (l_pobj) NSCLC/NNP
C056507_D002289 NONE gemcitabine/NN (r_compound) combination/NN (r_compound) chemotherapy/NN (l_prep) within/IN (l_pobj) approach/NN (l_prep) in/IN (l_pobj) carcinoma/NN -PUNC- gemcitabine/NN (r_compound) combination/NN (r_conj) paclitaxel/NN (r_pobj) of/IN (r_prep) toxicity/NN (r_conj) rate/NN (r_conj) feasibility/NN (r_dobj) determine/VB (l_xcomp) treat/VB (l_dobj) NSCLC/NN -PUNC- gemcitabine/NN (r_conj) treated/VBN (l_nsubjpass) patients/NNS (l_prep) with/IN (l_pobj) NSCLC/NNP -PUNC- gemcitabine/NN (r_conj) combination/NN (r_nsubjpass) tolerated/VBN (l_conj) shows/VBZ (l_prep) in/IN (l_pobj) NSCLC/NNP
D002945_D064420 NONE cisplatin/NN (r_conj) paclitaxel/NN (r_pobj) of/IN (r_prep) toxicity/NN
D017239_D064420 NONE paclitaxel/NN (r_pobj) of/IN (r_prep) toxicity/NN
D017239_D002289 NONE Paclitaxel/NNP (l_conj) cisplatin/NN (l_conj) chemotherapy/NN (l_prep) within/IN (l_pobj) approach/NN (l_prep) in/IN (l_pobj) carcinoma/NN -PUNC- paclitaxel/NN (r_pobj) of/IN (r_prep) toxicity/NN (r_conj) rate/NN (r_conj) feasibility/NN (r_dobj) determine/VB (l_xcomp) treat/VB (l_dobj) NSCLC/NN -PUNC- paclitaxel/NN (r_pobj) of/IN (r_prep) combination/NN (r_pobj) with/IN (r_prep) treated/VBN (l_nsubjpass) patients/NNS (l_prep) with/IN (l_pobj) NSCLC/NNP -PUNC- paclitaxel/NN (r_pobj) of/IN (r_prep) combination/NN (r_nsubjpass) tolerated/VBN (l_conj) shows/VBZ (l_prep) in/IN (l_pobj) NSCLC/NNP
15325671
D017239_D001943 NONE paclitaxel/NN (l_conj) melphalan/NN (l_conj) cyclophosphamide/NN (l_conj) thiotepa/NNS (l_conj) carboplatin/VB (l_dobj) regimen/NN (l_prep) for/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) cancer/NN
D013852_D001943 NONE thiotepa/NNS (l_conj) carboplatin/VB (l_dobj) regimen/NN (l_prep) for/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) cancer/NN
D003520_D001943 NONE cyclophosphamide/NN (r_npadvmod) based/VBN (r_amod) chemotherapy/NN (l_prep) for/IN (l_pobj) cancer/NN -PUNC- cyclophosphamide/NN (l_conj) thiotepa/NNS (l_conj) carboplatin/VB (l_dobj) regimen/NN (l_prep) for/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) cancer/NN -PUNC- cyclophosphamide/NN (r_dobj) receiving/VBG (r_acl) cancer/NN
D018943_D006973 NONE anthracyclines/NNS (r_pobj) of/IN (r_prep) use/NN (r_conj) mellitus/NN (r_conj) smoking/NN (r_conj) history/NN (r_appos) presence/NN (l_prep) of/IN (l_pobj) electrocardiogram/NN (l_appos) abnormalities/NNS (l_appos) hypertension/NN
D018943_D003920 NONE anthracyclines/NNS (r_pobj) of/IN (r_prep) use/NN (r_conj) mellitus/NN
D018943_D006333 NONE anthracyclines/NNS (r_pobj) of/IN (r_prep) use/NN (r_conj) mellitus/NN (r_conj) smoking/NN (r_conj) history/NN (r_appos) presence/NN (r_appos) characteristics/NNS (r_conj) cancer/NN (l_acl) receiving/VBG (l_prep) as/IN (l_pobj) part/NN (l_prep) of/IN (l_pobj) regimen/NN (l_acl) assess/VB (l_dobj) association/NN (l_prep) between/IN (l_pobj) presence/NN (l_prep) of/IN (l_pobj) failure/NN -PUNC- anthracyclines/NNS (r_pobj) of/IN (r_prep) use/NN (r_conj) mellitus/NN (r_conj) smoking/NN (r_conj) history/NN (r_appos) presence/NN (r_appos) characteristics/NNS (r_conj) cancer/NN (l_acl) receiving/VBG (l_prep) as/IN (l_pobj) part/NN (l_prep) of/IN (l_pobj) regimen/NN (l_acl) assess/VB (l_dobj) association/NN (l_prep) between/IN (l_pobj) presence/NN (l_prep) of/IN (l_pobj) failure/NN (l_appos) CHF/NNP
D003520_D066126 NONE cyclophosphamide/NN (r_npadvmod) based/VBN (r_amod) chemotherapy/NN (r_pobj) with/IN (r_prep) association/NN (r_pobj) in/IN (r_prep) observed/VBD (l_nsubj) toxicity/NN -PUNC- cyclophosphamide/NN (r_npadvmod) related/VBN (r_amod) toxicity/NN
D008558_D001943 NONE melphalan/NN (l_conj) cyclophosphamide/NN (l_conj) thiotepa/NNS (l_conj) carboplatin/VB (l_dobj) regimen/NN (l_prep) for/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) cancer/NN
D018943_D001943 NONE anthracyclines/NNS (r_pobj) of/IN (r_prep) use/NN (r_conj) mellitus/NN (r_conj) smoking/NN (r_conj) history/NN (r_appos) presence/NN (r_appos) characteristics/NNS (r_conj) cancer/NN
D003520_D006973 NONE cyclophosphamide/NN (r_dobj) receiving/VBG (r_acl) cancer/NN (l_conj) characteristics/NNS (l_appos) presence/NN (l_prep) of/IN (l_pobj) electrocardiogram/NN (l_appos) abnormalities/NNS (l_appos) hypertension/NN
D003520_D006333 CID cyclophosphamide/NN (r_dobj) receiving/VBG (l_prep) as/IN (l_pobj) part/NN (l_prep) of/IN (l_pobj) regimen/NN (l_acl) assess/VB (l_dobj) association/NN (l_prep) between/IN (l_pobj) presence/NN (l_prep) of/IN (l_pobj) failure/NN -PUNC- cyclophosphamide/NN (r_dobj) receiving/VBG (l_prep) as/IN (l_pobj) part/NN (l_prep) of/IN (l_pobj) regimen/NN (l_acl) assess/VB (l_dobj) association/NN (l_prep) between/IN (l_pobj) presence/NN (l_prep) of/IN (l_pobj) failure/NN (l_appos) CHF/NNP -PUNC- cyclophosphamide/NN (r_dobj) following/VBG (r_prep) developed/VBD (l_dobj) grade/NN (l_appos) CHF/NNP -PUNC- cyclophosphamide/NN (r_pobj) during/IN (r_prep) monitoring/NN (r_nsubj) predict/VB (l_dobj) development/NN (l_compound) CHF/NNP
D016190_D001943 NONE carboplatin/VB (l_dobj) regimen/NN (l_prep) for/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) cancer/NN
D003520_D003920 NONE cyclophosphamide/NN (r_dobj) receiving/VBG (r_acl) cancer/NN (l_conj) characteristics/NNS (l_appos) presence/NN (l_appos) history/NN (l_conj) smoking/NN (l_conj) mellitus/NN
3015567
D009599_D007022 CID Nitroprusside/NNP (r_npadvmod) induced/VBN (r_amod) hypotension/NN -PUNC- nitroprusside/RB (r_advmod) induced/VBN (r_amod) hypotension/NN
D003345_D007022 NONE corticosterone/NN (r_compound) level/NN (r_pobj) at/IN (r_prep) occurs/VBZ (r_conj) observed/VBN (l_nsubjpass) Suppression/NN (l_appos) secretion/NN (l_prep) in/IN (l_pobj) response/NN (l_prep) to/IN (l_pobj) hypotension/NN
19767176
D010100_D009410 NONE oxygen/NN (r_compound) species/NNS (r_pobj) of/IN (r_prep) production/NN (r_nsubjpass) implicated/VBN (l_prep) in/IN (l_pobj) damage/NN -PUNC- oxygen/NN (r_compound) species/NNS (r_pobj) of/IN (r_prep) generation/NN (r_nsubj) plays/VBZ (l_dobj) role/NN (l_prep) in/IN (l_pobj) damage/NN
C020972_D013226 NONE dithiocarbamate/NN (r_nsubj) protects/VBZ (l_dobj) cortex/NN (l_prep) in/IN (l_pobj) model/NN (l_amod) epilepticus/NN -PUNC- PDTC/NNP (r_pobj) of/IN (r_prep) effect/NN (l_prep) on/IN (l_pobj) loss/NN (l_amod) associated/VBN (l_npadvmod) epilepticus/NN -PUNC- PDTC/NNP (r_pobj) with/IN (r_prep) Treatment/NN (r_nsubj) increased/VBD (l_advmod) epilepticus/NN -PUNC- PDTC/NNP (r_nmod) dose/NN (r_pobj) of/IN (r_prep) Administration/NN (r_nsubj) exert/VB (l_dobj) effects/NNS (l_prep) on/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) epilepticus/NN -PUNC- PDTC/NNP (r_npadvmod) treated/VBN (r_amod) rats/NNS (r_conj) vehicle-/NN (r_pobj) in/IN (r_prep) identified/VBN (l_prep) following/VBG (l_pobj) epilepticus/NN
D010100_D012640 NONE oxygen/NN (r_compound) species/NNS (r_pobj) of/IN (r_prep) generation/NN (r_nsubj) plays/VBZ (l_dobj) role/NN (l_prep) in/IN (l_pobj) damage/NN (l_amod) associated/VBN (l_npadvmod) seizure/NN
C020972_D009410 NONE PDTC/NNP (r_conj) inhibitor/NN (r_nsubj) protected/VBD (l_advcl) affect/VB (l_dobj) loss/NN
D010862_D013226 CID pilocarpine/NN (r_amod) model/NN (l_amod) epilepticus/NN -PUNC- pilocarpine/NN (r_compound) model/NN (r_pobj) in/IN (r_prep) evaluated/VBN (l_nsubjpass) effect/NN (l_prep) on/IN (l_pobj) loss/NN (l_amod) associated/VBN (l_npadvmod) epilepticus/NN
11875660
D001374_D009436 NONE 5-azacytidine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) exencephaly/NNS
20698227
D012254_D000740 NONE ribavirin/RB (r_conj) markers/NNS (r_dobj) angiogenesis/NN (r_pobj) between/IN (r_prep) link/NN (r_dobj) investigating/VBG (r_acl) study/NN (r_attr) is/VBZ (l_advcl) induced/VBD (l_dobj) anemia/NN
C473478_D006461 CID sunitinib/JJ (r_pobj) as/IN (r_prep) inhibitors/NNS (r_pobj) of/IN (r_prep) number/NN (r_nsubjpass) found/VBN (l_advcl) cause/VB (l_dobj) hemolysis/NN
D012254_D019698 NONE ribavirin/RB (r_conj) 2a/CD (r_pobj) by/IN (r_agent) treated/VBN (l_csubjpass) infected/VBN (l_prep) with/IN (l_pobj) virus/NN -PUNC- ribavirin/RB (r_conj) markers/NNS (r_dobj) angiogenesis/NN (r_pobj) between/IN (r_prep) link/NN (r_dobj) investigating/VBG (r_acl) study/NN (r_attr) is/VBZ (l_advcl) induced/VBD (l_dobj) anemia/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) C/NNP
C100416_D019698 NONE 2a/CD (r_pobj) by/IN (r_agent) treated/VBN (l_csubjpass) infected/VBN (l_prep) with/IN (l_pobj) virus/NN
D012254_D006461 NONE ribavirin/RB (r_nsubjpass) found/VBN (l_conj) found/VBN (l_advcl) cause/VB (l_dobj) hemolysis/NN
D012254_D000743 NONE ribavirin/RB (r_pobj) for/IN (r_prep) treatment/NN (r_pobj) of/IN (r_prep) target/NN (l_acl) associated/VBN (l_dobj) anemia/NN
C471405_D006461 CID sorafenib/NNS (r_conj) sunitinib/JJ (r_pobj) as/IN (r_prep) inhibitors/NNS (r_pobj) of/IN (r_prep) number/NN (r_nsubjpass) found/VBN (l_advcl) cause/VB (l_dobj) hemolysis/NN
15120741
D010862_D013226 CID pilocarpine/NN (r_compound) injection/NN (r_nsubj) causes/VBZ (l_dobj) SE/NNP (l_nmod) epilepticus/NN -PUNC- pilocarpine/NN (r_compound) injection/NN (r_nsubj) causes/VBZ (l_dobj) SE/NNP -PUNC- pilocarpine/NN (r_npadvmod) treated/VBN (r_amod) mice/NNS (r_conj) mice/NNS (r_pobj) from/IN (r_prep) cells/NNS (r_pobj) in/IN (r_prep) spike/NN (l_relcl) experience/VB (l_dobj) SE/NNP
D008274_D013226 NONE Mg(2+)-free/JJ (r_pobj) In/IN (r_prep) resulted/VBD (l_prep) in/IN (l_pobj) spike/NN (l_relcl) experience/VB (l_dobj) SE/NNP
D018698_D013226 NONE glutamate/NN (r_compound) receptor/NN (r_compound) antagonists/NNS (r_pobj) by/IN (r_agent) blocked/VBN (r_relcl) duration/NN (r_pobj) of/IN (r_prep) afterdischarges/NNS (r_conj) shifts/NNS (r_pobj) by/IN (r_prep) followed/VBD (r_advcl) resulted/VBD (l_prep) In/IN (l_pobj) survivors/NNS (l_compound) SE/NNP -PUNC- glutamate/NN (r_compound) photostimulation/NN (r_nsubj) resulted/VBD (l_prep) in/IN (l_pobj) responses/NNS (l_prep) of/IN (l_pobj) duration/NN (l_prep) in/IN (l_pobj) slices/NNS (l_prep) from/IN (l_pobj) survivors/NNS (l_compound) SE/NNP
D001640_D013226 NONE bicuculline/NN (r_pobj) In/IN (r_prep) resulted/VBD (l_prep) in/IN (l_pobj) spike/NN (l_relcl) experience/VB (l_dobj) SE/NNP
D010862_D012640 CID pilocarpine/NN (r_compound) injection/NN (r_nsubj) causes/VBZ (l_dobj) SE/NNP (l_conj) development/NN (l_prep) of/IN (l_pobj) seizures/NNS
2924746
D002220_D064420 NONE carbamazepine/NN (r_compound) treatment/NN (l_appos) efficacy/NN (l_conj) toxicity/NN
D019946_D012640 NONE glycol/NN (r_appos) vehicle/NN (r_nsubjpass) found/VBN (l_xcomp) exhibit/VB (l_dobj) properties/NNS (l_prep) against/IN (l_pobj) seizures/NNS
D005492_D064420 NONE folate/JJ (r_compound) concentrations/NNS (r_conj) plasma/NN (r_pobj) on/IN (r_prep) effect/NN (r_conj) toxicity/NN
D005481_D015430 NONE HFDE/NNP (r_npadvmod) induced/VBN (r_amod) seizures/NNS (r_pobj) against/IN (r_prep) protective/JJ (r_acomp) was/VBD (l_conj) was/VBD (l_advcl) measured/VBN (l_agent) by/IN (l_pobj) gain/NN
D002220_D012640 NONE CBZ/NN (r_pobj) by/IN (r_prep) protection/NN (r_pobj) of/IN (r_prep) measure/NN (r_attr) be/VB (r_xcomp) found/VBN (r_conj) induced/VBN (l_nsubj) Seizures/NNS -PUNC- CBZ/NN (r_pobj) by/IN (r_prep) protection/NN (r_pobj) of/IN (r_prep) measure/NN (r_attr) be/VB (l_prep) than/IN (l_pobj) seizures/NNS -PUNC- CBZ/NNP (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) was/VBD (l_acomp) protective/JJ (l_prep) against/IN (l_pobj) seizures/NNS
D002220_D015430 NONE CBZ/NNP (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) was/VBD (l_conj) was/VBD (l_advcl) measured/VBN (l_agent) by/IN (l_pobj) gain/NN
D005481_D012640 CID ether/NN (r_pobj) by/IN (r_prep) induced/VBN (l_nsubj) Seizures/NNS -PUNC- ether/NN (r_pobj) by/IN (r_prep) induced/VBN (l_conj) found/VBN (l_xcomp) be/VB (l_prep) than/IN (l_pobj) seizures/NNS -PUNC- HFDE/NNP (r_appos) ether/NN (r_pobj) by/IN (r_prep) induced/VBN (l_nsubj) Seizures/NNS -PUNC- HFDE/NNP (r_appos) ether/NN (r_pobj) by/IN (r_prep) induced/VBN (l_conj) found/VBN (l_xcomp) be/VB (l_prep) than/IN (l_pobj) seizures/NNS -PUNC- HFDE/NNP (r_npadvmod) induced/VBN (r_amod) seizures/NNS
D019946_D015430 NONE glycol/NN (r_appos) vehicle/NN (r_nsubjpass) found/VBN (l_xcomp) exhibit/VB (l_dobj) properties/NNS (l_prep) against/IN (l_pobj) seizures/NNS (l_conj) gain/NN
567256
D004054_D006394 CID diethylstilbestrol/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) liver/NN -PUNC- diethylstilbestrol/NN (r_pobj) with/IN (r_prep) liver/NN (r_pobj) of/IN (r_prep) adenocarcinoma/NN (r_pobj) for/IN (r_prep) treated/VBN (r_relcl) man/NN (r_pobj) in/IN (r_prep) occurred/VBD (l_nsubj) Angiosarcoma/NNP (l_prep) of/IN (l_pobj) liver/NN
D004054_D000230 NONE diethylstilbestrol/NN (r_pobj) with/IN (r_prep) liver/NN
D004054_D008113 CID diethylstilbestrol/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) liver/NN -PUNC- diethylstilbestrol/NN (r_pobj) with/IN (r_prep) liver/NN (r_pobj) of/IN (r_prep) adenocarcinoma/NN (r_pobj) for/IN (r_prep) treated/VBN (r_relcl) man/NN (r_pobj) in/IN (r_prep) occurred/VBD (l_nsubj) Angiosarcoma/NNP (l_prep) of/IN (l_pobj) liver/NN
D004054_D008113 NONE diethylstilbestrol/NN (r_pobj) with/IN (r_prep) liver/NN
12757899
D004958_D012640 NONE Estradiol/NN (r_nsubj) reduces/VBZ (l_dobj) injury/NN (l_amod) induced/VBN (l_npadvmod) seizure/NN -PUNC- estradiol/NN (r_pobj) of/IN (r_prep) effects/NNS (l_prep) on/IN (l_pobj) threshold/NN (l_compound) seizure/NN
D008094_D013226 CID lithium/NN (r_compound) pilocarpine/NN (r_npadvmod) induced/VBN (r_amod) SE/NNP
D007608_D001930 NONE acid/NN (r_npadvmod) induced/VBN (r_amod) status/NN (r_pobj) by/IN (r_agent) induced/VBN (r_advcl) protect/VBP (l_dobj) rats/NNS (l_prep) from/IN (l_pobj) injury/NN
D007608_D013226 NONE acid/NN (r_npadvmod) induced/VBN (r_amod) status/NN (l_appos) SE/NNP (l_amod) epilepticus/NN -PUNC- acid/NN (r_npadvmod) induced/VBN (r_amod) status/NN (l_appos) SE/NNP
D010862_D013226 CID pilocarpine/NN (r_npadvmod) induced/VBN (r_amod) SE/NNP
D004958_D013226 NONE estradiol/NN (r_pobj) of/IN (r_prep) effects/NNS (l_conj) rats/NNS (l_acl) subjected/VBN (l_prep) to/IN (l_pobj) SE/NNP
D012834_D013226 NONE silver/NN (r_npadvmod) stained/VBN (r_amod) CA3/NN (r_pobj) of/IN (r_prep) extent/NN (r_nsubjpass) evaluated/VBN (l_prep) after/IN (l_pobj) SE/NNP
D004958_D001930 NONE Estradiol/NN (r_nsubj) reduces/VBZ (l_dobj) injury/NN
1378968
D003404_D051437 NONE creatinine/NN (r_compound) levels/NNS (r_dobj) decrease/NN (r_conj) increase/VB (r_xcomp) tended/VBD (r_conj) failed/VBD (l_xcomp) accentuante/NN (l_dobj) progression/NN (l_prep) of/IN (l_pobj) failure/NN
D008094_D007676 CID lithium/NN (r_npadvmod) induced/VBN (r_amod) failure/NN
D008094_D006973 CID Lithium/NN (r_nsubj) caused/VBD (l_dobj) proteinuria/NN (l_conj) hypertension/NN -PUNC- Li/NNP (r_npadvmod) induced/VBN (r_amod) nephropathy/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) proteinuria/NN (l_conj) hypertension/NN
D008094_D011507 CID Lithium/NN (r_nsubj) caused/VBD (l_dobj) proteinuria/NN -PUNC- Li/NNP (r_npadvmod) induced/VBN (r_amod) nephropathy/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) proteinuria/NN
D008094_D051437 NONE lithium/NN (r_npadvmod) induced/VBN (r_amod) nephropathy/NN (r_pobj) with/IN (r_prep) Rats/NNS (r_nsubjpass) subjected/VBN (l_prep) in/IN (l_pobj) attempt/NN (l_acl) induce/VB (l_dobj) hyperfiltration/NN (l_conj) progression/NN (l_prep) of/IN (l_pobj) failure/NN -PUNC- lithium/NN (r_nmod) rats/NNS (r_pobj) in/IN (r_prep) levels/NNS (r_dobj) decrease/NN (r_conj) increase/VB (r_xcomp) tended/VBD (r_conj) failed/VBD (l_xcomp) accentuante/NN (l_dobj) progression/NN (l_prep) of/IN (l_pobj) failure/NN
D008094_D005921 NONE Lithium/NN (r_nsubj) caused/VBD (l_prep) in/IN (l_pobj) absence/NN (l_prep) of/IN (l_pobj) glomerulosclerosis/NN
D008094_D007674 NONE lithium/NN (r_npadvmod) induced/VBN (r_amod) nephropathy/NN -PUNC- Li/NNP (r_npadvmod) induced/VBN (r_amod) nephropathy/NN
15899738
D003401_D001281 CID creatine/NN (r_compound) supplementation/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) fibrillation/NN
D003401_D001145 NONE creatine/NN (l_prep) to/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) arrhythmia/NN
9727773
D001067_D006976 CID suppressants/NNS (r_pobj) with/IN (r_prep) associated/VBN (r_acl) incidence/NN (l_prep) of/IN (l_pobj) hypertension/NN -PUNC- suppressant/NN (r_compound) drugs/NNS (r_pobj) of/IN (r_prep) intake/NN (r_pobj) with/IN (r_prep) associated/VBN (r_relcl) disease/NN (r_attr) is/VBZ (l_nsubj) hypertension/NN -PUNC- suppressants/NNS (r_dobj) taken/VBN (l_ccomp) was/VBD (l_nsubj) diagnosis/NN (l_prep) of/IN (l_pobj) hypertension/NN -PUNC- suppressants/NNS (r_pobj) of/IN (r_prep) prescription/NN (r_pobj) of/IN (r_prep) policy/NN (r_nsubj) lead/VB (l_prep) to/IN (l_pobj) incidence/NN (l_prep) of/IN (l_pobj) hypertension/NN
603022
D005702_D062787 NONE hydrobromide/RB (r_nsubjpass) used/VBN (l_prep) in/IN (l_pobj) patient/JJ (l_acl) demonstrating/NN (l_dobj) effects/NNS (l_prep) of/IN (l_pobj) overdosage/NN
D012601_D062787 CID scopolamine/NN (r_nmod) overdosage/NN -PUNC- hyoscine/NN (r_nmod) overdosage/NN
15804801
D017239_D003323 CID paclitaxel/NN (r_compound) eluting/VBG (r_amod) stent/NN (r_pobj) of/IN (r_prep) implantation/NN (r_pobj) after/IN (r_prep) aneurysm/NN -PUNC- paclitaxel/NN (r_compound) eluting/VBG (r_amod) stent/NN (r_dobj) receiving/VBG (r_pcomp) after/IN (r_prep) developed/VBD (l_dobj) aneurysm/NN
18442015
D004872_D006471 CID D2/NN (r_pobj) of/IN (r_prep) coadministration/NN (r_pobj) by/IN (r_prep) induced/VBN (l_nsubj) release/NN (l_conj) peroxide/NN (l_appos) permeability/NN (l_prep) in/IN (l_pcomp) modulating/VBG (l_dobj) hemorrhage/NN
D014700_D014456 NONE verapamil/NN (r_pobj) of/IN (r_prep) effect/NN (l_prep) on/IN (l_pobj) ulcers/NNS -PUNC- verapamil/NN (r_pobj) of/IN (r_prep) effect/NN (l_prep) on/IN (l_pobj) model/NN (l_compound) ulcer/NN -PUNC- verapamil/NN (r_pobj) by/IN (r_agent) ameliorated/VBN (r_acomp) were/VBD (l_nsubj) ulcer/NN -PUNC- verapamil/NN (r_pobj) by/IN (r_agent) ameliorated/VBN (r_relcl) generation/NN (l_ccomp) produce/VB (l_dobj) ulcer/NN
D002118_D050197 NONE calcium/NN (r_pobj) as/IN (r_prep) parameters/NNS (l_amod) atherosclerotic/JJ -PUNC- calcium/NN (r_pobj) as/IN (r_prep) parameters/NNS (r_nsubjpass) obtained/VBN (l_prep) in/IN (l_pobj) rats/NNS (l_amod) atherosclerotic/JJ
D004872_D014456 CID D2/NN (r_pobj) of/IN (r_prep) coadministration/NN (r_pobj) by/IN (r_prep) induced/VBN (l_nsubj) release/NN (l_conj) peroxide/NN (l_appos) permeability/NN (l_prep) in/IN (l_pcomp) modulating/VBG (l_dobj) hemorrhage/NN (l_conj) ulcer/NN
D014700_D006471 NONE verapamil/NN (r_pobj) of/IN (r_prep) effect/NN (l_prep) on/IN (l_pobj) ulcers/NNS (l_amod) hemorrhagic/JJ -PUNC- verapamil/NN (r_pobj) by/IN (r_agent) ameliorated/VBN (r_acomp) were/VBD (l_nsubj) ulcer/NN (l_amod) hemorrhagic/JJ -PUNC- verapamil/NN (r_pobj) by/IN (r_agent) ameliorated/VBN (r_relcl) generation/NN (l_ccomp) produce/VB (l_dobj) ulcer/NN (l_amod) hemorrhagic/JJ
D006632_D014456 NONE histamine/NN (r_compound) release/NN (l_conj) peroxide/NN (l_appos) permeability/NN (l_prep) in/IN (l_pcomp) modulating/VBG (l_dobj) hemorrhage/NN (l_conj) ulcer/NN -PUNC- histamine/NN (r_compound) concentration/NN (l_conj) permeability/NN (l_conj) content/NN (l_conj) areas/NNS (l_compound) ulcer/NN -PUNC- histamine/NN (r_compound) release/NN (r_conj) diffusion/NN (r_pobj) including/VBG (r_prep) factors/NNS (r_pobj) with/IN (r_prep) accompanied/VBN (l_nsubj) ulcers/NNS -PUNC- histamine/NN (r_pobj) of/IN (r_prep) correlation/NN (l_prep) to/IN (l_conj) to/IN (l_pobj) ulcer/NN -PUNC- histamine/NN (r_compound) release/NN (r_conj) generation/NN (l_ccomp) produce/VB (l_dobj) ulcer/NN
D002784_D014456 CID cholesterol/NN (r_conj) D2/NN (r_pobj) of/IN (r_prep) coadministration/NN (r_pobj) by/IN (r_prep) induced/VBN (l_nsubj) release/NN (l_conj) peroxide/NN (l_appos) permeability/NN (l_prep) in/IN (l_pcomp) modulating/VBG (l_dobj) hemorrhage/NN (l_conj) ulcer/NN
D006632_D050197 NONE histamine/NN (r_compound) release/NN (l_conj) peroxide/NN (l_appos) permeability/NN (l_prep) in/IN (l_pcomp) modulating/VBG (l_dobj) hemorrhage/NN (l_prep) in/IN (l_pobj) rats/NNS (l_prep) with/IN (l_pobj) atherosclerosis/NN -PUNC- histamine/NN (r_pobj) of/IN (r_prep) correlation/NN (r_nsubjpass) found/VBN (l_prep) in/IN (l_pobj) rats/NNS (l_amod) atherosclerotic/JJ -PUNC- histamine/NN (r_compound) release/NN (r_conj) generation/NN (l_ccomp) produce/VB (l_nsubj) Atherosclerosis/NN
D004872_D050197 CID D2/NN (r_pobj) of/IN (r_prep) coadministration/NN (r_pobj) by/IN (r_prep) induced/VBN (l_nsubj) release/NN (l_conj) peroxide/NN (l_appos) permeability/NN (l_prep) in/IN (l_pcomp) modulating/VBG (l_dobj) hemorrhage/NN (l_prep) in/IN (l_pobj) rats/NNS (l_prep) with/IN (l_pobj) atherosclerosis/NN -PUNC- D2/NN (r_dobj) containing/VBG (l_advcl) induce/VB (l_dobj) atherosclerosis/NN
D002784_D006471 CID cholesterol/NN (r_conj) D2/NN (r_pobj) of/IN (r_prep) coadministration/NN (r_pobj) by/IN (r_prep) induced/VBN (l_nsubj) release/NN (l_conj) peroxide/NN (l_appos) permeability/NN (l_prep) in/IN (l_pcomp) modulating/VBG (l_dobj) hemorrhage/NN
D006632_D006471 NONE histamine/NN (r_compound) release/NN (l_conj) peroxide/NN (l_appos) permeability/NN (l_prep) in/IN (l_pcomp) modulating/VBG (l_dobj) hemorrhage/NN -PUNC- histamine/NN (r_pobj) of/IN (r_prep) correlation/NN (l_prep) to/IN (l_pobj) hemorrhage/NN -PUNC- histamine/NN (r_compound) release/NN (r_conj) generation/NN (l_ccomp) produce/VB (l_dobj) ulcer/NN (l_amod) hemorrhagic/JJ
D014700_D050197 NONE verapamil/NN (r_pobj) of/IN (r_prep) effect/NN (l_prep) on/IN (l_pobj) ulcers/NNS (l_prep) in/IN (l_pobj) rats/NNS (l_amod) atherosclerotic/JJ -PUNC- verapamil/NN (r_pobj) by/IN (r_agent) ameliorated/VBN (r_relcl) generation/NN (l_ccomp) produce/VB (l_nsubj) Atherosclerosis/NN
D010634_D014456 NONE luminal/JJ (r_amod) content/NN (l_conj) areas/NNS (l_compound) ulcer/NN -PUNC- luminal/JJ (r_amod) content/NN (r_conj) generation/NN (r_conj) release/NN (r_conj) diffusion/NN (r_pobj) including/VBG (r_prep) factors/NNS (r_pobj) with/IN (r_prep) accompanied/VBN (l_nsubj) ulcers/NNS
D002784_D050197 CID cholesterol/NN (r_conj) D2/NN (r_pobj) of/IN (r_prep) coadministration/NN (r_pobj) by/IN (r_prep) induced/VBN (l_nsubj) release/NN (l_conj) peroxide/NN (l_appos) permeability/NN (l_prep) in/IN (l_pcomp) modulating/VBG (l_dobj) hemorrhage/NN (l_prep) in/IN (l_pobj) rats/NNS (l_prep) with/IN (l_pobj) atherosclerosis/NN -PUNC- cholesterol/NN (r_conj) D2/NN (r_dobj) containing/VBG (l_advcl) induce/VB (l_dobj) atherosclerosis/NN -PUNC- cholesterol/NN (r_conj) calcium/NN (r_pobj) as/IN (r_prep) parameters/NNS (l_amod) atherosclerotic/JJ -PUNC- cholesterol/NN (r_conj) calcium/NN (r_pobj) as/IN (r_prep) parameters/NNS (r_nsubjpass) obtained/VBN (l_prep) in/IN (l_pobj) rats/NNS (l_amod) atherosclerotic/JJ
17532790
D007980_D004409 CID DOPA/NNP (r_npadvmod) induced/VBN (r_amod) dyskinesia/NN -PUNC- DOPA/NNP (r_npadvmod) induced/VBN (r_amod) dyskinesia/NN -PUNC- DOPA/NNP (r_npadvmod) induced/VBN (r_amod) dyskinesia/NN (l_appos) LID/NNP -PUNC- DOPA/NNP (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) after/IN (r_prep) arise/VBP (r_relcl) complications/NNS (r_pobj) among/IN (r_prep) is/VBZ (l_nsubj) dyskinesia/NN -PUNC- DOPA/NNP (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) after/IN (r_prep) arise/VBP (r_relcl) complications/NNS (r_pobj) among/IN (r_prep) is/VBZ (l_nsubj) dyskinesia/NN (l_appos) LID/NNP -PUNC- DOPA/NNP (r_pobj) with/IN (r_prep) treated/VBD (l_conj) allocated/VBN (l_prep) to/IN (l_pobj) groups/NNS (l_acl) based/VBN (l_prep) on/IN (l_pobj) presence/NN (l_conj) absence/NN (l_prep) of/IN (l_pobj) LID/NNP
D016627_D010300 NONE 6-hydroxydopamine/CD (r_compound) lesion/NN (r_compound) rat/NN (r_compound) model/NN (l_prep) of/IN (l_pobj) PD/NNP
D001971_D010300 NONE bromocriptine/NN (r_conj) DOPA/NNP (r_appos) changes/NNS (l_acl) occurring/VBG (l_prep) at/IN (l_pobj) level/NN (l_acl) obtained/VBN (l_prep) from/IN (l_pobj) model/NN (l_prep) of/IN (l_pobj) PD/NNP
D007980_D010300 NONE DOPA/NNP (r_npadvmod) induced/VBN (r_amod) dyskinesia/NN (r_nsubj) is/VBZ (l_prep) among/IN (l_pobj) complications/NNS (l_relcl) arise/VBP (l_prep) in/IN (l_pobj) patients/NNS (l_nmod) disease/NN -PUNC- DOPA/NNP (r_npadvmod) induced/VBN (r_amod) dyskinesia/NN (r_nsubj) is/VBZ (l_prep) among/IN (l_pobj) complications/NNS (l_relcl) arise/VBP (l_prep) in/IN (l_pobj) patients/NNS (l_nmod) PD/NNP -PUNC- DOPA/NNP (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) after/IN (r_prep) arise/VBP (l_prep) in/IN (l_pobj) patients/NNS (l_nmod) disease/NN -PUNC- DOPA/NNP (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) after/IN (r_prep) arise/VBP (l_prep) in/IN (l_pobj) patients/NNS (l_nmod) PD/NNP -PUNC- DOPA/NNP (r_appos) changes/NNS (l_acl) occurring/VBG (l_prep) at/IN (l_pobj) level/NN (l_acl) obtained/VBN (l_prep) from/IN (l_pobj) model/NN (l_prep) of/IN (l_pobj) PD/NNP
14513889
D007654_D009422 NONE Ketoconazole/NNP (r_npadvmod) induced/VBN (l_dobj) sequelae/NNS
2445283
D012254_D000740 CID ribavirin/NN (r_nsubj) has/VBZ (l_conj) managed/VBN (l_nsubjpass) anemia/NN
D012254_D006478 NONE ribavirin/NN (r_pobj) of/IN (r_prep) effect/NN (r_conj) Tolerance/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) fever/NN -PUNC- ribavirin/NN (r_pobj) of/IN (r_prep) effect/NN (r_conj) Tolerance/NN (r_nsubjpass) studied/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) fever/NN -PUNC- ribavirin/NN (r_pobj) of/IN (r_prep) effect/NN (r_conj) Tolerance/NN (r_nsubjpass) studied/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) fever/NN (l_appos) AHF/NNP -PUNC- ribavirin/NN (r_nsubj) has/VBZ (l_dobj) effect/NN (l_prep) in/IN (l_pobj) cases/NNS (l_prep) of/IN (l_pobj) AHF/NNP -PUNC- ribavirin/RB (r_pobj) of/IN (r_prep) effect/NN (l_prep) during/IN (l_pobj) days/NNS (l_prep) of/IN (l_pobj) AHF/NNP
D012254_D014766 NONE ribavirin/RB (r_pobj) of/IN (r_prep) Administration/NN (r_nsubj) resulted/VBD (l_prep) in/IN (l_pobj) neutralization/NN (l_prep) of/IN (l_pobj) viremia/NN
19843802
D004837_D006973 CID epinephrine/NN (r_pobj) of/IN (r_prep) bolus/NN (r_nsubj) provoked/VBD (l_dobj) crisis/NN (l_amod) hypertensive/JJ
18410508
D015632_D020258 NONE MPTP/NNP (r_conj) METH/NNP (r_pobj) by/IN (r_agent) caused/VBN (r_acl) damage/NN (r_nsubj) is/VBZ (l_prep) for/IN (l_pobj) system/NN (l_prep) in/IN (l_pobj) models/NNS (l_prep) of/IN (l_pobj) neurotoxicity/NN -PUNC- MPTP/NNP (r_conj) METH/NNP (r_pobj) by/IN (r_agent) caused/VBN (r_acl) damage/NN (r_nsubj) is/VBZ (r_advcl) hypothesized/VBD (l_ccomp) plays/VBZ (l_dobj) role/NN (l_prep) in/IN (l_pobj) neurotoxicity/NN
D004298_D020258 NONE DA/NNP (r_compound) system/NN (l_prep) in/IN (l_pobj) models/NNS (l_prep) of/IN (l_pobj) neurotoxicity/NN -PUNC- DA/NNP (r_compound) system/NN (r_pobj) for/IN (r_prep) is/VBZ (r_advcl) hypothesized/VBD (l_ccomp) plays/VBZ (l_dobj) role/NN (l_prep) in/IN (l_pobj) neurotoxicity/NN
D004298_D009422 NONE DA/NNP (r_compound) neurons/NNS (r_pobj) of/IN (r_prep) neurodegeneration/NN -PUNC- DA/NNP (r_compound) system/NN (r_pobj) for/IN (r_prep) is/VBZ (l_nsubj) damage/NN
D015632_D009422 CID MPTP/NNP (r_npadvmod) induced/VBN (r_amod) neurodegeneration/NN -PUNC- MPTP/NNP (r_conj) METH/NNP (r_pobj) by/IN (r_agent) caused/VBN (r_acl) damage/NN
D008694_D009422 CID METH/NNP (r_pobj) by/IN (r_agent) caused/VBN (r_acl) damage/NN -PUNC- METH/NNP (r_npadvmod) induced/VBN (r_amod) neurotoxicity/NN (r_pobj) in/IN (r_prep) role/NN (r_dobj) plays/VBZ (r_ccomp) hypothesized/VBD (l_advcl) is/VBZ (l_nsubj) damage/NN
D008694_D020258 NONE Methamphetamine/NN (r_npadvmod) induced/VBN (r_amod) activation/NN (l_nmod) neurotoxicity/NN -PUNC- METH/NNP (r_pobj) by/IN (r_agent) caused/VBN (r_acl) damage/NN (r_nsubj) is/VBZ (l_prep) for/IN (l_pobj) system/NN (l_prep) in/IN (l_pobj) models/NNS (l_prep) of/IN (l_pobj) neurotoxicity/NN -PUNC- METH/NNP (r_pobj) by/IN (r_agent) caused/VBN (r_acl) damage/NN (r_nsubj) is/VBZ (r_advcl) hypothesized/VBD (l_ccomp) plays/VBZ (l_dobj) role/NN (l_prep) in/IN (l_pobj) neurotoxicity/NN -PUNC- METH/NNP (r_npadvmod) induced/VBN (r_amod) neurotoxicity/NN (r_pobj) in/IN (r_prep) role/NN (r_dobj) plays/VBZ (r_ccomp) hypothesized/VBD (l_advcl) is/VBZ (l_prep) for/IN (l_pobj) system/NN (l_prep) in/IN (l_pobj) models/NNS (l_prep) of/IN (l_pobj) neurotoxicity/NN -PUNC- METH/NNP (r_npadvmod) induced/VBN (r_amod) neurotoxicity/NN -PUNC- METH/NNP (r_pobj) with/IN (r_prep) treated/VBN (l_conj) examined/VBN (l_prep) for/IN (l_pobj) neurotoxicity/NN -PUNC- METH/NNP (r_compound) neurotoxicity/NN
16904497
D013256_D011128 NONE steroid/NN (r_compound) injection/NN (r_pobj) after/IN (r_prep) syndrome/NN
D014221_D011128 NONE triamcinolone/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) report/NN (l_prep) of/IN (l_pobj) syndrome/NN
D013256_D017116 NONE steroid/NN (r_compound) injection/NN (r_pobj) for/IN (r_prep) scheduled/VBN (l_nsubjpass) woman/NN (l_prep) with/IN (l_pobj) pain/NN
D013256_D011843 NONE steroid/NN (r_compound) injections/NNS (r_conj) therapy/NN (r_attr) are/VBP (l_nsubj) methods/NNS (l_prep) of/IN (l_pobj) radiculopathy/NN
D002045_D011128 CID bupivacaine/NN (r_conj) triamcinolone/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) report/NN (l_prep) of/IN (l_pobj) syndrome/NN
D013256_D010146 NONE steroid/NN (r_compound) injection/NN (r_pobj) for/IN (r_prep) scheduled/VBN (l_nsubjpass) woman/NN (l_prep) with/IN (l_pobj) pain/NN
D013256_D009422 NONE steroid/NN (r_compound) injections/NNS (r_pobj) after/IN (r_prep) vigilance/NN (l_prep) for/IN (l_pobj) deterioration/NN
8372922
7269015
D002066_D003556 CID Busulfan/NNS (r_npadvmod) induced/VBN (r_amod) cystitis/NN -PUNC- busulfan/NNS (r_npadvmod) induced/VBN (r_amod) cystitis/NN -PUNC- busulfan/NNS (r_amod) cystitis/NN -PUNC- busulfan/NNS (r_amod) cystitis/NN (l_conj) cystitis/NN
D002066_D006470 CID Busulfan/NNS (r_npadvmod) induced/VBN (r_amod) cystitis/NN -PUNC- busulfan/NNS (r_npadvmod) induced/VBN (r_amod) cystitis/NN
D002066_D002277 NONE busulfan/NNS (r_pobj) of/IN (r_prep) tendency/NN (r_pobj) of/IN (r_prep) view/NN (r_pobj) In/IN (l_advcl) induce/VB (l_dobj) atypia/NN (l_conj) carcinoma/NN
D003520_D003556 NONE cyclophosphamide/NN (r_npadvmod) induced/VBN (r_conj) radiation/NN (r_nmod) cystitis/NN (r_conj) cystitis/NN -PUNC- cyclophosphamide/NN (r_npadvmod) induced/VBN (r_conj) radiation/NN (r_nmod) cystitis/NN
18439803
D001224_D012640 NONE aspartate/NN (r_conj) glutamate/NN (r_pobj) of/IN (r_prep) reduction/NN (r_pobj) by/IN (r_agent) offset/VBN (r_conj) was/VBD (r_ccomp) suggested/VBN (l_prep) Based/VBN (l_prep) on/IN (l_pobj) finding/NN (l_acl) protect/VB (l_dobj) animals/NNS (l_prep) against/IN (l_pobj) seizure/NN -PUNC- aspartate/NN (r_conj) glutamate/NN (r_pobj) in/IN (r_prep) increases/NNS (r_dobj) reduce/VB (r_relcl) finding/NN (r_appos) VPA/NNP (r_pobj) like/IN (r_prep) account/VB (l_prep) for/IN (l_pobj) activity/NN (l_acl) observed/VBN (l_prep) in/IN (l_pobj) seizure/NN
C108761_D012640 NONE N-(2-propylpentanoyl)urea/NNP (r_pobj) of/IN (r_prep) effects/NNS (l_prep) in/IN (l_pobj) seizure/NN -PUNC- VPU/NNS (r_nsubj) was/VBD (l_advcl) exhibiting/VBG (l_dobj) dose/NN (l_prep) of/IN (l_pobj) mg/kg/NNS (l_prep) in/IN (l_pcomp) protecting/VBG (l_prep) against/IN (l_pobj) seizure/NN -PUNC- VPU/NNPS (r_nsubj) protect/VB (l_dobj) animals/NNS (l_prep) against/IN (l_pobj) seizure/NN -PUNC- VPU/NNP (r_nsubj) reduce/VB (r_relcl) finding/NN (r_appos) VPA/NNP (r_pobj) like/IN (r_prep) account/VB (l_prep) for/IN (l_pobj) activity/NN (l_acl) observed/VBN (l_prep) in/IN (l_pobj) seizure/NN
D014635_D012640 NONE VPA/NNP (r_pobj) than/IN (r_prep) potent/JJ (r_acomp) was/VBD (l_advcl) exhibiting/VBG (l_dobj) dose/NN (l_prep) of/IN (l_pobj) mg/kg/NNS (l_prep) in/IN (l_pcomp) protecting/VBG (l_prep) against/IN (l_pobj) seizure/NN -PUNC- VPA/NNP (r_pobj) for/IN (r_prep) value/NN (r_nsubj) was/VBD (r_advcl) exhibiting/VBG (l_dobj) dose/NN (l_prep) of/IN (l_pobj) mg/kg/NNS (l_prep) in/IN (l_pcomp) protecting/VBG (l_prep) against/IN (l_pobj) seizure/NN -PUNC- VPA/NNP (r_conj) VPU/NNPS (r_nsubj) protect/VB (l_dobj) animals/NNS (l_prep) against/IN (l_pobj) seizure/NN -PUNC- VPA/NNP (r_pobj) like/IN (r_prep) account/VB (l_prep) for/IN (l_pobj) activity/NN (l_acl) observed/VBN (l_prep) in/IN (l_pobj) seizure/NN
D000596_D012640 NONE acid/NN (r_compound) neurotransmitters/NNS (r_pobj) on/IN (r_prep) effects/NNS (l_prep) in/IN (l_pobj) seizure/NN -PUNC- acid/NN (r_compound) neurotransmitters/NNS (r_pobj) of/IN (r_prep) reduction/NN (r_nsubj) was/VBD (r_ccomp) suggested/VBN (l_prep) Based/VBN (l_prep) on/IN (l_pobj) finding/NN (l_acl) protect/VB (l_dobj) animals/NNS (l_prep) against/IN (l_pobj) seizure/NN
D018698_D012640 NONE glutamate/NN (r_pobj) of/IN (r_prep) reduction/NN (r_pobj) by/IN (r_agent) offset/VBN (r_conj) was/VBD (r_ccomp) suggested/VBN (l_prep) Based/VBN (l_prep) on/IN (l_pobj) finding/NN (l_acl) protect/VB (l_dobj) animals/NNS (l_prep) against/IN (l_pobj) seizure/NN -PUNC- glutamate/NN (r_pobj) in/IN (r_prep) increases/NNS (r_dobj) reduce/VB (r_relcl) finding/NN (r_appos) VPA/NNP (r_pobj) like/IN (r_prep) account/VB (l_prep) for/IN (l_pobj) activity/NN (l_acl) observed/VBN (l_prep) in/IN (l_pobj) seizure/NN
D010862_D012640 CID pilocarpine/NN (r_npadvmod) induced/VBN (r_amod) seizure/NN -PUNC- pilocarpine/NN (r_npadvmod) induced/VBN (r_amod) seizure/NN -PUNC- pilocarpine/NN (r_npadvmod) induced/VBN (r_amod) seizure/NN -PUNC- pilocarpine/NN (r_npadvmod) induced/VBN (r_amod) increases/NNS (r_dobj) reduce/VB (r_relcl) finding/NN (r_appos) VPA/NNP (r_pobj) like/IN (r_prep) account/VB (l_prep) for/IN (l_pobj) activity/NN (l_acl) observed/VBN (l_prep) in/IN (l_pobj) seizure/NN -PUNC- pilocarpine/NN (r_npadvmod) induced/VBN (r_amod) seizure/NN
12041669
D010396_D000741 CID penicillamine/NN (r_npadvmod) induced/VBN (r_amod) anemia/NN -PUNC- penicillamine/NN (r_compound) therapy/NN (r_nsubjpass) described/VBN (l_nsubjpass) patient/NN (l_relcl) received/VBD (l_prep) for/IN (l_pobj) anemia/NN -PUNC- penicillamine/NN (r_npadvmod) induced/VBN (r_amod) anemia/NN
D000961_D000741 NONE globulin/NN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) anemia/NN -PUNC- globulin/NN (r_compound) therapy/NN (r_dobj) received/VBD (l_prep) for/IN (l_pobj) anemia/NN -PUNC- globulin/NN (r_dobj) Use/NN (r_nsubj) be/VB (l_attr) treatment/NN (l_prep) of/IN (l_pobj) anemia/NN
11206082
D001569_D012640 NONE benzodiazepine/NN (r_amod) site/NN (r_pobj) of/IN (r_prep) agonist/NN (r_appos) carboline-3-carboxylate/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) seizures/NNS
D010433_D012640 CID pentylenetetrazol/NN (r_npadvmod) induced/VBN (r_conj) picrotoxin-/NN (r_amod) seizures/NNS
C036150_D012640 CID carboline/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS -PUNC- carboline-3-carboxylate/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) seizures/NNS -PUNC- CCM/NNP (r_appos) carboline-3-carboxylate/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) seizures/NNS
D003975_D012640 NONE diazepam/NN (r_npadvmod) induced/VBN (r_amod) anxiolysis/NN (r_dobj) measured/VBD (l_dobj) sedation/NN (l_prep) by/IN (l_pcomp) recording/VBG (l_dobj) states/NNS (l_conj) seizures/NNS -PUNC- diazepam/NN (r_npadvmod) induced/VBN (r_amod) sedation/NN (l_prep) by/IN (l_pcomp) recording/VBG (l_dobj) states/NNS (l_conj) seizures/NNS
D005680_D012640 NONE GABA(A/NNP (r_nmod) ligands/NNS (r_pobj) of/IN (r_prep) effects/NNS (r_pobj) to/IN (r_prep) sensitive/JJ (r_acomp) are/VBP (l_nsubj) lines/NNS (l_acl) selected/VBN (l_prep) for/IN (l_pobj) sensitivities/NNS (l_prep) to/IN (l_pobj) seizures/NNS -PUNC- GABA(A/NNP (r_nmod) site/NN (r_pobj) of/IN (r_prep) agonist/NN (r_appos) carboline-3-carboxylate/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) seizures/NNS
D010852_D012640 CID picrotoxin-/NN (r_amod) seizures/NNS
11147747
C047426_D014549 CID venlafaxine/NN (r_dobj) taking/VBG (r_advcl) experienced/VBD (l_dobj) incontinence/NN -PUNC- venlafaxine/NNP (r_pobj) on/IN (r_prep) developed/VBD (r_relcl) third/NN (r_conj) paroxetine/NN (r_pobj) to/IN (r_prep) developed/VBD (l_dobj) secondary/JJ (l_compound) incontinence/NN
D018490_D014549 CID antidepressants/NNS (l_conj) incontinence/NN -PUNC- antidepressants/NNS (r_pobj) to/IN (r_prep) secondary/JJ (r_amod) incontinence/NN
D016651_D014549 CID carbonate/NN (r_dobj) taking/VBG (r_relcl) cases/NNS (r_pobj) of/IN (r_prep) 2/CD (r_pobj) In/IN (r_prep) contributed/VBN (l_prep) to/IN (l_pobj) incontinence/NN
D017374_D014549 CID paroxetine/NN (r_pobj) to/IN (r_prep) developed/VBD (l_dobj) secondary/JJ (l_compound) incontinence/NN
D012701_D014549 NONE serotonin/NN (r_compound) paroxetine/NN (r_pobj) to/IN (r_prep) developed/VBD (l_dobj) secondary/JJ (l_compound) incontinence/NN
D020280_D014549 CID sertraline/NN (r_conj) paroxetine/NN (r_pobj) to/IN (r_prep) developed/VBD (l_dobj) secondary/JJ (l_compound) incontinence/NN
8649546
D007980_D004409 CID levodopa/NN (r_npadvmod) induced/VBN (r_amod) dyskinesia/NN -PUNC- levodopa/RB (r_npadvmod) induced/VBN (r_amod) dyskinesia/NN
D011433_D004409 NONE propranolol/NN (r_pcomp) by/IN (r_prep) Improvement/NN (l_prep) of/IN (l_pobj) dyskinesia/NN -PUNC- propranolol/NN (r_dobj) received/VBN (l_nsubj) patients/NNS (l_acl) suffering/VBG (l_prep) with/IN (l_pobj) dyskinesia/NN
D007980_D010300 NONE levodopa/NN (r_npadvmod) induced/VBN (r_amod) dyskinesia/NN (r_pobj) of/IN (r_prep) Improvement/NN (l_prep) by/IN (l_pcomp) propranolol/NN (l_prep) in/IN (l_pobj) disease/NN -PUNC- levodopa/RB (r_npadvmod) induced/VBN (r_amod) dyskinesia/NN (l_prep) in/IN (l_pobj) PD/NNP
D011433_D010300 NONE propranolol/NN (l_prep) in/IN (l_pobj) disease/NN -PUNC- propranolol/NN (r_dobj) received/VBN (l_nsubj) patients/NNS (l_acl) suffering/VBG (l_prep) from/IN (l_pobj) disease/NN -PUNC- propranolol/NN (r_dobj) received/VBN (l_nsubj) patients/NNS (l_acl) suffering/VBG (l_prep) from/IN (l_pobj) disease/NN (l_appos) PD/NNP
8643971
D002945_D010051 NONE cisplatin/NN (r_compound) combination/NN (r_nsubjpass) used/VBN (l_conj) improved/VBN (l_dobj) duration/NN (l_prep) in/IN (l_pobj) patients/NNS (l_compound) cancer/NN
D002945_D006258 NONE cisplatin/NN (l_prep) as/IN (l_pobj) therapy/NN (l_prep) for/IN (l_pobj) cancers/NNS -PUNC- cisplatin/NN (r_compound) combination/NN (r_nsubjpass) used/VBN (r_conj) reported/VBD (l_dobj) rate/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) cancer/NN -PUNC- cisplatin/NN (r_pobj) with/IN (r_prep) combined/VBN (l_prep) with/IN (l_pobj) support/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) head/NN (l_conj) carcinoma/NN -PUNC- cisplatin/NN (r_advmod) is/VBZ (l_attr) regimen/NN (l_prep) for/IN (l_pobj) head/NN (l_conj) cancer/NN
D002945_D064420 NONE cisplatin/NN (r_pobj) with/IN (r_prep) combined/VBN (r_acl) doses/NNS (r_pobj) of/IN (r_prep) response/NN (l_conj) toxicity/NN
D017239_D064420 NONE paclitaxel/NN (r_compound) doses/NNS (r_pobj) of/IN (r_prep) response/NN (l_conj) toxicity/NN -PUNC- paclitaxel/NN (r_compound) doses/NNS (r_dobj) incorporate/VBP (l_conj) permitted/VBN (l_advcl) permits/VBZ (l_nsubj) toxicity/NN
D017239_D006258 NONE paclitaxel/NN (r_pobj) of/IN (r_prep) study/NN (r_dobj) phase/NN (l_conj) cisplatin/NN (l_prep) as/IN (l_pobj) therapy/NN (l_prep) for/IN (l_pobj) cancers/NNS -PUNC- paclitaxel/NN (r_pobj) of/IN (r_prep) study/NN (r_pobj) of/IN (r_prep) results/NNS (r_nsubj) reported/VBD (l_dobj) rate/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) cancer/NN -PUNC- Taxol/NNP (r_appos) paclitaxel/NN (r_pobj) of/IN (r_prep) study/NN (r_pobj) of/IN (r_prep) results/NNS (r_nsubj) reported/VBD (l_dobj) rate/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) cancer/NN -PUNC- paclitaxel/NN (r_nmod) combination/NN (r_nsubjpass) used/VBN (r_conj) reported/VBD (l_dobj) rate/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) cancer/NN -PUNC- paclitaxel/NN (r_compound) doses/NNS (l_acl) combined/VBN (l_prep) with/IN (l_pobj) support/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) head/NN (l_conj) carcinoma/NN -PUNC- Paclitaxel/NNP (r_nsubj) is/VBZ (l_attr) regimen/NN (l_prep) for/IN (l_pobj) head/NN (l_conj) cancer/NN
D017239_D010051 NONE paclitaxel/NN (r_pobj) of/IN (r_prep) study/NN (r_pobj) of/IN (r_prep) results/NNS (r_nsubj) reported/VBD (l_conj) used/VBN (l_conj) improved/VBN (l_dobj) duration/NN (l_prep) in/IN (l_pobj) patients/NNS (l_compound) cancer/NN -PUNC- Taxol/NNP (r_appos) paclitaxel/NN (r_pobj) of/IN (r_prep) study/NN (r_pobj) of/IN (r_prep) results/NNS (r_nsubj) reported/VBD (l_conj) used/VBN (l_conj) improved/VBN (l_dobj) duration/NN (l_prep) in/IN (l_pobj) patients/NNS (l_compound) cancer/NN -PUNC- paclitaxel/NN (r_nmod) combination/NN (r_nsubjpass) used/VBN (l_conj) improved/VBN (l_dobj) duration/NN (l_prep) in/IN (l_pobj) patients/NNS (l_compound) cancer/NN
3800626
D010423_D005355 CID pentazocine/NN (r_advmod) induced/VBN (r_amod) myopathy/NNS -PUNC- pentazocine/NN (r_compound) injection/NN (r_pobj) of/IN (r_prep) effect/NN (r_attr) is/VBZ (l_nsubj) myopathy/NN -PUNC- pentazocine/NN (r_advmod) induced/VBN (r_amod) myopathy/NNS -PUNC- pentazocine/NN (r_advmod) induced/VBN (r_amod) myopathy/NNS (r_pobj) with/IN (r_prep) woman/NN (r_pobj) In/IN (r_prep) showed/VBD (l_prep) in/IN (l_pobj) addition/NN (l_prep) to/IN (l_pobj) myopathy/NN
D010423_D020425 CID pentazocine/NN (r_advmod) induced/VBN (r_amod) myopathy/NNS (r_pobj) due/IN (r_prep) neuropathy/NN (l_prep) of/IN (l_pobj) nerve/NN
D010423_D009408 CID pentazocine/NN (r_advmod) induced/VBN (r_amod) myopathy/NNS (r_pobj) due/IN (r_prep) neuropathy/NN (l_prep) of/IN (l_pobj) nerve/NN -PUNC- pentazocine/NN (r_npadvmod) induced/VBN (r_compound) myopathy/NN (r_pobj) by/IN (r_agent) affected/VBN (r_acl) muscle/NN (r_pobj) due/IN (r_amod) neuropathy/NN
D010423_D009135 CID pentazocine/NN (r_advmod) induced/VBN (r_amod) myopathy/NNS -PUNC- pentazocine/NN (r_compound) injection/NN (r_pobj) of/IN (r_prep) effect/NN (r_attr) is/VBZ (l_nsubj) myopathy/NN -PUNC- pentazocine/NN (r_npadvmod) induced/VBN (r_compound) myopathy/NN -PUNC- pentazocine/NN (r_advmod) induced/VBN (r_amod) myopathy/NNS -PUNC- pentazocine/NN (r_advmod) induced/VBN (r_amod) myopathy/NNS (r_pobj) with/IN (r_prep) woman/NN (r_pobj) In/IN (r_prep) showed/VBD (l_prep) in/IN (l_pobj) addition/NN (l_prep) to/IN (l_pobj) myopathy/NN
14596845
D000661_D019966 NONE amphetamine/NN (r_pobj) of/IN (r_prep) dose/NN (r_pobj) to/IN (r_prep) sensitization/NN (r_dobj) causes/VBZ (l_nsubj) diet/NN (l_acl) promoting/VBG (l_dobj) dependency/NN
D013395_D006948 CID sucrose/NN (r_dobj) experienced/VBN (r_relcl) animals/NNS (r_nsubj) were/VBD (l_acomp) hyperactive/JJ -PUNC- sucrose/NN (r_appos) groups/NNS (r_pobj) with/IN (r_prep) compared/VBN (r_prep) were/VBD (l_acomp) hyperactive/JJ -PUNC- sucrose/NN (r_conj) amphetamine/NN (r_pobj) with/IN (r_prep) chow/NN (r_appos) groups/NNS (r_pobj) with/IN (r_prep) compared/VBN (r_prep) were/VBD (l_acomp) hyperactive/JJ
D000661_D006948 CID amphetamine/NN (r_pobj) of/IN (r_prep) dose/NN (r_pobj) to/IN (r_prep) sensitization/NN -PUNC- amphetamine/NN (r_pobj) of/IN (r_prep) dose/NN (r_pobj) to/IN (r_prep) show/VB (l_dobj) sensitization/NN -PUNC- amphetamine/NN (r_pobj) to/IN (r_prep) response/NN (r_pobj) in/IN (r_prep) were/VBD (l_acomp) hyperactive/JJ -PUNC- amphetamine/NN (r_compound) injection/NN (r_pobj) by/IN (r_agent) followed/VBN (r_acl) sucrose/NN (r_appos) groups/NNS (r_pobj) with/IN (r_prep) compared/VBN (r_prep) were/VBD (l_acomp) hyperactive/JJ -PUNC- amphetamine/NN (r_compound) injection/NN (r_pobj) by/IN (r_agent) followed/VBN (r_acl) chow/NN (r_appos) groups/NNS (r_pobj) with/IN (r_prep) compared/VBN (r_prep) were/VBD (l_acomp) hyperactive/JJ -PUNC- amphetamine/NN (r_pobj) with/IN (r_prep) chow/NN (r_appos) groups/NNS (r_pobj) with/IN (r_prep) compared/VBN (r_prep) were/VBD (l_acomp) hyperactive/JJ
983936
D006854_D009202 NONE hydrocortisone/NN (l_prep) on/IN (l_pobj) injury/NN
D004837_D009202 CID epinephrine/NN (r_npadvmod) induced/VBN (r_amod) injury/NN -PUNC- epinephrine/NN (r_amod) infusion/NN (r_appos) injury/NN
D001241_D009202 NONE acid/NN (l_conj) dipyridamole/NN (l_conj) hydrocortisone/NN (l_prep) on/IN (l_pobj) injury/NN
D004176_D009202 NONE dipyridamole/NN (l_conj) hydrocortisone/NN (l_prep) on/IN (l_pobj) injury/NN
D004837_D009203 NONE epinephrine/NN (r_amod) infusion/NN (r_appos) injury/NN (r_dobj) producing/VBG (r_pcomp) for/IN (r_prep) model/NN (r_nsubjpass) developed/VBN (l_advcl) study/VB (l_dobj) effects/NNS (l_prep) of/IN (l_pobj) agents/NNS (l_relcl) alter/VB (l_dobj) evolution/NN (l_prep) of/IN (l_pobj) infarction/NN
424937
D008750_D008107 NONE methyldopa/NN (r_pobj) to/IN (r_prep) related/VBN (r_acl) disease/NN -PUNC- methyldopa/NN (l_conj) dysfunction/NN
D008750_D017114 NONE methyldopa/NN (r_npadvmod) induced/VBN (r_amod) hepatitis/NN (r_pobj) of/IN (r_prep) episode/NN (r_pobj) after/IN (r_prep) recommenced/VBN (r_advcl) developed/VBD (l_dobj) hepatitis/NN
D008750_D056486 CID methyldopa/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubj) Patterns/NNS (l_prep) of/IN (l_pobj) injury/NN -PUNC- methyldopa/NN (r_npadvmod) induced/VBN (r_amod) hepatitis/NN -PUNC- methyldopa/NN (r_pobj) between/IN (r_prep) relationship/NN (r_nsubjpass) proved/VBN (l_prep) with/IN (l_pobj) recurrence/NN (l_prep) of/IN (l_pobj) hepatitis/NN
D008750_D017093 NONE methyldopa/NN (r_dobj) taking/VBG (r_relcl) another/DT (r_nsubj) showed/VBD (r_conj) presented/VBN (l_prep) in/IN (l_pobj) failure/NN
3503576
D003676_D006311 NONE deferoxamine/NN (r_compound) therapy/NN (r_dobj) receiving/VBG (r_acl) patients/NNS (r_pobj) in/IN (r_prep) studies/NNS (l_prep) of/IN (l_pobj) neurotoxicity/NN -PUNC- deferoxamine/NN (r_pobj) with/IN (r_prep) receiving/VBG (r_relcl) anemia/NN (r_pobj) with/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) documented/VBN (l_nsubjpass) neurotoxicity/NN -PUNC- deferoxamine/NN (r_compound) doses/NNS (r_dobj) receiving/VBG (r_advcl) restarted/VBN (l_prep) with/IN (l_pobj) doses/NNS (l_prep) depending/VBG (l_prep) on/IN (l_pobj) degree/NN (l_prep) of/IN (l_pobj) abnormality/NN -PUNC- deferoxamine/NN (r_dobj) receiving/VBG (r_conj) receiving/VBG (r_acl) patients/NNS (r_pobj) in/IN (r_prep) demonstrated/VBD (l_prep) provided/VBD (l_pcomp) convincing/JJ (l_dobj) evidence/NN (l_prep) for/IN (l_pobj) relation/NN (l_prep) between/IN (l_pobj) administration/NN (l_conj) ototoxicity/NN -PUNC- deferoxamine/NN (r_compound) administration/NN (l_conj) ototoxicity/NN
D007501_D006311 NONE iron/NN (r_compound) therapy/NN (r_dobj) receiving/VBG (r_relcl) anemia/NN (r_pobj) with/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) documented/VBN (l_nsubjpass) neurotoxicity/NN
D007501_D000740 NONE iron/NN (r_compound) therapy/NN (r_dobj) receiving/VBG (r_relcl) anemia/NN
D007501_D014786 NONE iron/NN (r_compound) therapy/NN (r_dobj) receiving/VBG (r_relcl) anemia/NN (r_pobj) with/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) documented/VBN (l_nsubjpass) neurotoxicity/NN
D003676_D014786 NONE deferoxamine/NN (r_pobj) with/IN (r_prep) receiving/VBG (r_relcl) anemia/NN (r_pobj) with/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) documented/VBN (l_nsubjpass) neurotoxicity/NN
D003676_D064420 NONE deferoxamine/NN (r_compound) doses/NNS (r_dobj) receiving/VBG (r_advcl) restarted/VBN (l_conj) demonstrated/VBN (l_nsubjpass) toxicity/NN
D003676_D000740 NONE deferoxamine/NN (r_pobj) with/IN (r_prep) receiving/VBG (r_relcl) anemia/NN
7890216
D002118_D042882 NONE calcium/NN (r_dobj) containing/VBG (r_acl) stones/NNS (r_conj) duct/NN (r_dobj) have/VB (r_conj) induced/VBN (l_dobj) stones/NNS -PUNC- calcium/NN (r_dobj) containing/VBG (r_acl) stones/NNS (r_conj) duct/NN (r_dobj) have/VB (r_conj) induced/VBN (l_ccomp) are/VBP (l_prep) in/IN (l_pobj) common/JJ (l_prep) with/IN (l_pobj) disease/NN -PUNC- calcium/NN (r_dobj) containing/VBG (r_acl) stones/NNS
D002784_D042882 NONE cholesterol/NN (r_conj) %/NN (r_dobj) contained/VBD (r_ccomp) showed/VBD (l_nsubj) analysis/NN (l_prep) of/IN (l_pobj) stones/NNS -PUNC- cholesterol/NN (r_nsubj) rich/JJ (r_acomp) were/VBD (r_ccomp) suggesting/VBG (r_advcl) showed/VBD (l_dobj) dissolution/NN (l_compound) stone/NN -PUNC- cholesterol/NN (r_conj) multiple/JJ (r_conj) small/JJ (r_acomp) are/VBP (r_ccomp) induced/VBN (l_dobj) stones/NNS -PUNC- cholesterol/NN (r_conj) multiple/JJ (r_conj) small/JJ (r_acomp) are/VBP (l_prep) in/IN (l_pobj) common/JJ (l_prep) with/IN (l_pobj) disease/NN -PUNC- cholesterol/NN (r_conj) multiple/JJ (r_conj) small/JJ (r_acomp) are/VBP (r_ccomp) induced/VBN (l_conj) have/VB (l_dobj) duct/NN (l_conj) stones/NNS
D015282_D000172 NONE Octreotide/NNP (l_appos) treatment/NN (l_prep) for/IN (l_pobj) acromegaly/NNS -PUNC- octreotide/NN (r_pobj) in/IN (r_prep) methods/NNS (r_pobj) by/IN (r_agent) investigated/VBN (l_conj) treated/VBD (l_dobj) patients/NNS (l_compound) acromegalic/JJ
D015282_D042882 CID octreotide/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) stones/NNS -PUNC- Octreotide/NNP (r_nsubj) induces/VBZ (l_dobj) stones/NNS -PUNC- octreotide/NN (r_pobj) in/IN (r_prep) methods/NNS (r_pobj) by/IN (r_agent) investigated/VBN (l_conj) treated/VBD (l_prep) with/IN (l_pobj) stones/NNS -PUNC- octreotide/NN (r_advmod) induced/VBN (l_dobj) stones/NNS -PUNC- octreotide/NN (r_advmod) induced/VBN (l_ccomp) are/VBP (l_prep) in/IN (l_pobj) common/JJ (l_prep) with/IN (l_pobj) disease/NN -PUNC- octreotide/NN (r_advmod) induced/VBN (l_conj) have/VB (l_dobj) duct/NN (l_conj) stones/NNS
D014580_D042882 NONE acid/NN (r_pobj) to/IN (r_prep) response/NN (r_appos) Composition/NN (l_prep) of/IN (l_pobj) stones/NNS
3403780
D000082_D003128 NONE Paracetamol/NN (r_npadvmod) associated/VBN (r_amod) coma/NN
D000082_D017114 CID paracetamol/JJ (r_compound) ingestion/NN (r_pobj) following/VBG (r_prep) failure/NN (l_conj) failure/NN
D000082_D000138 CID Paracetamol/NN (r_npadvmod) associated/VBN (r_amod) coma/NN (l_appos) acidosis/NN -PUNC- paracetamol/JJ (r_compound) ingestion/NN (r_pobj) following/VBG (r_prep) failure/NN (r_nsubjpass) presented/VBN (l_nsubjpass) case/NN (l_prep) of/IN (l_pobj) acidosis/NN
D000082_D017093 NONE Paracetamol/NN (r_npadvmod) associated/VBN (r_amod) coma/NN (l_appos) acidosis/NN (l_conj) failure/NN
D000082_D058186 CID paracetamol/JJ (r_compound) ingestion/NN (r_pobj) following/VBG (r_prep) failure/NN (l_conj) failure/NN
D000082_D058186 NONE Paracetamol/NN (r_npadvmod) associated/VBN (r_amod) coma/NN (l_appos) acidosis/NN (l_conj) failure/NN
3076126
D015248_D051437 NONE gemfibrozil/NN (r_conj) cyclosporin/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (r_pobj) in/IN (r_prep) reported/VBN (l_prep) in/IN (l_pobj) cases/NNS (l_prep) with/IN (l_pobj) failure/NN
D008148_D009135 NONE lovastatin/NN (r_pobj) with/IN (r_prep) reported/VBN (r_conj) associated/VBN (r_acl) Myopathy/NNP
D009525_D051437 NONE niacin/NN (r_conj) gemfibrozil/NN (r_conj) cyclosporin/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (r_pobj) in/IN (r_prep) reported/VBN (l_prep) in/IN (l_pobj) cases/NNS (l_prep) with/IN (l_pobj) failure/NN
D008148_D051437 CID lovastatin/NN (r_pobj) with/IN (r_prep) reported/VBN (l_prep) in/IN (l_pobj) cases/NNS (l_prep) with/IN (l_pobj) failure/NN
D009525_D009212 NONE niacin/NN (r_conj) gemfibrozil/NN (r_conj) cyclosporin/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (r_pobj) in/IN (r_prep) reported/VBN (r_conj) associated/VBN (l_prep) in/IN (l_pobj) cases/NNS (l_prep) with/IN (l_pobj) myoglobinuria/NNS
D016572_D009135 CID cyclosporin/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (r_pobj) in/IN (r_prep) reported/VBN (r_conj) associated/VBN (r_acl) Myopathy/NNP
D015248_D009212 NONE gemfibrozil/NN (r_conj) cyclosporin/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (r_pobj) in/IN (r_prep) reported/VBN (r_conj) associated/VBN (l_prep) in/IN (l_pobj) cases/NNS (l_prep) with/IN (l_pobj) myoglobinuria/NNS
D008148_D009212 CID lovastatin/NN (r_pobj) with/IN (r_prep) reported/VBN (r_conj) associated/VBN (l_prep) in/IN (l_pobj) cases/NNS (l_prep) with/IN (l_pobj) myoglobinuria/NNS
D016572_D009212 NONE cyclosporin/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (r_pobj) in/IN (r_prep) reported/VBN (r_conj) associated/VBN (l_prep) in/IN (l_pobj) cases/NNS (l_prep) with/IN (l_pobj) myoglobinuria/NNS
D009525_D009135 CID niacin/NN (r_conj) gemfibrozil/NN (r_conj) cyclosporin/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (r_pobj) in/IN (r_prep) reported/VBN (r_conj) associated/VBN (r_acl) Myopathy/NNP
D015248_D009135 CID gemfibrozil/NN (r_conj) cyclosporin/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (r_pobj) in/IN (r_prep) reported/VBN (r_conj) associated/VBN (r_acl) Myopathy/NNP
D016572_D051437 NONE cyclosporin/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (r_pobj) in/IN (r_prep) reported/VBN (l_prep) in/IN (l_pobj) cases/NNS (l_prep) with/IN (l_pobj) failure/NN
17343925
D012906_D034381 CID smoking/NN (r_pobj) of/IN (r_prep) influence/NN (r_nsubjpass) estimated/VBN (l_advcl) associated/VBN (l_prep) with/IN (l_pcomp) hearing/VBG (l_dobj) loss/NN -PUNC- smoking/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pcomp) hearing/VBG (l_dobj) loss/NN
7988234
D017706_D000799 CID lisinopril/NN (r_compound) therapy/NN (r_pobj) to/IN (r_prep) history/NN (l_prep) of/IN (l_pobj) angioedema/NN
D004155_D000799 NONE diphenhydramine/NN (r_conj) steroids/NNS (r_pobj) with/IN (r_prep) resolved/VBD (l_nsubj) angioedema/NN
D008790_D000799 CID metoprolol/NN (r_pobj) of/IN (r_prep) administration/NN (r_dobj) following/VBG (r_prep) Angioedema/NNP -PUNC- metoprolol/NN (r_nsubjpass) given/VBN (l_advcl) resulting/VBG (l_prep) in/IN (l_pobj) angioedema/NN
D013256_D000799 NONE steroids/NNS (r_pobj) with/IN (r_prep) resolved/VBD (l_nsubj) angioedema/NN
4812392
D001379_D011565 NONE azathioprine/NN (r_pobj) with/IN (r_prep) psoriasis/NN -PUNC- Azathioprine/JJ (r_det) treatment/NN (r_nsubj) benefited/VBD (l_prep) out/IN (l_prep) of/IN (l_pobj) patients/NNS (l_acl) suffering/VBG (l_prep) from/IN (l_pobj) psoriasis/NN
D001379_D056486 NONE azathioprine/JJ (r_amod) therapy/NN (r_nsubjpass) continued/VBN (l_advcl) detected/VBN (l_nsubjpass) damage/NN
8701950
D001241_D000743 NONE aspirin/NN (r_conj) corticosteroids/NNS (r_conj) replacement/NN (r_appos) discontinuation/NN (r_nsubj) led/VBD (l_prep) to/IN (l_pobj) resolution/NN (l_prep) of/IN (l_pobj) MAHA/NNP
D016559_D000743 CID FK506/NNP (r_dobj) complicating/VBG (l_nsubj) anemia/NN -PUNC- tacrolimus/NNP (r_nmod) therapy/NN (r_appos) FK506/NNP (r_dobj) complicating/VBG (l_nsubj) anemia/NN -PUNC- FK506/NNP (r_nmod) therapy/NN (r_pobj) under/IN (r_prep) recipients/NNS (r_pobj) in/IN (r_prep) episodes/NNS (l_prep) of/IN (l_pobj) anemia/NN -PUNC- FK506/NNP (r_nmod) therapy/NN (r_pobj) under/IN (r_prep) recipients/NNS (r_pobj) in/IN (r_prep) episodes/NNS (l_prep) of/IN (l_pobj) anemia/NN (l_appos) MAHA/NNP -PUNC- tacrolimus/NNP (r_nmod) therapy/NN (r_pobj) under/IN (r_prep) recipients/NNS (r_pobj) in/IN (r_prep) episodes/NNS (l_prep) of/IN (l_pobj) anemia/NN -PUNC- tacrolimus/NNP (r_nmod) therapy/NN (r_pobj) under/IN (r_prep) recipients/NNS (r_pobj) in/IN (r_prep) episodes/NNS (l_prep) of/IN (l_pobj) anemia/NN (l_appos) MAHA/NNP -PUNC- FK506/NNP (r_pobj) of/IN (r_prep) discontinuation/NN (r_nsubj) led/VBD (l_prep) to/IN (l_pobj) resolution/NN (l_prep) of/IN (l_pobj) MAHA/NNP -PUNC- FK506/NNP (r_pobj) of/IN (r_prep) reintroduction/NN (r_nsubj) led/VBD (l_prep) to/IN (l_pobj) recurrence/NN (l_prep) of/IN (l_pobj) MAHA/NNP -PUNC- FK506-associated/VBN (r_amod) MAHA/NNP -PUNC- FK506/NNP (r_nsubj) seem/VB (l_oprd) A/NNP (l_appos) drug/NN (l_acl) known/VBN (l_xcomp) induce/VB (l_dobj) MAHA/NNP
D016572_D000743 NONE A/NNP (l_appos) drug/NN (l_acl) known/VBN (l_xcomp) induce/VB (l_dobj) MAHA/NNP -PUNC- CyA/NN (r_appos) A/NNP (l_appos) drug/NN (l_acl) known/VBN (l_xcomp) induce/VB (l_dobj) MAHA/NNP
D004176_D000743 NONE dipyridamole/NN (r_conj) aspirin/NN (r_conj) corticosteroids/NNS (r_conj) replacement/NN (r_appos) discontinuation/NN (r_nsubj) led/VBD (l_prep) to/IN (l_pobj) resolution/NN (l_prep) of/IN (l_pobj) MAHA/NNP
D000305_D000743 NONE corticosteroids/NNS (r_conj) replacement/NN (r_appos) discontinuation/NN (r_nsubj) led/VBD (l_prep) to/IN (l_pobj) resolution/NN (l_prep) of/IN (l_pobj) MAHA/NNP
1527456
D008012_D014012 NONE lignocaine/NN (r_pobj) of/IN (r_prep) instillation/NN (r_pobj) by/IN (r_prep) Treatment/NN (l_prep) of/IN (l_pobj) tinnitus/NN -PUNC- lidocaine/NN (r_appos) lignocaine/NN (r_pobj) of/IN (r_prep) instillation/NN (r_pobj) by/IN (r_prep) Treatment/NN (l_prep) of/IN (l_pobj) tinnitus/NN -PUNC- lignocaine/NN (r_pobj) of/IN (r_prep) instillation/NN (r_pobj) by/IN (r_prep) treating/VBG (l_dobj) IST/NNP -PUNC- lidocaine/NN (r_appos) lignocaine/NN (r_pobj) of/IN (r_prep) instillation/NN (r_pobj) by/IN (r_prep) treating/VBG (l_dobj) IST/NNP
8437969
D011899_D001145 NONE ranitidine/NN (r_compound) treatment/NN (r_pobj) during/IN (r_prep) recur/VB (r_conj) disappeared/VBD (l_ccomp) related/VBN (l_nsubjpass) arrhythmias/NNS
D002927_D001145 NONE cimetidine/NN (r_compound) administration/NN (r_pobj) to/IN (r_prep) related/VBN (l_nsubjpass) arrhythmias/NNS
D002927_D054138 CID cimetidine/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) arrest/NN -PUNC- cimetidine/NN (r_dobj) receiving/VBG (r_advcl) recurrent/JJ (l_appos) episodes/NNS (l_prep) of/IN (l_pobj) arrest/NN -PUNC- cimetidine/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) case/NN (l_prep) of/IN (l_pobj) arrest/NN
D002927_D006331 NONE cimetidine/NN (r_dobj) receiving/VBG (r_advcl) recurrent/JJ (r_appos) man/NN (l_conj) history/NN (l_prep) of/IN (l_pobj) disease/NN
D002927_D001919 CID cimetidine/NN (r_pobj) of/IN (r_prep) infusions/NNS (r_pobj) of/IN (r_prep) administration/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) bradyarrhythmias/NNS
D002927_D007938 NONE cimetidine/NN (r_dobj) receiving/VBG (r_advcl) recurrent/JJ (r_appos) man/NN (l_prep) with/IN (l_pobj) leukemia/NN
322550
D009599_D002303 NONE nitroprusside/JJ (r_amod) infusion/NN (r_nsubj) produced/VBD (l_conj) increased/VBN (l_conj) decreased/VBD (l_dobj) output/NN -PUNC- nitroprusside/JJ (r_amod) levels/NNS (r_pobj) During/IN (r_prep) alter/VB (l_conj) produce/VBP (l_dobj) decreases/NNS (l_prep) in/IN (l_pobj) pressure/NN (l_conj) output/NN
D014867_D002303 NONE H2O/NNP (r_punct) levels/NNS (r_conj) alter/VB (l_conj) produce/VBP (l_dobj) decreases/NNS (l_prep) in/IN (l_pobj) pressure/NN (l_conj) output/NN
D014867_D007022 NONE H2O/NNP (r_punct) levels/NNS (r_conj) alter/VB (l_conj) produce/VBP (l_dobj) decreases/NNS (l_prep) in/IN (l_pobj) pressure/NN (l_conj) output/NN
D009599_D007022 CID nitroprusside/RB (r_advmod) induced/VBN (r_amod) hypotension/NN -PUNC- nitroprusside/JJ (r_amod) infusion/NN (r_nsubj) produced/VBD (l_dobj) decrease/NN (l_prep) in/IN (l_pobj) pressure/NN -PUNC- Nitroprusside/NNP (r_nsubj) caused/VBD (l_dobj) decreases/NNS (l_prep) in/IN (l_pobj) pressure/NN
D009599_D007022 NONE nitroprusside/JJ (r_amod) levels/NNS (r_pobj) During/IN (r_prep) alter/VB (l_conj) produce/VBP (l_dobj) decreases/NNS (l_prep) in/IN (l_pobj) pressure/NN (l_conj) output/NN
9249847
D014700_D013611 CID verapamil/NN (r_nmod) ablation/NN (r_pobj) after/IN (r_prep) induced/VBD (l_dobj) tachycardia/NN -PUNC- verapamil/NN (r_nmod) block/NN (r_pobj) after/IN (r_prep) beats/NNS (r_pobj) by/IN (r_agent) caused/VBN (r_acl) QRS/UH (r_nsubj) established/VBD (l_dobj) attack/NN (l_compound) AVRT/NN
D014700_D002311 NONE verapamil/NN (r_nmod) ablation/NN (l_conj) cardiomyopathy/NN
D014700_D014927 NONE verapamil/NN (r_nmod) ablation/NN (l_prep) in/IN (l_pobj) patient/NN (l_prep) with/IN (l_pobj) syndrome/NN
19803309
D013390_D014313 CID suxamethonium/NN (r_pobj) of/IN (r_prep) dose/NN (r_pobj) following/VBG (r_prep) threatening/VBG (l_dobj) spasm/NN
D013390_D009224 NONE suxamethonium/NN (r_pobj) of/IN (r_prep) dose/NN (r_pobj) following/VBG (r_prep) threatening/VBG (r_ccomp) developed/VBD (r_relcl) primigravida/NN (r_pobj) in/IN (r_prep) case/NN (l_prep) of/IN (l_pobj) congenita/NN
15649445
D018698_D004409 NONE glutamate/NN (r_compound) uptake/NN (r_dobj) change/VBP (l_conj) elicit/VBP (l_dobj) dyskinesia/NN -PUNC- glutamate/NN (r_compound) uptake/NN (r_pobj) in/IN (r_prep) decrease/NN (r_nsubj) correlates/VBZ (l_prep) with/IN (l_pobj) increase/NN (l_prep) in/IN (l_pobj) incidence/NN (l_prep) of/IN (l_pobj) diskinesia/NN
D012110_D004409 CID reserpine/NN (r_nsubj) change/VBP (l_conj) elicit/VBP (l_dobj) dyskinesia/NN -PUNC- Reserpine-/NNP (l_conj) dyskinesia/NN -PUNC- Reserpine-/NNP (r_nsubj) are/VBP (l_attr) models/NNS (l_prep) of/IN (l_pobj) dyskinesia/JJ -PUNC- Reserpine-/NNP (r_nsubj) are/VBP (l_attr) models/NNS (l_prep) of/IN (l_pobj) dyskinesia/JJ (l_appos) TD/NN -PUNC- reserpine/NN (r_pobj) by/IN (r_prep) induced/VBD (l_dobj) dyskinesia/NN
D006220_D004409 CID haloperidol/NN (r_compound) change/VBP (l_conj) elicit/VBP (l_dobj) dyskinesia/NN -PUNC- haloperidol/NN (r_npadvmod) induced/VBN (r_amod) dyskinesia/NN -PUNC- haloperidol/NN (r_npadvmod) induced/VBN (r_amod) dyskinesia/NN (r_conj) Reserpine-/NNP (r_nsubj) are/VBP (l_attr) models/NNS (l_prep) of/IN (l_pobj) dyskinesia/JJ -PUNC- haloperidol/NN (r_npadvmod) induced/VBN (r_amod) dyskinesia/NN (r_conj) Reserpine-/NNP (r_nsubj) are/VBP (l_attr) models/NNS (l_prep) of/IN (l_pobj) dyskinesia/JJ (l_appos) TD/NN -PUNC- haloperidol/NN (r_compound) administration/NN (r_conj) reserpine/NN (r_pobj) by/IN (r_prep) induced/VBD (l_dobj) dyskinesia/NN
10091617
D012642_D010300 NONE Selegiline/NNP (r_advmod) induced/VBN (l_dobj) hypotension/NN (l_prep) in/IN (l_pobj) disease/NN -PUNC- selegiline/NN (r_dobj) receive/VB (r_xcomp) randomized/VBN (r_acl) mortality/NN (r_dobj) found/VBD (l_nsubj) trial/NN (l_nmod) Group/NNP (l_compound) Disease/NNP -PUNC- selegiline/NN (r_dobj) receive/VB (r_xcomp) randomized/VBN (r_acl) mortality/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disease/NN -PUNC- selegiline/NN (r_dobj) receive/VB (r_xcomp) randomized/VBN (r_acl) mortality/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disease/NN (l_appos) PD/NNP -PUNC- selegiline/RB (r_dobj) receiving/VBG (r_acl) patients/NNS (l_compound) PD/NNP -PUNC- selegiline/NN (r_pobj) on/IN (r_prep) marked/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_compound) PD/NNP
D007980_D007024 NONE dopa/NNP (r_conj) therapy/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) hypotension/NN -PUNC- dopa/NNP (r_pobj) with/IN (r_prep) combination/NN (r_pobj) in/IN (r_prep) selegiline/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) hypotension/NN
D012642_D007024 CID Selegiline/NNP (r_advmod) induced/VBN (l_dobj) hypotension/NN -PUNC- selegiline/NN (r_pobj) with/IN (r_prep) therapy/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) hypotension/NN -PUNC- selegiline/NN (r_pobj) of/IN (r_prep) withdrawal/NN (r_pobj) by/IN (r_agent) abolished/VBN (r_relcl) hypotension/NN -PUNC- selegiline/NN (r_dobj) stopping/VBG (l_prep) in/IN (l_pobj) expectation/NN (l_acl) shed/VB (l_prep) on/IN (l_pobj) mechanisms/NNS (l_relcl) causes/VBZ (l_dobj) hypotension/NN -PUNC- selegiline/NN (r_pobj) on/IN (r_prep) marked/VBN (r_relcl) hypotension/NN -PUNC- selegiline/NN (r_pobj) of/IN (r_prep) withdrawal/NN (r_pobj) after/IN (r_prep) ameliorated/VBN (l_nsubjpass) hypotension/NN -PUNC- selegiline/NN (r_dobj) Stopping/VBG (r_csubj) reduced/VBD (l_dobj) pressures/NNS -PUNC- selegiline/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) hypotension/NN
D007980_D010300 NONE dopa/NN (r_nsubj) compared/VBN (r_conj) found/VBD (l_nsubj) trial/NN (l_nmod) Group/NNP (l_compound) Disease/NNP -PUNC- dopa/NN (r_nsubj) compared/VBN (r_conj) found/VBD (l_dobj) mortality/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disease/NN -PUNC- dopa/NN (r_nsubj) compared/VBN (r_conj) found/VBD (l_dobj) mortality/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disease/NN (l_appos) PD/NNP -PUNC- dopa/NN (r_dobj) taking/VBG (r_acl) those/DT (r_pobj) with/IN (r_prep) compared/VBN (r_conj) found/VBD (l_nsubj) trial/NN (l_nmod) Group/NNP (l_compound) Disease/NNP -PUNC- dopa/NN (r_dobj) taking/VBG (r_acl) those/DT (r_pobj) with/IN (r_prep) compared/VBN (r_conj) found/VBD (l_dobj) mortality/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disease/NN -PUNC- dopa/NN (r_dobj) taking/VBG (r_acl) those/DT (r_pobj) with/IN (r_prep) compared/VBN (r_conj) found/VBD (l_dobj) mortality/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disease/NN (l_appos) PD/NNP
1085609
D007538_D012640 CID isoniazid/NN (r_amod) therapy/NN (r_pobj) due/IN (r_amod) convulsions/NNS -PUNC- isoniazid/NN (r_pobj) on/IN (r_prep) infant/NN (r_nsubjpass) admitted/VBN (l_prep) after/IN (l_pobj) days/NNS (l_prep) of/IN (l_pobj) fits/NNS -PUNC- isoniazid/NN (r_relcl) aetiology/NN (r_dobj) suggesting/VBG (r_advcl) ceased/VBD (l_nsubj) fits/NNS
D011736_D012640 NONE pyridoxine/NN (r_nmod) convulsions/NNS -PUNC- pyridoxine/NN (r_dobj) administering/VBG (r_pcomp) of/IN (r_prep) hours/NNS (r_pobj) within/IN (r_prep) ceased/VBD (l_nsubj) fits/NNS -PUNC- pyridoxine/JJ (r_compound) deficiency/NN (r_pobj) of/IN (r_prep) aetiology/NN (r_dobj) suggesting/VBG (r_advcl) ceased/VBD (l_nsubj) fits/NNS
D007538_D014376 NONE isoniazid/NN (r_pobj) on/IN (r_prep) infant/NN (l_prep) because/IN (l_pobj) tuberculosis/NN
19473225
D018698_D020258 NONE glutamate/NN (r_nsubjpass) claimed/VBN (l_xcomp) ameliorate/VB (l_dobj) neurotoxicity/NN -PUNC- glutamine/NN (r_conj) glutamate/NN (r_nsubjpass) claimed/VBN (l_xcomp) ameliorate/VB (l_dobj) neurotoxicity/NN
D000596_D020258 NONE acid/NN (r_compound) glutamine/NN (r_conj) glutamate/NN (r_nsubjpass) claimed/VBN (l_xcomp) ameliorate/VB (l_dobj) neurotoxicity/NN
D000596_D010523 NONE acid/NN (r_compound) glutamine/NN (r_conj) glutamate/NN (r_nsubjpass) claimed/VBN (r_advcl) is/VBZ (l_nsubj) neuropathy/NN
D017239_D020258 NONE paclitaxel/NN (r_pobj) with/IN (r_prep) chemotherapy/NN (r_pobj) for/IN (r_prep) factor/NN (r_attr) is/VBZ (l_advcl) claimed/VBN (l_xcomp) ameliorate/VB (l_dobj) neurotoxicity/NN -PUNC- PAC/NNP (r_appos) chemotherapy/NN (r_pobj) for/IN (r_prep) factor/NN (r_attr) is/VBZ (l_advcl) claimed/VBN (l_xcomp) ameliorate/VB (l_dobj) neurotoxicity/NN -PUNC- PAC/NNP (r_compound) neurotoxicity/NN
D018698_D010523 NONE glutamate/NN (r_compound) supplementation/NN (r_nsubj) failed/VBD (l_xcomp) protect/VB (l_prep) against/IN (l_pobj) neurotoxicity/NN -PUNC- glutamate/NN (r_nsubjpass) claimed/VBN (r_advcl) is/VBZ (l_nsubj) neuropathy/NN -PUNC- glutamine/NN (r_conj) glutamate/NN (r_nsubjpass) claimed/VBN (r_advcl) is/VBZ (l_nsubj) neuropathy/NN -PUNC- glutamate/NN (r_compound) supplementation/NN (l_prep) for/IN (l_pcomp) preventing/VBG (l_dobj) neuropathy/NN -PUNC- glutamate/NN (r_compound) supplementation/NN (r_nsubj) fails/VBZ (l_xcomp) protect/VB (l_prep) against/IN (l_pobj) neurotoxicity/NN
D017239_D010523 CID paclitaxel/NN (r_pobj) of/IN (r_prep) neurotoxicity/NN -PUNC- paclitaxel/NN (r_pobj) with/IN (r_prep) chemotherapy/NN (r_pobj) for/IN (r_prep) factor/NN (r_attr) is/VBZ (l_nsubj) neuropathy/NN -PUNC- PAC/NNP (r_appos) chemotherapy/NN (r_pobj) for/IN (r_prep) factor/NN (r_attr) is/VBZ (l_nsubj) neuropathy/NN -PUNC- PAC/NNP (r_compound) neurotoxicity/NN (r_dobj) ameliorate/VB (r_xcomp) claimed/VBN (r_advcl) is/VBZ (l_nsubj) neuropathy/NN -PUNC- PAC/NNP (r_npadvmod) induced/VBN (r_amod) neuropathy/NN -PUNC- PAC/NNP (r_pobj) of/IN (r_prep) neurotoxicity/NN
D017239_D010051 NONE PAC/NNP (r_npadvmod) containing/VBG (r_amod) regimen/NN (r_pobj) of/IN (r_prep) cycles/NNS (r_pobj) following/VBG (r_prep) analysis/NN (r_pobj) for/IN (r_prep) available/JJ (r_acomp) were/VBD (l_nsubj) patients/NNS (l_compound) cancer/NN
D018698_D010051 NONE glutamate/NN (r_pobj) by/IN (r_agent) supplemented/VBN (l_ccomp) were/VBD (l_nsubj) patients/NNS (l_compound) cancer/NN
12695819
D016559_D009422 NONE tacrolimus/NNS (l_relcl) developed/VBD (l_dobj) complications/NNS
D016559_D020258 NONE tacrolimus/NN (r_npadvmod) induced/VBN (r_amod) neurotoxicity/NN -PUNC- tacrolimus/NN (r_npadvmod) induced/VBN (r_amod) neurotoxicity/NN
15863244
D010894_D006345 NONE piroxicam/NN (r_nmod) inhibitor/NN (r_pobj) to/IN (r_prep) exposed/VBN (r_acl) fetuses/NNS (r_pobj) for/IN (r_prep) performed/VBN (l_nsubjpass) analysis/NN (l_prep) for/IN (l_pobj) defects/NNS
D010894_D064420 NONE piroxicam/NN (r_compound) study/NN (r_conj) DFU/NNP (r_appos) inhibitors/NNS (r_pobj) of/IN (r_prep) toxicity/NN -PUNC- piroxicam/NN (r_pobj) of/IN (r_prep) toxicity/NN -PUNC- piroxicam/NN (r_pobj) of/IN (r_prep) dose/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) rats/NNS (r_pobj) in/IN (r_prep) found/VBN (l_nsubjpass) toxicity/NN
D010894_D009139 CID piroxicam/NN (r_pobj) of/IN (r_prep) dose/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) rats/NNS (r_pobj) in/IN (r_prep) found/VBN (l_nsubjpass) toxicity/NN (l_appos) retardation/NN (l_conj) increase/NN (l_prep) of/IN (l_pobj) variations/NNS
D010894_D009436 NONE piroxicam/NN (r_nmod) inhibitor/NN (r_pobj) to/IN (r_prep) exposed/VBN (r_acl) fetuses/NNS (r_pobj) for/IN (r_prep) performed/VBN (l_nsubjpass) analysis/NN (l_prep) for/IN (l_pobj) defects/NNS
C106876_D064420 NONE DFU/NNP (r_appos) inhibitors/NNS (r_pobj) of/IN (r_prep) toxicity/NN -PUNC- DFU/NNP (r_conj) toxicity/NN -PUNC- phenyl-2(5H)-furanon/XX (l_ccomp) was/VBD (l_xcomp) evaluate/VB (l_dobj) toxicity/NN -PUNC- DFU/NNP (r_nmod) toxicity/NN
D010894_D005317 CID piroxicam/NN (r_pobj) of/IN (r_prep) dose/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) rats/NNS (r_pobj) in/IN (r_prep) found/VBN (l_nsubjpass) toxicity/NN (l_appos) retardation/NN
15278670
D004737_D012640 NONE enflurane/NN (r_conj) sevoflurane/NN (r_pobj) between/IN (r_prep) threshold/NN (l_amod) convulsive/JJ -PUNC- enflurane/NN (r_conj) sevoflurane/NN (r_pobj) of/IN (r_prep) concentrations/NNS (r_nsubjpass) administered/VBN (l_conj) decreased/VBD (l_nsubj) pressure/NN (l_prep) at/IN (l_pobj) convulsions/NNS -PUNC- enflurane/NN (r_conj) %/NN (r_pobj) in/IN (r_conj) decreased/VBD (l_nsubj) pressure/NN (l_prep) at/IN (l_pobj) convulsions/NNS
D001030_D012640 NONE Apamin/NNP (r_nsubj) had/VBD (l_dobj) tendency/NN (l_acl) decrease/VB (l_dobj) threshold/NN (l_amod) convulsive/JJ
D008012_D012640 CID lidocaine/NN (r_npadvmod) induced/VBN (r_amod) convulsions/NNS -PUNC- lidocaine/NN (r_npadvmod) induced/VBN (r_amod) convulsions/NNS -PUNC- lidocaine/NN (r_compound) infusion/NN (r_pobj) with/IN (r_prep) was/VBD (l_nsubj) threshold/NN (l_amod) convulsive/JJ -PUNC- lidocaine/JJ (r_compound) toxicity/NN (r_pobj) of/IN (r_prep) effect/NN (l_amod) convulsive/JJ
D008012_D064420 NONE lidocaine/JJ (r_compound) toxicity/NN
C009250_D064420 NONE sevoflurane/NN (r_nsubj) reduces/VBZ (l_dobj) effect/NN (l_prep) of/IN (l_pobj) toxicity/NN
C009250_D012640 NONE sevoflurane/NN (r_pobj) of/IN (r_prep) effects/NNS (l_prep) on/IN (l_pobj) convulsions/NNS -PUNC- sevoflurane/NN (l_prep) on/IN (l_pobj) convulsions/NNS -PUNC- sevoflurane/NN (r_pobj) of/IN (r_prep) concentration/NN (r_nsubj) was/VBD (r_relcl) l(-1/NN (r_pobj) to/IN (r_prep) increasing/VBG (r_advcl) was/VBD (l_nsubj) threshold/NN (l_amod) convulsive/JJ -PUNC- sevoflurane/NN (r_pobj) between/IN (r_prep) threshold/NN (l_amod) convulsive/JJ -PUNC- sevoflurane/NN (r_pobj) of/IN (r_prep) concentrations/NNS (r_nsubjpass) administered/VBN (l_conj) decreased/VBD (l_nsubj) pressure/NN (l_prep) at/IN (l_pobj) convulsions/NNS -PUNC- sevoflurane/NN (r_pobj) in/IN (r_prep) decreased/VBD (l_nsubj) pressure/NN (l_prep) at/IN (l_pobj) convulsions/NNS -PUNC- sevoflurane/NN (r_nsubj) reduces/VBZ (l_dobj) effect/NN (l_amod) convulsive/JJ
D008012_D003866 NONE lidocaine/JJ (r_compound) toxicity/NN (r_pobj) of/IN (r_prep) effect/NN (r_dobj) reduces/VBZ (l_conj) carries/VBZ (l_prep) due/IN (l_pcomp) to/IN (l_pobj) depression/NN
C009250_D003866 NONE sevoflurane/NN (r_nsubj) reduces/VBZ (l_conj) carries/VBZ (l_prep) due/IN (l_pcomp) to/IN (l_pobj) depression/NN
6518066
D008094_D006331 NONE lithium/NN (r_pobj) to/IN (r_prep) exposed/VBN (r_csubj) provide/VB (l_dobj) assessment/NN (l_prep) of/IN (l_pobj) presence/NN (l_prep) of/IN (l_pobj) malformations/NNS -PUNC- lithium/NN (r_npadvmod) induced/VBN (r_amod) malformations/NNS
D008094_D004437 CID lithium/NN (l_conj) anomaly/NN
227508
-1_D006973 NONE nalozone/NN (r_pobj) by/IN (r_agent) reversed/VBN (r_conj) inhibited/VBN (r_conj) rats/NNS (l_amod) hypertensive/JJ -PUNC- 3H]-naloxone/CD (r_pobj) of/IN (r_prep) binding/NN (r_dobj) influence/VB (l_prep) In/IN (l_pobj) membranes/NNS (l_prep) from/IN (l_pobj) rats/NNS (l_amod) hypertensive/JJ -PUNC- 3H]-dihydroergocryptine/CD (r_nummod) nM/NNP (r_pobj) of/IN (r_prep) binding/NN (r_dobj) influence/VB (r_conj) influence/VB (l_prep) In/IN (l_pobj) membranes/NNS (l_prep) from/IN (l_pobj) rats/NNS (l_amod) hypertensive/JJ
D008750_D007022 CID methyldopa/NN (r_pobj) of/IN (r_prep) effect/NN (l_amod) hypotensive/JJ
D009270_D007022 NONE naloxone/NN (r_pobj) by/IN (r_agent) reversed/VBN (l_nsubjpass) effect/NN (l_amod) hypotensive/JJ
D009270_D006973 NONE naloxone/NN (r_nsubj) influence/VB (r_conj) influence/VB (l_prep) In/IN (l_pobj) membranes/NNS (l_prep) from/IN (l_pobj) rats/NNS (l_amod) hypertensive/JJ
D003000_D006973 NONE clonidine/NN (r_pobj) by/IN (r_agent) produced/VBN (r_acl) pressure/NN (r_pobj) in/IN (r_prep) decrease/NN (r_dobj) rats/NNS (l_amod) hypertensive/JJ -PUNC- clonidine/NN (r_preconj) In/IN (l_pobj) membranes/NNS (l_prep) from/IN (l_pobj) rats/NNS (l_amod) hypertensive/JJ -PUNC- clonidine/NN (r_npadvmod) suppressible/NN (r_amod) binding/NN (r_dobj) influence/VB (r_conj) influence/VB (l_prep) In/IN (l_pobj) membranes/NNS (l_prep) from/IN (l_pobj) rats/NNS (l_amod) hypertensive/JJ
18186898
D016559_D005198 CID tacrolimus/NN (r_pobj) by/IN (r_agent) triggered/VBN (r_relcl) dysfunction/NN (r_pobj) from/IN (r_prep) resulted/VBN (l_nsubj) dysfunction/NN
D016559_D009135 CID tacrolimus/NN (r_pobj) by/IN (r_agent) triggered/VBN (r_relcl) dysfunction/NN (r_pobj) from/IN (r_prep) resulted/VBN (l_nsubj) dysfunction/NN (l_conj) myopathy/NNS
D019259_D028361 NONE lamivudine/NN (r_pobj) by/IN (r_agent) augmented/VBN (r_conj) triggered/VBN (r_relcl) dysfunction/NN
D020123_D000138 NONE sirolimus/NN (r_pobj) by/IN (r_agent) replaced/VBN (r_conj) suspected/VBN (l_xcomp) be/VB (l_attr) cause/NN (l_prep) of/IN (l_pobj) acidosis/NN -PUNC- sirolimus/NN (l_conj) acidosis/NN
D019259_D005198 CID lamivudine/NN (r_pobj) by/IN (r_agent) augmented/VBN (r_conj) triggered/VBN (r_relcl) dysfunction/NN (r_pobj) from/IN (r_prep) resulted/VBN (l_nsubj) dysfunction/NN
D016559_D000138 NONE tacrolimus/NN (r_nsubjpass) suspected/VBN (l_xcomp) be/VB (l_attr) cause/NN (l_prep) of/IN (l_pobj) acidosis/NN -PUNC- tacrolimus/NN (r_nsubjpass) suspected/VBN (l_conj) replaced/VBN (l_agent) by/IN (l_pobj) sirolimus/NN (l_conj) acidosis/NN
D019259_D009135 CID lamivudine/NN (r_pobj) by/IN (r_agent) augmented/VBN (r_conj) triggered/VBN (r_relcl) dysfunction/NN (r_pobj) from/IN (r_prep) resulted/VBN (l_nsubj) dysfunction/NN (l_conj) myopathy/NNS
D019259_D006509 NONE Lamivudine/NNP (r_nsubjpass) added/VBN (l_prep) because/IN (l_pobj) infection/NN
D016559_D028361 NONE tacrolimus/NN (r_pobj) by/IN (r_agent) triggered/VBN (r_relcl) dysfunction/NN
20880751
D007980_D004409 CID Levodopa/NNP (r_npadvmod) induced/VBN (l_dobj) dyskinesias/NNS -PUNC- levodopa/NN (r_npadvmod) induced/VBN (r_amod) dyskinesias/NNS -PUNC- levodopa/NN (r_npadvmod) induced/VBN (r_amod) dyskinesias/NNS
D018698_D004409 NONE glutamate/NN (r_compound) receptors/NNS (l_conj) systems/NNS (l_prep) in/IN (l_pobj) pathophysiology/NN (l_prep) of/IN (l_pobj) dyskinesias/NNS
D004298_D004409 NONE dopamine/NN (r_compound) precursor/NN (r_pobj) of/IN (r_prep) use/NN (r_nsubjpass) complicated/VBN (l_agent) by/IN (l_pobj) fluctuations/NNS (l_conj) dyskinesias/NNS -PUNC- dopamine/NN (r_compound) subtypes/NNS (l_conj) receptors/NNS (l_conj) systems/NNS (l_prep) in/IN (l_pobj) pathophysiology/NN (l_prep) of/IN (l_pobj) dyskinesias/NNS
D007980_D010300 NONE Levodopa/NNP (r_npadvmod) induced/VBN (l_dobj) dyskinesias/NNS (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disease/NN -PUNC- Levodopa/NNP (r_nsubj) is/VBZ (l_attr) drug/NN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) disease/NN
18752389
C532833_D056486 NONE acid/NN (r_pobj) of/IN (r_prep) glucuronidation/NN (r_dobj) inhibited/VBN (l_advcl) resulting/VBG (l_prep) in/IN (l_pobj) exposure/NN (l_conj) hepatotoxicity/NN
D019821_D056486 NONE simvastatin/NN (r_pobj) with/IN (r_prep) maintained/VBN (l_prep) for/IN (l_pobj) months/NNS (l_prep) before/IN (l_pobj) conversion/NN (l_prep) without/IN (l_pobj) evidence/NN (l_prep) of/IN (l_pobj) hepatotoxicity/NN -PUNC- simvastatin/NN (r_amod) exposure/NN (l_conj) hepatotoxicity/NN -PUNC- simvastatin/NN (r_amod) exposure/NN (r_attr) is/VBZ (l_nsubj) mechanism/NN (l_prep) of/IN (l_pobj) hepatotoxicity/NN
D015283_D003866 NONE escitalopram/NNP (r_conj) Simvastatinezetimibe/NNP (l_relcl) taking/VBG (l_prep) for/IN (l_pobj) depression/NN
C492458_D003866 NONE Simvastatinezetimibe/NNP (l_relcl) taking/VBG (l_prep) for/IN (l_pobj) depression/NN
C492458_D017093 NONE ezetimibe/NN (r_npadvmod) induced/VBN (r_amod) failure/NN -PUNC- ezetimibe/NN (r_npadvmod) induced/VBN (r_amod) failure/NN
C108606_D056486 NONE ezetimibe/NN (r_pobj) with/IN (r_prep) published/VBN (l_nsubjpass) events/NNS (l_amod) hepatotoxic/JJ -PUNC- Ezetimibe/NNP (r_nsubj) undergoes/VBZ (l_conj) inhibited/VBN (l_advcl) resulting/VBG (l_prep) in/IN (l_pobj) exposure/NN (l_conj) hepatotoxicity/NN -PUNC- ezetimibe/NN (r_compound) inhibition/NN (r_pobj) by/IN (r_prep) exposure/NN (r_attr) is/VBZ (l_nsubj) mechanism/NN (l_prep) of/IN (l_pobj) hepatotoxicity/NN
D014530_D056486 NONE diphosphate/NN (r_compound) glucoronosyltransferases/NNS (r_pobj) by/IN (r_prep) glucuronidation/NN (r_dobj) undergoes/VBZ (l_conj) inhibited/VBN (l_advcl) resulting/VBG (l_prep) in/IN (l_pobj) exposure/NN (l_conj) hepatotoxicity/NN
D019821_D017114 NONE simvastatin/NN (r_nmod) day/NN (r_pobj) from/IN (r_prep) conversion/NN (r_pobj) after/IN (r_prep) necessitating/VBG (r_acl) failure/NN
D015283_D056486 NONE escitalopram/NNP (r_conj) Simvastatinezetimibe/NNP (r_nsubjpass) discontinued/VBN (l_conj) excluded/VBN (l_nsubjpass) causes/NNS (l_prep) of/IN (l_pobj) hepatotoxicity/NN
C492458_D056486 CID ezetimibe/NN (r_appos) agent/NN (r_conj) ezetimibe/NN (r_pobj) with/IN (r_prep) published/VBN (l_nsubjpass) events/NNS (l_amod) hepatotoxic/JJ -PUNC- Simvastatinezetimibe/NNP (r_nsubjpass) discontinued/VBN (l_conj) excluded/VBN (l_nsubjpass) causes/NNS (l_prep) of/IN (l_pobj) hepatotoxicity/NN -PUNC- simvastatinezetimibe/NN (r_npadvmod) induced/VBN (r_amod) hepatotoxicity/NN -PUNC- ezetimibe/NN (r_pobj) with/IN (r_prep) hepatotoxicity/NN
C492458_D017114 CID mg/NN (r_nummod) day/NN (r_npadvmod) ezetimibe/NN (r_dobj) simvastatin/NN (r_advcl) necessitating/VBG (r_acl) failure/NN
17111419
C102006_D064420 NONE citrate/JJ (r_compound) toxicity/NN -PUNC- citrate/JJ (r_compound) toxicity/NN -PUNC- citrate/JJ (r_compound) toxicity/NN
C102006_D006996 CID citrate/NN (r_compound) anticoagulant/NN (r_pobj) by/IN (r_prep) reaction/NN (l_acl) resulting/VBG (l_prep) in/IN (l_pobj) hypocalcemia/NN -PUNC- citrate/JJ (r_compound) toxicity/NN (r_pobj) to/IN (r_pcomp) due/IN (r_amod) reactions/NNS (r_dobj) prevent/VB (r_xcomp) help/VB (r_xcomp) recommended/VBN (l_nsubjpass) screening/NN (l_prep) for/IN (l_pobj) medications/NNS (l_conj) conditions/NNS (l_acl) predisposing/VBG (l_prep) to/IN (l_pobj) hypocalcemia/NN
D049994_D006996 NONE diuretic/NN (r_amod) loop/NN (l_relcl) cause/VB (l_dobj) hypocalcemia/NN
D002118_D006996 NONE calcium/NN (r_compound) chelation/NN (r_pobj) to/IN (r_prep) reaction/NN (l_acl) resulting/VBG (l_prep) in/IN (l_pobj) hypocalcemia/NN
D002125_C536214 NONE gluconate/NN (r_pobj) with/IN (r_prep) treatment/NN (r_nsubjpass) initiated/VBN (l_conj) subsided/VBD (l_nsubj) contractions/NNS
D002034_D006996 NONE bumetanide/NN (r_nsubj) is/VBZ (l_attr) loop/NN (l_relcl) cause/VB (l_dobj) hypocalcemia/NN
10520387
D015742_D017202 NONE propofol/NN (r_nmod) mixtures/NNS (r_pobj) of/IN (r_prep) any/DT (r_pobj) of/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) use/NN (r_dobj) recommend/VB (l_prep) Due/IN (l_pobj) risk/NN (l_prep) of/IN (l_pobj) tachycardia/NN (l_acl) inducing/VBG (l_dobj) ischemia/NN
D004809_D017202 NONE ephedrine/NN (r_nmod) mixtures/NNS (r_pobj) of/IN (r_prep) any/DT (r_pobj) of/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) use/NN (r_dobj) recommend/VB (l_prep) Due/IN (l_pobj) risk/NN (l_prep) of/IN (l_pobj) tachycardia/NN (l_acl) inducing/VBG (l_dobj) ischemia/NN
D015742_D013610 CID propofol/NN (r_pobj) with/IN (r_prep) combination/NN (r_pobj) in/IN (r_prep) use/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) tachycardia/NNS -PUNC- propofol/NN (r_nmod) mixtures/NNS (r_pobj) of/IN (r_prep) any/DT (r_pobj) of/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) use/NN (r_dobj) recommend/VB (l_prep) Due/IN (l_pobj) risk/NN (l_prep) of/IN (l_pobj) tachycardia/NN
D004809_D007022 NONE ephedrine/NN (r_pobj) of/IN (r_prep) doses/NNS (r_dobj) adding/VBG (l_xcomp) propofol/NN (l_prep) in/IN (l_pobj) order/NN (l_acl) obtund/VB (l_dobj) response/NN (l_amod) hypotensive/JJ -PUNC- ephedrine/NN (r_pobj) of/IN (r_prep) addition/NN (r_nsubj) appears/VBZ (l_xcomp) be/VB (l_attr) method/NN (l_prep) of/IN (l_pcomp) obtunding/VBG (l_dobj) response/NN (l_amod) hypotensive/JJ
D015742_D007022 CID propofol/NN (l_prep) in/IN (l_pobj) order/NN (l_acl) obtund/VB (l_dobj) response/NN (l_amod) hypotensive/JJ -PUNC- propofol/NN (r_acl) addition/NN (r_nsubj) appears/VBZ (l_xcomp) be/VB (l_attr) method/NN (l_prep) of/IN (l_pcomp) obtunding/VBG (l_dobj) response/NN (l_amod) hypotensive/JJ -PUNC- propofol/NN (r_advcl) obtunding/VBG (l_dobj) response/NN (l_amod) hypotensive/JJ
D004809_D013610 CID ephedrine/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) tachycardia/NNS -PUNC- ephedrine/NN (r_nmod) mixtures/NNS (r_pobj) of/IN (r_prep) any/DT (r_pobj) of/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) use/NN (r_dobj) recommend/VB (l_prep) Due/IN (l_pobj) risk/NN (l_prep) of/IN (l_pobj) tachycardia/NN
18560792
D010479_D006349 NONE pergolide/NN (r_pobj) with/IN (r_prep) treated/VBN (l_nsubj) disease/NN -PUNC- pergolide/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (r_pobj) in/IN (r_prep) reported/VBN (l_nsubjpass) abnormalities/NNS -PUNC- pergolide/NN (r_pobj) of/IN (r_prep) role/NN (r_pobj) of/IN (r_prep) suggestive/JJ (r_amod) pattern/NN (l_prep) of/IN (l_pobj) regurgitation/NN -PUNC- Pergolide/NNP (r_nsubjpass) discontinued/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disease/NN -PUNC- pergolide/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) frequency/NN (l_prep) of/IN (l_pobj) regurgitation/NN
D004298_D006349 NONE dopamine/NN (r_compound) agonists/NNS (r_pobj) to/IN (r_prep) converted/VBN (r_advcl) is/VBZ (r_ccomp) reveals/VBZ (r_conj) treated/VBN (r_acl) frequency/NN (l_prep) of/IN (l_pobj) regurgitation/NN
D010479_D006333 NONE pergolide/NN (r_pobj) of/IN (r_prep) role/NN (r_pobj) of/IN (r_prep) suggestive/JJ (r_amod) pattern/NN (r_nsubjpass) observed/VBN (l_dobj) patients/NNS (l_prep) including/VBG (l_pobj) two/CD (l_prep) with/IN (l_pobj) failure/NN -PUNC- Pergolide/NNP (r_nsubjpass) discontinued/VBN (l_advcl) resulting/VBG (l_prep) in/IN (l_pobj) grade/NN (l_prep) at/IN (l_pobj) transthoracic/NN (l_conj) patients/NNS (l_prep) with/IN (l_pobj) failure/NN
D004298_D010300 NONE dopamine/NN (r_compound) agonists/NNS (r_pobj) to/IN (r_prep) converted/VBN (r_advcl) is/VBZ (r_ccomp) reveals/VBZ (r_conj) treated/VBN (r_acl) frequency/NN (l_prep) of/IN (l_pobj) regurgitation/NN (l_prep) in/IN (l_pobj) patients/NNS (l_compound) PD/NNP
D010479_D010300 NONE pergolide/NN (r_pobj) with/IN (r_prep) treated/VBN (l_nsubj) disease/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disease/NN -PUNC- pergolide/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (l_prep) with/IN (l_pobj) disease/NN -PUNC- pergolide/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (l_prep) with/IN (l_pobj) disease/NN (l_appos) PD/NNP -PUNC- pergolide/NN (r_pobj) with/IN (r_prep) treated/VBN (l_nsubj) patients/NNS (l_compound) PD/NNP -PUNC- pergolide/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) frequency/NN (l_prep) of/IN (l_pobj) regurgitation/NN (l_prep) in/IN (l_pobj) patients/NNS (l_compound) PD/NNP
17020434
C055162_D001281 NONE Clopidogrel/NNP (l_compound) Fibrillation/NNP -PUNC- clopidogrel/JJ (r_dobj) platelet/NN (r_xcomp) superior/JJ (r_acomp) is/VBZ (r_ccomp) demonstrated/VBN (l_nsubj) Trial/NN (l_compound) Clopidogrel/NNP (l_compound) Fibrillation/NNP
D000804_D001281 NONE II/CD (r_nummod) drugs/NNS (r_conj) inhibitors/NNS (r_nsubj) hold/VBP (l_dobj) promise/NN (l_prep) in/IN (l_pobj) fibrillation/NN
D014812_D056486 NONE K/NNP (r_compound) drugs/NNS (r_pobj) as/IN (r_prep) efficient/JJ (r_acomp) be/VB (r_xcomp) found/VBN (l_conj) withdrawn/VBN (l_prep) because/IN (l_pobj) tests/NNS (l_compound) function/NN
D001241_D020521 NONE aspirin/NN (r_nsubj) reduces/VBZ (r_conj) reduces/VBZ (l_dobj) risk/NN (l_prep) of/IN (l_pobj) stroke/NN -PUNC- aspirin/NN (l_prep) in/IN (l_pcomp) preventing/VBG (l_dobj) strokes/NNS
D014859_D004617 NONE warfarin/NN (r_nsubj) is/VBZ (l_acomp) superior/JJ (l_xcomp) platelet/NN (l_prep) in/IN (l_pobj) events/NNS
C081309_D004617 NONE Irbesartan/NNP (r_pobj) with/IN (r_prep) Trial/NN (r_nsubj) demonstrated/VBN (l_ccomp) is/VBZ (l_acomp) superior/JJ (l_xcomp) platelet/NN (l_prep) in/IN (l_pobj) events/NNS
C081309_D001281 NONE Irbesartan/NNP (r_pobj) with/IN (r_prep) Trial/NN (l_compound) Clopidogrel/NNP (l_compound) Fibrillation/NNP
D000809_D001281 NONE Angiotensin/NN (r_npadvmod) converting/VBG (r_amod) inhibitors/NNS (r_nsubj) hold/VBP (l_dobj) promise/NN (l_prep) in/IN (l_pobj) fibrillation/NN
C426686_D004617 NONE Ximelagatran/NN (r_nsubjpass) found/VBN (l_xcomp) be/VB (l_acomp) efficient/JJ (l_prep) in/IN (l_pobj) prevention/NN (l_prep) of/IN (l_pobj) events/NNS
D000809_D020257 NONE Angiotensin/NN (r_npadvmod) converting/VBG (r_amod) inhibitors/NNS (r_nsubj) hold/VBP (l_dobj) promise/NN (l_prep) in/IN (l_pobj) fibrillation/NN (l_prep) through/IN (l_pobj) remodelling/NN
D014859_D020521 NONE warfarin/NN (r_nsubj) reduces/VBZ (l_dobj) risk/NN (l_prep) of/IN (l_pobj) stroke/NN -PUNC- warfarin/VB (r_nsubj) is/VBZ (l_acomp) superior/JJ (l_prep) to/IN (l_pobj) aspirin/NN (l_prep) in/IN (l_pcomp) preventing/VBG (l_dobj) strokes/NNS
D014812_D004617 NONE K/NNP (r_compound) drugs/NNS (r_pobj) as/IN (r_prep) efficient/JJ (l_prep) in/IN (l_pobj) prevention/NN (l_prep) of/IN (l_pobj) events/NNS
C055162_D004617 NONE Clopidogrel/NNP (r_compound) Trial/NN (r_nsubj) demonstrated/VBN (l_ccomp) is/VBZ (l_acomp) superior/JJ (l_xcomp) platelet/NN (l_prep) in/IN (l_pobj) events/NNS -PUNC- clopidogrel/JJ (r_dobj) platelet/NN (l_prep) in/IN (l_pobj) events/NNS
C426686_D056486 CID Ximelagatran/NN (r_nsubjpass) found/VBN (l_conj) withdrawn/VBN (l_prep) because/IN (l_pobj) tests/NNS (l_compound) function/NN
D001241_D001281 NONE aspirin/NN (r_conj) clopidogrel/JJ (r_dobj) platelet/NN (r_xcomp) superior/JJ (r_acomp) is/VBZ (r_ccomp) demonstrated/VBN (l_nsubj) Trial/NN (l_compound) Clopidogrel/NNP (l_compound) Fibrillation/NNP
D014859_D001281 NONE warfarin/NN (r_nsubj) is/VBZ (r_ccomp) demonstrated/VBN (l_nsubj) Trial/NN (l_compound) Clopidogrel/NNP (l_compound) Fibrillation/NNP
D000804_D020257 NONE II/CD (r_nummod) drugs/NNS (r_conj) inhibitors/NNS (r_nsubj) hold/VBP (l_dobj) promise/NN (l_prep) in/IN (l_pobj) fibrillation/NN (l_prep) through/IN (l_pobj) remodelling/NN
C479958_D001281 NONE Idraparinux/NNP (r_nsubjpass) evaluated/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) fibrillation/NN
D001241_D004617 NONE aspirin/NN (r_conj) clopidogrel/JJ (r_dobj) platelet/NN (l_prep) in/IN (l_pobj) events/NNS
2396046
D010634_D006528 NONE phenobarbital/NN (r_dobj) containing/VBG (r_acl) diet/NN (r_dobj) fed/VBD (r_conj) fed/VBD (l_nsubj) nodules/NNS (l_conj) carcinomas/NNS -PUNC- phenobarbital/NN (r_dobj) containing/VBG (r_acl) diet/NN (r_dobj) fed/VBD (r_conj) fed/VBD (l_advcl) developed/VBN (l_nsubj) nodule/NN (l_conj) carcinoma/NN -PUNC- phenobarbital/RB (r_npadvmod) containing/VBG (r_amod) diet/NN (r_dobj) fed/VBD (r_conj) was/VBD (l_nsubj) incidence/NN (l_prep) of/IN (l_conj) of/IN (l_pobj) carcinomas/NNS
D002794_D006528 CID choline/NN (r_npadvmod) supplemented/VBN (r_amod) diet/NN (r_dobj) fed/VBD (l_nsubj) nodules/NNS (l_conj) carcinomas/NNS -PUNC- choline/NN (r_npadvmod) supplemented/VBN (r_amod) diet/NN (r_dobj) fed/VBD (l_advcl) developed/VBN (l_nsubj) nodule/NN (l_conj) carcinoma/NN -PUNC- choline/NN (r_npadvmod) devoid/JJ (r_amod) diet/NN (r_dobj) fed/VBD (r_conj) was/VBD (l_nsubj) incidence/NN (l_prep) of/IN (l_conj) of/IN (l_pobj) carcinomas/NNS -PUNC- choline/NN (r_npadvmod) devoid/JJ (r_amod) diet/NN (r_dobj) fed/VBD (r_conj) was/VBD (l_nsubj) incidence/NN (l_prep) of/IN (l_conj) of/IN (l_pobj) carcinomas/NNS
3997294
D000638_D013617 NONE amiodarone/NN (l_prep) for/IN (l_pobj) control/NN (l_prep) of/IN (l_pobj) tachyarrhythmias/NNS
D000638_D010490 CID amiodarone/NN (r_compound) therapy/NN (r_pobj) during/IN (r_prep) effusion/NN
D013256_D011014 NONE steroid/NN (r_compound) therapy/NN (r_conj) prompt/JJ (r_conj) withdrawal/NN (r_dobj) indicates/VBZ (l_dobj) need/NN (l_prep) for/IN (l_pobj) diagnosis/NN (l_prep) of/IN (l_pobj) pneumonitis/NN
D000638_D002318 NONE amiodarone/NN (r_pobj) with/IN (r_prep) treated/VBN (l_nsubjpass) patient/NN (l_prep) with/IN (l_pobj) disease/NN
D000638_D011014 CID amiodarone/NN (r_compound) pneumonitis/NN -PUNC- amiodarone/NN (r_pobj) of/IN (r_prep) withdrawal/NN (r_dobj) indicates/VBZ (l_dobj) need/NN (l_prep) for/IN (l_pobj) diagnosis/NN (l_prep) of/IN (l_pobj) pneumonitis/NN
D000638_D009422 NONE amiodarone/NN (r_compound) therapy/NN (r_pobj) during/IN (r_prep) effusion/NN (l_conj) neuropathy/NN
D000638_D010996 CID amiodarone/NN (r_compound) therapy/NN (r_pobj) during/IN (r_prep) effusion/NN
1720453
D007069_D064420 NONE ifosfamide/NN (r_pobj) of/IN (r_prep) m2/NN (r_pobj) of/IN (r_prep) dose/NN (r_pobj) with/IN (r_prep) correlated/VBN (l_nsubjpass) toxicity/NN
D003404_D011507 NONE creatinine/NN (r_compound) clearance/NN (r_conj) osmolarity/NN (r_conj) pH/NN (r_conj) aminoaciduria/JJ (r_conj) proteinuria/NN
D007069_D007674 CID ifosfamide/JJ (r_amod) toxicity/NN
D007069_D009369 NONE ifosfamide/NN (r_pobj) of/IN (r_prep) m2/NN (r_pobj) of/IN (r_prep) dose/NN (l_conj) predominance/NN (l_prep) of/IN (l_pobj) involvement/NN (l_compound) tumor/NN
D010710_D000608 NONE phosphate/NN (r_nmod) reabsorption/NN (r_conj) clearance/NN (r_conj) osmolarity/NN (r_conj) pH/NN (r_conj) aminoaciduria/JJ
D010710_D005198 NONE phosphate/NN (r_compound) reabsorption/NN (r_conj) microglobulinuria/NN (r_pobj) with/IN (r_prep) patients/NNS (r_dobj) included/VBD (r_conj) included/VBD (l_dobj) patients/NNS (l_relcl) developed/VBD (l_dobj) toxicity/NN (l_acl) resulting/VBG (l_prep) in/IN (l_pobj) syndrome/NN -PUNC- phosphate/NN (r_compound) reabsorption/NN (r_conj) microglobulinuria/NN (r_pobj) with/IN (r_prep) patients/NNS (r_dobj) included/VBD (r_conj) included/VBD (l_dobj) patients/NNS (l_relcl) developed/VBD (l_dobj) toxicity/NN (l_acl) resulting/VBG (l_prep) in/IN (l_pobj) syndrome/NN (l_appos) TDFS/NNP
D003404_D006030 NONE creatinine/NN (r_compound) clearance/NN (r_conj) osmolarity/NN (r_conj) pH/NN (r_conj) aminoaciduria/JJ (r_conj) proteinuria/NN (r_conj) glucosuria/NN
D010710_D011507 NONE phosphate/NN (r_nmod) reabsorption/NN (r_conj) clearance/NN (r_conj) osmolarity/NN (r_conj) pH/NN (r_conj) aminoaciduria/JJ (r_conj) proteinuria/NN
D010710_D064420 NONE phosphate/NN (r_compound) reabsorption/NN (r_conj) microglobulinuria/NN (r_pobj) with/IN (r_prep) patients/NNS (r_dobj) included/VBD (r_conj) included/VBD (l_dobj) patients/NNS (l_relcl) developed/VBD (l_dobj) toxicity/NN
D010710_D006030 NONE phosphate/NN (r_nmod) reabsorption/NN (r_conj) clearance/NN (r_conj) osmolarity/NN (r_conj) pH/NN (r_conj) aminoaciduria/JJ (r_conj) proteinuria/NN (r_conj) glucosuria/NN
D007069_C535700 NONE ifosfamide/JJ (r_amod) toxicity/NN (r_pobj) of/IN (r_prep) up/NN (r_nsubj) treated/VBN (l_prep) for/IN (l_pobj) tumors/NNS -PUNC- ifosfamide/JJ (r_compound) protocol/NN (r_dobj) received/VBN (r_relcl) function/NN (l_prep) with/IN (l_pobj) tumors/NNS -PUNC- ifosfamide/JJ (r_compound) protocol/NN (l_appos) Society/NNP (l_prep) of/IN (l_pobj) Study/NNP (l_compound) Tumor/NNP -PUNC- ifosfamide/NN (r_pobj) of/IN (r_prep) efficacy/NN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) tumors/NNS
D003404_D000608 NONE creatinine/NN (r_compound) clearance/NN (r_conj) osmolarity/NN (r_conj) pH/NN (r_conj) aminoaciduria/JJ
12063090
D004177_D059350 NONE metamizol/NN (r_conj) morphine/NN (r_pobj) between/IN (r_prep) interaction/NN (r_dobj) show/VBP (l_advcl) suggesting/VBG (l_ccomp) be/VB (l_acomp) useful/JJ (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) pain/NN
D009020_D003248 CID morphine/NN (r_compound) antinociception/NN (l_conj) constipation/NN -PUNC- morphine/NN (r_pobj) of/IN (r_prep) combination/NN (r_pobj) of/IN (r_prep) effects/NNS (l_amod) antinociceptive/NN (l_conj) constipating/JJ -PUNC- morphine/NN (r_nsubj) inhibited/VBD (l_advcl) suggesting/VBG (l_ccomp) develop/VB (l_prep) to/IN (l_pobj) effects/NNS (l_amod) constipating/JJ -PUNC- morphine/NN (r_pobj) by/IN (r_agent) produced/VBN (r_acl) that/DT (r_pobj) to/IN (r_prep) similar/JJ (r_amod) transit/NN (r_dobj) inhibited/VBD (l_advcl) suggesting/VBG (l_ccomp) potentiate/VB (l_dobj) constipation/NN -PUNC- morphine/NN (r_npadvmod) induced/VBN (r_amod) constipation/NN
D004177_D003248 NONE Metamizol/NNP (r_nsubj) potentiates/VBZ (l_dobj) antinociception/NN (l_conj) constipation/NN -PUNC- metamizol/NN (r_pobj) with/IN (r_prep) effects/NNS (l_amod) antinociceptive/NN (l_conj) constipating/JJ -PUNC- metamizol/NN (r_nsubj) potentiate/VB (l_dobj) constipation/NN
D002606_D010146 NONE charcoal/NN (r_compound) meal/NN (r_compound) test/NN (r_nsubjpass) used/VBN (r_conj) assessed/VBN (l_conj) model/NN (l_amod) induced/VBN (l_npadvmod) pain/NN
D009020_D059350 NONE morphine/NN (r_pobj) between/IN (r_prep) interaction/NN (r_dobj) show/VBP (l_advcl) suggesting/VBG (l_ccomp) be/VB (l_acomp) useful/JJ (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) pain/NN
15515654
D003676_D006311 NONE DFO/NNP (r_pobj) than/IN (r_prep) other/JJ (r_amod) factor/NN (l_compound) ototoxic/JJ
D003676_D034381 NONE DFO/NNP (r_poss) role/NN (l_prep) in/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) impairment/NN
D003676_D006319 CID DFO/NNP (r_compound) reduction/NN (r_pobj) to/IN (r_prep) submitted/VBN (l_nsubjpass) Subjects/NNS (l_prep) with/IN (l_pobj) SNHL/NNP
11279304
D003630_D015470 NONE daunorubicin/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) leukemia/NN -PUNC- DNR)-containing/NN (r_compound) regimen/NNS (r_appos) daunorubicin/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) leukemia/NN -PUNC- DNR/NNP (r_npadvmod) containing/VBG (r_amod) regimen/NN (r_pobj) with/IN (r_prep) treated/VBN (l_nsubjpass) patients/NNS (l_prep) with/IN (l_pobj) leukemia/NN
D018943_D066126 NONE anthracycline/NN (r_advmod) induced/VBN (r_amod) cardiotoxicity/NN -PUNC- Anthracyclines/NNS (r_nsubj) are/VBP (l_conj) cause/VBP (l_dobj) cardiotoxicity/NN -PUNC- anthracycline/NN (r_amod) therapy/NN (r_pobj) of/IN (r_prep) cardiotoxicity/NN -PUNC- anthracycline/NN (r_advmod) induced/VBN (r_amod) cardiotoxicity/NN -PUNC- anthracycline/NN (r_advmod) induced/VBN (r_compound) cardiotoxicity/NN
D003630_D066126 NONE daunorubicin/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) leukemia/NN (r_pobj) with/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) cardiotoxicity/NN -PUNC- DNR)-containing/NN (r_compound) regimen/NNS (r_appos) daunorubicin/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) leukemia/NN (r_pobj) with/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) cardiotoxicity/NN
D018943_D015470 NONE anthracycline/NN (r_advmod) induced/VBN (r_amod) cardiotoxicity/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) leukemia/NN
D018943_D006331 NONE anthracycline/NN (r_amod) therapy/NN (r_pobj) of/IN (r_prep) cardiotoxicity/NN (r_nsubj) highlights/VBZ (l_dobj) need/NN (l_acl) search/VB (l_prep) for/IN (l_pobj) methods/NNS (l_relcl) are/VBP (l_acomp) sensitive/JJ (l_conj) capable/JJ (l_prep) of/IN (l_pcomp) predicting/VBG (l_dobj) dysfunction/NN
D003630_D006333 CID DNR/NNP (r_pobj) given/VBN (r_acl) failure/NN
3107448
D013453_D056486 NONE sulfonylureas/NNS (r_pobj) with/IN (r_prep) reported/VBN (l_nsubjpass) hepatotoxicity/NN -PUNC- sulfonylurea/NN (r_nsubj) exist/VBP (l_nsubj) reports/NNS (l_prep) of/IN (l_pobj) hepatotoxicity/NN
D005905_D056486 CID Glyburide/NN (r_npadvmod) induced/VBN (r_amod) hepatitis/NN -PUNC- glyburide/NN (r_pobj) For/IN (r_prep) exist/VBP (l_nsubj) reports/NNS (l_prep) of/IN (l_pobj) hepatotoxicity/NN -PUNC- glyburide/NN (r_amod) therapy/NN (r_pobj) of/IN (r_prep) initiation/NN (r_pobj) after/IN (r_prep) developed/VBD (l_dobj) syndrome/NN -PUNC- Glyburide/NNP (r_nsubj) produce/VB (l_dobj) illness/NN
D005905_D003924 NONE glyburide/NN (r_amod) therapy/NN (r_pobj) of/IN (r_prep) initiation/NN (r_pobj) after/IN (r_prep) developed/VBD (l_nsubj) patients/NNS (l_prep) with/IN (l_pobj) mellitus/NN
12589964
D004317_D006331 NONE doxorubicin/NN (r_pobj) of/IN (r_prep) model/NN (r_pobj) in/IN (r_prep) damage/NN (r_pobj) of/IN (r_prep) diagnosis/NN (r_pobj) for/IN (r_prep) investigated/VBD (l_conj) examined/VBD (l_dobj) relationship/NN (l_prep) with/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) disorders/NNS -PUNC- DOX)-induced/VBN (r_amod) cardiomyopathy/NN (r_appos) model/NN (r_pobj) in/IN (r_prep) damage/NN (r_pobj) of/IN (r_prep) diagnosis/NN (r_pobj) for/IN (r_prep) investigated/VBD (l_conj) examined/VBD (l_dobj) relationship/NN (l_prep) with/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) disorders/NNS
D004317_D005355 NONE DOX/NNP (r_pobj) given/VBN (r_prep) rats/NNS (r_pobj) from/IN (r_prep) hearts/NNS (r_pobj) of/IN (r_prep) evaluation/NN (r_nsubj) revealed/VBD (l_dobj) degrees/NNS (l_prep) of/IN (l_pobj) fibrosis/NN
D004317_D064420 NONE DOX/NNP (r_compound) rats/NNS (r_pobj) of/IN (r_prep) Eighteen/CD (r_nsubj) died/VBD (l_prep) of/IN (l_pobj) toxicity/NN
D004317_D066126 NONE DOX/NNP (r_pobj) after/IN (r_prep) amount/NN (r_pobj) between/IN (r_prep) discrepancy/NN (r_attr) was/VBD (r_advcl) is/VBZ (l_acomp) likely/JJ (l_ccomp) indicates/VBZ (l_conj) be/VB (l_attr) marker/NN (l_prep) for/IN (l_pobj) prediction/NN (l_prep) of/IN (l_pobj) cardiotoxicity/NN -PUNC- DOX/NNP (r_nsubj) indicates/VBZ (l_conj) be/VB (l_attr) marker/NN (l_prep) for/IN (l_pobj) prediction/NN (l_prep) of/IN (l_pobj) cardiotoxicity/NN
D004317_D009202 CID doxorubicin/NN (r_npadvmod) induced/VBN (r_amod) rats/NNS (r_pobj) in/IN (r_prep) damage/NN -PUNC- doxorubicin/NN (r_npadvmod) induced/VBN (r_amod) rats/NNS (l_amod) cardiomyopathy/NN -PUNC- doxorubicin/NN (r_pobj) of/IN (r_prep) model/NN (r_pobj) in/IN (r_prep) damage/NN -PUNC- doxorubicin/NN (r_pobj) of/IN (r_prep) model/NN (l_appos) cardiomyopathy/NN -PUNC- DOX)-induced/VBN (r_amod) cardiomyopathy/NN (r_appos) model/NN (r_pobj) in/IN (r_prep) damage/NN -PUNC- DOX)-induced/VBN (r_amod) cardiomyopathy/NN -PUNC- DOX/NNP (r_pobj) after/IN (r_prep) markers/NNS (r_pobj) Among/IN (r_prep) showed/VBD (l_dobj) ability/NN (l_acl) detect/VB (l_dobj) damage/NN
D004317_D017202 NONE DOX/NNP (r_pobj) after/IN (r_prep) markers/NNS (l_prep) of/IN (l_pobj) injury/NN
9812111
D006220_D019958 NONE haloperidol/NN (l_prep) for/IN (l_pobj) psychosis/NN (l_conj) behaviors/NNS -PUNC- haloperidol/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) of/IN (r_prep) efficacy/NN (r_dobj) compare/VB (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) psychosis/NN (l_conj) behaviors/NNS -PUNC- haloperidol/NN (r_pobj) with/IN (r_prep) observed/VBN (r_nsubj) apply/VB (l_prep) to/IN (l_pobj) neuroleptics/NNS (l_acl) used/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) psychosis/NN (l_conj) behaviors/NNS
D006220_D011595 NONE haloperidol/NN (r_appos) A/NNP (r_dobj) completed/VBD (r_relcl) patients/NNS (r_pobj) For/IN (r_prep) was/VBD (l_acomp) efficacious/JJ (l_prep) to/IN (l_pobj) haloperidol/NN (l_prep) for/IN (l_pobj) scores/NNS (l_prep) on/IN (l_conj) on/IN (l_pobj) agitation/NN -PUNC- haloperidol/NN (l_prep) for/IN (l_pobj) scores/NNS (l_prep) on/IN (l_conj) on/IN (l_pobj) agitation/NN
D006220_D000544 NONE haloperidol/NN (l_prep) for/IN (l_pobj) psychosis/NN (l_prep) in/IN (l_pobj) disease/NN -PUNC- haloperidol/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) of/IN (r_prep) efficacy/NN (r_dobj) compare/VB (l_prep) in/IN (l_pobj) treatment/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disease/NN -PUNC- haloperidol/NN (r_appos) phase/NN (r_preconj) In/IN (r_prep) compared/VBN (l_prep) in/IN (l_pobj) outpatients/NNS (l_prep) with/IN (l_pobj) disease/NN -PUNC- haloperidol/NN (r_conj) phase/NN (r_preconj) In/IN (r_prep) compared/VBN (l_prep) in/IN (l_pobj) outpatients/NNS (l_prep) with/IN (l_pobj) disease/NN -PUNC- haloperidol/NN (r_pobj) with/IN (r_prep) observed/VBN (r_nsubj) apply/VB (l_prep) to/IN (l_pobj) neuroleptics/NNS (l_acl) used/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_compound) disease/NN
D006220_D001480 CID haloperidol/NN (r_pobj) for/IN (r_prep) profile/NN (r_dobj) indicated/VBD (l_advcl) developed/VBD (l_acomp) moderate/JJ (l_prep) to/TO (l_pobj) signs/NNS
D006220_D011618 NONE haloperidol/NN (l_prep) for/IN (l_pobj) psychosis/NN -PUNC- haloperidol/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) of/IN (r_prep) efficacy/NN (r_dobj) compare/VB (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) psychosis/NN -PUNC- haloperidol/NN (r_appos) A/NNP (r_dobj) completed/VBD (r_relcl) patients/NNS (r_pobj) For/IN (r_prep) was/VBD (l_acomp) efficacious/JJ (l_prep) to/IN (l_pobj) haloperidol/NN (l_prep) for/IN (l_pobj) scores/NNS (l_prep) on/IN (l_pobj) factor/NN (l_compound) psychosis/NN -PUNC- haloperidol/NN (l_prep) for/IN (l_pobj) scores/NNS (l_prep) on/IN (l_pobj) factor/NN (l_compound) psychosis/NN -PUNC- haloperidol/NN (r_pobj) with/IN (r_prep) observed/VBN (r_nsubj) apply/VB (l_prep) to/IN (l_pobj) neuroleptics/NNS (l_acl) used/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) psychosis/NN
7468724
D013726_D007752 NONE terbutaline/JJ (r_compound) treatment/NN (l_prep) for/IN (l_pobj) labor/NN -PUNC- terbutaline/NN (l_prep) for/IN (l_pobj) labor/NN
D013726_D002318 CID terbutaline/JJ (r_compound) treatment/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) complications/NNS -PUNC- terbutaline/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (r_pobj) in/IN (r_prep) occurred/VBD (l_nsubj) complications/NNS
7802851
D000525_D016584 NONE alprazolam/NN (r_pobj) of/IN (r_prep) efficacy/NN (l_prep) in/IN (l_pobj) disorder/NN -PUNC- alprazolam/NN (r_xcomp) randomised/VBN (l_prep) In/IN (l_pobj) London/NNP (l_conj) patients/NNS (l_relcl) met/VBD (l_dobj) criteria/NNS (l_prep) for/IN (l_pobj) disorder/NN
D000525_D001523 NONE alprazolam/NN (r_compound) patients/NNS (r_nsubj) developed/VBD (l_dobj) reactions/NNS (l_prep) of/IN (l_pobj) depression/NN (l_conj) enuresis/NN (l_conj) disinhibition/NN (l_conj) aggression/NN -PUNC- alprazolam/NN (r_compound) patients/NNS (r_nsubj) developed/VBD (l_dobj) reactions/NNS (l_conj) effects/NNS (l_appos) sedation/NN (l_conj) irritability/NN
D000525_D000379 NONE alprazolam/NN (r_pobj) of/IN (r_prep) efficacy/NN (l_prep) in/IN (l_pobj) disorder/NN (l_prep) with/IN (l_pobj) agoraphobia/NNP -PUNC- alprazolam/NN (r_xcomp) randomised/VBN (l_prep) In/IN (l_pobj) London/NNP (l_conj) patients/NNS (l_relcl) met/VBD (l_dobj) criteria/NNS (l_prep) for/IN (l_pobj) disorder/NN (l_prep) with/IN (l_pobj) agoraphobia/NNP
D000525_D001259 CID alprazolam/NN (r_compound) patients/NNS (r_nsubj) developed/VBD (l_dobj) reactions/NNS (l_conj) effects/NNS (l_appos) sedation/NN (l_conj) irritability/NN (l_conj) memory/NN (l_conj) loss/NN (l_conj) ataxia/NN
D000525_D008569 CID alprazolam/NN (r_compound) patients/NNS (r_nsubj) developed/VBD (l_dobj) reactions/NNS (l_conj) effects/NNS (l_appos) sedation/NN (l_conj) irritability/NN (l_conj) memory/NN
D000525_D003866 CID alprazolam/NN (r_compound) patients/NNS (r_nsubj) developed/VBD (l_dobj) reactions/NNS (l_prep) of/IN (l_pobj) depression/NN
D000525_D015431 CID alprazolam/NN (r_compound) patients/NNS (r_nsubj) developed/VBD (l_dobj) reactions/NNS (l_conj) effects/NNS (l_appos) sedation/NN (l_conj) irritability/NN (l_conj) memory/NN (l_conj) loss/NN
D000525_D004775 CID alprazolam/NN (r_compound) patients/NNS (r_nsubj) developed/VBD (l_dobj) reactions/NNS (l_prep) of/IN (l_pobj) depression/NN (l_conj) enuresis/NN
2265898
C009265_D001523 NONE levodopa/JJ (r_compound) preparation/NN (r_dobj) receiving/VBG (l_conj) had/VBD (l_dobj) onset/NN (l_prep) of/IN (l_pobj) seizures/NNS (l_nmod) hallucinosis/NN
C009265_D004827 CID carbidopa/NN (l_nsubj) epilepsy/NN
C009265_D012640 NONE levodopa/JJ (r_compound) preparation/NN (r_dobj) receiving/VBG (l_conj) had/VBD (l_dobj) onset/NN (l_prep) of/IN (l_pobj) seizures/NNS
C009265_D007676 NONE levodopa/JJ (r_compound) preparation/NN (r_dobj) receiving/VBG (l_ccomp) had/VBD (l_dobj) failure/NN
8558192
C030852_C562729 NONE vinorelbine/NN (r_pobj) of/IN (r_prep) trial/NN (l_prep) in/IN (l_pobj) carcinoma/NN -PUNC- vinorelbine/NN (r_pobj) of/IN (r_prep) effects/NNS (r_conj) rate/NN (l_acl) administered/VBN (l_prep) as/IN (l_pobj) agent/NN (l_prep) in/IN (l_pobj) carcinoma/NN -PUNC- VNB/NNP (r_appos) vinorelbine/NN (r_pobj) of/IN (r_prep) effects/NNS (r_conj) rate/NN (l_acl) administered/VBN (l_prep) as/IN (l_pobj) agent/NN (l_prep) in/IN (l_pobj) carcinoma/NN -PUNC- VNB/NNP (r_nsubj) is/VBZ (l_attr) agent/NN (l_prep) in/IN (l_pobj) carcinoma/NN
D002945_D064420 NONE cisplatin/NN (r_npadvmod) based/VBN (r_amod) chemotherapy/NN (r_pobj) with/IN (r_prep) pretreated/VBN (r_csubj) were/VBD (l_acomp) assessable/JJ (l_prep) for/IN (l_pobj) toxicity/NN
C030852_D064420 NONE VNB/NNP (r_nsubjpass) tolerated/VBN (l_conj) occurred/VBD (l_nsubj) toxicity/NN -PUNC- VNB/NNP (r_pobj) of/IN (r_prep) evaluation/NN (r_nsubjpass) warranted/VBN (l_prep) Given/VBN (l_pobj) profile/NN (l_conj) toxicity/NN
18208574
D006493_D013921 CID heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN -PUNC- heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN -PUNC- heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN (l_appos) assay/NN (l_nmod) HIT/NN -PUNC- heparin/JJ (r_compound) concentration/NN (r_pobj) of/IN (r_prep) characteristics/NNS (r_dobj) utilizes/VBZ (l_advcl) correlate/VB (l_dobj) density/NN (l_prep) of/IN (l_pobj) thrombocytopenia/NN -PUNC- heparin/JJ (r_compound) concentration/NN (r_pobj) of/IN (r_prep) characteristics/NNS (r_dobj) utilizes/VBZ (l_advcl) correlate/VB (l_dobj) density/NN (l_prep) of/IN (l_pobj) thrombocytopenia/NN (l_appos) assay/NN (l_nmod) HIT/NN -PUNC- heparin/NN (r_pobj) to/IN (r_prep) exposure/NN (r_pobj) after/IN (r_prep) Patients/NNS (l_prep) with/IN (l_pobj) decrease/NN (l_conj) thrombocytopenia/NNP -PUNC- heparin/NN (r_pobj) of/IN (r_prep) concentration/NN (r_pobj) with/IN (r_prep) inhibition/NN (r_dobj) had/VBD (r_relcl) heparin/NN (r_pobj) to/IN (r_prep) exposure/NN (r_pobj) after/IN (r_prep) Patients/NNS (l_prep) with/IN (l_pobj) decrease/NN (l_conj) thrombocytopenia/NNP
D006493_D013927 CID heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN (r_pobj) with/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) thrombosis/NN -PUNC- heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN (l_appos) assay/NN (l_prep) with/IN (l_pobj) thrombosis/NN -PUNC- heparin/JJ (r_compound) concentration/NN (r_pobj) of/IN (r_prep) characteristics/NNS (r_dobj) utilizes/VBZ (l_advcl) correlate/VB (l_dobj) density/NN (l_prep) of/IN (l_pobj) thrombocytopenia/NN (l_appos) assay/NN (l_prep) with/IN (l_pobj) thrombosis/NN
10743446
D002211_D006930 CID capsaicin/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) effects/NNS (l_prep) of/IN (l_pobj) ketamine/NN (l_prep) on/IN (l_pobj) hyperalgesia/NN -PUNC- capsaicin/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) effect/NN (l_prep) of/IN (l_pobj) administration/NN (l_prep) on/IN (l_pobj) hyperalgesia/NN
D007649_D006930 NONE ketamine/NN (l_prep) on/IN (l_pobj) hyperalgesia/NN -PUNC- ketamine/NN (r_pobj) of/IN (r_prep) administration/NN (l_prep) on/IN (l_pobj) hyperalgesia/NN -PUNC- Ketamine/NN (r_nsubj) reduced/VBD (l_dobj) area/NN (l_prep) of/IN (l_pobj) hyperalgesia/NN -PUNC- ketamine/NN (r_pobj) of/IN (r_prep) effects/NNS (l_prep) on/IN (l_pobj) hyperalgesia/NN -PUNC- ketamine/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubj) suggest/VBP (l_ccomp) mediated/VBN (l_nsubjpass) types/NNS (l_prep) of/IN (l_pobj) hyperalgesia/NN
D007649_D010146 NONE ketamine/NN (r_pobj) of/IN (r_prep) administration/NN (l_prep) on/IN (l_pobj) hyperalgesia/NN (l_nmod) pain/NN -PUNC- Ketamine/NN (r_nsubj) reduced/VBD (l_conj) tended/VBD (l_xcomp) reduce/VB (l_dobj) pain/NN
D008012_D010146 NONE lidocaine/NN (r_conj) ketamine/NN (r_pobj) of/IN (r_prep) administration/NN (l_prep) on/IN (l_pobj) hyperalgesia/NN (l_nmod) pain/NN
D002211_D010146 CID capsaicin/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) effect/NN (l_prep) of/IN (l_pobj) administration/NN (l_prep) on/IN (l_pobj) hyperalgesia/NN (l_nmod) pain/NN
D008012_D006930 NONE lidocaine/NN (r_conj) ketamine/NN (l_prep) on/IN (l_pobj) hyperalgesia/NN -PUNC- lidocaine/NN (r_conj) ketamine/NN (r_pobj) of/IN (r_prep) administration/NN (l_prep) on/IN (l_pobj) hyperalgesia/NN -PUNC- Lidocaine/NN (r_nsubj) reduced/VBD (l_dobj) area/NN (l_prep) of/IN (l_pobj) hyperalgesia/NN -PUNC- lidocaine/NN (r_conj) ketamine/NN (r_pobj) of/IN (r_prep) effects/NNS (l_prep) on/IN (l_pobj) hyperalgesia/NN -PUNC- lidocaine/NN (r_conj) ketamine/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubj) suggest/VBP (l_ccomp) mediated/VBN (l_nsubjpass) types/NNS (l_prep) of/IN (l_pobj) hyperalgesia/NN
18996674
D003042_D011317 CID cocaine/NN (r_compound) user/NN (r_appos) man/NN (r_nsubj) presented/VBN (l_prep) on/IN (l_pobj) occasions/NNS (l_prep) with/IN (l_pobj) history/NN (l_prep) of/IN (l_pobj) priapism/NN -PUNC- cocaine/NN (r_compound) use/NN (r_pobj) after/IN (r_prep) history/NN (l_prep) of/IN (l_pobj) priapism/NN
D004837_D011317 NONE epinephrine/NN (l_appos) treatment/NN (l_prep) for/IN (l_pobj) priapism/NN
84204
D002927_D051437 NONE cimetidine/FW (r_conj) dysfunction/NN
D002927_D008107 NONE cimetidine/FW (r_conj) dysfunction/NN
D002927_D003221 CID cimetidine/NN (r_npadvmod) associated/VBN (r_amod) confusion/NN -PUNC- cimetidine/NN (r_npadvmod) associated/VBN (r_amod) confusion/NN
16181582
D014635_D001927 CID Valproate/NNP (r_npadvmod) induced/VBN (r_amod) encephalopathy/NN -PUNC- Valproate/NNP (r_npadvmod) induced/VBN (r_amod) encephalopathy/NN -PUNC- valproate/NN (r_npadvmod) induced/VBN (r_amod) encephalopathy/NN
D014635_D004827 NONE Valproate/NNP (r_npadvmod) induced/VBN (r_amod) encephalopathy/NN (r_nsubj) is/VBZ (l_attr) syndrome/NN (l_relcl) manifest/VB (l_prep) in/RP (l_pobj) individuals/NNS (l_amod) epileptic/JJ
9698967
D008619_D006973 CID mepivacaine/NN (r_amod) mg/NN (r_pobj) with/IN (r_prep) block/NN (r_pobj) of/IN (r_prep) performance/NN (r_pobj) after/IN (r_prep) min/NN (r_appos) group/NN (r_appos) observed/VBN (l_nsubjpass) increase/NN (l_prep) in/IN (l_pobj) pressure/NN
D008619_D004387 NONE mepivacaine/NN (r_amod) mg/NN (r_pobj) with/IN (r_prep) block/NN (r_pobj) of/IN (r_prep) performance/NN (r_pobj) after/IN (r_prep) min/NN (r_appos) group/NN (l_prep) for/IN (l_pobj) correction/NN (l_prep) of/IN (l_pobj) contracture/NN
D004837_D006973 CID adrenaline/NN (r_dobj) containing/VBG (r_pcomp) with/IN (r_prep) block/NN (r_pobj) of/IN (r_prep) performance/NN (r_pobj) after/IN (r_prep) min/NN (r_appos) group/NN (r_appos) observed/VBN (l_nsubjpass) increase/NN (l_prep) in/IN (l_pobj) pressure/NN
D008619_D001281 CID mepivacaine/NN (r_amod) mg/NN (r_pobj) with/IN (r_prep) block/NN (r_pobj) of/IN (r_prep) performance/NN (r_pobj) after/IN (r_prep) min/NN (r_appos) group/NN (r_appos) observed/VBN (l_nsubjpass) increase/NN (l_acl) accompanied/VBN (l_agent) by/IN (l_pobj) fibrillation/NN
D004837_D011595 NONE adrenaline/NN (r_dobj) containing/VBG (r_pcomp) with/IN (r_prep) block/NN (r_pobj) of/IN (r_prep) performance/NN (r_pobj) after/IN (r_prep) min/NN (r_appos) group/NN (r_appos) observed/VBN (l_nsubjpass) increase/NN (l_acl) accompanied/VBN (l_agent) by/IN (l_pobj) fibrillation/NN (l_conj) agitation/NN
D008619_D011595 NONE mepivacaine/NN (r_amod) mg/NN (r_pobj) with/IN (r_prep) block/NN (r_pobj) of/IN (r_prep) performance/NN (r_pobj) after/IN (r_prep) min/NN (r_appos) group/NN (r_appos) observed/VBN (l_nsubjpass) increase/NN (l_acl) accompanied/VBN (l_agent) by/IN (l_pobj) fibrillation/NN (l_conj) agitation/NN
D004837_D001281 CID adrenaline/NN (r_dobj) containing/VBG (r_pcomp) with/IN (r_prep) block/NN (r_pobj) of/IN (r_prep) performance/NN (r_pobj) after/IN (r_prep) min/NN (r_appos) group/NN (r_appos) observed/VBN (l_nsubjpass) increase/NN (l_acl) accompanied/VBN (l_agent) by/IN (l_pobj) fibrillation/NN
D008619_D019954 NONE mepivacaine/NN (r_amod) mg/NN (r_pobj) with/IN (r_prep) block/NN (r_pobj) of/IN (r_prep) performance/NN (r_pobj) after/IN (r_prep) min/NN (r_appos) group/NN (r_appos) observed/VBN (l_nsubjpass) increase/NN (l_acl) accompanied/VBN (l_agent) by/IN (l_pobj) fibrillation/NN (l_conj) agitation/NN (l_conj) shouts/NNS
D004837_D014474 NONE adrenaline/NN (r_dobj) containing/VBG (r_pcomp) with/IN (r_prep) block/NN (r_pobj) of/IN (r_prep) performance/NN (r_pobj) after/IN (r_prep) min/NN (r_appos) group/NN (r_appos) observed/VBN (l_nsubjpass) increase/NN (l_acl) accompanied/VBN (l_agent) by/IN (l_pobj) fibrillation/NN (l_conj) agitation/NN (l_conj) shouts/NNS (l_prep) of/IN (l_pobj) consciousness/NN
D004837_D004387 NONE adrenaline/NN (r_dobj) containing/VBG (r_pcomp) with/IN (r_prep) block/NN (r_pobj) of/IN (r_prep) performance/NN (r_pobj) after/IN (r_prep) min/NN (r_appos) group/NN (l_prep) for/IN (l_pobj) correction/NN (l_prep) of/IN (l_pobj) contracture/NN
D004837_D019954 NONE adrenaline/NN (r_dobj) containing/VBG (r_pcomp) with/IN (r_prep) block/NN (r_pobj) of/IN (r_prep) performance/NN (r_pobj) after/IN (r_prep) min/NN (r_appos) group/NN (r_appos) observed/VBN (l_nsubjpass) increase/NN (l_acl) accompanied/VBN (l_agent) by/IN (l_pobj) fibrillation/NN (l_conj) agitation/NN (l_conj) shouts/NNS
D008619_D014474 NONE mepivacaine/NN (r_amod) mg/NN (r_pobj) with/IN (r_prep) block/NN (r_pobj) of/IN (r_prep) performance/NN (r_pobj) after/IN (r_prep) min/NN (r_appos) group/NN (r_appos) observed/VBN (l_nsubjpass) increase/NN (l_acl) accompanied/VBN (l_agent) by/IN (l_pobj) fibrillation/NN (l_conj) agitation/NN (l_conj) shouts/NNS (l_prep) of/IN (l_pobj) consciousness/NN
11532387
D012701_D001480 NONE serotonin/NN (r_compound) dopamine/NN (r_compound) antagonist/NN (r_appos) risperidone/NN (r_pobj) of/IN (r_prep) profile/NN (r_pobj) to/IN (r_prep) related/VBN (l_nsubjpass) mechanism/NN (l_prep) of/IN (l_pobj) RS/NN -PUNC- serotonin/NN (r_compound) dopamine/NN (r_compound) antagonist/NN (r_appos) risperidone/NN (r_pobj) of/IN (r_prep) profile/NN (r_pobj) to/IN (r_prep) related/VBN (l_advcl) suggesting/VBG (l_dobj) influence/NN (l_prep) in/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) RS/NN -PUNC- serotonin/NN (r_compound) system/NN (r_pobj) of/IN (r_prep) influence/NN (r_dobj) suggesting/VBG (r_advcl) related/VBN (l_nsubjpass) mechanism/NN (l_prep) of/IN (l_pobj) RS/NN -PUNC- serotonin/NN (r_compound) system/NN (r_pobj) of/IN (r_prep) influence/NN (l_prep) in/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) RS/NN
D004298_D013375 NONE dopamine/NN (r_compound) antagonist/NN (r_appos) risperidone/NN (r_pobj) of/IN (r_prep) profile/NN (r_pobj) to/IN (r_prep) related/VBN (l_nsubjpass) mechanism/NN (l_prep) of/IN (l_pobj) RS/NN
D012701_D013375 NONE serotonin/NN (r_compound) dopamine/NN (r_compound) antagonist/NN (r_appos) risperidone/NN (r_pobj) of/IN (r_prep) profile/NN (r_pobj) to/IN (r_prep) related/VBN (l_nsubjpass) mechanism/NN (l_prep) of/IN (l_pobj) RS/NN -PUNC- serotonin/NN (r_compound) system/NN (r_pobj) of/IN (r_prep) influence/NN (r_dobj) suggesting/VBG (r_advcl) related/VBN (l_nsubjpass) mechanism/NN (l_prep) of/IN (l_pobj) RS/NN
D018967_D013375 CID risperidone/NN (r_pobj) of/IN (r_prep) reduction/NN (r_pobj) during/IN (r_prep) syndrome/NN -PUNC- risperidone/NN (r_pobj) of/IN (r_prep) profile/NN (r_pobj) to/IN (r_prep) related/VBN (l_nsubjpass) mechanism/NN (l_prep) of/IN (l_pobj) RS/NN
D018967_D001480 CID risperidone/NN (r_pobj) of/IN (r_prep) reduction/NN (r_pobj) during/IN (r_prep) syndrome/NN -PUNC- risperidone/NN (r_pobj) of/IN (r_prep) reduction/NN (r_pobj) during/IN (r_prep) developed/VBN (l_dobj) RS/NN -PUNC- risperidone/NN (r_pobj) of/IN (r_prep) profile/NN (r_pobj) to/IN (r_prep) related/VBN (l_nsubjpass) mechanism/NN (l_prep) of/IN (l_pobj) RS/NN -PUNC- risperidone/NN (r_pobj) of/IN (r_prep) profile/NN (r_pobj) to/IN (r_prep) related/VBN (l_advcl) suggesting/VBG (l_dobj) influence/NN (l_prep) in/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) RS/NN
D004298_D001480 NONE dopamine/NN (r_compound) antagonist/NN (r_appos) risperidone/NN (r_pobj) of/IN (r_prep) profile/NN (r_pobj) to/IN (r_prep) related/VBN (l_nsubjpass) mechanism/NN (l_prep) of/IN (l_pobj) RS/NN -PUNC- dopamine/NN (r_compound) antagonist/NN (r_appos) risperidone/NN (r_pobj) of/IN (r_prep) profile/NN (r_pobj) to/IN (r_prep) related/VBN (l_advcl) suggesting/VBG (l_dobj) influence/NN (l_prep) in/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) RS/NN
7248170
D002251_D006529 NONE tetrachloride/NN (r_advmod) induced/VBN (r_amod) cirrhosis/NN (r_pobj) to/TO (r_prep) relationship/NN (r_appos) enlargement/NN (l_prep) of/IN (l_pobj) liver/NN -PUNC- tetrachloride/NN (r_advmod) given/VBN (l_conj) increased/VBN (l_prep) by/IN (l_pcomp) giving/VBG (l_prep) at/IN (l_pobj) peak/NN (l_prep) of/IN (l_pobj) enlargement/NN (l_prep) of/IN (l_pobj) liver/NN -PUNC- tetrachloride/NN (r_advmod) calibrating/VBG (r_dative) giving/VBG (l_prep) at/IN (l_pobj) peak/NN (l_prep) of/IN (l_pobj) enlargement/NN (l_prep) of/IN (l_pobj) liver/NN
D002251_D001284 NONE tetrachloride/NN (r_advmod) given/VBN (l_nsubj) ascites/VBZ (l_conj) albumin/NN (l_conj) splenomegaly/JJ (l_conj) atrophy/NN -PUNC- tetrachloride/NN (r_advmod) calibrating/VBG (r_dative) giving/VBG (r_pcomp) by/IN (r_prep) increased/VBN (r_conj) given/VBN (l_nsubj) ascites/VBZ (l_conj) albumin/NN (l_conj) splenomegaly/JJ (l_conj) atrophy/NN
D010634_D005355 NONE Phenobarbitone/NNP (r_npadvmod) induced/VBN (r_amod) enlargement/NN (l_appos) relationship/NN (l_prep) to/TO (l_pobj) cirrhosis/NN
D010634_D008103 CID phenobarbitone/NN (r_npadvmod) primed/VBN (r_amod) rat/NN (r_pobj) in/IN (r_prep) given/VBN (l_nsubj) ascites/VBZ (l_nsubj) yield/NN (l_prep) of/IN (l_pobj) cirrhosis/NN (l_prep) of/IN (l_pobj) liver/NN -PUNC- phenobarbitone/NN (r_npadvmod) induced/VBN (r_amod) enlargement/NN (r_pobj) of/IN (r_prep) peak/NN (r_pobj) at/IN (r_prep) giving/VBG (r_pcomp) by/IN (r_prep) increased/VBN (r_conj) given/VBN (l_nsubj) ascites/VBZ (l_nsubj) yield/NN (l_prep) of/IN (l_pobj) cirrhosis/NN (l_prep) of/IN (l_pobj) liver/NN
D002251_D001201 NONE tetrachloride/NN (r_advmod) given/VBN (l_nsubj) ascites/VBZ -PUNC- tetrachloride/NN (r_advmod) calibrating/VBG (r_dative) giving/VBG (r_pcomp) by/IN (r_prep) increased/VBN (r_conj) given/VBN (l_nsubj) ascites/VBZ
D002251_D005355 NONE tetrachloride/NN (r_advmod) induced/VBN (r_amod) cirrhosis/NN
D010634_D013163 NONE phenobarbitone/NN (r_npadvmod) primed/VBN (r_amod) rat/NN (r_pobj) in/IN (r_prep) given/VBN (l_nsubj) ascites/VBZ (l_conj) albumin/NN (l_conj) splenomegaly/JJ -PUNC- phenobarbitone/NN (r_npadvmod) induced/VBN (r_amod) enlargement/NN (r_pobj) of/IN (r_prep) peak/NN (r_pobj) at/IN (r_prep) giving/VBG (r_pcomp) by/IN (r_prep) increased/VBN (r_conj) given/VBN (l_nsubj) ascites/VBZ (l_conj) albumin/NN (l_conj) splenomegaly/JJ
D002251_D013163 NONE tetrachloride/NN (r_advmod) given/VBN (l_nsubj) ascites/VBZ (l_conj) albumin/NN (l_conj) splenomegaly/JJ -PUNC- tetrachloride/NN (r_advmod) calibrating/VBG (r_dative) giving/VBG (r_pcomp) by/IN (r_prep) increased/VBN (r_conj) given/VBN (l_nsubj) ascites/VBZ (l_conj) albumin/NN (l_conj) splenomegaly/JJ
D010634_D001284 NONE phenobarbitone/NN (r_npadvmod) primed/VBN (r_amod) rat/NN (r_pobj) in/IN (r_prep) given/VBN (l_nsubj) ascites/VBZ (l_conj) albumin/NN (l_conj) splenomegaly/JJ (l_conj) atrophy/NN -PUNC- phenobarbitone/NN (r_npadvmod) induced/VBN (r_amod) enlargement/NN (r_pobj) of/IN (r_prep) peak/NN (r_pobj) at/IN (r_prep) giving/VBG (r_pcomp) by/IN (r_prep) increased/VBN (r_conj) given/VBN (l_nsubj) ascites/VBZ (l_conj) albumin/NN (l_conj) splenomegaly/JJ (l_conj) atrophy/NN
D010634_D001201 NONE phenobarbitone/NN (r_npadvmod) primed/VBN (r_amod) rat/NN (r_pobj) in/IN (r_prep) given/VBN (l_nsubj) ascites/VBZ -PUNC- phenobarbitone/NN (r_npadvmod) induced/VBN (r_amod) enlargement/NN (r_pobj) of/IN (r_prep) peak/NN (r_pobj) at/IN (r_prep) giving/VBG (r_pcomp) by/IN (r_prep) increased/VBN (r_conj) given/VBN (l_nsubj) ascites/VBZ
D002251_D008103 CID tetrachloride/NN (r_advmod) given/VBN (l_nsubj) ascites/VBZ (l_nsubj) yield/NN (l_prep) of/IN (l_pobj) cirrhosis/NN (l_prep) of/IN (l_pobj) liver/NN -PUNC- tetrachloride/NN (r_advmod) calibrating/VBG (r_dative) giving/VBG (r_pcomp) by/IN (r_prep) increased/VBN (r_conj) given/VBN (l_nsubj) ascites/VBZ (l_nsubj) yield/NN (l_prep) of/IN (l_pobj) cirrhosis/NN (l_prep) of/IN (l_pobj) liver/NN
D010634_D006529 CID Phenobarbitone/NNP (r_npadvmod) induced/VBN (r_amod) enlargement/NN (l_prep) of/IN (l_pobj) liver/NN -PUNC- phenobarbitone/NN (r_npadvmod) primed/VBN (r_amod) rat/NN (r_pobj) in/IN (r_prep) given/VBN (l_conj) increased/VBN (l_prep) by/IN (l_pcomp) giving/VBG (l_prep) at/IN (l_pobj) peak/NN (l_prep) of/IN (l_pobj) enlargement/NN (l_prep) of/IN (l_pobj) liver/NN -PUNC- phenobarbitone/NN (r_npadvmod) induced/VBN (r_amod) enlargement/NN (l_prep) of/IN (l_pobj) liver/NN
354896
D008012_D006323 CID Lidocaine/NN (r_npadvmod) induced/VBN (r_amod) asystole/NN
D008012_D001919 NONE lidocaine/NN (r_pobj) to/IN (r_prep) idiosyncrasy/NN (r_dobj) represented/VBD (r_conj) had/VBD (l_dobj) conditions/NNS (l_relcl) predisposed/VBN (l_prep) to/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) bradyarrhythmias/NNS
D008012_D003866 NONE lidocaine/NN (r_pobj) of/IN (r_prep) bolus/NN (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) resulted/VBD (l_prep) in/IN (l_pobj) depression/NN
2096243
C017367_D019965 CID Carmofur/NN (r_npadvmod) induced/VBN (r_amod) disorders/NNS -PUNC- carmofur/NN (r_npadvmod) induced/VBN (r_amod) leukoencephalopathy/NN (r_pobj) of/IN (r_prep) onset/NN (r_pobj) after/IN (r_prep) period/NN (r_pobj) in/IN (r_prep) female/NN (r_pobj) in/IN (r_prep) observed/VBN (l_nsubjpass) disorder/NN
C017367_D056784 CID carmofur/NN (r_npadvmod) induced/VBN (r_amod) leukoencephalopathy/NN -PUNC- carmofur/NN (r_npadvmod) induced/VBN (r_amod) leukoencephalopathy/JJ
C017367_D010554 NONE carmofur/NN (r_npadvmod) induced/VBN (r_amod) leukoencephalopathy/JJ (r_nsubj) result/VB (l_prep) in/IN (l_pobj) syndrome/NN
3187073
D005472_D013610 NONE 5-FU/CD (r_compound) treatment/NN (r_pobj) on/IN (r_prep) patients/NNS (r_nsubj) be/VB (l_conj) discontinued/VBN (l_advcl) observed/VBN (l_nsubjpass) pain/NN (l_conj) tachyarrhythmia/NN
D005472_D002637 CID 5-FU/CD (r_compound) treatment/NN (r_pobj) on/IN (r_prep) patients/NNS (r_nsubj) be/VB (l_conj) discontinued/VBN (l_advcl) observed/VBN (l_nsubjpass) pain/NN
11569530
D020117_D016171 CID cisapride/NN (r_conj) terodiline/NN (r_conj) terfenadine/NN (r_appos) investigated/VBN (l_nsubjpass) TDP/NNP -PUNC- cisapride/JJ (r_conj) terodiline/NN (r_conj) terfenadine/NN (r_appos) clinic/NN (r_pobj) in/IN (r_prep) shown/VBN (l_dobj) TDP/NNP
D016593_D016171 CID terfenadine/NN (r_appos) market/NN (r_pobj) from/IN (r_prep) withdrawal/NN (r_pobj) to/IN (r_prep) led/VBN (r_relcl) effect/NN (r_attr) is/VBZ (l_nsubj) TDP/NNP -PUNC- terfenadine/NN (r_appos) investigated/VBN (l_nsubjpass) TDP/NNP -PUNC- terfenadine/NN (r_appos) clinic/NN (r_pobj) in/IN (r_prep) shown/VBN (l_dobj) TDP/NNP
C063968_D016171 NONE E4031/NNP (r_conj) cisapride/NN (r_conj) terodiline/NN (r_conj) terfenadine/NN (r_appos) investigated/VBN (l_nsubjpass) TDP/NNP
C010637_D016171 CID terodiline/NN (r_conj) terfenadine/NN (r_appos) market/NN (r_pobj) from/IN (r_prep) withdrawal/NN (r_pobj) to/IN (r_prep) led/VBN (r_relcl) effect/NN (r_attr) is/VBZ (l_nsubj) TDP/NNP -PUNC- terodiline/NN (r_conj) terfenadine/NN (r_appos) investigated/VBN (l_nsubjpass) TDP/NNP -PUNC- terodiline/NN (r_conj) terfenadine/NN (r_appos) clinic/NN (r_pobj) in/IN (r_prep) shown/VBN (l_dobj) TDP/NNP
6534871
D007545_D009203 CID isoproterenol/NN (r_npadvmod) induced/VBN (r_amod) infarction/NN
2950248
D004176_D003324 NONE dipyridamole/NN (r_compound) therapy/NN (r_pobj) of/IN (r_prep) effect/NN (r_pobj) as/IN (r_prep) reported/VBN (l_advcl) demonstrated/VBN (l_xcomp) occur/VB (l_prep) with/IN (l_pobj) disease/NN -PUNC- dipyridamole/NN (r_dep) induced/VBN (r_amod) ischemia/NN (r_nsubjpass) demonstrated/VBN (l_xcomp) occur/VB (l_prep) with/IN (l_pobj) disease/NN
D004176_D000787 CID dipyridamole/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) occurred/VBD (l_nsubj) Angina/NNP
D004176_D017202 NONE Dipyridamole/NNP (r_npadvmod) induced/VBN (r_amod) ischemia/NN -PUNC- dipyridamole/NN (r_compound) therapy/NN (r_pobj) of/IN (r_prep) effect/NN (r_pobj) as/IN (r_prep) reported/VBN (l_advcl) demonstrated/VBN (l_nsubjpass) ischemia/NN -PUNC- dipyridamole/NN (r_dep) induced/VBN (r_amod) ischemia/NN
D004176_D007511 NONE dipyridamole/NN (r_npadvmod) induced/VBN (r_amod) ischemia/NN
88336
D009567_D062787 CID nitrazepam/NN (r_pobj) of/IN (r_prep) overdose/NN -PUNC- nitrazepam/JJ (r_amod) overdose/NN
D000431_D062787 NONE alcohol/NN (r_compound) withdrawal/NN (r_compound) symptoms/NNS (r_pobj) for/IN (r_prep) received/VBD (l_conj) took/VBD (l_dobj) overdose/NN
D009567_D013375 NONE nitrazepam/NN (r_pobj) of/IN (r_prep) overdose/NN (r_dobj) took/VBD (r_conj) received/VBD (l_prep) for/IN (l_pobj) symptoms/NNS
D002719_D003128 CID chlormethiazole/NN (r_compound) intoxication/NN (r_pobj) with/IN (r_prep) those/DT (r_pobj) of/IN (r_prep) two/CD (r_conj) overdose/NN (r_pobj) with/IN (r_prep) patient/NN (r_nsubj) conformed/VBD (l_prep) to/IN (l_pobj) criteria/NNS (l_prep) of/IN (l_pobj) coma/NN
D002719_D013375 NONE chlormethiazole/NN (r_pobj) of/IN (r_prep) doses/NNS (r_dobj) received/VBD (l_prep) for/IN (l_pobj) symptoms/NNS
D002719_D062787 NONE chlormethiazole/NN (r_pobj) of/IN (r_prep) doses/NNS (r_dobj) received/VBD (l_conj) took/VBD (l_dobj) overdose/NN -PUNC- chlormethiazole/NN (r_compound) intoxication/NN (r_pobj) with/IN (r_prep) those/DT (r_pobj) of/IN (r_prep) two/CD (r_conj) overdose/NN
D009567_D003128 CID nitrazepam/JJ (r_amod) overdose/NN (r_pobj) with/IN (r_prep) patient/NN (r_nsubj) conformed/VBD (l_prep) to/IN (l_pobj) criteria/NNS (l_prep) of/IN (l_pobj) coma/NN
D000431_D013375 NONE alcohol/NN (r_compound) withdrawal/NN (r_compound) symptoms/NNS
8421099
D015282_D002764 NONE octreotide/NN (r_compound) therapy/NN (r_pobj) during/IN (r_prep) formation/NN (l_prep) of/IN (l_pobj) sludge/NN (l_conj) gallstones/NNS (l_conj) cholecystitis/NN
D015282_D000172 NONE octreotide/NN (r_appos) analog/NN (r_pobj) of/IN (r_prep) effects/NNS (l_prep) on/IN (l_pobj) function/NN (l_prep) in/IN (l_pobj) patients/NNS (l_compound) acromegalic/JJ -PUNC- octreotide/NN (r_appos) analog/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (l_prep) with/IN (l_pobj) acromegaly/NNS -PUNC- octreotide/NN (r_compound) therapy/NN (l_prep) in/IN (l_pobj) patients/NNS (l_compound) acromegalic/JJ -PUNC- octreotide/NN (r_compound) therapy/NN (l_prep) of/IN (l_pobj) patients/NNS (l_compound) acromegalic/JJ
D015282_D042882 CID octreotide/NN (r_appos) analog/NN (r_pobj) of/IN (r_prep) effects/NNS (l_prep) on/IN (l_pobj) function/NN (l_conj) formation/NN (l_compound) gallstone/NN -PUNC- octreotide/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) During/IN (r_prep) developed/VBD (l_conj) had/VBD (l_dobj) gallstones/NNS -PUNC- octreotide/NN (r_pobj) of/IN (r_prep) withdrawal/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) without/IN (l_pobj) gallstones/NNS -PUNC- octreotide/NN (r_compound) therapy/NN (r_pobj) during/IN (r_prep) formation/NN (l_prep) of/IN (l_pobj) sludge/NN (l_conj) gallstones/NNS
D015282_D041881 CID octreotide/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) During/IN (r_prep) developed/VBD (l_conj) had/VBD (l_conj) developed/VBD (l_dobj) cholecystitis/NN
18217897
D013792_D009101 NONE Thalidomide/NNP (r_nsubj) is/VBZ (l_attr) agent/NN (l_prep) with/IN (l_pobj) activity/NN (l_prep) in/IN (l_pobj) myeloma/NN
D013792_D009369 NONE Thalidomide/NNP (r_nsubj) limited/VBN (l_prep) in/IN (l_pobj) lymphomas/NNS (l_appos) trial/NN (l_prep) of/IN (l_pobj) Cancer/NNP
D013792_D008228 NONE Thalidomide/NNP (r_nsubj) limited/VBN (l_prep) in/IN (l_pobj) lymphomas/NNS
C467567_D008223 NONE lenalidomide/NN (r_appos) agent/NN (r_pobj) with/IN (r_prep) reported/VBN (r_acl) level/NN (r_pobj) with/IN (r_prep) contrast/NN (r_conj) demonstrate/VB (l_dobj) rate/NN (l_prep) in/IN (l_pobj) lymphomas/NNS
D013792_D007938 NONE Thalidomide/NNP (r_nsubj) limited/VBN (l_prep) in/IN (l_pobj) lymphomas/NNS (l_appos) trial/NN (l_prep) of/IN (l_pobj) Cancer/NNP (l_conj) B./NNP (l_compound) Leukemia/NNP
D013792_D020522 NONE Thalidomide/NNP (r_nsubj) is/VBZ (l_attr) agent/NN (l_prep) with/IN (l_pobj) activity/NN (l_prep) in/IN (l_pobj) myeloma/NN (l_conj) lymphoma/NN
D013792_D008223 NONE Thalidomide/NNP (r_nsubj) is/VBZ (l_attr) agent/NN (l_prep) with/IN (l_pobj) activity/NN (l_prep) in/IN (l_pobj) myeloma/NN (l_conj) lymphoma/NN (l_conj) lymphoma/NN -PUNC- thalidomide/NN (r_dobj) received/VBD (l_nsubj) patients/NNS (l_prep) with/IN (l_pobj) lymphomas/NNS -PUNC- thalidomide/NN (r_pobj) to/IN (r_prep) rate/NN (l_prep) in/IN (l_pobj) lymphomas/NNS
9195768
D018170_D010292 CID sumatriptan/NN (r_pobj) of/IN (r_prep) use/NN (r_dobj) following/VBG (r_prep) sensations/NNS
18081909
C026098_C562694 NONE LEV/NNP (r_pobj) with/IN (r_prep) treated/VBN (l_nsubjpass) man/NN (l_acl) suffering/VBG (l_prep) from/IN (l_pobj) epilepsy/NN
D014635_C562694 NONE valproate/VB (r_xcomp) added/VBN (r_conj) treated/VBN (l_nsubjpass) man/NN (l_acl) suffering/VBG (l_prep) from/IN (l_pobj) epilepsy/NN -PUNC- VPA/NNP (r_dobj) valproate/VB (r_xcomp) added/VBN (r_conj) treated/VBN (l_nsubjpass) man/NN (l_acl) suffering/VBG (l_prep) from/IN (l_pobj) epilepsy/NN
D014635_D012640 NONE valproate/VB (r_xcomp) added/VBN (r_conj) treated/VBN (l_nsubjpass) man/NN (l_acl) suffering/VBG (l_prep) with/IN (l_pobj) seizures/NNS -PUNC- VPA/NNP (r_dobj) valproate/VB (r_xcomp) added/VBN (r_conj) treated/VBN (l_nsubjpass) man/NN (l_acl) suffering/VBG (l_prep) with/IN (l_pobj) seizures/NNS
C026098_D012640 NONE LEV/NNP (r_pobj) with/IN (r_prep) treated/VBN (l_nsubjpass) man/NN (l_acl) suffering/VBG (l_prep) with/IN (l_pobj) seizures/NNS -PUNC- LEV/NNP (r_pobj) of/IN (r_prep) discontinuation/NN (r_pobj) Following/VBG (l_preconj) improved/VBN (l_conj) decreased/VBD (l_nsubj) frequency/NN (l_compound) seizure/NN
C026098_D001927 CID levetiracetam/NN (r_pcomp) by/IN (r_prep) induced/VBN (l_nsubj) Encephalopathy/JJ -PUNC- levetiracetam/FW (r_amod) encephalopathy/JJ -PUNC- LEV)-induced/VBN (r_amod) encephalopathy/JJ
D014635_D001927 CID valproate/VB (r_xcomp) added/VBN (r_conj) induced/VBN (l_nsubj) Encephalopathy/JJ
3629586
D015790_D006402 NONE cefonicid/NN (r_pobj) of/IN (r_prep) effects/NNS (l_appos) model/NN (l_prep) of/IN (l_pobj) hematotoxicity/NN -PUNC- cefonicid/NN (r_dobj) receiving/VBG (r_acl) dogs/NNS (r_pobj) of/IN (r_prep) %/NN (r_pobj) in/IN (r_prep) occurred/VBD (r_conj) was/VBD (l_attr) compromising/NN (l_prep) of/IN (l_pobj) cytopenias/NNS -PUNC- cefonicid/NN (r_amod) dogs/NNS (r_nsubj) showed/VBD (l_ccomp) reproduced/VBN (l_nsubjpass) syndrome/NN -PUNC- cefonicid/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) induce/VB (l_dobj) hematotoxicity/NN -PUNC- cefonicid/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) induce/VB (l_dobj) hematotoxicity/NN (l_amod) similar/JJ (l_prep) to/IN (l_pobj) dyscrasias/NNS
C021341_D009503 CID cefazedone/NN (r_conj) cefonicid/NN (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) caused/VBD (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) anemia/NN (l_conj) neutropenia/NN
D015790_D064420 NONE cefonicid/NN (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) caused/VBD (l_prep) In/IN (l_pobj) studies/NNS (l_compound) toxicity/NN
C021341_D000740 CID cefazedone/NN (r_conj) cefonicid/NN (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) caused/VBD (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) anemia/NN -PUNC- cefazedone/NN (r_conj) cefonicid/NN (r_dobj) receiving/VBG (r_acl) dogs/NNS (r_pobj) of/IN (r_prep) %/NN (r_pobj) in/IN (r_prep) occurred/VBD (r_conj) was/VBD (l_nsubj) anemia/NN
D015790_D000740 CID cefonicid/NN (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) caused/VBD (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) anemia/NN -PUNC- cefonicid/NN (r_dobj) receiving/VBG (r_acl) dogs/NNS (r_pobj) of/IN (r_prep) %/NN (r_pobj) in/IN (r_prep) occurred/VBD (r_conj) was/VBD (l_nsubj) anemia/NN
C021341_D013921 CID cefazedone/NN (r_conj) cefonicid/NN (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) caused/VBD (l_ccomp) thrombocytopenia/NN
D002511_D006402 NONE cephalosporin/JJ (r_amod) hematotoxicity/NN -PUNC- Cephalosporin/JJ (r_amod) antibiotics/NNS (r_nsubj) cause/VBP (l_dobj) variety/NN (l_prep) of/IN (l_pobj) disturbances/NNS -PUNC- cephalosporin/NN (r_pobj) with/IN (r_prep) rechallenge/VB (r_pobj) Upon/IN (r_prep) reproduced/VBN (l_nsubjpass) syndrome/NN -PUNC- cephalosporin/NN (r_advmod) induced/VBN (r_amod) dyscrasias/NNS (r_pobj) to/IN (r_prep) similar/JJ (r_amod) hematotoxicity/NN -PUNC- cephalosporin/NN (r_advmod) induced/VBN (r_amod) dyscrasias/NNS
C021341_D064420 NONE cefazedone/NN (r_conj) cefonicid/NN (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) caused/VBD (l_prep) In/IN (l_pobj) studies/NNS (l_compound) toxicity/NN
C021341_D006402 NONE cefazedone/NN (r_conj) cefonicid/NN (r_pobj) of/IN (r_prep) effects/NNS (l_appos) model/NN (l_prep) of/IN (l_pobj) hematotoxicity/NN -PUNC- cefazedone/NN (r_conj) cefonicid/NN (r_dobj) receiving/VBG (r_acl) dogs/NNS (r_pobj) of/IN (r_prep) %/NN (r_pobj) in/IN (r_prep) occurred/VBD (r_conj) was/VBD (l_attr) compromising/NN (l_prep) of/IN (l_pobj) cytopenias/NNS -PUNC- cefazedone)-treated/VBN (r_amod) dogs/NNS (r_nsubj) showed/VBD (l_ccomp) reproduced/VBN (l_nsubjpass) syndrome/NN -PUNC- cefazedone/NN (r_conj) cefonicid/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) induce/VB (l_dobj) hematotoxicity/NN -PUNC- cefazedone/NN (r_conj) cefonicid/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) induce/VB (l_dobj) hematotoxicity/NN (l_amod) similar/JJ (l_prep) to/IN (l_pobj) dyscrasias/NNS
D015790_D009503 CID cefonicid/NN (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) caused/VBD (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) anemia/NN (l_conj) neutropenia/NN
D015790_D013921 CID cefonicid/NN (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) caused/VBD (l_ccomp) thrombocytopenia/NN
8864707
D010672_D062787 CID phenytoin/NNP (r_compound) overdosages/NNS -PUNC- phenytoin/JJ (r_compound) overdosage/NN -PUNC- phenytoin/JJ (r_compound) medication/NN (r_nsubj) was/VBD (r_ccomp) is/VBZ (r_conj) result/VB (l_nsubj) overdosage/NN
D010672_D002526 NONE phenytoin/JJ (r_compound) medication/NN (l_conj) atrophy/NN -PUNC- phenytoin/JJ (r_compound) overdosage/NN (r_nsubj) result/VB (l_prep) in/IN (l_pobj) atrophy/NN -PUNC- phenytoin/JJ (r_compound) overdosage/NN (r_nsubj) result/VB (l_conj) is/VBZ (l_ccomp) was/VBD (l_attr) cause/NN (l_prep) of/IN (l_pobj) atrophy/NN -PUNC- phenytoin/JJ (r_compound) medication/NN (r_nsubj) was/VBD (r_ccomp) is/VBZ (r_conj) result/VB (l_prep) in/IN (l_pobj) atrophy/NN -PUNC- phenytoin/JJ (r_compound) medication/NN (r_nsubj) was/VBD (l_attr) cause/NN (l_prep) of/IN (l_pobj) atrophy/NN
D010672_D012640 NONE phenytoin/JJ (r_compound) levels/NNS (r_pobj) of/IN (r_prep) elevation/NN (r_conj) duration/NN (l_compound) seizure/NN
D010672_D004827 NONE phenytoin/NNP (r_compound) overdosages/NNS (r_pobj) after/IN (r_prep) volumetry/NN (l_prep) in/IN (l_pobj) patients/NNS (l_amod) epileptic/JJ
1009330
C005253_D003556 NONE Picloxydine/NNP (r_compound) irrigations/NNS (r_nsubj) appeared/VBD (l_xcomp) have/VB (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) cystitis/NN
D007612_D003556 CID kanamycin/NN (r_compound) colistin/NN (r_nmod) irrigations/NNS (r_pobj) of/IN (r_prep) percentage/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) cystitis/NN
D011206_D003556 CID iodine/NN (r_conj) colistin/NN (r_nmod) irrigations/NNS (r_pobj) of/IN (r_prep) percentage/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) cystitis/NN
C010882_D003556 CID digluconate/NN (r_npadvmod) associated/VBN (r_amod) cystitis/NN
D003091_D003556 CID colistin/NN (r_nmod) irrigations/NNS (r_pobj) of/IN (r_prep) percentage/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) cystitis/NN
C004658_D003556 NONE choloroaniline/NN (r_appos) product/NN (r_nsubj) is/VBZ (l_attr) factor/NN (l_prep) in/IN (l_pobj) cystitis/NN
12596116
D015282_D006976 CID Octreotide/NNP (r_npadvmod) induced/VBN (l_dobj) hypoxemia/NN (l_conj) hypertension/NN -PUNC- octreotide/NN (r_advmod) developed/VBD (l_nsubj) hypertension/NN
D015282_D000860 NONE Octreotide/NNP (r_npadvmod) induced/VBN (l_dobj) hypoxemia/NN
D015282_D005402 NONE octreotide/NN (r_advmod) developed/VBD (l_advcl) enhance/VB (l_dobj) resolution/NN (l_prep) of/IN (l_pobj) fistula/NN
19631624
D018817_D008569 CID ecstasy/NN (r_compound) users/NNS (r_pobj) in/IN (r_prep) deficits/NNS -PUNC- ecstasy/NN (r_compound) users/NNS (r_nsubj) display/VBP (l_dobj) impairments/NNS (l_prep) in/IN (l_pobj) performance/NN (l_nmod) learning/NN (l_conj) memory/NN
D018817_D007859 CID ecstasy/NN (r_compound) users/NNS (r_pobj) in/IN (r_prep) deficits/NNS -PUNC- ecstasy/NN (r_compound) users/NNS (r_nsubj) display/VBP (l_dobj) impairments/NNS (l_prep) in/IN (l_pobj) performance/NN (l_nmod) learning/NN (l_conj) memory/NN
D002188_D007859 NONE cannabis/NN (r_compound) users/NNS (r_pobj) in/IN (r_prep) hypoactivity/NN (r_conj) hyperactivity/NN (r_appos) Deficits/NNS (l_prep) in/IN (l_pobj) learning/NN (l_conj) memory/NN
D018817_D006948 NONE ecstasy/NN (r_npadvmod) specific/JJ (r_amod) hyperactivity/NN
D002188_D008569 NONE cannabis/NN (r_compound) users/NNS (r_pobj) in/IN (r_prep) hypoactivity/NN (r_conj) hyperactivity/NN (r_appos) Deficits/NNS (l_prep) in/IN (l_pobj) learning/NN (l_conj) memory/NN
D002188_D006948 NONE cannabis/NN (r_compound) users/NNS (r_pobj) in/IN (r_prep) hypoactivity/NN (r_conj) hyperactivity/NN
D018817_D020258 NONE ecstasy/NN (r_npadvmod) specific/JJ (r_amod) effects/NNS (r_nsubjpass) related/VBN (l_prep) to/IN (l_pobj) vulnerability/NN (l_prep) to/IN (l_pobj) effects/NNS (l_amod) neurotoxic/JJ -PUNC- ecstasy/NN (r_pobj) of/IN (r_prep) effects/NNS (l_amod) neurotoxic/JJ
15632880
D013148_D006947 CID Spironolactone/NNP (r_npadvmod) induced/VBN (l_dobj) insufficiency/NN (l_conj) hyperkalemia/NN -PUNC- spironolactone/NN (r_pobj) of/IN (r_prep) use/NN (r_dobj) evaluating/VBG (r_acl) trial/NN (r_nsubj) reported/VBD (l_dobj) risk/NN (l_prep) of/IN (l_pobj) hyperkalemia/NN -PUNC- spironolactone/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (r_pobj) in/IN (r_prep) insufficiency/NN (r_conj) hyperkalemia/NN -PUNC- spironolactone/NN (r_pobj) of/IN (r_prep) discontinuation/NN (r_dobj) required/VBD (l_prep) due/IN (l_pobj) hyperkalemia/NN -PUNC- Spironolactone/NNP (r_npadvmod) induced/VBN (r_amod) hyperkalemia/NN
D013148_D051437 CID Spironolactone/NNP (r_npadvmod) induced/VBN (l_dobj) insufficiency/NN -PUNC- spironolactone/NN (r_pobj) of/IN (r_prep) use/NN (r_dobj) evaluating/VBG (r_acl) trial/NN (r_nsubj) reported/VBD (l_dobj) risk/NN (l_prep) of/IN (l_pobj) hyperkalemia/NN (l_conj) insufficiency/NN -PUNC- spironolactone/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (r_pobj) in/IN (r_prep) insufficiency/NN -PUNC- spironolactone/NN (r_pobj) of/IN (r_prep) discontinuation/NN (r_dobj) required/VBD (l_prep) due/IN (l_pobj) hyperkalemia/NN (l_conj) failure/NN -PUNC- Spironolactone/NNP (r_npadvmod) induced/VBN (r_amod) hyperkalemia/NN (r_nmod) insufficiency/NN
D011188_D051437 NONE K(+/NNP (r_appos) hyperkalemia/NN (r_dobj) developed/VBD (r_relcl) patients/NNS (r_attr) were/VBD (l_nsubj) Cases/NNS (l_appos) L/NN (l_conj) insufficiency/NN
D011188_D006947 NONE K(+/NNP (r_appos) hyperkalemia/NN -PUNC- potassium/NN (r_compound) levels/NNS (r_dobj) had/VBD (r_conj) were/VBD (l_nsubj) Patients/NNS (l_relcl) developed/VBD (l_dobj) hyperkalemia/NN -PUNC- potassium/NN (r_compound) supplement/NN (r_compound) doses/NNS (r_conj) levels/NNS (r_dobj) had/VBD (r_conj) were/VBD (l_nsubj) Patients/NNS (l_relcl) developed/VBD (l_dobj) hyperkalemia/NN
D003404_D051437 NONE creatinine/NN (r_conj) weight/NN (r_dobj) had/VBD (l_nsubj) Patients/NNS (l_relcl) developed/VBD (l_dobj) insufficiency/NN
D049971_D051437 NONE thiazide/NN (r_amod) diuretics/NNS (r_pobj) with/IN (r_prep) treated/VBN (r_xcomp) likely/JJ (r_acomp) were/VBD (r_conj) required/VBD (r_conj) had/VBD (l_nsubj) Patients/NNS (l_relcl) developed/VBD (l_dobj) insufficiency/NN
D013148_D006333 NONE Spironolactone/NNP (r_npadvmod) induced/VBN (l_dobj) insufficiency/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) failure/NN -PUNC- spironolactone/NN (l_prep) in/IN (l_pobj) patients/NNS (l_compound) failure/NN -PUNC- spironolactone/NN (r_pobj) of/IN (r_prep) benefits/NNS (r_nsubjpass) reported/VBN (r_advcl) changed/VBN (l_nsubj) treatments/NNS (l_prep) for/IN (l_pobj) failure/NN -PUNC- spironolactone/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (l_compound) failure/NN -PUNC- spironolactone/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (l_compound) failure/NN
D011188_D003920 NONE potassium/NN (r_compound) levels/NNS (r_dobj) had/VBD (r_conj) were/VBD (l_acomp) older/JJR (l_conj) likely/JJ (l_xcomp) have/VB (l_dobj) diabetes/NNS -PUNC- potassium/NN (r_compound) supplement/NN (r_compound) doses/NNS (r_conj) levels/NNS (r_dobj) had/VBD (r_conj) were/VBD (l_acomp) older/JJR (l_conj) likely/JJ (l_xcomp) have/VB (l_dobj) diabetes/NNS
9660111
D012110_D007035 CID reserpine/NN (r_compound) hypothermia/VBN
D003000_D010554 NONE clonidine/NN (r_pobj) by/IN (r_agent) evoked/VBN (r_acl) aggressiveness/NN
D004298_D006948 NONE dopamine/NN (r_compound) D2/NN (r_appos) dipropyloaminotetralin/NN (r_conj) quinpirole/NN (r_conj) amphetamine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) hyperactivity/NN
D014299_D007035 NONE TRI/NNP (r_nsubj) antagonize/VB (l_dobj) hypothermia/VBN
D014299_D006948 CID TRI/NNP (r_nsubj) increases/VBZ (l_dobj) hyperactivity/NN
D019257_D006948 CID quinpirole/NN (r_conj) amphetamine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) hyperactivity/NN
D010656_D010554 NONE phenylephrine/NN (l_acl) evaluated/VBN (l_conj) aggressiveness/NN
D003913_D006948 CID amphetamine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) hyperactivity/NN
D006916_D007035 NONE 5-hydroxytryptophan/JJ (r_poss) head/NN (r_compound) twitches/NNS (r_dobj) potentiate/VB (r_conj) antagonize/VB (l_dobj) hypothermia/VBN
17931375
D006493_D010146 CID heparin/JJ (r_compound) injection/NN (l_prep) on/IN (l_pobj) bruising/VBG (l_conj) pain/NN -PUNC- heparin/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) following/VBG (r_prep) effect/NN (l_prep) of/IN (l_pobj) duration/NN (l_prep) on/IN (l_pobj) bruising/VBG (l_conj) pain/NN -PUNC- heparin/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) following/VBG (r_prep) prevent/VB (l_dobj) bruising/NN (l_conj) pain/NN -PUNC- heparin/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) following/VBG (r_prep) prevent/VB (r_acl) methods/NNS (r_nsubjpass) studied/VBN (r_advcl) documented/JJ (l_nsubjpass) effect/NN (l_prep) of/IN (l_pobj) duration/NN (l_prep) on/IN (l_pobj) occurrence/NN (l_prep) of/IN (l_pobj) bruising/VBG (l_conj) pain/NN -PUNC- heparin/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) following/VBG (r_prep) had/VBD (l_dobj) effect/NN (l_prep) on/IN (l_pobj) bruising/VBG (l_conj) pain/NN
D006493_D003288 CID heparin/JJ (r_compound) injection/NN (l_prep) on/IN (l_pobj) bruising/VBG -PUNC- heparin/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) following/VBG (r_prep) effect/NN (l_prep) of/IN (l_pobj) duration/NN (l_prep) on/IN (l_pobj) bruising/VBG -PUNC- heparin/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) following/VBG (r_prep) prevent/VB (l_dobj) bruising/NN -PUNC- heparin/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) following/VBG (r_prep) prevent/VB (r_acl) methods/NNS (r_nsubjpass) studied/VBN (r_advcl) documented/JJ (l_nsubjpass) effect/NN (l_prep) of/IN (l_pobj) duration/NN (l_prep) on/IN (l_pobj) occurrence/NN (l_prep) of/IN (l_pobj) bruising/VBG -PUNC- heparin/NN (r_pobj) on/IN (r_prep) bruising/NN -PUNC- heparin/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) following/VBG (r_prep) had/VBD (l_dobj) effect/NN (l_prep) on/IN (l_pobj) bruising/VBG
1130930
D002512_D009846 NONE sodium/NN (r_pobj) of/IN (r_prep) combination/NN (r_dobj) receiving/VBG (r_advcl) developed/VBD (l_dobj) necrosis/NN (l_acl) characterized/VBN (l_agent) by/IN (l_pobj) failure/NN
D002512_D007674 NONE cephalothin/NN (r_compound) gentamicin/NN (r_compound) regimen/NN (r_pobj) of/IN (r_prep) Nephrotoxicity/NN
D005839_D007674 NONE gentamicin/NN (r_compound) regimen/NN (r_pobj) of/IN (r_prep) Nephrotoxicity/NN
D005839_D009846 NONE sulfate/NN (r_compound) therapy/NN (r_dobj) gentamicin/NN (r_conj) receiving/VBG (r_advcl) developed/VBD (l_dobj) necrosis/NN (l_acl) characterized/VBN (l_agent) by/IN (l_pobj) failure/NN
D002512_D007683 CID sodium/NN (r_pobj) of/IN (r_prep) combination/NN (r_dobj) receiving/VBG (r_advcl) developed/VBD (l_dobj) necrosis/NN
D005839_D051437 NONE sulfate/NN (r_compound) therapy/NN (r_dobj) gentamicin/NN (r_conj) receiving/VBG (r_advcl) developed/VBD (l_dobj) necrosis/NN (l_acl) characterized/VBN (l_agent) by/IN (l_pobj) failure/NN
D002512_D051437 NONE sodium/NN (r_pobj) of/IN (r_prep) combination/NN (r_dobj) receiving/VBG (r_advcl) developed/VBD (l_dobj) necrosis/NN (l_acl) characterized/VBN (l_agent) by/IN (l_pobj) failure/NN
D005839_D007683 CID sulfate/NN (r_compound) therapy/NN (r_dobj) gentamicin/NN (r_conj) receiving/VBG (r_advcl) developed/VBD (l_dobj) necrosis/NN
11587867
D014750_-1 NONE vincristine/NN (r_pobj) to/IN (r_prep) exposed/VBN (r_acl) areas/NNS (r_pobj) in/IN (r_prep) transformation/NN
D014750_D054198 NONE vincristine/NN (r_compound) instillation/NN (l_prep) in/IN (l_pobj) girl/NN (l_prep) with/IN (l_pobj) leucemia/NN -PUNC- vincristine/NN (r_compound) instillation/NN (l_prep) in/IN (l_pobj) girl/NN (l_prep) with/IN (l_pobj) leucemia/NN (l_conj) man/NN (l_prep) with/IN (l_pobj) lymphoma/NN
D014750_D003711 CID vincristine/NN (r_pobj) to/IN (r_prep) exposed/VBN (r_acl) areas/NNS (r_pobj) in/IN (r_prep) transformation/NN (r_conj) degeneration/NN (l_prep) of/IN (l_pobj) myelin/NN (l_conj) axons/NNS
D014750_D001927 NONE vincristin/NN (r_compound) administration/NN (r_pobj) due/IN (r_prep) myeloencephalopathy/NN
D014750_D009410 CID vincristine/NN (r_pobj) to/IN (r_prep) exposed/VBN (r_acl) areas/NNS (r_pobj) in/IN (r_prep) transformation/NN (r_conj) degeneration/NN (l_prep) of/IN (l_pobj) myelin/NN (l_conj) axons/NNS
11007689
D016559_D057049 CID tacrolimus/NN (r_npadvmod) associated/VBN (r_amod) microangiopathy/NN -PUNC- tacrolimus/NN (r_pobj) to/IN (r_prep) switching/VBG (r_nsubjpass) reported/VBN (l_xcomp) be/VB (l_attr) option/NN (l_prep) in/IN (l_pobj) setting/NN (l_prep) of/IN (l_pobj) TMA/NNP -PUNC- tacrolimus/NN (r_pobj) of/IN (r_prep) application/NN (r_pobj) With/IN (r_prep) recognized/VBN (l_nsubjpass) TMA/NNP -PUNC- tacrolimus/NN (r_npadvmod) associated/VBN (r_amod) TMA/NNP -PUNC- tacrolimus/NN (r_conj) cyclosporine/NN (r_pobj) to/IN (r_prep) exposed/VBN (r_acl) patients/NNS (r_pobj) in/IN (r_prep) recurrence/NN (l_prep) of/IN (l_pobj) TMA/NNP -PUNC- tacrolimus/NN (r_pobj) of/IN (r_prep) Introduction/NN (r_nsubj) resulted/VBD (l_prep) in/IN (l_pobj) recurrence/NN (l_prep) of/IN (l_pobj) TMA/NNP -PUNC- tacrolimus/NN (r_pobj) to/IN (r_prep) switched/VBN (r_relcl) Patients/NNS (r_nsubjpass) monitored/VBN (l_prep) for/IN (l_pobj) signs/NNS (l_prep) of/IN (l_pobj) TMA/NNP
D016572_D057049 CID Cyclosporine/NN (l_conj) microangiopathy/NN -PUNC- cyclosporine/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) microangiopathy/NN -PUNC- cyclosporine/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) microangiopathy/NN (l_appos) TMA/NNP -PUNC- cyclosporine/NN (r_npadvmod) induced/VBN (r_amod) TMA/NNP -PUNC- cyclosporine/NN (r_pobj) to/IN (r_prep) exposed/VBN (r_acl) patients/NNS (r_pobj) in/IN (r_prep) recurrence/NN (l_prep) of/IN (l_pobj) TMA/NNP -PUNC- cyclosporine/NN (r_npadvmod) induced/VBN (r_amod) TMA/NNP -PUNC- cyclosporine/NN (r_pobj) of/IN (r_prep) withdrawal/NN (r_pobj) to/IN (r_prep) responded/VBD (r_relcl) TMA/NNP -PUNC- cyclosporine/NN (r_pobj) from/IN (r_prep) switched/VBN (r_relcl) Patients/NNS (r_nsubjpass) monitored/VBN (l_prep) for/IN (l_pobj) signs/NNS (l_prep) of/IN (l_pobj) TMA/NNP
20528871
C104457_D006402 CID AraG/NNP (r_pobj) than/IN (r_prep) combination/NN (r_pobj) for/IN (r_prep) greater/JJR (r_acomp) was/VBD (l_nsubj) toxicity/NN
D003520_D015458 NONE cyclophosphamide/NN (r_conj) etoposide/RB (r_conj) nelarabine/NN (l_prep) in/IN (l_pobj) leukaemia/NN (l_conj) lymphoma/NN -PUNC- cyclophosphamide/NN (r_conj) VP/NNP (r_appos) d/SYM (r_pobj) with/IN (r_prep) AraG/NNP (r_appos) nelarabine/JJ (r_pobj) of/IN (r_prep) d/SYM (r_pobj) of/IN (r_prep) combination/NN (r_nsubjpass) used/VBN (l_prep) in/IN (l_pobj) children/NNS (l_prep) with/IN (l_pobj) leukaemia/NN (l_conj) lymphoma/NN -PUNC- CPM/NNP (r_appos) VP/NNP (r_appos) d/SYM (r_pobj) with/IN (r_prep) AraG/NNP (r_appos) nelarabine/JJ (r_pobj) of/IN (r_prep) d/SYM (r_pobj) of/IN (r_prep) combination/NN (r_nsubjpass) used/VBN (l_prep) in/IN (l_pobj) children/NNS (l_prep) with/IN (l_pobj) leukaemia/NN (l_conj) lymphoma/NN
C104457_D015458 NONE nelarabine/NN (l_prep) in/IN (l_pobj) leukaemia/NN (l_conj) lymphoma/NN -PUNC- nelarabine/JJ (r_pobj) of/IN (r_prep) d/SYM (r_pobj) of/IN (r_prep) combination/NN (r_nsubjpass) used/VBN (l_prep) in/IN (l_pobj) children/NNS (l_prep) with/IN (l_pobj) leukaemia/NN (l_conj) lymphoma/NN -PUNC- AraG/NNP (r_appos) nelarabine/JJ (r_pobj) of/IN (r_prep) d/SYM (r_pobj) of/IN (r_prep) combination/NN (r_nsubjpass) used/VBN (l_prep) in/IN (l_pobj) children/NNS (l_prep) with/IN (l_pobj) leukaemia/NN (l_conj) lymphoma/NN
D003520_D016399 NONE cyclophosphamide/NN (r_conj) etoposide/RB (r_conj) nelarabine/NN (l_prep) in/IN (l_pobj) leukaemia/NN (l_conj) lymphoma/NN -PUNC- cyclophosphamide/NN (r_conj) VP/NNP (r_appos) d/SYM (r_pobj) with/IN (r_prep) AraG/NNP (r_appos) nelarabine/JJ (r_pobj) of/IN (r_prep) d/SYM (r_pobj) of/IN (r_prep) combination/NN (r_nsubjpass) used/VBN (l_prep) in/IN (l_pobj) children/NNS (l_prep) with/IN (l_pobj) leukaemia/NN (l_conj) lymphoma/NN -PUNC- CPM/NNP (r_appos) VP/NNP (r_appos) d/SYM (r_pobj) with/IN (r_prep) AraG/NNP (r_appos) nelarabine/JJ (r_pobj) of/IN (r_prep) d/SYM (r_pobj) of/IN (r_prep) combination/NN (r_nsubjpass) used/VBN (l_prep) in/IN (l_pobj) children/NNS (l_prep) with/IN (l_pobj) leukaemia/NN (l_conj) lymphoma/NN
D005047_D016399 NONE etoposide/RB (r_conj) nelarabine/NN (l_prep) in/IN (l_pobj) leukaemia/NN (l_conj) lymphoma/NN -PUNC- etoposide/NN (r_pobj) of/IN (r_prep) d/SYM (r_pobj) with/IN (r_prep) AraG/NNP (r_appos) nelarabine/JJ (r_pobj) of/IN (r_prep) d/SYM (r_pobj) of/IN (r_prep) combination/NN (r_nsubjpass) used/VBN (l_prep) in/IN (l_pobj) children/NNS (l_prep) with/IN (l_pobj) leukaemia/NN (l_conj) lymphoma/NN -PUNC- VP/NNP (r_appos) d/SYM (r_pobj) with/IN (r_prep) AraG/NNP (r_appos) nelarabine/JJ (r_pobj) of/IN (r_prep) d/SYM (r_pobj) of/IN (r_prep) combination/NN (r_nsubjpass) used/VBN (l_prep) in/IN (l_pobj) children/NNS (l_prep) with/IN (l_pobj) leukaemia/NN (l_conj) lymphoma/NN
C104457_D009422 CID AraG/NNP (r_pobj) to/IN (r_prep) attributable/JJ (r_amod) effects/NNS (r_nsubj) included/VBD (l_dobj) neuropathy/NN -PUNC- AraG/NN (r_dobj) giving/VBG (r_pcomp) of/IN (r_prep) safety/NN (r_dobj) supports/VBZ (l_advcl) monitored/VBN (l_nsubjpass) toxicity/NN
D005047_D015458 NONE etoposide/RB (r_conj) nelarabine/NN (l_prep) in/IN (l_pobj) leukaemia/NN (l_conj) lymphoma/NN -PUNC- etoposide/NN (r_pobj) of/IN (r_prep) d/SYM (r_pobj) with/IN (r_prep) AraG/NNP (r_appos) nelarabine/JJ (r_pobj) of/IN (r_prep) d/SYM (r_pobj) of/IN (r_prep) combination/NN (r_nsubjpass) used/VBN (l_prep) in/IN (l_pobj) children/NNS (l_prep) with/IN (l_pobj) leukaemia/NN (l_conj) lymphoma/NN -PUNC- VP/NNP (r_appos) d/SYM (r_pobj) with/IN (r_prep) AraG/NNP (r_appos) nelarabine/JJ (r_pobj) of/IN (r_prep) d/SYM (r_pobj) of/IN (r_prep) combination/NN (r_nsubjpass) used/VBN (l_prep) in/IN (l_pobj) children/NNS (l_prep) with/IN (l_pobj) leukaemia/NN (l_conj) lymphoma/NN
D003520_D009422 NONE cyclophosphamide/NN (r_conj) etoposide/NN (r_pobj) with/IN (r_prep) synchrony/NN (r_pobj) in/IN (r_prep) therapy/NN (r_pobj) as/IN (r_prep) giving/VBG (r_pcomp) of/IN (r_prep) safety/NN (r_dobj) supports/VBZ (l_advcl) monitored/VBN (l_nsubjpass) toxicity/NN
C104457_D016399 NONE nelarabine/NN (l_prep) in/IN (l_pobj) leukaemia/NN (l_conj) lymphoma/NN -PUNC- nelarabine/JJ (r_pobj) of/IN (r_prep) d/SYM (r_pobj) of/IN (r_prep) combination/NN (r_nsubjpass) used/VBN (l_prep) in/IN (l_pobj) children/NNS (l_prep) with/IN (l_pobj) leukaemia/NN (l_conj) lymphoma/NN -PUNC- AraG/NNP (r_appos) nelarabine/JJ (r_pobj) of/IN (r_prep) d/SYM (r_pobj) of/IN (r_prep) combination/NN (r_nsubjpass) used/VBN (l_prep) in/IN (l_pobj) children/NNS (l_prep) with/IN (l_pobj) leukaemia/NN (l_conj) lymphoma/NN
C104457_D059352 CID AraG/NNP (r_pobj) to/IN (r_prep) attributable/JJ (r_amod) effects/NNS (r_nsubj) included/VBD (l_dobj) neuropathy/NN (l_conj) pain/NN
D005047_D009422 NONE etoposide/NN (r_pobj) with/IN (r_prep) synchrony/NN (r_pobj) in/IN (r_prep) therapy/NN (r_pobj) as/IN (r_prep) giving/VBG (r_pcomp) of/IN (r_prep) safety/NN (r_dobj) supports/VBZ (l_advcl) monitored/VBN (l_nsubjpass) toxicity/NN
3358181
D012312_D002318 NONE ritodrine/NN (r_pobj) of/IN (r_prep) infusion/NN (r_pobj) of/IN (r_prep) cessation/NN (r_pobj) after/IN (r_prep) complications/NNS
D012312_D007752 NONE ritodrine/RB (l_prep) for/IN (l_pobj) labor/NN -PUNC- ritodrine/NN (r_pobj) of/IN (r_prep) effects/NNS (r_pobj) between/IN (r_prep) interactions/NNS (r_dobj) risk/VB (l_nsubj) patients/NNS (l_acl) receiving/VBG (l_dobj) ritodrine/RB (l_prep) for/IN (l_pobj) labor/NN
D012312_D014693 CID ritodrine/JJ (r_compound) therapy/NN (r_pobj) after/IN (r_prep) section/NN (r_pobj) during/IN (r_prep) tachyarrhythmias/NNS
D010656_D007022 NONE phenylephrine/NN (l_relcl) treat/VB (l_dobj) patients/NNS (l_amod) hypotensive/JJ
D010656_D013610 NONE phenylephrine/NN (l_relcl) treat/VB (l_prep) with/IN (l_pobj) tachycardia/NNS
3615541
D000661_D006948 CID amphetamine/NN (r_npadvmod) induced/VBN (r_amod) hyperactivity/NN
D002116_D006948 NONE calcitonin/NN (r_compound) injections/NNS (r_pobj) by/IN (r_prep) antagonism/NN (l_prep) of/IN (l_pobj) hyperactivity/NN
2024540
D011224_D006333 NONE prazosin/NN (r_conj) enalapril/NN (r_pobj) of/IN (r_prep) safety/NN (l_prep) in/IN (l_pobj) phase/NN (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) failure/NN
D000806_D006333 NONE inhibitors/NNS (r_appos) enzyme/NN (r_dobj) converting/VBG (l_prep) into/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) failure/NN
D011224_D007022 CID prazosin/NN (r_npadvmod) controlled/VBN (r_amod) trial/NN (r_nsubjpass) designed/VBN (l_prep) compared/VBD (l_pobj) incidence/NN (l_prep) of/IN (l_pobj) hypotension/NN -PUNC- prazosin/NN (r_dobj) received/VBD (r_relcl) patients/NNS (r_pobj) than/IN (r_prep) hypotension/NN
D004656_D007022 NONE enalapril/NN (r_appos) inhibitor/NN (r_pobj) of/IN (r_prep) safety/NN (r_dobj) assess/VB (r_advcl) designed/VBN (l_prep) compared/VBD (l_pobj) incidence/NN (l_prep) of/IN (l_pobj) hypotension/NN -PUNC- enalapril/RB (r_dobj) received/VBD (r_relcl) Patients/NNS (r_nsubj) experienced/VBD (l_dobj) hypotension/NN
D000806_D007022 CID inhibitors/NNS (r_appos) enzyme/NN (r_dobj) converting/VBG (l_prep) into/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) failure/NN (l_conj) cases/NNS (l_prep) of/IN (l_pobj) hypotension/NN -PUNC- inhibitor/NN (r_pobj) of/IN (r_prep) safety/NN (r_dobj) assess/VB (r_advcl) designed/VBN (l_prep) compared/VBD (l_pobj) incidence/NN (l_prep) of/IN (l_pobj) hypotension/NN
D004656_D006333 NONE enalapril/NN (r_pobj) of/IN (r_prep) safety/NN (l_prep) in/IN (l_pobj) phase/NN (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) failure/NN
6538499
D011092_D064420 NONE 400/CD (r_nummod) glycol/NN (l_advcl) adriamycin/JJ (l_dobj) toxicity/NN
D004317_D007939 NONE ADR/NNP (r_compound) activity/NN (l_prep) in/IN (l_pobj) leukemia/NN
D004317_D002286 NONE ADR/NNP (r_compound) activity/NN (l_relcl) tumor/NN
D004317_D064420 NONE adriamycin/JJ (l_dobj) toxicity/NN
D004317_D009202 CID ADR/NNP (r_npadvmod) induced/VBN (r_amod) alterations/NNS
20588063
D011692_D009401 CID aminonucleoside/JJ (r_amod) nephrosis/NN -PUNC- aminonucleoside/JJ (r_amod) nephrosis/NN
16428221
D008774_D019969 NONE methylphenidate/NN (r_compound) intake/NN (r_pobj) after/IN (r_prep) reported/VBN (r_conj) documented/VBN (l_nsubjpass) vasculitis/NN (l_acl) associated/VBN (l_prep) with/IN (l_pobj) abuse/NN
D008774_D002544 NONE methylphenidate/NN (r_compound) intake/NN (r_pobj) after/IN (r_prep) reported/VBN (l_nsubjpass) stroke/NN -PUNC- methylphenidate/NN (r_pobj) with/IN (r_prep) treated/VBN (l_conj) suffered/VBD (l_prep) from/IN (l_pobj) strokes/NNS
D008774_D014657 NONE methylphenidate/NN (l_dobj) vasculitis/NN -PUNC- methylphenidate/NN (r_compound) therapy/NN (r_pobj) of/IN (r_prep) history/NN (r_conj) symptoms/NNS (r_pobj) with/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) considered/VBN (l_nsubjpass) methylphenidate/NN (l_dobj) vasculitis/NN
D008774_D020293 CID methylphenidate/NN (r_compound) intake/NN (r_dobj) following/VBG (r_prep) vasculitis/NNS -PUNC- methylphenidate/NN (r_compound) intake/NN (r_pobj) after/IN (r_prep) reported/VBN (r_conj) documented/VBN (l_nsubjpass) vasculitis/NN
D008774_D006948 NONE methylphenidate/NN (r_pobj) with/IN (r_prep) treated/VBN (l_prep) due/IN (l_pobj) hyperactivity/NN
6666578
D010396_D001018 CID penicillamine/NN (r_compound) induced/VBN (l_advmod) angiopathy/NN
6386793
D000639_D014786 CID amitriptyline/NN (r_pobj) with/IN (r_prep) than/IN (r_prep) less/JJR (r_acomp) were/VBD (l_nsubj) incidence/NN (l_prep) of/IN (l_pobj) effects/NNS (l_conj) frequency/NN (l_prep) of/IN (l_pobj) vision/NN
D000639_D003866 NONE amitriptyline/NN (r_conj) dothiepin/JJ (r_nsubjpass) compared/VBN (l_prep) to/IN (l_pobj) placebo/NN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) outpatients/NNS (l_amod) depressed/JJ -PUNC- amitriptyline/NN (r_conj) Dothiepin/JJ (r_nsubj) were/VBD (l_acomp) effective/JJ (l_prep) in/IN (l_pcomp) alleviating/VBG (l_dobj) symptoms/NNS (l_prep) of/IN (l_pobj) illness/NN -PUNC- amitriptyline/NN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) outpatients/NNS (l_amod) depressed/JJ
D000639_D014987 CID amitriptyline/NN (r_pobj) with/IN (r_prep) than/IN (r_prep) less/JJR (r_acomp) were/VBD (l_nsubj) incidence/NN (l_prep) of/IN (l_pobj) effects/NNS (l_conj) frequency/NN (l_prep) of/IN (l_pobj) vision/NN (l_conj) mouth/NN
D000928_D003866 NONE antidepressant/NN (r_amod) drug/NN (l_acl) associated/VBN (l_prep) with/IN (l_pobj) effects/NNS (l_prep) than/IN (l_pobj) amitriptyline/NN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) outpatients/NNS (l_amod) depressed/JJ
D004308_D003866 NONE hydrochloride/NN (r_pobj) of/IN (r_prep) efficacy/NN (r_pobj) of/IN (r_prep) study/NN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) disorder/NN -PUNC- dothiepin/JJ (r_nsubjpass) compared/VBN (l_prep) to/IN (l_pobj) placebo/NN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) outpatients/NNS (l_amod) depressed/JJ -PUNC- Dothiepin/JJ (r_nsubj) were/VBD (l_acomp) effective/JJ (l_prep) in/IN (l_pcomp) alleviating/VBG (l_dobj) symptoms/NNS (l_prep) of/IN (l_pobj) illness/NN -PUNC- Dothiepin/NNP (r_nsubjpass) found/VBN (l_xcomp) be/VB (l_attr) drug/NN (l_acl) associated/VBN (l_prep) with/IN (l_pobj) effects/NNS (l_prep) than/IN (l_pobj) amitriptyline/NN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) outpatients/NNS (l_amod) depressed/JJ
D004308_D014987 NONE dothiepin/JJ (r_pobj) with/IN (r_prep) less/JJR (r_acomp) were/VBD (l_nsubj) incidence/NN (l_prep) of/IN (l_pobj) effects/NNS (l_conj) frequency/NN (l_prep) of/IN (l_pobj) vision/NN (l_conj) mouth/NN
D004308_D014786 NONE dothiepin/JJ (r_pobj) with/IN (r_prep) less/JJR (r_acomp) were/VBD (l_nsubj) incidence/NN (l_prep) of/IN (l_pobj) effects/NNS (l_conj) frequency/NN (l_prep) of/IN (l_pobj) vision/NN
12369736
C065046_D009069 CID 93129/CD (r_nummod) CP/NNP (r_appos) agonist/NN (r_conj) modification/NN (r_conj) shell/NN (r_pobj) into/IN (r_prep) microinjected/VBN (r_acl) ligands/NNS (r_pobj) by/IN (r_agent) modified/VBN (l_nsubjpass) hyperlocomotion/NN
D003042_D009069 CID cocaine/NN (r_npadvmod) induced/VBN (r_amod) hyperactivity/NN -PUNC- cocaine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) hyperactivity/NN -PUNC- cocaine/NN (r_pobj) to/IN (r_prep) prior/RB (r_advmod) administered/VBN (l_conj) attenuated/VBD (l_dobj) hyperactivity/NN -PUNC- cocaine/NN (r_nsubj) induced/VBN (r_ccomp) indicate/VBP (l_ccomp) modified/VBN (l_nsubjpass) hyperlocomotion/NN
C103477_D009069 NONE 55562/CD (r_nummod) GR/NNP (r_nsubj) administered/VBN (l_conj) attenuated/VBD (l_dobj) hyperactivity/NN -PUNC- 55562/CD (r_nummod) GR/NNP (r_appos) antagonist/NN (r_pobj) of/IN (r_prep) effects/NNS (r_pobj) in/IN (r_prep) consisting/VBG (r_acl) modification/NN (r_conj) shell/NN (r_pobj) into/IN (r_prep) microinjected/VBN (r_acl) ligands/NNS (r_pobj) by/IN (r_agent) modified/VBN (l_nsubjpass) hyperlocomotion/NN
8073369
C007112_D009140 NONE coniine/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) deformations/NNS -PUNC- coniine/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) deformations/NNS (r_nsubj) were/VBD (l_attr) flexion/NN (l_prep) of/IN (l_pobj) toes/NNS
D009538_D002543 CID nicotine/NN (r_nmod) chicks/NNS (r_pobj) in/IN (r_prep) occurred/VBD (l_nsubj) hemorrhage/NN
D009538_D009140 NONE nicotine/NN (r_compound) sulfate/NN (r_conj) coniine/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) deformations/NNS -PUNC- nicotine/NN (r_compound) sulfate/NN (r_conj) coniine/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) deformations/NNS (r_nsubj) were/VBD (l_attr) flexion/NN (l_prep) of/IN (l_pobj) toes/NNS
C007112_D001176 CID coniine/NN (r_nsubj) failed/VBN (l_xcomp) produce/VB (l_dobj) arthrogryposis/NN -PUNC- coniine/RB (r_npadvmod) induced/VBN (r_amod) arthrogryposis/NN
20621845
D002122_D017545 CID CaCl2-induced/VBN (r_amod) aneurysm/NN -PUNC- chloride/NN (r_pobj) by/IN (r_prep) establish/VB (l_dobj) model/NN (l_prep) of/IN (l_pobj) aneurysm/NN -PUNC- chloride/NN (r_pobj) by/IN (r_prep) establish/VB (l_dobj) model/NN (l_prep) of/IN (l_pobj) aneurysm/NN (l_appos) TAA/NNP -PUNC- chloride/NN (r_pobj) by/IN (r_prep) establish/VB (r_xcomp) designed/VBN (l_conj) metalloproteinases/NNS (l_conj) inhibitors/NNS (l_prep) in/IN (l_pobj) formation/NN (l_compound) TAA/NNP -PUNC- CaCl(2))-induced/VBN (r_amod) injury/NN (r_appos) chloride/NN (r_pobj) by/IN (r_prep) establish/VB (l_dobj) model/NN (l_prep) of/IN (l_pobj) aneurysm/NN -PUNC- CaCl(2))-induced/VBN (r_amod) injury/NN (r_appos) chloride/NN (r_pobj) by/IN (r_prep) establish/VB (l_dobj) model/NN (l_prep) of/IN (l_pobj) aneurysm/NN (l_appos) TAA/NNP -PUNC- CaCl(2))-induced/VBN (r_amod) injury/NN (r_appos) chloride/NN (r_pobj) by/IN (r_prep) establish/VB (r_xcomp) designed/VBN (l_conj) metalloproteinases/NNS (l_conj) inhibitors/NNS (l_prep) in/IN (l_pobj) formation/NN (l_compound) TAA/NNP -PUNC- )/-RRB- (r_punct) establishes/VBZ (l_dobj) model/NN (l_compound) TAA/NNP
D002122_D014652 NONE chloride/NN (l_appos) injury/NN -PUNC- CaCl(2))-induced/VBN (r_amod) injury/NN
18329269
D006220_D010300 NONE haloperidol/NN (r_npadvmod) induced/VBN (r_amod) model/NN (l_prep) for/IN (l_pobj) disease/NN
D006220_D002375 CID haloperidol/NN (r_npadvmod) induced/VBN (r_amod) model/NN (l_compound) catalepsy/NN
18791946
D002939_D013921 CID ciprofloxacin/NNS (r_pobj) with/IN (r_prep) associated/VBN (r_acl) thrombocytopenia/JJ -PUNC- ciprofloxacin/NNS (r_nsubj) precipitate/VB (l_dobj) thrombocytopenia/JJ
D002939_D007565 CID ciprofloxacin/NNS (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) reported/VBN (l_prep) with/IN (l_pobj) pain/NN (l_conj) jaundice/NN
D002939_D000743 CID ciprofloxacin/NNS (r_pobj) with/IN (r_prep) associated/VBN (r_acl) thrombocytopenia/JJ (l_conj) anaemia/NN -PUNC- ciprofloxacin/NNS (r_nsubj) precipitate/VB (l_dobj) thrombocytopenia/JJ (l_conj) anaemia/NN
D002939_D015746 CID ciprofloxacin/NNS (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) reported/VBN (l_prep) with/IN (l_pobj) pain/NN
D002939_D014552 NONE ciprofloxacin/NNS (r_pobj) of/IN (r_prep) administration/NN (l_prep) for/IN (l_pobj) suspect/NN (l_prep) of/IN (l_pobj) infection/NN
2611118
D004008_D006521 NONE sodium/NN (r_compound) therapy/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) hepatitis/NN -PUNC- sodium/NN (r_pobj) with/IN (r_prep) therapy/NN (r_pobj) after/IN (r_prep) developed/VBD (l_dobj) hepatitis/NN
D004008_D056486 CID diclofenac/NNP (r_pobj) by/IN (r_agent) induced/VBN (r_conj) recorded/VBN (l_nsubjpass) abnormalities/NNS (l_prep) of/IN (l_pobj) function/NN -PUNC- diclofenac/NNP (r_pobj) by/IN (r_agent) induced/VBN (l_nsubj) hepatitis/NN
6634932
D010042_D017180 CID ouabain/RB (r_npadvmod) induced/VBN (r_amod) tachycardias/NNS
C002616_D017180 NONE UM-272/NNP (r_punct) dimethylpropranolol/NNP (r_nsubjpass) administered/VBN (l_prep) to/IN (l_pobj) dogs/NNS (l_prep) with/IN (l_pobj) tachycardias/NNS -PUNC- dimethylpropranolol/NNP (r_nsubjpass) administered/VBN (l_prep) to/IN (l_pobj) dogs/NNS (l_prep) with/IN (l_pobj) tachycardias/NNS -PUNC- UM-272/NNP (r_punct) converted/VBD (l_dobj) tachycardia/NN
12789195
D008914_D004194 NONE minoxidil/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubj) Pseudoacromegaly/NNS -PUNC- minoxidil/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) from/IN (r_prep) resulted/VBD (r_relcl) patient/NN (l_prep) with/IN (l_pobj) pseudoacromegaly/NNS -PUNC- minoxidil/JJ (r_amod) use/NN (r_pobj) of/IN (r_prep) effect/NN (r_pobj) as/IN (r_prep) report/NN (l_prep) of/IN (l_pobj) pseudoacromegaly/NNS
3970039
D001379_D008228 CID azathioprine/NN (r_conj) agents/NNS (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) lymphoma/NN
D001379_D009369 NONE azathioprine/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) studies/NNS (r_attr) been/VBN (l_conj) increased/VBN (l_nsubjpass) incidence/NN (l_prep) of/IN (l_pobj) most/JJS (l_prep) of/IN (l_pobj) cancers/NNS
D000477_D015470 CID agents/NNS (r_pobj) with/IN (r_prep) treated/VBN (r_csubj) have/VBP (l_dobj) risk/NN (l_prep) of/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) leukemia/NN -PUNC- agents/NNS (r_nsubjpass) associated/VBN (r_conj) have/VBP (l_dobj) risk/NN (l_prep) of/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) leukemia/NN
D003520_D001172 NONE cyclophosphamide/NN (r_conj) azathioprine/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) studies/NNS (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) arthritis/NN
D001379_D001172 NONE azathioprine/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) studies/NNS (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) arthritis/NN
D000477_D009369 NONE agents/NNS (r_appos) drugs/NNS (r_pobj) of/IN (r_prep) use/NN (r_nsubjpass) reserved/VBN (r_conj) collected/VBN (l_nsubjpass) Data/NNS (l_prep) on/IN (l_pobj) risk/NN (l_prep) of/IN (l_pobj) malignancy/NN
D003520_D001749 CID Cyclophosphamide/NNP (r_compound) therapy/NN (r_nsubj) increases/VBZ (l_dobj) risk/NN (l_prep) of/IN (l_pobj) carcinoma/NN (l_prep) of/IN (l_pobj) bladder/NN
D000477_D008228 CID agents/NNS (r_pobj) with/IN (r_prep) treated/VBN (r_csubj) have/VBP (l_conj) associated/VBN (l_prep) with/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) lymphoma/NN -PUNC- agents/NNS (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) lymphoma/NN
D003520_D002277 CID Cyclophosphamide/NNP (r_compound) therapy/NN (r_nsubj) increases/VBZ (l_dobj) risk/NN (l_prep) of/IN (l_pobj) carcinoma/NN (l_prep) of/IN (l_pobj) bladder/NN
D001379_D015470 NONE azathioprine/NN (r_conj) agents/NNS (r_nsubjpass) associated/VBN (r_conj) have/VBP (l_dobj) risk/NN (l_prep) of/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) leukemia/NN
D000477_D001172 NONE agents/NNS (r_appos) drugs/NNS (r_pobj) of/IN (r_prep) use/NN (r_nsubjpass) reserved/VBN (r_conj) collected/VBN (l_nsubjpass) Data/NNS (l_prep) on/IN (l_pobj) risk/NN (l_prep) of/IN (l_pobj) malignancy/NN (l_prep) in/IN (l_pobj) arthritis/NN -PUNC- agents/NNS (r_appos) drugs/NNS (r_pobj) of/IN (r_prep) use/NN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) arthritis/NN
D003520_D009369 NONE cyclophosphamide/NN (r_conj) azathioprine/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) studies/NNS (r_attr) been/VBN (l_conj) increased/VBN (l_nsubjpass) incidence/NN (l_prep) of/IN (l_pobj) most/JJS (l_prep) of/IN (l_pobj) cancers/NNS
18726058
D010208_D003389 NONE papaverine/NN (r_pobj) with/IN (r_prep) cases/NNS (r_pobj) in/IN (r_prep) described/VBN (l_nsubjpass) dysfunction/NN -PUNC- papaverine/NN (r_pobj) from/IN (r_prep) deficits/NNS
D010208_D020301 NONE hydrochloride/NN (r_nsubj) is/VBZ (l_attr) vasodilator/NN (l_acl) used/VBD (l_xcomp) manage/VB (l_dobj) vasospasm/NN -PUNC- papaverine/NN (r_dobj) received/VBD (l_prep) for/IN (l_pobj) vasospasm/NN -PUNC- papaverine/NN (r_nsubjpass) used/VBN (l_prep) as/IN (l_pobj) action/NN (l_acl) manage/VB (l_dobj) vasospasm/NN -PUNC- papaverine/NN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) vasospasm/NN
18464113
D019259_D009369 NONE Lamivudine/NNP (l_prep) for/IN (l_pobj) prevention/NN (l_prep) of/IN (l_pobj) reactivation/NN (l_prep) in/IN (l_pobj) patients/NNS (l_compound) cancer/NN -PUNC- lamivudine/NN (r_dobj) received/VBD (l_nsubj) patients/NNS (l_compound) cancer/NN -PUNC- lamivudine/NN (r_dobj) receive/VB (r_relcl) group/NN (r_pobj) with/IN (r_prep) compared/VBN (r_prep) received/VBD (l_nsubj) patients/NNS (l_compound) cancer/NN -PUNC- lamivudine/NN (r_nsubj) decreases/VBZ (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) reactivation/NN (l_conj) morbidity/NN (l_prep) in/IN (l_pobj) patients/NNS (l_compound) cancer/NN
D019259_D006509 NONE Lamivudine/NNP (l_prep) for/IN (l_pobj) prevention/NN (l_prep) of/IN (l_pobj) reactivation/NN (l_compound) virus/NN (l_compound) B/NNP -PUNC- lamivudine/NN (r_dobj) received/VBD (l_nsubj) patients/NNS (l_relcl) have/VBP (l_dobj) malignancies/NNS (l_prep) with/IN (l_pobj) infection/NN -PUNC- lamivudine/NN (r_dobj) receive/VB (r_relcl) group/NN (r_pobj) with/IN (r_prep) compared/VBN (r_prep) received/VBD (l_nsubj) patients/NNS (l_relcl) have/VBP (l_dobj) malignancies/NNS (l_prep) with/IN (l_pobj) infection/NN
D019259_D056486 NONE lamivudine/NN (r_compound) group/NN (r_pobj) In/IN (r_prep) observed/VBN (l_nsubjpass) hepatitis/NN
D006514_D009369 NONE antigen/NN (r_nmod) patients/NNS (l_compound) cancer/NN -PUNC- HBSAG/NNP (r_nmod) patients/NNS (l_compound) cancer/NN
D019259_D019337 NONE lamivudine/NN (r_dobj) received/VBD (l_nsubj) patients/NNS (l_relcl) have/VBP (l_dobj) malignancies/NNS -PUNC- lamivudine/NN (r_dobj) receive/VB (r_relcl) group/NN (r_pobj) with/IN (r_prep) compared/VBN (r_prep) received/VBD (l_nsubj) patients/NNS (l_relcl) have/VBP (l_dobj) malignancies/NNS
D006514_D006509 CID antigen/NN (r_nmod) patients/NNS (r_pobj) in/IN (r_prep) reactivation/NN (l_compound) virus/NN (l_compound) B/NNP -PUNC- HBSAG/NNP (r_nmod) patients/NNS (r_pobj) in/IN (r_prep) reactivation/NN (l_compound) virus/NN (l_compound) B/NNP
16330766
C040029_D009437 NONE gabapentin/NN (l_appos) drug/NN (l_amod) effective/JJ (l_prep) in/IN (l_pobj) patients/NNS (l_compound) pain/NN
D002211_D006930 CID capsaicin/NN (r_npadvmod) induced/VBN (r_amod) hyperalgesia/NN
C040029_D006930 NONE gabapentin/NN (r_npadvmod) induced/VBN (r_amod) modulation/NN (l_prep) in/IN (l_pobj) response/NN (l_prep) to/IN (l_pobj) stimulation/NN (l_prep) of/IN (l_pobj) skin/NN (l_conj) hyperalgesia/NN
2522601
D002220_D003873 CID carbamazepine/NN (r_pobj) to/IN (r_prep) Hypersensitivity/NN (l_acl) presenting/VBG (l_prep) with/IN (l_pobj) reaction/NN (l_conj) eosinophilia/NN (l_conj) erythroderma/NN -PUNC- carbamazepine/NN (r_pobj) to/IN (r_prep) hypersensitivity/NN (r_nsubj) presented/VBN (l_prep) with/IN (l_pobj) erythroderma/NN
D002220_D007955 CID carbamazepine/NN (r_pobj) to/IN (r_prep) Hypersensitivity/NN (l_acl) presenting/VBG (l_prep) with/IN (l_pobj) reaction/NN -PUNC- carbamazepine/NN (r_pobj) to/IN (r_prep) hypersensitivity/NN (r_nsubj) presented/VBN (r_relcl) patient/NN (l_conj) reaction/NN
D002220_D007010 CID carbamazepine/NN (r_pobj) to/IN (r_prep) hypersensitivity/NN (r_nsubj) presented/VBN (r_relcl) patient/NN (l_conj) reaction/NN (l_conj) eosinophilia/NN (l_conj) hyponatremia/NN
D002220_D004802 NONE carbamazepine/NN (r_pobj) to/IN (r_prep) Hypersensitivity/NN (l_acl) presenting/VBG (l_prep) with/IN (l_pobj) reaction/NN (l_conj) eosinophilia/NN -PUNC- carbamazepine/NN (r_pobj) to/IN (r_prep) hypersensitivity/NN (r_nsubj) presented/VBN (r_relcl) patient/NN (l_conj) reaction/NN (l_conj) eosinophilia/NN
D002220_D004342 CID carbamazepine/NN (r_pobj) to/IN (r_prep) Hypersensitivity/NN -PUNC- carbamazepine/NN (r_pobj) to/IN (r_prep) hypersensitivity/NN
D002220_D051437 CID carbamazepine/NN (r_pobj) to/IN (r_prep) Hypersensitivity/NN (l_acl) presenting/VBG (l_prep) with/IN (l_pobj) reaction/NN (l_conj) failure/NN -PUNC- carbamazepine/NN (r_pobj) to/IN (r_prep) hypersensitivity/NN (r_nsubj) presented/VBN (r_relcl) patient/NN (l_conj) reaction/NN (l_conj) eosinophilia/NN (l_conj) hyponatremia/NN (l_conj) failure/NN
1732369
D004317_D006331 NONE doxorubicin/NN (r_pobj) due/IN (r_amod) damage/NN -PUNC- doxorubicin/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) survivors/NNS (r_dobj) differentiate/VB (r_xcomp) using/VBG (r_xcomp) performed/VBN (l_advcl) develop/VB (l_dobj) test/NN (l_prep) for/IN (l_pobj) damage/NN
D004317_D009369 NONE doxorubicin/NN (r_npadvmod) treated/VBN (r_amod) survivors/NNS (l_prep) of/IN (l_pobj) cancer/NN -PUNC- doxorubicin/NN (r_pobj) due/IN (r_amod) damage/NN (r_pobj) for/IN (r_prep) test/NN (r_dobj) develop/VB (r_advcl) performed/VBN (l_xcomp) using/VBG (l_xcomp) differentiate/VB (l_dobj) survivors/NNS (l_prep) of/IN (l_pobj) cancer/NN -PUNC- doxorubicin/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) survivors/NNS (l_prep) of/IN (l_pobj) cancer/NN
D004280_D009369 NONE Dobutamine/NNP (r_nsubj) stress/VBP (l_appos) indicator/NN (l_prep) of/IN (l_pobj) function/NN (l_prep) in/IN (l_pobj) survivors/NNS (l_prep) of/IN (l_pobj) cancer/NN -PUNC- dobutamine/NN (r_compound) infusion/NN (r_dobj) using/VBG (l_xcomp) differentiate/VB (l_dobj) survivors/NNS (l_prep) of/IN (l_pobj) cancer/NN
D004280_D006331 NONE dobutamine/NN (r_compound) infusion/NN (r_dobj) using/VBG (r_xcomp) performed/VBN (l_advcl) develop/VB (l_dobj) test/NN (l_prep) for/IN (l_pobj) damage/NN
D004317_D009202 CID Doxorubicin/NNP (r_nsubj) is/VBZ (l_attr) agent/NN (l_acl) known/VBN (l_xcomp) cause/VB (l_dobj) cardiomyopathy/NN
10791295
D001058_D010554 CID apomorphine/NN (r_pobj) of/IN (r_prep) Development/NN (r_nsubj) induced/VBN (l_dobj) behavior/NN -PUNC- apomorphine/NN (r_pobj) of/IN (r_prep) development/NN (r_nsubj) induced/VBN (l_dobj) behavior/NN -PUNC- apomorphine/NN (r_compound) treatment/NN (r_nsubj) induced/VBD (l_dobj) development/NN (l_prep) of/IN (l_pobj) behavior/NN -PUNC- apomorphine/NN (r_compound) treatment/NN (r_nsubj) induced/VBD (l_advcl) evidenced/VBN (l_agent) by/IN (l_pobj) intensity/NN (l_prep) of/IN (l_pobj) aggressiveness/NN -PUNC- apomorphine/NN (r_preconj) the/DT (r_det) behavior/NN
9653867
D013974_D013971 CID Thyroxine/NNP (r_compound) abuse/NN (l_appos) case/NN (l_prep) of/IN (l_pobj) thyrotoxicosis/NN -PUNC- thyroxine/NN (r_compound) abuse/NN (r_nsubjpass) considered/VBN (l_advcl) remains/VBZ (l_nsubj) cause/NN (l_prep) for/IN (l_pobj) thyrotoxicosis/NN
D013974_D001068 NONE thyroxine/NN (r_compound) abuse/NN (r_nsubjpass) considered/VBN (r_ccomp) reminds/VBZ (r_conj) illustrates/VBZ (l_dobj) derangements/NNS (l_prep) of/IN (l_pobj) function/NN (l_acl) seen/VBN (l_prep) with/IN (l_pcomp) eating/VBG (l_dobj) disorders/NNS
2572625
C084599_D056486 CID Clotiazepam/NNP (r_npadvmod) induced/VBN (r_amod) hepatitis/NN -PUNC- clotiazepam/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) of/IN (r_prep) onset/NN (r_pobj) after/IN (r_prep) developed/VBD (l_dobj) hepatitis/NN -PUNC- clotiazepam/NN (r_xcomp) related/VBN (r_acl) administration/NN (r_nsubj) interfere/VB (l_conj) induce/VB (l_dobj) relapse/NN (l_prep) of/IN (l_pobj) hepatitis/NN -PUNC- clotiazepam/NN (r_nsubj) induce/VB (l_dobj) hepatitis/NN -PUNC- clotiazepam/NN (r_nsubj) induce/VB (l_conj) suggests/VBZ (l_ccomp) is/VBZ (l_attr) hepatotoxicity/NN -PUNC- clotiazepam/NN (r_pobj) between/IN (r_prep) hepatotoxicity/NN (r_attr) is/VBZ (r_ccomp) suggests/VBZ (r_conj) induce/VB (l_dobj) hepatitis/NN -PUNC- clotiazepam/NN (r_pobj) between/IN (r_prep) hepatotoxicity/NN
D001569_D056486 NONE benzodiazepines/NNS (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) interfere/VB (l_conj) induce/VB (l_dobj) relapse/NN (l_prep) of/IN (l_pobj) hepatitis/NN -PUNC- benzodiazepines/NNS (r_conj) clotiazepam/NN (r_pobj) between/IN (r_prep) hepatotoxicity/NN (r_attr) is/VBZ (r_ccomp) suggests/VBZ (r_conj) induce/VB (l_dobj) hepatitis/NN -PUNC- benzodiazepines/NNS (r_conj) clotiazepam/NN (r_pobj) between/IN (r_prep) hepatotoxicity/NN
C084599_D047508 NONE clotiazepam/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) of/IN (r_prep) onset/NN (r_pobj) after/IN (r_prep) developed/VBD (l_prep) with/IN (l_pobj) necrosis/NN
C013295_D047508 NONE thienodiazepine/NN (r_amod) derivative/NN (r_appos) patient/NN (l_relcl) developed/VBD (l_prep) with/IN (l_pobj) necrosis/NN
C013295_D056486 NONE thienodiazepine/NN (r_amod) derivative/NN (r_appos) patient/NN (l_relcl) developed/VBD (l_dobj) hepatitis/NN
21029050
D013390_D001049 CID succinylcholine/NN (r_pobj) after/IN (r_prep) mutations/NNS (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) apnea/NN -PUNC- succinylcholine/NN (r_pobj) of/IN (r_prep) action/NN (r_pobj) of/IN (r_prep) duration/NN (r_pobj) with/IN (r_prep) patients/NNS (r_pobj) of/IN (r_prep) eleven/CD (r_nsubj) had/VBD (l_advcl) indicating/VBG (l_ccomp) is/VBZ (l_attr) reason/NN (l_prep) for/IN (l_pobj) period/NN (l_prep) of/IN (l_pobj) apnea/NN
18631865
D020123_D051436 NONE rapamycin/NNS (r_nmod) inhibitors/NNS (r_pobj) of/IN (r_prep) target/NN (r_pobj) to/IN (r_prep) conversion/NN (l_prep) in/IN (l_pobj) recipients/NNS (l_prep) with/IN (l_pobj) nephropathy/NN -PUNC- sirolimus/NN (r_appos) inhibitors/NNS (r_pobj) of/IN (r_prep) target/NN (r_pobj) to/IN (r_prep) conversion/NN (l_prep) in/IN (l_pobj) recipients/NNS (l_prep) with/IN (l_pobj) nephropathy/NN
D020123_D011507 CID sirolimus/NN (r_pobj) to/IN (r_prep) due/JJ (r_acomp) was/VBD (l_nsubj) proteinuria/NN -PUNC- sirolimus/NN (r_pobj) to/IN (r_prep) due/JJ (r_acomp) was/VBD (r_csubj) remained/VBD (l_advcl) observed/VBN (l_nsubjpass) proteinuria/NN -PUNC- sirolimus/NN (r_compound) therapy/NN (r_pobj) during/IN (r_prep) observed/VBN (r_advcl) remained/VBD (l_csubj) was/VBD (l_nsubj) proteinuria/NN -PUNC- sirolimus/NN (r_compound) therapy/NN (r_pobj) during/IN (r_prep) observed/VBN (l_nsubjpass) proteinuria/NN -PUNC- sirolimus/NN (r_nmod) novo/NNP (r_dobj) received/VBD (r_relcl) patients/NNS (r_pobj) in/IN (r_conj) in/IN (r_prep) observed/VBN (r_advcl) remained/VBD (l_csubj) was/VBD (l_nsubj) proteinuria/NN -PUNC- sirolimus/NN (r_nmod) novo/NNP (r_dobj) received/VBD (r_relcl) patients/NNS (r_pobj) in/IN (r_conj) in/IN (r_prep) observed/VBN (l_nsubjpass) proteinuria/NN
19356307
C032208_D003704 NONE alcohol/NN (r_pobj) of/IN (r_prep) effects/NNS (l_compound) dementia/NN
C032208_D008569 NONE alcohol/NN (r_nsubj) relieved/VBD (l_ccomp) showed/VBD (l_dobj) ability/NN (l_acl) improve/VB (l_dobj) memory/NN (l_amod) impaired/VBN -PUNC- alcohol/NN (r_nsubj) relieved/VBD (l_dobj) deficit/NN (l_prep) of/IN (l_pobj) memory/NN
D012601_D003704 NONE scopolamine/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubj) Components/NNS (l_prep) of/IN (l_pobj) dementia/NN
D012601_D008569 CID scopolamine/NN (r_pobj) by/IN (r_agent) impaired/VBN -PUNC- scopolamine/NN (r_pobj) by/IN (r_agent) impaired/VBN (r_amod) memory/NN (r_dobj) improve/VB (r_acl) ability/NN (r_dobj) showed/VBD (r_ccomp) relieved/VBD (l_dobj) deficit/NN (l_prep) of/IN (l_pobj) memory/NN
C008281_D003704 NONE limonene/NN (r_nmod) alcohol/NN (r_pobj) of/IN (r_prep) effects/NNS (l_compound) dementia/NN
9390208
D005472_D064420 NONE 5-FU/CD (l_conj) benefit/NN (l_conj) toxicity/NN
D008942_D001943 NONE mitoxantrone/NN (r_pobj) by/IN (r_prep) cancer/NN -PUNC- mitoxantrone/NN (r_pobj) by/IN (r_prep) treated/VBD (l_dobj) patients/NNS (l_prep) with/IN (l_pobj) cancer/NN
D002955_D064420 NONE leucovorin/NN (r_conj) 5-FU/CD (l_conj) benefit/NN (l_conj) toxicity/NN
C085788_D064420 NONE MFL/NNP (r_appos) 5-FU/CD (l_conj) benefit/NN (l_conj) toxicity/NN -PUNC- regimen/NN (r_nsubj) achieves/VBZ (l_conj) induces/VBZ (l_dobj) toxicity/NN
D008942_D064420 NONE mitoxantrone/NN (r_pobj) by/IN (r_prep) cancer/NN (r_pobj) of/IN (r_prep) Treatment/NN (l_conj) infusion/NN (l_prep) of/IN (l_pobj) 5-FU/CD (l_conj) benefit/NN (l_conj) toxicity/NN
D005472_D001943 NONE 5-FU/CD (r_pobj) of/IN (r_prep) infusion/NN (r_conj) Treatment/NN (l_prep) of/IN (l_pobj) cancer/NN -PUNC- 5-FU/CD (r_pobj) of/IN (r_prep) infusion/NN (r_conj) day/NN (r_pobj) on/IN (r_prep) treated/VBD (l_dobj) patients/NNS (l_prep) with/IN (l_pobj) cancer/NN
D002955_D001943 NONE leucovorin/NN (r_conj) 5-FU/CD (r_pobj) of/IN (r_prep) infusion/NN (r_conj) Treatment/NN (l_prep) of/IN (l_pobj) cancer/NN -PUNC- leucovorin/NN (r_pobj) with/IN (r_prep) treated/VBD (l_dobj) patients/NNS (l_prep) with/IN (l_pobj) cancer/NN
C085788_D001943 NONE MFL/NNP (r_appos) 5-FU/CD (r_pobj) of/IN (r_prep) infusion/NN (r_conj) Treatment/NN (l_prep) of/IN (l_pobj) cancer/NN
9587734
D013390_D004342 CID suxamethonium/NN (r_pobj) to/IN (r_prep) hypersensitivity/NN
D013390_D006323 CID Suxamethonium/NN (r_npadvmod) induced/VBN (r_amod) arrest/NN -PUNC- suxamethonium/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) following/VBG (r_prep) case/NN (l_prep) of/IN (l_pobj) arrest/NN -PUNC- suxamethonium/NN (l_appos) arrest/NN
D013390_D003643 NONE Suxamethonium/NN (r_npadvmod) induced/VBN (r_amod) arrest/NN (l_conj) death/NN -PUNC- suxamethonium/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) following/VBG (r_prep) case/NN (l_prep) of/IN (l_pobj) arrest/NN (l_conj) death/NN -PUNC- suxamethonium/NN (r_pobj) to/IN (r_prep) hypersensitivity/NN (r_pobj) by/IN (r_agent) caused/VBN (l_nsubjpass) death/NN
D013390_D006947 CID suxamethonium/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) following/VBG (r_prep) case/NN (l_prep) of/IN (l_pobj) arrest/NN (l_conj) death/NN (l_prep) as/IN (l_pobj) result/NN (l_prep) of/IN (l_pobj) hyperkalaemia/NN -PUNC- suxamethonium/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) following/VBG (r_prep) signs/NNS (l_prep) of/IN (l_conj) of/IN (l_pobj) any/DT (l_prep) of/IN (l_pobj) conditions/NNS (l_prep) for/IN (l_pobj) hyperkalaemia/NN
D013390_D001919 CID suxamethonium/NN (l_appos) arrest/NN (l_amod) bradycardia/NN
8231633
D002045_D064420 NONE bupivacaine/NN (r_npadvmod) induced/VBN (r_amod) toxicity/NN -PUNC- bupivacaine/NN (r_npadvmod) induced/VBN (r_amod) toxicity/NN
D015764_D012640 NONE bepridil/NN (r_pcomp) with/IN (r_prep) pronounced/VBN (r_acomp) was/VBD (l_ccomp) modified/VBN (l_conj) decreased/VBD (l_dobj) time/NN (l_relcl) obtain/VB (l_dobj) convulsions/NNS
D002045_D012640 CID bupivacaine/NN (r_pobj) of/IN (r_prep) activity/NN (r_nsubj) was/VBD (r_auxpass) modified/VBN (l_conj) decreased/VBD (l_dobj) time/NN (l_relcl) obtain/VB (l_dobj) convulsions/NNS -PUNC- bupivacaine/NN (r_npadvmod) induced/VBN (r_amod) convulsions/NNS
D002118_D012640 NONE calcium/NN (r_compound) channel/NN (r_compound) blockers/NNS (r_nsubj) decreased/VBD (l_dobj) time/NN (l_relcl) obtain/VB (l_dobj) convulsions/NNS
D002118_D064420 NONE calcium/NN (r_compound) channel/NN (r_compound) blockers/NNS (l_prep) on/IN (l_pobj) toxicity/NN -PUNC- calcium/NN (r_compound) channel/NN (r_compound) blockers/NNS (l_prep) on/IN (l_pobj) toxicity/NN
20722491
C110904_D003967 CID capecitabine/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubj) are/VBP (l_attr) diarrhea/NN
C110904_D013280 CID capecitabine/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubj) are/VBP (l_attr) diarrhea/NN (l_appos) nausea/NN (l_conj) vomiting/NN (l_conj) stomatitis/JJ
C110904_D060831 CID capecitabine/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubj) are/VBP (l_attr) diarrhea/NN (l_appos) nausea/NN (l_conj) vomiting/NN (l_conj) stomatitis/JJ (l_conj) syndrome/NN
D005472_D009369 NONE 5-FU/CD (r_nsubj) been/VBN (l_attr) mainstay/NN (l_prep) of/IN (l_pobj) treatment/NN (l_prep) for/IN (l_pobj) tumors/NNS
D005472_D015179 NONE 5-FU/CD (r_nsubj) been/VBN (l_attr) mainstay/NN (l_prep) of/IN (l_pobj) treatment/NN (l_prep) for/IN (l_pobj) tumors/NNS (l_prep) including/VBG (l_pobj) colorectal/NN (l_conj) breast/NN (l_conj) cancers/NNS
C110904_D014839 CID capecitabine/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubj) are/VBP (l_attr) diarrhea/NN (l_appos) nausea/NN (l_conj) vomiting/NN
D005472_D001943 NONE 5-FU/CD (r_nsubj) been/VBN (l_attr) mainstay/NN (l_prep) of/IN (l_pobj) treatment/NN (l_prep) for/IN (l_pobj) tumors/NNS (l_prep) including/VBG (l_pobj) colorectal/NN (l_conj) breast/NN (l_conj) cancers/NNS
C110904_D008107 NONE Capecitabine/NNP (r_nsubj) has/VBZ (l_conj) given/VBN (l_prep) to/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) dysfunctions/NNS
C110904_D007674 NONE capecitabine/NN (r_pobj) of/IN (r_prep) safety/NN (l_prep) in/IN (l_pobj) populations/NNS (l_prep) as/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disease/NN -PUNC- Capecitabine/NNP (r_nsubj) has/VBZ (l_conj) given/VBN (l_prep) to/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) dysfunctions/NNS
C110904_D009325 CID capecitabine/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubj) are/VBP (l_attr) diarrhea/NN (l_appos) nausea/NN
D005472_D006258 NONE 5-FU/CD (r_nsubj) been/VBN (l_attr) mainstay/NN (l_prep) of/IN (l_pobj) treatment/NN (l_prep) for/IN (l_pobj) tumors/NNS (l_prep) including/VBG (l_pobj) colorectal/NN (l_conj) breast/NN (l_conj) cancers/NNS
7930386
D002997_D012893 CID Clomipramine/NNP (r_npadvmod) induced/VBN (r_amod) disturbance/NN -PUNC- clomipramine/NN (r_compound) administration/NN (r_pobj) by/IN (r_agent) induced/VBN (r_conj) examine/VB (l_dobj) role/NN (l_prep) of/IN (l_pobj) disturbance/NN
19269743
D002211_D010146 CID capsaicin/NN (r_npadvmod) induced/VBN (r_amod) pain/NN -PUNC- capsaicin/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) of/IN (r_prep) injections/NNS (r_dobj) received/VBD (l_prep) In/IN (l_pobj) order/NN (l_acl) address/VB (l_dobj) memory/NN (l_compound) pain/NN -PUNC- capsaicin/NN (r_compound) doses/NNS (r_pobj) across/IN (r_prep) discriminate/VB (l_dobj) magnitude/NN (l_compound) pain/NN
2632720
D006854_D006973 NONE cortisol/NN (r_compound) levels/NNS (r_nsubjpass) achieved/VBN (l_conj) demonstrated/VBD (l_dobj) hypertension/NN
D007654_D006973 CID ketoconazole/JJ (r_compound) treatment/NN (r_pobj) of/IN (r_prep) complication/NN (r_pobj) as/IN (r_prep) hypertension/NN -PUNC- ketoconazole/JJ (r_pobj) with/IN (r_prep) basis/NN (r_pobj) on/IN (r_prep) treated/VBN (l_advcl) developed/VBN (l_dobj) hypertension/NN -PUNC- ketoconazole/JJ (r_compound) therapy/NN (r_dobj) following/VBG (r_prep) achieved/VBN (l_conj) demonstrated/VBD (l_dobj) hypertension/NN -PUNC- ketoconazole/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) with/IN (r_prep) treatment/NN (r_nsubj) induce/VB (l_dobj) blockade/NN (l_acl) leading/VBG (l_prep) to/IN (l_pobj) hypertension/NN
D007654_D003480 NONE ketoconazole/JJ (r_pobj) with/IN (r_prep) basis/NN (r_pobj) on/IN (r_prep) treated/VBN (l_nsubj) patients/NNS (l_prep) with/IN (l_pobj) syndrome/NN
1987816
D008094_D011141 CID Lithium/NN (r_npadvmod) induced/VBN (r_amod) polyuria/NN
2224762
C027260_D009369 NONE 4'-0-tetrahydropyranyladriamycin/NNP (r_dobj) bolus/NN (r_appos) Phase/NN (r_nsubjpass) done/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) in/IN (l_pobj) status/NN (l_prep) with/IN (l_pobj) tumors/NNS -PUNC- Pirarubicin/NNP (r_appos) 4'-0-tetrahydropyranyladriamycin/NNP (r_dobj) bolus/NN (r_appos) Phase/NN (r_nsubjpass) done/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) in/IN (l_pobj) status/NN (l_prep) with/IN (l_pobj) tumors/NNS
1967484
D013469_D004421 CID Sulpiride/NNP (r_npadvmod) induced/VBN (l_dobj) dystonia/NN -PUNC- sulpiride/NN (r_compound) therapy/NN (r_dobj) starting/VBG (r_pcomp) after/IN (r_prep) developed/VBD (l_dobj) dystonia/NN -PUNC- sulpiride/NN (r_npadvmod) induced/VBN (r_amod) dystonia/NN
D013469_D004409 NONE sulpiride/NN (r_npadvmod) induced/VBN (l_dobj) dyskinesia/JJ
D013469_D010302 NONE sulpiride/NN (r_npadvmod) induced/VBN (l_dobj) dyskinesia/JJ (l_conj) parkinsonism/NN
1639466
D004656_D006973 NONE enalapril/NN (r_npadvmod) treated/VBN (r_amod) 8)/CD (r_appos) controls/NNS (r_appos) groups/NNS (r_pobj) to/IN (r_prep) assigned/VBN (l_prep) after/IN (l_pobj) clipping/VBG (l_prep) of/IN (l_pobj) artery/NN (l_appos) rats/NNS (l_amod) hypertensive/JJ -PUNC- enalapril/NN (r_npadvmod) treated/VBN (r_amod) 8)/CD (r_appos) controls/NNS (l_amod) hypertensive/JJ -PUNC- enalapril/NN (r_npadvmod) treated/VBN (r_amod) group/NN (r_pobj) in/IN (r_prep) lower/JJR (l_prep) compared/VBN (l_prep) with/IN (l_pobj) controls/NNS (l_amod) hypertensive/JJ
D009568_D006978 NONE nitrendipine/NN (l_prep) on/IN (l_pobj) nephrosclerosis/NN (l_prep) in/IN (l_pobj) rats/NNS (l_prep) with/IN (l_pobj) hypertension/NN -PUNC- nitrendipine/NN (r_appos) channel/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) of/IN (r_prep) effect/NN (r_nsubjpass) studied/VBN (l_prep) in/IN (l_pobj) rats/NNS (l_prep) with/IN (l_pobj) kidney/NN (l_appos) hypertension/NN
D004656_D000419 NONE enalapril/NN (r_dobj) converting/VBG (l_prep) on/IN (l_pobj) pressure/NN (l_conj) albuminuria/NN
D000809_D006978 NONE angiotensin/NN (r_conj) nitrendipine/NN (r_appos) channel/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) of/IN (r_prep) effect/NN (r_nsubjpass) studied/VBN (l_prep) in/IN (l_pobj) rats/NNS (l_prep) with/IN (l_pobj) kidney/NN (l_appos) hypertension/NN
D004656_D005921 NONE enalapril/JJ (r_compound) treatment/NN (r_pobj) after/IN (r_prep) change/VB (l_nsubj) excretion/NN (l_conj) glomerulosclerosis/NN
D002118_D006978 NONE calcium/NN (r_compound) channel/NN (r_pobj) of/IN (r_prep) effect/NN (l_appos) nitrendipine/NN (l_prep) on/IN (l_pobj) nephrosclerosis/NN (l_prep) in/IN (l_pobj) rats/NNS (l_prep) with/IN (l_pobj) hypertension/NN -PUNC- calcium/NN (r_compound) channel/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) of/IN (r_prep) effect/NN (r_nsubjpass) studied/VBN (l_prep) in/IN (l_pobj) rats/NNS (l_prep) with/IN (l_pobj) kidney/NN (l_appos) hypertension/NN
D004656_D006978 NONE enalapril/NN (r_dobj) converting/VBG (r_acl) angiotensin/NN (r_conj) nitrendipine/NN (r_appos) channel/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) of/IN (r_prep) effect/NN (r_nsubjpass) studied/VBN (l_prep) in/IN (l_pobj) rats/NNS (l_prep) with/IN (l_pobj) kidney/NN (l_appos) hypertension/NN
D009568_D000419 CID nitrendipine/NN (l_conj) angiotensin/NN (l_acl) converting/VBG (l_prep) on/IN (l_pobj) pressure/NN (l_conj) albuminuria/NN -PUNC- nitrendipine/NN (r_npadvmod) treated/VBN (r_amod) albuminuria/NN
D009568_D006973 NONE nitrendipine/NN (r_advmod) treated/VBN (r_conj) 8)/CD (r_appos) controls/NNS (r_appos) groups/NNS (r_pobj) to/IN (r_prep) assigned/VBN (l_prep) after/IN (l_pobj) clipping/VBG (l_prep) of/IN (l_pobj) artery/NN (l_appos) rats/NNS (l_amod) hypertensive/JJ -PUNC- nitrendipine/NN (r_advmod) treated/VBN (r_conj) 8)/CD (r_appos) controls/NNS (l_amod) hypertensive/JJ -PUNC- nitrendipine/NN (r_npadvmod) treated/VBN (r_amod) albuminuria/NN (r_pobj) in/IN (r_prep) increased/VBD (l_prep) compared/VBN (l_prep) with/IN (l_pobj) hr/NN (l_prep) in/IN (l_pobj) controls/NNS (l_amod) hypertensive/JJ -PUNC- nitrendipine/NN (r_npadvmod) treated/VBN (r_amod) group/NN (r_pobj) in/IN (r_prep) increased/VBN (l_prep) compared/VBN (l_prep) with/IN (l_pobj) controls/NNS (l_amod) hypertensive/JJ -PUNC- nitrendipine/NN (r_npadvmod) treated/VBN (r_amod) group/NN (r_pobj) in/IN (r_prep) was/VBD (l_conj) lower/JJR (l_prep) compared/VBN (l_prep) with/IN (l_pobj) controls/NNS (l_amod) hypertensive/JJ
D002118_D000419 NONE calcium/NN (r_compound) channel/NN (l_appos) nitrendipine/NN (l_conj) angiotensin/NN (l_acl) converting/VBG (l_prep) on/IN (l_pobj) pressure/NN (l_conj) albuminuria/NN
D002118_D009400 NONE calcium/NN (r_compound) channel/NN (r_pobj) of/IN (r_prep) effect/NN (l_appos) nitrendipine/NN (l_prep) on/IN (l_pobj) nephrosclerosis/NN
D009568_D005921 NONE nitrendipine/NN (r_npadvmod) treated/VBN (r_amod) group/NN (r_pobj) in/IN (r_prep) increased/VBN (l_nsubjpass) index/NN (l_compound) glomerulosclerosis/NN
D000809_D000419 NONE angiotensin/NN (l_acl) converting/VBG (l_prep) on/IN (l_pobj) pressure/NN (l_conj) albuminuria/NN
D009568_D009400 CID nitrendipine/NN (l_prep) on/IN (l_pobj) nephrosclerosis/NN
2334618
D009020_D020182 CID morphine/NN (r_compound) infusion/NN (r_dobj) had/VBD (r_relcl) patients/NNS (r_pobj) in/IN (r_prep) occurred/VBD (l_nsubj) obstructive/JJ (l_appos) P/NN (l_conj) apnoea/NN
D002045_D001049 NONE bupivacaine/NN (r_pobj) of/IN (r_prep) infusion/NN (r_dobj) receiving/VBG (r_acl) patients/NNS (r_conj) patients/NNS (r_pobj) between/IN (r_prep) compared/VBN (l_nsubjpass) incidence/NN (l_prep) of/IN (l_pobj) apnoea/NN
D009020_D013610 NONE morphine/NN (r_compound) infusion/NN (r_compound) group/NN (r_pobj) in/IN (r_prep) beats/NNS (r_conj) tachyarrhythmias/NNS
D009020_D020181 CID morphine/NN (r_compound) infusion/NN (r_dobj) had/VBD (r_relcl) patients/NNS (r_pobj) in/IN (r_prep) occurred/VBD (l_nsubj) obstructive/JJ (l_appos) P/NN (l_conj) apnoea/NN
D009020_D001049 NONE morphine/NN (r_pobj) of/IN (r_prep) infusion/NN (r_dobj) receiving/VBG (r_acl) patients/NNS (r_pobj) between/IN (r_prep) compared/VBN (l_nsubjpass) incidence/NN (l_prep) of/IN (l_pobj) apnoea/NN
D009020_D018879 CID morphine/NN (r_compound) infusion/NN (r_compound) group/NN (r_pobj) in/IN (r_prep) beats/NNS
2887062
D001971_D015175 NONE bromocriptine/NN (r_amod) treatment/NN (r_pobj) after/IN (r_prep) prolactinomas/NNS -PUNC- bromocriptine/NN (r_pobj) of/IN (r_prep) effects/NNS (l_prep) on/IN (l_pobj) cells/NNS (l_compound) prolactinoma/NN -PUNC- bromocriptine/NN (r_pobj) of/IN (r_prep) effects/NNS (r_dobj) clarify/VB (r_advcl) applied/VBN (l_prep) to/IN (l_pobj) cells/NNS (l_compound) prolactinoma/NN -PUNC- bromocriptine/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) after/IN (r_prep) h/NN (r_conj) applied/VBN (l_advcl) clarify/VB (l_dobj) effects/NNS (l_prep) on/IN (l_pobj) cells/NNS (l_compound) prolactinoma/NN -PUNC- bromocriptine/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) after/IN (r_prep) h/NN (r_conj) applied/VBN (l_prep) to/IN (l_pobj) cells/NNS (l_compound) prolactinoma/NN
D004967_D015175 CID estrogen/NN (r_npadvmod) induced/VBN (r_amod) prolactinomas/NNS -PUNC- estrogen/NN (r_npadvmod) induced/VBN (r_amod) cells/NNS (r_pobj) to/IN (r_prep) applied/VBN (l_advcl) clarify/VB (l_dobj) effects/NNS (l_prep) on/IN (l_pobj) cells/NNS (l_compound) prolactinoma/NN -PUNC- estrogen/NN (r_npadvmod) induced/VBN (r_amod) cells/NNS (l_compound) prolactinoma/NN
D001971_D000236 NONE bromocriptine/JJ (r_amod) treatment/NN (l_prep) of/IN (l_pobj) cells/NNS (l_compound) adenoma/NN
8690168
C015445_D003920 NONE blue/JJ (r_dobj) employing/VBG (r_advcl) studied/VBN (l_prep) after/IN (l_pobj) induction/NN (l_prep) of/IN (l_pobj) diabetes/NNS
D013311_D003920 NONE streptozotocin/NNS (r_pobj) by/IN (r_prep) induction/NN (l_prep) of/IN (l_pobj) diabetes/NNS -PUNC- streptozotocin/JJ (r_amod) diabetic/JJ
D013311_D003928 CID streptozotocin/NNS (r_npadvmod) induced/VBN (r_amod) nephropathy/NN
D006497_D003928 NONE sulphate/NN (r_npadvmod) associated/VBN (r_amod) sites/NNS (l_prep) in/IN (l_pobj) membrane/NN (l_prep) of/IN (l_pobj) rats/NNS (l_prep) with/IN (l_pobj) nephropathy/NN
D006497_D003920 NONE sulphate/NN (r_npadvmod) associated/VBN (r_amod) sites/NNS (r_nsubjpass) studied/VBN (l_prep) after/IN (l_pobj) induction/NN (l_prep) of/IN (l_pobj) diabetes/NNS -PUNC- sulphate/NN (r_compound) charge/NN (r_compound) density/NN (r_nsubjpass) found/VBN (l_prep) in/IN (l_pobj) rats/NNS (l_amod) diabetic/JJ
6747681
D000431_D014786 NONE ethanol/NN (r_compound) diluent/NN (r_pobj) of/IN (r_prep) concentration/NN (r_nsubjpass) lowered/VBN (r_advcl) decreased/VBD (l_nsubj) frequency/NN (l_prep) of/IN (l_pobj) loss/NN
D002330_D005910 NONE BCNU/NNP (r_compound) chemotherapy/NN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) gliomas/NNS -PUNC- BCNU/NNP (r_nmod) 1,3-bis-(2-chloroethyl)-1-nitrosourea/NN (r_pobj) of/IN (r_prep) clearance/NN (r_pobj) Because/IN (r_prep) provide/VB (l_dobj) advantage/NN (l_prep) over/IN (l_pobj) administration/NN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) gliomas/NNS -PUNC- 1,3-bis-(2-chloroethyl)-1-nitrosourea/NN (r_pobj) of/IN (r_prep) clearance/NN (r_pobj) Because/IN (r_prep) provide/VB (l_dobj) advantage/NN (l_prep) over/IN (l_pobj) administration/NN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) gliomas/NNS
D002330_D001254 NONE BCNU/NNP (r_compound) therapy/NN (r_pobj) of/IN (r_prep) courses/NNS (r_dobj) received/VBD (l_nsubj) patients/NNS (l_prep) to/IN (l_pobj) astrocytomas/NN
12574103
D003907_D006973 CID dexamethasone/NN (r_compound) programs/NNS (r_compound) hypertension/NN -PUNC- dexamethasone/NN (r_nsubj) programmed/VBD (l_dobj) increase/NN (l_prep) in/IN (l_pobj) pressure/NN -PUNC- dexamethasone/NN (r_dobj) received/VBD (r_relcl) rats/NNS (r_nsubj) elevated/VBN (l_dobj) pressures/NNS -PUNC- dexamethasone/NN (r_nsubj) results/VBZ (l_prep) in/IN (l_pobj) reduction/NN (l_prep) in/IN (l_pobj) number/NN (l_conj) glomerulosclerosis/NN (l_conj) hypertension/NN
D003907_D005921 NONE dexamethasone/NN (r_dobj) given/VBN (l_advcl) had/VBD (l_dobj) glomeruli/NNS (l_prep) with/IN (l_pobj) glomerulosclerosis/NN -PUNC- dexamethasone/NN (r_nsubj) results/VBZ (l_prep) in/IN (l_pobj) reduction/NN (l_prep) in/IN (l_pobj) number/NN (l_conj) glomerulosclerosis/NN
D003907_D007674 CID dexamethasone/NN (r_compound) programs/NNS (r_compound) hypertension/NN (l_conj) injury/NN -PUNC- dexamethasone/NN (r_nsubj) programmed/VBD (l_dobj) increase/NN (l_prep) in/IN (l_pobj) pressure/NN (l_conj) injury/NN -PUNC- dexamethasone/NN (r_dobj) administered/VBN (r_csubj) had/VBD (l_dobj) reduction/NN (l_prep) in/IN (l_pobj) number/NN -PUNC- dexamethasone/NN (r_dobj) received/VBD (r_relcl) rats/NNS (r_nsubj) elevated/VBN (r_ccomp) have/VB (l_dobj) reduction/NN (l_prep) in/IN (l_pobj) number/NN -PUNC- dexamethasone/NN (r_nsubj) results/VBZ (l_prep) in/IN (l_pobj) reduction/NN (l_prep) in/IN (l_pobj) number/NN
7420681
D014031_D051437 CID sulfate/NN (r_conj) sulfate/NN (r_pobj) of/IN (r_prep) day/NN (r_appos) kg/NNS (r_pobj) with/IN (r_prep) treated/VBN (r_conj) patients/NNS (r_nsubjpass) followed/VBN (l_prep) for/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) failure/NN -PUNC- tobramycin/RB (r_npadvmod) treated/VBN (r_amod) patients/NNS (r_pobj) of/IN (r_prep) %/NN (r_pobj) of/IN (r_prep) Five/CD (r_nsubj) had/VBD (l_dobj) failure/NN -PUNC- tobramycin/JJ (r_acomp) was/VBD (r_advcl) associated/VBN (l_prep) with/IN (l_pobj) failure/NN
D005839_D007674 NONE gentamicin/NN (r_conj) nephrotoxicity/NN -PUNC- sulfate/NN (r_nsubj) continue/VBP (l_xcomp) demonstrate/VB (l_dobj) ototoxicity/NN (l_conj) nephrotoxicity/NN
D014031_D006311 NONE sulfate/NN (r_conj) sulfate/NN (r_nsubj) continue/VBP (l_xcomp) demonstrate/VB (l_dobj) ototoxicity/NN
D005839_D051437 CID sulfate/NN (r_pobj) of/IN (r_prep) day/NN (r_appos) kg/NNS (r_pobj) with/IN (r_prep) treated/VBN (r_conj) patients/NNS (r_nsubjpass) followed/VBN (l_prep) for/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) failure/NN -PUNC- gentamicin/NN (r_npadvmod) treated/VBN (r_amod) patients/NNS (r_pobj) of/IN (r_prep) 16/CD (r_nsubj) had/VBD (l_dobj) failure/NN -PUNC- gentamicin/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) failure/NN
D000617_D051437 NONE aminoglycoside/NN (r_npadvmod) related/VBN (r_amod) failure/NN
D014031_D007674 NONE tobramycin/JJ (r_pobj) of/IN (r_prep) nephrotoxicity/NN -PUNC- sulfate/NN (r_conj) sulfate/NN (r_nsubj) continue/VBP (l_xcomp) demonstrate/VB (l_dobj) ototoxicity/NN (l_conj) nephrotoxicity/NN
D005839_D006311 NONE sulfate/NN (r_nsubj) continue/VBP (l_xcomp) demonstrate/VB (l_dobj) ototoxicity/NN
16867021
D000661_D002375 NONE amphetamine/NN (r_npadvmod) induced/VBN (r_amod) activities/NNS (r_conj) behavior/NN (r_dobj) study/VB (l_dobj) effect/NN (l_prep) of/IN (l_pobj) ligands/NNS (l_prep) on/IN (l_pobj) catalepsy/NN -PUNC- amphetamine/NN (r_conj) apomorphine/NN (r_nsubjpass) used/VBN (r_advcl) induced/VBN (l_nsubjpass) Catalepsy/NNP -PUNC- amphetamine/NN (r_npadvmod) induced/VBN (r_amod) hyperactivity/NN (r_dobj) reducing/VBG (r_conj) potentiating/VBG (l_dobj) catalepsy/NN
D006220_D006948 NONE haloperidol/NN (r_npadvmod) induced/VBN (r_amod) catalepsy/NN (r_dobj) potentiating/VBG (l_conj) reducing/VBG (l_dobj) hyperactivity/NN
D000661_D006948 CID amphetamine/NN (r_npadvmod) induced/VBN (r_amod) hyperactivity/NN -PUNC- amphetamine/NN (r_npadvmod) induced/VBN (r_amod) hyperactivity/NN
D006220_D002375 CID haloperidol/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubjpass) Catalepsy/NNP -PUNC- haloperidol/NN (r_pobj) to/IN (r_prep) prior/RB (r_advmod) resulted/VBD (l_prep) in/IN (l_pobj) increase/NN (l_prep) in/IN (l_pobj) catalepsy/NN -PUNC- haloperidol/NN (r_npadvmod) induced/VBN (r_amod) catalepsy/NN
C052075_D006948 NONE THP/NNP (r_nmod) time/NN (r_npadvmod) traveled/VBD (l_prep) On/IN (l_pobj) hyperactivity/NN -PUNC- THP/NNP (r_nsubj) exhibited/VBD (l_dobj) profile/NN (l_prep) by/IN (l_pcomp) potentiating/VBG (l_conj) reducing/VBG (l_dobj) hyperactivity/NN
D001058_D002375 NONE apomorphine/NN (r_npadvmod) induced/VBN (r_amod) behavior/NN (r_dobj) study/VB (l_dobj) effect/NN (l_prep) of/IN (l_pobj) ligands/NNS (l_prep) on/IN (l_pobj) catalepsy/NN -PUNC- apomorphine/NN (r_nsubjpass) used/VBN (r_advcl) induced/VBN (l_nsubjpass) Catalepsy/NNP -PUNC- apomorphine/NN (r_dobj) reducing/VBG (r_conj) reducing/VBG (r_conj) potentiating/VBG (l_dobj) catalepsy/NN
C052075_D002375 CID thioperamide/JJ (r_conj) microg/NN (r_parataxis) methylhistamine/NN (r_nsubj) cause/VB (l_dobj) catalepsy/NN -PUNC- THP/NNP (r_appos) thioperamide/JJ (r_conj) microg/NN (r_parataxis) methylhistamine/NN (r_nsubj) cause/VB (l_dobj) catalepsy/NN -PUNC- THP/NNP (r_nsubj) exhibited/VBD (l_dobj) profile/NN (l_prep) by/IN (l_pcomp) potentiating/VBG (l_dobj) catalepsy/NN
D006632_D002375 NONE histamine/NN (r_nmod) ligands/NNS (l_prep) on/IN (l_pobj) catalepsy/NN
D001058_D006948 NONE apomorphine/NN (r_dobj) reducing/VBG (r_conj) reducing/VBG (l_dobj) hyperactivity/NN
C069357_D002375 NONE methylhistamine/NN (r_nsubj) cause/VB (l_dobj) catalepsy/NN -PUNC- RAMH/NNP (r_appos) methylhistamine/NN (r_nsubj) cause/VB (l_dobj) catalepsy/NN
16403073
D007654_D008133 CID ketoconazole/RB (r_dobj) taking/VBG (r_pcomp) after/IN (r_prep) torsades/NNS (r_conj) developed/VBD (l_dobj) interval/NN -PUNC- ketoconazole/JJ (r_nsubjpass) administered/VBN (l_prep) to/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) factors/NNS (l_prep) for/IN (l_pobj) syndrome/NN
D007654_D003324 NONE ketoconazole/RB (r_dobj) taking/VBG (r_pcomp) after/IN (r_prep) torsades/NNS (r_conj) developed/VBD (r_relcl) woman/NN (l_prep) with/IN (l_pobj) disease/NN
D007654_D009181 NONE ketoconazole/RB (r_dobj) taking/VBG (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) infection/NN
D007654_D016171 CID Ketoconazole/NNP (r_nsubj) induced/VBD (l_dobj) pointes/FW -PUNC- ketoconazole/RB (r_dobj) taking/VBG (r_pcomp) after/IN (r_prep) torsades/NNS (l_dobj) pointes/FW -PUNC- ketoconazole/RB (r_dobj) taking/VBG (r_pcomp) after/IN (r_prep) torsades/NNS (l_dobj) pointes/FW (l_appos) TdP/NN -PUNC- ketoconazole/RB (r_nsubj) prolong/VB (l_conj) induce/VB (l_dobj) TdP./NN
137340
D009388_D006948 NONE neostigmine/NN (r_conj) methscopolamine/NN (r_nsubj) had/VBD (l_dobj) effect/NN (l_prep) on/IN (l_pobj) hyperactivity/NN
D010134_D006948 NONE chlorophenylalamine/NN (r_pobj) with/IN (r_prep) pretreatment/NN (r_nsubj) caused/VBD (l_dobj) change/NN (l_prep) in/IN (l_pobj) hyperactivity/NN
D012601_D006948 CID scopolamine/NN (r_pobj) by/IN (r_agent) potentiated/VBN (l_nsubjpass) hyperactivity/NN
D010830_D006948 NONE physostigmine/NN (r_pobj) by/IN (r_agent) attenuated/VBN (r_conj) potentiated/VBN (l_nsubjpass) hyperactivity/NN
D012701_D006948 NONE serotonin/NN (r_compound) depletor/NN (r_nsubj) caused/VBD (l_dobj) change/NN (l_prep) in/IN (l_pobj) hyperactivity/NN
D019832_D006948 NONE methscopolamine/NN (r_nsubj) had/VBD (l_dobj) effect/NN (l_prep) on/IN (l_pobj) hyperactivity/NN
D009020_D006948 CID morphine/NN (r_npadvmod) induced/VBN (r_amod) increase/NN (l_prep) in/IN (l_pobj) activity/NN -PUNC- morphine/NN (r_npadvmod) induced/VBN (r_amod) increase/NN (l_prep) in/IN (l_pobj) activity/NN -PUNC- morphine/NN (r_compound) HC1/NNP (r_pobj) of/IN (r_prep) mg/kg/NN (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) produced/VBD (l_dobj) increase/NN (l_prep) in/IN (l_pobj) activity/NN -PUNC- morphine/NN (r_npadvmod) induced/VBN (r_amod) hyperactivity/NN -PUNC- morphine/NN (r_pobj) by/IN (r_agent) produced/VBN (r_acl) hyperactivity/NN
7858459
D002955_D013274 NONE acid/NN (l_prep) for/IN (l_pobj) adenocarcinoma/NN
D005472_D003221 CID 5-fluorouracil/CD (r_punct) of/IN (r_prep) infusion/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubj) confusion/NN -PUNC- 5-fluorouracil/CD (r_punct) of/IN (r_prep) dose/NN (r_nmod) infusion/NN (r_pobj) during/IN (r_prep) lasting/VBG (r_advcl) lapsed/VBD (r_conj) developed/VBD (l_dobj) symptoms/NNS (l_prep) of/IN (l_pobj) confusion/NN -PUNC- 5-fluorouracil/CD (r_punct) of/IN (r_prep) dose/NN (r_nmod) infusion/NN (r_pobj) during/IN (r_prep) lasting/VBG (r_advcl) lapsed/VBD (r_conj) developed/VBD (l_dobj) symptoms/NNS (l_prep) of/IN (l_pobj) confusion/NN (l_conj) disorientation/NN
D002945_D013274 NONE cisplatinum/NN (l_appos) hours/NNS (l_conj) acid/NN (l_prep) for/IN (l_pobj) adenocarcinoma/NN
C007744_D020258 NONE fluorocitrate/NN (r_conj) fluoroacetate/NN (r_pobj) by/IN (r_prep) blockade/NN (r_pobj) to/IN (r_prep) due/JJ (r_acomp) be/VB (l_nsubj) pathogenesis/NN (l_prep) of/IN (l_pobj) neurotoxicity/NN
D005472_D001523 NONE 5-fluorouracil/CD (r_punct) of/IN (r_prep) dose/NN (r_nmod) infusion/NN (r_pobj) during/IN (r_prep) lasting/VBG (r_advcl) lapsed/VBD (r_conj) developed/VBD (l_dobj) symptoms/NNS (l_prep) of/IN (l_pobj) confusion/NN (l_conj) disorientation/NN (l_conj) irritability/NN
D002955_D001523 NONE acid/NN (r_compound) infusion/NN (r_pobj) during/IN (r_prep) lasting/VBG (r_advcl) lapsed/VBD (r_conj) developed/VBD (l_dobj) symptoms/NNS (l_prep) of/IN (l_pobj) confusion/NN (l_conj) disorientation/NN (l_conj) irritability/NN
D005472_D020258 NONE 5-fluorouracil/CD (r_punct) suspected/VBN (l_nsubjpass) neurotoxicity/NN -PUNC- 5-fluorouracil/CD (r_punct) neurotoxicity/NN
D005463_D020258 NONE fluoroacetate/NN (r_pobj) by/IN (r_prep) blockade/NN (r_pobj) to/IN (r_prep) due/JJ (r_acomp) be/VB (l_nsubj) pathogenesis/NN (l_prep) of/IN (l_pobj) neurotoxicity/NN
D005472_D003128 CID 5-fluorouracil/CD (r_punct) of/IN (r_prep) dose/NN (r_nmod) infusion/NN (r_pobj) during/IN (r_prep) lasting/VBG (r_advcl) lapsed/VBD (l_prep) into/IN (l_pobj) coma/NN
D002955_D003128 CID acid/NN (r_compound) infusion/NN (r_pobj) during/IN (r_prep) lasting/VBG (r_advcl) lapsed/VBD (l_prep) into/IN (l_pobj) coma/NN
D005047_D013274 NONE etoposide/NN (r_conj) cisplatinum/NN (l_appos) hours/NNS (l_conj) acid/NN (l_prep) for/IN (l_pobj) adenocarcinoma/NN
D002955_D003221 CID acid/NN (r_conj) infusion/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubj) confusion/NN -PUNC- acid/NN (r_compound) infusion/NN (r_pobj) during/IN (r_prep) lasting/VBG (r_advcl) lapsed/VBD (r_conj) developed/VBD (l_dobj) symptoms/NNS (l_prep) of/IN (l_pobj) confusion/NN -PUNC- acid/NN (r_compound) infusion/NN (r_pobj) during/IN (r_prep) lasting/VBG (r_advcl) lapsed/VBD (r_conj) developed/VBD (l_dobj) symptoms/NNS (l_prep) of/IN (l_pobj) confusion/NN (l_conj) disorientation/NN
D005472_D009369 NONE 5-fluorouracil/CD (r_punct) folinic/JJ (r_amod) therapy/NN (r_nsubj) become/VBN (l_attr) regimen/NN (l_prep) for/IN (l_pobj) cancers/NNS
D002955_D020258 NONE acid/NN (r_nsubj) was/VBD (r_advcl) suspected/VBN (l_nsubjpass) neurotoxicity/NN
D013831_D020258 NONE thiamine/NN (r_compound) deficiency/NN (r_conj) blockade/NN (r_pobj) to/IN (r_prep) due/JJ (r_acomp) be/VB (l_nsubj) pathogenesis/NN (l_prep) of/IN (l_pobj) neurotoxicity/NN
D002955_D009369 NONE acid/NN (r_compound) infusion/NN (r_compound) therapy/NN (r_nsubj) become/VBN (l_attr) regimen/NN (l_prep) for/IN (l_pobj) cancers/NNS
D005472_D013274 NONE 5-fluorouracil/CD (r_punct) m2/24/NN (r_compound) hours/NNS (l_conj) acid/NN (l_prep) for/IN (l_pobj) adenocarcinoma/NN
C007419_D020258 NONE dihydrouracil/VBN (r_compound) dehydrogenase/NN (r_compound) deficiency/NN (r_conj) deficiency/NN (r_conj) blockade/NN (r_pobj) to/IN (r_prep) due/JJ (r_acomp) be/VB (l_nsubj) pathogenesis/NN (l_prep) of/IN (l_pobj) neurotoxicity/NN
20477932
D003042_D007859 CID Cocaine/NN (r_nsubj) causes/VBZ (l_dobj) memory/NN (l_conj) learning/VBG (l_dobj) impairments/NNS
D003042_D064420 NONE cocaine/NN (r_compound) toxicity/NN -PUNC- cocaine/NN (r_conj) brain/NN (r_nmod) behaviour/NN (r_pobj) in/IN (r_prep) status/NN (r_pobj) between/IN (r_prep) association/NN (r_conj) increase/NN (r_pobj) including/VBG (r_prep) toxicity/NN
C052342_D007859 NONE topiramate/NN (r_pobj) by/IN (r_prep) prevention/NN (r_conj) involvement/NN (r_appos) memory/NN (l_conj) learning/VBG (l_dobj) impairments/NNS
D003042_D008569 CID Cocaine/NN (r_nsubj) causes/VBZ (l_dobj) memory/NN (l_conj) learning/VBG (l_dobj) impairments/NNS
D009569_D019970 NONE oxide/NN (r_compound) synthase/NN (l_conj) therapy/NN (l_prep) for/IN (l_pobj) addiction/NN
C052342_D019970 NONE topiramate/NN (r_pobj) of/IN (r_prep) effect/NN (r_conj) learning/NN (r_conj) activity/NN (r_conj) synthase/NN (l_conj) therapy/NN (l_prep) for/IN (l_pobj) addiction/NN
C052342_D008569 NONE topiramate/NN (r_pobj) by/IN (r_prep) prevention/NN (r_conj) involvement/NN (r_appos) memory/NN (l_conj) learning/VBG (l_dobj) impairments/NNS
D003042_D019970 NONE cocaine/NN (r_compound) administration/NN (r_pobj) of/IN (r_prep) model/NN (r_pobj) in/IN (r_prep) evaluated/VBN (l_nsubjpass) activity/NN (l_appos) stress/NN (l_conj) synthase/NN (l_conj) therapy/NN (l_prep) for/IN (l_pobj) addiction/NN
12921865
D011280_D012640 NONE Allopregnanolone/NN (r_nsubjpass) tested/VBN (l_prep) for/IN (l_pobj) ability/NN (l_acl) suppress/VB (l_dobj) expression/NN (l_appos) effect/NN (l_conj) development/NN (l_prep) of/IN (l_pobj) seizures/NNS -PUNC- pregnan-20-one/NNP (r_advmod) 3alpha/CD (r_appos) Allopregnanolone/NN (r_nsubjpass) tested/VBN (l_prep) for/IN (l_pobj) ability/NN (l_acl) suppress/VB (l_dobj) expression/NN (l_appos) effect/NN (l_conj) development/NN (l_prep) of/IN (l_pobj) seizures/NNS -PUNC- pregnanolone/NN (r_appos) Allopregnanolone/NN (r_nsubjpass) tested/VBN (l_prep) for/IN (l_pobj) ability/NN (l_acl) suppress/VB (l_dobj) expression/NN (l_appos) effect/NN (l_conj) development/NN (l_prep) of/IN (l_pobj) seizures/NNS -PUNC- pregnan-20-one/NNP (r_parataxis) pregnanolone/NN (r_appos) Allopregnanolone/NN (r_nsubjpass) tested/VBN (l_prep) for/IN (l_pobj) ability/NN (l_acl) suppress/VB (l_dobj) expression/NN (l_appos) effect/NN (l_conj) development/NN (l_prep) of/IN (l_pobj) seizures/NNS -PUNC- allopregnanolone/NN (r_pobj) of/IN (r_prep) derivative/NN (r_appos) ganaxolone/NN (r_conj) pregnanolone/NN (r_appos) Allopregnanolone/NN (r_nsubjpass) tested/VBN (l_prep) for/IN (l_pobj) ability/NN (l_acl) suppress/VB (l_dobj) expression/NN (l_appos) effect/NN (l_conj) development/NN (l_prep) of/IN (l_pobj) seizures/NNS -PUNC- allopregnanolone/NN (r_nsubj) inhibited/VBD (r_advcl) suppressed/VBD (l_dobj) expression/NN (l_prep) of/IN (l_pobj) seizures/NNS
D013256_D009422 NONE steroids/NNS (r_nsubj) demonstrate/VBP (l_dobj) actions/NNS (l_relcl) have/VBP (l_dobj) relevance/NN (l_prep) for/IN (l_pobj) host/NN (l_prep) of/IN (l_pobj) disorders/NNS
D013256_D001523 NONE steroids/NNS (r_nsubj) demonstrate/VBP (l_dobj) actions/NNS (l_relcl) have/VBP (l_dobj) relevance/NN (l_prep) for/IN (l_pobj) host/NN (l_prep) of/IN (l_pobj) disorders/NNS
D005680_D012640 NONE acid/NN (l_appos) receptor/NN (l_prep) against/IN (l_pobj) increase/NN (l_prep) in/IN (l_pobj) sensitivity/NN (l_prep) to/IN (l_pobj) effects/NNS (l_prep) of/IN (l_pobj) cocaine/NN (l_acl) engendered/VBN (l_agent) by/IN (l_pobj) administration/NN (l_appos) kindling/NN (l_compound) seizure/NN -PUNC- GABA(A/NNP (r_appos) acid/NN (l_appos) receptor/NN (l_prep) against/IN (l_pobj) increase/NN (l_prep) in/IN (l_pobj) sensitivity/NN (l_prep) to/IN (l_pobj) effects/NNS (l_prep) of/IN (l_pobj) cocaine/NN (l_acl) engendered/VBN (l_agent) by/IN (l_pobj) administration/NN (l_appos) kindling/NN (l_compound) seizure/NN -PUNC- GABA(A/NN (r_nmod) modulators/NNS (r_pobj) of/IN (r_prep) All/DT (r_nsubj) suppressed/VBD (l_dobj) expression/NN (l_prep) of/IN (l_pobj) seizures/NNS
D013256_D012640 NONE steroids/NNS (l_prep) against/IN (l_pobj) seizures/NNS -PUNC- steroid/NN (l_relcl) modulate/VBP (l_dobj) acid/NN (l_appos) receptor/NN (l_prep) against/IN (l_pobj) increase/NN (l_prep) in/IN (l_pobj) sensitivity/NN (l_prep) to/IN (l_pobj) effects/NNS (l_prep) of/IN (l_pobj) cocaine/NN (l_acl) engendered/VBN (l_agent) by/IN (l_pobj) administration/NN (l_appos) kindling/NN (l_compound) seizure/NN
D003042_D012640 CID cocaine/NN (r_compound) seizures/NNS -PUNC- cocaine/NN (l_acl) engendered/VBN (l_agent) by/IN (l_pobj) administration/NN (l_appos) kindling/NN (l_compound) seizure/NN -PUNC- cocaine/NN (r_compound) administration/NN (l_appos) kindling/NN (l_compound) seizure/NN -PUNC- cocaine/NN (r_npadvmod) kindled/VBN (r_amod) seizures/NNS -PUNC- cocaine/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) by/IN (r_agent) induced/VBN (l_csubjpass) Kindled/VBN (l_dobj) seizures/NNS
C105051_D012640 NONE ganaxolone/NN (r_conj) pregnanolone/NN (r_appos) Allopregnanolone/NN (r_nsubjpass) tested/VBN (l_prep) for/IN (l_pobj) ability/NN (l_acl) suppress/VB (l_dobj) expression/NN (l_appos) effect/NN (l_conj) development/NN (l_prep) of/IN (l_pobj) seizures/NNS -PUNC- pregnan-20-one/NNP (r_appos) 3alpha/CD (r_appos) allopregnanolone/NN (r_pobj) of/IN (r_prep) derivative/NN (r_appos) ganaxolone/NN (r_conj) pregnanolone/NN (r_appos) Allopregnanolone/NN (r_nsubjpass) tested/VBN (l_prep) for/IN (l_pobj) ability/NN (l_acl) suppress/VB (l_dobj) expression/NN (l_appos) effect/NN (l_conj) development/NN (l_prep) of/IN (l_pobj) seizures/NNS -PUNC- ganaxolone/NN (r_conj) allopregnanolone/NN (r_nsubj) inhibited/VBD (r_advcl) suppressed/VBD (l_dobj) expression/NN (l_prep) of/IN (l_pobj) seizures/NNS
16740173
20667451
D002220_D003072 CID carbamazepine/NN (r_conj) phenobarbitone/NN (r_pobj) in/IN (r_prep) damage/NN (r_conj) dysfunction/NN -PUNC- carbamazepine/NN (r_conj) phenobarbitone/NN (r_conj) drugs/NNS (r_nsubj) are/VBP (l_acomp) known/JJ (l_xcomp) cause/VB (l_dobj) impairment/NN -PUNC- carbamazepine/NN (r_npadvmod) induced/VBN (r_conj) phenobarbitone-/JJ (r_nmod) impairment/NN -PUNC- carbamazepine/NN (r_conj) phenobarbitone/NN (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) caused/VBD (l_dobj) impairment/NN (l_prep) of/IN (l_pobj) learning/NN (l_conj) memory/NN -PUNC- carbamazepine/NN (r_conj) phenobarbitone/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) rats/NNS (r_pobj) in/IN (r_prep) damage/NN (r_conj) functions/NNS -PUNC- carbamazepine/NN (r_compound) therapy/NN (r_conj) phenobarbitone/NN (l_prep) in/IN (l_pcomp) preventing/VBG (l_dobj) impairment/NN
D010634_D003072 CID phenobarbitone/NN (r_pobj) in/IN (r_prep) damage/NN (r_conj) dysfunction/NN -PUNC- phenobarbitone/NN (r_conj) drugs/NNS (r_nsubj) are/VBP (l_acomp) known/JJ (l_xcomp) cause/VB (l_dobj) impairment/NN -PUNC- phenobarbitone-/JJ (r_nmod) impairment/NN -PUNC- phenobarbitone/NN (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) caused/VBD (l_dobj) impairment/NN (l_prep) of/IN (l_pobj) learning/NN (l_conj) memory/NN -PUNC- phenobarbitone/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) rats/NNS (r_pobj) in/IN (r_prep) damage/NN (r_conj) functions/NNS -PUNC- phenobarbitone/NN (l_prep) in/IN (l_pcomp) preventing/VBG (l_dobj) impairment/NN
D003474_D003072 NONE Curcumin/NN (r_nsubj) ameliorates/VBZ (l_dobj) dysfunction/NN -PUNC- curcumin/NN (r_compound) administration/NN (r_pobj) of/IN (r_prep) effect/NN (l_prep) on/IN (l_pobj) impairment/NN -PUNC- curcumin/NN (r_compound) administration/NN (r_nsubj) prevented/VBD (l_dobj) impairment/NN -PUNC- curcumin/NN (r_nsubj) has/VBZ (l_dobj) effect/NN (l_prep) in/IN (l_pcomp) mitigating/VBG (l_dobj) deterioration/NN (l_prep) of/IN (l_pobj) functions/NNS -PUNC- curcumin/NN (r_nsubjpass) considered/VBN (l_advcl) phenobarbitone/NN (l_prep) in/IN (l_pcomp) preventing/VBG (l_dobj) impairment/NN
10807237
D003042_D000783 NONE cocaine/NN (r_npadvmod) related/VBN (r_amod) aneurysms/NNS -PUNC- cocaine/NN (r_npadvmod) related/VBN (r_amod) aneurysms/NNS -PUNC- Cocaine/NN (r_compound) use/NN (r_nsubj) predisposed/VBN (l_prep) at/IN (l_conj) in/IN (l_pobj) aneurysms/NNS
D003042_D017542 CID Cocaine/NN (r_compound) use/NN (r_nsubj) predisposed/VBN (l_dobj) rupture/NN
12090760
D015215_D000740 CID azidothymidine/RB (r_advmod) induced/VBN (r_amod) anemia/NN -PUNC- Azidothymidine/NNP (r_nsubjpass) reversed/VBN (l_nsubjpass) anemia/NN -PUNC- AZT)-induced/VBN (r_compound) anemia/NN
11897407
D007545_D007238 NONE isoproterenol/NN (r_pobj) with/IN (r_prep) obtained/VBN (r_conj) implies/VBZ (l_nsubj) model/NN (l_acl) used/VBN (l_xcomp) produce/VB (l_dobj) infarction/NN -PUNC- isoproterenol/JJ (r_compound) administration/NN (r_pobj) after/IN (r_prep) h/NN (r_npadvmod) developed/VBD (l_dobj) infarct/NN
D007545_D009203 CID isoproterenol/NN (r_npadvmod) induced/VBN (r_amod) infarction/NN -PUNC- isoproterenol/NN (r_npadvmod) induced/VBN (r_amod) infarction/NN
D005937_D007238 NONE acid/NN (r_pobj) on/IN (r_prep) based/VBN (r_acl) radiopharmaceutical/NN (l_amod) avid/JJ (l_npadvmod) infarct/NN
C067171_D009203 NONE glucarate/NN (l_prep) for/IN (l_pobj) detection/NN (l_prep) of/IN (l_pobj) infarction/NN -PUNC- glucarate/NN (r_nsubj) was/VBD (l_conj) used/VBN (l_xcomp) study/VB (l_dobj) biodistribution/NN (l_prep) in/IN (l_pobj) rats/NNS (l_prep) with/IN (l_pobj) infarction/NN
12084448
D007069_D009207 CID ifosfamide/NN (r_pobj) of/IN (r_prep) infusion/NN (r_pobj) after/IN (r_prep) disabling/VBG (l_dobj) myoclonus/NN -PUNC- ifosfamide/JJ (r_pobj) of/IN (r_prep) infusion/NN (r_pobj) during/IN (r_prep) presence/NN (r_nsubj) suggest/VBP (l_ccomp) associated/VBN (l_nsubjpass) myoclonus/NN -PUNC- IFX/NNP (r_pobj) of/IN (r_prep) use/NN (r_pobj) with/IN (r_prep) associated/VBN (l_nsubjpass) myoclonus/NN
D007069_D010954 NONE ifosfamide/NN (r_pobj) of/IN (r_prep) infusion/NN (l_prep) for/IN (l_pobj) plasmacytoma/NN
D007069_D020820 NONE Ifosfamide/NNP (r_compound) encephalopathy/NN (l_acl) presenting/VBG (l_prep) with/IN (l_pobj) asterixis/NNS -PUNC- ifosfamide/NN (r_pobj) of/IN (r_prep) administration/NN (r_nsubjpass) discontinued/VBN (l_conj) resolved/VBD (l_nsubj) asterixis/NNS -PUNC- ifosfamide/JJ (r_pobj) of/IN (r_prep) infusion/NN (r_pobj) during/IN (r_prep) presence/NN (l_prep) of/IN (l_pobj) asterixis/NNS -PUNC- IFX/NNP (r_pobj) of/IN (r_prep) use/NN (r_pobj) with/IN (r_prep) associated/VBN (r_ccomp) suggest/VBP (l_nsubj) presence/NN (l_prep) of/IN (l_pobj) asterixis/NNS
D007069_D001927 CID Ifosfamide/NNP (r_compound) encephalopathy/NN
8752018
D014635_D001714 NONE sodium/NN (r_dobj) divalproex/NN (r_advcl) switching/VBG (l_dobj) patients/NNS (l_amod) bipolar/JJ -PUNC- sodium/NN (r_pobj) with/IN (r_prep) substitution/NN (r_nsubj) was/VBD (l_acomp) helpful/JJ (l_prep) in/IN (l_pcomp) reducing/VBG (l_dobj) cognitive/JJ (l_acl) attributed/VBN (l_prep) to/IN (l_pobj) lithium/NN (l_prep) in/IN (l_pobj) patients/NNS (l_amod) bipolar/JJ -PUNC- sodium/NN (r_nsubj) was/VBD (l_attr) alternative/NN (l_prep) to/IN (l_pobj) lithium/NN (l_prep) in/IN (l_pobj) patients/NNS (l_amod) bipolar/JJ
D008094_D003072 CID Lithium/NN (r_npadvmod) associated/VBN (r_amod) deficits/NNS -PUNC- lithium/NN (r_pobj) of/IN (r_prep) effects/NNS (r_pobj) of/IN (r_prep) management/NN (r_pobj) about/IN (r_prep) written/VBN (r_advcl) remain/VBP (l_nsubj) effects/NNS (l_prep) as/IN (l_pobj) deficits/NNS -PUNC- lithium/NN (r_pobj) of/IN (r_prep) effects/NNS (r_pobj) of/IN (r_prep) management/NN (r_pobj) about/IN (r_prep) written/VBN (r_advcl) remain/VBP (l_nsubj) effects/NNS (l_prep) as/IN (l_pobj) deficits/NNS (l_conj) loss/NN (l_prep) of/IN (l_pobj) creativity/NN -PUNC- lithium/NN (r_pobj) of/IN (r_prep) effects/NNS (r_pobj) of/IN (r_prep) management/NN (r_pobj) about/IN (r_prep) written/VBN (r_advcl) remain/VBP (l_nsubj) effects/NNS (l_prep) as/IN (l_pobj) deficits/NNS (l_conj) loss/NN (l_conj) impairments/NNS -PUNC- lithium/NN (r_compound) effects/NNS (l_prep) as/IN (l_pobj) deficits/NNS -PUNC- lithium/NN (r_compound) effects/NNS (l_prep) as/IN (l_pobj) deficits/NNS (l_conj) loss/NN (l_prep) of/IN (l_pobj) creativity/NN -PUNC- lithium/NN (r_compound) effects/NNS (l_prep) as/IN (l_pobj) deficits/NNS (l_conj) loss/NN (l_conj) impairments/NNS -PUNC- lithium/NN (r_pobj) from/IN (r_prep) switching/VBG (l_advcl) divalproex/NN (l_xcomp) alleviate/VB (l_dobj) impairments/NNS -PUNC- lithium/NN (r_pobj) of/IN (r_prep) substitution/NN (r_nsubj) was/VBD (l_acomp) helpful/JJ (l_prep) in/IN (l_pcomp) reducing/VBG (l_dobj) cognitive/JJ (l_conj) motivational/JJ (l_conj) deficits/NNS -PUNC- lithium/NN (r_pobj) to/IN (r_prep) attributed/VBN (r_acl) cognitive/JJ (l_conj) motivational/JJ (l_conj) deficits/NNS -PUNC- lithium/NN (l_prep) in/IN (l_pobj) patients/NNS (l_acl) experiencing/VBG (l_dobj) deficits/NNS -PUNC- lithium/NN (l_prep) in/IN (l_pobj) patients/NNS (l_acl) experiencing/VBG (l_dobj) deficits/NNS (l_conj) loss/NN (l_prep) of/IN (l_pobj) creativity/NN -PUNC- lithium/NN (l_prep) in/IN (l_pobj) patients/NNS (l_acl) experiencing/VBG (l_dobj) deficits/NNS (l_conj) loss/NN (l_prep) of/IN (l_pobj) creativity/NN (l_conj) impairments/NNS
D008094_D011141 NONE lithium/NN (r_pobj) of/IN (r_prep) effects/NNS (l_prep) as/IN (l_pobj) polyuria/NN -PUNC- lithium/NN (r_compound) effects/NNS (r_nsubj) remain/VBP (l_advcl) written/VBN (l_prep) about/IN (l_pobj) management/NN (l_prep) of/IN (l_pobj) effects/NNS (l_prep) as/IN (l_pobj) polyuria/NN
D008094_D001714 NONE Lithium/NN (r_nsubj) remains/VBZ (l_attr) treatment/NN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) disorder/NN -PUNC- lithium/NN (r_pobj) from/IN (r_prep) switching/VBG (l_dobj) patients/NNS (l_amod) bipolar/JJ -PUNC- lithium/NN (r_pobj) of/IN (r_prep) substitution/NN (r_nsubj) was/VBD (l_acomp) helpful/JJ (l_prep) in/IN (l_pcomp) reducing/VBG (l_dobj) cognitive/JJ (l_acl) attributed/VBN (l_prep) to/IN (l_pobj) lithium/NN (l_prep) in/IN (l_pobj) patients/NNS (l_amod) bipolar/JJ -PUNC- lithium/NN (l_prep) in/IN (l_pobj) patients/NNS (l_amod) bipolar/JJ -PUNC- lithium/NN (l_prep) in/IN (l_pobj) patients/NNS (l_amod) bipolar/JJ
D008094_D014202 NONE lithium/NN (r_pobj) of/IN (r_prep) effects/NNS (l_prep) as/IN (l_pobj) polyuria/NN (l_conj) tremor/NN -PUNC- lithium/NN (r_compound) effects/NNS (r_nsubj) remain/VBP (l_advcl) written/VBN (l_prep) about/IN (l_pobj) management/NN (l_prep) of/IN (l_pobj) effects/NNS (l_prep) as/IN (l_pobj) polyuria/NN (l_conj) tremor/NN
D014635_D003072 NONE sodium/NN (r_dobj) divalproex/NN (r_advcl) reduced/VBN (r_acl) deficits/NNS -PUNC- sodium/NN (r_dobj) divalproex/NN (l_xcomp) alleviate/VB (l_dobj) impairments/NNS -PUNC- sodium/NN (r_pobj) with/IN (r_prep) substitution/NN (r_nsubj) was/VBD (l_acomp) helpful/JJ (l_prep) in/IN (l_pcomp) reducing/VBG (l_dobj) cognitive/JJ (l_conj) motivational/JJ (l_conj) deficits/NNS -PUNC- sodium/NN (r_nsubj) was/VBD (l_attr) alternative/NN (l_prep) to/IN (l_pobj) lithium/NN (l_prep) in/IN (l_pobj) patients/NNS (l_acl) experiencing/VBG (l_dobj) deficits/NNS -PUNC- sodium/NN (r_nsubj) was/VBD (l_attr) alternative/NN (l_prep) to/IN (l_pobj) lithium/NN (l_prep) in/IN (l_pobj) patients/NNS (l_acl) experiencing/VBG (l_dobj) deficits/NNS (l_conj) loss/NN (l_prep) of/IN (l_pobj) creativity/NN -PUNC- sodium/NN (r_nsubj) was/VBD (l_attr) alternative/NN (l_prep) to/IN (l_pobj) lithium/NN (l_prep) in/IN (l_pobj) patients/NNS (l_acl) experiencing/VBG (l_dobj) deficits/NNS (l_conj) loss/NN (l_prep) of/IN (l_pobj) creativity/NN (l_conj) impairments/NNS
6888657
D004967_D010911 NONE estrogen/NN (r_npadvmod) induced/VBN (r_amod) tumors/NNS
D004054_D010911 CID diethylstilbestrol/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubjpass) tumors/NNS -PUNC- DES/NNP (r_npadvmod) implanted/VBN (r_parataxis) induced/VBN (l_nsubjpass) tumors/NNS
D004054_D009369 NONE DES/NNP (r_npadvmod) induced/VBN (r_amod) tumor/NN
7628595
D002955_D064420 NONE acid/NN (r_compound) supplementation/NN (l_prep) in/IN (l_pcomp) preventing/VBG (l_dobj) toxicity/NN
D014805_D001855 NONE B12/NN (l_conj) supplementation/NN (l_prep) in/IN (l_pcomp) preventing/VBG (l_dobj) suppression/NN -PUNC- B12/NN (l_conj) levels/NNS (l_conj) development/NN (l_prep) of/IN (l_pobj) myelosuppression/NN -PUNC- B12/NN (r_nsubj) seem/VB (l_oprd) useful/JJ (l_prep) in/IN (l_pcomp) preventing/VBG (l_conj) reducing/VBG (l_dobj) myelotoxicity/NN
D015215_D064420 NONE zidovudine/NN (r_pobj) of/IN (r_prep) toxicity/NN
D015215_D015658 NONE ZDV/NNP (r_dobj) receive/VB (r_xcomp) randomized/VBN (l_nsubjpass) virus/NN (l_appos) patients/NNS (l_amod) HIV)-infected/VBN
D014805_D064420 NONE B12/NN (l_conj) supplementation/NN (l_prep) in/IN (l_pcomp) preventing/VBG (l_dobj) toxicity/NN
D002955_D001855 NONE acid/NN (r_compound) supplementation/NN (l_prep) in/IN (l_pcomp) preventing/VBG (l_dobj) suppression/NN -PUNC- acid/NN (r_compound) supplementation/NN (r_conj) B12/NN (r_nsubj) seem/VB (l_oprd) useful/JJ (l_prep) in/IN (l_pcomp) preventing/VBG (l_conj) reducing/VBG (l_dobj) myelotoxicity/NN
D015215_D001855 CID zidovudine/NNP (r_nmod) suppression/NN -PUNC- ZDV)-induced/VBN (r_amod) suppression/NN -PUNC- ZDV/NNP (r_compound) therapy/NN (r_pobj) of/IN (r_prep) supplementation/NN (r_conj) B12/NN (r_nsubj) seem/VB (l_oprd) useful/JJ (l_prep) in/IN (l_pcomp) preventing/VBG (l_conj) reducing/VBG (l_dobj) myelotoxicity/NN -PUNC- ZDV/NNP (r_npadvmod) induced/VBN (r_amod) myelotoxicity/NN
D005492_D001855 NONE folate/JJ (r_compound) levels/NNS (l_conj) development/NN (l_prep) of/IN (l_pobj) myelosuppression/NN
18261172
D000806_D007674 NONE ACEi/NNP (r_nmod) therapy/NN (r_pobj) with/IN (r_prep) used/VBN (l_conj) increased/VBD (l_dobj) dysfunction/NN
D020123_D007674 NONE sirolmus/NN (r_nsubj) lacks/VBZ (l_dobj) effects/NNS (l_amod) nephrotoxic/JJ -PUNC- Srl/NNP (r_appos) sirolmus/NN (r_nsubj) lacks/VBZ (l_dobj) effects/NNS (l_amod) nephrotoxic/JJ -PUNC- Srl/NNP (r_pobj) with/IN (r_prep) associated/VBN (r_acl) proteinuria/NN (r_nsubjpass) reported/VBN (l_ccomp) lacks/VBZ (l_dobj) effects/NNS (l_amod) nephrotoxic/JJ -PUNC- Srl/NNP (r_nsubjpass) used/VBN (l_conj) increased/VBD (l_dobj) dysfunction/NN
D000806_D011507 NONE inhibitor/NN (r_nsubj) reduced/VBN (l_dobj) development/NN (l_compound) proteinuria/NN -PUNC- ACEi/NNP (r_nmod) therapy/NN (l_acl) monitored/VBD (l_prep) for/IN (l_pobj) proteinuria/NN
D057911_D011507 NONE blocker/NN (r_nmod) therapy/NN (r_conj) inhibitor/NN (r_nsubj) reduced/VBN (l_dobj) development/NN (l_compound) proteinuria/NN -PUNC- ARB/NNP (r_nmod) therapy/NN (r_conj) inhibitor/NN (r_nsubj) reduced/VBN (l_dobj) development/NN (l_compound) proteinuria/NN -PUNC- ARB/NNP (r_compound) therapy/NN (l_acl) monitored/VBD (l_prep) for/IN (l_pobj) proteinuria/NN
D057911_D007674 NONE ARB/NNP (r_compound) therapy/NN (r_pobj) with/IN (r_prep) used/VBN (l_conj) increased/VBD (l_dobj) dysfunction/NN
D020123_D011507 CID sirolimus/NN (r_npadvmod) based/VBN (r_amod) immunosuppression/NN (r_pobj) to/IN (r_prep) switch/NN (r_pobj) after/IN (r_prep) Development/NN (l_prep) of/IN (l_pobj) proteinuria/NN -PUNC- sirolmus/NN (r_nsubj) lacks/VBZ (r_ccomp) reported/VBN (l_nsubjpass) proteinuria/NN -PUNC- Srl/NNP (r_appos) sirolmus/NN (r_nsubj) lacks/VBZ (r_ccomp) reported/VBN (l_nsubjpass) proteinuria/NN -PUNC- Srl/NNP (r_pobj) with/IN (r_prep) associated/VBN (r_acl) proteinuria/NN -PUNC- Srl/NNP (r_pobj) with/IN (r_prep) associated/VBN (r_acl) incidence/NN (l_prep) of/IN (l_pobj) proteinuria/NN -PUNC- Srl/NNP (r_pobj) to/IN (r_prep) switch/NN (r_pobj) after/IN (r_prep) develop/VB (l_nsubj) proteinuria/NN -PUNC- Srl/NNP (r_nsubjpass) used/VBN (l_prep) with/IN (l_pobj) therapy/NN (l_acl) monitored/VBD (l_prep) for/IN (l_pobj) proteinuria/NN
9334596
D013739_D007172 NONE testosterone/NN (r_pobj) of/IN (r_prep) results/NNS (l_prep) in/IN (l_pobj) patients/NNS (l_acl) referred/VBD (l_prep) because/IN (l_pobj) dysfunction/NN -PUNC- testosterone/NN (r_compound) levels/NNS (r_pobj) of/IN (r_prep) Most/JJS (r_nsubj) seemed/VBD (l_xcomp) result/VB (l_prep) because/IN (l_conj) have/VB (l_dobj) role/NN (l_prep) in/IN (l_pobj) dysfunction/NN -PUNC- testosterone/NN (r_pobj) of/IN (r_prep) effects/NNS (l_prep) in/IN (l_pobj) dysfunction/NN
D013739_D006177 NONE testosterone/NN (r_pobj) for/IN (r_prep) screened/VBN (l_conj) screened/VBN (l_prep) on/IN (l_pobj) basis/NN (l_prep) of/IN (l_pobj) desire/NN (l_conj) gynecomastia/NN -PUNC- testosterone/NN (r_conj) gynecomastia/NN -PUNC- testosterone/NN (r_conj) gynecomastia/NN
D013739_D010911 NONE testosterone/NN (r_compound) determination/NN (r_pobj) after/IN (r_prep) discovered/VBN (l_nsubjpass) tumors/NNS
D013739_D007027 NONE testosterone/NN (r_compound) levels/NNS (r_pobj) of/IN (r_prep) Most/JJS (r_nsubj) seemed/VBD (l_xcomp) result/VB (l_prep) from/IN (l_pobj) dysfunction/NN
C004648_D007006 NONE heptylate/NN (l_conj) gonadotropin/NN (l_prep) for/IN (l_pobj) hypogonadism/NN
D001971_D007006 NONE bromocriptine/NN (r_conj) hypogonadism/NN
C004648_D006966 NONE heptylate/NN (l_conj) gonadotropin/NN (l_prep) for/IN (l_pobj) hypogonadism/NN (l_conj) bromocriptine/NN (l_prep) for/IN (l_pobj) hyperprolactinemia/NN
D013739_D020018 CID testosterone/NN (r_pobj) for/IN (r_prep) screened/VBN (l_conj) screened/VBN (l_prep) on/IN (l_pobj) basis/NN (l_prep) of/IN (l_pobj) desire/NN -PUNC- testosterone/NN (r_conj) gynecomastia/NN (r_conj) desire/NN -PUNC- testosterone/NN (r_dobj) Determining/VBG (l_prep) in/IN (l_pobj) cases/NNS (l_prep) of/IN (l_pobj) desire/NN -PUNC- testosterone/NN (r_pobj) with/IN (r_prep) cases/NNS (r_pobj) of/IN (r_prep) %/NN (r_dobj) missed/VBN (l_csubj) Determining/VBG (l_prep) in/IN (l_pobj) cases/NNS (l_prep) of/IN (l_pobj) desire/NN -PUNC- testosterone/NN (r_nsubjpass) determined/VBN (l_prep) in/IN (l_pobj) cases/NNS (l_prep) of/IN (l_pobj) desire/NN -PUNC- testosterone/NN (r_conj) gynecomastia/NN (r_conj) desire/NN
D001971_D006966 NONE bromocriptine/NN (l_prep) for/IN (l_pobj) hyperprolactinemia/NN
3341566
D009599_D007022 CID nitroprusside/RB (r_advmod) induced/VBN (r_amod) hypotension/NN -PUNC- SNP/NNP (r_compound) group/NN (r_pobj) in/IN (r_prep) that/DT (r_pobj) with/IN (r_prep) compared/VBN (r_prep) higher/RBR (r_acomp) was/VBD (l_prep) During/IN (l_pobj) hypotension/NN -PUNC- SNP/NNP (r_compound) groups/NNS (r_pobj) in/IN (r_prep) Hg/NNP (l_prep) during/IN (l_pobj) hypotension/NN
D009599_D006470 NONE nitroprusside/RB (r_advmod) induced/VBN (r_amod) hypotension/NN (r_pobj) during/IN (r_prep) than/IN (r_prep) is/VBZ (l_prep) during/IN (l_pobj) hemorrhage/NN -PUNC- nitroprusside/NN (r_advcl) decreased/VBN (l_prep) for/IN (l_pobj) minutes/NNS (l_prep) by/IN (l_pobj) hemorrhage/NN -PUNC- nitroprusside/NN (r_advcl) decreased/VBN (l_prep) for/IN (l_pobj) minutes/NNS (l_prep) by/IN (l_pobj) hemorrhage/NN (l_appos) HEM/NNP -PUNC- SNP/NNP (r_dep) n/CC (r_npadvmod) nitroprusside/NN (r_advcl) decreased/VBN (l_prep) for/IN (l_pobj) minutes/NNS (l_prep) by/IN (l_pobj) hemorrhage/NN -PUNC- SNP/NNP (r_dep) n/CC (r_npadvmod) nitroprusside/NN (r_advcl) decreased/VBN (l_prep) for/IN (l_pobj) minutes/NNS (l_prep) by/IN (l_pobj) hemorrhage/NN (l_appos) HEM/NNP -PUNC- SNP/NNP (r_compound) group/NN (r_pobj) in/IN (r_prep) that/DT (r_pobj) with/IN (r_prep) compared/VBN (r_prep) higher/RBR (r_acomp) was/VBD (l_prep) During/IN (l_pobj) hypotension/NN (l_amod) induced/VBN (l_npadvmod) HEM/NNP -PUNC- SNP/NNP (r_compound) group/NN (r_pobj) in/IN (r_prep) Hg/NNP (r_appos) mm/NN (r_pobj) with/IN (r_prep) compared/VBN (r_prep) Hg/NNP (l_prep) in/IN (l_pobj) group/NN (l_compound) HEM/NNP -PUNC- SNP/NNP (r_compound) groups/NNS (l_nmod) HEM/NNP
7449470
D004317_D066126 NONE doxorubicin/NN (r_compound) cardiotoxicity/NN -PUNC- adriamycin/NNS (r_pobj) of/IN (r_prep) use/NN (r_dobj) limits/VBZ (r_relcl) complication/NN (r_attr) is/VBZ (l_nsubj) toxicity/NN
19729346
D010098_D010146 NONE oxycodone/NN (r_pobj) of/IN (r_prep) dose/NN (r_pobj) of/IN (r_prep) effects/NNS (r_dobj) measured/VBD (l_dobj) adults/NNS (l_relcl) suffering/VBG (l_prep) from/IN (l_pobj) pain/NN
D010098_D059350 NONE oxycodone/NN (r_pobj) of/IN (r_prep) dose/NN (r_pobj) to/IN (r_prep) response/NN (r_pobj) in/IN (r_prep) changes/NNS (r_dobj) suffering/VBG (l_prep) from/IN (l_pobj) pain/NN
11928786
D016642_D020258 NONE Zyban/NNP (r_nsubj) caused/VBD (l_dobj) toxicity/NN
D000241_D012640 NONE adenosine/NN (r_pobj) with/IN (r_prep) treated/VBN (r_conj) treated/VBN (l_nsubjpass) seizures/NNS
D016642_D064420 NONE Bupropion/NNP (r_nmod) toxicity/NN -PUNC- Zyban/NNP (r_nmod) toxicity/NN
D000241_D013610 NONE adenosine/NN (r_pobj) with/IN (r_prep) treated/VBN (r_conj) treated/VBN (l_prep) with/IN (l_pobj) diazepam/NN (l_conj) tachycardia/NN
D016642_D002318 NONE Zyban/NNP (r_nsubj) caused/VBD (l_dobj) toxicity/NN
D003975_D012640 NONE diazepam/NN (r_pobj) with/IN (r_prep) treated/VBN (l_nsubjpass) seizures/NNS
D016642_D062787 NONE Zyban/NNP (r_nsubj) caused/VBD (l_dobj) toxicity/NN (l_prep) in/IN (l_pobj) overdose/NN
D003975_D013610 NONE diazepam/NN (l_conj) tachycardia/NN
3173180
D008795_D006463 CID metronidazole/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) after/IN (r_prep) syndrome/NN -PUNC- metronidazole/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) after/IN (r_prep) developed/VBD (l_dobj) syndrome/NN -PUNC- metronidazole/NN (r_pobj) of/IN (r_prep) involvement/NN (l_prep) in/IN (l_pobj) aetiology/NN (l_prep) of/IN (l_pobj) syndrome/NN -PUNC- metronidazole/NN (r_pobj) of/IN (r_prep) involvement/NN (r_nsubjpass) established/VBN (r_advcl) suggest/VBP (l_nsubj) action/NN (l_conj) evidence/NN (l_prep) of/IN (l_pobj) changes/NNS (l_prep) in/IN (l_pobj) syndrome/NN -PUNC- metronidazole/NN (r_pobj) of/IN (r_prep) involvement/NN (r_nsubjpass) established/VBN (r_advcl) suggest/VBP (l_dobj) link/NN (l_prep) between/IN (l_pobj) treatment/NN (l_conj) cases/NNS (l_prep) of/IN (l_pobj) syndrome/NN -PUNC- metronidazole/NN (r_amod) treatment/NN (r_pobj) between/IN (r_prep) link/NN (r_dobj) suggest/VBP (l_advcl) established/VBN (l_nsubjpass) involvement/NN (l_prep) in/IN (l_pobj) aetiology/NN (l_prep) of/IN (l_pobj) syndrome/NN -PUNC- metronidazole/NN (r_amod) treatment/NN (r_pobj) between/IN (r_prep) link/NN (r_dobj) suggest/VBP (l_nsubj) action/NN (l_conj) evidence/NN (l_prep) of/IN (l_pobj) changes/NNS (l_prep) in/IN (l_pobj) syndrome/NN -PUNC- metronidazole/NN (r_amod) treatment/NN (l_conj) cases/NNS (l_prep) of/IN (l_pobj) syndrome/NN
7352670
D006221_D007022 CID halothane/NN (r_compound) anesthesia/NN (l_conj) nitroprusside/NN (l_parataxis) evaluated/VBN (l_nsubjpass) hypotension/NN -PUNC- halothane/NN (r_pobj) of/IN (r_prep) effects/NNS (l_amod) hypotensive/JJ
D000809_D007022 NONE angiotensin/NN (r_compound) system/NN (l_prep) in/IN (l_pobj) maintenance/NN (l_prep) during/IN (l_pobj) anesthesia/NN (l_conj) nitroprusside/NN (l_parataxis) evaluated/VBN (l_nsubjpass) hypotension/NN -PUNC- angiotensin/NN (r_compound) system/NN (l_prep) in/IN (l_pcomp) antagonizing/VBG (l_dobj) effects/NNS (l_amod) hypotensive/JJ
D009599_D007022 CID nitroprusside/NN (l_parataxis) evaluated/VBN (l_nsubjpass) hypotension/NN -PUNC- SNP)-induced/VBN (r_amod) hypotension/NN -PUNC- SNP/NNP (r_conj) halothane/NN (r_pobj) of/IN (r_prep) effects/NNS (l_amod) hypotensive/JJ
D009599_D006973 NONE nitroprusside/NN (r_advmod) hypertensive/JJ -PUNC- SNP/NNP (r_compound) infusion/NN (r_pobj) During/IN (r_prep) demonstrated/VBD (l_dobj) increase/NN (l_prep) in/IN (l_pobj) pressure/NN
D012504_D006973 NONE saralasin/NN (r_pobj) by/IN (r_agent) prevented/VBN (r_acl) hypertensive/JJ -PUNC- saralasin/NN (r_npadvmod) treated/VBN (r_amod) animals/NNS (r_nsubj) showed/VBD (r_advcl) demonstrated/VBD (l_dobj) increase/NN (l_prep) in/IN (l_pobj) pressure/NN
2234245
D003676_D014786 NONE desferrioxamine/NN (r_dobj) receiving/VBG (r_acl) patients/NNS (r_pobj) in/IN (r_prep) toxicity/NN -PUNC- desferrioxamine/NN (r_dobj) receiving/VBG (r_acl) patients/NNS (r_pobj) During/IN (r_prep) monitored/VBN (l_prep) for/IN (l_pobj) detection/NN (l_prep) of/IN (l_pobj) toxicity/NN -PUNC- desferrioxamine/NN (r_dobj) receiving/VBG (r_acl) patients/NNS (r_pobj) in/IN (r_prep) complication/NN (r_attr) is/VBZ (l_nsubj) toxicity/NN
D003676_D006311 NONE desferrioxamine/NN (r_dobj) receiving/VBG (r_acl) patients/NNS (r_pobj) in/IN (r_prep) toxicity/NN -PUNC- desferrioxamine/NN (r_dobj) receiving/VBG (r_acl) patients/NNS (r_pobj) During/IN (r_prep) monitored/VBN (l_prep) for/IN (l_pobj) detection/NN (l_prep) of/IN (l_pobj) toxicity/NN -PUNC- desferrioxamine/NN (r_dobj) receiving/VBG (r_acl) patients/NNS (r_pobj) in/IN (r_prep) complication/NN (r_attr) is/VBZ (l_nsubj) toxicity/NN
D003676_D064420 NONE desferrioxamine/NN (r_pobj) of/IN (r_prep) doses/NNS (r_dobj) receiving/VBG (r_acl) patients/NNS (r_pobj) in/IN (r_prep) appeared/VBD (l_nsubj) toxicity/NN
-1_D064420 NONE aluminium/NN (r_conj) ferritin/NN (r_nmod) levels/NNS (r_pobj) of/IN (r_prep) normalization/NN (r_pobj) with/IN (r_prep) coincided/VBD (r_conj) appeared/VBD (l_nsubj) toxicity/NN
D003676_D034381 NONE Desferrioxamine/NNP (r_compound) withdrawal/NN (r_nsubj) resulted/VBD (l_conj) reversal/NN (l_prep) of/IN (l_pcomp) hearing/NN (l_dobj) loss/NN
2266990
D008454_D012817 CID mazindol/NN (r_pobj) to/IN (r_prep) attributable/JJ (r_amod) effects/NNS (r_nsubj) included/VBN (l_dobj) appetite/NN (l_appos) change/NN (l_conj) symptoms/NNS -PUNC- mazindol/NN (r_amod) dosage/NN (r_nsubjpass) reduced/VBN (l_ccomp) included/VBN (l_dobj) appetite/NN (l_appos) change/NN (l_conj) symptoms/NNS
D008454_D001068 CID mazindol/NN (r_pobj) to/IN (r_prep) attributable/JJ (r_amod) effects/NNS (r_nsubj) included/VBN (l_dobj) appetite/NN -PUNC- mazindol/NN (r_amod) dosage/NN (r_nsubjpass) reduced/VBN (l_ccomp) included/VBN (l_dobj) appetite/NN
D008454_D020388 NONE mazindol/NN (l_prep) in/IN (l_pobj) dystrophy/NN -PUNC- mazindol/NN (r_pobj) of/IN (r_prep) trial/NN (r_dobj) conducted/VBD (l_prep) in/IN (l_pobj) boys/NNS (l_prep) with/IN (l_pobj) dystrophy/NN -PUNC- Mazindol/JJ (r_compound) doses/NNS (r_nsubj) slow/VBP (l_dobj) progression/NN (l_prep) of/IN (l_pobj) weakness/NN (l_prep) in/IN (l_pobj) dystrophy/NN
D008454_D014987 CID mazindol/NN (r_pobj) to/IN (r_prep) attributable/JJ (r_amod) effects/NNS (r_nsubj) included/VBN (l_dobj) appetite/NN (l_appos) mouth/NN -PUNC- mazindol/NN (r_amod) dosage/NN (r_nsubjpass) reduced/VBN (l_ccomp) included/VBN (l_dobj) appetite/NN (l_appos) mouth/NN
D008454_D018908 NONE Mazindol/JJ (r_compound) doses/NNS (r_nsubj) slow/VBP (l_dobj) progression/NN (l_prep) of/IN (l_pobj) weakness/NN
14659530
D012701_D008881 NONE serotonin/NN (r_compound) release/NN (r_pobj) with/IN (r_prep) correlation/NN (r_conj) concentration/NN (r_appos) peptide/NN (r_pobj) in/IN (r_prep) increase/NN (r_appos) attack/NN (l_compound) migraine/JJ -PUNC- serotonin/NN (r_nmod) content/NN (r_pobj) in/IN (r_prep) changes/NNS (r_dobj) investigate/VB (l_conj) attack/NN (l_compound) migraine/JJ -PUNC- 5-hydroxytriptamine/NN (r_punct) ,/, (r_punct) 5-HT/CD (r_nmod) content/NN (r_pobj) in/IN (r_prep) changes/NNS (r_dobj) investigate/VB (l_conj) attack/NN (l_compound) migraine/JJ -PUNC- 5-HT/CD (r_nmod) content/NN (r_pobj) in/IN (r_prep) changes/NNS (r_dobj) investigate/VB (l_conj) attack/NN (l_compound) migraine/JJ -PUNC- 5-HT/CD (r_nummod) content/NN (r_nsubj) tended/VBD (l_xcomp) be/VB (l_prep) in/IN (l_pobj) subjects/NNS (l_relcl) experienced/VBD (l_dobj) attack/NN (l_compound) migraine/JJ -PUNC- serotonin/NN (r_compound) content/NN (r_nsubj) decreased/VBD (l_prep) after/IN (l_pobj) nitroglycerin/NN (l_prep) in/IN (l_pobj) subjects/NNS (l_prep) with/IN (l_pobj) attack/NN (l_compound) migraine/JJ -PUNC- serotonin/NN (r_compound) content/NN (r_nsubj) decreased/VBD (l_conj) observed/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) attack/NN (l_compound) migraine/JJ -PUNC- serotonin/NN (r_compound) release/NN (r_nsubj) provoke/VB (l_dobj) migraine/NN
D005996_D008881 NONE nitroglycerin/NN (r_pobj) by/IN (r_agent) provoked/VBN (r_acl) attack/NN (l_compound) migraine/JJ -PUNC- nitroglycerin/NN (r_compound) application/NN (r_pobj) after/IN (r_conj) before/RB (r_advmod) collected/VBN (l_conj) min/NN (l_prep) after/IN (l_pobj) beginning/NN (l_prep) of/IN (l_pobj) attack/NN (l_compound) migraine/JJ -PUNC- nitroglycerin/NN (l_prep) in/IN (l_pobj) subjects/NNS (l_prep) with/IN (l_pobj) attack/NN (l_compound) migraine/JJ -PUNC- nitroglycerin/NN (r_pobj) after/IN (r_prep) decreased/VBD (l_conj) observed/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) attack/NN (l_compound) migraine/JJ
D005996_D006261 NONE nitroglycerin/NN (r_pobj) by/IN (r_agent) provoked/VBN (r_acl) attack/NN (r_conj) investigate/VB (l_dobj) changes/NNS (l_prep) during/IN (l_pobj) headache/NN
D012701_D006261 NONE serotonin/NN (r_nmod) content/NN (r_pobj) in/IN (r_prep) changes/NNS (l_prep) during/IN (l_pobj) headache/NN -PUNC- 5-hydroxytriptamine/NN (r_punct) ,/, (r_punct) 5-HT/CD (r_nmod) content/NN (r_pobj) in/IN (r_prep) changes/NNS (l_prep) during/IN (l_pobj) headache/NN -PUNC- 5-HT/CD (r_nmod) content/NN (r_pobj) in/IN (r_prep) changes/NNS (l_prep) during/IN (l_pobj) headache/NN -PUNC- serotonin/NN (r_compound) release/NN (r_nsubj) provoke/VB (r_ccomp) counteract/VB (l_dobj) headache/NN
D015740_D008881 NONE peptide/NN (r_pobj) in/IN (r_prep) increase/NN (r_appos) attack/NN (l_compound) migraine/JJ -PUNC- CGRP/NN (r_nmod) concentration/NN (r_appos) peptide/NN (r_pobj) in/IN (r_prep) increase/NN (r_appos) attack/NN (l_compound) migraine/JJ -PUNC- peptide/NN (r_nmod) content/NN (r_pobj) in/IN (r_prep) changes/NNS (r_dobj) investigate/VB (l_conj) attack/NN (l_compound) migraine/JJ -PUNC- CGRP/NN (r_nmod) concentration/NN (r_nmod) content/NN (r_pobj) in/IN (r_prep) changes/NNS (r_dobj) investigate/VB (l_conj) attack/NN (l_compound) migraine/JJ -PUNC- CGRP/NN (r_compound) concentration/NN (r_nsubj) increased/VBD (l_prep) during/IN (l_pobj) attack/NN (l_compound) migraine/JJ -PUNC- CGRP/NN (r_compound) concentration/NN (r_nsubj) increased/VBD (l_conj) returned/VBD (l_prep) after/IN (l_pobj) cessation/NN (l_prep) of/IN (l_pobj) migraine/NN -PUNC- CGRP/NNP (r_compound) concentrations/NNS (r_nsubj) failed/VBD (l_xcomp) change/VB (l_prep) during/IN (l_conj) in/IN (l_pobj) subjects/NNS (l_prep) with/IN (l_pobj) attack/NN (l_compound) migraine/JJ -PUNC- CGRP/NNP (r_compound) concentration/NN (r_nsubj) was/VBD (l_conj) platelet/NN (l_ccomp) tended/VBD (l_xcomp) be/VB (l_prep) in/IN (l_pobj) subjects/NNS (l_relcl) experienced/VBD (l_dobj) attack/NN (l_compound) migraine/JJ -PUNC- CGRP/NN (r_compound) concentration/NN (r_nsubj) correlates/VBZ (l_prep) with/IN (l_pobj) timing/NN (l_prep) of/IN (l_pobj) headache/NN (l_compound) migraine/JJ -PUNC- CGRP/NN (r_compound) concentration/NN (r_nsubj) correlates/VBZ (r_acl) fact/NN (r_nsubj) suggests/VBZ (l_dobj) relationship/NN (l_prep) between/IN (l_pobj) CGRP/NN (l_conj) migraine/NN -PUNC- CGRP/NN (r_pobj) between/IN (r_prep) relationship/NN (r_dobj) suggests/VBZ (l_nsubj) fact/NN (l_acl) correlates/VBZ (l_prep) with/IN (l_pobj) timing/NN (l_prep) of/IN (l_pobj) headache/NN (l_compound) migraine/JJ -PUNC- CGRP/NN (l_conj) migraine/NN -PUNC- CGRP/NN (r_compound) release/NN (r_conj) headache/NN (r_dobj) counteract/VB (l_ccomp) provoke/VB (l_dobj) migraine/NN
D009569_D008881 NONE NO/RB (r_intj) induced/VBN (r_amod) attack/NN (l_compound) migraine/JJ
D015740_D006261 NONE peptide/NN (r_nmod) content/NN (r_pobj) in/IN (r_prep) changes/NNS (l_prep) during/IN (l_pobj) headache/NN -PUNC- CGRP/NN (r_nmod) concentration/NN (r_nmod) content/NN (r_pobj) in/IN (r_prep) changes/NNS (l_prep) during/IN (l_pobj) headache/NN -PUNC- CGRP/NNP (r_compound) concentrations/NNS (r_nsubj) failed/VBD (l_xcomp) change/VB (l_prep) during/IN (l_pobj) headache/NN -PUNC- CGRP/NN (r_compound) concentration/NN (r_nsubj) correlates/VBZ (l_prep) with/IN (l_pobj) timing/NN (l_prep) of/IN (l_pobj) headache/NN -PUNC- CGRP/NN (r_pobj) between/IN (r_prep) relationship/NN (r_dobj) suggests/VBZ (l_nsubj) fact/NN (l_acl) correlates/VBZ (l_prep) with/IN (l_pobj) timing/NN (l_prep) of/IN (l_pobj) headache/NN -PUNC- CGRP/NN (r_compound) release/NN (r_conj) headache/NN
9293063
D003613_D006222 CID danazol/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) with/IN (r_prep) association/NN (r_pobj) in/IN (r_prep) occurring/VBG (r_acl) hamartoma/NN -PUNC- danazol/NN (r_compound) treatment/NN (r_pobj) on/IN (r_prep) been/VBN (r_relcl) patient/NN (r_pobj) in/IN (r_prep) developed/VBD (r_relcl) hamartoma/NN
D003613_D001650 CID danazol/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) with/IN (r_prep) association/NN (r_pobj) in/IN (r_prep) occurring/VBG (r_acl) hamartoma/NN -PUNC- danazol/NN (r_compound) treatment/NN (r_pobj) on/IN (r_prep) been/VBN (r_relcl) patient/NN (r_pobj) in/IN (r_prep) developed/VBD (r_relcl) hamartoma/NN
12523465
C022189_D012640 NONE Zonisamide/NNP (r_nsubj) is/VBZ (l_attr) drug/NN (l_acl) used/VBN (l_xcomp) treat/VB (l_dobj) types/NNS (l_prep) of/IN (l_pobj) seizures/NNS
C022189_D006212 CID zonisamide/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) hallucinations/NNS -PUNC- zonisamide/NN (r_amod) treatment/NN (r_pobj) after/IN (r_prep) altered/VBD (r_conj) experienced/VBD (r_relcl) patients/NNS (r_dobj) describe/VBP (l_advcl) reported/VBN (l_nsubjpass) hallucinations/NNS -PUNC- zonisamide/NN (r_amod) treatment/NN (r_pobj) after/IN (r_prep) altered/VBD (r_conj) experienced/VBD (l_dobj) hallucinations/NNS
18023325
D004221_D010523 CID disulfiram/NN (r_compound) overdose/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) neuropathy/NN
D004221_D011115 NONE disulfiram/NN (r_compound) intoxication/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) polyneuropathy/NN
D004221_D010243 NONE disulfiram/NN (r_compound) intoxication/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) polyneuropathy/NN (r_dobj) superimposed/VBN (r_conj) was/VBD (l_attr) case/NN (l_prep) of/IN (l_pobj) palsy/JJ
D004221_D014826 CID disulfiram/NN (r_compound) intoxication/NN (r_pobj) after/IN (r_prep) palsy/JJ -PUNC- disulfiram/NN (r_compound) overdose/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) neuropathy/NN (r_nsubj) is/VBZ (l_conj) is/VBZ (l_attr) report/NN (l_acl) leading/VBG (l_prep) to/IN (l_pobj) palsy/JJ
D004221_D062787 NONE disulfiram/NN (r_compound) overdose/NN
16858720
D014859_D006470 NONE warfarin/JJ (r_compound) drug/NN (r_compound) interaction/NN (r_nsubj) contributed/VBN (l_prep) to/IN (l_pobj) haemorrhage/NN -PUNC- warfarin/JJ (r_compound) drug/NN (r_compound) interaction/NN (r_nsubj) contributed/VBN (l_conj) considered/VBN (l_nsubjpass) complication/NN (l_amod) bleeding/VBG -PUNC- warfarin/JJ (r_compound) patients/NNS (r_pobj) of/IN (r_prep) %/NN (r_pobj) in/IN (r_prep) contributed/VBN (l_prep) to/IN (l_pobj) haemorrhage/NN -PUNC- warfarin/JJ (r_compound) patients/NNS (r_pobj) of/IN (r_prep) %/NN (r_pobj) in/IN (r_prep) contributed/VBN (l_conj) considered/VBN (l_nsubjpass) complication/NN (l_amod) bleeding/VBG
D014859_D002543 CID warfarin/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) haemorrhage/NN -PUNC- warfarin/RB (r_npadvmod) induced/VBN (r_amod) haemorrhages/NNS -PUNC- warfarin/JJ (r_pobj) due/IN (r_prep) evaluate/VB (l_dobj) frequency/NN (l_prep) of/IN (l_pobj) haemorrhages/NNS -PUNC- warfarin/JJ (r_compound) drug/NN (r_compound) interactions/NNS (r_conj) warfarin/JJ (r_pobj) due/IN (r_prep) evaluate/VB (l_dobj) frequency/NN (l_prep) of/IN (l_pobj) haemorrhages/NNS -PUNC- warfarin/JJ (r_nmod) interactions/NNS (r_nsubj) caused/VBN (l_dobj) haemorrhage/NN -PUNC- warfarin/JJ (r_compound) drug/NN (r_conj) warfarin/JJ (r_nmod) interactions/NNS (r_nsubj) caused/VBN (l_dobj) haemorrhage/NN -PUNC- warfarin/JJ (r_compound) treatment/NN (r_pobj) to/IN (r_prep) related/VBN (r_amod) as/IN (r_prep) assessed/VBN (l_prep) Among/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) haemorrhage/NN -PUNC- Warfarin/NNP (r_npadvmod) induced/VBN (r_amod) haemorrhages/NNS -PUNC- warfarin/RB (r_npadvmod) related/VBN (r_amod) haemorrhages/NNS -PUNC- warfarin/NN (r_pobj) with/IN (r_prep) interact/VB (r_xcomp) known/VBN (r_acl) drugs/NNS (r_dobj) prescribing/VBG (r_advcl) taken/VBN (r_advcl) prevented/VBN (l_nsubjpass) proportion/NN (l_prep) of/IN (l_pobj) haemorrhages/NNS
6308277
D002110_D064420 NONE caffeine/NN (r_compound) toxicity/NN -PUNC- caffeine/NN (r_pobj) of/IN (r_prep) effects/NNS (r_dobj) augment/VB (r_xcomp) reported/VBN (r_advcl) focused/VBN (l_prep) on/IN (l_pobj) possibility/NN (l_acl) reduced/VBD (l_dobj) toxicity/NN -PUNC- caffeine/NN (r_pobj) of/IN (r_prep) toxicity/NN
D000082_D012640 NONE acetaminophen/NN (r_pobj) with/IN (r_prep) pretreatment/NN (r_nsubj) increased/VBD (l_dobj) interval/NN (l_prep) between/IN (l_pobj) administration/NN (l_conj) onset/NN (l_prep) of/IN (l_pobj) convulsions/NNS -PUNC- acetaminophen/NN (r_pobj) with/IN (r_prep) pretreatment/NN (r_nsubj) increased/VBD (l_conj) reduced/VBD (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) seizures/NNS -PUNC- acetaminophen/NN (r_pobj) with/IN (r_prep) pretreatment/NN (r_conj) onset/NN (l_prep) of/IN (l_pobj) convulsions/NNS -PUNC- acetaminophen/NN (r_pobj) with/IN (r_prep) pretreatment/NN (r_conj) onset/NN (r_conj) administration/NN (r_pobj) between/IN (r_prep) interval/NN (r_dobj) increased/VBD (l_conj) reduced/VBD (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) seizures/NNS -PUNC- acetaminophen/NN (r_pobj) by/IN (r_agent) reduced/VBN (l_nsubjpass) frequency/NN (l_prep) of/IN (l_pobj) seizures/NNS -PUNC- acetaminophen/FW (r_nsubj) modify/VB (l_dobj) seizures/NNS
D002110_D012640 CID caffeine/NN (r_pobj) of/IN (r_prep) administration/NN (l_conj) onset/NN (l_prep) of/IN (l_pobj) convulsions/NNS -PUNC- caffeine/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) between/IN (r_prep) interval/NN (r_dobj) increased/VBD (l_conj) reduced/VBD (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) seizures/NNS -PUNC- caffeine/NN (r_pobj) of/IN (r_prep) presence/NN (r_pobj) in/IN (r_prep) produced/VBN (r_acl) seizures/NNS (r_pobj) of/IN (r_prep) incidence/NN (r_dobj) reduced/VBD (r_conj) increased/VBD (l_dobj) interval/NN (l_prep) between/IN (l_pobj) administration/NN (l_conj) onset/NN (l_prep) of/IN (l_pobj) convulsions/NNS -PUNC- caffeine/NN (r_pobj) of/IN (r_prep) presence/NN (r_pobj) in/IN (r_prep) produced/VBN (r_acl) seizures/NNS -PUNC- caffeine/NN (r_pobj) after/IN (r_prep) frequency/NN (l_prep) of/IN (l_pobj) seizures/NNS -PUNC- caffeine/NN (r_pobj) of/IN (r_prep) absence/NN (r_pobj) In/IN (r_prep) modify/VB (l_dobj) seizures/NNS
D000082_D064420 NONE acetaminophen/NN (r_pobj) by/IN (r_prep) Reduction/NN (l_prep) in/IN (l_pobj) toxicity/NN -PUNC- acetaminophen/NN (r_pobj) of/IN (r_prep) presence/NN (r_nsubj) reduced/VBD (l_dobj) toxicity/NN
D010433_D012640 CID pentylenetetrezol/NN (r_pobj) of/IN (r_prep) dose/NN (r_dobj) alter/VB (r_conj) modify/VB (l_dobj) seizures/NNS
10526274
C056507_D064420 NONE GEM/NNP (r_nsubj) obtain/VB (l_prep) with/IN (l_pobj) toxicity/NN -PUNC- GEM/NNP (r_pobj) of/IN (r_prep) combination/NN (r_pobj) of/IN (r_prep) efficacy/NN (l_conj) toxicity/NN
D002945_D002289 NONE cisplatin/NN (r_dobj) receive/VB (r_relcl) years/NNS (r_npadvmod) age/NN (l_nsubj) Gemcitabine/NNP (l_conj) vinorelbine/NN (l_prep) in/IN (l_pobj) patients/NNS (l_compound) carcinoma/NN -PUNC- cisplatin/NN (r_dobj) receiving/VBG (r_pcomp) to/IN (r_prep) contraindication/NN (r_pobj) with/IN (r_prep) those/DT (r_conj) NSCLC/NNP -PUNC- cisplatin/NN (r_dobj) receiving/VBG (r_pcomp) to/IN (r_prep) contraindication/NN (r_dobj) had/VBD (r_conj) were/VBD (r_conj) /=/NFP (r_punct) included/VBN (l_nsubjpass) patients/NNS (l_prep) with/IN (l_pobj) NSCLC/NNP
D002945_D064420 NONE cisplatin/NN (r_dobj) receiving/VBG (r_pcomp) to/IN (r_prep) contraindication/NN (r_pobj) with/IN (r_prep) those/DT (r_conj) NSCLC/NNP (r_pobj) with/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) combination/NN (r_pobj) of/IN (r_prep) efficacy/NN (l_conj) toxicity/NN
C056507_D002289 NONE Gemcitabine/NNP (l_conj) vinorelbine/NN (l_prep) in/IN (l_pobj) patients/NNS (l_compound) carcinoma/NN -PUNC- GEM/NNP (r_pobj) of/IN (r_prep) combination/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) NSCLC/NNP
C030852_D002289 NONE vinorelbine/NN (l_prep) in/IN (l_pobj) patients/NNS (l_compound) carcinoma/NN -PUNC- VNB/NNP (r_conj) GEM/NNP (r_pobj) of/IN (r_prep) combination/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) NSCLC/NNP
C030852_D064420 NONE VNB/NNP (r_conj) GEM/NNP (r_pobj) of/IN (r_prep) combination/NN (r_pobj) of/IN (r_prep) efficacy/NN (l_conj) toxicity/NN
2375138
D008874_D006323 CID midazolam/RB (r_npadvmod) associated/VBN (r_amod) arrest/NN -PUNC- midazolam/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) case/NN (l_prep) of/IN (l_pobj) arrest/NN
D008874_D003643 NONE midazolam/RB (r_npadvmod) associated/VBN (r_amod) arrest/NN (l_conj) death/NN -PUNC- midazolam/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) case/NN (l_prep) of/IN (l_pobj) arrest/NN (l_conj) death/NN
17639754
D014859_D006470 CID warfarin/NN (r_pobj) between/IN (r_prep) interaction/NN (r_pobj) of/IN (r_prep) result/NN (r_attr) be/VB (r_xcomp) appear/VBP (r_relcl) complications/NNS (l_compound) bleeding/NN
D064704_D006470 CID levofloxacin/JJ (r_conj) warfarin/NN (r_pobj) between/IN (r_prep) interaction/NN (r_pobj) of/IN (r_prep) result/NN (r_attr) be/VB (r_xcomp) appear/VBP (r_relcl) complications/NNS (l_compound) bleeding/NN
9855119
D016559_D005355 NONE FK506/NNP (r_compound) nephropathy/NN (r_nsubj) consisted/VBD (r_ccomp) angiodegeneration/NN (l_appos) biopsies/NNS (l_conj) glomerulosclerosis/NN (l_conj) form/NN (l_prep) of/IN (l_pobj) fibrosis/NN
D016559_D005923 CID FK506/NNP (r_compound) nephropathy/NN (r_nsubj) consisted/VBD (r_ccomp) angiodegeneration/NN (l_appos) biopsies/NNS (l_conj) glomerulosclerosis/NN
D003404_D007674 NONE creatinine/NN (r_compound) levels/NNS (l_prep) of/IN (l_pobj) patients/NNS (l_prep) in/IN (l_pobj) group/NN (l_compound) nephropathy/NN -PUNC- creatinine/NN (r_compound) levels/NNS (r_nsubj) were/VBD (l_acomp) higher/JJR (l_prep) than/IN (l_pobj) those/DT (l_prep) in/IN (l_pobj) group/NN (l_compound) FK506-nephropathy/NNP
D016559_D005922 NONE FK506/NN (r_compound) nephropathy/NN (r_conj) findings/NNS (r_conj) nephropathy/NN -PUNC- FK506/NN (r_compound) nephropathy/NN (r_conj) nephropathy/NN (r_conj) findings/NNS (r_conj) nephropathy/NN
D016559_D007674 NONE FK506/NN (r_compound) nephropathy/NN -PUNC- FK506/NN (r_compound) nephropathy/NN (l_conj) nephropathy/NN -PUNC- FK506/NN (r_compound) nephropathy/NN (r_conj) nephropathy/NN -PUNC- FK506/NN (r_compound) nephropathy/NN -PUNC- FK506/NN (r_compound) nephropathy/NN -PUNC- FK506/NNP (r_compound) nephropathy/NN -PUNC- FK506/NN (r_compound) nephropathy/NN -PUNC- FK506/NN (r_compound) nephropathy/NN (r_compound) group/NN (r_pobj) in/IN (r_prep) patients/NNS (r_pobj) of/IN (r_prep) levels/NNS (r_nsubj) were/VBD (l_acomp) higher/JJR (l_prep) than/IN (l_pobj) those/DT (l_prep) in/IN (l_pobj) group/NN (l_compound) FK506-nephropathy/NNP -PUNC- FK506-nephropathy/NNP (r_compound) group/NN (r_pobj) in/IN (r_prep) those/DT (r_pobj) than/IN (r_prep) higher/JJR (r_acomp) were/VBD (l_nsubj) levels/NNS (l_prep) of/IN (l_pobj) patients/NNS (l_prep) in/IN (l_pobj) group/NN (l_compound) nephropathy/NN -PUNC- FK506-nephropathy/NNP -PUNC- FK506/NNP (r_compound) nephropathy/NN -PUNC- FK506/NNP (r_compound) nephropathy/NN (r_nsubj) consists/VBZ (r_ccomp) demonstrates/VBZ (l_conj) suggests/VBZ (l_ccomp) is/VBZ (l_nsubj) nephropathy/NN -PUNC- FK506/NN (r_compound) nephropathy/NN (r_nsubj) is/VBZ (r_ccomp) suggests/VBZ (r_conj) demonstrates/VBZ (l_ccomp) consists/VBZ (l_nsubj) nephropathy/NN -PUNC- FK506/NN (r_compound) nephropathy/NN
6387529
D003975_D008569 CID diazepam/NN (r_pobj) for/IN (r_prep) greater/JJR (r_acomp) was/VBD (r_conj) impaired/VBD (l_dobj) recall/NN
D011433_D008569 CID propranolol/NN (r_advcl) diazepam/NN (r_pobj) for/IN (r_prep) greater/JJR (r_acomp) was/VBD (r_conj) impaired/VBD (l_dobj) recall/NN
D003975_D000379 NONE diazepam/NN (r_pobj) of/IN (r_prep) effects/NNS (l_conj) propranolol/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disorder/NN (l_conj) agoraphobia/NNP -PUNC- diazepam/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) of/IN (r_prep) effects/NNS (r_nsubj) propranolol/NN (r_advcl) investigated/VBN (l_nsubjpass) dose/NN (l_prep) on/IN (l_pobj) performance/NN (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disorders/NNS (l_conj) agoraphobia/NNP
D011433_D016584 NONE propranolol/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disorder/NN -PUNC- propranolol/NN (r_advcl) investigated/VBN (l_nsubjpass) dose/NN (l_prep) on/IN (l_pobj) performance/NN (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disorders/NNS
D011433_D000379 NONE propranolol/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disorder/NN (l_conj) agoraphobia/NNP -PUNC- propranolol/NN (r_advcl) investigated/VBN (l_nsubjpass) dose/NN (l_prep) on/IN (l_pobj) performance/NN (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disorders/NNS (l_conj) agoraphobia/NNP
D003975_D016584 NONE diazepam/NN (r_pobj) of/IN (r_prep) effects/NNS (l_conj) propranolol/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disorder/NN -PUNC- diazepam/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) of/IN (r_prep) effects/NNS (r_nsubj) propranolol/NN (r_advcl) investigated/VBN (l_nsubjpass) dose/NN (l_prep) on/IN (l_pobj) performance/NN (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disorders/NNS
891050
D006493_D001002 NONE heparin/JJ (r_pobj) with/IN (r_prep) treated/VBN (l_conj) rose/VBD (l_conj) stopped/VBN (l_prep) after/IN (l_pobj) onset/NN (l_prep) of/IN (l_pobj) anuria/NN
D003276_D006463 CID contraceptives/NNS (r_dobj) taking/VBG (r_acl) woman/NN (r_pobj) in/IN (r_prep) syndrome/NN -PUNC- contraceptives/NNS (r_dobj) taking/VBG (r_acl) woman/NN (r_pobj) in/IN (r_prep) syndrome/NN (l_appos) HUS/NNP
D004176_D001002 NONE dipyridamole/NN (r_conj) heparin/JJ (r_pobj) with/IN (r_prep) treated/VBN (l_conj) rose/VBD (l_conj) stopped/VBN (l_prep) after/IN (l_pobj) onset/NN (l_prep) of/IN (l_pobj) anuria/NN
12483326
D016190_D064420 NONE carboplatin/NN (r_amod) toxicity/NN
D002945_D009916 NONE cisplatin/NN (r_pcomp) than/IN (r_prep) effects/NNS (r_dobj) have/VB (r_xcomp) said/VBN (l_ccomp) known/JJ (l_auxpass) are/VBP (l_nsubj) toxicity/NN
D016190_D009916 NONE carboplatin/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) after/IN (r_prep) toxicity/NN -PUNC- carboplatin/NN (r_nsubjpass) said/VBN (l_ccomp) known/JJ (l_auxpass) are/VBP (l_nsubj) toxicity/NN -PUNC- carboplatin/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) after/IN (r_prep) experienced/VBD (l_dobj) case/NN (l_prep) of/IN (l_pobj) toxicity/NN
D016190_D005909 NONE carboplatin/NN (r_pobj) of/IN (r_prep) injection/NN (l_prep) for/IN (l_pobj) glioblastomas/NNS -PUNC- carboplatin/NN (r_pobj) of/IN (r_prep) injection/NN (l_prep) for/IN (l_pobj) glioblastomas/NNS
D016190_D005128 NONE carboplatin/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) after/IN (r_prep) toxicity/NN -PUNC- carboplatin/NN (r_nsubjpass) said/VBN (l_ccomp) known/JJ (l_auxpass) are/VBP (l_nsubj) toxicity/NN -PUNC- carboplatin/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) after/IN (r_prep) experienced/VBD (l_dobj) case/NN (l_prep) of/IN (l_pobj) toxicity/NN -PUNC- carboplatin/NN (r_pobj) of/IN (r_prep) injection/NN (r_dobj) performing/VBG (r_advcl) be/VB (l_acomp) aware/JJ (l_prep) of/IN (l_pobj) toxicity/NN
D002945_D005128 NONE cisplatin/NN (r_pcomp) than/IN (r_prep) effects/NNS (r_dobj) have/VB (r_xcomp) said/VBN (l_ccomp) known/JJ (l_auxpass) are/VBP (l_nsubj) toxicity/NN
9351491
D006220_D010302 CID haloperidol/NN (r_conj) risperidone/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) subjects/NNS (r_pobj) in/IN (r_prep) observed/VBN (l_nsubjpass) parkinsonism/NN
D018967_D010302 CID risperidone/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) subjects/NNS (r_pobj) in/IN (r_prep) observed/VBN (l_nsubjpass) parkinsonism/NN
D018967_D011618 NONE risperidone/NN (r_poss) profile/NN (r_nsubj) produce/VB (l_dobj) efficacy/NN (l_prep) for/IN (l_pobj) symptoms/NNS
8829025
D009543_D006973 NONE nifedipine/NN (r_dobj) receiving/VBG (r_relcl) patients/NNS (l_amod) hypertensive/JJ -PUNC- nifedipine/NN (r_dobj) receiving/VBG (r_acl) patients/NNS (r_dobj) comprising/VBG (r_acl) other/JJ (r_conj) group/NN (l_acl) comprising/VBG (l_dobj) patients/NNS (l_amod) hypertensive/JJ -PUNC- nifedipine/NN (r_pobj) of/IN (r_prep) impact/NN (r_nsubj) be/VB (l_attr) factor/NN (l_prep) in/IN (l_pcomp) selecting/VBG (l_xcomp) treat/VB (l_dobj) hypertension/NN
D009543_D007674 NONE nifedipine/NN (r_pobj) of/IN (r_prep) impact/NN (l_prep) on/IN (l_pcomp) reducing/VBG (l_dobj) nephrotoxicity/NN
D016559_D006973 CID tacrolimus/NNS (r_dobj) receiving/VBG (r_acl) patients/NNS (r_pobj) of/IN (r_prep) groups/NNS (r_nsubjpass) compared/VBN (l_appos) group/NN (l_acl) comprising/VBG (l_dobj) patients/NNS (l_amod) hypertensive/JJ -PUNC- tacrolimus/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) nephrotoxicity/NN (r_dobj) reducing/VBG (r_pcomp) on/IN (r_prep) impact/NN (r_nsubj) be/VB (l_attr) factor/NN (l_prep) in/IN (l_pcomp) selecting/VBG (l_xcomp) treat/VB (l_dobj) hypertension/NN
D016559_D007674 NONE tacrolimus/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) nephrotoxicity/NN
17612891
D003024_D012559 NONE clozapine/NN (r_pobj) of/IN (r_prep) commencement/NN (r_pobj) after/IN (r_prep) developed/VBD (l_nsubj) male/NN (l_prep) with/IN (l_pobj) schizophrenia/NN
D003024_D009205 CID clozapine/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) myocarditis/NN -PUNC- clozapine/NN (r_pobj) of/IN (r_prep) commencement/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) case/NN (l_prep) of/IN (l_pobj) myocarditis/NN -PUNC- clozapine/NN (r_pobj) of/IN (r_prep) commencement/NN (r_pobj) after/IN (r_prep) developed/VBD (l_dobj) onset/NN (l_prep) of/IN (l_pobj) myocarditis/NN -PUNC- clozapine/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) complication/NN (r_attr) is/VBZ (l_nsubj) Myocarditis/NNP
D003024_D011618 NONE clozapine/NN (r_pobj) Considering/VBG (r_csubj) remains/VBZ (l_attr) standard/NN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) psychosis/NN
1420741
D005672_D015212 NONE acid/NN (r_pobj) of/IN (r_prep) use/NN (l_prep) at/IN (l_pobj) level/NN (l_prep) in/IN (l_pobj) disease/NN
D016572_D003424 NONE cyclosporin/NN (r_pobj) to/IN (r_prep) similar/JJ (r_amod) properties/NNS (r_pobj) with/IN (r_prep) antibiotic/NN (r_appos) Treatment/NN (l_prep) of/IN (l_pobj) disease/NN
D005672_D003424 NONE acid/NN (r_pobj) with/IN (r_prep) disease/NN -PUNC- acid/NN (r_compound) treatment/NN (r_pobj) of/IN (r_prep) tolerability/NN (r_conj) pharmacodynamics/NNS (r_dobj) estimate/VB (r_advcl) undertaken/VBN (l_prep) Because/IN (l_pobj) need/NN (l_prep) for/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) treatments/NNS (l_prep) for/IN (l_pobj) disease/NN -PUNC- acid/NN (r_nsubj) be/VB (l_prep) in/IN (l_pobj) patients/NNS (l_compound) disease/NN
234669
D000628_D007040 NONE aminophylline/NN (r_pobj) of/IN (r_prep) infusion/NN (r_nsubj) resulted/VBD (l_advcl) produced/VBN (l_agent) by/IN (l_pobj) hypoventilation/NN
D002245_D014693 NONE dioxide/NN (r_conj) PO2/NNP (r_appos) oxygen/NN (r_pobj) of/IN (r_prep) pressures/NNS (r_nsubjpass) kept/VBN (r_advcl) reduced/VBN (l_nsubjpass) threshold/NN (l_compound) fibrillation/NN -PUNC- CO2/NNP (r_appos) dioxide/NN (r_conj) PO2/NNP (r_appos) oxygen/NN (r_pobj) of/IN (r_prep) pressures/NNS (r_nsubjpass) kept/VBN (r_advcl) reduced/VBN (l_nsubjpass) threshold/NN (l_compound) fibrillation/NN
D000628_D014693 CID aminophylline/NN (r_pobj) of/IN (r_prep) Effects/NNS (l_prep) for/IN (l_pcomp) initiating/VBG (l_dobj) fibrillation/NN -PUNC- aminophylline/NN (l_prep) on/IN (l_pobj) threshold/NN (l_compound) fibrillation/NN -PUNC- aminophylline/NN (r_pobj) of/IN (r_prep) infusion/NN (r_pobj) During/IN (r_prep) reduced/VBN (l_nsubjpass) threshold/NN (l_compound) fibrillation/NN -PUNC- aminophylline/NN (r_pobj) of/IN (r_prep) infusion/NN (r_nsubj) resulted/VBD (l_prep) in/IN (l_pobj) decrease/NN (l_prep) in/IN (l_pobj) threshold/NN (l_compound) fibrillation/NN
C093415_D014693 NONE PO2/NNP (r_appos) oxygen/NN (r_pobj) of/IN (r_prep) pressures/NNS (r_nsubjpass) kept/VBN (r_advcl) reduced/VBN (l_nsubjpass) threshold/NN (l_compound) fibrillation/NN
D010100_D014693 NONE oxygen/NN (r_pobj) of/IN (r_prep) pressures/NNS (r_nsubjpass) kept/VBN (r_advcl) reduced/VBN (l_nsubjpass) threshold/NN (l_compound) fibrillation/NN
D000628_D001145 NONE aminophylline/NN (r_appos) agents/NNS (r_nsubj) play/VB (l_advcl) contribute/VB (l_prep) to/IN (l_pobj) incidence/NN (l_prep) of/IN (l_pobj) arrhythmias/NNS
D000628_D012131 NONE aminophylline/NN (r_pobj) of/IN (r_prep) Effects/NNS (l_prep) for/IN (l_pcomp) initiating/VBG (l_prep) during/IN (l_pobj) failure/NN -PUNC- aminophylline/NN (r_pobj) of/IN (r_prep) effects/NNS (l_conj) during/IN (l_pobj) failure/NN -PUNC- aminophylline/NN (r_pobj) of/IN (r_prep) infusion/NN (r_nsubj) resulted/VBD (l_advcl) produced/VBN (l_nsubjpass) failure/NN -PUNC- aminophylline/NN (r_appos) agents/NNS (r_nsubj) play/VB (l_advcl) contribute/VB (l_prep) to/IN (l_pobj) incidence/NN (l_prep) of/IN (l_pobj) arrhythmias/NNS (l_prep) in/IN (l_pobj) failure/NN
12684739
D020888_D005128 CID GVG/NNP (r_pobj) of/IN (r_prep) effects/NNS (r_dobj) explored/VBD (l_prep) Given/VBN (l_pobj) success/NN (l_prep) for/IN (l_pcomp) treating/VBG (l_dobj) abuse/NN (l_conj) risk/NN (l_prep) of/IN (l_pobj) defects/NNS -PUNC- GVG/NNP (r_pobj) of/IN (r_prep) effects/NNS (r_dobj) explored/VBD (l_prep) Given/VBN (l_pobj) success/NN (l_prep) for/IN (l_pcomp) treating/VBG (l_dobj) abuse/NN (l_conj) risk/NN (l_prep) of/IN (l_pobj) defects/NNS (l_appos) VFD/NNP
D020888_D019966 NONE GVG/NNP (r_pobj) of/IN (r_prep) effects/NNS (r_dobj) explored/VBD (l_prep) Given/VBN (l_pobj) success/NN (l_prep) for/IN (l_pcomp) treating/VBG (l_dobj) abuse/NN
D003042_D019966 NONE cocaine/NN (r_npadvmod) induced/VBN (r_amod) increases/NNS (r_pobj) on/IN (r_prep) GVG/NNP (r_pobj) of/IN (r_prep) effects/NNS (r_dobj) explored/VBD (l_prep) Given/VBN (l_pobj) success/NN (l_prep) for/IN (l_pcomp) treating/VBG (l_dobj) abuse/NN
D004298_D019966 NONE dopamine/NN (r_appos) accumbens/NNS (r_oprd) explored/VBD (l_prep) Given/VBN (l_pobj) success/NN (l_prep) for/IN (l_pcomp) treating/VBG (l_dobj) abuse/NN -PUNC- DA/NNP (r_appos) dopamine/NN (r_appos) accumbens/NNS (r_oprd) explored/VBD (l_prep) Given/VBN (l_pobj) success/NN (l_prep) for/IN (l_pcomp) treating/VBG (l_dobj) abuse/NN
D003042_D005128 NONE cocaine/NN (r_npadvmod) induced/VBN (r_amod) increases/NNS (r_pobj) on/IN (r_prep) GVG/NNP (r_pobj) of/IN (r_prep) effects/NNS (r_dobj) explored/VBD (l_prep) Given/VBN (l_pobj) success/NN (l_prep) for/IN (l_pcomp) treating/VBG (l_dobj) abuse/NN (l_conj) risk/NN (l_prep) of/IN (l_pobj) defects/NNS -PUNC- cocaine/NN (r_npadvmod) induced/VBN (r_amod) increases/NNS (r_pobj) on/IN (r_prep) GVG/NNP (r_pobj) of/IN (r_prep) effects/NNS (r_dobj) explored/VBD (l_prep) Given/VBN (l_pobj) success/NN (l_prep) for/IN (l_pcomp) treating/VBG (l_dobj) abuse/NN (l_conj) risk/NN (l_prep) of/IN (l_pobj) defects/NNS (l_appos) VFD/NNP
D004298_D005128 NONE dopamine/NN (r_appos) accumbens/NNS (r_oprd) explored/VBD (l_prep) Given/VBN (l_pobj) success/NN (l_prep) for/IN (l_pcomp) treating/VBG (l_dobj) abuse/NN (l_conj) risk/NN (l_prep) of/IN (l_pobj) defects/NNS -PUNC- dopamine/NN (r_appos) accumbens/NNS (r_oprd) explored/VBD (l_prep) Given/VBN (l_pobj) success/NN (l_prep) for/IN (l_pcomp) treating/VBG (l_dobj) abuse/NN (l_conj) risk/NN (l_prep) of/IN (l_pobj) defects/NNS (l_appos) VFD/NNP -PUNC- DA/NNP (r_appos) dopamine/NN (r_appos) accumbens/NNS (r_oprd) explored/VBD (l_prep) Given/VBN (l_pobj) success/NN (l_prep) for/IN (l_pcomp) treating/VBG (l_dobj) abuse/NN (l_conj) risk/NN (l_prep) of/IN (l_pobj) defects/NNS -PUNC- DA/NNP (r_appos) dopamine/NN (r_appos) accumbens/NNS (r_oprd) explored/VBD (l_prep) Given/VBN (l_pobj) success/NN (l_prep) for/IN (l_pcomp) treating/VBG (l_dobj) abuse/NN (l_conj) risk/NN (l_prep) of/IN (l_pobj) defects/NNS (l_appos) VFD/NNP
3409645
D008727_D007172 CID methotrexate/NNP (r_pobj) of/IN (r_prep) taking/NN (r_conj) was/VBD (l_nsubj) Impotence/NN
19211690
D013739_D007674 NONE testosterone/NN (r_pobj) by/IN (r_agent) mediated/VBN (r_acl) angiotensinogen/NN (r_pobj) of/IN (r_prep) upregulation/NN (r_pobj) in/IN (r_prep) dimorphism/NN (l_relcl) causes/VBZ (l_dobj) increases/NNS (l_prep) in/IN (l_pobj) BP/NNP (l_conj) injury/NN -PUNC- Testosterone/NN (r_compound) replacement/NN (r_nsubj) increased/VBD (l_npadvmod) BP/NNP (l_appos) injury/NN -PUNC- Testosterone/NN (r_nsubj) contributes/VBZ (l_prep) to/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) hypertension/NN (l_conj) injury/NN
D017673_D006973 NONE salt/NN (r_npadvmod) sensitive/JJ (r_amod) rats/NNS (r_pobj) in/IN (r_prep) upregulation/NN (r_conj) hypertension/NN
D000809_D006973 NONE angiotensin/NN (r_compound) system/NN (r_pobj) of/IN (r_prep) upregulation/NN (r_pobj) through/IN (r_prep) contributes/VBZ (l_prep) to/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) hypertension/NN
D000809_D007674 NONE angiotensin/NN (r_compound) system/NN (r_pobj) of/IN (r_prep) upregulation/NN (r_pobj) through/IN (r_prep) contributes/VBZ (l_prep) to/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) hypertension/NN (l_conj) injury/NN
D013739_D006973 NONE Testosterone/NN (r_npadvmod) dependent/JJ (r_amod) hypertension/NN -PUNC- Testosterone/NN (r_nsubj) contributes/VBZ (l_prep) to/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) hypertension/NN
17879945
D019438_D050197 CID ritonavir/VBZ (r_compound) treatment/NN (r_nsubj) increases/VBZ (l_dobj) formation/NN (l_compound) lesion/NN
10739826
D003276_D054556 CID contraceptives/NNS (l_conj) risk/NN (l_prep) of/IN (l_pobj) thromboembolism/NN -PUNC- contraceptives/NNS (r_pobj) with/IN (r_prep) associated/VBN (r_acl) thromboembolism/NN -PUNC- contraceptives/NNS (r_pobj) with/IN (r_prep) associated/VBN (r_acl) thromboembolism/NN (l_appos) VTE/NNP -PUNC- OC/NNP (r_appos) contraceptives/NNS (r_pobj) with/IN (r_prep) associated/VBN (r_acl) thromboembolism/NN -PUNC- OC/NNP (r_appos) contraceptives/NNS (r_pobj) with/IN (r_prep) associated/VBN (r_acl) thromboembolism/NN (l_appos) VTE/NNP -PUNC- OC/NNP (r_compound) use/NN (r_pobj) of/IN (r_prep) patterns/NNS (r_pobj) between/IN (r_prep) distinguish/VB (l_nsubj) studies/NNS (l_relcl) assessed/VBD (l_dobj) risk/NN (l_prep) of/IN (l_pobj) thromboembolism/NN -PUNC- OC/NNP (r_compound) use/NN (r_pobj) of/IN (r_prep) patterns/NNS (r_pobj) between/IN (r_prep) distinguish/VB (l_nsubj) studies/NNS (l_relcl) assessed/VBD (l_dobj) risk/NN (l_prep) of/IN (l_pobj) thromboembolism/NN (l_appos) VTE/NNP -PUNC- OC/NNP (r_pobj) of/IN (r_prep) users/NNS (r_pobj) for/IN (r_prep) ratio/NN (l_prep) of/IN (l_pobj) VTE/NN
17175308
D020123_D007674 NONE SRL/NNP (r_pobj) with/IN (r_prep) treated/VBN (l_prep) due/IN (l_pobj) nephropathy/NN (l_advmod) CAN/VB
D020123_D051436 NONE SRL/NNP (r_pobj) with/IN (r_prep) treated/VBN (l_prep) due/IN (l_pobj) nephropathy/NN
D020123_D011507 CID sirolimus/VB (r_pobj) to/TO (r_prep) conversion/NN (r_pobj) after/IN (r_prep) Proteinuria/NNP -PUNC- sirolimus/NN (r_compound) therapy/NN (r_pobj) of/IN (r_prep) consequence/NN (r_pobj) as/IN (r_prep) reported/VBN (l_nsubjpass) proteinuria/NN -PUNC- SRL/NN (r_compound) conversion/NN (r_pobj) after/IN (r_prep) displayed/VBD (l_dobj) proteinuria/NN -PUNC- SRL/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) after/IN (r_prep) was/VBD (l_nsubj) proteinuria/NN
3856631
D008727_D008577 NONE methotrexate/NNP (r_pobj) with/IN (r_prep) leukemia/NN
D008727_D054198 NONE methotrexate/NNP (r_compound) regimen/NN (r_pobj) with/IN (r_prep) treated/VBN (l_nsubjpass) children/NNS (l_prep) with/IN (l_pobj) leukemia/NN -PUNC- methotrexate/NNP (r_compound) concentrations/NNS (r_dobj) maintain/VB (r_conj) achieve/VB (r_xcomp) designed/VBN (r_relcl) regimen/NN (r_pobj) with/IN (r_prep) treated/VBN (l_nsubjpass) children/NNS (l_prep) with/IN (l_pobj) leukemia/NN -PUNC- methotrexate/NN (r_nsubj) is/VBZ (l_attr) treatment/NN (l_prep) for/IN (l_pobj) induction/NN (l_prep) after/IN (l_pobj) relapse/NN (l_prep) in/IN (l_pobj) leukemia/NN
D001663_D064420 NONE bilirubin/NN (r_amod) elevations/NNS (r_conj) transaminase/NN (r_attr) were/VBD (l_nsubj) toxicities/NNS
D001663_D052016 NONE bilirubin/NN (r_amod) elevations/NNS (r_conj) transaminase/NN (l_appos) neutropenia/NN (l_conj) mucositis/NN
D008727_D002493 NONE methotrexate/NNP (r_compound) regimen/NN (r_pobj) with/IN (r_prep) treated/VBN (l_nsubjpass) children/NNS (l_relcl) developed/VBD (l_dobj) disease/NN -PUNC- methotrexate/NNP (r_compound) concentrations/NNS (r_dobj) maintain/VB (r_conj) achieve/VB (r_xcomp) designed/VBN (r_relcl) regimen/NN (r_pobj) with/IN (r_prep) treated/VBN (l_nsubjpass) children/NNS (l_relcl) developed/VBD (l_dobj) disease/NN
D001663_D009503 NONE bilirubin/NN (r_amod) elevations/NNS (r_conj) transaminase/NN (l_appos) neutropenia/NN
7423039
D004317_D066126 CID adriamycin/JJ (r_amod) cardiotoxicity/NN -PUNC- adriamycin/NNS (r_pobj) of/IN (r_prep) effects/NNS (l_amod) cardiotoxic/JJ
3750012
D010396_D009157 CID penicillamine/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) gravis/NN -PUNC- penicillamine/NN (r_pobj) after/IN (r_prep) had/VBD (l_dobj) gravis/NN
D010396_D001172 NONE penicillamine/NN (l_conj) therapy/NN (l_prep) for/IN (l_pobj) arthritis/NN -PUNC- penicillamine/NN (l_conj) therapy/NN (l_prep) for/IN (l_pobj) arthritis/NN
D002738_D009157 CID chloroquine/NN (r_amod) therapy/NN (r_conj) penicillamine/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) gravis/NN -PUNC- chloroquine/NN (r_compound) therapy/NN (r_conj) penicillamine/NN (r_pobj) after/IN (r_prep) had/VBD (l_dobj) gravis/NN
D002738_D001172 NONE chloroquine/NN (r_amod) therapy/NN (l_prep) for/IN (l_pobj) arthritis/NN -PUNC- chloroquine/NN (r_compound) therapy/NN (l_prep) for/IN (l_pobj) arthritis/NN
6133211
D012460_D015212 NONE sulphasalazine/NN (r_pobj) with/IN (r_prep) treatment/NN (r_dobj) received/VBD (r_relcl) disease/NN
D012460_D000013 NONE sulphasalazine/NN (r_pobj) with/IN (r_prep) treatment/NN (r_dobj) received/VBD (r_relcl) disease/NN (r_pobj) with/IN (r_prep) mothers/NNS (r_pobj) of/IN (r_prep) born/VBN (r_acl) infants/NNS (r_nsubjpass) found/VBN (l_xcomp) have/VB (l_dobj) anomalies/NNS
8410052
D010862_D013226 CID pilocarpine/NN (r_npadvmod) induced/VBN (r_amod) status/NN (r_pobj) by/IN (r_agent) evoked/VBN (l_advmod) epilepticus/NN
D010862_D002544 CID pilocarpine/NN (r_npadvmod) induced/VBN (r_amod) status/NN (r_pobj) by/IN (r_agent) evoked/VBN (l_nsubjpass) Infarcts/NNS (l_prep) in/IN (l_pobj) reticulata/NNS
D019344_D001480 NONE lactate/NN (r_pobj) of/IN (r_prep) infusion/NN (r_pobj) by/IN (r_agent) produced/VBN (l_nsubjpass) injury/NN (l_prep) in/IN (l_pobj) cortex/NN
1664218
D000677_D002289 NONE amsacrine/NN (r_compound) analogue/NN (r_pobj) of/IN (r_prep) study/NN (l_prep) in/IN (l_pobj) cancer/NN
C042315_D002289 NONE CI-921/NNP (r_punct) (/-LRB- (r_punct) NSC/NNP (r_appos) study/NN (l_prep) in/IN (l_pobj) cancer/NN -PUNC- 343499/CD (r_nummod) NSC/NNP (r_appos) study/NN (l_prep) in/IN (l_pobj) cancer/NN
15145918
D008750_D007022 CID methyldopa/NN (r_conj) rilmenidine/NN (r_amod) rats/NNS (r_pobj) In/IN (r_prep) elicited/VBD (l_dobj) hypotension/NN -PUNC- methyldopa/NN (r_pobj) to/IN (r_prep) response/NN (l_amod) hypotensive/JJ -PUNC- methyldopa/NN (r_pobj) to/IN (r_prep) response/NN (r_dobj) enhanced/VBD (l_prep) in/IN (l_pobj) contrast/NN (l_prep) to/IN (l_pobj) effect/NN (l_prep) on/IN (l_pobj) hypotension/NN -PUNC- methyldopa/NN (r_compound) hypotension/NN -PUNC- methyldopa/NN (r_compound) estrogen/NN (r_compound) interaction/NN (r_pobj) in/IN (r_prep) control/NN (r_pobj) for/IN (r_prep) role/NN (r_dobj) highlight/VB (r_conj) downregulates/VBZ (l_conj) hypotension/NN
D048288_D007022 NONE I1-imidazoline/NNP (r_punct) mediated/VBN (r_conj) alpha2-adrenergic/JJ (r_amod) hypotension/NN
C032302_D007022 CID rilmenidine/NN (r_amod) rats/NNS (r_pobj) In/IN (r_prep) elicited/VBD (l_dobj) hypotension/NN -PUNC- rilmenidine/JJ (r_amod) hypotension/NN (r_pobj) on/IN (r_prep) effect/NN (r_pobj) to/IN (r_prep) contrast/NN (r_pobj) in/IN (r_prep) enhanced/VBD (l_dobj) response/NN (l_amod) hypotensive/JJ -PUNC- rilmenidine/JJ (r_amod) hypotension/NN
D004967_D007022 NONE estrogen/NN (l_prep) of/IN (l_pobj) hypotension/NN -PUNC- estrogen/NN (r_nsubj) modulates/VBZ (l_dobj) effect/NN (l_amod) hypotensive/JJ -PUNC- estrogen/NN (r_nsubj) downregulates/VBZ (l_conj) hypotension/NN -PUNC- estrogen/NN (r_compound) interaction/NN (r_pobj) in/IN (r_prep) control/NN (r_pobj) for/IN (r_prep) role/NN (r_dobj) highlight/VB (r_conj) downregulates/VBZ (l_conj) hypotension/NN
D003000_D007022 NONE clonidine/NN (r_pobj) of/IN (r_prep) effect/NN (l_amod) hypotensive/JJ
D008750_D001523 NONE methyldopa/NN (r_compound) hypotension/NN (r_nsubjpass) paralleled/VBN (l_prep) with/IN (l_pobj) reduction/NN (l_conj) activity/NN
3125768
C032943_D009127 NONE metocurine/NN (r_pobj) with/IN (r_prep) abolished/VBN (l_nsubjpass) rigidity/NN
D015760_D009127 CID alfentanil/NN (r_npadvmod) induced/VBN (r_amod) rigidity/NN -PUNC- alfentanil/NN (r_npadvmod) induced/VBN (r_amod) rigidity/NN -PUNC- alfentanil/NN (r_advcl) prevented/VBN (l_nsubjpass) rigidity/NN
9523805
D008012_D009422 CID lidocaine/NN (r_pobj) with/IN (r_prep) than/IN (r_prep) incidence/NN (r_appos) symptoms/NNS -PUNC- lidocaine/NN (r_amod) anesthesia/NN (r_dobj) follow/VBP (l_nsubj) symptoms/NNS -PUNC- lidocaine/NN (r_amod) anesthesia/NN (r_dobj) follow/VBP (l_nsubj) symptoms/NNS (l_appos) TNSs/NNS -PUNC- lidocaine/NN (l_conj) bupivacaine/NN (l_prep) with/IN (l_pobj) respect/NN (l_prep) to/IN (l_pobj) duration/NN (l_prep) of/IN (l_pobj) action/NN (l_conj) risk/NN (l_prep) of/IN (l_pobj) TNSs/NNS -PUNC- lidocaine/NN (r_dobj) receiving/VBG (l_dobj) TNSs/NNS -PUNC- lidocaine/NN (r_dobj) receiving/VBG (r_acl) patients/NNS (r_nsubj) had/VBD (l_conj) had/VBD (l_dobj) TNSs/NNS -PUNC- lidocaine/NN (r_xcomp) preferable/JJ (r_acomp) be/VB (l_advcl) has/VBZ (l_dobj) duration/NN (l_conj) incidence/NN (l_prep) of/IN (l_pobj) TNSs/NNS
D002045_D009422 NONE bupivacaine/NN (r_conj) prilocaine/NN (r_pobj) with/IN (r_prep) incidence/NN (r_appos) symptoms/NNS -PUNC- bupivacaine/NN (r_pobj) with/IN (r_prep) infrequent/JJ (r_acomp) are/VBP (r_conj) follow/VBP (l_nsubj) symptoms/NNS -PUNC- bupivacaine/NN (r_pobj) with/IN (r_prep) infrequent/JJ (r_acomp) are/VBP (r_conj) follow/VBP (l_nsubj) symptoms/NNS (l_appos) TNSs/NNS -PUNC- bupivacaine/NN (l_prep) with/IN (l_pobj) respect/NN (l_prep) to/IN (l_pobj) duration/NN (l_prep) of/IN (l_pobj) action/NN (l_conj) risk/NN (l_prep) of/IN (l_pobj) TNSs/NNS -PUNC- bupivacaine/NN (r_dobj) receiving/VBG (r_acl) patients/NNS (r_pobj) of/IN (r_prep) none/NN (r_nsubj) had/VBD (r_conj) had/VBD (l_nsubj) patients/NNS (l_acl) receiving/VBG (l_dobj) TNSs/NNS -PUNC- bupivacaine/NN (r_dobj) receiving/VBG (r_acl) patients/NNS (r_pobj) of/IN (r_prep) none/NN (r_nsubj) had/VBD (l_dobj) TNSs/NNS
D011318_D009422 CID prilocaine/NN (r_pobj) with/IN (r_prep) incidence/NN (r_appos) symptoms/NNS -PUNC- prilocaine/JJ (l_prep) with/IN (l_pobj) lidocaine/NN (l_conj) bupivacaine/NN (l_prep) with/IN (l_pobj) respect/NN (l_prep) to/IN (l_pobj) duration/NN (l_prep) of/IN (l_pobj) action/NN (l_conj) risk/NN (l_prep) of/IN (l_pobj) TNSs/NNS -PUNC- prilocaine/NN (r_dobj) receiving/VBG (r_acl) patients/NNS (r_nsubj) had/VBD (l_nsubj) patients/NNS (l_acl) receiving/VBG (l_dobj) TNSs/NNS -PUNC- prilocaine/NN (r_dobj) receiving/VBG (r_acl) patients/NNS (r_nsubj) had/VBD (l_conj) had/VBD (l_dobj) TNSs/NNS -PUNC- Prilocaine/NNP (r_nsubj) be/VB (l_advcl) has/VBZ (l_dobj) duration/NN (l_conj) incidence/NN (l_prep) of/IN (l_pobj) TNSs/NNS
11672959
D012460_D056486 CID sulphasalazine/NN (r_pobj) of/IN (r_prep) course/NN (r_pobj) of/IN (r_prep) day/NN (r_pobj) on/IN (r_prep) beginning/VBG (r_advcl) developed/VBD (l_dobj) constellation/NN (l_prep) of/IN (l_pobj) dermatitis/NN (l_conj) fever/NN (l_conj) lymphadenopathy/NN (l_conj) hepatitis/NN
D012460_D008206 CID sulphasalazine/NN (r_pobj) of/IN (r_prep) course/NN (r_pobj) of/IN (r_prep) day/NN (r_pobj) on/IN (r_prep) beginning/VBG (r_advcl) developed/VBD (l_dobj) constellation/NN (l_prep) of/IN (l_pobj) dermatitis/NN (l_conj) fever/NN (l_conj) lymphadenopathy/NN
D012460_D001172 NONE sulphasalazine/NN (l_prep) for/IN (l_pobj) arthritis/NN
D012460_D003872 CID sulphasalazine/NN (r_pobj) of/IN (r_prep) course/NN (r_pobj) of/IN (r_prep) day/NN (r_pobj) on/IN (r_prep) beginning/VBG (r_advcl) developed/VBD (l_dobj) constellation/NN (l_prep) of/IN (l_pobj) dermatitis/NN
D012460_D005334 CID sulphasalazine/NN (r_pobj) of/IN (r_prep) course/NN (r_pobj) of/IN (r_prep) day/NN (r_pobj) on/IN (r_prep) beginning/VBG (r_advcl) developed/VBD (l_dobj) constellation/NN (l_prep) of/IN (l_pobj) dermatitis/NN (l_conj) fever/NN
2385256
D008274_D020511 NONE magnesium/NN (r_pobj) of/IN (r_prep) effects/NNS (r_pobj) to/IN (r_prep) sensitive/JJ (r_acomp) are/VBP (r_relcl) Patients/NNS (r_nsubjpass) suspected/VBN (l_prep) of/IN (l_pcomp) having/VBG (l_dobj) disorder/NN (l_prep) of/IN (l_pobj) transmission/NN
D008274_D009157 CID magnesium/NN (r_compound) administration/NN (r_pobj) after/IN (r_prep) weakness/NN (r_pobj) as/IN (r_prep) presenting/VBG (r_acl) gravis/NN -PUNC- magnesium/NN (r_compound) administration/NN (r_pobj) after/IN (r_prep) paralysis/NN (r_nsubjpass) described/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) gravis/NN
D008274_D009468 NONE magnesium/NN (r_compound) administration/NN (r_pobj) after/IN (r_prep) became/VBD (r_relcl) disease/NN
D008274_D010243 NONE magnesium/NN (r_compound) administration/NN (r_pobj) after/IN (r_prep) paralysis/NN
D008274_D011225 NONE magnesium/NN (r_compound) administration/NN (l_prep) for/IN (l_pobj) preeclampsia/NN
D008274_D011782 NONE magnesium/NN (r_compound) administration/NN (r_pobj) after/IN (r_prep) became/VBD (l_acomp) quadriplegic/JJ
10683478
D001058_D007035 CID Apomorphine/NNP (r_nsubjpass) selected/VBN (l_dobj) ability/NN (l_acl) induce/VB (l_dobj) hypothermia/NN -PUNC- apomorphine/NN (l_prep) as/IN (l_pobj) hypothermia/NN
D004298_D007035 NONE dopamine/NN (r_relcl) changes/NNS (r_dobj) produce/VB (r_conj) induce/VB (l_dobj) hypothermia/NN
D001058_D006948 CID apomorphine/NN (r_npadvmod) induced/VBN (r_amod) hyperactivity/NN
D018491_D007035 NONE agonist/NN (r_appos) Apomorphine/NNP (r_nsubjpass) selected/VBN (l_dobj) ability/NN (l_acl) induce/VB (l_dobj) hypothermia/NN
4027862
D003891_D003693 CID Desipramine/NN (r_npadvmod) induced/VBN (r_amod) delirium/NN -PUNC- Desipramine/NNP (r_nsubj) developed/VBD (l_dobj) delirium/NN
10721819
D001971_D001919 NONE Bromocriptine/NNP (r_npadvmod) induced/VBN (r_amod) hypotension/NN (r_nsubj) was/VBD (l_advcl) reversed/VBN (l_prep) to/IN (l_pobj) bradycardia/NNS -PUNC- bromocriptine/NN (r_npadvmod) induced/VBN (r_amod) tachycardia/NN (r_dobj) reversed/VBD (l_prep) to/IN (l_pobj) bradycardia/NNP -PUNC- bromocriptine/NN (r_pobj) of/IN (r_prep) tachycardia/NN (r_nsubj) appears/VBZ (l_xcomp) predominate/VB (l_conj) mask/VB (l_dobj) bradycardia/NN
D001971_D007022 CID bromocriptine/NN (r_nsubj) induced/VBD (l_dobj) hypotension/NN -PUNC- Bromocriptine/NNP (r_npadvmod) induced/VBN (r_amod) hypotension/NN
D007545_D001919 CID isoproterenol/JJ (r_compound) pretreatment/NN (r_pobj) by/IN (r_prep) unaffected/JJ (r_acomp) was/VBD (l_advcl) reversed/VBN (l_prep) to/IN (l_pobj) bradycardia/NNS -PUNC- isoproterenol/JJ (r_compound) pretreatment/NN (r_nsubj) abolished/VBD (l_conj) reversed/VBD (l_prep) to/IN (l_pobj) bradycardia/NNP
D004298_D013610 NONE dopamine/NN (r_compound) D2/NN (r_compound) receptors/NNS (r_pobj) at/IN (r_prep) bradycardia/NN (r_dobj) mask/VB (r_conj) predominate/VB (r_xcomp) appears/VBZ (l_nsubj) tachycardia/NN
D007545_D013610 NONE isoproterenol/NN (l_prep) on/IN (l_pobj) tachycardia/NN -PUNC- isoproterenol/NN (r_pobj) with/IN (r_prep) pretreatment/NN (r_nsubj) abolish/VB (l_dobj) tachycardia/NN -PUNC- isoproterenol/JJ (r_compound) pretreatment/NN (r_pobj) by/IN (r_prep) unaffected/JJ (r_acomp) was/VBD (l_advcl) reversed/VBN (l_nsubjpass) tachycardia/NN -PUNC- isoproterenol/JJ (r_compound) pretreatment/NN (r_nsubj) abolished/VBD (l_conj) reversed/VBD (l_dobj) tachycardia/NN
D004294_D013610 NONE domperidone/NN (r_pobj) by/IN (r_agent) reduced/VBN (r_relcl) effect/NN (r_npadvmod) reversed/VBN (l_nsubjpass) tachycardia/NN
D004294_D007022 NONE domperidone/NN (r_pobj) by/IN (r_agent) reduced/VBN (r_relcl) effect/NN (r_npadvmod) reversed/VBN (r_advcl) was/VBD (l_nsubj) hypotension/NN
D007545_D007022 NONE isoproterenol/JJ (r_compound) pretreatment/NN (r_pobj) by/IN (r_prep) unaffected/JJ (r_acomp) was/VBD (l_nsubj) hypotension/NN
D004298_D001919 NONE dopamine/NN (r_compound) D2/NN (r_compound) receptors/NNS (r_pobj) at/IN (r_prep) bradycardia/NN
D004294_D001919 CID domperidone/NN (r_pobj) by/IN (r_agent) reduced/VBN (r_relcl) effect/NN (r_npadvmod) reversed/VBN (l_prep) to/IN (l_pobj) bradycardia/NNS
D001971_D013610 CID bromocriptine/NN (r_npadvmod) induced/VBN (r_amod) tachycardia/NN -PUNC- bromocriptine/NN (r_npadvmod) induced/VBN (r_amod) tachycardia/NN -PUNC- bromocriptine/NN (r_npadvmod) induced/VBN (r_amod) tachycardia/NN -PUNC- bromocriptine/NN (r_nsubj) induced/VBD (l_dobj) hypotension/NN (l_conj) tachycardia/NN -PUNC- Bromocriptine/NNP (r_npadvmod) induced/VBN (r_amod) hypotension/NN (r_nsubj) was/VBD (l_advcl) reversed/VBN (l_nsubjpass) tachycardia/NN -PUNC- bromocriptine/NN (r_npadvmod) induced/VBN (r_amod) tachycardia/NN -PUNC- bromocriptine/NN (r_pobj) of/IN (r_prep) tachycardia/NN
D007545_D006332 CID Isoproterenol/JJ (r_compound) pretreatment/NN (r_nsubj) caused/VBD (l_dobj) hypertrophy/NN
10342929
D000806_D000799 CID inhibitors/NNS (r_pobj) to/IN (r_pcomp) due/IN (r_prep) Angioedema/NNP -PUNC- inhibitor/NN (r_compound) treatment/NN (r_nsubj) is/VBZ (l_nsubj) incidence/NN (l_prep) of/IN (l_pobj) angioedema/NN
15275829
D000109_D012640 NONE acetylcholine/NN (r_compound) subunits/NNS (r_nsubj) are/VBP (l_prep) for/IN (l_pobj) seizures/NNS -PUNC- acetylcholine/NN (r_compound) receptors/NNS (r_pobj) to/IN (r_prep) Binding/NN (r_nsubj) elicits/VBZ (l_dobj) series/NN (l_prep) of/IN (l_pobj) behaviors/NNS (l_relcl) go/VBP (l_prep) to/IN (l_pobj) seizures/NNS
D009538_D006948 NONE nicotine/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS (l_conj) hypolocomotion/NN -PUNC- nicotine/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS (r_pobj) in/IN (r_prep) subunits/NNS (l_conj) hypolocomotion/NN -PUNC- nicotine/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS (l_conj) hypolocomotion/NN
D000109_D006948 NONE acetylcholine/NN (r_compound) subunits/NNS (r_nsubj) are/VBP (l_prep) for/IN (l_pobj) seizures/NNS (l_conj) hypolocomotion/NN
D000109_D014202 NONE acetylcholine/NN (r_compound) receptors/NNS (r_pobj) to/IN (r_prep) Binding/NN (r_nsubj) elicits/VBZ (l_dobj) series/NN (l_prep) of/IN (l_pobj) behaviors/NNS (l_relcl) go/VBP (l_prep) from/IN (l_pobj) exploration/NN (l_conj) sedation/NN (l_conj) tremors/NNS
D000109_D003643 NONE acetylcholine/NN (r_compound) receptors/NNS (r_pobj) to/IN (r_prep) Binding/NN (r_nsubj) elicits/VBZ (l_dobj) series/NN (l_prep) of/IN (l_pobj) behaviors/NNS (l_relcl) go/VBP (l_prep) to/IN (l_pobj) seizures/NNS (l_conj) death/NN
D009538_D012640 CID nicotine/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS -PUNC- nicotine/NN (r_pobj) of/IN (r_prep) Binding/NN (r_nsubj) elicits/VBZ (l_dobj) series/NN (l_prep) of/IN (l_pobj) behaviors/NNS (l_relcl) go/VBP (l_prep) to/IN (l_pobj) seizures/NNS -PUNC- nicotine/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS -PUNC- nicotine/NN (r_pobj) of/IN (r_prep) effects/NNS (r_pobj) to/IN (r_prep) sensitive/JJ (r_acomp) were/VBD (l_advcl) measured/VBN (l_conj) measured/VBN (l_prep) as/IN (l_pobj) sensitivity/NN (l_prep) to/IN (l_pobj) seizures/NNS -PUNC- nicotine/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS -PUNC- nicotine/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS -PUNC- nicotine/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS
D009538_D014202 NONE nicotine/NN (r_pobj) of/IN (r_prep) Binding/NN (r_nsubj) elicits/VBZ (l_dobj) series/NN (l_prep) of/IN (l_pobj) behaviors/NNS (l_relcl) go/VBP (l_prep) from/IN (l_pobj) exploration/NN (l_conj) sedation/NN (l_conj) tremors/NNS
D009538_D003643 NONE nicotine/NN (r_pobj) of/IN (r_prep) Binding/NN (r_nsubj) elicits/VBZ (l_dobj) series/NN (l_prep) of/IN (l_pobj) behaviors/NNS (l_relcl) go/VBP (l_prep) to/IN (l_pobj) seizures/NNS (l_conj) death/NN
1992636
D009853_D004417 CID omeprazole/NN (r_pobj) with/IN (r_prep) starting/VBG (r_pcomp) after/IN (r_prep) weakness/NN (l_conj) lethargy/NN (l_conj) shortness/NN (l_prep) of/IN (l_pobj) breath/NN
D009853_D053609 CID omeprazole/NN (r_pobj) with/IN (r_prep) starting/VBG (r_pcomp) after/IN (r_prep) weakness/NN (l_conj) lethargy/NN
D009853_D000743 CID omeprazole/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) anemia/NN -PUNC- omeprazole/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) with/IN (r_prep) reaction/NN (r_pobj) of/IN (r_prep) case/NN (l_appos) anemia/NN -PUNC- omeprazole/NN (r_nsubj) caused/VBD (l_ccomp) is/VBZ (l_nsubj) anemia/NN
11745184
D004999_D006311 NONE amifostine/NN (r_conj) cisplatin/NN (r_pobj) of/IN (r_prep) trials/NNS (r_nsubj) suggested/VBD (l_ccomp) reduced/VBN (l_nsubjpass) incidence/NN (l_prep) of/IN (l_pobj) nephrotoxicity/NN (l_conj) ototoxicity/NN
D004999_D001943 NONE WR-2721/NNP (r_nmod) amifostine/NN (r_pobj) of/IN (r_prep) trial/NN (l_prep) for/IN (l_pobj) carcinoma/NN -PUNC- amifostine/NN (r_pobj) of/IN (r_prep) trial/NN (l_prep) for/IN (l_pobj) carcinoma/NN -PUNC- amifostine/NN (r_conj) cisplatin/NN (r_pobj) of/IN (r_prep) combination/NN (r_pobj) of/IN (r_prep) study/NN (r_nsubjpass) conducted/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) carcinoma/NN
D002945_D064420 NONE cisplatin/NN (r_pobj) with/IN (r_prep) observed/VBN (r_advcl) limited/VBN (l_nsubj) toxicities/NNS -PUNC- cisplatin/NN (r_pcomp) with/IN (r_prep) associated/VBN (r_acl) toxicities/NNS -PUNC- cisplatin/VB (r_acl) amifostine/NN (r_pobj) of/IN (r_prep) addition/NN (r_pobj) with/IN (r_prep) observed/VBN (l_nsubjpass) effect/NN (l_conj) reduced/VBN (l_dobj) toxicity/NN
D002945_D020258 NONE cisplatin/NN (r_pobj) with/IN (r_prep) observed/VBN (r_advcl) limited/VBN (l_nsubj) toxicities/NNS (l_acl) associated/VBN (l_prep) with/IN (l_pcomp) cisplatin/NN (l_preconj) nephrotoxicity/NN (l_conj) ototoxicity/NN (l_conj) neurotoxicity/NN -PUNC- cisplatin/NN (l_preconj) nephrotoxicity/NN (l_conj) ototoxicity/NN (l_conj) neurotoxicity/NN
D002945_D007674 CID cisplatin/NN (r_pobj) with/IN (r_prep) observed/VBN (r_advcl) limited/VBN (l_nsubj) toxicities/NNS (l_acl) associated/VBN (l_prep) with/IN (l_pcomp) cisplatin/NN (l_preconj) nephrotoxicity/NN -PUNC- cisplatin/NN (l_preconj) nephrotoxicity/NN -PUNC- cisplatin/NN (r_pobj) of/IN (r_prep) trials/NNS (r_nsubj) suggested/VBD (l_ccomp) reduced/VBN (l_nsubjpass) incidence/NN (l_prep) of/IN (l_pobj) nephrotoxicity/NN -PUNC- cisplatin/NN (r_advmod) induced/VBN (r_amod) nephrotoxicity/NN
D004999_D009422 NONE amifostine/NN (r_conj) cisplatin/NN (r_pobj) of/IN (r_prep) trials/NNS (r_nsubj) suggested/VBD (l_ccomp) reduced/VBN (l_nsubjpass) incidence/NN (l_prep) of/IN (l_pobj) nephrotoxicity/NN (l_conj) ototoxicity/NN (l_conj) neuropathy/NN
D002945_D009369 NONE cisplatin/VB (r_acl) amifostine/NN (r_pobj) of/IN (r_prep) addition/NN (r_pobj) with/IN (r_prep) observed/VBN (l_nsubjpass) effect/NN (l_amod) protective/JJ (l_npadvmod) tumor/NN
D002945_D001943 NONE cisplatin/NN (r_nmod) amifostine/NN (r_pobj) of/IN (r_prep) trial/NN (l_prep) for/IN (l_pobj) carcinoma/NN -PUNC- Cisplatin/NNP (r_nsubj) has/VBZ (l_advcl) used/VBN (l_prep) as/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) carcinoma/NN -PUNC- cisplatin/NN (r_pobj) with/IN (r_prep) observed/VBN (r_advcl) limited/VBN (l_dobj) use/NN (l_prep) as/IN (l_pobj) treatment/NN (l_prep) for/IN (l_pobj) carcinoma/NN -PUNC- cisplatin/NN (r_pcomp) with/IN (r_prep) associated/VBN (r_acl) toxicities/NNS (r_nsubj) limited/VBN (l_dobj) use/NN (l_prep) as/IN (l_pobj) treatment/NN (l_prep) for/IN (l_pobj) carcinoma/NN -PUNC- cisplatin/NN (r_pobj) of/IN (r_prep) combination/NN (r_pobj) of/IN (r_prep) study/NN (r_nsubjpass) conducted/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) carcinoma/NN
D002945_D009422 CID cisplatin/NN (r_pobj) of/IN (r_prep) trials/NNS (r_nsubj) suggested/VBD (l_ccomp) reduced/VBN (l_nsubjpass) incidence/NN (l_prep) of/IN (l_pobj) nephrotoxicity/NN (l_conj) ototoxicity/NN (l_conj) neuropathy/NN -PUNC- cisplatin/NN (r_advmod) induced/VBN (r_amod) nephrotoxicity/NN (l_conj) ototoxicity/NN (l_conj) neuropathy/NN
D004999_D064420 NONE amifostine/NN (r_pobj) of/IN (r_prep) addition/NN (r_pobj) with/IN (r_prep) observed/VBN (l_nsubjpass) effect/NN (l_conj) reduced/VBN (l_dobj) toxicity/NN
D002945_D006311 CID cisplatin/NN (r_pobj) with/IN (r_prep) observed/VBN (r_advcl) limited/VBN (l_nsubj) toxicities/NNS (l_acl) associated/VBN (l_prep) with/IN (l_pcomp) cisplatin/NN (l_preconj) nephrotoxicity/NN (l_conj) ototoxicity/NN -PUNC- cisplatin/NN (l_preconj) nephrotoxicity/NN (l_conj) ototoxicity/NN -PUNC- cisplatin/NN (r_pobj) of/IN (r_prep) trials/NNS (r_nsubj) suggested/VBD (l_ccomp) reduced/VBN (l_nsubjpass) incidence/NN (l_prep) of/IN (l_pobj) nephrotoxicity/NN (l_conj) ototoxicity/NN -PUNC- cisplatin/NN (r_advmod) induced/VBN (r_amod) nephrotoxicity/NN (l_conj) ototoxicity/NN
D004999_D007674 NONE amifostine/NN (r_conj) cisplatin/NN (r_pobj) of/IN (r_prep) trials/NNS (r_nsubj) suggested/VBD (l_ccomp) reduced/VBN (l_nsubjpass) incidence/NN (l_prep) of/IN (l_pobj) nephrotoxicity/NN
D004999_D009369 NONE amifostine/NN (r_pobj) of/IN (r_prep) addition/NN (r_pobj) with/IN (r_prep) observed/VBN (l_nsubjpass) effect/NN (l_amod) protective/JJ (l_npadvmod) tumor/NN
20633755
D009943_D001049 CID poisons/NNS (r_pobj) by/IN (r_agent) deactivated/VBN (r_relcl) patients/NNS (r_pobj) in/IN (r_prep) apnea/NN -PUNC- compound/NN (r_pobj) by/IN (r_prep) attempt/NN (r_pobj) about/IN (r_prep) information/NN (r_nsubjpass) concealed/VBN (r_advcl) ensued/VBD (l_nsubj) apnea/NN
D013390_D001049 CID Suxamethonium/NNS (r_nsubj) induced/VBD (l_dobj) apnea/NN -PUNC- Suxamethonium/JJ (r_nsubj) causes/VBZ (l_dobj) apnea/NN
10706004
D012964_D006973 NONE sodium/NN (r_nmod) affinities/NNS (r_pobj) of/IN (r_prep) Changes/NNS (l_prep) during/IN (l_conj) after/IN (l_pobj) hypertension/NN -PUNC- Na/UH (r_nmod) K)-ATPase/NNP (r_pobj) of/IN (r_prep) affinities/NNS (r_pobj) of/IN (r_prep) Changes/NNS (l_prep) during/IN (l_conj) after/IN (l_pobj) hypertension/NN -PUNC- sodium/NN (r_compound) level/NN (r_pobj) of/IN (r_prep) elevation/NN (r_nsubjpass) documented/VBN (l_prep) In/IN (l_pobj) models/NNS (l_prep) of/IN (l_pobj) hypertension/NN -PUNC- Na+/NNP (r_pobj) of/IN (r_prep) transport/NN (r_pobj) in/IN (r_prep) disturbances/NNS (r_pobj) of/IN (r_prep) basis/NN (r_dobj) assess/VB (r_advcl) studied/VBD (l_dobj) response/NN (l_prep) of/IN (l_pobj) K)-ATPase/NNP (l_prep) to/IN (l_pobj) hypertension/NN -PUNC- Na/UH (r_nmod) K)-ATPase/NNP (l_prep) to/IN (l_pobj) hypertension/NN -PUNC- Na/NNP (r_npadvmod) increased/VBD (r_parataxis) activity/NN (l_prep) After/IN (l_pobj) recovery/NN (l_prep) from/IN (l_pobj) hypertension/NN -PUNC- Na+-extrusion/NN (r_pobj) by/IN (r_agent) accompanied/VBN (r_acl) hypertension/NN -PUNC- Na+-binding/NN (r_compound) properties/NNS (r_pobj) of/IN (r_prep) consequence/NN (r_pobj) as/IN (r_prep) accompanied/VBN (r_acl) hypertension/NN -PUNC- Na/UH (r_nmod) K)-ATPase/NNP (r_pobj) of/IN (r_prep) properties/NNS (r_pobj) of/IN (r_prep) consequence/NN (r_pobj) as/IN (r_prep) accompanied/VBN (r_acl) hypertension/NN
D011188_D006973 NONE K)-ATPase/NNP (r_pobj) of/IN (r_prep) affinities/NNS (r_pobj) of/IN (r_prep) Changes/NNS (l_prep) during/IN (l_conj) after/IN (l_pobj) hypertension/NN -PUNC- K)-ATPase/NNP (l_prep) to/IN (l_pobj) hypertension/NN -PUNC- K)-ATPase/NNP (r_nsubj) increased/VBD (r_parataxis) activity/NN (l_prep) After/IN (l_pobj) recovery/NN (l_prep) from/IN (l_pobj) hypertension/NN -PUNC- K)-ATPase/NNP (r_pobj) of/IN (r_prep) properties/NNS (r_pobj) of/IN (r_prep) consequence/NN (r_pobj) as/IN (r_prep) accompanied/VBN (r_acl) hypertension/NN
D009569_D006973 CID oxide/NN (r_npadvmod) deficient/JJ (r_amod) hypertension/NN -PUNC- NO/DT (r_det) synthesis/NN (r_pobj) of/IN (r_prep) Inhibition/NN (r_nsubj) induces/VBZ (l_dobj) hypertension/NN -PUNC- NO/JJ (r_npadvmod) deficient/JJ (r_amod) hypertension/NN -PUNC- NO/JJ (r_compound) synthase/NN (r_compound) inhibition/NN (r_pobj) by/IN (r_prep) rats/NNS (r_pobj) in/IN (r_prep) induced/VBN (r_advcl) studied/VBD (l_dobj) response/NN (l_prep) of/IN (l_pobj) K)-ATPase/NNP (l_prep) to/IN (l_pobj) hypertension/NN -PUNC- NO/JJ (r_compound) synthase/NN (r_pobj) of/IN (r_prep) Inhibition/NN (r_nsubj) induced/VBD (l_dobj) hypertension/NN
D009569_D003866 NONE NO/JJ (r_compound) synthase/NN (r_pobj) of/IN (r_prep) Inhibition/NN (r_nsubj) induced/VBD (l_dobj) hypertension/NN (l_acl) accompanied/VBN (l_agent) by/IN (l_pobj) Na+-extrusion/NN (l_amod) depressed/JJ
D011188_D003866 NONE K)-ATPase/NNP (r_pobj) of/IN (r_prep) properties/NNS (r_pobj) of/IN (r_prep) consequence/NN (r_pobj) as/IN (r_prep) accompanied/VBN (l_agent) by/IN (l_pobj) Na+-extrusion/NN (l_amod) depressed/JJ
D019331_D006973 NONE ester/NN (r_appos) kg/NNS (r_pobj) with/IN (r_prep) inhibition/NN (r_pobj) by/IN (r_prep) rats/NNS (r_pobj) in/IN (r_prep) induced/VBN (r_advcl) studied/VBD (l_dobj) response/NN (l_prep) of/IN (l_pobj) K)-ATPase/NNP (l_prep) to/IN (l_pobj) hypertension/NN -PUNC- NAME/NNP (r_appos) ester/NN (r_appos) kg/NNS (r_pobj) with/IN (r_prep) inhibition/NN (r_pobj) by/IN (r_prep) rats/NNS (r_pobj) in/IN (r_prep) induced/VBN (r_advcl) studied/VBD (l_dobj) response/NN (l_prep) of/IN (l_pobj) K)-ATPase/NNP (l_prep) to/IN (l_pobj) hypertension/NN
D000255_D006973 NONE ATP/NNP (r_conj) sodium/NN (r_nmod) affinities/NNS (r_pobj) of/IN (r_prep) Changes/NNS (l_prep) during/IN (l_conj) after/IN (l_pobj) hypertension/NN -PUNC- ATP/NNP (r_npadvmod) binding/VBG (r_amod) site/NN (r_pobj) of/IN (r_prep) affinity/NN (r_pobj) due/IN (r_prep) increased/VBD (r_parataxis) activity/NN (l_prep) After/IN (l_pobj) recovery/NN (l_prep) from/IN (l_pobj) hypertension/NN -PUNC- ATP/NNP (r_pobj) for/IN (r_prep) value/NN (r_pobj) from/IN (r_prep) revealed/VBN (r_advcl) activity/NN (l_prep) After/IN (l_pobj) recovery/NN (l_prep) from/IN (l_pobj) hypertension/NN
D012964_D003866 NONE Na+-extrusion/NN (l_amod) depressed/JJ -PUNC- Na+-binding/NN (r_compound) properties/NNS (r_pobj) of/IN (r_prep) consequence/NN (r_pobj) as/IN (r_prep) accompanied/VBN (l_agent) by/IN (l_pobj) Na+-extrusion/NN (l_amod) depressed/JJ -PUNC- Na/UH (r_nmod) K)-ATPase/NNP (r_pobj) of/IN (r_prep) properties/NNS (r_pobj) of/IN (r_prep) consequence/NN (r_pobj) as/IN (r_prep) accompanied/VBN (l_agent) by/IN (l_pobj) Na+-extrusion/NN (l_amod) depressed/JJ
1549199
D007980_D005767 CID levodopa/RB (r_npadvmod) induced/VBN (r_amod) psychosis/NN (r_conj) hypotension/NN (r_conj) disorders/NNS
D007980_D064420 NONE levodopa/NN (r_compound) therapy/NN (r_pobj) for/IN (r_prep) dose/NN (r_dobj) starting/NN (r_acl) correct/JJ (r_attr) is/VBZ (r_advcl) started/VBN (l_prep) following/VBG (l_pobj) rule/NN (l_relcl) attempt/VB (l_xcomp) titrate/VB (l_dobj) levodopa/NN (l_relcl) lead/VB (l_prep) to/IN (l_pobj) toxicity/NN -PUNC- levodopa/NN (l_relcl) lead/VB (l_prep) to/IN (l_pobj) toxicity/NN
D007980_D020447 CID levodopa/RB (r_npadvmod) induced/VBN (r_amod) psychosis/NN (l_conj) disturbances/NNS (l_conj) parasomnias/NNS
D002230_D064420 NONE carbidopa/NN (r_compound) levodopa/NN (l_relcl) lead/VB (l_prep) to/IN (l_pobj) toxicity/NN
D007980_D011618 NONE levodopa/RB (r_npadvmod) induced/VBN (r_amod) psychosis/NN
D007980_D012893 NONE levodopa/RB (r_npadvmod) induced/VBN (r_amod) psychosis/NN (l_conj) disturbances/NNS
D007980_D007024 CID levodopa/RB (r_npadvmod) induced/VBN (r_amod) psychosis/NN (r_conj) hypotension/NN
11773892
D016572_D007674 CID cyclosporine/VBP (r_appos) inhibitors/NNS (r_nsubjpass) known/VBN (l_xcomp) be/VB (l_acomp) nephrotoxic/JJ
D003404_D007676 NONE creatinine/NN (r_conj) CRF/NNP (r_conj) Controls/NNS (l_conj) CRF/NNP -PUNC- creatinine/NN (r_conj) CRF/NNP (r_conj) Controls/NNS (l_conj) CRF/NNP (l_conj) ESRD/NNP -PUNC- creatinine/NN (r_conj) CRF/NNP -PUNC- creatinine/NN (r_conj) CRF/NNP (r_conj) Controls/NNS (r_appos) groups/NNS (l_conj) n=45/JJ (l_nmod) ESRD/NNS -PUNC- creatinine/NN (r_compound) levels/NNS (r_dobj) had/VBD (l_nsubj) patients/NNS (l_nmod) CRF/NNP -PUNC- creatinine/NN (r_compound) levels/NNS (r_dobj) had/VBD (l_nsubj) patients/NNS (l_compound) ESRD/NNP -PUNC- creatinine/NN (r_conj) requirement/NN (r_appos) levels/NNS (r_dobj) had/VBD (l_nsubj) patients/NNS (l_nmod) CRF/NNP -PUNC- creatinine/NN (r_conj) requirement/NN (r_appos) levels/NNS (r_dobj) had/VBD (l_nsubj) patients/NNS (l_compound) ESRD/NNP -PUNC- creatinine/NN (r_pobj) of/IN (r_prep) increase/NN (r_nsubj) were/VBD (l_attr) factors/NNS (l_prep) for/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) CRF/NNP -PUNC- creatinine/NN (r_pobj) of/IN (r_prep) increase/NN (r_nsubj) were/VBD (l_attr) factors/NNS (l_prep) for/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) CRF/NNP (l_conj) ESRD/NNP -PUNC- creatinine/NN (r_dobj) have/VBP (l_nsubj) Patients/NNS (l_relcl) develop/VBP (l_dobj) ESRD/NNS -PUNC- creatinine/NN (r_pobj) of/IN (r_prep) increase/NN (r_nsubj) is/VBZ (l_acomp) predictive/JJ (l_prep) of/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) CRF/NNP -PUNC- creatinine/NN (r_pobj) of/IN (r_prep) increase/NN (r_nsubj) is/VBZ (l_acomp) predictive/JJ (l_prep) of/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) CRF/NNP (l_conj) ESRD/NNP
D003404_D006530 NONE creatinine/NN (r_compound) levels/NNS (l_appos) percentage/NN (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) syndrome/NN -PUNC- creatinine/NN (r_conj) requirement/NN (r_appos) levels/NNS (l_appos) percentage/NN (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) syndrome/NN -PUNC- creatinine/NN (r_dobj) have/VBP (l_conj) are/VBP (l_acomp) likely/JJ (l_xcomp) have/VB (l_dobj) syndrome/NN
D016559_D007674 CID tacrolimus/NN (r_conj) cyclosporine/VBP (r_appos) inhibitors/NNS (r_nsubjpass) known/VBN (l_xcomp) be/VB (l_acomp) nephrotoxic/JJ
4008111
D000638_D012848 CID Amiodarone/NN (r_npadvmod) induced/VBN (r_amod) block/NN -PUNC- amiodarone/NN (r_compound) administration/NN (r_pobj) due/JJ (r_prep) observed/VBD (l_dobj) block/NN -PUNC- amiodarone/NN (r_pobj) of/IN (r_prep) dosage/NN (r_pobj) in/IN (r_prep) Reduction/NN (r_nsubj) resulted/VBD (l_prep) in/IN (l_pobj) disappearance/NN (l_prep) of/IN (l_pobj) block/NN
D000638_D013617 NONE amiodarone/NN (r_compound) administration/NN (r_pobj) due/JJ (r_prep) observed/VBD (l_dobj) syndrome/NN (l_conj) tachycardia/NN
D000638_D009202 NONE amiodarone/NN (r_compound) administration/NN (l_prep) in/IN (l_pobj) boy/NN (l_prep) with/IN (l_pobj) cardiomyopathy/NN
D000638_D014927 NONE amiodarone/NN (r_compound) administration/NN (r_pobj) due/JJ (r_prep) observed/VBD (l_dobj) syndrome/NN
D000638_D012804 NONE amiodarone/NN (r_pobj) of/IN (r_prep) dosage/NN (r_pobj) in/IN (r_prep) Reduction/NN (r_nsubj) resulted/VBD (l_prep) in/IN (l_pobj) disappearance/NN (l_conj) persistence/NN (l_prep) of/IN (l_pobj) bradycardia/NNP
3496378
D014217_D004802 CID troleandomycin/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) occurred/VBD (l_conj) associated/VBN (l_prep) with/IN (l_pobj) hypereosinophilia/NNS
D014217_D002779 CID troleandomycin/NN (r_npadvmod) induced/VBN (r_amod) hepatitis/NN (r_pobj) after/IN (r_prep) cholestasis/NN -PUNC- troleandomycin/NN (r_npadvmod) induced/VBN (r_relcl) patient/NN (r_pobj) of/IN (r_prep) case/NN (r_dobj) report/VBP (l_ccomp) followed/VBN (l_agent) by/IN (l_pobj) cholestasis/NN -PUNC- troleandomycin/NN (r_npadvmod) induced/VBN (r_amod) hepatitis/NN (r_dobj) follow/VB (l_nsubj) cholestasis/NN
D014217_D056486 CID troleandomycin/NN (r_npadvmod) induced/VBN (r_amod) hepatitis/NN -PUNC- troleandomycin/NN (r_npadvmod) induced/VBN (r_relcl) patient/NN (r_pobj) of/IN (r_prep) case/NN (r_dobj) report/VBP (l_ccomp) followed/VBN (l_nsubjpass) hepatitis/NN -PUNC- troleandomycin/NN (r_npadvmod) induced/VBN (r_amod) hepatitis/NN
D014217_D007565 CID troleandomycin/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) occurred/VBD (l_nsubj) Jaundice/NN
8919272
D014635_D056486 NONE valproate/NNP (r_amod) encephalopathy/NNP (r_pobj) of/IN (r_prep) development/NN (r_pobj) upon/IN (r_prep) hyperammonemia/NN (l_nsubj) influence/NN (l_prep) of/IN (l_pobj) damage/NN
D014635_D022124 NONE valproate/NNP (r_amod) encephalopathy/NNP (r_pobj) of/IN (r_prep) development/NN (r_pobj) upon/IN (r_prep) hyperammonemia/NN
D014635_D001927 CID valproate/NN (l_nsubj) features/NNS (l_prep) of/IN (l_pobj) encephalopathy/NN -PUNC- valproate/NN (l_dobj) disorders/NNS (l_acl) indicating/VBG (l_dobj) damage/NN (l_appos) encephalopathy/JJ -PUNC- valproate/NNP (r_amod) encephalopathy/JJ -PUNC- valproate/NNP (r_amod) encephalopathy/NNP
D014635_D002526 NONE valproate/NN (l_dobj) disorders/NNS (l_acl) indicating/VBG (l_dobj) damage/NN -PUNC- valproate/NNP (r_amod) encephalopathy/JJ (r_appos) damage/NN
D014635_D009422 NONE valproate/NN (l_dobj) disorders/NNS -PUNC- valproate/NNP (r_amod) encephalopathy/JJ (r_appos) damage/NN (r_dobj) indicating/VBG (r_acl) disorders/NNS
2559236
D004656_D009401 NONE enalapril/NN (r_appos) inhibitor/NN (r_pobj) of/IN (r_prep) effect/NN (r_nsubjpass) assessed/VBN (l_prep) with/IN (l_pobj) nephrosis/NN -PUNC- enalapril/NN (r_pobj) of/IN (r_prep) effect/NN (l_prep) on/IN (l_pobj) progression/NN (l_prep) of/IN (l_pobj) injury/NN (l_prep) in/IN (l_pobj) nephrosis/NN
D004656_D007674 NONE enalapril/NN (r_pobj) of/IN (r_prep) effect/NN (l_prep) on/IN (l_pobj) progression/NN (l_prep) of/IN (l_pobj) injury/NN
D004656_D000419 NONE enalapril/DT (r_nsubj) reduced/JJ (l_prep) vs./IN (l_pobj) Hg/NNP (l_conj) pressure/NN (l_appos) +/-/SYM (l_prep) without/IN (l_pcomp) reducing/VBG (l_dobj) albuminuria/NN -PUNC- enalapril/NN (r_compound) treatment/NN (r_nsubj) reduced/VBN (r_amod) pressure/NN (l_prep) without/IN (l_pcomp) reducing/VBG (l_dobj) albuminuria/NN
D004317_D000419 CID adriamycin/NNS (r_pobj) of/IN (r_prep) dose/NN (r_dobj) given/VBN (l_advcl) divided/VBD (l_prep) into/IN (l_pobj) groups/NNS (l_acl) matched/VBN (l_prep) for/IN (l_pobj) albuminuria/NN
D004317_D009401 CID adriamycin/NNS (r_amod) nephrosis/NN -PUNC- adriamycin/JJ (r_amod) nephrosis/NN
D004317_D007674 NONE adriamycin/NNS (r_npadvmod) induced/VBN (r_amod) nephropathy/NN -PUNC- adriamycin/JJ (r_amod) nephrosis/NN (r_pobj) in/IN (r_prep) injury/NN
12653683
D012964_D009404 NONE sodium/NN (r_compound) channel/NN (l_appos) subunit/NN (l_appos) mRNA/NN (l_conj) expression/NN (l_prep) in/IN (l_pobj) rats/NNS (l_prep) with/IN (l_pobj) syndrome/NN -PUNC- sodium/NN (r_compound) excretion/NN (r_nsubjpass) decreased/VBN (l_prep) In/IN (l_pobj) syndrome/NN
D000450_D011507 NONE aldosterone/NN (r_compound) concentration/NN (l_conj) proteinuria/NN
D011692_D011507 CID PAN/NNP (r_pobj) of/IN (r_prep) dose/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) rats/NNS (r_pobj) in/IN (r_prep) studied/VBN (l_nsubjpass) courses/NNS (l_prep) of/IN (l_pobj) excretion/NN (l_conj) concentration/NN (l_conj) proteinuria/NN
D011692_D009404 CID aminonucleoside/RB (r_advmod) induced/VBN (r_amod) syndrome/NN -PUNC- aminonucleoside/NN (l_pobj) syndrome/NN -PUNC- PAN)-induced/VBN (r_amod) syndrome/NN -PUNC- PAN/NNP (r_npadvmod) induced/VBN (r_amod) syndrome/NN
D012964_D011507 NONE sodium/NN (r_compound) excretion/NN (l_conj) concentration/NN (l_conj) proteinuria/NN -PUNC- sodium/NN (r_compound) excretion/NN (r_pobj) of/IN (r_prep) kinetics/NNS (l_conj) appearance/NN (l_prep) of/IN (l_pobj) proteinuria/NN
D000450_D009404 NONE aldosterone/NN (r_pobj) by/IN (r_prep) regulation/NN (r_pobj) from/IN (r_prep) escape/VB (r_xcomp) appears/VBZ (r_conj) increased/VBN (l_prep) in/IN (l_pobj) phase/NN (l_prep) of/IN (l_pobj) model/NN (l_prep) of/IN (l_pobj) syndrome/NN
9522152
D002045_D009461 NONE bupivacaine/NN (r_pobj) of/IN (r_prep) injection/NN (r_dobj) following/VBG (r_acl) deficit/NN -PUNC- bupivacaine/NN (r_pobj) with/IN (r_prep) anaesthesia/NN (r_pobj) after/IN (r_prep) occurred/VBD (r_relcl) deficit/NN
12536034
D005680_D004832 NONE acid/NN (r_npadvmod) transmitted/VBN (r_amod) circuitry/NN (r_compound) accounts/VBZ (l_prep) for/IN (l_pobj) part/NN (l_prep) of/IN (l_pobj) neurophysiology/NN (l_prep) of/IN (l_pobj) epilepsy/NN
D002220_D004832 CID carbamazepine/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) present/VBP (l_dobj) patients/NNS (l_prep) with/IN (l_pobj) epilepsy/NN
D020888_D004832 CID vigabatrin/NN (r_conj) carbamazepine/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) present/VBP (l_dobj) patients/NNS (l_prep) with/IN (l_pobj) epilepsy/NN
18703024
D016291_D002375 NONE MK-801-induced/JJ (r_compound) locomotion/NN (r_conj) catalepsy/NN
D006220_D002375 CID haloperidol/NN (r_npadvmod) induced/VBN (r_amod) catalepsy/NN
1749407
D003042_D013927 NONE cocaine/NN (r_pobj) of/IN (r_prep) effect/NN (l_amod) thrombotic/JJ
D003042_D009203 CID Cocaine/NN (r_npadvmod) induced/VBN (r_amod) infarction/NN -PUNC- cocaine/NN (r_nsubj) result/VB (l_prep) in/IN (l_pobj) infarction/NN -PUNC- cocaine/NN (r_npadvmod) induced/VBN (r_amod) increase/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) demand/NN (r_pobj) in/IN (r_prep) increase/NN (r_pobj) from/IN (r_prep) result/VB (l_nsubj) infarction/NN
D003042_D013035 NONE cocaine/NN (r_npadvmod) induced/VBN (r_amod) vasoconstriction/NN (r_pobj) of/IN (r_prep) locus/NN (r_nsubj) remains/VBZ (r_conj) are/VBP (l_prep) With/IN (l_pobj) regard/NN (l_prep) to/IN (l_pobj) spasm/NN
D010100_D009203 NONE oxygen/NN (r_compound) demand/NN (r_pobj) in/IN (r_prep) increase/NN (r_pobj) from/IN (r_prep) result/VB (l_nsubj) infarction/NN
2894766
D012460_D002305 CID sulfasalazine/NN (r_compound) therapy/NN (r_dobj) receiving/VBG (r_relcl) man/NN (r_pobj) in/IN (r_prep) developed/VBN (r_acl) autoantibodies/NNS (r_conj) evidence/NN (l_prep) of/IN (l_pobj) tamponade/NN
D012460_D010996 CID sulfasalazine/NN (r_compound) therapy/NN (r_dobj) receiving/VBG (r_relcl) man/NN (r_pobj) in/IN (r_prep) developed/VBN (r_acl) autoantibodies/NNS (r_conj) evidence/NN (r_appos) effusions/NNS
D012460_D015212 NONE sulfasalazine/NN (r_dobj) use/VBP (l_xcomp) treat/VB (l_dobj) patients/NNS (l_prep) with/IN (l_pobj) disease/NN -PUNC- sulfasalazine/NN (r_npadvmod) induced/VBN (r_amod) syndrome/NN (r_pobj) of/IN (r_prep) signs/NNS (r_pobj) of/IN (r_prep) aware/JJ (r_acomp) be/VB (l_nsubj) Physicians/NNS (l_relcl) use/VBP (l_xcomp) treat/VB (l_dobj) patients/NNS (l_prep) with/IN (l_pobj) disease/NN
D012460_D003093 NONE sulfasalazine/NN (r_compound) therapy/NN (r_dobj) receiving/VBG (l_prep) for/IN (l_pobj) colitis/NN
D012460_D012700 NONE sulfasalazine/RB (r_npadvmod) induced/VBN (r_amod) lupus/NN (l_relcl) manifested/VBD (l_prep) with/IN (l_pobj) serositis/NN
D012460_D011014 CID sulfasalazine/NN (r_compound) therapy/NN (r_dobj) receiving/VBG (r_relcl) man/NN (r_pobj) in/IN (r_prep) developed/VBN (r_acl) autoantibodies/NNS (r_conj) evidence/NN (r_appos) effusions/NNS (l_dep) Pneumonitis/NNP
D012460_D008180 CID Sulfasalazine/NNP (r_npadvmod) induced/VBN (r_amod) erythematosus/NN -PUNC- sulfasalazine/RB (r_npadvmod) induced/VBN (r_amod) lupus/NN -PUNC- sulfasalazine/NN (r_dobj) use/VBP (r_relcl) Physicians/NNS (r_nsubj) be/VB (l_acomp) aware/JJ (l_prep) of/IN (l_pobj) signs/NNS (l_prep) of/IN (l_pobj) syndrome/NN -PUNC- sulfasalazine/NN (r_npadvmod) induced/VBN (r_amod) syndrome/NN
20098969
D008694_-1 NONE methamphetamine/NN (r_dobj) abusing/VBG (r_acl) patients/NNS (r_nsubj) present/VB (l_prep) with/IN (l_pobj) hygiene/NN (l_conj) xerostomia/NN (l_conj) caries/NNS (l_appos) mouth/NN -PUNC- methamphetamines/NNS (r_dobj) abusing/VBG (r_relcl) patients/NNS (r_dobj) manage/VBP (r_conj) recognize/VBP (r_ccomp) help/VB (r_advcl) presented/VBN (l_nsubjpass) case/NN (l_acl) showing/VBG (l_dobj) manifestations/NNS (l_prep) of/IN (l_pobj) mouth/NN
D008694_D003731 CID methamphetamine/NN (r_dobj) abusing/VBG (r_acl) patients/NNS (r_nsubj) present/VB (l_prep) with/IN (l_pobj) hygiene/NN (l_conj) xerostomia/NN (l_conj) caries/NNS -PUNC- methamphetamine/NN (r_pobj) of/IN (r_prep) use/NN (r_dobj) reported/VBD (l_conj) experienced/VBN (l_dobj) episodes/NNS
D008694_D014987 NONE methamphetamine/NN (r_dobj) abusing/VBG (r_acl) patients/NNS (r_nsubj) present/VB (l_prep) with/IN (l_pobj) hygiene/NN (l_conj) xerostomia/NN
D008694_D006212 NONE Methamphetamine/NN (r_nsubj) is/VBZ (l_attr) stimulant/NN (l_relcl) increases/VBZ (l_conj) produce/VB (l_dobj) effects/NNS (l_prep) as/IN (l_pobj) dysrhythmias/NNS (l_conj) hypertension/NN (l_conj) hallucinations/NNS
D008694_D001523 NONE Methamphetamine/NN (r_nsubj) is/VBZ (l_attr) stimulant/NN (l_relcl) increases/VBZ (l_conj) produce/VB (l_dobj) effects/NNS (l_prep) as/IN (l_pobj) dysrhythmias/NNS (l_conj) hypertension/NN (l_conj) hallucinations/NNS (l_conj) behavior/NN
D008694_D001145 NONE Methamphetamine/NN (r_nsubj) is/VBZ (l_attr) stimulant/NN (l_relcl) increases/VBZ (l_conj) produce/VB (l_dobj) effects/NNS (l_prep) as/IN (l_pobj) dysrhythmias/NNS
D008694_D006973 NONE Methamphetamine/NN (r_nsubj) is/VBZ (l_attr) stimulant/NN (l_relcl) increases/VBZ (l_conj) produce/VB (l_dobj) effects/NNS (l_prep) as/IN (l_pobj) dysrhythmias/NNS (l_conj) hypertension/NN
D008694_D057085 NONE methamphetamine/NN (r_dobj) abusing/VBG (r_acl) patients/NNS (r_nsubj) present/VB (l_prep) with/IN (l_pobj) hygiene/NN (l_conj) xerostomia/NN (l_conj) caries/NNS (l_conj) wear/NN
8387218
D015215_D064420 NONE zidovudine/NNP (r_pobj) to/IN (r_prep) intolerant/JJ (r_amod) individuals/NNS (r_pobj) in/IN (r_prep) didanosine/NN (r_pobj) of/IN (r_prep) use/NN (l_conj) toxicity/NN -PUNC- AZT/NNP (r_appos) individuals/NNS (r_pobj) in/IN (r_prep) didanosine/NN (r_pobj) of/IN (r_prep) use/NN (l_conj) toxicity/NN
D015215_D015658 NONE zidovudine/NNP (r_pobj) to/IN (r_prep) intolerant/JJ (r_amod) individuals/NNS (l_amod) positive/JJ -PUNC- AZT/NNP (r_appos) individuals/NNS (l_amod) positive/JJ
D016049_D003920 NONE didanosine/NN (r_dobj) ceasing/VBG (r_pcomp) on/IN (r_prep) returned/VBN (r_conj) require/VB (r_conj) developed/VBD (l_dobj) curves/VBZ (l_amod) characteristic/JJ (l_prep) of/IN (l_pobj) diabetes/NNS
D016049_D064420 NONE didanosine/NN (r_pobj) of/IN (r_prep) use/NN (l_conj) toxicity/NN -PUNC- ddI/NN (r_appos) didanosine/NN (r_pobj) of/IN (r_prep) use/NN (l_conj) toxicity/NN
D016049_D015658 NONE didanosine/NN (l_prep) in/IN (l_pobj) individuals/NNS (l_amod) positive/JJ -PUNC- ddI/NN (r_appos) didanosine/NN (l_prep) in/IN (l_pobj) individuals/NNS (l_amod) positive/JJ
D016049_D018149 CID didanosine/NN (r_dobj) ceasing/VBG (r_pcomp) on/IN (r_prep) returned/VBN (r_conj) require/VB (r_conj) developed/VBD (l_dobj) curves/VBZ
7862923
D003024_D012559 NONE clozapine/NN (r_conj) chlorpromazine/NN (r_conj) haloperidol/NN (r_dobj) using/VBG (r_acl) patients/NNS (l_amod) schizophrenic/JJ
D002220_D019965 NONE Carbamazepine/NNP (r_nsubjpass) switched/VBN (l_prep) among/IN (l_pobj) patients/NNS (l_amod) psychotic/JJ
D002220_D012559 NONE Carbamazepine/NNP (r_nsubjpass) switched/VBN (l_prep) among/IN (l_pobj) patients/NNS (l_amod) schizophrenic/JJ
D006220_D019965 NONE haloperidol/NN (r_dobj) using/VBG (r_acl) patients/NNS (l_amod) psychotic/JJ
D002746_D012559 NONE chlorpromazine/NN (r_conj) haloperidol/NN (r_dobj) using/VBG (r_acl) patients/NNS (l_amod) schizophrenic/JJ
D002746_D019965 NONE chlorpromazine/NN (r_conj) haloperidol/NN (r_dobj) using/VBG (r_acl) patients/NNS (l_amod) psychotic/JJ
D003024_D019965 NONE clozapine/NN (r_conj) chlorpromazine/NN (r_conj) haloperidol/NN (r_dobj) using/VBG (r_acl) patients/NNS (l_amod) psychotic/JJ
D006220_D012559 NONE haloperidol/NN (r_dobj) using/VBG (r_acl) patients/NNS (l_amod) schizophrenic/JJ
C036006_D019965 NONE oxcarbazepine/NN (r_pobj) to/IN (r_prep) switched/VBN (l_prep) among/IN (l_pobj) patients/NNS (l_amod) psychotic/JJ
C036006_D012559 NONE oxcarbazepine/NN (r_pobj) to/IN (r_prep) switched/VBN (l_prep) among/IN (l_pobj) patients/NNS (l_amod) schizophrenic/JJ
18417364
D010100_D009759 NONE oxygen/NN (r_nmod) levels/NNS (r_pobj) with/IN (r_prep) correlated/VBD (l_nsubj) NIN/NNP
D009538_D009759 CID Nicotine/NN (r_npadvmod) induced/VBN (r_amod) nystagmus/NN -PUNC- nicotine/NN (r_npadvmod) induced/VBN (r_amod) nystagmus/NN -PUNC- nicotine/NN (r_npadvmod) induced/VBN (r_amod) nystagmus/NN (l_appos) NIN/NNP
10669626
D014807_D002114 NONE D/JJ (r_conj) growth/NN (r_nmod) treatment/NN (r_nsubj) enhance/VB (l_prep) given/VBN (l_advcl) inhibit/VB (l_dobj) carboxylation/NN (l_prep) of/IN (l_pobj) protein/NN (l_appos) inhibitor/NN (l_compound) calcification/NN -PUNC- D/NN (r_npadvmod) treated/VBN (r_amod) rats/NNS (r_pobj) of/IN (r_prep) media/NNS (r_pobj) in/IN (r_prep) calcification/NN -PUNC- D/NN (r_pobj) by/IN (r_agent) produced/VBN (r_acl) calcium/NN (r_pobj) in/IN (r_prep) elevation/NN (r_pobj) on/IN (r_prep) effect/NN (r_dobj) had/VBD (r_advcl) explained/VBN (l_agent) by/IN (l_pobj) hypothesis/NN (l_acl) inhibits/VBZ (l_prep) as/IN (l_pobj) inhibitor/NN (l_compound) calcification/NN -PUNC- D/NN (r_pobj) between/IN (r_prep) synergy/NN (r_appos) D/NN (r_pobj) by/IN (r_agent) produced/VBN (r_acl) calcium/NN (r_pobj) in/IN (r_prep) elevation/NN (r_pobj) on/IN (r_prep) effect/NN (r_dobj) had/VBD (r_advcl) explained/VBN (l_agent) by/IN (l_pobj) hypothesis/NN (l_acl) inhibits/VBZ (l_prep) as/IN (l_pobj) inhibitor/NN (l_compound) calcification/NN
D014859_D061205 CID Warfarin/NNP (r_npadvmod) induced/VBN (r_amod) calcification/NN -PUNC- Warfarin/NNP (r_pobj) of/IN (r_prep) doses/NNS (r_dobj) given/VBN (r_prep) enhance/VB (l_dobj) extent/NN (l_prep) of/IN (l_pobj) calcification/NN -PUNC- Warfarin/NNP (r_npadvmod) treated/VBN (r_amod) rats/NNS (r_pobj) in/IN (r_prep) calcification/NN -PUNC- Warfarin/NNP (r_pobj) with/IN (r_prep) Treatment/NN (r_nsubj) caused/VBD (l_dobj) calcification/NN (l_prep) of/IN (l_pobj) media/NNS (l_compound) artery/NN -PUNC- Warfarin/NNP (r_compound) treatment/NN (r_pobj) of/IN (r_prep) weeks/NNS (r_pobj) after/IN (r_prep) detected/VBN (l_nsubjpass) calcification/NN -PUNC- Warfarin/NNP (r_npadvmod) induced/VBN (r_amod) calcification/NN -PUNC- Warfarin/NNP (r_pobj) with/IN (r_prep) groups/NNS (r_pobj) of/IN (r_prep) treatment/NN (r_nsubj) produced/VBD (l_dobj) calcification/NN (l_prep) of/IN (l_pobj) media/NNS (l_compound) artery/NN -PUNC- Warfarin/NNP (r_pobj) with/IN (r_prep) groups/NNS (r_pobj) of/IN (r_prep) treatment/NN (r_nsubj) produced/VBD (l_dobj) calcification/NN (l_conj) calcification/NN -PUNC- Warfarin/NNP (r_npadvmod) induced/VBN (r_amod) calcification/NN (r_pobj) to/IN (r_prep) resistant/JJ (r_acomp) was/VBD (r_relcl) groups/NNS (r_pobj) of/IN (r_prep) either/DT (r_pobj) with/IN (r_prep) compared/VBN (r_prep) rats/NNS (r_appos) relationship/NN (r_attr) was/VBD (l_advcl) determined/VBN (l_nsubjpass) explanation/NN (l_prep) for/IN (l_pobj) association/NN (l_prep) between/IN (l_pobj) calcification/NN -PUNC- Warfarin/NNP (r_npadvmod) induced/VBN (r_amod) calcification/NN (r_pobj) to/IN (r_prep) resistant/JJ (r_acomp) was/VBD (r_relcl) groups/NNS (r_pobj) of/IN (r_prep) either/DT (r_pobj) with/IN (r_prep) compared/VBN (r_prep) rats/NNS (r_appos) relationship/NN (l_prep) between/IN (l_pobj) phosphate/NN (l_conj) susceptibility/NN (l_prep) to/IN (l_pobj) calcification/NN -PUNC- Warfarin/NNP (r_npadvmod) induced/VBN (r_amod) calcification/NN -PUNC- Warfarin/NNP (r_npadvmod) induced/VBN (r_amod) calcification/NN -PUNC- Warfarin/NNP (r_conj) D/NN (r_pobj) between/IN (r_prep) synergy/NN (l_prep) in/IN (l_pobj) calcification/NN -PUNC- Warfarin/NNP (r_nsubjpass) known/VBN (l_xcomp) cause/VB (l_dobj) calcification/NN (l_prep) of/IN (l_pobj) media/NNS (l_compound) artery/NN -PUNC- Warfarin/NNP (r_conj) D/NNP (r_pobj) with/IN (r_prep) treated/VBN (r_acl) rats/NNS (r_pobj) in/IN (r_prep) calcification/NN
D014859_D002114 NONE Warfarin/NNP (r_pobj) of/IN (r_prep) doses/NNS (r_dobj) given/VBN (l_advcl) inhibit/VB (l_dobj) carboxylation/NN (l_prep) of/IN (l_pobj) protein/NN (l_appos) inhibitor/NN (l_compound) calcification/NN -PUNC- Warfarin/NNP (r_pobj) with/IN (r_prep) Treatment/NN (r_nsubj) caused/VBD (l_dobj) calcification/NN (l_conj) calcification/NN -PUNC- Warfarin/NNP (r_compound) administration/NN (r_nsubj) increased/VBD (l_dobj) extent/NN (l_prep) of/IN (l_pobj) calcification/NN -PUNC- Warfarin/NNP (r_compound) treatment/NN (r_nsubj) had/VBD (r_advcl) explained/VBN (l_agent) by/IN (l_pobj) hypothesis/NN (l_acl) inhibits/VBZ (l_prep) as/IN (l_pobj) inhibitor/NN (l_compound) calcification/NN -PUNC- Warfarin/NNP (r_nmod) D/NN (r_pobj) between/IN (r_prep) synergy/NN (r_appos) D/NN (r_pobj) by/IN (r_agent) produced/VBN (r_acl) calcium/NN (r_pobj) in/IN (r_prep) elevation/NN (r_pobj) on/IN (r_prep) effect/NN (r_dobj) had/VBD (r_advcl) explained/VBN (l_agent) by/IN (l_pobj) hypothesis/NN (l_acl) inhibits/VBZ (l_prep) as/IN (l_pobj) inhibitor/NN (l_compound) calcification/NN -PUNC- Warfarin/NNP (r_nsubj) inhibits/VBZ (l_prep) as/IN (l_pobj) inhibitor/NN (l_compound) calcification/NN
D015055_D002114 NONE carboxyglutamate/NN (r_compound) residues/NNS (r_nsubjpass) required/VBN (l_prep) as/IN (l_pobj) inhibitor/NN (l_compound) calcification/NN -PUNC- carboxyglutamate/NN (r_compound) residues/NNS (r_nsubjpass) required/VBN (r_advcl) required/VBN (l_prep) for/IN (l_pobj) accumulation/NN (l_prep) at/IN (l_pobj) sites/NNS (l_compound) calcification/NN
D002118_D002114 NONE calcium/NN (r_pobj) in/IN (r_prep) elevation/NN (r_pobj) on/IN (r_prep) effect/NN (r_dobj) had/VBD (r_advcl) explained/VBN (l_agent) by/IN (l_pobj) hypothesis/NN (l_acl) inhibits/VBZ (l_prep) as/IN (l_pobj) inhibitor/NN (l_compound) calcification/NN
D015055_D061205 NONE carboxylated/JJ (r_acomp) was/VBD (r_ccomp) showed/VBD (r_conj) found/VBN (l_prep) at/IN (l_pobj) sites/NNS (l_prep) of/IN (l_pobj) calcification/NN
D014807_D061205 NONE D./NNP (r_conj) growth/NN (r_pobj) by/IN (r_agent) accelerated/VBN (l_nsubjpass) calcification/NN -PUNC- D/JJ (r_conj) growth/NN (r_nmod) treatment/NN (r_nsubj) enhance/VB (l_dobj) extent/NN (l_prep) of/IN (l_pobj) calcification/NN -PUNC- D/NN (r_pobj) between/IN (r_prep) synergy/NN (l_prep) in/IN (l_pobj) calcification/NN -PUNC- D/NNP (r_pobj) of/IN (r_prep) doses/NNS (r_nsubjpass) known/VBN (l_xcomp) cause/VB (l_dobj) calcification/NN (l_prep) of/IN (l_pobj) media/NNS (l_compound) artery/NN -PUNC- D/NN (r_compound) dose/NN (l_prep) on/IN (l_pobj) calcification/NN -PUNC- D/NN (r_compound) dose/NN (r_pobj) of/IN (r_prep) effect/NN (l_conj) effect/NN (l_prep) of/IN (l_pobj) dose/NN (l_prep) on/IN (l_pobj) elevation/NN (l_relcl) suggests/VBZ (l_ccomp) induce/VB (l_dobj) calcification/NN -PUNC- D/NNP (r_compound) dose/NN (r_pobj) of/IN (r_prep) effect/NN (r_conj) effect/NN (l_prep) of/IN (l_pobj) dose/NN (l_prep) on/IN (l_pobj) calcification/NN -PUNC- D/NNP (r_compound) dose/NN (l_prep) on/IN (l_pobj) elevation/NN (l_relcl) suggests/VBZ (l_ccomp) induce/VB (l_dobj) calcification/NN -PUNC- D/NN (r_nsubj) induce/VB (r_ccomp) suggests/VBZ (r_relcl) elevation/NN (r_pobj) on/IN (r_prep) dose/NN (r_pobj) of/IN (r_prep) effect/NN (r_conj) effect/NN (l_prep) of/IN (l_pobj) dose/NN (l_prep) on/IN (l_pobj) calcification/NN -PUNC- D/NN (r_nsubj) induce/VB (l_dobj) calcification/NN -PUNC- D/NNP (r_pobj) with/IN (r_prep) treated/VBN (r_acl) rats/NNS (r_pobj) in/IN (r_prep) calcification/NN
D010710_D061205 NONE phosphate/NN (r_pobj) between/IN (r_prep) relationship/NN (r_attr) was/VBD (l_advcl) determined/VBN (l_nsubjpass) explanation/NN (l_prep) for/IN (l_pobj) association/NN (l_prep) between/IN (l_pobj) calcification/NN -PUNC- phosphate/NN (l_conj) susceptibility/NN (l_prep) to/IN (l_pobj) calcification/NN -PUNC- phosphate/NN (r_pobj) between/IN (r_prep) relationship/NN (l_appos) rats/NNS (l_prep) compared/VBN (l_prep) with/IN (l_pobj) either/DT (l_prep) of/IN (l_pobj) groups/NNS (l_relcl) was/VBD (l_acomp) resistant/JJ (l_prep) to/IN (l_pobj) calcification/NN -PUNC- phosphate/NN (r_pobj) of/IN (r_prep) levels/NNS (r_pobj) with/IN (r_prep) relationship/NN (r_attr) was/VBD (l_advcl) determined/VBN (l_nsubjpass) explanation/NN (l_prep) for/IN (l_pobj) association/NN (l_prep) between/IN (l_pobj) calcification/NN -PUNC- phosphate/NN (r_pobj) of/IN (r_prep) levels/NNS (r_pobj) with/IN (r_prep) relationship/NN (l_prep) between/IN (l_pobj) phosphate/NN (l_conj) susceptibility/NN (l_prep) to/IN (l_pobj) calcification/NN -PUNC- phosphate/NN (r_pobj) of/IN (r_prep) levels/NNS (r_pobj) with/IN (r_prep) relationship/NN (l_appos) rats/NNS (l_prep) compared/VBN (l_prep) with/IN (l_pobj) either/DT (l_prep) of/IN (l_pobj) groups/NNS (l_relcl) was/VBD (l_acomp) resistant/JJ (l_prep) to/IN (l_pobj) calcification/NN -PUNC- phosphate/NN (r_compound) levels/NNS (r_pobj) to/IN (r_prep) related/VBN (l_nsubjpass) susceptibility/NN (l_prep) to/IN (l_pobj) calcification/NN
D002118_D061205 NONE calcium/NN (r_pobj) of/IN (r_prep) elevation/NN (r_pobj) on/IN (r_prep) dose/NN (r_pobj) of/IN (r_prep) effect/NN (r_conj) effect/NN (l_prep) of/IN (l_pobj) dose/NN (l_prep) on/IN (l_pobj) calcification/NN -PUNC- calcium/NN (r_pobj) of/IN (r_prep) elevation/NN (l_relcl) suggests/VBZ (l_ccomp) induce/VB (l_dobj) calcification/NN -PUNC- calcium/NN (r_pobj) on/IN (r_prep) effect/NN (r_pobj) through/IN (r_prep) induce/VB (r_ccomp) suggests/VBZ (r_relcl) elevation/NN (r_pobj) on/IN (r_prep) dose/NN (r_pobj) of/IN (r_prep) effect/NN (r_conj) effect/NN (l_prep) of/IN (l_pobj) dose/NN (l_prep) on/IN (l_pobj) calcification/NN -PUNC- calcium/NN (r_pobj) on/IN (r_prep) effect/NN (r_pobj) through/IN (r_prep) induce/VB (l_dobj) calcification/NN
7881871
D010100_D007674 NONE oxygen/NN (r_compound) species/NNS (r_nsubjpass) implicated/VBN (l_prep) in/IN (l_pobj) pathogenesis/NN (l_prep) of/IN (l_pobj) nephropathy/NN
D011692_D007674 CID aminonucleoside/NN (r_advmod) induced/VBN (r_amod) nephropathy/NN -PUNC- aminonucleoside/NN (r_nmod) nephropathy/NN -PUNC- PAN)-induced/JJ (r_amod) nephropathy/NN -PUNC- PAN/NNP (r_compound) nephropathy/NN
D011692_D011507 CID aminonucleoside/NN (r_nmod) nephropathy/NN (r_pobj) of/IN (r_prep) pathogenesis/NN (r_pobj) in/IN (r_prep) implicated/VBN (l_prep) with/IN (l_pcomp) reducing/VBG (l_dobj) proteinuria/NN -PUNC- PAN)-induced/JJ (r_amod) nephropathy/NN (r_pobj) of/IN (r_prep) pathogenesis/NN (r_pobj) in/IN (r_prep) implicated/VBN (l_prep) with/IN (l_pcomp) reducing/VBG (l_dobj) proteinuria/NN -PUNC- PAN/NNP (r_compound) nephropathy/NN (r_pobj) in/IN (r_prep) injury/NN
D010100_D011507 NONE oxygen/NN (r_compound) species/NNS (r_nsubjpass) implicated/VBN (l_prep) with/IN (l_pcomp) reducing/VBG (l_dobj) proteinuria/NN
8595686
D008012_D010146 NONE lidocaine/NN (r_nsubj) reduces/VBZ (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) pain/NN
D013874_D010146 NONE Thiopentone/NN (r_compound) pretreatment/NN (l_prep) for/IN (l_pobj) pain/NN -PUNC- thiopentone/NN (r_nsubj) reduces/VBZ (r_advcl) reduces/VBZ (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) pain/NN
D015742_D010146 CID propofol/JJ (r_amod) pain/NN -PUNC- propofol/JJ (r_amod) pain/NN -PUNC- propofol/JJ (r_amod) pain/NN
18308784
C035054_D007859 NONE Rg1/NNP (r_nsubj) restores/VBZ (l_dobj) impairment/NN (l_prep) of/IN (l_pobj) learning/VBG -PUNC- Rg1/NNP (l_advcl) ameliorate/VB (l_dobj) impairment/NN -PUNC- Rg1/NN (r_pobj) of/IN (r_prep) effect/NN (l_prep) on/IN (l_pobj) impairment/NN
D009020_D007859 CID morphine/NN (r_compound) administration/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) impairment/NN (l_prep) of/IN (l_pobj) learning/VBG -PUNC- morphine/NN (r_compound) administration/NN (r_pobj) by/IN (r_prep) impairment/NN
D036145_D007859 NONE ginsenoside/NN (r_pobj) as/IN (r_prep) ameliorate/VB (l_dobj) impairment/NN
2355241
D009638_D010300 NONE noradrenaline/NN (r_amod) levels/NNS (r_pobj) due/IN (r_amod) mechanism/NN (r_conj) effect/NN (r_dobj) reflect/VB (l_nsubj) incidence/NN (l_prep) as/IN (l_pobj) cause/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disease/NN -PUNC- noradrenaline/NN (r_amod) levels/NNS (l_prep) in/IN (l_pobj) brain/NN (l_amod) parkinsonian/JJ
D009638_D003643 NONE noradrenaline/NN (r_amod) levels/NNS (r_pobj) due/IN (r_amod) mechanism/NN (r_conj) effect/NN (r_dobj) reflect/VB (l_nsubj) incidence/NN (l_prep) as/IN (l_pobj) cause/NN (l_prep) of/IN (l_pobj) death/NN
D007980_D003643 NONE levodopa/NN (r_pobj) of/IN (r_prep) effect/NN (r_dobj) reflect/VB (l_nsubj) incidence/NN (l_prep) as/IN (l_pobj) cause/NN (l_prep) of/IN (l_pobj) death/NN
D007980_D010300 NONE levodopa/NN (r_pobj) of/IN (r_prep) effect/NN (r_dobj) reflect/VB (l_nsubj) incidence/NN (l_prep) as/IN (l_pobj) cause/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disease/NN -PUNC- levodopa/NN (r_pobj) of/IN (r_prep) effect/NN (l_conj) mechanism/NN (l_amod) due/IN (l_pobj) levels/NNS (l_prep) in/IN (l_pobj) brain/NN (l_amod) parkinsonian/JJ
D009638_D007022 NONE noradrenaline/NN (r_amod) levels/NNS (r_pobj) due/IN (r_amod) mechanism/NN (r_conj) effect/NN (l_amod) hypotensive/JJ -PUNC- noradrenaline/NN (r_amod) levels/NNS (r_pobj) due/IN (r_amod) mechanism/NN (l_amod) hypotensive/JJ
D007980_D002543 NONE levodopa/NN (r_pobj) of/IN (r_prep) effect/NN (r_dobj) reflect/VB (l_nsubj) incidence/NN (l_prep) of/IN (l_pobj) haemorrhage/NN
D007980_D007022 CID levodopa/NN (r_pobj) of/IN (r_prep) effect/NN (l_amod) hypotensive/JJ -PUNC- levodopa/NN (r_pobj) of/IN (r_prep) effect/NN (l_conj) mechanism/NN (l_amod) hypotensive/JJ
D009638_D002543 NONE noradrenaline/NN (r_amod) levels/NNS (r_pobj) due/IN (r_amod) mechanism/NN (r_conj) effect/NN (r_dobj) reflect/VB (l_nsubj) incidence/NN (l_prep) of/IN (l_pobj) haemorrhage/NN
11642480
D015283_D003865 NONE citalopram/NN (r_pobj) with/IN (r_prep) treatment/NN (l_prep) by/IN (l_pobj) boy/NN (l_prep) with/IN (l_pobj) depression/NN
D015283_D003866 NONE citalopram/NN (r_pobj) on/IN (r_prep) adolescent/NN (l_amod) depressed/JJ
D015283_D004409 CID citalopram/NN (r_pobj) on/IN (r_prep) adolescent/NN (r_pobj) in/IN (r_prep) twitching/VBG -PUNC- citalopram/NN (r_pobj) with/IN (r_prep) treatment/NN (l_prep) by/IN (l_pobj) boy/NN (l_prep) with/IN (l_pobj) depression/NN (l_relcl) exhibited/VBD (l_dobj) twitching/NN
18544179
C009250_D001919 NONE sevoflurane/NN (r_npadvmod) sparing/VBG (r_amod) effect/NN (r_dobj) had/VBD (l_conj) depression/NN (l_conj) hypotension/NN (l_conj) bradycardia/NN
D003907_D020250 NONE dexamethasone/NN (r_pobj) with/IN (r_prep) %/NN (r_conj) %/NN (r_pobj) from/IN (r_prep) discharge/NN (r_pobj) to/IN (r_prep) prior/RB (r_advmod) reduce/VB (r_conj) reduce/VB (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) nausea/NN (l_conj) vomiting/NN -PUNC- Dexamethasone/NNP (r_nsubj) had/VBD (l_dobj) effect/NN (l_prep) on/IN (l_pobj) incidence/NN (l_prep) of/IN (l_pobj) nausea/NN (l_conj) vomiting/NN
D003907_D009325 NONE dexamethasone/NN (r_pobj) with/IN (r_prep) %/NN (r_conj) %/NN (r_pobj) from/IN (r_prep) discharge/NN (r_pobj) to/IN (r_prep) prior/RB (r_advmod) reduce/VB (l_conj) moderate/JJ (l_prep) to/TO (l_pobj) nausea/NN
C009250_D014839 NONE sevoflurane/NN (r_pobj) after/IN (r_prep) reduces/VBZ (l_dobj) nausea/NN (l_conj) vomiting/NN
D005283_D001919 CID Fentanyl/NNP (r_nsubj) reduce/VB (l_conj) had/VBD (l_conj) depression/NN (l_conj) hypotension/NN (l_conj) bradycardia/NN
C009250_D020250 NONE sevoflurane/NN (r_pobj) with/IN (r_prep) advantages/NNS (r_pobj) Despite/IN (r_prep) occurs/VBZ (l_nsubj) nausea/NN (l_conj) vomiting/NN -PUNC- sevoflurane/NN (r_compound) anaesthesia/NN (r_pobj) after/IN (r_prep) h/NN (r_pobj) in/IN (r_prep) examined/VBD (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) nausea/NN (l_conj) vomiting/NN -PUNC- sevoflurane/NN (r_relcl) supplement/NN (r_attr) be/VB (r_xcomp) appears/VBZ (l_advcl) exacerbated/VBD (l_dobj) nausea/NN (l_conj) vomiting/VBG
C009250_D007022 NONE sevoflurane/NN (r_npadvmod) sparing/VBG (r_amod) effect/NN (r_dobj) had/VBD (l_conj) depression/NN (l_conj) hypotension/NN
D005283_D012131 CID Fentanyl/NNP (r_nsubj) reduce/VB (l_conj) had/VBD (l_conj) depression/NN
D005283_D020250 CID fentanyl/NN (r_pobj) of/IN (r_prep) Omission/NN (r_nsubj) reduce/VB (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) nausea/NN (l_conj) vomiting/NN -PUNC- fentanyl/NN (r_nmod) dexamethasone/NN (r_pobj) with/IN (r_prep) %/NN (r_conj) %/NN (r_pobj) from/IN (r_prep) discharge/NN (r_pobj) to/IN (r_prep) prior/RB (r_advmod) reduce/VB (r_conj) reduce/VB (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) nausea/NN (l_conj) vomiting/NN -PUNC- fentanyl/NN (r_compound) dexamethasone/NN (r_pobj) with/IN (r_prep) %/NN (r_conj) %/NN (r_pobj) from/IN (r_prep) discharge/NN (r_pobj) to/IN (r_prep) prior/RB (r_advmod) reduce/VB (r_conj) reduce/VB (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) nausea/NN (l_conj) vomiting/NN -PUNC- fentanyl/NN (r_compound) groups/NNS (r_dobj) Combining/VBG (r_csubj) revealed/VBD (l_advcl) reducing/VBG (l_dobj) nausea/NN (l_conj) vomiting/NN -PUNC- fentanyl/NN (r_nsubj) exacerbated/VBD (l_dobj) nausea/NN (l_conj) vomiting/VBG
C009250_D010149 NONE sevoflurane/NN (r_relcl) supplement/NN (r_attr) be/VB (r_xcomp) appears/VBZ (l_advcl) exacerbated/VBD (l_dobj) nausea/NN (l_conj) vomiting/VBG (l_prep) without/IN (l_pobj) improvement/NN (l_prep) in/IN (l_pobj) pain/NN
D005283_D010149 NONE fentanyl/NN (r_nsubj) exacerbated/VBD (l_dobj) nausea/NN (l_conj) vomiting/VBG (l_prep) without/IN (l_pobj) improvement/NN (l_prep) in/IN (l_pobj) pain/NN
C009250_D010146 NONE sevoflurane/NN (r_pobj) after/IN (r_prep) reduces/VBZ (l_prep) without/IN (l_pcomp) increasing/VBG (l_dobj) pain/NN -PUNC- sevoflurane/NN (r_compound) anaesthesia/NN (r_pobj) after/IN (r_prep) h/NN (r_pobj) in/IN (r_prep) examined/VBD (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) nausea/NN (l_conj) vomiting/NN (l_conj) pain/NN
C009250_D012131 NONE sevoflurane/NN (r_npadvmod) sparing/VBG (r_amod) effect/NN (r_dobj) had/VBD (l_conj) depression/NN
D003907_D014839 NONE dexamethasone/NN (r_pobj) with/IN (r_prep) %/NN (r_conj) %/NN (r_pobj) from/IN (r_prep) discharge/NN (r_pobj) to/IN (r_prep) prior/RB (r_advmod) reduce/VB (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) vomiting/NN
D005283_D014839 NONE fentanyl/NN (r_dobj) Omitting/VBG (r_csubj) reduces/VBZ (l_dobj) nausea/NN (l_conj) vomiting/NN -PUNC- fentanyl/NN (r_pobj) of/IN (r_prep) Omission/NN (r_nsubj) reduce/VB (l_conj) reduce/VB (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) vomiting/NN -PUNC- fentanyl/NN (r_nmod) dexamethasone/NN (r_pobj) with/IN (r_prep) %/NN (r_conj) %/NN (r_pobj) from/IN (r_prep) discharge/NN (r_pobj) to/IN (r_prep) prior/RB (r_advmod) reduce/VB (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) vomiting/NN -PUNC- fentanyl/NN (r_compound) dexamethasone/NN (r_pobj) with/IN (r_prep) %/NN (r_conj) %/NN (r_pobj) from/IN (r_prep) discharge/NN (r_pobj) to/IN (r_prep) prior/RB (r_advmod) reduce/VB (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) vomiting/NN
D005283_D010146 NONE fentanyl/NN (r_dobj) Omitting/VBG (r_csubj) reduces/VBZ (l_prep) without/IN (l_pcomp) increasing/VBG (l_dobj) pain/NN -PUNC- fentanyl/NN (r_pobj) of/IN (r_prep) omission/NN (r_pobj) by/IN (r_prep) unaffected/JJ (r_acomp) were/VBD (l_nsubj) severity/NN (l_compound) Pain/NN
C009250_D009325 NONE sevoflurane/NN (r_pobj) after/IN (r_prep) reduces/VBZ (l_dobj) nausea/NN
D005283_D007022 CID Fentanyl/NNP (r_nsubj) reduce/VB (l_conj) had/VBD (l_conj) depression/NN (l_conj) hypotension/NN
D005283_D009325 NONE fentanyl/NN (r_dobj) Omitting/VBG (r_csubj) reduces/VBZ (l_dobj) nausea/NN -PUNC- fentanyl/NN (r_pobj) of/IN (r_prep) Omission/NN (r_nsubj) reduce/VB (l_conj) reduce/VB (l_conj) moderate/JJ (l_prep) to/TO (l_pobj) nausea/NN -PUNC- fentanyl/NN (r_nmod) dexamethasone/NN (r_pobj) with/IN (r_prep) %/NN (r_conj) %/NN (r_pobj) from/IN (r_prep) discharge/NN (r_pobj) to/IN (r_prep) prior/RB (r_advmod) reduce/VB (l_conj) moderate/JJ (l_prep) to/TO (l_pobj) nausea/NN -PUNC- fentanyl/NN (r_compound) dexamethasone/NN (r_pobj) with/IN (r_prep) %/NN (r_conj) %/NN (r_pobj) from/IN (r_prep) discharge/NN (r_pobj) to/IN (r_prep) prior/RB (r_advmod) reduce/VB (l_conj) moderate/JJ (l_prep) to/TO (l_pobj) nausea/NN -PUNC- fentanyl/NN (r_compound) groups/NNS (r_dobj) Combining/VBG (r_csubj) revealed/VBD (l_advcl) reducing/VBG (l_dobj) nausea/NN (l_conj) vomiting/NN (l_conj) nausea/NN -PUNC- fentanyl/NN (r_compound) groups/NNS (r_dobj) Combining/VBG (r_csubj) revealed/VBD (l_advcl) decreased/VBN (l_nsubjpass) nausea/NN
3173179
D014700_D009203 CID Verapamil/NNP (r_compound) withdrawal/NN (l_prep) as/IN (l_pobj) cause/NN (l_prep) of/IN (l_pobj) infarction/NN -PUNC- verapamil/NN (r_pobj) of/IN (r_prep) withdrawal/NN (r_conj) introduction/NN (r_pobj) with/IN (r_prep) coincided/VBD (l_nsubj) infarction/NN
D014700_D006973 NONE Verapamil/NNP (r_compound) withdrawal/NN (l_prep) as/IN (l_pobj) cause/NN (l_prep) of/IN (l_pobj) infarction/NN (l_prep) in/IN (l_pobj) woman/NN (l_amod) hypertensive/JJ -PUNC- verapamil/NN (r_pobj) of/IN (r_prep) withdrawal/NN (l_prep) in/IN (l_pobj) woman/NN (l_prep) with/IN (l_pobj) hypertension/NN
D002216_D009203 NONE captopril/NN (r_pobj) of/IN (r_prep) introduction/NN (r_pobj) with/IN (r_prep) coincided/VBD (l_nsubj) infarction/NN
D002216_D006973 NONE captopril/NN (r_pobj) of/IN (r_prep) introduction/NN (l_conj) withdrawal/NN (l_prep) in/IN (l_pobj) woman/NN (l_prep) with/IN (l_pobj) hypertension/NN
3371379
D002118_D020258 NONE calcium/NN (r_compound) entry/NN (r_compound) blocker/NN (r_pobj) of/IN (r_prep) discontinuation/NN (r_pobj) after/IN (r_prep) recovery/NN (r_dobj) showed/VBD (l_nsubj) patients/NNS (l_prep) with/IN (l_pobj) signs/NNS (l_prep) of/IN (l_pobj) neurotoxicity/NN
D014700_D020258 CID Verapamil/NNP (r_npadvmod) induced/VBN (l_dobj) neurotoxicity/NN -PUNC- verapamil/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) after/IN (r_prep) signs/NNS (l_prep) of/IN (l_pobj) neurotoxicity/NN
D002220_D020258 CID carbamazepine/NN (r_compound) neurotoxicity/NN -PUNC- carbamazepine/JJ (r_compound) neurotoxicity/NN
12820454
D016729_D000740 CID acetate/NN (r_dobj) received/VBD (l_conj) evaluated/VBN (l_prep) for/IN (l_pobj) anemia/NN -PUNC- A/NNP (r_appos) acetate/NN (r_dobj) received/VBD (l_conj) evaluated/VBN (l_prep) for/IN (l_pobj) anemia/NN
D005485_D000740 CID flutamide/NN (r_nmod) tid/NN (r_conj) days/NNS (r_appos) acetate/NN (r_dobj) received/VBD (l_conj) evaluated/VBN (l_prep) for/IN (l_pobj) anemia/NN
1867351
D015767_D008288 NONE mefloquine/NN (r_pobj) with/IN (r_prep) treatment/NN (r_conj) prophylaxis/NN (l_compound) malaria/NN
3560096
D013467_D006947 CID sulindac/NN (r_compound) therapy/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) Hyperkalemia/NNP -PUNC- sulindac/NN (r_compound) administration/NN (r_pobj) of/IN (r_prep) days/NNS (r_pobj) within/IN (r_prep) developed/VBD (l_nsubj) hyperkalemia/VBD -PUNC- sulindac/NN (l_conj) hyperkalemia/NN
D011188_D006947 NONE potassium/NN (r_dobj) effect/NN (r_xcomp) known/VBN (r_acl) medications/NNS (r_nsubjpass) given/VBN (r_advcl) is/VBZ (l_acomp) suggestive/JJ (l_prep) of/IN (l_pobj) relationship/NN (l_prep) between/IN (l_pobj) sulindac/NN (l_conj) hyperkalemia/NN
D007213_D006947 CID indomethacin/NN (r_pobj) as/IN (r_prep) NSAID/NNP (r_appos) agents/NNS (r_pobj) of/IN (r_prep) complication/NN (r_pobj) as/IN (r_prep) recognized/VBN (l_nsubjpass) Hyperkalemia/NNP
809711
D005996_D007022 CID Nitroglycerin/NNP (r_nsubjpass) shown/VBN (r_ccomp) potentiated/VBN (l_agent) by/IN (l_pobj) agents/NNS (l_relcl) reverse/VBP (l_dobj) hypotension/NN -PUNC- nitroglycerin/NN (r_npadvmod) induced/VBN (r_amod) hypotension/NN
D005996_D009203 NONE nitroglycerin/NN (r_pobj) of/IN (r_prep) effects/NNS (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) infarction/NN -PUNC- Nitroglycerin/NNP (r_nsubjpass) shown/VBN (l_xcomp) reduce/VB (l_prep) during/IN (l_pobj) infarction/NN -PUNC- nitroglycerin/NN (r_npadvmod) induced/VBN (r_amod) hypotension/NN (r_dobj) reverse/VBP (r_relcl) agents/NNS (r_pobj) by/IN (r_agent) potentiated/VBN (l_ccomp) shown/VBN (l_xcomp) reduce/VB (l_prep) during/IN (l_pobj) infarction/NN -PUNC- nitroglycerin/NN (r_dobj) received/VBD (l_nsubj) patients/NNS (l_prep) with/IN (l_pobj) infarctions/NNS -PUNC- nitroglycerin/NN (r_pobj) to/IN (r_prep) phenylephrine/NN (r_pobj) of/IN (r_prep) addition/NN (r_nsubj) is/VBZ (l_acomp) beneficial/JJ (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) infarction/NN
D010656_D009203 NONE phenylephrine/NN (l_prep) of/IN (l_pobj) effects/NNS (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) infarction/NN -PUNC- phenylephrine/NN (r_pobj) of/IN (r_prep) addition/NN (r_nsubj) is/VBZ (l_acomp) beneficial/JJ (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) infarction/NN
18162529
D004967_D006966 NONE estrogen/NN (r_npadvmod) induced/VBN (r_amod) surge/NN (r_conj) secretion/NN (r_appos) parameters/NNS (r_dobj) inhibited/VBD (l_nsubj) hyperprolactinemia/NN
D004298_D006966 NONE dopamine/NN (r_compound) antagonist/NN (r_compound) sulpiride/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) hyperprolactinemia/NN
D013469_D006966 CID sulpiride/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) hyperprolactinemia/NN
D013256_D006966 NONE steroid/NN (r_npadvmod) dependent/JJ (r_amod) manner/NN (r_pobj) in/IN (r_prep) inhibited/VBN (l_agent) by/IN (l_pobj) hyperprolactinemia/NN
D004958_D006966 NONE estradiol/NN (r_pobj) on/IN (r_prep) dependent/JJ (r_acomp) are/VBP (l_nsubj) levels/NNS (l_conj) signaling/NN (l_conj) inhibition/NN (l_amod) hyperprolactinemic/JJ -PUNC- estradiol/NN (r_pobj) of/IN (r_prep) levels/NNS (r_pobj) of/IN (r_prep) presence/NN (r_pobj) in/IN (r_conj) caused/VBD (l_nsubj) hyperprolactinemia/NN
D012313_D006966 NONE acid/NN (r_compound) levels/NNS (l_conj) signaling/NN (l_conj) inhibition/NN (l_amod) hyperprolactinemic/JJ
